TempP

Aus coViki

(Unterschied zwischen Versionen)

Wechseln zu: Navigation, Suche

Aktuelle Version vom 15. September 2021, 13:56 Uhr

cont as TempP(1)

C7592035 ?. Weitere Metaanalyse zu chinesischer Arzneitherapie bei COVID-19.
C7569105 2020. Kortikosteroide senken die 28-Tage-Mortalität.
C7569096 2020. Remdesivir wirkt bei mittelschwerem Verlauf.
C7569089 2020. Konvaleszentenplasma in Abhängigkeit von der IgG-Konzentration wirksam.
C7574989 ?. COVID-19 ? Therapiemöglichkeiten mit chinesischen Arzneimitteln in der Akutphase und Rekonvaleszenz.
C7565236 2020. Multiple drugs: Coronavirus disease 2019 (COVID-19) and lack of efficacy: case report.
C7565230 2020. Azithromycin/hydroxychloroquine: Cardiac disorders following off label use: 5 case reports.
C7565217 2020. Remdesivir-related acute kidney injury in patients with COVID-19.
C7565214 2020. Adalimumab/methotrexate: COVID-19 infection: case report.
C7565212 2020. Favipiravir/hydroxychloroquine/oseltamivir: Tonic clonic seizures following off label use: case report.
C7561306 ?. Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab?.
C7549423 ?. Begrenzte Evidenz für chinesische Arzneitherapie bei COVID-19: Systematisches Review und Metaanalyse.
C7547645 2020. Unexpected better outcome in a liver transplant recipient with COVID-19: a beneficial effect of tacrolimus??.
C7546940 2020. Antibacterials/chloroquine/tocilizumab: Kidney and hepatic injury: case report.
C7546932 2020. Favipiravir: Hyperuricaemia and acute gouty arthritis following off-label use: case report.
C7546930 2020. Multiple drugs: Lack of efficacy: case report.
C7546926 2020. Hydroxychloroquine: Allergic reaction in the form of erythema multiforme during off label treatment: case report.
C7546924 2020. Azithromycin/hydroxychloroquine/propofol: Off-label use and propofol infusion syndrome: case report.
C7546922 2020. Cladribine/hydroxychloroquine: COVID-19-pneumonia lymphopenia and off label use: case report.
C7546936 2020. Multiple drugs: Lack of efficacy: case report.
C7546931 2020. Hydroxychloroquine: Sinus bradycardia and QTc prolongation following off-label use: case report.
C7546929 2020. Dexamethasone/prednisone/tocilizumab: Worsening of Strongyloides infection: case report.
C7546925 2020. Avelumab/pembrolizumab: COVID-19 infection and recurrent infusion reactions: case report.
C7538275 ?. Matrix metalloproteinase inhibitors identified from Camellia sinensis for COVID-19 prophylaxis: an in silico approach.
C7538068 ?. Virological cure clinical efficacy and safety of Remdesivir supplementation against SARS-CoV 2 infection; evidence from human studies.
C7530884 2020. Methotrexate: Lack of efficacy: case report.
C7530876 2020. Azithromycin: Wide QRS complex tachyarrhythmia following off-label use: case report.
C7530873 2020. Immunosuppressants/Lopinavir/ritonavir: Elevated drug level Covid 19 and reactivation of Herpes Zoster: 2 case reports.
C7530869 2020. Lopinavir/ritonavir/tocilizumab: Hypertriglyceridaemia following off-label use: 2 case reports.
C7530867 2020. Azithromycin/hydroxychloroquine: QTc interval prolongation: case report.
C7530864 2020. Prednisolone: COVID-19 pneumonia: case report.
C7530852 2020. Lopinavir/ritonavir: Maculopapular rash following off-label use: case report.
C7530849 2020. Hydroxychloroquine: Generalised pustular figurate erythema: 2 case reports.
C7530847 2020. Immunosuppressants: COVID-19 and secondary infections: 3 case reports.
C7530882 2020. Azacitidine: No therapeutic response: case report.
C7530878 2020. Hydroxychloroquine- and chloroquine-related cardiovascular events.
C7530875 2020. Hydroxychloroquine in early pregnancy: risk of birth defects.
C7530871 2020. Multiple drugs: Acute pancreatitis hypertriglyceridaemia and off-label use in coronavirus disease 2019: 2 case reports.
C7530868 2020. Monoclonal antibodies: Impaired humoral immunity: 5 case reports.
C7530857 2020. Multiple drugs: Prolonged viral shedding time and off-label use: case report.
C7530850 2020. Paracetamol: No therapeutic response: case report.
C7530844 2020. Immunosuppressants/CAR T-cell therapies: COVID-19 infection: 2 case reports.
C7548860 2020. CORTICOSTEROID TREATMENT IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA.
C7548774 2020. THE USE OF TOCILIZUMAB AT A COMMUNITY HOSPITAL DURING THE COVID-19 PANDEMIC IN THE EPICENTER OF NORTHERN NEW JERSEY.
C7548762 2020. A RECOVERED CASE OF COVID-19 MYOCARDITIS TREATED WITH IV IMMUNOGLOBULIN.
C7548738 2020. THE ASSOCIATION OF IL-6 VALUE INTERLEUKIN INHIBITORS AND OUTCOMES OF PATIENTS WITH COVID-19 IN NEW YORK CITY.
C7548730 2020. COVID-19 VENTILATOR DEPENDENT RESPIRATORY FAILURE SUCCESSFULLY TREATED WITH ANTIINFLAMMATORY BOTANICALS.
C7548673 2020. HYDROXYCHLOROQUINE AND COVID-19: A META-ANALYSIS.
C7548671 2020. TOCILIZUMAB USE IN SEVERE COVID-19: A SINGLE CENTER EXPERIENCE.
C7548587 2020. LUNG ABSCESSES IN A PATIENT TREATED WITH TOCILIZUMAB FOR COVID-19 PNEUMONIA COMPLICATED BY SEVERE HYPOXEMIC RESPIRATORY FAILURE.
C7550165 2020. A REMARKABLE RESPONSE TO ANGIOTENSIN II THERAPY IN SEVERE SARS-COV-2 INFECTION.
C7548795 2020. THE ANTI-INFECTIVE AND IMMUNOMODULATOR PARADOX: INCREASED RISK OF COINFECTION WITH HYDROXYCHLOROQUINE IN CRITICAL PATIENTS WITH COVID-19.
C7548775 2020. HEMOLYTIC ANEMIA AND METHEMOGLOBINEMIA DUE TO HYDROXYCHLOROQUINE USE FOR COVID-19 TREATMENT IN A GLUCOSE-6-PHOSPHATE DEHYDROGENASE-DEFICIENT PATIENT.
C7548709 2020. THE SIGNIFICANCE OF ORAL ASCORBIC ACID IN PATIENTS WITH COVID-19.
C7548682 2020. CONVALESCENT PLASMA THERAPY IN CRITICALLY ILL PATIENTS WITH LATE STAGE COVID-19.
C7548660 2020. IMPROVED SURVIVAL OUTCOME IN PATIENTS WITH SARS-COV-2 (COVID-19) ARDS WITH TOCILIZUMAB ADMINISTRATION.
C7548656 2020. A DRY COUGH CONUNDRUM: A RARE CASE OF PNEUMOCYSTIS JIROVECII PNEUMONIA IN SYSTEMIC LUPUS ERYTHEMATOUS PATIENT ON HYDROXYCHLOROQUINE.
C7548636 2020. ANAPHYLACTIC SHOCK IN A PREGNANT PATIENT WITH COVID-19 IN THE SETTING OF CONVALESCENT PLASMA TRANSFUSION.
C7548634 2020. CYTOMEGALOVIRUS COLITIS POST IL-6 INHIBITOR USE IN COVID-19 INFECTION.
C7548624 2020. NITRIC OXIDE IS A POWERFUL ANTI-CORONAVIRUS-INHALED AGENT THAT ACTS WITHIN HOURS.
C7548604 2020. CORONAVIRUS DISEASE 2019 AND CAVEATS OF IMMUNOMODULATORS.
33487301 2021. Nutritional status assessment in patients with Covid-19 after discharge from the intensive care unit.
C7543043 ?. The potential of lactoferrin ovotransferrin and lysozyme as antiviral and immune-modulating agents in COVID-19.
C7543042 ?. In silico analysis of protein/peptide-based inhalers against SARS-CoV-2.
C7485645 ?. Use of corticosteroid injections in current COVID pandemic ? Time to rethink!!
C7581319 2020. TCT CONNECT-217 Hydroxychloroquine and Azithromycin Usage in African American Patients With Coronavirus Disease 2019 (COVID-19) and Their Effects on QT Interval.
C7590838 ?. Combating COVID-19: The role of drug repurposing and medicinal plants.
33491033 ?. Impact of Serum 25(OH) Vitamin D Level on Mortality in Patients with COVID-19 in Turkey.
C7544924 ?. In silico allicin induced S-thioallylation of SARS-CoV-2 main protease.
C7574546 2020. A new perspective for mitigation of SARS-CoV-2 infection: priming the innate immune system for viral attack.
33380375 ?. Phytopharmaceuticals mediated Furin and TMPRSS2 receptor blocking: can it be a potential therapeutic option for Covid-19?
33485605 ?. Herbal immune-boosters: Substantial warriors of pandemic Covid-19 battle.

C7565225 2020. Rituximab: Prolongation and worsening of COVID-2019-infection: case report.
C7565220 2020. Hydroxychloroquine: Acute generalised exanthematous pustulosis following off-label use: case report.
C7565216 2020. Methotrexate: COVID-19 infection: case report.
C7565201 2020. Methotrexate/methylprednisolone/prednisone: Prolonged SARS-CoV-2 infection and masking of the symptoms of SARS-CoV-2 infection: case report.
C7565239 2020. Tocilizumab: Septic shock following off-label use: case report.
C7565232 2020. Hydroxychloroquine: Acute haemolytic anaemia direct Coombs negative following off-label use: case report.
C7529470 2020. Potential therapeutic target identification in the novel 2019 coronavirus: insight from homology modeling and blind docking study.
C7527303 2020. TAT-peptide conjugated repurposing drug against SARS-CoV-2 main protease (3CLpro): Potential therapeutic intervention to combat COVID-19.
C7556163 2020. Unraveling the SARS-CoV-2 Main Protease Mechanism Using Multiscale Methods.
C7586461 ?. SARS-CoV-2 Proteome Microarray for Mapping COVID-19 Antibody Interactions at Amino Acid Resolution.
C7586456 ?. Identifying SARS-CoV-2 Entry Inhibitors through Drug Repurposing Screens of SARS-S and MERS-S Pseudotyped Particles.
C7571299 ?. Virtual and In Vitro Antiviral Screening Revive Therapeutic Drugs for COVID-19.
C7571300 ?. Ebselen Disulfiram Carmofur PX-12 Tideglusib and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors.
C7553038 ?. Development of a High-Throughput Homogeneous AlphaLISA Drug Screening Assay for the Detection of SARS-CoV-2 Nucleocapsid.
33496642 2020. Potential role for nitazoxanide in treating SARS-CoV-2 infection.
33349491 ?. Do Systemic Corticosteroids Reduce Mortality in Critically Ill Adult Patients With COVID-19?
C7530554 2020. Belief and Usage of Traditional Chinese Medicine as Preventative Measure against COVID-19 Infection During the Pandemic among Chinese Immigrants in Canada.
C7528906 2020. Hydroxychloroquine and Potential Drug Interactions in Older Adults.
C7527307 ?. Development of multi-epitope peptide-based vaccines against SARS-CoV-2.
C7531593 2021. Potential therapeutic value of dexmedetomidine in COVID-19 patients admitted to ICU.
C7566798 2020. Inflammation malnutrition and SARS-CoV-2 infection: A disastrous combination?.

33072652 2020. Sudden Death Following Suicide with Colchicine and Chloroquine.
32736876 2020. Propiedades antivirales y antiinflamatorias de ivermectina y su potencial uso en COVID-19.
33341233 2020. The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ?
33049581 2020. The mechanisms of hydroxychloroquine in rheumatoid arthritis treatment: Inhibition of dendritic cell functions via Toll like receptor 9 signaling.
32621739 2020. Early combination of Tocilizumab and Corticosteroids: An upgrade in anti-inflammatory therapy for severe COVID.
32805024 2020. Implications of COVI-19 antibody dynamics for immunity and convalescent plasma therapy.
33051326 2020. Considerations pour la prise en charge securitaire d'une infection au SRAS-CoV-2 au moyen de chloroquine, d'hydroxychloroquine et d'azithromycine.
33065363 2021. Thioredoxin-albumin fusion protein prevents urban aerosol-induced lung injury via suppressing oxidative stress-related neutrophil extracellular trap formation.
33067760 2020. Child behaviour during dental care under nitrous oxide sedation: a cohort study using two different gas distribution systems.
33117508 2020. Prospects of plasmapheresis for patients with severe COVID-19.
33133107 2020. Editorial: Immune-Modulatory Effects of Vitamin D.
33117343 2020. Azithromycin Differentially Alters TCR-Activated Helper T Cell Subset Phenotype and Effector Function.
33015114 2020. Editorial: Nutrition, Immunity and Viral Infections.
33132549 2020. Tocilizumab and COVID-19.
33061476 2020. Human Umbilical Cord Mesenchymal Stem Cells for Adjuvant Treatment of a Critically Ill COVID-19 Patient: A Case Report.
32916818 2020. mRNA Vaccine Era-Mechanisms, Drug Platform and Clinical Prospection.
32911795 2020. An Update on Vitamin D Metabolism.
33042489 2020. Can Zinc Be an Option for Prevention of Corona Virus Disease 2019?
32869923 2020. A biflavonoid-rich extract from Selaginella moellendorffii Hieron. induces apoptosis via STAT3 and Akt/NF-kappaB signalling pathways in laryngeal carcinoma.
33071519 2020. Repurposing Hepatitis C Direct -acting antivirals against COVID-19.
33111199 2021. Bacillus Calmette-Guerin (BCG) Vaccine-associated Complications in Immunodeficient Patients Following Stem Cell Transplantation.
32932587 2020. Selective Apheresis of C-Reactive Protein for Treatment of Indications with Elevated CRP Concentrations.
32858837 2020. Understanding the Relationship between Glutathione, TGF-beta, and Vitamin D in Combating Mycobacterium tuberculosis Infections.
33073066 2021. Safety of Remdesivir in Patients With Acute Kidney Injury or CKD.
33078031 2021. Optimizing the production of vitamin D in white button mushrooms (Agaricus bisporus) using ultraviolet radiation and measurement of its stability.
33122970 2020. Luteolin Attenuates IL-1beta-Induced THP-1 Adhesion to ARPE-19 Cells via Suppression of NF-kappaB and MAPK Pathways.
32967141 2020. Recent Advances in the Synthesis and Biological Activity of 8-Hydroxyquinolines.
33296987 2020. Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment.
33009505 2020. Convalescent plasma trial shows no benefit.
32933052 2020. Clinical Significance of Analysis of Vitamin D Status in Various Diseases.
32931286 2020. Expanding Access to Remdesivir via an Improved Pyrrolotriazine Synthesis: Supply Centered Synthesis.
32867272 2020. Kinins and Their Receptors in Infectious Diseases.
32937880 2020. Immunostimulating RNA Delivered by P1500 PEGylated Cationic Liposomes Limits Influenza Infection in C57Bl/6 Mice.
33026598 2020. Role of vitamin D in diabetic retinopathy: Pathophysiological and clinical aspects.
33052207 2020. Remdesivir : forme inhalee en pediatrie.
32842641 2020. Plant-Derived Nutraceuticals and Immune System Modulation: An Evidence-Based Overview.

33515005 2021. Habitual use of vitamin D supplements and risk of coronavirus disease 2019 (COVID-19) infection: a prospective study in UK Biobank.
33399201 2021. Hospital-Based Donor Recruitment and Predonation Serologic Testing for COVID-19 Convalescent Plasma.
33399186 2021. Importance of the Lipid-Bound Character of Vitamin D Binding Protein in the Evaluation of Vitamin D Status in COVID-19 Patients.
33483744 2021. Developing statewide remdesivir use criteria.
33493729 2021. The outcome of fluticasone nasal spray on anosmia and triamcinolone oral paste in dysgeusia in COVID-19 patients.
33410395 2021. COVID-19 and Corticosteroids: Unfamiliar but Potentially Fatal Infections That Can Arise following Short-Course Steroid Treatment.
33508271 2021. Validation of LC-MS/MS methods for determination of remdesivir and its metabolites GS-441524 and GS-704277 in acidified human plasma and their application in COVID-19 related clinical studies.
33469977 2021. Molecular Simulations suggest Vitamins, Retinoids and Steroids as Ligands of the Free Fatty Acid Pocket of the SARS-CoV-2 Spike Protein.
33464672 2021. Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine.
33387615 2021. Monitoring neutrophil-to-lymphocyte ratio in patients with coronavirus disease 2019 receiving tocilizumab.
33420963 2021. Pilot trial of high-dose vitamin C in critically ill COVID-19 patients.
33395345 2021. Speed Versus Efficacy: Quantifying Potential Tradeoffs in COVID-19 Vaccine Deployment.
33395339 2021. A Public Health COVID-19 Vaccination Strategy to Maximize the Health Gains for Every Single Vaccine Dose.
33460347 2021. SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn.
33456770 2021. Protease inhibitor GC376 for COVID-19: Lessons learned from feline infectious peritonitis.
33520220 2021. When to call it off: Defining the role of low-dose corticosteroids in thwarting the progression of non-severe COVID-19.
33489115 2021. Remdesivir therapy in patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials.
33440983 2021. Antiviral treatment in COVID-19: which is the most promising?-a narrative review.
33381234 2020. Low-dose radiation therapy for coronavirus disease-2019 pneumonia: Is it time to look beyond apprehensions?
33440681 2021. Viroinformatics-Based Analysis of SARS-CoV-2 Core Proteins for Potential Therapeutic Targets.
33401749 2021. Role of Melatonin on Virus-Induced Neuropathogenesis-A Concomitant Therapeutic Strategy to Understand SARS-CoV-2 Infection.
33515606 2021. Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development.
33444702 2021. Inhibition of coronavirus infection by a synthetic STING agonist in primary human airway system.
33422611 2021. The rocaglate CR-31-B (-) inhibits SARS-CoV-2 replication at non-cytotoxic, low nanomolar concentrations in vitro and ex vivo.
33512610 2021. Apoptosis induced by SARS-CoV-2: can we target it?
33512650 2021. Strong Binding of Leupeptin with TMPRSS2 Protease May Be an Alternative to Camostat and Nafamostat for SARS-CoV-2 Repurposed Drug: Evaluation from Molecular Docking and Molecular Dynamics Simulations.
33519322 2021. Drug repositioning based on similarity constrained probabilistic matrix factorization: COVID-19 as a case study.
33485847 2021. Pharmacoinformatics approach based identification of potential Nsp15 endoribonuclease modulators for SARS-CoV-2 inhibition.
33483203 2020. Reply to "Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19".
33389097 2021. Safety of lymphocytes immunotherapy during the COVID-19 outbreak in Wuhan, China.
33485639 2020. New COVID-19 Vaccines, Its Cost and Shelf Life: A Cost Effectiveness Analysis.
33380359 2020. COVID-19 Vaccines: New Developments and the Road Ahead.
33459817 2021. Addressing the potential role of curcumin in the prevention of COVID-19 by targeting the Nsp9 replicase protein through molecular docking.
33398691 2021. Role of specialized pro-resolving lipid mediators and their receptors in virus infection: a promising therapeutic strategy for SARS-CoV-2 cytokine storm.
33492523 2021. Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study.
33457430 2021. Chemical profiling of selected Ayurveda formulations recommended for COVID-19.
33483287 2021. Hydroxychloroquine for the treatment of COVID-19 and its potential cardiovascular toxicity: Hero or villain?
33454058 2021. The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease.
33388129 2021. Remdesivir: From Ebola to COVID-19.
33387885 2021. In silico study of the potential interactions of 4'-acetamidechalcones with protein targets in SARS-CoV-2.
33477032 2021. ATP biphasically modulates LLPS of SARS-CoV-2 nucleocapsid protein and specifically binds its RNA-binding domain.
33515531 2021. PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking.
33482149 2021. Biochemical features and mutations of key proteins in SARS-CoV-2 and their impacts on RNA therapeutics.
33439253 2021. Antivirals that target the host IMPalpha/beta1-virus interface.
33469510 2021. A domain-based vaccine construct against SARS-CoV-2, the causative agent of COVID-19 pandemic: development of self-amplifying mRNA and peptide vaccines.
33381848 2020. FBA reveals guanylate kinase as a potential target for antiviral therapies against SARS-CoV-2.
33409924 2021. Olfactory Disturbances as Presenting Manifestation Among Egyptian Patients with COVID-19: Possible Role of Zinc.
33513850 2021. Promising Extracellular Vesicle-Based Vaccines against Viruses, Including SARS-CoV-2.
33508618 2021. The direct evidence and mechanism of traditional Chinese medicine treatment of COVID-19.
33486202 2021. Human endeavor for anti-SARS-CoV-2 pharmacotherapy: A major strategy to fight the pandemic.
33378989 2021. Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size.
33486212 2021. Impact of virus genetic variability and host immunity for the success of COVID-19 vaccines.
33454595 2021. The role of iron in the pathogenesis of COVID-19 and possible treatment with lactoferrin and other iron chelators.
33426074 2020. Molecular Insights into the MAPK Cascade during Viral Infection: Potential Crosstalk between HCQ and HCQ Analogues.
33424013 2021. Discovery of New Fusion Inhibitor Peptides against SARS-CoV-2 by Targeting the Spike S2 Subunit.
33430299 2021. Bioactive Terpenes and Their Derivatives as Potential SARS-CoV-2 Proteases Inhibitors from Molecular Modeling Studies.
33445810 2021. Cytokines and Chemokines in SARS-CoV-2 Infections-Therapeutic Strategies Targeting Cytokine Storm.
33396926 2020. Potential Medicinal Plants for the Treatment of Dengue Fever and Severe Acute Respiratory Syndrome-Coronavirus.
33450541 2021. Broad-spectrum antivirals of protoporphyrins inhibit the entry of highly pathogenic emerging viruses.
33515918 2021. Potential inhibitors interacting in Neuropilin-1 to develop an adjuvant drug against COVID-19, by molecular docking.
33458647 2021. Review of pharmacologic and immunologic agents in the management of COVID-19.
33390423 2021. Tetracycline plus macrolide: A potential therapeutic regimen for COVID-19?
33390384 2021. Latest updates on COVID-19 vaccines.
33443562 2021. Vaccinations in CLL: implications for COVID-19.
33478471 2021. Allergen fragrance molecules: a potential relief for COVID-19.
33446136 2021. Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study.
33430799 2021. JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis.
33413329 2021. Computational analysis to repurpose drugs for COVID-19 based on transcriptional response of host cells to SARS-CoV-2.
33482902 2021. A pilot trial of human amniotic fluid for the treatment of COVID-19.
33472855 2021. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial.
33419750 2021. Successful treatment of severe COVID-19 pneumonia and hyperinflammatory syndrome with tocilizumab.
33509890 2021. Convalescent plasma for COVID-19 complicated by ARDS due to TRALI.
33472840 2021. Effect of micronutrient supplements on influenza and other respiratory tract infections among adults: a systematic review and meta-analysis.
33504571 2021. Does vitamin D supplementation prevent SARS-CoV-2 infection in military personnel? Review of the evidence.
33521556 2020. Micronutrient deficiencies in patients with COVID-19: how metabolomics can contribute to their prevention and replenishment.
33521536 2020. Responsibility for vitamin D supplementation of elderly care home residents in England: falling through the gap between medicine and food.
33441373 2021. Rationale for azithromycin in COVID-19: an overview of existing evidence.
33483637 2021. Oral side effects of COVID-19 vaccine.
33454964 2021. Oral ivermectin for a scabies outbreak in a long-term care facility: potential value in preventing COVID-19 and associated mortality.
33524158 2021. Convalescent plasma for COVID-19 - encouraging signals of efficacy.
33482025 2021. Early mortality benefit with COVID-19 convalescent plasma: a matched control study.
33504378 2021. Optimising COVID-19 vaccine efficacy by ensuring nutritional adequacy.
33468263 2021. Vitamin A in resistance to and recovery from infection: relevance to SARS-CoV2.
33518836 2021. Helmet mask and tocilizumab for a patient with hemophagocytic lymphohistiocytosis syndrome and COVID-19: a case report.
33497434 2021. Identifying anti-coronavirus peptides by incorporating different negative datasets and imbalanced learning strategies.
33480398 2021. DrugRepV: a compendium of repurposed drugs and chemicals targeting epidemic and pandemic viruses.
33461215 2021. Ligand-based approach for predicting drug targets and for virtual screening against COVID-19.
33406222 2021. Exploration of natural compounds with anti-SARS-CoV-2 activity via inhibition of SARS-CoV-2 Mpro.
33406218 2021. A comprehensive drug repurposing study for COVID19 treatment: novel putative dihydroorotate dehydrogenase inhibitors show association to serotonin-dopamine receptors.
33497123 2021. Monoclonal Antibodies Receive EUA to Treat Mild to Moderate COVID-19.
33517757 2021. Clozapine Intoxication in COVID-19.
33439703 2021. The Need for Novel Approaches in Assessing the Value of COVID-19 Vaccines.
33416244 2020. Effects of Hydroxychloroquine With or Without Azithromycin on QT Interval in COVID-19: A Systematic Review. Electrophysiology Collaborative Consortium for Meta-analysis-Electram Investigators.
33481405 2021. Aspirin in Coronavirus Disease 2019-Related Acute Respiratory Distress Syndrome: An Old, Low-Cost Therapy With a Strong Rationale.
33395337 2021. WHO recommends corticosteroids for patients with severe or critical COVID-19.
33395331 2021. In severe COVID-19, adding lopinavir-ritonavir to usual care did not improve mortality at 28 days.
33524290 2021. The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 >/=7 days after the 2nd dose.
33524282 2021. In inpatients with COVID-19, none of remdesivir, hydroxychloroquine, lopinavir, or interferon beta-1a differed from standard care for in-hospital mortality.
33524280 2021. Tocilizumab did not reduce hypoxemic respiratory failure or death in hospitalized patients with COVID-19.
33509798 2021. Response to: 'Correspondence on 'Anti-inflammatory therapy for COVID-19 infection: the case for colchicine by Perricone et al.
33509794 2021. Correspondence on 'Anti-inflammatory therapy for COVID-19 infection: the case for colchicine'.
33504481 2021. Correspondence on 'Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome'.
33504480 2021. Response to: 'Correspondence on 'Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome by Kawada.
33452005 2021. Correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine'.
33459727 2020. Adverse effects, pharmacological interactions, and cardiovascular drugs in COVID-19 treatment.
33472834 2021. Covid-19: Arthritis drug trial for severe illness is stopped early after increase in deaths.
33446489 2021. Covid-19: Convalescent plasma may cut deaths in patients not on ventilation, study indicates.
33436419 2021. How the Oxford-AstraZeneca covid-19 vaccine was made.
33455917 2021. Cyclosporine: hope for severe COVID-19?
33401333 2021. COVID-19 and the revival of passive immunization: Antibody therapy for inhibiting SARS-CoV-2 and preventing host cell infection: IUPHAR review: 31.
33512003 2021. Neurological risks and benefits of cytokine-based treatments in coronavirus disease 2019: from preclinical to clinical evidence.
33502877 2021. Are clarithromycin, azithromycin and their analogues effective in the treatment of COVID19?

33521606 2021. Antiviral activity of sulfated polysaccharides from marine algae and its application in combating COVID-19: Mini review.
33481336 2021. Generation of enzymatically competent SARS-CoV-2 decoy receptor ACE2-Fc in glycoengineered Nicotiana benthamiana.
33430659 2021. Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors.
33513419 2021. Potential effect of Maxing Shigan decoction against coronavirus disease 2019 (COVID-19) revealed by network pharmacology and experimental verification.
33485971 2021. Dissecting the novel mechanism of reduning injection in treating Coronavirus Disease 2019 (COVID-19) based on network pharmacology and experimental verification.
33485973 2021. Chinese herbal medicine: Fighting SARS-CoV-2 infection on all fronts.
33514385 2021. Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein.
33426604 2021. ACE-2-interacting Domain of SARS-CoV-2 (AIDS) Peptide Suppresses Inflammation to Reduce Fever and Protect Lungs and Heart in Mice: Implications for COVID-19 Therapy.
33403500 2021. Pharmacotherapeutics of SARS-CoV-2 Infections.
33491033 2021. Impact of Serum 25(OH) Vitamin D Level on Mortality in Patients with COVID-19 in Turkey.
33491026 2021. Editorial: COVID19 Vaccination in Frail People. Lots of Hope and Some Questions.
33398242 2021. Potential therapeutic approaches of microRNAs for COVID-19: Challenges and opportunities.
33456225 2020. A brief outlook on the current emerging trends of COVID 19 vaccines.
33388760 2021. Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of COVID-19 in Children and Adolescents.
33495677 2021. Comments on potential re-purposing of medicines against high-altitude illnesses towards SARS-CoV2: possibilities and pitfalls.
33472369 2021. ACE-2-Derived Biomimetic Peptides for the Inhibition of Spike Protein of SARS-CoV-2.
33439850 2021. Diet, Nutrition, Obesity, and Their Implications for COVID-19 Mortality: Development of a Marginalized Two-Part Model for Semicontinuous Data.
33437926 2021. A Call to Action: "Low-Dose Radiation May Help Cure COVID-19..." [Taps Mic] "...Is This Thing On?"
33437924 2021. Low-Dose Radiation Therapy for COVID-19: Promises and Pitfalls.
33390434 2020. Increased secondary infection in COVID-19 patients treated with steroids in New York City.
33485468 2021. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial.
33485467 2021. Optimism and caution for an inactivated COVID-19 vaccine.
33493450 2021. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial.
33493449 2021. The right place for IL-1 inhibition in COVID-19.
33484632 2021. Realising the potential of SARS-CoV-2 vaccines-a long shot?
33460572 2021. Assessing the importance of interleukin-6 in COVID-19 - Authors' reply.
33460569 2021. Assessing the importance of interleukin-6 in COVID-19.
33461387 2021. Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies.
33476632 2021. Protective effect of Rosuvastatin on Azithromycin induced cardiotoxicity in a rat model.
33513400 2021. Cardiovascular protective properties of oxytocin against COVID-19.
33402630 2021. Is there a role for inhaled ciclesonide in the treatment of COVID-19?
33513822 2021. Caged Dexamethasone/Quercetin Nanoparticles, Formed of the Morphogenetic Active Inorganic Polyphosphate, are Strong Inducers of MUC5AC.
33413833 2021. Inverse Relationship of Maximal Exercise Capacity to Hospitalization Secondary to Coronavirus Disease 2019.
33413825 2021. Micro-Thrombosis, Perfusion Defects, and Worsening Oxygenation in COVID-19 Patients: A Word of Caution on the Use of Convalescent Plasma.
33413824 2021. In Reply - Micro-Thrombosis, Perfusion Defects, and Worsening Oxygenation in COVID-19 Patients: A Word of Caution on the Use of Convalescent Plasma.
33419872 2021. Pneumococcal Conjugate Vaccine Protection against Coronavirus-Associated Pneumonia Hospitalization in Children Living with and without HIV.
33468703 2021. Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses In Vitro.
33424100 2020. Physical Activity Outdoors as an Alternative to Lockdown: the Three Cs Strategy.
33388144 2021. Reaccion transfusional a plasma hiperinmune en pacientes con infeccion grave por COVID-19.
33380371 2021. Efectividad de los glucocorticoides en pacientes hospitalizados por neumonia grave por SARS-CoV-2.
33392390 2021. Relationship between MMR vaccination and severity of Covid-19 infection. Survey among primary care physicians.
33422363 2021. Tackling the COVID-19 "cytokine storm" with microRNA mimics directly targeting the 3'UTR of pro-inflammatory mRNAs.
33385879 2021. Phenylmethimazole is a candidate drug for the treatment of severe forms of coronavirus disease 2019 (COVID-19) as well as other virus-induced "cytokines storm".
33385878 2021. The plausible mechanisms of tramadol for treatment of COVID-19.
33485026 2021. Daylight is critical to preserve 5-methoxytryptophol levels in suspected and confirmed COVID-19 patients.
33482620 2021. Fecal microbiota transplantation for COVID-19; a potential emerging treatment strategy.
33460992 2021. Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19.
33421690 2021. Platelet hyperactivity in COVID-19: Can the tomato extract Fruitflow(R) be used as an antiplatelet regime?
33505216 2021. Exploring the Pivotal Immunomodulatory and Anti-Inflammatory Potentials of Glycyrrhizic and Glycyrrhetinic Acids.
33481741 2020. La bioseguridad de las vacunas anti-COVID-19.
33481727 2020. Plasma de convalecientes como terapia para la neumonia por COVID-19 grave.
33429732 2021. Anti-IL6 treatment of serious COVID-19 disease: A monocentric retrospective experience.
33453392 2021. Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening pipeline and in-vitro validation assays.
33482357 2021. Could targeting immunometabolism be a way to control the burden of COVID-19 infection?
33430200 2021. Intravenous Immunoglobulins at the Crossroad of Autoimmunity and Viral Infections.
33451069 2021. Development of Coronavirus Treatments Using Neutralizing Antibodies.
33402220 2021. SARS-CoV-2: vaccines in the pandemic era.
33464512 2021. Anaphylaxie-Risiko bei der COVID-19-Impfung: Empfehlungen fur das praktische Management.
33507892 2021. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine - United States, December 21, 2020-January 10, 2021.
33444297 2021. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020.
33382675 2021. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020.
33464543 2021. Cell-Based High-Throughput Screening Protocol for Discovering Antiviral Inhibitors Against SARS-COV-2 Main Protease (3CLpro).
33400086 2021. COVID-19: inflammatory responses, structure-based drug design and potential therapeutics.
33400085 2021. First structure-activity relationship analysis of SARS-CoV-2 virus main protease (Mpro) inhibitors: an endeavor on COVID-19 drug discovery.
33398633 2021. Identification of novel inhibitors of angiotensin-converting enzyme 2 (ACE-2) receptor from Urtica dioica to combat coronavirus disease 2019 (COVID-19).
33389560 2021. CoViTris2020 and ChloViD2020: a striking new hope in COVID-19 therapy.
33389441 2021. The anti-HCV, Sofosbuvir, versus the anti-EBOV Remdesivir against SARS-CoV-2 RNA dependent RNA polymerase in silico.
33492566 2021. Computational assessment of saikosaponins as adjuvant treatment for COVID-19: molecular docking, dynamics, and network pharmacology analysis.
33389440 2021. Designing of peptide aptamer targeting the receptor-binding domain of spike protein of SARS-CoV-2: an in silico study.
33503834 2021. Antiviral Activity of Jamaican Medicinal Plants and Isolated Bioactive Compounds.
33467029 2021. Natural and Nature-Derived Products Targeting Human Coronaviruses.
33466743 2021. Cheminformatics-Based Identification of Potential Novel Anti-SARS-CoV-2 Natural Compounds of African Origin.
33500564 2021. The lung-gut axis during viral respiratory infections: the impact of gut dysbiosis on secondary disease outcomes.
33471984 2021. Monoclonal Antibodies to Disrupt Progression of Early Covid-19 Infection.
33440088 2021. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.
33440086 2021. (A Little) Clarity on Convalescent Plasma for Covid-19.
33406353 2021. Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults.
33391623 2020. Manganese nanodepot augments host immune response against coronavirus.
33418136 2021. iRGD conjugated nimbolide liposomes protect against endotoxin induced acute respiratory distress syndrome.
33510133 2021. A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication.
33483491 2021. A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses.
33473140 2021. Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape.
33473130 2021. The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery.
33446655 2021. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice.
33436624 2021. Mechanism of SARS-CoV-2 polymerase stalling by remdesivir.
33436577 2021. A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein.
33436573 2021. Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity.
33431876 2021. Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections.
33431856 2021. Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry.
33432129 2021. Immune readouts from the Oxford COVID-19 vaccine.
33394134 2021. NF-kappaB signalling as a pharmacological target in COVID-19: potential roles for IKKbeta inhibitors.
33416933 2021. Chloroquine/hydroxychloroquine: an inflammasome inhibitor in severe COVID-19?
33443616 2021. Efficacy of synthetic glucocorticoids in COVID-19 endothelites.
33425362 2021. Oral probiotics in coronavirus disease 2019: connecting the gut-lung axis to viral pathogenesis, inflammation, secondary infection and clinical trials.
33495468 2021. Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters.
33495451 2021. The double-sided effects of Mycobacterium Bovis bacillus Calmette-Guerin vaccine.
33435521 2021. Magnesium in Infectious Diseases in Older People.
33498631 2021. Protective Effects of Lactoferrin against SARS-CoV-2 Infection In Vitro.
33466642 2021. Effectiveness of In-Hospital Cholecalciferol Use on Clinical Outcomes in Comorbid COVID-19 Patients: A Hypothesis-Generating Study.
33419325 2020. Nutritional and Behavioral Approaches to Body Composition and Low-Grade Chronic Inflammation Management for Older Adults in the Ordinary and COVID-19 Times.
33412367 2021. Prospective options of algae-derived nutraceuticals as supplements to combat COVID-19 and human coronavirus diseases.
33456092 2021. COVID-19: Analysis of Drug Repositioning Practice.
33445955 2021. Repurposing drugs during the COVID-19 pandemic and beyond.
33430081 2021. Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection.
33419184 2021. Immunogenicity of Multiple Doses of pDNA Vaccines against SARS-CoV-2.
33455739 2021. Inmunomodulacion mediante CONVEHY(R) para COVID-19: de la tormenta al anticiclon de citoquinas.
33493900 2021. Carrying out pseudo dual nucleic acid detection from sample to visual result in a polypropylene bag with CRISPR/Cas12a.
33419743 2021. Covid-19: Arthritis drugs improve survival in intensive care patients, shows study.
33408068 2021. Covid-19 vaccination: What's the evidence for extending the dosing interval?
33514589 2021. Incre<iframe src="http://www.kidney.de/amapp.php?a=g recruitment into covid-19 trials.
33428504 2021. Formulation and stability study of hydroxychloroquine sulfate oral suspensions.
33497594 2021. The Potential Role of Photobiomodulation in Long COVID-19 Patients Rehabilitation.

33476998 2021. Predictive value of the prognostic nutritional index for the severity of coronavirus disease 2019.
33450678 2021. Micronutrients and bioactive substances: Their potential roles in combating COVID-19.
33421827 2021. Sarcopenia: An underlying treatment target during the COVID-19 pandemic.
33418230 2021. Increased risk for COVID-19 in patients with vitamin D deficiency.
33426364 2021. Friend or foe? ACE2 inhibitors and GLP-1R agonists in COVID-19 treatment.
33408570 2020. Hydroxychloroquine Use in Patients With COVID-19: A Brief Perspective on Current Clinical Trials.
33426262 2021. Matched cohort study on the efficacy of tocilizumab in patients with COVID-19.
33506065 2021. Thymosin Alpha 1 Mitigates Cytokine Storm in Blood Cells From Coronavirus Disease 2019 Patients.
33425070 2020. BCG Vaccine does not Protect Against COVID-19.
33456654 2020. Use of tocilizumab in a patient with severe COVID-19 in a Teaching Hospital in Ghana: a case report.
33456653 2020. Promotion of unproved and potential dangerous measures in fighting COVID-19 pandemic: urgent need for vigilant appropriate public communication and generation of scientific evidence.
33425157 2020. A review of COVID-19 vaccines in development: 6 months into the pandemic.
33480519 2021. Why two doses of the BNT162b2 mRNA Covid-19 vaccine? A different strategy to speed up the vaccination process: single-dose of the BNT162b2 mRNA Covid-19 and other vaccines.
33504008 2021. Identification of 37 Heterogeneous Drug Candidates for Treatment of COVID-19 via a Rational Transcriptomics-Based Drug Repurposing Approach.
33477294 2021. COVID-19-The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection.
33435273 2021. Interactions of Potential Anti-COVID-19 Compounds with Multispecific ABC and OATP Drug Transporters.
33437147 2021. Effects on LOS may not justify cost of remdesivir for severe COVID-19.
33389725 2021. Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes.
33389724 2021. SARS-CoV-2 therapeutics: how far do we stand from a remedy?
33421347 2021. Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview.
33515763 2021. A combination of phototherapy modalities for extensive lip lesions in a patient with SARS-CoV-2 infection.
33422697 2021. Can photodynamic therapy be repurposed to treat oral lesions of COVID-19?
33463909 2021. 17beta-estradiol reduces SARS-CoV-2 infection in vitro.
33485605 2020. Herbal immune-boosters: Substantial warriors of pandemic Covid-19 battle.
33380375 2020. Phytopharmaceuticals mediated Furin and TMPRSS2 receptor blocking: can it be a potential therapeutic option for Covid-19?
33419674 2020. Effects and safety of herbal medicines among community-dwelling residents during COVID-19 pandemic: A large prospective, randomized controlled trial (RCT).
33495692 2021. Localized Plasmonic Photothermal Therapy as a Life-saving Treatment Paradigm for Hospitalized COVID-19 Patients.
33382685 2020. A novel virtual screening procedure identifies Pralatrexate as inhibitor of SARS-CoV-2 RdRp and it reduces viral replication in vitro.
33395417 2021. Zinc against COVID-19? Symptom surveillance and deficiency risk groups.
33507958 2021. High-dose corticosteroid pulse therapy increases the survival rate in COVID-19 patients at risk of hyper-inflammatory response.
33497420 2021. Temporal development and neutralising potential of antibodies against SARS-CoV-2 in hospitalised COVID-19 patients: An observational cohort study.
33493227 2021. Screening, simulation, and optimization design of small molecule inhibitors of the SARS-CoV-2 spike glycoprotein.
33481950 2021. Serum Amyloid P inhibits single stranded RNA-induced lung inflammation, lung damage, and cytokine storm in mice.
33444408 2021. Quercetin as a potential treatment for COVID-19-induced acute kidney injury: Based on network pharmacology and molecular docking study.
33417604 2021. Computational drug repurposing strategy predicted peptide-based drugs that can potentially inhibit the interaction of SARS-CoV-2 spike protein with its target (humanACE2).
33411791 2021. Therapeutic plasma exchange for coronavirus disease-2019 triggered cytokine release syndrome; a retrospective propensity matched control study.
33406138 2021. The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: A systematic review and meta-analysis of randomized trials.
33382734 2020. The use of methylprednisolone in COVID-19 patients: A propensity score matched retrospective cohort study.
33465165 2021. Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2.
33382547 2021. Remdesivir-based therapy improved the recovery of patients with COVID-19 in the multicenter, real-world SARSTer study.
33481361 2020. Polymers with antiviral properties: A brief review.
33481360 2020. Focus on COVID-19: Antiviral polymers in drugs and vaccines.
33452205 2021. Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection.
33390763 2021. Rapid determination of remdesivir (SARS-CoV-2 drug) in human plasma for therapeutic drug monitoring in COVID-19-Patients.
33516093 2021. Blood omega-3 fatty acids and death from COVID-19: A pilot study.
33420956 2021. Pan-coronavirus fusion inhibitors as the hope for today and tomorrow.
33387249 2021. In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors.
33392622 2021. Fluvoxamine, melatonin and COVID-19.
33465426 2021. Antihistamines and azithromycin as a treatment for COVID-19 on primary health care - A retrospective observational study in elderly patients.
33489300 2020. Vitamin D and COVID-19: evidence and recommendations for supplementation.
33415646 2021. Potential Role of Zinc in the COVID-19 Disease Process and its Probable Impact on Reproduction.
33461535 2021. Surfactant therapy for COVID-19 related ARDS: a retrospective case-control pilot study.
33399672 2020. Corticoides para el tratamiento de COVID-19.
33388902 2021. Colchicine as an adjunct to heparin for prophylaxis of venous thromboembolism in patients with COVID-19.
33386447 2021. COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases.
33447107 2021. Effects of Vitamin D on COVID-19 Infection and Prognosis: A Systematic Review.
33458569 2021. Re-reading ACT, BCG, and Low COVID-19 in Africa.
33503560 2021. Molecular structure, NBO analysis of the hydrogen-bonded interactions, spectroscopic (FT-IR, FT-Raman), drug likeness and molecular docking of the novel anti COVID-2 molecule (2E)-N-methyl-2-[(4-oxo-4H-chromen-3-yl)methylidene]-hydrazinecarbothioamide (Dimer) - quantum chemical approach.
33514427 2021. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.
33511519 2021. Mesenchymal Stem Cell-Derived Extracellular Vesicles Carrying miRNA as a Potential Multi Target Therapy to COVID-19: an In Silico Analysis.
33511518 2021. Stem Cell Therapy Potency in Personalizing Severe COVID-19 Treatment.
33432484 2021. Proposed Mechanisms of Targeting COVID-19 by Delivering Mesenchymal Stem Cells and Their Exosomes to Damaged Organs.
33423157 2021. Stem Cells as Potential Therapeutics and Targets for Infection by COVID19 - Special Issue on COVID19 in Stem Cell Reviews and Reports.
33415541 2021. Dimethyl Fumarate Can Enhance the Potential Therapeutic Effects of Epidermal Neural Crest Stem Cells in COVID-19 Patients.
33414832 2020. Human Mesenchymal Stem Cells: The Present Alternative for High-Incidence Diseases, Even SARS-Cov-2.
33400390 2021. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.
33502567 2021. COVID-19 pneumonia treated with ultra-low doses of radiotherapy (ULTRA-COVID study): a single institution report of two cases.
33437137 2021. Combination and tricombination therapy to destabilize the structural integrity of COVID-19 by some bioactive compounds with antiviral drugs: insights from molecular docking study.
33382449 2020. Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs.
33408775 2021. The 2020 race towards SARS-CoV-2 specific vaccines.
33391531 2021. Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of in vitro, in vivo, and clinical trials.
33391497 2021. Rapid design and development of CRISPR-Cas13a targeting SARS-CoV-2 spike protein.
33433109 2021. Kortikosteroider til sykehjemspasienter med covid-19?
33428032 2021. Reviews on Biological Activity, Clinical Trial and Synthesis Progress of Small Molecules for the Treatment of COVID-19.
33484708 2021. Chloroquine may induce endothelial injury through lysosomal dysfunction and oxidative stress.
33425684 2021. Nicotinic cholinergic system and COVID-19: In silico evaluation of nicotinic acetylcholine receptor agonists as potential therapeutic interventions.
33478889 2021. A look-back at convalescent plasma to treat COVID-19.
33461918 2021. New generation of vaccines and convalescent plasma therapy for management of CoV-2: Perspectives from the UK and potential deployment in the current global pandemic.
33388249 2021. The use of convalescent plasma for pediatric patients with SARS-CoV-2: A systematic literature review.
33462569 2021. The Intersection of Photopheresis and COVID-19 Vaccination.
33515686 2021. Could shear stress mimetics delay complications in COVID-19?
33424125 2021. Polysaccharides obtained from natural edible sources and their role in modulating the immune system: Biologically active potential that can be exploited against COVID-19.
33446406 2021. Slaying SARS-CoV-2 One (Single-domain) Antibody at a Time.
33505872 2021. Antiviral drugs against severe acute respiratory syndrome coronavirus 2 infection triggering the coronavirus disease-19 pandemic.
33441235 2021. Anaphylactic reactions to novel mRNA SARS-CoV-2/COVID-19 vaccines.
33478794 2021. Immunoinformatics prediction of overlapping CD8(+) T-cell, IFN-gamma and IL-4 inducer CD4(+) T-cell and linear B-cell epitopes based vaccines against COVID-19 (SARS-CoV-2).
33478787 2021. Immuno-informatics approach for B-cell and T-cell epitope based peptide vaccine design against novel COVID-19 virus.
33429880 2021. Current State of the First COVID-19 Vaccines.
33406785 2021. SARS-CoV-2/COVID-19 Vaccines: The Promises and the Challenges Ahead.
33513693 2021. COVID-19 Infection and Previous BCG Vaccination Coverage in the Ecuadorian Population.
33499326 2021. Optimising Vaccine Dose in Inoculation against SARS-CoV-2, a Multi-Factor Optimisation Modelling Study to Maximise Vaccine Safety and Efficacy.
33494530 2021. Delivery of mRNA Vaccine against SARS-CoV-2 Using a Polyglucin:Spermidine Conjugate.
33494381 2021. Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses.
33478109 2021. Nanomaterial Delivery Systems for mRNA Vaccines.
33440794 2021. Who Is Really at Risk for Anaphylaxis Due to COVID-19 Vaccine?
33440640 2021. SARS-CoV-2 Spike Protein Elicits Cell Signaling in Human Host Cells: Implications for Possible Consequences of COVID-19 Vaccines.
33396667 2020. Plant-Based Drugs and Vaccines for COVID-19.
33394351 2020. Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19.
33421743 2021. Network analysis and molecular mapping for SARS-CoV-2 to reveal drug targets and repurposing of clinically developed drugs.
33387788 2021. Dexamethasone inhibits SARS-CoV-2 spike pseudotyped virus viropexis by binding to ACE2.
33503819 2021. Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188.
33498923 2021. Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CL(pro) Inhibitors.
33477902 2021. Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies.
33477376 2021. Quinacrine, an Antimalarial Drug with Strong Activity Inhibiting SARS-CoV-2 Viral Replication In Vitro.
33466921 2021. Domains and Functions of Spike Protein in Sars-Cov-2 in the Context of Vaccine Design.
33451132 2021. Systematic Search for SARS-CoV-2 Main Protease Inhibitors for Drug Repurposing: Ethacrynic Acid as a Potential Drug.
33396343 2020. Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval.
33396594 2020. PSGL-1 Inhibits the Incorporation of SARS-CoV and SARS-CoV-2 Spike Glycoproteins into Pseudovirions and Impairs Pseudovirus Attachment and Infectivity.
33396578 2020. Interferon-alpha2b Treatment for COVID-19 Is Associated with Improvements in Lung Abnormalities.
33425204 2021. Efficacy of broccoli and glucoraphanin in COVID-19: From hypothesis to proof-of-concept with three experimental clinical cases.
33386950 2021. COVID-19 and BCG: where's the challenge?
33438061 2021. Impfung gegen SARS-CoV-2 bei entzundlich rheumatischen Erkrankungen : Empfehlungen der DGRh fur Arzte und Patienten.

33440401 2021. Convergent evidence for the antiviral effects of several FDA-approved phenothiazine antipsychotics against SARS-CoV-2 and other coronaviruses.
33386025 2021. Identifying the natural polyphenol catechin as a multi-targeted agent against SARS-CoV-2 for the plausible therapy of COVID-19: an integrated computational approach.
33456058 2021. Les vaccins a ARN anti-COVID-19.
33495684 2021. Luteolin and abyssinone II as potential inhibitors of SARS-CoV-2: an in silico molecular modeling approach in battling the COVID-19 outbreak.
33503163 2021. Reacoes adversas a medicamentos em pacientes com COVID-19 no Brasil: analise das notificacoes espontaneas do sistema de farmacovigilancia brasileiro.
33404925 2021. Promising Therapy for Heart Failure in Patients with Severe COVID-19: Calming the Cytokine Storm.
33387252 2021. QTc Prolongation in COVID-19 Patients Using Chloroquine.
33425407 2020. The Safe Administration of Remdesivir in a Patient with Acute Kidney Injury Requiring Hemodialysis.
33425279 2020. Plasmapheresis with corticosteroids and antiviral: a life-saving treatment for severe cases of Covid 19.
33425262 2020. A brief review of the latest pharmacological treatments of COVID-19.
33479399 2021. COVID-19 vaccines: where we stand and challenges ahead.
33421384 2021. The Neutrophil-to-Lymphocyte Ratio Determines Clinical Efficacy of Corticosteroid Therapy in Patients with COVID-19.
33488836 2021. Engineered Aptamers for Enhanced COVID-19 Theranostics.
33521696 2021. Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency.
33473156 2021. Dalbavancin: novel candidate for COVID-19 treatment.
33522308 2021. Estrogen and Androgen Receptor Inhibitors: Unexpected Allies in the Fight Against COVID-19.
33502716 2021. Effective treatment with Tocilizumab in a COVID-19 patient on maintenance hemodialysis: A case report.
33462575 2021. Mass spectrometry reveals potential of beta-lactams as SARS-CoV-2 M(pro) inhibitors.
33424029 2021. Synthetic strategies for pyrrolo[2,1-f][1,2,4]triazine: the parent moiety of antiviral drug remdesivir.
33519023 2021. Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease.
33518774 2021. Exploring the new potential antiviral constituents of Moringa oliefera for SARS-COV-2 pathogenesis: An in silico molecular docking and dynamic studies.
33518775 2020. Identification of potential inhibitors of SARS-CoV-2 main protease from Aloe vera compounds: A molecular docking study.
33518858 2020. Structure features of peptide-type SARS-CoV main protease inhibitors: Quantitative structure activity relationship study.
33453180 2021. A Reserve System for the Equitable Allocation of a Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine.
33493441 2021. Surfactant for the Treatment of ARDS in a Patient With Coronavirus Disease 2019.
33422222 2021. Zinc and Coronavirus Disease 2019: Causal or Casual Association?
33420601 2021. Chinese Medicine in Fighting against Covid-19: Role and Inspiration.
33489151 2021. Tocilizumab-induced cytomegalovirus colitis in a patient with COVID-19.
33521390 2021. Antivirals for COVID-19: A critical review.
33486146 2021. Unilateral axillary Adenopathy in the setting of COVID-19 vaccine.
33429060 2021. Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to "potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases".
33515458 2021. Absence of vaccine-enhanced disease with unexpected positive protection against SARS-CoV-2 by inactivated vaccine given within three days of virus challenge in Syrian hamster model.
33515255 2021. The Olympiad of SARS-CoV-2 vaccinology: Fundamentals to Complement Technical Frontiers.
33515253 2021. Tocilizumab in COVID-19: Give it time!
33515252 2021. The impact of vaccination on COVID-19 outbreaks in the United States.
33503230 2021. The case against delaying SARS-CoV-2 mRNA vaccine boosting doses.
33503229 2021. Antioxidant therapy in COVID-19: The crucial role of early treatment and antioxidant typology.
33502467 2021. Accelerate COVID-19 Vaccine Rollout by Delaying the Second Dose of mRNA Vaccines.
33493302 2021. Making sense of contradictory evidence in Covid-19 trials.
33402859 2020. Early Experience With Methylprednisolone on SARS-CoV-2 Infection in the African American Population, a Retrospective Analysis.
33476807 2021. Prophylaxis for COVID-19: a systematic review.
33380357 2020. Association between iron status and the risk of adverse outcomes in COVID-19.
33487301 2021. Nutritional status assessment in patients with Covid-19 after discharge from the intensive care unit.
33487263 2021. Anthropometric assessment in ambulatory nutrition amid the COVID-19 pandemic: Possibilities for the remote and in-person care.
33402269 2021. Optimal Timing for COVID-19 Vaccination in Oncology Patients Receiving Chemotherapy?
33501997 2021. Physiologically-Based Pharmacokinetic Modeling of Remdesivir and Its Metabolites to Support Dose Selection for the Treatment of Pediatric Patients With COVID-19.
33406317 2021. Rationale for Effective Prophylaxis Against COVID-19 Through Simultaneous Blockade of Both Endosomal and Non-Endosomal SARS-CoV-2 Entry into Host Cell.
33520676 2021. Spectroscopic investigation on the affinity of SARS-CoV-2 spike protein to gold nano-particles.
33520528 2020. High Dose Steroid Therapy to Prevent Severe Hypoxia in COVID-19 Patients: A Potential Solution for Low Resource Clinical Setting.
33486832 2021. Exacerbation of psoriasis following hydroxychloroquine in a patient with suspected COVID-19.
33406308 2021. Cutaneous manifestations of COVID-19: An unusual presentation with edematous plaques and pruritic, erythematous papules, and comment on the role of bradykinin storm and its therapeutic implications.
33403227 2020. Drug Repurposing for Prevention and Treatment of COVID-19: A Clinical Landscape.
33402882 2020. Effectiveness of Convalescent Plasma Therapy for COVID-19 Patients in Hunan, China.
33496060 2021. Targeting cyclooxygenase enzyme for the adjuvant COVID-19 therapy.
33499310 2021. The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of COVID-19.
33494244 2021. Exercise, Immune System, Nutrition, Respiratory and Cardiovascular Diseases during COVID-19: A Complex Combination.
33451007 2021. Favipiravir in Therapy of Viral Infections.
33447309 2020. COVID-19 and Possible Pharmacological Preventive Options.
33426360 2020. Anti-tumor necrosis factor agents and COVID-19: A word of caution.
33450319 2021. Development of nanoparticle-delivery systems for antiviral agents: A review.
33439960 2021. Critical analysis on the use of cholecalciferol as a COVID-19 intervention: a narrative review.
33424398 2021. In silico evaluation of flavonoids as effective antiviral agents on the spike glycoprotein of SARS-CoV-2.
33424377 2021. Probiotics, prebiotics, and COVID-19 infection: A review article.
33457042 2021. A large-scale transcriptional study reveals inhibition of COVID-19 related cytokine storm by traditional chinese medicines.
33471276 2021. Evaluation of the efficacy and safety of hydroxychloroquine in comparison with chloroquine in moderate and severe patients with COVID-19.
33441564 2021. Ontological modeling and analysis of experimentally or clinically verified drugs against coronavirus infection.
33420186 2021. ABBV-744 as a potential inhibitor of SARS-CoV-2 main protease enzyme against COVID-19.
33483539 2021. First principle simulation of coated hydroxychloroquine on Ag, Au and Pt nanoparticles.
33479401 2021. Catechin and curcumin interact with S protein of SARS-CoV2 and ACE2 of human cell membrane: insights from computational studies.
33479261 2021. Autumn COVID-19 surge dates in Europe correlated to latitudes, not to temperature-humidity, pointing to vitamin D as contributing factor.
33446817 2021. Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages.
33441985 2021. Contact residue contributions to interaction energies between SARS-CoV-1 spike proteins and human ACE2 receptors.
33441909 2021. Corticosteroid treatment has no effect on hospital mortality in COVID-19 patients.
33436985 2021. Antiviral activity of lambda-carrageenan against influenza viruses and severe acute respiratory syndrome coronavirus 2.
33436946 2021. The association of Coronavirus Disease-19 mortality and prior bacille Calmette-Guerin vaccination: a robust ecological analysis using unsupervised machine learning.
33425427 2020. Potential of Plant Bioactive Compounds as SARS-CoV-2 Main Protease (M(pro)) and Spike (S) Glycoprotein Inhibitors: A Molecular Docking Study.
33514688 2021. Constrained surfaces: promising therapeutic targets for COVID-19 determined by systematically mutational analysis.
33423577 2021. A High-Throughput RNA Displacement Assay for Screening SARS-CoV-2 nsp10-nsp16 Complex toward Developing Therapeutics for COVID-19.
33457315 2020. The Many Faces of Covid-19: Organizing Pneumonia (OP) Pattern HRCT Features.
33504502 2021. Covid-19 controversies: the tocilizumab chapter.
33500251 2021. Covid-19: Moderna plans booster doses to counter variants.
33483332 2021. Covid-19: Reports from Israel suggest one dose of Pfizer vaccine could be less effective than expected.
33381648 2020. Letter to the Editor: Possible Drug-Drug Interactions Between Cannabinoids and Candidate COVID-19 Drugs.
33445938 2020. Ročni obdobi, vitamin D a COVID-19.
33386649 2021. Novel quantitative structure-activity relationship model to predict activities of natural products against COVID-19.
33443248 2021. Synthesis and immunological evaluation of synthetic peptide based anti-SARS-CoV-2 vaccine candidates.
33524090 2021. Antiviral drug discovery: preparing for the next pandemic.
33434052 2021. DAMPening Mortality in COVID-19: Therapeutic Insights From Basic Cardiometabolic Studies on S100A8/A9.
33394522 2021. Clinical manifestations and impact on daily life of allergy to polyethylene glycol (PEG) in ten patients.
33480877 2021. Convalescent Plasma: Education and Administration Implications.
33480870 2021. COVID-19 Vaccines: Preparing for Vaccination in the Context of Clinical Oncology Care.
33410139 2021. Nonspecific Binding Considerations in the Rational Design and Development of Small Molecule COVID-19 Therapeutics.
33410134 2021. Mechanistic Modeling of SARS-CoV-2 and Other Infectious Diseases and the Effects of Therapeutics.
33480424 2021. Host cell glutamine metabolism as a potential antiviral target.
33404204 2021. Hybrid physiologically-based pharmacokinetic model for remdesivir: Application to SARS-CoV-2.
33404133 2021. Chloroquine and hydroxychloroquine provoke arrhythmias at concentrations higher than those clinically used to treat COVID-19: A simulation study.
33403775 2021. Compassionate use of ruxolitinib in patients with SARS-Cov-2 infection not on mechanical ventilation: Short-term effects on inflammation and ventilation.
33441063 2021. Deep learning in the quest for compound nomination for fighting COVID-19.
33509001 2021. The nutritional status of the elderly patient infected with COVID-19: the forgotten risk factor?
33504301 2021. Phenylbenzopyrone of flavonoids as a potential scaffold to prevent SARS-CoV-2 replication by inhibiting its MPRO main protease.
33459226 2021. Therapeutic agents against COVID-19 with clinical evidence.
33459225 2021. Natural agents modulating ACE-2: A review of compounds with potential against SARS-CoV-2 infections.
33430748 2021. In silico Prediction and Designing of Potential siRNAs to be Used as Antivirals Against SARS-CoV-2.
33430746 2021. Natural Products, a Potential Therapeutic Modality in Management and Treatment of nCoV-19 Infection: Preclinical and Clinical based Evidence.
33388014 2021. Use of Natural Compounds as a potential therapeutic agent against COVID-19.
33438550 2021. Regenerative Medicine Approaches in COVID -19 Pneumonia.
33463470 2021. An Updated Review on Betacoronavirus Viral Entry Inhibitors: Learning from Past Discoveries to Advance COVID-19 Drug Discovery.
33497492 2021. A finding associated with favipiravir-associated photosensitivity: Yellow-green fluorescence in the lunulae, scalp, and face.
33517789 2021. Study on mechanism of matrine in treatment of COVID-19 combined with liver injury by network pharmacology and molecular docking technology.
33401328 2021. Efficacy and Safety of Tocilizumab for Coronavirus Disease 2019 (Covid-19) Patients: A Systematic Review and Meta-analysis.
33513649 2021. Steroide in der Infektionsmedizin.
33459251 2021. The Role of Nutrition during the COVID-19 Pandemic: What We Know.

33520579 2021. Screening of potent drug inhibitors against SARS-CoV-2 RNA polymerase: an in silico approach.
33500874 2021. Perspective on therapeutic and diagnostic potential of camel nanobodies for coronavirus disease-19 (COVID-19).
33457176 2021. Factual insights of the allosteric inhibition mechanism of SARS-CoV-2 main protease by quercetin: an in silico analysis.
33457172 2021. Designing a next generation multi-epitope based peptide vaccine candidate against SARS-CoV-2 using computational approaches.
33457171 2021. In silico docking analysis revealed the potential of phytochemicals present in Phyllanthus amarus and Andrographis paniculata, used in Ayurveda medicine in inhibiting SARS-CoV-2.
33417425 2021. Early Returns on Small Molecule Therapeutics for SARS-CoV-2.
33479570 2021. Influence of 4'-Substitution on the Activity of Gemcitabine and Its ProTide Against VZV and SARS-CoV-2.
33480671 2021. Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered via Lipid Nanoparticles.
33464829 2021. Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates.
33398250 2020. Structure-Based Virtual Screening and Biochemical Validation to Discover a Potential Inhibitor of the SARS-CoV-2 Main Protease.
33456449 2021. Complexity analysis of cold chain transportation in a vaccine supply chain considering activity inspection and time-delay.
33422546 2021. Advances in gene-based vaccine platforms to address the COVID-19 pandemic.
33421475 2021. Recombinant protein vaccines, a proven approach against coronavirus pandemics.
33400957 2021. Self-assembled mRNA vaccines.
33428995 2021. Nanocarrier vaccines for SARS-CoV-2.
33482248 2021. SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?
33465451 2021. In silico T cell epitope identification for SARS-CoV-2: Progress and perspectives.
33491915 2021. Broad-Spectrum Antiviral Agents Based on Multivalent Inhibitors of Viral Infectivity.
33458958 2021. Next-Generation Vaccines: Nanoparticle-Mediated DNA and mRNA Delivery.
33520645 2021. Vitamin-D and COVID-19: time for the profession to take a stand.
33520646 2020. The potential contribution of traditional, complementary and integrative treatments in acute viral respiratory tract infections: Rapid Reviews in response to the COVID-19 pandemic.
33439972 2021. Western Dietary Pattern Antioxidant Intakes and Oxidative Stress: Importance During the SARS-CoV-2/COVID-19 Pandemic.
33471354 2021. A review of Ciclesonide in COVID-19. Still a long way to go.
33393643 2020. Clinical outcome, viral response and safety profile of chloroquine in COVID-19 patients - initial experience.
33465050 2021. Fighting the storm: could novel anti-TNFalpha and anti-IL-6 C. sativa cultivars tame cytokine storm in COVID-19?
33489449 2020. TaibUVID nutritional supplements help rapid cure of COVID-19 infection and rapid reversion to negative nasopharyngeal swab PCR: for better public prophylaxis and treatment of COVID-19 pandemic.
33415017 2020. Tannic acid suppresses SARS-CoV-2 as a dual inhibitor of the viral main protease and the cellular TMPRSS2 protease.
33417877 2021. Meta-Analysis of the Effect of Aspirin on Mortality in COVID-19.
33489475 2020. Perspectives: potential therapeutic approach with inhalation of ACE2-derived peptides for SARS-CoV-2 infection.
33502950 2021. Soluble ACE2 as a potential therapy for COVID-19.
33404354 2021. Exploring the link between vitamin D and clinical outcomes in COVID-19.
33404365 2021. Remote ischemic conditioning for acute respiratory distress syndrome in COVID-19.
33496642 2020. Potential role for nitazoxanide in treating SARS-CoV-2 infection.
33437355 2020. Role of azithromycin in antiviral treatment: enhancement of interferon-dependent antiviral pathways and mitigation of inflammation may rely on inhibition of the MAPK cascade?
33397585 2021. Mesenchymal stromal cells to fight SARS-CoV-2: Taking advantage of a pleiotropic therapy.
33484986 2021. Potential beneficial role of probiotics on the outcome of COVID-19 patients: An evolving perspective.
33390567 2021. Analytical methods for the determination of remdesivir as a promising antiviral candidate drug for the COVID-19 pandemic.
33385574 2021. Why do we lack a specific magic anti-COVID-19 drug? Analyses and solutions.
33422991 2021. Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice.
33418497 2021. Understanding the pharmacokinetics of Favipiravir: Implications for treatment of influenza and COVID-19.
33495752 2021. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial.
33521339 2021. Multiple sclerosis, B cell therapy, and the COVID-19 vaccine.
33520331 2020. The Scientific Foundation of Chinese Herbal Medicine against COVID-19.
33472816 2021. Is it safe to use remdesivir in combination with a combined p-glycoprotein and CYP3A4 inhibitor?
33520016 2021. COVID-19, prevention and treatment with herbal medicine in the herbal markets of Sale Prefecture, North-Western Morocco.
33520014 2021. Two pronged approach for prevention and therapy of COVID-19 (Sars-CoV-2) by a multi-targeted herbal drug, a component of ayurvedic decoction.
33520015 2020. Analysis of the mechanism of Shufeng Jiedu capsule prevention and treatment for COVID-19 by network pharmacology tools.
33524687 2021. RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic.
33508085 2021. Is COVID-19 lockdown associated with vitamin D deficiency?
33506949 2021. Quinacrine as a potential treatment for COVID-19 virus infection.
33506948 2021. Safety and efficacy of oral lopinavir/ritonavir in pediatric patients with coronavirus disease: a nationwide comparative analysis.
33506946 2021. Remdesivir as a broad-spectrum antiviral drug against COVID-19.
33504238 2021. Tocilizumab for the treatment of COVID-19.
33475441 2021. SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19.
33499687 2021. Clinical course of severe patients with COVID-19 treated with tocilizumab: report from a cohort study in Spain.
33435759 2021. Immunoinformatics-guided designing and in silico analysis of epitope-based polyvalent vaccines against multiple strains of human coronavirus (HCoV).
33435774 2021. COVID-19 vaccine: where are we now and where should we go?
33443475 2021. Remdesivir y reduccion de mortalidad en pacientes con COVID-19: analisis sistematizado de subgrupos de los ensayos clinicos.
33449359 2021. Dynamics and electrostatics define an allosteric druggable site within the receptor-binding domain of SARS-CoV-2 spike protein.
33520970 2020. Perinatal Cells: A Promising COVID-19 Therapy?
33520943 2020. In silico Analysis Revealed Potential Anti-SARS-CoV-2 Main Protease Activity by the Zonulin Inhibitor Larazotide Acetate.
33521056 2020. In vitro Dissolution Profile at Different Biological pH Conditions of Hydroxychloroquine Sulfate Tablets Is Available for the Treatment of COVID-19.
33521032 2020. Predictive Value of Prognostic Nutritional Index on COVID-19 Severity.
33472895 2021. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting.
33462654 2021. Impfempfehlungen der Standigen Impfkommission (STIKO) : Impfungen bei Immundefizienz und Impfung gegen COVID-19.
33482433 2021. Is prognostic nutritional index a predictive marker for estimating all-cause in-hospital mortality in COVID-19 patients with cardiovascular risk factors?
33467131 2021. Can Optimum Solar Radiation Exposure or Supplemented Vitamin D Intake Reduce the Severity of COVID-19 Symptoms?
33524396 2021. Potent mouse monoclonal antibodies that block SARS-CoV-2 infection.
33416020 2021. Searching for potential drugs against SARS-CoV-2 through virtual screening on several molecular targets.
33413032 2021. Identification of potential SARS-CoV-2 M(pro) inhibitors integrating molecular docking and water thermodynamics.
33403946 2021. In silico design of multi-epitope-based peptide vaccine against SARS-CoV-2 using its spike protein.
33509045 2021. Applying high throughput and comprehensive immunoinformatics approaches to design a trivalent subunit vaccine for induction of immune response against emerging human coronaviruses SARS-CoV, MERS-CoV and SARS-CoV-2.
33491579 2021. Molecular basis for the repurposing of histamine H2-receptor antagonist to treat COVID-19.
33491569 2021. RNA dependent RNA polymerase (RdRp) as a drug target for SARS-CoV2.
33427102 2021. ACE2-derived peptides interact with the RBD domain of SARS-CoV-2 spike glycoprotein, disrupting the interaction with the human ACE2 receptor.
33474735 2021. AAMC Discusses Monoclonal Antibody Therapeutics for SARS-CoV-2 Infection.
33511638 2021. Potential COVID-19 Therapeutic Agents and Vaccines: An Evidence-Based Review.
33491508 2021. Scutellaria baicalensis extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease in vitro.
33442304 2021. Experimental Pharmacotherapy for COVID-19: The Latest Advances.
33391636 2020. Extracellular vesicles containing ACE2 efficiently prevent infection by SARS-CoV-2 Spike protein-containing virus.
33458853 2021. Potential health benefits of zinc supplementation for the management of COVID-19 pandemic.
33380377 2020. Vaccine efficacy against COVID-19: A foresight on the host-associated factors.
33519145 2021. Evaluating the potency of Sulawesi propolis compounds as ACE-2 inhibitors through molecular docking for COVID-19 drug discovery preliminary study.
33519144 2021. Probiotic lactobacilli: Can be a remediating supplement for pandemic COVID-19. A review.
33464639 2021. Role of vitamin D in regulating COVID-19 severity-An immunological perspective.
33523654 2021. Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models.
33512007 2021. Vitamin D deficiency is associated with COVID-19 positivity and severity of the disease.
33503267 2021. Oxygen-ozone autohemotherapy against COVID-19 needs to fit highly experienced, customized, and standardized protocols to succeed.
33475170 2021. Zinc treatment of outpatient COVID-19: A retrospective review of 28 consecutive patients.
33475167 2021. Targeting SARS-CoV-2 viral proteases as a therapeutic strategy to treat COVID-19.
33511655 2021. Early remdesivir treatment in COVID-19: Why wait another day?
33448426 2021. Clinical efficacy of Methylprednisolone and the combined use of Lopinavir/Ritonavir with Arbidol in treatment of Coronavirus Disease 2019.
33493301 2021. Available drugs and supplements for rapid deployment for treatment of COVID-19.
33516966 2021. A potential solution to avoid overdose of mixed drugs in the event of Covid-19: Nanomedicine at the heart of the Covid-19 pandemic.
33518856 2021. A computational approach for the screening of potential antiviral compounds against SARS-CoV-2 protease: Ionic liquid vs herbal and natural compounds.
33518854 2021. Charge-transfer chemistry of azithromycin, the antibiotic used worldwide to treat the coronavirus disease (COVID-19). Part II: Complexation with several pi-acceptors (PA, CLA, CHL).
33395259 2021. Antiviral Activity of 7-Substituted 7-Deazapurine Ribonucleosides, Monophosphate Prodrugs, and Triphoshates against Emerging RNA Viruses.
33468299 2021. Vacina para a COVID-19: Da Teoria a Pratica.
33523540 2021. Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series.
33504509 2021. Is sitagliptin effective for the treatment of COVID-19?
33386655 2021. Primary prevention of COVID-19: Advocacy for vaccination from a neurological perspective.
33423554 2021. SARS-CoV-2 protein drug targets landscape: a potential pharmacological insight view for the new drug development.
33400393 2021. Overview of antiviral drug candidates targeting coronaviral 3C-like main proteases.
33448695 2020. Vitamin D to prevent COVID-19: recommendations for the design of clinical trials.
33491580 2021. Immunomodulatory and anti-cytokine therapeutic potential of curcumin and its derivatives for treating COVID-19 - a computational modeling.
33491573 2021. Exploring potential inhibitor of SARS-CoV2 replicase from FDA approved drugs using insilico drug discovery methods.
33459176 2021. Molecular docking and simulation studies of natural compounds of Vitex negundo L. against papain-like protease (PL(pro)) of SARS CoV-2 (coronavirus) to conquer the pandemic situation in the world.
33459174 2021. Withanolides from Withania somnifera as an immunity booster and their therapeutic options against COVID-19.
33433137 2021. Pandemic aspect of dexamethasone: Molecular mechanisms and clinical application.
33504214 2021. A Psoriatic Patient-Based Survey on the Understanding of the Use of Vaccines While on Biologics During the COVID-19 Pandemic.
33507143 2021. Targeting novel structural and functional features of coronavirus protease nsp5 (3CL(pro), M(pro)) in the age of COVID-19.
33386773 2021. SARS-CoV-2 nucleocapsid protein intranasal inoculation induces local and systemic T cell responses in mice.

33426632 2021. COVID-19 vaccination in immunocompromised patients.
33503192 2021. Antiviral activity of Brazilian Green Propolis extract against SARS-CoV-2 (Severe Acute Respiratory Syndrome - Coronavirus 2) infection: case report and review.
33504561 2021. Pregnancy, breastfeeding and the SARS-CoV-2 vaccine: an ethics-based framework for shared decision-making.
33408097 2021. Remdesivir for patients with COVID-19.
33473151 2021. Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents.
33505639 2021. Spontaneous binding of potential COVID-19 drugs (Camostat and Nafamostat) to human serine protease TMPRSS2.
33398234 2021. Computational design of SARS-CoV-2 spike glycoproteins to increase immunogenicity by T cell epitope engineering.
33391634 2021. Exploiting cheminformatic and machine learning to navigate the available chemical space of potential small molecule inhibitors of SARS-CoV-2.
33391633 2021. Computational modelling supports that dengue virus envelope antibodies can bind to SARS-CoV-2 receptor binding sites: Is pre-exposure to dengue virus protective against COVID-19 severity?
33422642 2021. Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials.
33495742 2021. Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: The TACROVID trial protocol.
33397463 2021. Early corticosteroids are associated with lower mortality in critically ill patients with COVID-19: a cohort study.
33490955 2021. Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis.
33437559 2021. Influenza Vaccination Quality Improvement as a Model for COVID-19 Prophylaxis.
33425565 2021. The Flu Vaccination May Have a Protective Effect on the Course of COVID-19 in the Pediatric Population: When Does Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Meet Influenza?
33409034 2020. Treatment Experience With Inhaled Corticosteroids in Combination with Remdesivir and Dexamethasone Among COVID-19 Patients Admitted to a Rural Community Hospital: A Case Series.
33409026 2020. The Role of Vitamin C as Adjuvant Therapy in COVID-19.
33510989 2020. Tocilizumab for COVID-19 Acute Respiratory Distress Syndrome: Outcomes Assessment Using the WHO Ordinal Scale.
33489621 2020. Is There any Additional Benefit of Multiple Doses of Tocilizumab in COVID-19 Patients?
33475900 2021. Hydroxychloroquine and COVID-19: a Rheumatologist's Take on the Lessons Learned.
33409442 2020. COVID-19 and Telenutrition: Remote Consultation in Clinical Nutrition Practice.
33390762 2021. Exogenous pulmonary surfactant: A review focused on adjunctive therapy for severe acute respiratory syndrome coronavirus 2 including SP-A and SP-D as added clinical marker.
33403480 2021. Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor.
33457366 2020. Treatment of Crimean-Congo Haemorrhagic Fever by Favipiravir in a Patient with Novel Coronavirus Co-Infection.
33415491 2021. A novel approach to managing COVID-19 patients; results of lopinavir plus doxycycline cohort.
33439342 2021. A novel approach to managing COVID-19 patients: results of lopinavir plus doxycycline cohort-authors' reply.
33404753 2021. Remdesivir for COVID-19 pneumonia: still undecided, but it might all be about adequate timing.
33452110 2021. A prospective, observational study to evaluate adverse drug reactions in patients with COVID-19 treated with remdesivir or hydroxychloroquine: a preliminary report.
33425074 2021. Network pharmacology-based analysis of Zukamu granules for the treatment of COVID-19.
33423905 2021. Flying higher than politics: The goal of preventive medicine at the time of the COVID-19 pandemic.
33486200 2021. The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2.
33483798 2021. Severe sinus bradycardia associated with Remdesivir in a child with severe SARS-CoV-2 infection.
33464367 2021. Severe sinus bradycardia associated with remdesivir in a child with severe SARS-COV-2 infection-reply.
33428898 2021. Dexamethasone: Therapeutic potential, risks, and future projection during COVID-19 pandemic.
33387467 2021. Unraveling the mechanism of arbidol binding and inhibition of SARS-CoV-2: Insights from atomistic simulations.
33482181 2021. A review of potential suggested drugs for coronavirus disease (COVID-19) treatment.
33497607 2021. Repositioning of histamine H1 receptor antagonist: Doxepin inhibits viropexis of SARS-CoV-2 Spike pseudovirus by blocking ACE2.
33509962 2021. Is high-dose glucocorticoid beneficial in COVID-19?
33511068 2020. Extraordinary Survival Benefits of Severe and Critical Patients with COVID-19 by Immune Modulators: The Outcome of a Clinical Trial in Bangladesh.
33381197 2020. Screening for a Potential Therapeutic Agent from the Herbal Formula in the 4(th) Edition of the Chinese National Guidelines for the Initial-Stage Management of COVID-19 via Molecular Docking.
33500777 2020. Option-based guarantees to accelerate urgent, high-risk vaccines: a new market-shaping approach.
33495727 2021. Polyphenols as promising biologically active substances for preventing SARS-CoV-2: A review with research evidence and underlying mechanisms.
33418408 2021. An in-silico evaluation of different bioactive molecules of tea for their inhibition potency against non structural protein-15 of SARS-CoV-2.
33412235 2021. Promising phytochemicals of traditional Indian herbal steam inhalation therapy to combat COVID-19 - An in silico study.
33435315 2021. Probiotic Effects against Virus Infections: New Weapons for an Old War.
33475983 2021. Does herbal therapy for COVID-19 have implications for forensic practice?
33469529 2020. Nitric Oxide Rele<iframe src="http://www.kidney.de/amapp.php?a=g Hydrogel Nanoparticles Decreases Epithelial Cell Injuries Associated With Airway Reopening.
33426009 2020. Investigating the Potential for Ultraviolet Light to Modulate Morbidity and Mortality From COVID-19: A Narrative Review and Update.
33392268 2020. Thromboinflammation and COVID-19: The Role of Exercise in the Prevention and Treatment.
33469541 2020. Combating COVID-19 With Mesenchymal Stem/Stromal Cell Therapy: Promise and Challenges.
33384971 2020. NOX-Dependent Signaling Dysregulation in Severe COVID-19: Clues to Effective Treatments.
33381464 2020. What Can Cellular Redox, Iron, and Reactive Oxygen Species Suggest About the Mechanisms and Potential Therapy of COVID-19?
33425850 2020. Computational Prediction of Potential Inhibitors of the Main Protease of SARS-CoV-2.
33488592 2020. Rapid GMP-Compliant Expansion of SARS-CoV-2-Specific T Cells From Convalescent Donors for Use as an Allogeneic Cell Therapy for COVID-19.
33424848 2020. COVID-19: Coronavirus Vaccine Development Updates.
33424838 2020. The Artificial-Liver Blood-Purification System Can Effectively Improve Hypercytokinemia for COVID-19.
33408715 2020. Akt-Fas to Quell Aberrant T Cell Differentiation and Apoptosis in Covid-19.
33391285 2020. A Potent SARS-CoV-2 Neutralizing Human Monoclonal Antibody That Reduces Viral Burden and Disease Severity in Syrian Hamsters.
33425942 2020. Humidified Warmed CO2 Treatment Therapy Strategies Can Save Lives With Mitigation and Suppression of SARS-CoV-2 Infection: An Evidence Review.
33415116 2020. The Need for Antiviral Drugs for Pandemic Coronaviruses From a Global Health Perspective.
33490110 2020. Molecular Docking and Molecular Dynamics Aided Virtual Search of OliveNet Directory for Secoiridoids to Combat SARS-CoV-2 Infection and Associated Hyperinflammatory Responses.
33425995 2020. Exploring the Potential of Carbon Dots to Combat COVID-19.
33425994 2020. Molecular Docking Studies on the Anti-viral Effects of Compounds From Kabasura Kudineer on SARS-CoV-2 3CL(pro).
33392263 2020. The Leukotriene Receptor Antagonist Montelukast as a Potential COVID-19 Therapeutic.
33392261 2020. Identification of Potential Inhibitors of 3CL Protease of SARS-CoV-2 From ZINC Database by Molecular Docking-Based Virtual Screening.
33381519 2020. Potential Mechanisms for Traditional Chinese Medicine in Treating Airway Mucus Hypersecretion Associated With Coronavirus Disease 2019.
33505983 2020. Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study.
33385008 2020. Probiotics as a Weapon in the Fight Against COVID-19.
33489899 2020. COVID-19: High-JAKing of the Inflammatory "Flight" by Ruxolitinib to Avoid the Cytokine Storm.
33447586 2020. Complement Inhibition in Severe COVID-19 Acute Respiratory Distress Syndrome.
33442386 2020. Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic.
33424586 2020. Autophagy Modulation in Lymphocytes From COVID-19 Patients: New Therapeutic Target in SARS-COV-2 Infection.
33390999 2020. Commentary: Does Lithium Deserve a Place in the Treatment Against COVID-19? A Preliminary Observational Study in Six Patients, Case Report.
33390994 2020. COVID-19 Disease and Vitamin D: A Mini-Review.
33390974 2020. Hydroxychloroquine as a Chemoprophylactic Agent for COVID-19: A Clinico-Pharmacological Review.
33390967 2020. Repurposing Approved Drugs for Guiding COVID-19 Prophylaxis: A Systematic Review.
33390952 2020. Potential Simultaneous Inhibitors of Angiotensin-Converting Enzyme 2 and Transmembrane Protease, Serine 2.
33390948 2020. The Large Action of Chlorpromazine: Translational and Transdisciplinary Considerations in the Face of COVID-19.
33384605 2020. Current Evidence of Interleukin-6 Signaling Inhibitors in Patients With COVID-19: A Systematic Review and Meta-Analysis.
33505321 2020. Stimulating the Resolution of Inflammation Through Omega-3 Polyunsaturated Fatty Acids in COVID-19: Rationale for the COVID-Omega-F Trial.
33424618 2020. The Effects of Displacing Sedentary Behavior With Two Distinct Patterns of Light Activity on Health Outcomes in Older Adults (Implications for COVID-19 Quarantine).
33490659 2021. Can limonene be a possible candidate for evaluation as an agent or adjuvant against infection, immunity, and inflammation in COVID-19?
33462562 2021. Traditional foods with their constituent's antiviral and immune system modulating properties.
33458435 2021. In silico validation of potent phytochemical orientin as inhibitor of SARS-CoV-2 spike and host cell receptor GRP78 binding.
33421583 2021. Impact of colchicine on mortality in patients with COVID-19: A meta-analysis.
33473017 2021. Chloroquine nasal drops in asymptomatic & mild COVID-19: An exploratory randomized clinical trial.
33448317 2021. Vitamin D, zinc and glutamine: Synergistic action with OncoTherad immunomodulator in interferon signaling and COVID19 (Review).
33491759 2021. Immune-checkpoint inhibitors from cancer to COVID19: A promising avenue for the treatment of patients with COVID19 (Review).
33523564 2021. Emerging COVID-19 vaccines: A rheumatology perspective.
33517559 2021. Adverse drug reactions in SARS-COV-2 hospitalised patients: a case series with a focus on drug-drug interactions-comment.
33521604 2021. Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model.
33388478 2020. mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach.
33524876 2021. COVID-19 convalescent plasma composition and immunological effects in severe patients.
33519133 2021. An Open Clinical Evaluation Of Selected Siddha Regimen In Expediting The Management Of Covid-19 -A Randomized Controlled Study.
33519134 2020. Pathophysiology of COVID-19 and Host centric approaches of Ayurveda.
33518853 2021. Computational study on peptidomimetic inhibitors against SARS-CoV-2 main protease.
33518802 2021. In silico assessment and sonochemical synthesis of 2-alkynyl 3-chloropyrazines as prospective ligands for SARS-CoV-2.
33518801 2021. Molecular docking identification for the efficacy of some zinc complexes with chloroquine and hydroxychloroquine against main protease of COVID-19.
33518803 2021. Inhibitory capacity of chloroquine against SARS-COV-2 by effective binding with angiotensin converting enzyme-2 receptor: An insight from molecular docking and MD-simulation studies.
33493479 2021. Safety and Pharmacokinetic Assessments of a Novel Ivermectin Nasal Spray Formulation in a Pig Model.
33523655 2021. Retrained Generic Antibodies Can Recognize SARS-CoV-2.
33508197 2021. On Drug-Membrane Permeability of Antivirals for SARS-CoV-2.
33439735 2021. Butyrate Regulates COVID-19-Relevant Genes in Gut Epithelial Organoids From Normotensive Rats.
33406943 2021. Statins as an adjunctive therapy for COVID-19: the biological and clinical plausibility.
33390092 2021. The impact of probiotics on interactions within the microbiota-gut-lung triad in COVID-19.
33435749 2021. Dietary supplements, vitamins and minerals as potential interventions against viruses: Perspectives for COVID-19.
33488303 2020. Opportunities for Health Promotion: Highlighting Herbs and Spices to Improve Immune Support and Well-being.
33500022 2021. Molecular Docking of Azithromycin, Ritonavir, Lopinavir, Oseltamivir, Ivermectin and Heparin Interacting with Coronavirus Disease 2019 Main and Severe Acute Respiratory Syndrome Coronavirus-2 3C-Like Proteases.
33510536 2021. COVID-19 Vaccine Development to Vaccination.
33509969 2021. LETTER TO THE EDITOR: ON POTENTIAL USE OF RADIOLABELED ANTIBODIES FOR IMAGING AND TREATMENT OF COVID-19.
33483330 2021. COVID-19 Vaccination: An Overview and Education Tool for Nuclear Medicine Technologists.
33455524 2021. Clinical Consideration of Glucocorticoids in COVID-19.

33447376 2020. Effects of rapid recruitment and dissemination on Covid-19 mortality: the RECOVERY trial.
33447372 2020. Computational screening for potential drug candidates against the SARS-CoV-2 main protease.
33519469 2020. Inhibition of SARS-CoV-2 by Highly Potent Broad-Spectrum Anti-Coronaviral Tylophorine-Based Derivatives.
33519467 2020. 3-Hydroxyphthalic Anhydride-Modified Chicken Ovalbumin as a Potential Candidate Inhibits SARS-CoV-2 Infection by Disrupting the Interaction of Spike Protein With Host ACE2 Receptor.
33519463 2020. TLR9 and COVID-19: A Multidisciplinary Theory of a Multifaceted Therapeutic Target.
33519460 2020. Methylene Blue Inhibits the SARS-CoV-2 Spike-ACE2 Protein-Protein Interaction-a Mechanism that can Contribute to its Antiviral Activity Against COVID-19.
33519449 2020. A Review on Plant Bioactive Compounds and Their Modes of Action Against Coronavirus Infection.
33490124 2020. The Strategy of Boosting the Immune System Under the COVID-19 Pandemic.
33457429 2021. Compounds of Citrus medica and Zingiber officinale for COVID-19 inhibition: in silico evidence for cues from Ayurveda.
33415989 2021. Can natural products stop the SARS-CoV-2 virus? A docking and molecular dynamics study of a natural product database.
33404263 2020. Existing antiviral options against SARS-CoV-2 replication in COVID-19 patients.
33432269 2020. Exploring the effect of ritonavir and TMC-310911 on SARS-CoV-2 and SARS-CoV main proteases: potential from a molecular perspective.
33387518 2021. Tacrolimus: Unlikely Harmful and Perhaps Helpful in Liver Transplant Recipients with COVID-19.
33484690 2021. Reply: The New Foe and Old Friends: Are We Ready for Microbiota-based Therapeutics in Treating COVID-19 Patients?
33453230 2021. Reply.
33388317 2020. Letter to the editor: Famotidine and mortality in COVID-19.
33387529 2020. Famotidine and COVID-19.
33487665 2021. COVID-19 Treatment: Drug Safety Prior to Conception and During Pregnancy and Breastfeeding.
33428154 2021. Screening druggable targets and predicting therapeutic drugs for COVID-19 via integrated bioinformatics analysis.
33413610 2021. An integrated in silico immuno-genetic analytical platform provides insights into COVID-19 serological and vaccine targets.
33482326 2021. Transcriptome network analyses in human coronavirus infections suggest a rational use of immunomodulatory drugs for COVID-19 therapy.
33412759 2020. Druggability for COVID-19: in silico discovery of potential drug compounds against nucleocapsid (N) protein of SARS-CoV-2.
33432441 2021. PI3K/AKT signaling pathway: a possible target for adjuvant therapy in COVID-19.
33386081 2021. Network machine learning maps phytochemically rich "Hyperfoods" to fight COVID-19.
33426490 2021. Editorial Comment to Successful recovery from coronavirus disease 2019 in a living kidney transplant recipient using low-dose methylprednisolone.
33465283 2021. Efficacy of canakinumab in mild or severe COVID-19 pneumonia.
33418320 2021. BCG immunomodulation: From the 'hygiene hypothesis' to COVID-19.
33492637 2021. A review of COVID-19 convalescent plasma use in COVID-19 with focus on proof of efficacy.
33397150 2021. An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases.
33432283 2021. Evaluation of certain medicinal plants compounds as new potential inhibitors of novel corona virus (COVID-19) using molecular docking analysis.
33425648 2021. In silico investigation of saponins and tannins as potential inhibitors of SARS-CoV-2 main protease (M(pro)).
33425647 2021. Designing a conserved peptide-based subunit vaccine against SARS-CoV-2 using immunoinformatics approach.
33437070 2020. Hyperbaric oxygen therapy: Can it be a novel supportive therapy in COVID-19?
33495676 2021. COVID-19 and Gut Microbiota: A Potential Connection.
33384519 2020. Evaluating the Efficacy and Safety of the Existing Repurposed Pharmacological Agents for Treating COVID-19: A Meta-analysis and Systematic Review of Clinical Trials.
33384506 2020. A Retrospective Observational Study of Hypoxic COVID-19 Patients Treated with Immunomodulatory Drugs in a Tertiary Care Hospital.
33384504 2020. Immunomodulation and COVID-19: Is There a Winning Combination?
33446983 2020. Intravenous Immunoglobulin may Reverse Multisystem Inflammation in COVID-19 Pneumonitis and Guillain-Barre Syndrome.
33424043 2021. Restoring Good Health in Elderly with Diverse Gut Microbiome and Food Intake Restriction to Combat COVID-19.
33390627 2020. Recent Clinical Trials on Natural Products and Traditional Chinese Medicine Combating the COVID-19.
33469896 2021. BCG Vaccination Protection Against COVID-19: Correspondence.
33484407 2021. The Efficacy and Safety of Hydroxychloroquine in Patients with COVID-19: A Multicenter National Retrospective Cohort.
33500636 2021. Review on Up-to-Date Status of Candidate Vaccines for COVID-19 Disease.
33422682 2021. Identification of SARS-CoV-2 CTL epitopes for development of a multivalent subunit vaccine for COVID-19.
33495884 2021. Worldwide inverse correlation between Bacille Calmette-Guerin (BCG) immunization and COVID-19 mortality.
33389708 2021. Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence.
33521241 2021. Manipulated bio antimicrobial peptides from probiotic bacteria as proposed drugs for COVID-19 disease.
33457495 2021. In silico exploration of novel protease inhibitors against coronavirus 2019 (COVID-19).
33521757 2021. Structural Basis of SARS-CoV-2 Polymerase Inhibition by Favipiravir.
33524979 2021. Principles and Challenges in anti-COVID-19 Vaccine Development.
33476982 2021. Ozone therapy for the treatment of COVID-19 pneumonia: A scoping review.
33450596 2021. Different characteristics of critical COVID-19 and thinking of treatment strategies in non-elderly and elderly severe adult patients.
33429331 2021. The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies.
33418248 2021. Could cilostazol be beneficial in COVID-19 treatment? Thinking about phosphodiesterase-3 as a therapeutic target.
33412395 2021. Combination therapy of IFNbeta1 with lopinavir-ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients.
33421928 2021. Safety and efficacy of ozone therapy in mild to moderate COVID-19 patients: A phase 1/11 randomized control trial (SEOT study).
33515687 2021. Chloroquine for treatment of COVID-19 results in subtherapeutic exposure and prolonged QTc intervals.
33476734 2021. Reply to the letter to the editor "Azithromycin, treatment in COVID-19".
33476733 2021. Azithromycin, a questionable treatment for COVID-19.
33400975 2021. Passive immunization and its rebirth in the era of the COVID-19 pandemic.
33408033 2021. Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19.
33408032 2021. Advanced statistical methods and designs for clinical trials for COVID-19.
33408031 2021. Response to the use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.
33408029 2021. Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes.
33408028 2021. Response to advances statistical methods and designs for clinical trials for COVID-19.
33408027 2021. Response to effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.
33408026 2021. Uncertain effects of hydroxychloroquine and azithromycin on SARS-Cov-2 viral load.
33408025 2021. Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients.
33408024 2021. Letter to the editor about "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".
33408022 2021. Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial.
33408021 2021. Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".
33408020 2021. Use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.
33408019 2021. Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.
33408018 2021. Doxycycline as an Alternative to Azithromycin in Elderly Patients.
33408017 2021. Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.
33405321 2021. Efficacy and safety of OM-85 in paediatric recurrent respiratory tract infections which could have a possible protective effect on COVID-19 pandemic: A meta-analysis.
33417696 2021. Temporal Analysis of Serial Donations Reveals Decrease in Neutralizing Capacity and Justifies Revised Qualifying Criteria for Coronavirus Disease 2019 Convalescent Plasma.
33411937 2021. Coronavirus Disease 2019 Convalescent Plasma and the Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer.
33433587 2021. Nature and dimensions of the systemic hyper-inflammation and its attenuation by convalescent plasma in severe COVID-19.
33511686 2021. Tocilizumab in COVID-19 interstitial pneumonia.
33520685 2021. Mushroom-derived bioactive compounds potentially serve as the inhibitors of SARS-CoV-2 main protease: An in silico approach.
33520684 2021. Analyzing the potential therapeutic mechanism of Huashi Baidu Decoction on severe COVID-19 through integrating network pharmacological methods.
33520683 2021. Anti-COVID-19 drug candidates: A review on potential biological activities of natural products in the management of new coronavirus infection.
33520682 2021. Molecular docking analysis of rutin reveals possible inhibition of SARS-CoV-2 vital proteins.
33521616 2021. Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab.
33480414 2021. From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?
33516648 2021. Role of Famotidine and Other Acid Reflux Medications for SARS-CoV-2: A Pilot Study.
33521397 2021. Integrating Integrins: A New Way to Increase Our COVID-19 Armamentarium?
33518628 2021. Inactivation of SARS-CoV-2 by Catechins from Green Tea.
33518623 2021. Nasopharyngeal SARS-CoV-2 Viral Load Response among COVID-19 Patients Receiving Favipiravir.
33524312 2021. Next-generation COVID-19 vaccines: here come the proteins.
33524311 2021. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.
33521772 2021. Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis.
33521771 2021. Metformin: an inexpensive and effective treatment in people with diabetes and COVID-19?
33521768 2020. Tackling immunosenescence to improve COVID-19 outcomes and vaccine response in older adults.
33521732 2021. COVID-19 vaccines: the pandemic will not end overnight.
33463480 2021. The Role of Justicia Adhatoda as prophylaxis for COVID-19 - Analysis based on docking study.
33493866 2021. Ergosterol peroxide exhibits antiviral and immunomodulatory abilities against porcine deltacoronavirus (PDCoV) via suppression of NF-kappaB and p38/MAPK signaling pathways in vitro.
33414160 2021. Insight into vaccine development for Alpha-coronaviruses based on structural and immunological analyses of spike proteins.
33414159 2021. COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice.
33468542 2021. The time for COVID-19 vaccination.
33441348 2021. Non-steroidal anti-inflammatory drugs dampen the cytokine and antibody response to SARS-CoV-2 infection.
33507218 2021. SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants.
33404587 2021. Sorting Out Whether Vitamin D Deficiency Raises COVID-19 Risk.
33464336 2021. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial.
33404585 2021. Problems With Paying People to Be Vaccinated Against COVID-19.
33475702 2021. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine.
33475716 2021. Neutralizing Monoclonal Antibody for Mild to Moderate COVID-19.
33475701 2021. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
33512398 2021. Can We Protect Pregnant Women and Young Infants From COVID-19 Through Maternal Immunization?
33515791 2021. Hydroxychloroquine in systemic and autoimmune diseases: Where are we now?
33444566 2021. Vitamin D and COVID-19: why the controversy?

33392487 2021. Cyclosporine A and COVID19 - The COQUIMA cohort - Author's reply.
33392485 2021. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial.
33385129 2021. Cyclosporine A and COVID-19 - The COQUIMA cohort.
33385128 2021. Cyclosporine A and COVID19 - The COQUIMA cohort.
33385124 2021. Prioritizing incarcerated populations for COVID-19 vaccination and vaccine trials.
33471720 2020. Considerations for Gut Microbiota and Probiotics in Patients with Diabetes Amidst the Covid-19 Pandemic: A Narrative Review.
33380209 2020. Vitamin D Status and COVID-19 Clinical Outcomes in Hospitalized Patients.
33452994 2021. Patients hospitalized with COVID-19 have low levels of 25-hydroxyvitamin D.
33413989 2020. Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: Prospective, non-randomized trial.
33401173 2021. A novel screening strategy of anti-SARS-CoV-2 drugs via blocking interaction between Spike RBD and ACE2.
33387537 2021. Urinary trace elements in association with disease severity and outcome in patients with COVID-19.
33447984 2021. Hydroxychloroquine in COVID-19: therapeutic promises, current status, and environmental implications.
33427370 2021. A systematic review of experimental evidence for antiviral effects of ivermectin and an in silico analysis of ivermectin's possible mode of action against SARS-CoV-2.
33520339 2020. Lifestyle factors in the prevention of COVID-19.
33387629 2021. Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine.
33408016 2021. Can we use hydroxychloroquine to treat COVID-19 now?
33408015 2021. Response to uncertain effect of hydroxychloroquine and azithromycin on SARS-CoV-2 viral load.
33408014 2021. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited.
33515771 2021. Efficacy of ribavirin and interferon-alpha therapy for hospitalized patients with COVID-19: A multicenter, retrospective cohort study.
33493690 2021. A short discussion about the SARS-CoV-2 mRNA-1273 vaccine.
33476760 2021. Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19.
33401034 2021. Low vitamin D status is associated with coronavirus disease 2019 outcomes: a systematic review and meta-analysis.
33385581 2021. Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study.
33434674 2021. Efficacy evaluation of intravenous immunoglobulin in non-severe patients with COVID-19: A retrospective cohort study based on propensity score matching.
33437199 2021. Clinical characteristics and impacts of traditional Chinese medicine treatment on the convalescents of COVID-19.
33390810 2021. DCs-based therapies: potential strategies in severe SARS-CoV-2 infection.
33390800 2021. Perspective Adjunctive Therapies for COVID-19: Beyond Antiviral Therapy.
33416113 2021. Unraveling the roles of vitamin D status and melanin during Covid19 (Review).
33498909 2021. Membrane Microvesicles as Potential Vaccine Candidates.
33488318 2021. Could Dermaseptin Analogue be a Competitive Inhibitor for ACE2 Towards Binding with Viral Spike Protein Causing COVID19?: Computational Investigation.
33427662 2020. Immunomodulatory Low-Dose Whole-Lung Radiation for Patients with COVID-19-Related Pneumonia.
33460304 2020. Your help is needed in the fight against COVID-19: Please contribute to the COVID-19 Global Rheumatology Alliance Registry.
33487035 2021. The coronavirus disease (COVID-19) - A supportive approach with selected micronutrients.
33425283 2021. Ayurvedic metal nanoparticles could be novel antiviral agents against SARS-CoV-2.
33488306 2020. The Long Haul of COVID-19 Recovery: Immune Rejuvenation versus Immune Support.
33507321 2021. The ten reasons why corticosteroid therapy reduces mortality in severe COVID-19. Author's reply.
33388793 2021. Ten reasons why corticosteroid therapy reduces mortality in severe COVID-19.
33398609 2021. COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs.
33400161 2021. The need for a correct oxygen-ozone autohemotherapy (O3-AHT) in patients with mild to moderate COVID-19 pneumonia.
33400157 2021. Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study.
33390490 2021. Immediate Amelioration of Severe Respiratory Distress in Sjogren's Syndrome with COVID-19 Treated with a Single Dose of Off-label Tocilizumab.
33409846 2021. Active vitamin D supplementation and COVID-19 infections: review.
33409844 2021. Step zero: optimising nutrition for physical and mental health wellbeing during COVID-19.
33433843 2021. Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks?
33490902 2021. High-throughput rational design of the remdesivir binding site in the RdRp of SARS-CoV-2: implications for potential resistance.
33426509 2021. A multi-pronged approach targeting SARS-CoV-2 proteins using ultra-large virtual screening.
33443334 2021. Convalescent Whole Blood Donors Screening Strategies for Providing Efficient and Safe COVID-19 Survivors' Plasma and Other Blood Components.
33425697 2020. The coronavirus disease 2019 main protease inhibitor from Andrographis paniculata (Burm. f) Ness.
33485650 2021. mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis.
33482251 2021. An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology.
33440213 2021. Chronic hydroxychloroquine therapy and COVID-19 outcomes: A retrospective case-control analysis.
33492492 2021. Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus.
33524316 2021. SARS-CoV-2 evolution and vaccines: cause for concern?
33521656 2021. Divergent effects of acute versus chronic glucocorticoids in COVID-19.
33521667 2021. Hydroxychloroquine in the prevention of COVID-19 mortality.
33521676 2021. Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19 - Authors' reply.
33521675 2021. Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19.
33521674 2021. Efficacy matters: broadening complement inhibition in COVID-19.
33521673 2021. Efficacy matters: broadening complement inhibition in COVID-19 - Authors' reply.
33521663 2020. Mavrilimumab for severe COVID-19 - Authors' reply.
33521662 2020. Mavrilimumab for severe COVID-19.
33521661 2020. Mavrilimumab for severe COVID-19.
33521660 2020. Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment.
33521666 2020. GM-CSF in the treatment of COVID-19: a new conductor in the pathogenesis of cytokine storm?
33491234 2021. A Narrative Review of Pharmacologic Treatments for COVID-19: Safety Considerations and Ototoxicity.
33459118 2021. Antibodies to watch in 2021.
33520672 2021. FDA Recommended Potent Drugs against Covid-19: Insight through Molecular Docking.
33521747 2021. A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice.
33521295 2021. Unresolved questions about the treatment of COVID-19 with corticosteroids.
33521297 2020. Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection.
33521304 2020. Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience.
33521302 2020. Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia.
33521623 2021. AI drug discovery screening for COVID-19 reveals zafirlukast as a repurposing candidate.
33520634 2021. Tocilizumab administration in COVID-19 patients: Water on the fire or gasoline?
33460213 2021. What coronavirus 3C-like protease tells us: From structure, substrate selectivity, to inhibitor design.
33519030 2020. Nutricion y pandemia de la COVID-19.
33524563 2021. Inhibitory efficiency of potential drugs against SARS-CoV-2 by blocking human angiotensin converting enzyme-2: Virtual screening and molecular dynamics study.
33520405 2021. Small interfering RNA: a tailored approach to explore the therapeutic potential in COVID-19.
33523609 2021. Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19.
33509749 2021. [Mechanism and material basis of Lianhua Qingwen capsule for improving clinical cure rate of COVID-19: a study based on network pharmacology and molecular docking technology].
33497482 2021. Germicidal UV Sources and Systems(dagger).
33438214 2021. Bare-bulb Upper-Room Germicidal Ultraviolet-C (GUV) Indoor Air Disinfection for COVID-19(dagger).
33511704 2021. Spices and herbs: Potential antiviral preventives and immunity boosters during COVID-19.
33452734 2021. Exploring the treatment of COVID-19 with Yinqiao powder based on network pharmacology.
33448101 2021. In silico and in vitro evaluation of kaempferol as a potential inhibitor of the SARS-CoV-2 main protease (3CLpro).
33524017 2021. A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease.
33524041 2021. Metabolomic/lipidomic profiling of COVID-19 and individual response to tocilizumab.
33427193 2021. Nutritional knowledge, attitude and behaviours regarding Coronavirus Disease 2019 among residents of Gonabad, Iran.
33416888 2021. Rapid recovery of taste and smell in a patient with SARS-CoV-2 following convalescent plasma therapy.
33482671 2021. Allergische Reaktionen auf COVID-19-Impfungen - Was HNO-Arzte wissen sollten - Teil 1: Allgemeine Aspekte von Allergien auf Impfstoffe, immunologische Grundlagen von Allergien auf Impfstoffe, Immunmechanismen von allergischen und pseudoallergischen Reaktionen, Teil 2: Charakteristiken der mRNA-Impfstoffe BNT162b2 und mRNA-1273 zur Prophylaxe von COVID-19 und assoziierte Immunphanomene, Teil 3: Praktische Aspekte der Prophylaxe, Diagnostik und Therapie von Allergien auf COVID-19-Impfstoffe.
33524996 2021. Allergische Reaktionen auf COVID-19-Impfungen - Was HNO-Arzte wissen sollten - Teil 1: Allgemeine Aspekte von Allergien auf Impfstoffe, immunologische Grundlagen von Allergien auf Impfstoffe, Immunmechanismen von allergischen und pseudoallergischen Reaktionen; Teil 2: Charakteristiken der mRNA-Impfstoffe BNT162b2 und mRNA-1273 zur Prophylaxe von COVID-19, weitere Impfstoff-Kandidaten und assoziierte Immunphanomene; Teil 3: Praktische Aspekte der Prophylaxe, Diagnostik und Therapie von Allergien auf COVID-19-Impfstoffe.
33429407 2020. Timing of remdesivir for COVID-19.
33443491 2020. Remdesivir (Veklury) for COVID-19.
33443490 2020. An EUA for bamlanivimab - a monoclonal antibody for COVID-19.
33451175 2020. An EUA for baricitinib (Olumiant) for COVID-19.
33451174 2020. An EUA for casirivimab and imdevimab for COVID-19.
33393116 2021. Therapeutic targets and potential agents for the treatment of COVID-19.
33382060 2020. Terapias celulares para el COVID-19: Una revision sistematica viva.
33397236 2021. A mini review on emerging targets and Approaches for the synthesis of Anti-Viral compounds: In perspective to COVID-19.
33405340 2021. QSAR Modeling of SARS-CoV M(pro) Inhibitors Identifies Sufugolix, Cenicriviroc, Proglumetacin, and other Drugs as Candidates for Repurposing against SARS-CoV-2.
33513050 2021. How IvIg Can Mitigate Covid-19 Disease: A Symmetrical Immune Network Model.
33400280 2020. Standardized 25-Hydroxyvitamin D Measurements in Parkinson's Disease Patients With COVID-19.
33400277 2020. Reply to: Standardized 25-Hydroxyvitamin D Measurements in Parkinson's Disease Patients With COVID-19.
33432224 2021. Hunt for improved monoclonals against coronavirus gathers pace.
33432247 2021. A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent.
33494096 2021. Global absence and targeting of protective immune states in severe COVID-19.
33514888 2021. How to redesign COVID vaccines so they protect against variants.
33510489 2021. Novavax offers first evidence that COVID vaccines protect people against variants.
33471372 2021. Extreme Exposure to Filtered Far-UVC: A Case Study.
33389761 2021. Oral nano-curcumin formulation efficacy in management of mild to moderate hospitalized coronavirus disease-19 patients: An open label nonrandomized clinical trial.
33507610 2021. Phytotherapeutic options for the treatment of COVID-19: A concise viewpoint.
33452160 2021. Vitamin D and COVID-19: causal factor or bystander?

33434117 2021. Vitamin D Deficiency and Low Serum Calcium as Predictors of Poor Prognosis in Patients with Severe COVID-19.
33487918 2020. Convalescent plasma therapy in COVID 19: Every dark cloud has a silver lining.
33413968 2021. 'BhAVI-23'-A spice-herb based dietary infusion possessing in-vitro anti-viral potential.
33491541 2021. Drivers of Infectious Disease Seasonality: Potential Implications for COVID-19.
33495424 2020. The prognosis and short-term efficacy of corticosteroid therapy for COVID-19 patients.
33397223 2021. Virtual screening of curcumin and its analogs against the spike surface glycoprotein of SARS-CoV-2 and SARS-CoV.
33397209 2021. Molecular mechanism of inhibition of COVID-19 main protease by beta-adrenoceptor agonists and adenosine deaminase inhibitors using in silico methods.
33478342 2021. In silico evaluation of lapachol derivatives binding to the Nsp9 of SARS-CoV-2.
33475021 2021. In silico study indicates antimalarials as direct inhibitors of SARS-CoV-2-RNA dependent RNA polymerase.
33459192 2021. An in silico analysis of Ibuprofen enantiomers in high concentrations of sodium chloride with SARS-CoV-2 main protease.
33459182 2021. Identification of 1,2,3-triazole-phthalimide derivatives as potential drugs against COVID-19: a virtual screening, docking and molecular dynamic study.
33446077 2021. Prospecting for Cressa cretica to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2.
33446058 2021. Bacillus species; a potential source of anti-SARS-CoV-2 main protease inhibitors.
33438525 2021. Enfuvirtide, an HIV-1 fusion inhibitor peptide, can act as a potent SARS-CoV-2 fusion inhibitor: an in silico drug repurposing study.
33427588 2021. Predictive medicinal metabolites from Momordica dioica against comorbidity related proteins of SARS-CoV-2 infections.
33382023 2020. Fisetin 8-C-glucoside as entry inhibitor in SARS CoV-2 infection: molecular modelling study.
33382021 2020. Virtual repurposing of ursodeoxycholate and chenodeoxycholate as lead candidates against SARS-Cov2-Envelope protein: A molecular dynamics investigation.
33423911 2021. Successful Management of COVID-19 With Adalimumab in a Post-Coronary Artery Bypass Graft Surgery Patient.
33426541 2020. Potentials of Interferons and Hydroxychloroquine for the Prophylaxis and Early Treatment of COVID-19.
33468620 2021. Ipomoeassin-F inhibits the in vitro biogenesis of the SARS-CoV-2 spike protein and its host cell membrane receptor.
33474624 2021. C1 Esterase Inhibition: Targeting Multiple Systems in COVID-19.
33458752 2020. Relationship Between Dietary Variety and Frailty in Older Japanese Women During the Period of Restriction on Outings Due to COVID-19.
33476835 2021. Convalescent plasma: Alternative or promising therapy?
33460844 2021. Hydroxychloroquine serum concentrations in non-critical care patients infected with SARS-CoV-2.
33385588 2021. Antiviral activity of interferon-based combination therapy in critically ill patients with COVID-19: Preliminary observations.
33441177 2021. Observations on the use of Bruton's tyrosine kinase inhibitors in SAR-CoV-2 and cancer.
33426096 2020. Cellular and Molecular Immunology Approaches for the Development of Immunotherapies against the New Coronavirus (SARS-CoV-2): Challenges to Near-Future Breakthroughs.
33402301 2021. Suspected cholestatic liver injury induced by favipiravir in a patient with COVID-19.
33493919 2021. Identification of potential SARS-CoV-2 entry inhibitors by targeting the interface region between the spike RBD and human ACE2.
33493917 2021. The growing complexity of COVID-19 drug and vaccine candidates: challenges and critical transitions.
33486372 2021. Bioinformatics prediction of B and T cell epitopes within the spike and nucleocapsid proteins of SARS-CoV2.
33509217 2021. Anti-inflammatory potential of Quercetin in COVID-19 treatment.
33447071 2021. Understanding COVID-19 Pandemic: Molecular Mechanisms and Potential Therapeutic Strategies. An Evidence-Based Review.
33414643 2020. Calcio-Herbal Medicine Divya-Swasari-Vati Ameliorates SARS-CoV-2 Spike Protein-Induced Pathological Features and Inflammation in Humanized Zebrafish Model by Moderating IL-6 and TNF-alpha Cytokines.
33433387 2021. Excipients as Potential Agents of Anaphylaxis in Vaccines: Analyzing the Formulations of Currently Authorized COVID-19 Vaccines.
33393485 2021. The Century of mRNA Vaccines: COVID-19 Vaccines and Allergy.
33432258 2021. Quantum chemical studies on molecular structure, AIM, ELF, RDG and antiviral activities of hybrid hydroxychloroquine in the treatment of COVID-19: Molecular docking and DFT calculations.
33390681 2021. Computational investigations of three main drugs and their comparison with synthesized compounds as potent inhibitors of SARS-CoV-2 main protease (M(pro)): DFT, QSAR, molecular docking, and in silico toxicity analysis.
33463095 2021. The Impact of the Coronavirus Disease-2019 Pandemic on Childhood Obesity and Vitamin D Status.
33425294 2020. Computational Biology Analysis of COVID-19 Receptor-Binding Domains: A Target Site for Indocyanine Green Through Antimicrobial Photodynamic Therapy.
33425284 2020. Application of Laser Blue Light With a Wavelength of 405 nm in the Treatment of Patients With the Virus COVID-19.
33500211 2021. Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?
33390633 2021. Charge-transfer chemistry of azithromycin, the antibiotic used worldwide to treat the coronavirus disease (COVID-19). Part I: Complexation with iodine in different solvents.
33390634 2021. Excited-state electronic properties, structural studies, noncovalent interactions, and inhibition of the novel severe acute respiratory syndrome coronavirus 2 proteins in Ripretinib by first-principle simulations.
33500591 2021. Probing CAS database as prospective antiviral agents against SARS-CoV-2 main protease.
33390613 2021. Synthesis of novel indolo[3,2-c]isoquinoline derivatives bearing pyrimidine, piperazine rings and their biological evaluation and docking studies against COVID-19 virus main protease.
33424034 2021. Pyrrolo[2,3-b]quinoxalines in attenuating cytokine storm in COVID-19: their sonochemical synthesis and in silico / in vitro assessment.
33457350 2020. Waiting for Godot: A cross sectional survey based analysis of the hydroxychloroquine prophylaxis strategy against COVID-19 in India.
33493945 2021. Inositol and vitamin D may naturally protect human reproduction and women undergoing assisted reproduction from Covid-19 risk.
33437230 2021. In-silico analysis of the inhibition of the SARS-CoV-2 main protease by some active compounds from selected African plants.
33443088 2021. Identification of SARS-CoV-2 Nucleocapsid and Spike T-Cell Epitopes for Assessing T-Cell Immunity.
33497729 2021. Antiviral activity of bioactive phytocompounds against coronavirus: An update.
33417058 2021. A case of shock after 10 days systemic corticosteroid therapy for COVID-19.
33478708 2021. Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19.
33427208 2021. Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022.
33476300 2021. Treatment of severe COVID-19 with convalescent plasma in Bronx, NYC.
33520251 2021. Chloroquine and COVID-19: role as a bitter taste receptor agonist?
33518950 2020. Can vitamin D offer protection against the coronavirus?
33494567 2021. Vitamin D in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients with non-invasive ventilation support.
33520633 2021. In-silico drug repurposing study: Amprenavir, enalaprilat, and plerixafor, potential drugs for destabilizing the SARS-CoV-2 S-protein-angiotensin-converting enzyme 2 complex.
33520632 2021. Biflavonoid as potential 3-chymotrypsin-like protease (3CLpro) inhibitor of SARS-Coronavirus.
33518780 2021. inverted question markEs la nutricion el factor de riesgo olvidado en la infeccion por COVID-19?
33519022 2021. Principales desafios del desequilibrio electrolitico en pacientes geriatricos con COVID-19 y riesgo de prolongacion del intervalo QT.
33382930 2020. Mega doses of retinol: A possible immunomodulation in Covid-19 illness in resource-limited settings.
33515320 2021. SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis.
33502499 2021. Baricitinib set to join the Covid-19 therapeutic arsenal?
33519274 2021. Fighting against the second wave of COVID-19: Can honeybee products help protect against the pandemic?
33519272 2021. In-silico network-based analysis of drugs used against COVID-19: Human well-being study.
33519276 2021. In silico prediction and experimental validation of siRNAs targeting ORF1ab of MERS-CoV in Vero cell line.
33519275 2021. Potential bangle (Zingiber montanum J.Konig) rhizome extract as a supplement to prevent and reduce symptoms of Covid-19.
33519339 2021. Safety and Efficacy of Convalescent Plasma for Severe COVID-19: Interim Report of a Multicenter Phase II Study from Saudi Arabia.
33519336 2021. Convalescent Plasma in COVID-19: To what Degree should Clinicians Rely on Currently Available Data?
33397677 2021. Stereotypic neutralizing VH antibodies against SARS-CoV-2 spike protein receptor binding domain in patients with COVID-19 and healthy individuals.
33514629 2021. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera.
33495306 2021. Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.
33495308 2021. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19.
33495307 2021. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody.
33436526 2021. Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape.
33436524 2021. Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice.
33516820 2021. Edible plant-derived exosomal microRNAs: Exploiting a cross-kingdom regulatory mechanism for targeting SARS-CoV-2.
33483756 2021. Cardiotoxic Potential of Hydroxychloroquine, Chloroquine and Azithromycin in Adult Human Primary Cardiomyocytes.
33518427 2021. COVID-19 neutralizing antibody-based therapies in humoral immune deficiencies: A narrative review.
33518428 2021. WITHDRAWN: New Generation of vaccines and convalescent plasma therapy for management of CoV-2: Perspectives from the UK and potential deployment in the current global pandemic.
33458811 2021. COVID-19 convalescent plasma donor characteristics, product disposition, and comparison with standard apheresis donors.
33448402 2021. Neutralizing activity to SARS-CoV-2 of convalescent and control plasma used in a randomized controlled trial.
33521322 2021. Statins in patients with COVID-19: a retrospective cohort study in Iranian COVID-19 patients.
33523551 2021. Clinical course of severe COVID19 treated with tocilizumab and antivirals post-allogeneic stem cell transplant with extensive chronic GVHD.
33519087 2021. Review article: Probiotics, prebiotics and dietary approaches during COVID-19 pandemic.
33519086 2020. Food policy, nutrition and nutraceuticals in the prevention and management of COVID-19: Advice for healthcare professionals.
33522946 2021. High-dose vitamin D versus placebo to prevent complications in COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial (CARED-TRIAL).
33516600 2021. Recombinant SARS-CoV-2 RBD with a built in T helper epitope induces strong neutralization antibody response.
33524990 2021. BNT162b vaccines protect rhesus macaques from SARS-CoV-2.
33481519 2021. Corticosteroids in the Management of Pregnant Patients With Coronavirus Disease (COVID-19).
33481518 2021. Corticosteroids in the Management of Pregnant Patients With Coronavirus Disease (COVID-19).
33411888 2021. Monte Carlo Simulation of SARS-CoV-2 Radiation-Induced Inactivation for Vaccine Development.
33401979 2021. Using in silico modelling and FRET-based assays in the discovery of novel FDA-approved drugs as inhibitors of MERS-CoV helicase.
33423931 2021. Copper in infectious disease: Using both sides of the penny.
33482680 2021. Protective Effects of Statins Administration in European and North American Patients Infected with COVID-19: A Meta-analysis.
33443365 2021. H2S As A Therapeutic Adjuvant Against COVID-19: Why and How?
33448169 2020. [Mechanism and intervention of mucosal immune regulation based on "lung and large intestine being interior-exteriorly related" theory of traditional Chinese medicine].
33415866 2020. [Effect of moxibustion on clinical symptoms, peripheral inflammatory indexes and T lymphocyte subsets in COVID-19 patients].
33496147 2020. [Potential therapies for COVID-19 cardiovascular complications using artemisinin and its derivatives intervene based on its cardiovascular protection].
33463485 2020. [Effectiveness of convalescent plasma for treatment of coronavirus disease 2019 patients].
33623472 2021. Corona-Cov-2 (COVID-19) and ginseng: Comparison of possible use in COVID-19 and influenza.
33657907 2021. A cross-sectional study of physical activity behaviour and associations with wellbeing during the UK coronavirus lockdown.
33640005 2021. COVID-19 vaccines for patients with cancer: benefits likely outweigh risks.
33563499 2021. EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients.
33816085 2021. Appropriate use of essential oils and their components in the management of upper respiratory tract symptoms in patients with COVID-19.
33774141 2021. Rapid decrease of SARS-CoV-2 circulation in a large Italian hospital six weeks after the start of the immunization program.
33547169 2021. IL-1 Receptor Antagonist Anakinra in the Treatment of COVID-19 Acute Respiratory Distress Syndrome: A Retrospective, Observational Study.
33763494 2021. Hydroxychloroquine Effects on TLR Signalling: Underexposed but Unneglectable in COVID-19.
33745918 2021. IL-6 inhibition in the treatment of COVID-19: A meta-analysis and meta-regression.
33549625 2021. Early clinical experience with imatinib in COVID-19: Searching for a dual effect.
33716109 2021. Short durations of corticosteroids for hospitalised COVID-19 patients are associated with a high readmission rate.
33582204 2021. Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: Results of a large multicenter study.
33577902 2021. Oral corticoid, aspirin, anticoagulant, colchicine, and furosemide to improve the outcome of hospitalized COVID-19 patients - the COCAA-COLA cohort study.
33639176 2021. In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy.
33678548 2021. Efficacy and safety of hydroxychloroquine/chloroquine against SARS-CoV-2 infection: A systematic review and meta-analysis.
33676844 2021. A retrospective analysis of clinical efficacy of ribavirin in adults hospitalized with severe COVID-19.
33690202 2021. The influence of vitamin-C intake on blood glucose measurements in COVID-19 pandemic.
33715012 2021. Comment on: Nature and Dimensions of the Systemic Hyper-inflammation and Its Attenuation by Convalescent Plasma in Severe COVID-19.
33585890 2021. A Phase II Safety and Efficacy Study on Prognosis of Moderate Pneumonia in Coronavirus Disease 2019 Patients With Regular Intravenous Immunoglobulin Therapy.
33725725 2021. Rapidly Incre<iframe src="http://www.kidney.de/amapp.php?a=g SARS-CoV-2 Neutralization by Intravenous Immunoglobulins Produced from Plasma Collected During the 2020 Pandemic.
33535239 2021. Lessons From Bacille Calmette-Guerin for SARS-CoV-2 Vaccine Candidates.
33647555 2021. The find of COVID-19 vaccine: Challenges and opportunities.
33647553 2021. Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir.
33751982 2021. COVID-19 infection, inception and immunity: Observations and recommendations in the light of vitamin D?
33743371 2021. Combating COVID-19: The role of drug repurposing and medicinal plants.
33776469 2021. Evaluation of Adjunctive Photobiomodulation (PBMT) for COVID-19 Pneumonia via Clinical Status and Pulmonary Severity Indices in a Preliminary Trial.
33758527 2021. Coronil, a Tri-Herbal Formulation, Attenuates Spike-Protein-Mediated SARS-CoV-2 Viral Entry into Human Alveolar Epithelial Cells and Pro-Inflammatory Cytokines Production by Inhibiting Spike Protein-ACE-2 Interaction.
33679136 2021. The Implications of Zinc Therapy in Combating the COVID-19 Global Pandemic.
33574690 2021. Analysis of the Effect of Proton-Pump Inhibitors on the Course of COVID-19.
33583756 2021. Early therapeutic interventions of traditional Chinese medicine in COVID-19 patients: A retrospective cohort study.
33547011 2021. Impact of the COVID-19 pandemic on intention to use traditional Chinese medicine: A cross-sectional study based on the theory of planned behavior.
33663244 2021. Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS.
33634528 2021. Inhibition of SARS-CoV-2 replication using calcineurin inhibitors: are concentrations required clinically achievable?
33648905 2021. Safety of New mRNA Vaccines Against COVID-19 in Severely Allergic Patients.
33574015 2021. Delving Into COVID-19 Vaccination-Induced Anaphylaxis: Are mRNA Vaccines Safe in Mast Cell Disorders?
33558797 2021. Combined docking methods and molecular dynamics to identify effective antiviral 2, 5-diaminobenzophenonederivatives against SARS-CoV-2.
33531790 2021. Enhanced production of camptothecin by immobilized callus of Ophiorrhiza mungos and a bioinformatic insight into its potential antiviral effect against SARS-CoV-2.
33686812 2021. Estimating Baseline Incidence of Conditions Potentially Associated with Vaccine Adverse Events: a Call for Surveillance System Using the Korean National Health Insurance Claims Data.
33783147 2021. COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases: Clinical Guidance of the Korean College of Rheumatology.
33754512 2021. Clinical and Virologic Effectiveness of Remdesivir Treatment for Severe Coronavirus Disease 2019 (COVID-19) in Korea: a Nationwide Multicenter Retrospective Cohort Study.
33559409 2021. What We Do Know and Do Not Yet Know about COVID-19 Vaccines as of the Beginning of the Year 2021.
33627186 2021. The use of integrative therapy based on Yoga and Ayurveda in the treatment of a high-risk case of COVID-19/SARS-CoV-2 with multiple comorbidities: a case report.
33755450 2021. Direct Observation of Protonation State Modulation in SARS-CoV-2 Main Protease upon Inhibitor Binding with Neutron Crystallography.
33560998 2021. Artificial Intelligence-Aided Precision Medicine for COVID-19: Strategic Areas of Research and Development.
33638553 2021. Interaction effects between angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and steroid or antiviral therapies in COVID-19: A population-based study.
33629384 2021. A pilot double-blind safety and feasibility randomized controlled trial of high-dose intravenous zinc in hospitalized COVID-19 patients.
33620107 2021. Potential remdesivir-related transient bradycardia in patients with coronavirus disease 2019 (COVID-19).
33590901 2021. Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19.
33590886 2021. Comment on Hadadi et al., Does recombinant human erythropoietin administration in critically ill COVID-19 patients have miraculous therapeutic effects? J. Med. Virol. 2020; 92:915-918.
33580518 2021. Three salvianolic acids inhibit 2019-nCoV spike pseudovirus viropexis by binding to both its RBD and receptor ACE2.
33527424 2021. SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma.
33666253 2021. In vitro activity of itraconazole against SARS-CoV-2.
33666250 2021. Efficacy of corticosteroid in patients with COVID-19: A multi-center retrospective study and meta-analysis.
33666244 2021. Is a single dose of mRNA vaccine sufficient for COVID-19 survivors?
33666241 2021. Vitamin D axis status and the severity of COVID-19.
33656189 2021. Letter to Editor in response to the article "Vitamin D insufficiency as a potential culprit in critical COVID-19 patients".
33580540 2021. Outpatient metformin use is associated with reduced severity of COVID-19 disease in adults with overweight or obesity.
33527314 2021. Raloxifene as a treatment option for viral infections.
33746189 2021. Clinical Effect of Traditional Chinese Medicine Shenhuang Granule in Critically Ill Patients with COVID-19: A Single-Centered, Retrospective, Observational Study.
33632620 2021. Low blood zinc concentrations in patients with poor clinical outcome during SARS-CoV-2 infection: is there a need to supplement with zinc COVID-19 patients?
33623736 2020. COVID-19 and Phosphodiesterase Enzyme Type 5 Inhibitors.
33623735 2020. Hydroxychloroquine Toxicity Management: A Literature Review in COVID-19 Era.
33775667 2021. Engineered Ultra-High Affinity Synthetic Antibodies for SARS-CoV-2 Neutralization and Detection.
33753053 2021. Platforms for Personalized Polytherapeutics Discovery in COVID-19.
33693723 2021. What makes (hydroxy)chloroquine ineffective against COVID-19: insights from cell biology.
33556646 2021. Interaction of small molecules with the SARS-CoV-2 papain-like protease: In silico studies and in vitro validation of protease activity inhibition using an enzymatic inhibition assay.
33684603 2021. Ensemble-based screening of natural products and FDA-approved drugs identified potent inhibitors of SARS-CoV-2 that work with two distinct mechanisms.
33647752 2021. Pinpointing the potential hits for hindering interaction of SARS-CoV-2 S-protein with ACE2 from the pool of antiviral phytochemicals utilizing molecular docking and molecular dynamics (MD) simulations.
33612899 2021. Rational design of potent anti-COVID-19 main protease drugs: An extensive multi-spectrum in silico approach.
33753950 2021. Binding and drug displacement study of colchicine and bovine serum albumin in presence of azithromycin using multispectroscopic techniques and molecular dynamic simulation.
33641023 2021. Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (M(pro)) of SARS-CoV-2.
33583954 2021. Computational search for drug repurposing to identify potential inhibitors against SARS-COV-2 using Molecular Docking, QTAIM and IQA methods in viral Spike protein - Human ACE2 interface.
33526951 2021. 5-((1H-imidazol-1-yl)methyl)quinolin-8-ol as potential antiviral SARS-CoV-2 candidate: Synthesis, crystal structure, Hirshfeld surface analysis, DFT and molecular docking studies.
33612858 2021. "Identification of Nafamostat and VR23 as COVID-19 drug candidates by targeting 3CL(pro) and PL(pro)."
33603214 2021. Ensuring continued progress for development of COVID-19 therapeutics in children.
33680575 2021. DisCoVering potential candidates of RNAi-based therapy for COVID-19 using computational methods.
33615115 2021. Stapled ACE2 peptidomimetics designed to target the SARS-CoV-2 spike protein do not prevent virus internalization.
33676968 2021. Antiviral peptides against Coronaviridae family: A review.
33816211 2021. Hydroxychloroquine in the prophylaxis of COVID 19: A survey of safety on the healthcare workers in India.
33660201 2021. Nanoparticle-Mediated Cytoplasmic Delivery of Messenger RNA Vaccines: Challenges and Future Perspectives.
33668390 2021. Evaluation of the Antiviral Activity of Sitagliptin-Glatiramer Acetate Nano-Conjugates against SARS-CoV-2 Virus.
33572332 2021. Conjugation of Mannans to Enhance the Potency of Liposome Nanoparticles for the Delivery of RNA Vaccines.
33562240 2021. Therapeutic Potential of Mesenchymal Stem Cells and Their Products in Lung Diseases-Intravenous Administration versus Inhalation.
33652894 2021. Repurposing of Sitagliptin- Melittin Optimized Nanoformula against SARS-CoV-2: Antiviral Screening and Molecular Docking Studies.
33668969 2021. Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical Peculiarities.
33688154 2021. WTP for COVID-19 vaccine in Chile.
33564224 2021. COVID-19 vaccination predicted to be cost effective in USA.
33759544 2021. Predictive association of ABCB1 C3435T genetic polymorphism with the efficacy or safety of lopinavir and ritonavir in COVID-19 patients.
33542445 2021. Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs.
33779964 2021. The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis.
33666864 2021. Perspectives on glucocorticoid treatment for COVID-19: a systematic review.
33625686 2021. Evaluation of effects of chronic nasal steroid use on rhinological symptoms of COVID-19 with SNOT-22 questionnaire.
33608850 2021. In-hospital use of statins is associated with a reduced risk of mortality in coronavirus-2019 (COVID-19): systematic review and meta-analysis.
33604795 2021. Amantadine in the prevention of clinical symptoms caused by SARS-CoV-2.
33781873 2021. Understanding the heart-brain axis response in COVID-19 patients: A suggestive perspective for therapeutic development.
33710753 2021. Hemoadsorption eliminates remdesivir from the circulation: Implications for the treatment of COVID-19.
33687995 2021. Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics.
33662449 2021. SARS-CoV-2 and other coronaviruses negatively influence mitochondrial quality control: beneficial effects of melatonin.
33601001 2021. A systematic review of photodynamic therapy as an antiviral treatment: Potential guidance for dealing with SARS-CoV-2.
33564274 2021. Quantum mechanical studies of the adsorption of Remdesivir, as an effective drug for treatment of COVID-19, on the surface of pristine, COOH-functionalized and S-, Si- and Al- doped carbon nanotubes.
33580917 2021. Breastfeeding importance and its therapeutic potential against SARS-CoV-2.
33527774 2021. Lingonberry polyphenols: Potential SARS-CoV-2 inhibitors as nutraceutical tools?
33685739 2021. Out-patient physiotherapy service delivery post COVID-19: opportunity for a re-set and a new normal?
33637412 2021. Effect and safety of Chinese herbal medicine granules in patients with severe coronavirus disease 2019 in Wuhan, China: a retrospective, single-center study with propensity score matching.
33593628 2021. Toxicity as prime selection criterion among SARS-active herbal medications.
33596494 2021. Randomized placebo-controlled pilot clinical trial on the efficacy of ayurvedic treatment regime on COVID-19 positive patients.
33587321 2021. Oroxylin A is a severe acute respiratory syndrome coronavirus 2-spiked pseudotyped virus blocker obtained from Radix Scutellariae using angiotensin-converting enzyme II/cell membrane chromatography.
33564969 2021. Glucocorticoid use in patients with adrenal insufficiency following administration of the COVID-19 vaccine: a pituitary society statement.
33673316 2021. COVID-19 Crisis: How Can Plant Biotechnology Help?
33647008 2021. Success of prophylactic antiviral therapy for SARS-CoV-2: Predicted critical efficacies and impact of different drug-specific mechanisms of action.
33544720 2021. SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19.
33657114 2021. Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial.

33620862 2021. COVID (SARS-COV-2) Vaccine
33666876 2021. Vitamin D deficiency, secondary hyperparathyroidism and respiratory insufficiency in hospitalized patients with COVID-19.
33685335 2021. In silico identification of novel SARS-COV-2 2'-O-methyltransferase (nsp16) inhibitors: structure-based virtual screening, molecular dynamics simulation and MM-PBSA approaches.
33641565 2021. Exposure of human intestinal epithelial cells and primary human hepatocytes to trypsin-like serine protease inhibitors with potential antiviral effect.
33605108 2021. The Role of Convalescent Plasma and Tocilizumab in the Management of COVID-19 Infection: A Cohort of 110 Patients from a Tertiary Care Hospital in Oman.
33605118 2021. A Case Series of Severe Hospitalized COVID-19 Patients Treated with Tocilizumab and Glucocorticoids: A Report from Saudi Arabian Hospital.
33631276 2021. Evaluating the Traditional Chinese Medicine (TCM) Officially Recommended in China for COVID-19 Using Ontology-Based Side-Effect Prediction Framework (OSPF) and Deep Learning.
33716085 2021. Artemisia annua L. extracts inhibit the in vitro replication of SARS-CoV-2 and two of its variants.
33529638 2021. Efficacy and safety assessment of severe COVID-19 patients with Chinese medicine: A retrospective case series study at early stage of the COVID-19 epidemic in Wuhan, China.
33587756 2021. European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics.
33752263 2021. Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases - practical recommendations. A position statement of ETFAD with external experts.
33650226 2021. Insights into Sars-CoV-2 vaccination in patients with chronic plaque psoriasis on systemic treatments.
33787349 2021. Licorice: A Potential Herb in Overcoming SARS-CoV-2 Infections.
33554423 2021. Role of vitamin D in COVID-19 infections and deaths.
33786534 2021. News About the Extracellular Vesicles from Mesenchymal Stem Cells: Functions, Therapy and Protection from COVID-19.
33772438 2021. Chronotherapy in COVID-19 Disease.
33711156 2021. Impact of systemic corticosteroids on mortality in older adults with critical COVID-19 pneumonia.
33678903 2021. Inhibitory efficacy of RNA virus drugs against SARS-CoV-2 proteins: An extensive study.
33814612 2021. Unmasking of crucial structural fragments for coronavirus protease inhibitors and its implications in COVID-19 drug discovery.
33758509 2021. Corticosteroids Use in Pregnant Women with COVID-19: Recommendations from Available Evidence.
33544324 2021. A Role for Extracellular Vesicles in SARS-CoV-2 Therapeutics and Prevention.
33534108 2021. Repurposing of Tetracyclines for COVID-19 Neurological and Neuropsychiatric Manifestations: A Valid Option to Control SARS-CoV-2-Associated Neuroinflammation?
33721079 2021. Neurology and vaccinations: considerations in the context of COVID-19/SARS-COV-2.
33537898 2021. Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19.
33638680 2021. Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab.
33611630 2021. Bell's palsy following COVID-19 vaccination.
33692301 2021. Physical compatibility of nafamostat with analgesics, sedatives, and muscle relaxants for coronavirus disease treatment.
33693698 2021. Risk of Malnutrition Is Common in Patients with Coronavirus Disease 2019 (COVID-19) in Wuhan, China: A Cross-sectional Study.
33575730 2021. Malnutrition Prolongs the Hospitalization of Patients with COVID-19 Infection: A Clinical Epidemiological Analysis.
33643836 2021. Virucidal activity of oral care products against SARS-CoV-2 in vitro.
33527524 2021. Reported orofacial adverse effects of COVID-19 vaccines: The knowns and the unknowns.
33716511 2021. Recommendations and Guidance for Steroid Injection Therapy and COVID-19 Vaccine Administration from the American Society of Pain and Neuroscience (ASPN).
33649442 2021. Previous viral symptoms and individual mothers influenced the leveled duration of human milk antibodies cross-reactive to S1 and S2 subunits from SARS-CoV-2, HCoV-229E, and HCoV-OC43.
33578937 2021. Statin Therapy and the Risk of COVID-19: A Cohort Study of the National Health Insurance Service in South Korea.
33782640 2021. The potential of miRNA-based therapeutics in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection: a review.
33552628 2021. Accurate and sensitive determination of hydroxychloroquine sulfate used on COVID-19 patients in human urine, serum and saliva samples by GC-MS.
33549875 2021. Vitamin C supplementation is necessary for patients with coronavirus disease: An ultra-high-performance liquid chromatography-tandem mass spectrometry finding.
33548872 2021. Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC-MS/MS method in human serum.
33688448 2021. Potential therapeutic and pharmacological strategies for SARS-CoV2.
33793885 2021. Propolis antiviral and immunomodulatory activity: a review and perspectives for COVID-19 treatment.
33684397 2021. Insilico drug repurposing using FDA approved drugs against Membrane protein of SARS-CoV-2.
33657325 2021. An Active Site Inhibitor Induces Conformational Penalties for ACE2 Recognition by the Spike Protein of SARS-CoV-2.
33577324 2021. Kobophenol A Inhibits Binding of Host ACE2 Receptor with Spike RBD Domain of SARS-CoV-2, a Lead Compound for Blocking COVID-19.
33776343 2021. Structure-based inhibitor screening of natural products against NSP15 of SARS-CoV-2 revealed thymopentin and oleuropein as potent inhibitors.
33667055 2021. Elevated clozapine levels and toxic effects after SARS-CoV-2 vaccination.
33703870 2021. COVID-19 infection causes a reduction in neutrophil counts in patients taking clozapine.
33589559 2021. Rethinking Physical Activity Promotion During the COVID-19 Pandemic: Focus on a 24-hour Day.
33775882 2021. Physical activity and its relationship with COVID-19 cases and deaths: Analysis of U.S. counties.
33775818 2021. Therapeutic and prognostic role of vitamin D for COVID-19 infection: A systematic review and meta-analysis of 43 observational studies.
33569200 2021. Hydroxychloroquine and chloroquine for treatment of coronavirus disease 19 (COVID-19): a systematic review and meta-analysis of randomized and non-randomized controlled trials.
33615209 2021. Benefits of early aggressive immunomodulatory therapy (tocilizumab and methylprednisolone) in COVID-19: Single center cohort study of 685 patients.
33789686 2021. Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis.
33635318 2021. What can we learn from COVID-19 vaccine R&D in China? A discussion from a public policy perspective.
33620081 2021. 'Blue toes' following vaccination with the BNT162b2 mRNA COVID-19 vaccine.
33663198 2021. Can we use mesenchymal stem cell transplantation for COVID-19 patients in puerperium period?
33573494 2021. The evolving use of hyperbaric oxygen therapy during the COVID-19 pandemic.
33748377 2021. "COVID arm": A reaction to the Moderna vaccine.
33782672 2021. Regression of Coronary Aneurysms With Intravenous Immunoglobulins and Steroids for COVID-19 Adult Multisystem Inflammatory Syndrome.
33760094 2021. Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19.
33739433 2021. Association of Vitamin D Levels, Race/Ethnicity, and Clinical Characteristics With COVID-19 Test Results.
33774074 2021. The link between COVID-19 and VItamin D (VIVID): A systematic review and meta-analysis.
33639316 2021. Multi-targeting approach for nsp3, nsp9, nsp12 and nsp15 proteins of SARS-CoV-2 by Diosmin as illustrated by molecular docking and molecular dynamics simulation methodologies.
33729874 2021. Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity.
33744495 2021. COVID-19 Vaccine Decisions: Considering the Choices and Opportunities.
33776146 2021. Green micellar solvent-free HPLC and spectrofluorimetric determination of favipiravir as one of COVID-19 antiviral regimens.
33572117 2021. Fluoxetine Can Inhibit SARS-CoV-2 In Vitro.
33668694 2021. Antiviral Activity of Vacuolar ATPase Blocker Diphyllin against SARS-CoV-2.
33688701 2021. Statin therapy is associated with less ICU admissions in COVID-19 patients. A preliminary analysis of the current observations.
33709676 2021. The administration of S. salivarius K12 to children may reduce the rate of SARS-CoV-2 infection.
33661860 2021. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Janssen COVID-19 Vaccine - United States, February 2021.
33793460 2021. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021.
33551490 2021. COVID-19 Convalescent Plasma: from donation to treatment - A Systematic Review & Single Center Experience.
33750821 2021. Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2.
33785743 2021. Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial.
33658497 2021. Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques.
33654090 2021. Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques.
33741945 2021. Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model.
33741941 2021. Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infection.
33731724 2021. A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies.
33707427 2021. SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface.
33649323 2021. S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates.
33558541 2021. Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide.
33547300 2021. Efficacy and tolerability of bevacizumab in patients with severe Covid-19.
33536425 2021. A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2.
33637713 2021. Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19.
33531496 2021. Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors.
33589624 2021. Causal network models of SARS-CoV-2 expression and aging to identify candidates for drug repurposing.
33568665 2021. Potential health and economic impacts of dexamethasone treatment for patients with COVID-19.
33542537 2021. COVID-19 vaccines: acting on the evidence.
33785883 2021. Antibody responses to SARS-CoV-2 infection are attenuated in infliximab-treated patients with IBD.
33564149 2021. Targeting autoantibodies in COVID-19.
33674759 2021. COVID-19 vaccines: modes of immune activation and future challenges.
33658707 2021. Are COVID-19 vaccines safe in pregnancy?
33558753 2021. COVID-19 vaccines and kidney disease.
33587164 2021. Interferon-beta offers promising avenues to COVID-19 treatment: a systematic review and meta-analysis of clinical trial studies.
33640181 2021. Consenso multidisciplinar sobre la valoracion y el tratamiento nutricional y dietetico en pacientes con enfermedad renal cronica e infeccion por SARS-CoV-2. Consenso de nutricion en enfermedad renal cronica e infeccion por SARS-CoV-2.
33693778 2021. Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases.
33786291 2021. In silico studies of selected multi-drug targeting against 3CLpro and nsp12 RNA-dependent RNA-polymerase proteins of SARS-CoV-2 and SARS-CoV.
33585155 2021. Exploring the active constituents of Oroxylum indicum in intervention of novel coronavirus (COVID-19) based on molecular docking method.
33527083 2021. To stress or not to stress: Brain-behavior-immune interaction may weaken or promote the immune response to SARS-CoV-2.
33555604 2021. COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) in patients with multiple sclerosis: a statement by a working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society.
33411196 2021. Acupuncture helps to regain the consciousness of a COVID-19 patient complicated with hypoxic-ischemic encephalopathy: a case report.
33760858 2021. Reduced mortality in COVID-19 patients treated with colchicine: Results from a retrospective, observational study.
33750975 2021. DNA vaccine candidate encoding SARS-CoV-2 spike proteins elicited potent humoral and Th1 cell-mediated immune responses in mice.
33735271 2021. A comprehensive SARS-CoV-2 genomic analysis identifies potential targets for drug repurposing.
33730088 2021. COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients.
33730022 2021. Immuno-informatics design of a multimeric epitope peptide based vaccine targeting SARS-CoV-2 spike glycoprotein.
33725021 2021. Knowledge of medical professionals, their practices, and their attitudes toward traditional Chinese medicine for the prevention and treatment of coronavirus disease 2019: A survey in Sichuan, China.
33667247 2021. Development and validation of an LC-MS/MS method for determination of hydroxychloroquine, its two metabolites, and azithromycin in EDTA-treated human plasma.
33674391 2021. COVID-19 Drugs Chloroquine and Hydroxychloroquine, but Not Azithromycin and Remdesivir, Block hERG Potassium Channels.
33658349 2021. Potent Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain.
33622961 2021. A comparative analysis of SARS-CoV-2 antivirals characterizes 3CL(pro) inhibitor PF-00835231 as a potential new treatment for COVID-19.

33551489 2021. Magnesium and Vitamin D Deficiency as a Potential Cause of Immune Dysfunction, Cytokine Storm and Disseminated Intravascular Coagulation in covid-19 patients.
33551236 2021. The need for precision nutrition, genetic variation and resolution in Covid-19 patients.
33620659 2021. Glucose-6-phosphate dehydrogenase deficiency and hydroxychloroquine in the COVID-19 era: a mini review.
33625681 2021. Bioinformatics Analysis of SARS-CoV-2 to Approach an Effective Vaccine Candidate Against COVID-19.
33722265 2021. Clinical and immunological effects of mRNA vaccines in malignant diseases.
33632261 2021. mRNA vaccine for cancer immunotherapy.
33593376 2021. mRNA vaccine: a potential therapeutic strategy.
33631104 2021. Remdesivir is a delayed translocation inhibitor of SARS-CoV-2 replication.
33604809 2021. Role of vitamin D in treating COVID-19-associated coagulopathy: problems and perspectives.
33587232 2021. Therapeutic opportunities of edible antiviral plants for COVID-19.
33675510 2021. Exploring naphthyl derivatives as SARS-CoV papain-like protease (PLpro) inhibitors and its implications in COVID-19 drug discovery.
33786727 2021. Pharmacoinformatics-based identification of transmembrane protease serine-2 inhibitors from Morus Alba as SARS-CoV-2 cell entry inhibitors.
33765239 2021. In silico evaluation of potential inhibitory activity of remdesivir, favipiravir, ribavirin and galidesivir active forms on SARS-CoV-2 RNA polymerase.
33582935 2021. Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19.
33571463 2021. Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines.
33723514 2021. In vitro characterization of engineered red blood cells as viral traps against HIV-1 and SARS-CoV-2.
33573318 2021. COVID-19 Prophylaxis Efforts Based on Natural Antiviral Plant Extracts and Their Compounds.
33573088 2021. In Silico Study of Polyunsaturated Fatty Acids as Potential SARS-CoV-2 Spike Protein Closed Conformation Stabilizers: Epidemiological and Computational Approaches.
33525415 2021. Chloroquine and Hydroxychloroquine Interact Differently with ACE2 Domains Reported to Bind with the Coronavirus Spike Protein: Mediation by ACE2 Polymorphism.
33525411 2021. Computational Determination of Potential Multiprotein Targeting Natural Compounds for Rational Drug Design Against SARS-COV-2.
33530467 2021. Current Updates on Naturally Occurring Compounds Recognizing SARS-CoV-2 Druggable Targets.
33562030 2021. Therapeutic Potential of Resveratrol in COVID-19-Associated Hemostatic Disorders.
33557115 2021. Combining Different Docking Engines and Consensus Strategies to Design and Validate Optimized Virtual Screening Protocols for the SARS-CoV-2 3CL Protease.
33669054 2021. Propolis, Bee Honey, and Their Components Protect against Coronavirus Disease 2019 (COVID-19): A Review of In Silico, In Vitro, and Clinical Studies.
33668085 2021. EGCG, a Green Tea Catechin, as a Potential Therapeutic Agent for Symptomatic and Asymptomatic SARS-CoV-2 Infection.
33672163 2021. Therapeutic Intervention of COVID-19 by Natural Products: A Population-Specific Survey Directed Approach.
33672721 2021. Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease.
33669720 2021. In Silico Screening of the DrugBank Database to Search for Possible Drugs against SARS-CoV-2.
33668428 2021. Nucleoside Analogs and Nucleoside Precursors as Drugs in the Fight against SARS-CoV-2 and Other Coronaviruses.
33578831 2021. Field-Template, QSAR, Ensemble Molecular Docking, and 3D-RISM Solvation Studies Expose Potential of FDA-Approved Marine Drugs as SARS-CoVID-2 Main Protease Inhibitors.
33590551 2021. The double-edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis.
33556628 2021. FN3-based monobodies selective for the receptor binding domain of the SARS-CoV-2 spike protein.
33657299 2021. Baricitinib Therapy in Covid-19 Pneumonia - An Unmet Need Fulfilled.
33631066 2021. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia.
33631065 2021. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.
33631064 2021. Interleukin-6 Receptor Inhibition in Covid-19 - Cooling the Inflammatory Soup.
33626250 2021. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.
33657292 2021. Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2.
33815564 2021. Role of nanotechnology behind the success of mRNA vaccines for COVID-19.
33758593 2021. Engineering a self-navigated MnARK nanovaccine for inducing potent protective immunity against novel coronavirus.
33753982 2021. 2D MXenes with antiviral and immunomodulatory properties: A pilot study against SARS-CoV-2.
33753282 2021. Cerium oxide nanoparticle delivery of microRNA-146a for local treatment of acute lung injury.
33662593 2021. Synthesis and immunogenicity assessment of a gold nanoparticle conjugate for the delivery of a peptide from SARS-CoV-2.
33815808 2021. Computational insights of phytochemical-driven disruption of RNA-dependent RNA polymerase-mediated replication of coronavirus: a strategic treatment plan against coronavirus disease 2019.
33580031 2020. Insights into the use of mesenchymal stem cells in COVID-19 mediated acute respiratory failure.
33785745 2021. Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters.
33767200 2021. The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization.
33741993 2021. Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease.
33741992 2021. Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2.
33619260 2021. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates.
33526776 2021. Piglet immunization with a spike subunit vaccine enhances disease by porcine epidemic diarrhea virus.
33580085 2020. Universal coronavirus vaccines: the time to start is now.
33580049 2020. Certainty of success: three critical parameters in coronavirus vaccine development.
33580061 2020. The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines.
33580080 2020. Applying lessons from the Ebola vaccine experience for SARS-CoV-2 and other epidemic pathogens.
33580058 2020. Plasma-based COVID-19 treatments in low- and middle-income nations pose a high risk of an HIV epidemic.
33580068 2020. Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19.
33580044 2020. COVID-19 vaccines: breaking record times to first-in-human trials.
33549288 2021. Herbal Medication to Enhance or Modulate Viral Infections.
33667020 2021. Nutrition Support in Patients With Acute Respiratory Distress Syndrome COVID-19.
33651909 2021. Early Enteral Nutrition in Mechanically Ventilated Patients With COVID-19 Infection.
33549452 2021. Excessive vitamin B12 and poor outcome in COVID-19 pneumonia.
33549427 2021. Nutrition and the Covid-19 pandemic: Three factors with high impact on community health.
33592454 2021. Probiotics: A potential immunomodulator in COVID-19 infection management.
33570583 2021. Nutritional perspectives for the prevention and mitigation of COVID-19.
33573173 2021. Phytonutrient and Nutraceutical Action against COVID-19: Current Review of Characteristics and Benefits.
33573169 2021. Micronutrients, Phytochemicals and Mediterranean Diet: A Potential Protective Role against COVID-19 through Modulation of PAF Actions and Metabolism.
33525447 2021. Vitamin D Supplementation to Prevent COVID-19 Infections and Deaths-Accumulating Evidence from Epidemiological and Intervention Studies Calls for Immediate Action.
33572045 2021. Low Zinc Levels at Admission Associates with Poor Clinical Outcomes in SARS-CoV-2 Infection.
33557013 2021. Diagnostic and Pharmacological Potency of Creatine in Post-Viral Fatigue Syndrome.
33652653 2021. Notable Developments for Vitamin D Amid the COVID-19 Pandemic, but Caution Warranted Overall: A Narrative Review.
33668240 2021. Vitamin D and Lung Outcomes in Elderly COVID-19 Patients.
33671491 2021. The Antiviral Properties of Human Milk: A Multitude of Defence Tools from Mother Nature.
33611766 2021. Roux-en-Y Gastric Bypass Downregulates Angiotensin-Converting Enzyme 2 (ACE2) Gene Expression in Subcutaneous White Adipose Tissue: A Putative Protective Mechanism Against Severe COVID-19.
33537364 2021. Tocilizumab for the Treatment of COVID-19 Among Hospitalized Patients: A Matched Retrospective Cohort Analysis.
33628858 2021. Is There Still a Place for Tocilizumab in Coronavirus Disease 2019?
33628857 2021. Impact of Interleukin-6 Receptor Blockade With Tocilizumab on Cardiac Injury in Patients With COVID-19: A Retrospective Cohort Study.
33623808 2021. Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19.
33604400 2021. Matched Cohort Study of Convalescent COVID-19 Plasma Treatment in Severely or Life Threateningly Ill COVID-19 Patients.
33556157 2021. Real-World Inpatient Use of Medications Repurposed for Coronavirus Disease 2019 in United States Hospitals, March-May 2020.
33553472 2021. A First Draft of the History of Treating Coronavirus Disease 2019: Use of Repurposed Medications in United States Hospitals.
33553467 2021. Cytokine and Chemokine Levels in Coronavirus Disease 2019 Convalescent Plasma.
33741691 2021. Melatonin may decrease risk for and aid treatment of COVID-19 and other RNA viral infections.
33778162 2021. Judicious use of low-dosage corticosteroids for non-severe COVID-19: A case report.
33717367 2020. Novel and Controversial Therapies in COVID-19.
33675508 2021. Ophthalmological Considerations for COVID-19 Vaccination in Patients with Inflammatory Eye Diseases and Autoimmune Disorders.
33628371 2021. Oxidative Imbalance as a Crucial Factor in Inflammatory Lung Diseases: Could Antioxidant Treatment Constitute a New Therapeutic Strategy?
33691012 2021. Feasibility of the vaccine development for SARS-CoV-2 and other viruses using the shell disorder analysis.
33691011 2021. SARS-CoV-2 Drug Discovery based on Intrinsically Disordered Regions.
33605425 2021. Do Corticosteroid Injections for the Treatment of Pain Influence the Efficacy of mRNA COVID-19 Vaccines?
33623607 2020. Psychiatric side effects of chloroquine in COVID-19 patients: two case reports.
33623604 2020. Cochrane corner: convalescent plasma or hyperimmune immunoglobulin for people with COVID-19.
33534822 2021. Rational design of multi epitope-based subunit vaccine by exploring MERS-COV proteome: Reverse vaccinology and molecular docking approach.
33765086 2021. Sieve analysis to understand how SARS-CoV-2 diversity can impact vaccine protection.
33765062 2021. Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model.
33657135 2021. A high-affinity RBD-targeting nanobody improves fusion partner's potency against SARS-CoV-2.
33571304 2021. Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors.
33644964 2021. The essential role of a physiatrist in recommending a COVID-19 vaccine.
33589486 2021. Inadvertent subcutaneous injection of COVID-19 vaccine.
33770348 2021. The Role of Mucosal Immunity and Recombinant Probiotics in SARS-CoV2 Vaccine Development.
33537958 2021. Systematic Network and Meta-analysis on the Antiviral Mechanisms of Probiotics: A Preventive and Treatment Strategy to Mitigate SARS-CoV-2 Infection.
33597253 2021. Bepridil is potent against SARS-CoV-2 in vitro.
33688035 2021. One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower respiratory tract infection.
33688034 2021. A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike.
33568500 2021. Reply to Ma and Wang: Reliability of various in vitro activity assays on SARS-CoV-2 main protease inhibitors.
33526596 2021. Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP.
33766889 2021. Generation of SARS-CoV-2 reporter replicon for high-throughput antiviral screening and testing.
33636189 2021. Targeting SARS-CoV-2 Nsp3 macrodomain structure with insights from human poly(ADP-ribose) glycohydrolase (PARG) structures with inhibitors.
33770364 2021. Understanding the phase separation characteristics of nucleocapsid protein provides a new therapeutic opportunity against SARS-CoV-2.
33586288 2021. Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naive human antibody library.
33771367 2021. Vaccination for COVID-19: benchmarks in public health and virus transmission.
33743214 2021. Vaccines for COVID-19: learning from ten phase II trials to inform clinical and public health vaccination programmes.

33685998 2021. SARS-CoV-2 vaccines in patients with SLE.
33627228 2021. Liquen plano en una paciente tras SARS-CoV-2 tratado con lopinavir/ritonavir.
33593637 2021. Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection.
33622529 2021. Glucocorticoides solos versus tocilizumab solo o glucocorticoides mas tocilizumab en pacientes con neumonia grave por SARS-CoV-2 e inflamacion moderada.
33715841 2021. Tocilizumab en el paciente con COVID-19.
33778159 2021. Lichen planus after SARS-CoV-2 infection treated with lopinavir/ritonavir.
33589878 2021. Transfusion reaction to hyperimmune plasma in patients with severe COVID-19 infection.
33585689 2021. Effectiveness of glucocorticoids in patients hospitalized for severe SARS-CoV-2 pneumonia.
33686372 2021. Indication of glucocorticoid pulses for patients with SARS-CoV-2 infection.
33763598 2021. Tocilizumab in patients infected by SARS-CoV2.
33817623 2021. Network bioinformatics analysis provides insight into drug repurposing for COVID-19.
33780778 2021. Anticholinergic drugs versus preprocedural mouth rinses for reduction of SARS-CoV-2 load in dental aerosols.
33780777 2021. Aminoglycosides and their potential as SARS-CoV-2 antivirals.
33735762 2021. Clofazimine: A potential therapeutic option for severe COVID-19.
33730601 2021. Etoricoxib may inhibit cytokine storm to treat COVID-19.
33571758 2021. Antihistamine and cationic amphiphilic drugs, old molecules as new tools against the COVID-19?
33561624 2021. The potential use of lactate blockers for the prevention of COVID-19 worst outcome, insights from exercise immunology.
33549964 2021. Airways to heaven: Caution needed when exercising during COVID-19.
33529978 2021. Could diet and exercise reduce risk of COVID-19 syndemic?
33657458 2021. Autism Spectrum Disorder patients may be susceptible to COVID-19 disease due to deficiency in melatonin.
33647606 2021. Old drug, new Trick? The rationale for the treatment of COVID-19 with activated protein C.
33640714 2021. Can bilirubin nanomedicine become a hope for the management of COVID-19?
33636587 2021. COVID-19, colchicine and glycemia.
33636586 2021. COVID-19-related arrhythmias and the possible effects of ranolazine.
33621842 2021. Pulmonary lipid modulation: A possible therapeutic target for SARS-CoV-2 infection.
33607405 2021. A genetic insight into vitamin D binding protein and COVID-19.
33744019 2021. Corticosteroids in COVID-19: A double-edged sword - a retrospective study.
33816370 2020. Efficacy and safety of chloroquine and hydroxychloroquine for COVID-19: A comprehensive evidence synthesis of clinical, animal, and in vitro studies.
33571171 2021. Risk Factors of Coronavirus Disease 2019-Related Mortality and Optimal Treatment Regimens: A Retrospective Study.
33776574 2021. Corticosteroid Pulses for Hospitalized Patients with COVID-19: Effects on Mortality.
33673527 2021. Antiviral and Immunomodulation Effects of Artemisia.
33673004 2021. Natural Products and Nutrients against Different Viral Diseases: Prospects in Prevention and Treatment of SARS-CoV-2.
33655919 2021. Oral high dose vitamin D for the treatment of diabetic patients with COVID-19: A protocol for systematic review and meta-analysis.
33761696 2021. Role of tocilizumab for concomitant systemic fungal infection in severe COVID-19 patient: Case report.
33725851 2021. Low-dose oral hydroxychloroquine led to impaired vision in a child with renal failure: Case report and literature review.
33530261 2021. Arbidol combined with the Chinese medicine Lianhuaqingwen capsule versus arbidol alone in the treatment of COVID-19.
33578548 2021. Effect of low-dose aspirin on mortality and viral duration of the hospitalized adults with COVID-19.
33623561 2020. Immunity, parasites, genetics and sex hormones: contributors to mild inflammatory responses in COVID-19?
33623551 2020. An alert on the incautious use of herbal medicines by sub-Saharan African populations to fight against the COVID-19.
33573530 2021. Use of hydroxychloroquine and chloroquine in patients with COVID-19: a meta-analysis of randomized clinical trials.
33682640 2021. Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection.
33573221 2021. Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization.
33669635 2021. Hypothiocyanite and Hypothiocyanite/Lactoferrin Mixture Exhibit Virucidal Activity In Vitro against SARS-CoV-2.
33671315 2021. Chloroquine and Hydroxychloroquine: Efficacy in the Treatment of the COVID-19.
33621264 2021. Development and validation of a prediction model for tocilizumab failure in hospitalized patients with SARS-CoV-2 infection.
33621254 2021. Retrospective analysis of 426 donors of a convalescent collective after mild COVID-19.
33606790 2021. Observational study of haloperidol in hospitalized patients with COVID-19.
33606702 2021. A Bayesian reanalysis of the effects of hydroxychloroquine and azithromycin on viral carriage in patients with COVID-19.
33596235 2021. Mapping major SARS-CoV-2 drug targets and assessment of druggability using computational fragment screening: Identification of an allosteric small-molecule binding site on the Nsp13 helicase.
33596218 2021. Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro.
33592050 2021. Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study.
33571320 2021. Development and evaluation of inhalable composite niclosamide-lysozyme particles: A broad-spectrum, patient-adaptable treatment for coronavirus infections and sequalae.
33727066 2021. Sequential doxycycline and colchicine combination therapy in Covid-19: The salutary effects.
33643864 2021. mRNA Vaccines for COVID-19: A Simple Explanation.
33677593 2021. The potential risks of delaying the second vaccine dose during the SARS-CoV-2 pandemic.
33486522 2021. Vitamin D supplementation, COVID-19 and disease severity: a meta-analysis.
33647971 2021. COVID-19 vaccine-related myositis.
33599247 2021. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos.
33778667 2021. Axillary Lymphadenopathy After mRNA COVID-19 Vaccination.
33625301 2021. Evolution of Lymphadenopathy at PET/MRI after COVID-19 Vaccination.
33625299 2021. Adenopathy Following COVID-19 Vaccination.
33625300 2021. Lymphadenopathy in COVID-19 Vaccine Recipients: Diagnostic Dilemma in Oncology Patients.
33625298 2021. Multidisciplinary Recommendations Regarding Post-Vaccine Adenopathy and Radiologic Imaging: Radiology Scientific Expert Panel.
33723519 2021. Potency of Mesenchymal Stem Cell and Its Secretome in Treating COVID-19.
33542837 2021. Low-Level Laser Therapy in Prevention of the Development of Endothelial Dysfunction and Clinical Experience of Treatment and Rehabilitation of COVID-19 Patients.
33547007 2021. Sustained coronavirus disease 2019-related organizing pneumonia successfully treated with corticosteroid.
33550151 2021. Colchicine and SARS-CoV-2: Management of the hyperinflammatory state.
33721697 2021. SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity.
33552890 2021. COVID-19 acute respiratory distress syndrome: can iloprost have a role for the treatment?
33657448 2021. Use of exogenous pulmonary surfactant in acute respiratory distress syndrome (ARDS): Role in SARS-CoV-2-related lung injury.
33658032 2021. Circulating Vitamin D levels status and clinical prognostic indices in COVID-19 patients.
33815804 2021. Nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019.
33732466 2021. Multimodality treatment in immunocompromised patients with severe COVID-19: the role of IL-6 inhibitor, intravenous immunoglobulin, and haemoperfusion.
33619449 2021. An integrated virtual screening of compounds from Carica papaya leaves against multiple protein targets of SARS-Coronavirus-2.
33677945 2021. Vitamin D and disease severity in coronavirus disease 19 (COVID-19).
33716310 2021. Precaucion con el uso de dexametasona en pacientes con COVID-19 en sus fases iniciales.
33776190 2021. Miocarditis aguda tras administracion de vacuna BNT162b2 contra la COVID-19.
33675220 2021. Real-life use of remdesivir in hospitalized patients with COVID-19.
33654051 2021. Impacto de la COVID-19 sobre las listas de espera quirurgicas.
33399749 2020. Tratamientos experimentales y coronavirus.
33480368 2020. El dilema de COVID-19: inverted question marksangre suficiente versus plasma convaleciente?
33612319 2021. Chez des sujets de 16 ans et plus, est-ce que le vaccin BNT162b2, un vaccin a ARN messager contre la COVID-19, est efficace et securitaire ?
33594794 2021. Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects.
33666285 2021. Vaccines for SARS coronavirus 2 and the new normal in vaccinology.
33621405 2021. Current views on the potentials of convalescent plasma therapy (CPT) as Coronavirus disease 2019 (COVID-19) treatment: A systematic review and meta-analysis based on recent studies and previous respiratory pandemics.
33580566 2020. Background to new treatments for COVID-19, including its chronicity, through altering elements of the cytokine storm.
33764494 2021. Vacunacion frente al SARS-CoV-2 en pacientes con esclerosis multiple.
33710296 2021. COVID-19 vaccination and antirheumatic therapy.
33542047 2021. Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial.
33544784 2020. Natural and semisynthetic candidate molecules for COVID-19 prophylaxis and treatment.
33776395 2021. Synthesis, Molecular Docking, In Silico ADME Predictions, and Toxicity Studies of N-Substituted-5-(4-Chloroquinolin-2-yl)-1,3,4-Thiadiazol-2-Amine Derivatives as COVID-19 Inhibitors.
33753960 2021. Natural product remedies for COVID-19: A focus on safety.
33614035 2021. Deficiency of antioxidants and increased oxidative stress in COVID-19 patients: A cross-sectional comparative study in Jigawa, Northwestern Nigeria.
33796310 2021. Tocilizumab and PMX-DHP have efficacy for severe COVID-19 pneumonia.
33656132 2021. Critical analysis on the use of cholecalciferol as a COVID-19 intervention: a narrative review.
33649700 2021. Screening of drug databank against WT and mutant main protease of SARS-CoV-2: Towards finding potential compound for repurposing against COVID-19.
33642896 2021. In silico analysis of quranic and prophetic medicinals plants for the treatment of infectious viral diseases including corona virus.
33732045 2021. Nano-formulation of herbo-mineral alternative medicine from linga chenduram and evaluation of antiviral efficacy.
33758570 2021. Structure insights of SARS-CoV-2 open state envelope protein and inhibiting through active phytochemical of ayurvedic medicinal plants from Withania somnifera.
33746538 2021. A comprehensive insight into the role of zinc deficiency in the renin-angiotensin and kinin-kallikrein system dysfunctions in COVID-19 patients.
33654454 2021. Screening of inhibitors against SARS-CoV-2 spike protein and their capability to block the viral entry mechanism: A viroinformatics study.
33551661 2021. Computational drug screening against the SARS-CoV-2 Saudi Arabia isolates through a multiple-sequence alignment approach.
33526965 2021. Identification of natural compounds as potent inhibitors of SARS-CoV-2 main protease using combined docking and molecular dynamics simulations.
33722251 2021. Extracorporeal cardiopulmonary resuscitation for severe chloroquine intoxication in a child - a case report.
33741598 2021. Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates.
33608249 2021. Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans.
33597251 2021. An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants.
33547083 2021. A lymph node-targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2.
33536217 2021. Leveraging systems biology for predicting modulators of inflammation in patients with COVID-19.
33686143 2021. The in-vitro effect of famotidine on sars-cov-2 proteases and virus replication.
33664446 2021. Polyunsaturated omega-3 fatty acids inhibit ACE2-controlled SARS-CoV-2 binding and cellular entry.
33664393 2021. Potential neutralizing antibodies discovered for novel corona virus using machine learning.

33576820 2021. Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial.
33576814 2021. Supplements for the Treatment of Mild COVID-19-Challenging Health Beliefs With Science From A to Z.
33769311 2021. IgV somatic mutation of human anti-SARS-CoV-2 monoclonal antibodies governs neutralization and breadth of reactivity.
33529170 2021. Dromedary camels as a natural source of neutralizing nanobodies against SARS-CoV-2.
33571168 2021. Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma.
33724265 2020. No Time to Waste: Real-World Repurposing of Generic Drugs as a Multifaceted Strategy Against COVID-19.
33666263 2021. Nutrition evaluation and management of critically ill patients with COVID-19 during post-intensive care rehabilitation.
33756482 2021. Pathophysiological Implication of Vitamin D in Diabetic Kidney Disease.
33647327 2021. Kidney disorders as serious adverse drug reactions of remdesivir in coronavirus disease 2019: a retrospective case-noncase study.
33775674 2021. Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients.
33585728 2021. Systematic Review of Safety and Efficacy of COVID-19 Vaccines in Patients With Kidney Disease.
33706472 2021. Baseline use of hydroxychloroquine or immunosuppressive drugs and the risk of coronavirus disease 2019.
33617777 2021. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
33617772 2021. MAb for symptomatic COVID-19 in correctional facilities: an important opportunity.
33610193 2021. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients.
33640037 2021. Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine.
33705696 2021. (18)F-fluorodeoxyglucose PET/CT findings in a systemic inflammatory response syndrome after COVID-19 vaccine.
33676597 2021. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.
33640038 2021. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals.
33684351 2021. Sex-disaggregated data in COVID-19 vaccine trials.
33545098 2021. Sputnik V COVID-19 vaccine candidate appears safe and effective.
33545094 2021. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.
33549168 2021. WHO international non-proprietary names: the need to distinguish COVID-19 vaccines.
33545096 2021. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
33765410 2021. Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection.
33743220 2021. Malnutrition risk in hospitalised COVID-19 patients receiving CPAP.
33770519 2021. WHO International Standard for anti-SARS-CoV-2 immunoglobulin.
33665645 2021. The potential of rapalogs to enhance resilience against SARS-CoV-2 infection and reduce the severity of COVID-19.
33773111 2021. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
33606999 2021. Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products.
33548196 2021. Inactivated COVID-19 vaccines to make a global impact.
33548194 2021. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
33639103 2021. Bell's palsy and SARS-CoV-2 vaccines.
33778791 2021. Convalescent plasma from people vaccinated after COVID-19 infection.
33817676 2021. Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19.
33655229 2021. COVID-19 drug practices risk antimicrobial resistance evolution.
33571468 2021. SARS-CoV-2 vaccination and phase 1 cancer clinical trials.
33556319 2021. Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial.
33817664 2021. Flare of rheumatoid arthritis after COVID-19 vaccination.
33655225 2021. Hydroxychloroquine treatment does not reduce COVID-19 mortality; underdosing to the wrong patients?
33655224 2021. Hydroxychloroquine treatment does not reduce COVID-19 mortality; underdosing to the wrong patients? - Authors' reply.
33817665 2021. The role of antirheumatics in patients with COVID-19.
33754144 2021. Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial.
33782671 2021. Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation.
33782670 2021. Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation - Authors' reply.
33655222 2021. Type I interferon, anti-interferon antibodies, and COVID-19.
33655221 2021. COVID-19 cytokine storm: targeting the appropriate cytokine.
33655220 2021. Perspective of patients with autoimmune diseases on COVID-19 vaccination.
33655219 2021. Vaccination against COVID-19: Expectations and concerns of patients with autoimmune and rheumatic diseases.
33655218 2021. Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study.
33619736 2021. The effect of climbing chalk powder on the infectivity of human coronavirus OC43.
33671893 2021. The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19.
33636175 2021. Targeting RAGE to prevent SARS-CoV-2-mediated multiple organ failure: Hypotheses and perspectives.
33745895 2021. Effects of metformin, insulin on COVID-19 patients with pre-existed type 2 diabetes: A multicentral retrospective study.
33789145 2021. Nanocurcumin improves Treg cell responses in patients with mild and severe SARS-CoV2.
33781826 2021. Heparin prevents in vitro glycocalyx shedding induced by plasma from COVID-19 patients.
33607159 2021. COVID-19, cytokines, inflammation, and spices: How are they related?
33593923 2021. A systems-based method to repurpose marketed therapeutics for antiviral use: a SARS-CoV-2 case study.
33687000 2021. Anti-fibrotic therapy for the treatment of pulmonary sequelae in patients healed by COVID-19.
33686995 2021. Early experience with anti-interleukin-6 therapy in COVID-19 hyperinflammation.
33686972 2021. The link between vitamin D deficiency and COVID-19.
33666135 2021. Bispecific VH/Fab antibodies targeting neutralizing and non-neutralizing Spike epitopes demonstrate enhanced potency against SARS-CoV-2.
33566210 2021. Photosynthetically Controlled Spirulina, but Not Solar Spirulina, Inhibits TNF-alpha Secretion: Potential Implications for COVID-19-Related Cytokine Storm Therapy.
33670191 2021. New Hopes for Drugs against COVID-19 Come from the Sea.
33589849 2021. Preparation of cerium molybdates and their antiviral activity against bacteriophage Phi6 and SARS-CoV-2.
33628136 2020. Why Not Encourage Physical Activity Outdoors and Inhaling Through the Uncovered Nose During the Coronavirus Lockdown?
33718003 2021. Encapsulation of bioactive agent (Curcumin, Moringa) in electrospun nanofibers - Some insights into recent research trends.
33816131 2021. Repurposing antiviral drugs on recently emerged viral infections: A review article.
33757717 2021. Role of vitamin D supplementation in aging patients with COVID-19.
33673930 2021. In Reply - Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019.
33673929 2021. Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019.
33549269 2021. Elevated Rate of HLA Antibodies in Male COVID-19 Convalescent Plasma Donors: A Risk Factor for Transfusion-Related Acute Lung Injury.
33714594 2021. Vitamin D Status Is Associated With In-Hospital Mortality and Mechanical Ventilation: A Cohort of COVID-19 Hospitalized Patients.
33817559 2021. Anti-Inflammatory treatment of COVID-19 pneumonia with tofacitinib alone or in combination with dexamethasone is safe and possibly superior to dexamethasone as a single agent in a predominantly African American cohort.
33748678 2021. Association Between Chronic Statin Use and 30-Day Mortality in Hospitalized Patients With COVID-19.
33585799 2021. Safety and Efficacy of Convalescent Plasma in Elderly COVID-19 Patients: The RESCUE Trial.
33585798 2021. Viral Respiratory Infections: An Ounce of Prevention Is Worth a Pound of Cure.
33785634 2021. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
33653892 2021. Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model.
33653891 2021. Development of Spike Receptor-Binding Domain Nanoparticles as a Vaccine Candidate against SARS-CoV-2 Infection in Ferrets.
33653888 2021. Genetically Engineered Live-Attenuated Middle East Respiratory Syndrome Coronavirus Viruses Confer Full Protection against Lethal Infection.
33653885 2021. The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19.
33563823 2021. Characterization of SARS-CoV-2 RNA, Antibodies, and Neutralizing Capacity in Milk Produced by Women with COVID-19.
33531392 2021. Reply to Marakasova and Baranova, "MMR Vaccine and COVID-19: Measles Protein Homology May Contribute to Cross-Reactivity or to Complement Activation Protection".
33531391 2021. MMR Vaccine and COVID-19: Measles Protein Homology May Contribute to Cross-Reactivity or to Complement Activation Protection.
33564221 2021. Structural modeling and analysis of the SARS-CoV-2 cell entry inhibitor camostat bound to the trypsin-like protease TMPRSS2.
33790352 2021. Computational drug repurposing study elucidating simultaneous inhibition of entry and replication of novel corona virus by Grazoprevir.
33790308 2021. Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial.
33785846 2021. Ivermectin reduces in vivo coronavirus infection in a mouse experimental model.
33767276 2021. Risk of QT prolongation through drug interactions between hydroxychloroquine and concomitant drugs prescribed in real world practice.
33762619 2021. Mining of high throughput screening database reveals AP-1 and autophagy pathways as potential targets for COVID-19 therapeutics.
33737631 2021. Lack of association of baseline 25-hydroxyvitamin D levels with disease severity and mortality in Indian patients hospitalized for COVID-19.
33737545 2021. Computational evidence for nitro derivatives of quinoline and quinoline N-oxide as low-cost alternative for the treatment of SARS-CoV-2 infection.
33737523 2021. Prioritizing antiviral drugs against SARS-CoV-2 by integrating viral complete genome sequences and drug chemical structures.
33723270 2021. The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue.
33707532 2021. Preclinical efficacy and safety analysis of gamma-irradiated inactivated SARS-CoV-2 vaccine candidates.
33692457 2021. Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma.
33692386 2021. Blockade of SARS-CoV-2 spike protein-mediated cell-cell fusion using COVID-19 convalescent plasma.
33692377 2021. Drug design and repurposing with DockThor-VS web server focusing on SARS-CoV-2 therapeutic targets and their non-synonym variants.
33564039 2021. Histone deacetylase inhibitors suppress ACE2 and ABO simultaneously, suggesting a preventive potential against COVID-19.
33558635 2021. Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity nanobody.
33547334 2021. An in silico deep learning approach to multi-epitope vaccine design: a SARS-CoV-2 case study.
33542325 2021. DNA-launched RNA replicon vaccines induce potent anti-SARS-CoV-2 immune responses in mice.
33542252 2021. Sensitive mass spectrometric determination of kinin-kallikrein system peptides in light of COVID-19.
33637783 2021. Exploratory analysis of immunization records highlights decreased SARS-CoV-2 rates in individuals with recent non-COVID-19 vaccinations.
33627767 2021. Identification of candidate repurposable drugs to combat COVID-19 using a signature-based approach.
33619344 2021. In silico detection of SARS-CoV-2 specific B-cell epitopes and validation in ELISA for serological diagnosis of COVID-19.
33794459 2021. Virtual screening of plant-derived compounds against SARS-CoV-2 viral proteins using computational tools.
33578259 2021. Potential interactions between COVID-19 vaccines and antiepileptic drugs.
33677470 2021. Targeting glucose metabolism for treatment of COVID-19.
33790219 2021. Newly synthesized M(pro) inhibitors as potential oral anti-SARS-CoV-2 agents.
33658482 2021. Clinical evidence of an interferon-glucocorticoid therapeutic synergy in COVID-19.

33758167 2021. Identification of bis-benzylisoquinoline alkaloids as SARS-CoV-2 entry inhibitors from a library of natural products.
33654055 2021. Study on the promotion of lymphocytes in patients with COVID-19 by broad-spectrum chemokine receptor inhibitor vMIP-II and its Mechanism of signal transmission in vitro.
33542181 2021. Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir.
33542177 2021. Evaluation of the immunomodulatory effects of anti-COVID-19 TCM formulae by multiple virus-related pathways.
33619243 2021. Therapeutic potential of C1632 by inhibition of SARS-CoV-2 replication and viral-induced inflammation through upregulating let-7.
33612824 2021. Efficacy and safety of systematic corticosteroids among severe COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials.
33531462 2021. Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need.
33568628 2021. Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial.
33724070 2021. Development of a High-Throughput Screening Assay to Identify Inhibitors of the SARS-CoV-2 Guanine-N7-Methyltransferase Using RapidFire Mass Spectrometry.
33786372 2021. Ultraefficiently Calming Cytokine Storm Using Ti3C2T x MXene.
33778374 2021. Compassionate Use of Rectal Ozone (O3) in Severe COVID-19 Pneumonia: a Case-Control Study.
33748676 2021. On BCG Vaccine Protection from COVID-19: A Review.
33644693 2021. Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment.
33623865 2021. The Evidence for High-Titer Convalescent Plasma in SARS-CoV-2.
33558862 2021. Ex vivo assay to evaluate the efficacy of drugs targeting sphingolipids in preventing SARS-CoV-2 infection of nasal epithelial cells.
33688491 2021. Placenta-derived mesenchymal stem cells (P-MSCs) for COVID-19 pneumonia-a regenerative dogma.
33691145 2021. Broad-Spectrum Anti-coronavirus Vaccines and Therapeutics to Combat the Current COVID-19 Pandemic and Future Coronavirus Disease Outbreaks.
33601098 2021. Medical progress: Stem cells as a new therapeutic strategy for COVID-19.
33550140 2021. Structural insights into SARS-CoV-2 infection and therapeutics development.
33648582 2021. Stem cells and COVID-19: are the human amniotic cells a new hope for therapies against the SARS-CoV-2 virus?
33575962 2021. P2Y14 Receptor as a Target for Neutrophilia Attenuation in Severe COVID-19 Cases: From Hematopoietic Stem Cell Recruitment and Chemotaxis to Thrombo-inflammation.
33575961 2021. Results and Prospects of Using Activator of Hematopoietic Stem Cell Differentiation in Complex Therapy for Patients with COVID-19.
33586320 2021. Mesenchymal stem cell immunomodulation: In pursuit of controlling COVID-19 related cytokine storm.
33527780 2021. Mesenchymal stromal cell delivery via an ex vivo bioreactor preclinical test system attenuates clot formation for intravascular application.
33726854 2021. Direct and indirect evidence of efficacy and safety of rapid exercise tests for exertional desaturation in Covid-19: a rapid systematic review.
33765902 2021. Clinical effectiveness of drugs in hospitalized patients with COVID-19: a systematic review and meta-analysis.
33624533 2021. An overview of vaccine development for COVID-19.
33664866 2021. MERS-CoV and SARS-CoV-2 replication can be inhibited by targeting the interaction between the viral spike protein and the nucleocapsid protein.
33558079 2021. Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19.
33579777 2021. Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19.
33662796 2021. Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19.
33685103 2021. Covid-19-vaksiner gir okt risiko for anafylaksi.
33723507 2021. Use of ivermectin in the treatment of Covid-19: A pilot trial.
33733663 2021. COVID-19 vaccines for low- and middle-income countries.
33678561 2021. Convalescent blood plasma (CBP) donated by recovered COVID-19 patients - A comment.
33574010 2021. Convalescent plasma therapy for severe Covid-19 in patients with hematological malignancies.
33637467 2021. Two patients with rituximab associated low gammaglobulin levels and relapsed covid-19 infections treated with convalescent plasma.
33663928 2021. Facts and challenges on global deployment of vaccines for the immunotherapy of the evolving SARS Cov-2 variants: What a new year, with a fast spreading South African and the most fearful Brazilian variants, as the unwanted gifts, imposing enormous crises to surmount.
33610448 2021. Immunotherapy for COVID-19: Evolving treatment of viral infection and associated adverse immunological reactions.
33677086 2021. Constraints and challenges in convalescent plasma collection amidst the Covid 19 pandemic- strategies and recommendations to overcome these.
33675992 2021. Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency.
33604922 2021. High-throughput detection of antibodies targeting the SARS-CoV-2 Spike in longitudinal convalescent plasma samples.
33604884 2021. A longitudinal study of convalescent plasma (CCP) donors and correlation of ABO group, initial neutralizing antibodies (nAb), and body mass index (BMI) with nAb and anti-nucleocapsid (NP) SARS-CoV-2 antibody kinetics: Proposals for better quality of CCP collections.
33590906 2021. Factors driving availability of COVID-19 convalescent plasma: Insights from a demand, production, and supply model.
33559248 2021. Impact of serological and PCR testing requirements on the selection of COVID-19 convalescent plasma donors.
33616966 2021. Decrease in serum antibodies to SARS-CoV-2 in convalescent plasma donors over time.
33615484 2021. Longitudinal analysis of SARS-CoV-2 antibodies in 8000 U.S. first-time convalescent plasma donations.
33586160 2021. COVID-19 convalescent plasma: Interim recommendations from the AABB.
33554362 2021. Selecting COVID-19 convalescent plasma for neutralizing antibody potency using a high-capacity SARS-CoV-2 antibody assay.
33633933 2021. Association between vaccinations and clinical manifestations in children with COVID-19.
33610763 2021. Caution advised when considering "Exceptional" extended or single dose COVID-19 vaccination strategies.
33578045 2021. AZD1222 (Covishield) vaccination for COVID-19: Experiences, challenges, and solutions in Nepal.
33549822 2021. Reply to Alizazgar J. Dangers of the use of hydroxychloroquine and azithromycin combination in COVID-19 patients.
33535106 2021. Risk of Strongyloides Hyperinfection Syndrome when prescribing dexamethasone in severe COVID-19.
33558789 2021. Role of food nutrients and supplementation in fighting against viral infections and boosting immunity: A review.
33785249 2021. Therapeutic Potential of Metformin in COVID-19: Reasoning for Its Protective Role.
33541791 2021. Repurposing Antimalarials to Tackle the COVID-19 Pandemic: (Trends in Parasitology 37, 8-11; 2021).
33750432 2021. Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial.
33573681 2021. Impact of intravenous lidocaine on clinical outcomes of patients with ARDS during COVID-19 pandemia (LidoCovid): A structured summary of a study protocol for a randomised controlled trial.
33779109 2021. The effect of the timing of dexamethasone administration in patients with COVID-19 pneumonia.
33679150 2021. Comparison of clinically approved molecules on SARS-CoV-2 drug target proteins: a molecular docking study.
33726487 2021. Antithrombin, COVID-19, and Fresh Frozen Plasma Treatment
33726482 2021. The Comparison of Lopinavir/Ritonavir Combination and Favipiravir In COVID-19 Treatment.
33646106 2021. Use of Hydroxychloroquine in Patients with COVID-19: A Retrospective Observational Study.
33676782 2021. Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment.
33707061 2021. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine.
33558107 2021. General determination of causation between Covid-19 vaccines and possible adverse events.
33640142 2021. Biosecurity risks associated with vaccine platform technologies.
33744042 2021. Natural unblinding of BCG vaccination trials.
33771389 2021. mRNA vaccines manufacturing: Challenges and bottlenecks.
33731271 2021. Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse.
33525459 2021. Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies.
33567790 2021. Exploring the Effect of Probiotics, Prebiotics, and Postbiotics in Strengthening Immune Activity in the Elderly.
33562203 2021. HIV mRNA Vaccines-Progress and Future Paths.
33562141 2021. Localized and Systemic Immune Responses against SARS-CoV-2 Following Mucosal Immunization.
33546347 2021. COVID-19 Vaccination: From Interesting Agent to the Patient.
33672450 2021. Spike S2 Subunit: The Dark Horse in the Race for Prophylactic and Therapeutic Interventions against SARS-CoV-2.
33670630 2021. COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform.
33668613 2021. Therapeutic Antibodies for the Treatment of Respiratory Tract Infections-Current Overview and Perspectives.
33673048 2021. SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond.
33670249 2021. Construction and Immunogenicity Comparison of Three Virus-Like Particles Carrying Different Combinations of Structural Proteins of Avian Coronavirus Infectious Bronchitis Virus.
33746069 2021. In silico Nigellidine (N. sativa) bind to viral spike/active-sites of ACE1/2, AT1/2 to prevent COVID-19 induced vaso-tumult/vascular-damage/comorbidity.
33638539 2020. Is the production of a Covid-19 vaccine using transformed Pasteurella plausible?
33781287 2021. Precision therapeutic targets for COVID-19.
33639976 2021. Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice.
33714753 2021. Development of a SARS-CoV-2 nucleocapsid specific monoclonal antibody.
33571798 2021. Exploring the efficacy of naturally occurring biflavone based antioxidants towards the inhibition of the SARS-CoV-2 spike glycoprotein mediated membrane fusion.
33660566 2021. Host Defence RNases as Antiviral Agents against Enveloped Single Stranded RNA Viruses.
33631219 2021. Protection against COVID-19 in African population: Immunology, genetics, and malaria clues for therapeutic targets.
33778130 2021. Vaccines and drugs under clinical trials for prevention and treatment of COVID-19.
33778129 2021. Computationally approached inhibition potential of Tinospora cordifolia towards COVID-19 targets.
33758772 2021. A molecular docking study of SARS-CoV-2 main protease against phytochemicals of Boerhavia diffusa Linn. for novel COVID-19 drug discovery.
33748347 2021. Respiratory delivery of favipiravir-tocilizumab combination through mucoadhesive protein-lipidic nanovesicles: prospective therapeutics against COVID-19.
33532517 2021. In silico virtual screening-based study of nutraceuticals predicts the therapeutic potentials of folic acid and its derivatives against COVID-19.
33572467 2021. Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture.
33572452 2021. Synthetic Messenger RNA-Based Vaccines: from Scorn to Hype.
33567520 2021. The Key Role of Nucleic Acid Vaccines for One Health.
33546185 2021. Thapsigargin Is a Broad-Spectrum Inhibitor of Major Human Respiratory Viruses: Coronavirus, Respiratory Syncytial Virus and Influenza A Virus.
33673529 2021. Demystifying Excess Immune Response in COVID-19 to Reposition an Orphan Drug for Down-Regulation of NF-kappaB: A Systematic Review.
33672333 2021. Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro.
33670023 2021. Rational Design of a Pan-Coronavirus Vaccine Based on Conserved CTL Epitopes.
33672785 2021. Recent Hydroxychloroquine Use Is Not Significantly Associated with Positive PCR Results for SARS-CoV-2: A Nationwide Observational Study in South Korea.
33669550 2021. Viral Vectors for COVID-19 Vaccine Development.
33671334 2021. Targeting the Complement Serine Protease MASP-2 as a Therapeutic Strategy for Coronavirus Infections.
33669276 2021. Safety and Outcomes Associated with the Pharmacological Inhibition of the Kinin-Kallikrein System in Severe COVID-19.
33669264 2021. Honeysuckle Aqueous Extracts Induced let-7a Suppress EV71 Replication and Pathogenesis In Vitro and In Vivo and Is Predicted to Inhibit SARS-CoV-2.
33672054 2021. Structure-Based Identification of Natural Products as SARS-CoV-2 M(pro) Antagonist from Echinacea angustifolia Using Computational Approaches.
33670363 2021. Berberine and Obatoclax Inhibit SARS-Cov-2 Replication in Primary Human Nasal Epithelial Cells In Vitro.
33786383 2021. Hydroxychloroquine-Induced cutaneous reaction in treatment of COVID-19.
33779831 2021. The advantages of drug treatment with statins in patients with SARS-CoV-2 infection.
33725201 2021. Profiles of current COVID-19 vaccines.
33721102 2021. Strong correlation between prevalence of severe vitamin D deficiency and population mortality rate from COVID-19 in Europe.

33643762 2021. Cordifolioside: potent inhibitor against M(pro) of SARS-CoV-2 and immunomodulatory through human TGF-beta and TNF-alpha.
33585152 2021. Screening of JAK-STAT modulators from the antiviral plants of Indian traditional system of medicine with the potential to inhibit 2019 novel coronavirus using network pharmacology.
33552835 2021. Mechanistic insight into anti-COVID-19 drugs: recent trends and advancements.
33560642 2021. Nebulized Nitroglycerin for Coronavirus Disease 2019-Associated Acute Respiratory Distress Syndrome: A Case Report.
33623818 2021. Rapidly Establishing a Hospital-Based Convalescent Plasma Collection Center With the Alyx Apheresis Collection Device.
33786375 2021. Potent Noncovalent Inhibitors of the Main Protease of SARS-CoV-2 from Molecular Sculpting of the Drug Perampanel Guided by Free Energy Perturbation Calculations.
33786374 2021. Potent SARS-CoV-2 Direct-Acting Antivirals Provide an Important Complement to COVID-19 Vaccines.
33527087 2021. A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice.
33527086 2021. Modeling the Binding Mechanism of Remdesivir, Favilavir, and Ribavirin to SARS-CoV-2 RNA-Dependent RNA Polymerase.
33527085 2021. De Novo Discovery of High-Affinity Peptide Binders for the SARS-CoV-2 Spike Protein.
33787221 2021. A Clinical-Stage Cysteine Protease Inhibitor blocks SARS-CoV-2 Infection of Human and Monkey Cells.
33787218 2021. Novel Compounds Targeting Neuropilin Receptor 1 with Potential To Interfere with SARS-CoV-2 Virus Entry.
33783182 2021. Inhibition of Human Coronaviruses by Antimalarial Peroxides.
33645977 2021. Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses.
33570381 2021. Challenges for Targeting SARS-CoV-2 Proteases as a Therapeutic Strategy for COVID-19.
33793189 2021. Nano-Enabled COVID-19 Vaccines: Meeting the Challenges of Durable Antibody Plus Cellular Immunity and Immune Escape.
33734675 2021. Membrane Nanoparticles Derived from ACE2-Rich Cells Block SARS-CoV-2 Infection.
33778286 2021. Ethyl Pyruvate as a Potential Defense Intervention against Cytokine Storm in COVID-19?
33778258 2021. Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine, and Pyronaridine: In Vitro Activity against SARS-CoV-2 and Potential Mechanisms.
33644594 2021. Novel Development of Predictive Feature Fingerprints to Identify Chemistry-Based Features for the Effective Drug Design of SARS-CoV-2 Target Antagonists and Inhibitors Using Machine Learning.
33615173 2021. Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial.
33583027 2021. Higher vs Lower Doses of Dexamethasone in Patients with COVID-19 and Severe Hypoxia (COVID STEROID 2) trial: Protocol for a secondary Bayesian analysis.
33533477 2021. Nitric oxide and COVID-19: Dose, timing and how to administer it might be crucial.
33583034 2021. Higher vs lower doses of dexamethasone in patients with COVID-19 and severe hypoxia (COVID STEROID 2) trial: Protocol and statistical analysis plan.
33525227 2020. Current Perspectives of convalescent plasma therapy in COVID-19.
33525212 2020. Efficacy and safety of sofosbuvir/ ledipasvir in treatment of patients with COVID-19; A randomized clinical trial.
33525254 2020. Treatment of COVID-19 in Pregnancy with Hydroxychloroquine and Azithromycin: a case report.
33582839 2021. Metformin use and risk of COVID-19 among patients with type II diabetes mellitus: an NHIS-COVID-19 database cohort study.
33818411 2021. Convalescent Plasma Therapy for COVID-19: Lessons from SARS-CoV, MERS-CoV, and H1N1 Infection.
33527327 2021. Acute disseminated encephalomyelitis after severe acute respiratory syndrome coronavirus 2 vaccination: a case report.
33527456 2021. It's time to change the recommendations on COVID-19 and human milk donations.
33723501 2021. Repurposing CFDA-approved drug carrimycin as an antiviral agent against human coronaviruses, including the currently pandemic SARS-CoV-2.
33614402 2021. Corilagin inhibits SARS-CoV-2 replication by targeting viral RNA-dependent RNA polymerase.
33642607 2020. COVID-19 and Oral Surgery: A narrative review of preoperative mouth rinses.
33612960 2021. Vitamine D et Covid-19.
33561453 2021. Current and prospective computational approaches and challenges for developing COVID-19 vaccines.
33539853 2021. Microarray patches enable the development of skin-targeted vaccines against COVID-19.
33786537 2021. Adsorption of SARS-CoV-2 Spike Protein S1 at Oxide Surfaces Studied by High-Speed Atomic Force Microscopy.
33615316 2021. Adsorption of SARS-CoV-2 Spike Protein S1 at Oxide Surfaces Studied by High-Speed Atomic Force Microscopy.
33751020 2021. Association of Vitamin D Status with SARS-CoV-2 Infection or COVID-19 Severity: A Systematic Review and Meta-analysis.
33783468 2021. Perspective: Nutritional Strategies Targeting the Gut Microbiome to Mitigate COVID-19 Outcomes.
33747847 2021. Nephrotoxicity of Chloroquine and Hydroxychloroquine in COVID-19 Patients.
33786369 2021. Drug Repurposing of Itraconazole and Estradiol Benzoate against COVID-19 by Blocking SARS-CoV-2 Spike Protein-Mediated Membrane Fusion.
33786368 2021. Sulfoglycodendrimer Therapeutics for HIV-1 and SARS-CoV-2.
33678621 2021. Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CL(pro) through high-throughput virtual screening and molecular dynamics simulation.
33735836 2021. Convalescent plasma to treat COVID-19: clinical experience and efficacy.
33638944 2021. The efficiency and safety of high-dose vitamin C in patients with COVID-19: a retrospective cohort study.
33581688 2021. Chemical composition and pharmacological mechanism of ephedra-glycyrrhiza drug pair against coronavirus disease 2019 (COVID-19).
33811756 2021. Beneficial effect of Arbidol in the management of COVID-19 infection.
33788172 2021. Severe vitamin D deficiency is not related to SARS-CoV-2 infection but may increase mortality risk in hospitalized adults: a retrospective case-control study in an Arab Gulf country.
33532128 2021. Metabolic Healthy Obesity, Vitamin D Status, and Risk of COVID-19.
33532123 2021. Low level of Vitamin C and dysregulation of Vitamin C transporter might be involved in the severity of COVID-19 Infection.
33815870 2021. Mesenchymal Stem Cells for the Compassionate Treatment of Severe Acute Respiratory Distress Syndrome Due to COVID 19.
33815867 2021. SARS-CoV-2: the "Uncensored" Truth about Its Origin and Adipose-Derived Mesenchymal Stem Cells as New Potential Immune-Modulatory Weapon.
33738381 2021. Progress in the risk assessment of hydroxychloroquine in frail elderly people.
33659771 2021. Bacillus Calmette-Guerin (BCG): the adroit vaccine.
33643776 2021. Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA: Position statement of the German Allergy Societies: Medical Association of German Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA).
33657648 2021. Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-mediated complement activation.
33722299 2021. COVID-19 vaccine testing & administration guidance for allergists/immunologists from the Canadian Society of Allergy and Clinical Immunology (CSACI).
33546745 2021. Rapid clinical recovery of a SARS-CoV-2 infected common variable immunodeficiency patient following the infusion of COVID-19 convalescent plasma.
33791156 2021. Screening strategy of TMPRSS2 inhibitors by FRET-based enzymatic activity for TMPRSS2-based cancer and COVID-19 treatment.
33617817 2021. Meta-analysis of the Effect of Colchicine on Mortality and Mechanical Ventilation in COVID-19.
33815925 2021. Efficacy and safety of chloroquine and hydroxychloroquine for treatment of COVID-19 patients-a systematic review and meta-analysis of randomized controlled trials.
33748918 2021. Treating Acute Decompensated Heart Failure in Patients with COVID-19 Using Intravenous Nitroglycerin in 5% Glutathione.
33742196 2021. Vitamin D and COVID-19: Can it be protective?
33714645 2021. Emergency department administration of COVID-19 antibody therapies: Early experience.
33821938 2021. COVID-19 vaccines in tribal communities save lives, preserve culture.
33791780 2021. Children's hospital celebrates successful COVID-19 vaccine rollout.
33798480 2021. Anti-severe acute respiratory syndrome coronavirus 2 antibodies induced in breast milk after Pfizer-BioNTech/BNT162b2 vaccination.
33812808 2021. Cord blood antibodies following maternal coronavirus disease 2019 vaccination during pregnancy.
33540139 2021. Coronavirus disease 2019 vaccine in pregnant women: not so far! The importance of counseling and the need for evidence-based data.
33822639 2021. In Silico investigation of the viroporin E as a vaccine target against SARS-CoV-2.
33534047 2021. Methylprednisolone in adults hospitalized with COVID-19 pneumonia : An open-label randomized trial (GLUCOCOVID).
33638618 2021. Silver nanoparticles as a potential treatment against SARS-CoV-2: A review.
33558825 2021. COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee.
33747340 2021. May polyethylene glycol be the cause of anaphylaxis to mRNA COVID-19 vaccines?
33728315 2021. Human menstrual blood-derived stem cells as immunoregulatory therapy in COVID-19: A case report and review of the literature.
33708343 2021. Targeting mesenchymal stem cell therapy for severe pneumonia patients.
33816150 2021. Are nucleotide inhibitors, already used for treating hepatitis C virus infection, a potential option for the treatment of COVID-19 compared with standard of care? A literature review.
33816149 2021. Bottom-up analysis of emergent properties of N-acetylcysteine as an adjuvant therapy for COVID-19.
33585175 2021. Emerging therapeutics in the management of COVID-19.
33691913 2021. Efficacy and safety of COVID-19 vaccines: a systematic review.
33606519 2021. Simultaneous Inhibition of SARS-CoV-2 Entry Pathways by Cyclosporine.
33738063 2021. Design and Structure-Activity Relationship of a Potent Furin Inhibitor Derived from Influenza Hemagglutinin.
33615193 2021. Glycosylation of SARS-CoV-2 Steers Evolutionary Outcomes in the Postvaccination Phase.
33615192 2021. Docking Prediction of Levodopa in the Receptor Binding Domain of Spike Protein of SARS-CoV-2.
33615189 2021. Identification of Novel MicroRNAs as Promising Therapeutics for SARS-CoV-2 by Regulating the EGFR-ADAM17 Axis: An In Silico Analysis.
33792500 2021. Allergic reactions to COVID-19 vaccines: statement of the Belgian Society for Allergy and Clinical Immunology (BelSACI).
33547771 2021. Allergic Reactions to COVID-19 Vaccines: An Allergist's Perspective.
33779985 2021. The potential neurological effect of the COVID-19 vaccines: A review.
33710026 2021. Tenofovir-based PrEP for COVID-19: an untapped opportunity?
33619997 2021. Darunavir/Cobicistat Is Associated with Negative Outcomes in HIV-Negative Patients with Severe COVID-19 Pneumonia.
33750742 2021. New SARS-CoV-2 Variants Challenge Vaccines Protection.
33787294 2021. Reply to "Unilateral Axillary Lymphadenopathy After Coronavirus Disease (COVID-19) Vaccination".
33617289 2021. Unilateral Axillary Lymphadenopathy After Coronavirus Disease (COVID-19) Vaccination.
33646823 2021. COVID-19 Vaccination-Related Uptake on FDG PET/CT: An Emerging Dilemma and Suggestions for Management.
33543649 2021. Management of Unilateral Axillary Lymphadenopathy Detected on Breast MRI in the Era of Coronavirus Disease (COVID-19) Vaccination.
33624520 2021. Coronavirus Disease (COVID-19) Vaccination Associated Axillary Adenopathy: Imaging Findings and Follow-Up Recommendations in 23 Women.
33617288 2021. Mitigating the Impact of Coronavirus Disease (COVID-19) Vaccinations on Patients Undergoing Breast Imaging Examinations: A Pragmatic Approach.
33528947 2021. BCG immunization and COVID-19 disease association.
33528938 2021. Inhaled corticosteroids may have a protective effect against coronavirus infection.
33811364 2021. Vaccines and Allergic reactions: The past, the current COVID-19 pandemic, and future perspectives.
33811358 2021. Management of anaphylaxis due to COVID-19 vaccines in the elderly.
33811344 2021. Skin tests in urticaria/angioedema and flushing to Pfizer-BioNTech SARS-CoV-2 vaccine: Limits of intradermal testing.
33609346 2021. Prakriti Analysis of COVID 19 Patients: An Observational Study.
33683189 2021. Add-On Chinese Medicine for Coronavirus Disease 2019 (ACCORD): A Retrospective Cohort Study of Hospital Registries.
33642127 2021. Neuroleptic malignant syndrome following COVID-19 vaccination.
33784482 2021. A Recombinant Fragment of Human Surfactant Protein D Binds Spike Protein and Inhibits Infectivity and Replication of SARS-CoV-2 in Clinical Samples.
33770450 2021. COVID-19 and Coagulopathy.
33759735 2021. What Are COVID-19 Vaccines?
33590992 2021. "Remdesivir-Associated Pancreatitis".

33564823 2021. Biases in evaluating the safety and effectiveness of drugs for covid-19: designing real-world evidence studies.
33599721 2021. Impact of hydroxychloroquine on disease progression and ICU admissions in patients with SARS-CoV-2 infection.
33617629 2021. Acute and severe ribavirin-associated hyperuricemia and acute kidney injury: An underrecognized adverse effect.
33606296 2021. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination.
33580970 2021. Familial thrombocytopenia flare-up following the first dose of mRNA-1273 Covid-19 vaccine.
33476455 2021. Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine.
33705721 2021. Bacillus Calmette-Guerin Vaccine and Nonspecific Immunity.
33667433 2021. Association of Pre-Admission Statin Use With Reduced In-Hospital Mortality in COVID-19.
33545113 2021. Inclusion of pregnant individuals among priority populations for coronavirus disease 2019 vaccination for all 50 states in the United States.
33539825 2021. Professionally responsible coronavirus disease 2019 vaccination counseling of obstetrical and gynecologic patients.
33529575 2021. The coronavirus disease 2019 vaccine in pregnancy: risks, benefits, and recommendations.
33775692 2021. Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study.
33727113 2021. Prioritization of pregnant individuals in state plans for coronavirus disease 2019 vaccination.
33621715 2021. Reply: Coronavirus disease 2019 vaccines in pregnancy.
33621714 2021. Coronavirus disease 2019 vaccines in pregnancy.
33540140 2021. Reply to: Coronavirus disease 2019 vaccine in pregnant women: not so far! The importance of counseling and the need for evidence-based data.
33771762 2021. Pregnant women's perspectives on severe acute respiratory syndrome coronavirus 2 vaccine.
33561380 2021. Carrageenan-containing over-the-counter nasal and oral sprays inhibit SARS-CoV-2 infection of airway epithelial cultures.
33632650 2021. The Benefits of Vaccinating With the First Available COVID-19 Coronavirus Vaccine.
33641268 2021. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine - United States, December 21, 2020-January 10, 2021.
33641264 2021. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine - United States, December 14-23, 2020.
33555140 2021. The advisory Committee on Immunization practices' updated interim recommendation for allocation of COVID-19 vaccine-United states, December 2020.
33720844 2021. Dexamethasone and COVID-19: Strategies in Low- and Middle-Income Countries to Tackle Steroid-Related Strongyloides Hyperinfection.
33774261 2021. COVID-19 vaccines: A race against time.
33771754 2021. Even vaccinated against COVID-19, we must continue to wear a mask.
33608752 2021. Screening and evaluation of anti-SARS-CoV-2 components from Ephedra sinica by ACE2/CMC-HPLC-IT-TOF-MS approach.
33612558 2021. Optimization of Analytical Procedure for In-hospital Rapid Quantification of Serum Level of Favipiravir in the Pharmacological Treatment of COVID-19.
33606889 2021. Re(I) Tricarbonyl Complexes as Coordinate Covalent Inhibitors for the SARS-CoV-2 Main Cysteine Protease.
33655614 2021. Targeting the Main Protease of SARS-CoV-2: From the Establishment of High Throughput Screening to the Design of Tailored Inhibitors.
33561300 2021. Aptamer Blocking Strategy Inhibits SARS-CoV-2 Virus Infection.
33775077 2021. Chloroquine and hydroxychloroquine - safety profile of potential COVID-19 drugs from the rheumatologist's perspective.
33781933 2021. Misdiagnosis of systemic allergic reactions to mRNA COVID-19 vaccines.
33775902 2021. Polyethylene glycol and polysorbate skin testing in the evaluation of coronavirus disease 2019 vaccine reactions: Early report.
33550776 2021. Review of COVID-19 Vaccines and Their Evidence in Older Adults.
33769829 2021. COVID-19 Vaccine: Practical Clinical Considerations.
33721523 2021. Correction: Remdesivir for Adults With COVID-19.
33560863 2021. Major Update: Remdesivir for Adults With COVID-19 : A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points.
33560862 2021. Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2).
33646837 2021. Risk Compensation and COVID-19 Vaccines.
33721540 2021. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19.
33721539 2021. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19.
33721533 2021. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19.
33617726 2021. Web Exclusive. Annals On Call - Pregnancy, Lactation, and the COVID-19 Vaccines.
33819057 2021. Administration of a Second Dose of the Moderna COVID-19 Vaccine After an Immediate Hypersensitivity Reaction With the First Dose: Two Case Reports.
33620016 2021. Effect of a genetically engineered interferon-alpha versus traditional interferon-alpha in the treatment of moderate-to-severe COVID-19: a randomised clinical trial.
33815783 2021. Oxford-AstraZeneca COVID-19 vaccine (AZD1222) is ideal for resource-constrained low- and middle-income countries.
33585031 2021. "Tocilizumab-an option for patients with COVID-19 associated cytokine release syndrome: A single center experience", a retrospective study-original article.
33552506 2021. SARS-CoV-2 vaccine candidates: A beginning of the end of COVID-19 pandemic- Editorial.
33794291 2021. Estrogen and COVID-19: friend or foe?
33691446 2021. The pharmacological mechanism of Huashi Baidu Formula for the treatment of COVID-19 by combined network pharmacology and molecular docking.
33762264 2021. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort.
33563595 2021. EULAR December 2020 View points on SARS-CoV-2 vaccination in patients with RMDs.
33547062 2021. EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19.
33589438 2021. Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider.
33807320 2021. Clinical Efficacy of Hydroxychloroquine in Patients with COVID-19: Findings from an Observational Comparative Study in Saudi Arabia.
33809983 2021. Comparative Investigation of Composition, Antifungal, and Anti-Inflammatory Effects of the Essential Oil from Three Industrial Hemp Varieties from Italian Cultivation.
33558301 2021. Remdesivir for COVID-19: Why Not Dose Higher?
33558300 2021. Considering Personalized Interferon Beta Therapy for COVID-19.
33558299 2021. AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19.
33558296 2021. Plitidepsin: a Repurposed Drug for the Treatment of COVID-19.
33526482 2021. Kinetic Characterization and Inhibitor Screening for the Proteases Leading to Identification of Drugs against SARS-CoV-2.
33649117 2021. The anti-influenza virus drug favipiravir has little effect on replication of SARS-CoV-2 in cultured cells.
33649113 2021. Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2.
33593840 2021. Anaphylaxis Due to Remdesivir.
33578849 2021. Potential Role of Antioxidant and Anti-Inflammatory Therapies to Prevent Severe SARS-Cov-2 Complications.
33535459 2021. Native High-Density Lipoproteins (HDL) with Higher Paraoxonase Exerts a Potent Antiviral Effect against SARS-CoV-2 (COVID-19), While Glycated HDL Lost the Antiviral Activity.
33713730 2021. Combined in silico and in vitro approaches identified the antipsychotic drug lurasidone and the antiviral drug elbasvir as SARS-CoV2 and HCoV-OC43 inhibitors.
33813272 2021. ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model.
33808612 2021. Changes in 25-(OH) Vitamin D Levels during the SARS-CoV-2 Outbreak: Lockdown-Related Effects and First-to-Second Wave Difference-An Observational Study from Northern Italy.
33799618 2021. Lymphadenopathy after BNT162b2 Covid-19 Vaccine: Preliminary Ultrasound Findings.
33801808 2021. Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2.
33800947 2021. Targeting MMP-Regulation of Inflammation to Increase Metabolic Tolerance to COVID-19 Pathologies: A Hypothesis.
33810129 2021. Antiviral Cyanometabolites-A Review.
33810011 2021. Deep Learning for Novel Antimicrobial Peptide Design.
33808721 2021. Comprehensive Virtual Screening of the Antiviral Potentialities of Marine Polycyclic Guanidine Alkaloids against SARS-CoV-2 (COVID-19).
33709491 2021. Synthetic Homogeneous Glycoforms of the SARS-CoV-2 Spike Receptor-Binding Domain Reveals Different Binding Profiles of Monoclonal Antibodies.
33684258 2021. Neutralizing Aptamers Block S/RBD-ACE2 Interactions and Prevent Host Cell Infection.
33683787 2021. A SARS-CoV-2 Spike Binding DNA Aptamer that Inhibits Pseudovirus Infection by an RBD-Independent Mechanism.
33735603 2021. A Role for Steroids in COVID-19-associated Pneumonitis at Six-Week Follow-Up?
33735602 2021. Reply: A Role for Steroids in COVID-19-associated Pneumonitis at Six-Week Follow-Up?
33721541 2021. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19.
33646836 2021. In high-risk adults, the Moderna vaccine had 94% efficacy against COVID-19 >/=14 d after the 2nd dose.
33646835 2021. In adults, the Oxford/AstraZeneca vaccine had 70% efficacy against COVID-19 >14 d after the 2nd dose.
33554941 2020. COVID-19 reminds us: community vitamin D deficiency.
33710649 2021. ANA Investigates: Neurological Complications of COVID-19 Vaccines.
33657863 2021. Mechanisms and Potential Roles of Glucose-Lowering Agents in COVID-19: A Review.
33757968 2021. Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases.
33741555 2021. Safety ofthefirstdose ofmRNA SARS-CoV-2vaccines inpatients with rheumatic and musculoskeletal diseases.
33607929 2021. N-Acetylcysteine and Hydrogen Sulfide in Coronavirus Disease 2019.
33704086 2020. The protease inhibitor lopinavir, boosted with ritonavir, as treatment for COVID-19: a rapid review.
33568494 2021. SARS-CoV-2 genome and antibodies in breastmilk: a systematic review and meta-analysis.
33740339 2021. No association between vitamin D status and COVID-19 infection in Sao Paulo, Brazil.
33636983 2021. Infliximab and Intravenous Gammaglobulin in Hospitalized Severe COVID-19 Patients in Intensive Care Unit.
33770443 2021. Nutraceutical management of metabolic syndrome as a palliative and a therapeutic to coronavirus disease (COVID) crisis.
33779073 2021. Prophylaxis of COVID-19 with Hydroxychloroquine and Chloroquine.
33728796 2021. American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1.
33645342 2021. Virus-associated ribozymes and nano carriers against COVID-19.
33786833 2021. SARS-CoV-2 (COVID-19) vaccination in dermatology patients on immunomodulatory and biologic agents: Recommendations from the Australasian Medical Dermatology Group.
33626309 2021. A clinical conundrum: clozapine and COVID-19.
33711361 2021. Mesenchymal stem cells: Biological characteristics and application in disease therapy.
33721722 2021. Wide-range direct detection of 25-hydroxyvitamin D3 using polyethylene-glycol-free gold nanorod based on LSPR aptasensor.
33797130 2021. Discovery of potent Covid-19 main protease inhibitors using integrated drug-repurposing strategy.
33687925 2021. Covid-19: Booster dose will be needed in autumn to avoid winter surge, says government adviser.
33664083 2021. Vitamin D and covid-19.
33658188 2021. Covid-19: Schedule breast screening before vaccine or 4 to 6 weeks after to avoid false positives, says guidance.
33757984 2021. Covid-19: variants and vaccination.
33757958 2021. Covid-19: Officials query data from AstraZeneca's US vaccine trial.
33753451 2021. Covid-19: AstraZeneca vaccine prevents 79% of symptomatic disease and 100% of severe disease, US study finds.
33653737 2021. Covid-19: Single dose of Pfizer and Oxford vaccines cuts risk of hospital admission by 80% in over 80s, data suggest.
33653708 2021. Covid-19: Where are we on vaccines and variants?
33741638 2021. Covid-19: AstraZeneca vaccine is not linked to increased risk of blood clots, finds European Medicine Agency.
33741559 2021. Covid-19: What do we know about Sputnik V and other Russian vaccines?

33711336 2021. Emetine suppresses SARS-CoV-2 replication by inhibiting interaction of viral mRNA with eIF4E.
33549572 2021. Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir.
33714660 2021. Influence of Cytokine Release Syndrome in Severe COVID-19 Patients Treated With Tocilizumab Over the Quantiferon TB Gold Plus Results.
33527308 2021. DPP4 Inhibitors and COVID-19-Holy Grail or Another Dead End?
33546870 2021. Immunoinformatics Approach for the Identification and Characterization of T Cell and B Cell Epitopes towards the Peptide-Based Vaccine against SARS-CoV-2.
33785208 2021. Probiotics in Prevention and Treatment of COVID-19: Current Perspective and Future Prospects.
33589286 2021. Bioinformatics Analysis for Screening of Therapeutic Drugs in COVID-19.
33747291 2021. It is time to consider an anti-inflammatory therapy based on the pathophysiology of COVID-19 infection during the right time window?
33745067 2021. The emerging role of probiotics as a mitigation strategy against coronavirus disease 2019 (COVID-19).
33656063 2021. BRAZILIAN IBD STUDY GROUP POSITION STATEMENT ON SARS-COV2 VACCINATION.
33787036 2021. Nutritional practice in critically ill COVID-19 patients: A multicenter ambidirectional cohort study in Wuhan and Jingzhou.
33664546 2021. COVID-19 vaccines - are we there yet?
33664542 2021. Evolving evidence for immunosuppressants in COVID-19.
33629195 2021. Does remote ischaemic conditioning reduce inflammation? A focus on innate immunity and cytokine response.
33782651 2021. Perspectives on plant flavonoid quercetin-based drugs for novel SARS-CoV-2.
33527080 2021. Virtual screening of phytochemical compounds as potential inhibitors against SARS-CoV-2 infection.
33526326 2021. The protective effect of rheumatic disease agents in COVID-19.
33723524 2021. Virus-inspired surface-nanoengineered antimicrobial liposome: A potential system to simultaneously achieve high activity and selectivity.
33527003 2021. Molecular dynamics analysis of phytochemicals from Ageratina adenophora against COVID-19 main protease (M(pro)) and human angiotensin-converting enzyme 2 (ACE2).
33520034 2021. Therapeutic potential of medicinal plants against COVID-19: The role of antiviral medicinal metabolites.
33817352 2021. Repurposing of approved drugs with potential to interact with SARS-CoV-2 receptor.
33681482 2021. In silico investigation of potential inhibitors to main protease and spike protein of SARS-CoV-2 in propolis.
33756342 2021. A tissue- and gender-specific regulation of the SARS-CoV-2 receptor ACE2 by p53 in pigs.
33571909 2021. 5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro.
33588235 2021. EGCG, a green tea polyphenol, inhibits human coronavirus replication in vitro.
33722535 2021. Dipeptidyl peptidase 4 inhibitors: Applications in innate immunity?
33628506 2021. A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild to Moderate COVID-19 Infections.
33731300 2021. Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate.
33552630 2021. Peptides-based vaccine against SARS-nCoV-2 antigenic fragmented synthetic epitopes recognized by T cell and beta-cell initiation of specific antibodies to fight the infection.
33532594 2021. IDentif.AI: Rapidly optimizing combination therapy design against severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) with digital drug development.
33795932 2021. The Relevance of Bioinformatics Applications in the Discovery of Vaccine Candidates and Potential Drugs for COVID-19 Treatment.
33693506 2021. COVID-19: disease pathways and gene expression changes predict methylprednisolone can improve outcome in severe cases.
33630276 2021. The Role of Diet and Supplementation of Natural Products in COVID-19 Prevention.
33574654 2021. Convalescent Plasma for the Treatment of Severe COVID-19.
33736953 2021. Phytochemicals against SARS-CoV as potential drug leads.
33727051 2021. Development of multi-epitope peptide-based vaccines against SARS-CoV-2.
33727050 2021. A brief review on potential application of mesenchymal stem cell and secretome in combating mortality and morbidity in COVID-19 patients.
33640332 2021. Exploring algae and cyanobacteria as a promising natural source of antiviral drug against SARS-CoV-2.
33608241 2021. Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment.
33589377 2021. Neutralizing monoclonal antibodies for COVID-19 treatment and prevention.
33542545 2021. COVID-19, adrenal gland, glucocorticoids, and adrenal insufficiency.
33761591 2021. Research progress of traditional Chinese medicine against COVID-19.
33561649 2021. Repurposing potential of Ayurvedic medicinal plants derived active principles against SARS-CoV-2 associated target proteins revealed by molecular docking, molecular dynamics and MM-PBSA studies.
33556871 2021. An update review of emerging small-molecule therapeutic options for COVID-19.
33550049 2021. Targets and strategies for vaccine development against SARS-CoV-2.
33529945 2021. Stem cell therapy in COVID-19: Pooled evidence from SARS-CoV-2, SARS-CoV, MERS-CoV and ARDS: A systematic review.
33721754 2021. Antiviral activity of oleandrin and a defined extract of Nerium oleander against SARS-CoV-2.
33811098 2021. Impact of corticosteroids in hospitalised COVID-19 patients.
33792391 2021. Treatment of COVID-19: a review of current and prospective pharmacotherapies.
33769885 2021. COVID-19 vaccines and vaccine administration.
33641685 2021. Zinc deficiency as a possible risk factor for increased susceptibility and severe progression of Corona Virus Disease 19.
33811310 2021. Supplementary Therapeutic Possibilities to Alleviate Myocardial Damage Due to Microvascular Dysfunction in Coronavirus Disease 2019 (COVID-19).
33811809 2021. BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection.
33811811 2021. Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2.
33799966 2021. Mesenchymal Stem Cell-Derived Exosomes Exhibit Promising Potential for Treating SARS-CoV-2-Infected Patients.
33798507 2021. Role of phytoconstituents in the management of COVID-19.
33821213 2021. COVID-19 into Chemical Science Perspective: Chemical Preventive Measures and Drug Development.
33820462 2021. Circadian clock modulating small molecules repurposing as inhibitors of SARS-CoV-2 M(pro) for pharmacological interventions in COVID-19 pandemic.
33821193 2021. Vitamin D and COVID-19 in an immunocompromised patient with multiple comorbidities-A Case Report.
33821192 2021. Combination of convalescent plasma therapy and repurposed drugs to treat severe COVID-19 patient with multimorbidity.
33558274 2021. Covid-19: First UK vaccine safety data are "reassuring," says regulator.
33541863 2021. Covid-19: Israel sees new infections plummet following vaccinations.
33536232 2021. Covid-19: New data on Oxford AstraZeneca vaccine backs 12 week dosing interval.
33536182 2021. Why aren't covid-19 vaccines being manufactured in standard prefilled syringes?
33632676 2021. Covid-19: Pfizer BioNTech vaccine reduced cases by 94% in Israel, shows peer reviewed study.
33627357 2021. Optimal dosing interval for covid-19 vaccines: we need clinical trial evidence and to consider past infection.
33622695 2021. Behind the scenes of the Pfizer BioNTech covid-19 vaccine trial.
33619168 2021. Defer vaccination of people who have had covid-19.
33619037 2021. Covid-19: First doses of vaccines in Scotland led to a substantial fall in hospital admissions.
33531342 2021. Covid-19: Russian vaccine efficacy is 91.6%, show phase III trial results.
33531333 2021. Covid-19: People who have had infection might only need one dose of mRNA vaccine.
33574097 2021. Covid-19: Arthritis drug tocilizumab reduces deaths in hospitalised patients, study shows.
33526412 2021. Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant.
33795232 2021. Covid-19: Pfizer reports 100% vaccine efficacy in children aged 12 to 15.
33795218 2021. Covid-19: Moderna and Pfizer vaccines prevent infections as well as symptoms, CDC study finds.
33760277 2021. Will AstraZeneca be able to provide clinical trial data on its COVID-19 vaccine efficacy in older adults?
33763917 2021. Liver and kidney function in patients with Covid-19 treated with remdesivir.
33742473 2021. Zinc supplementation as an adjunct therapy for COVID-19: Challenges and opportunities.
33539240 2021. Corticosteroids, mortality and mechanical ventilation in COVID-19.
33539237 2021. COVID-19 vaccination in the UK: is it time to celebrate?
33632683 2021. COVID-19 vaccine availability: what are the side effects?
33769552 2021. Dual inhibition of CB1 receptors and iNOS, as a potential novel approach to the pharmacological management of acute and long COVID-19.
33729819 2021. Could boron-containing compounds (BCCs) be effective against SARS-CoV-2 as anti-viral agent?
33618530 2021. Potential therapeutic road for targeting the SARS-CoV-2 at throat.
33618529 2021. The relationship between vitamin D and the severity of COVID-19.
33622040 2021. The Canadian Society of Breast Imaging/ Canadian Association of Radiologists' Recommendations for the Management of Axillary Adenopathy in Patients With Recent COVID-19 Vaccination.
33534645 2021. Challenges and Opportunities for COVID-19 Vaccines in Patients with Cancer.
33740455 2021. Antivirals with common targets against highly pathogenic viruses.
33740454 2021. Novel approaches for vaccine development.
33653052 2021. Combination anti-coronavirus therapies based on nonlinear mathematical models.
33647240 2021. Low risk of the TMPRSS2 inhibitor camostat mesylate and its metabolite GBPA to act as perpetrators of drug-drug interactions.
33651072 2021. Targeting SARS-CoV-2 spike protein by stapled hACE2 peptides.
33719401 2021. Chemical and Biochemical Aspects of Molecular Hydrogen in Treating Kawasaki Disease and COVID-19.
33797868 2021. Inspecting the Mechanism of Fragment Hits Binding on SARS-CoV-2 M(pro) by Using Supervised Molecular Dynamics (SuMD) Simulations.
33660489 2021. 25-Hydroxyvitamin D concentrations in COVID-19 patients hospitalized in intensive care unit during the first wave and the second wave of the pandemic.
33554566 2021. Vitamin-D levels and intensive care unit outcomes of a cohort of critically ill COVID-19 patients.
33813758 2021. Adverse reactions to COVID-19 vaccines: A practical approach.
33719087 2021. Dietary deprivation during the COVID-19 pandemic producing acquired vulval zinc-deficiency dermatitis.
33577095 2021. The "coloring wipes" phenomenon: a peculiar skin pigmentation induced by ascorbic acid observed during lockdown.
33719081 2021. Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.
33684970 2021. Nicorandil a magic bullet or a double edged sword in critically ill COVID-19 patients?
33560913 2020. CRISPR-Cas13 as an Antiviral Strategy for Coronavirus Disease 2019.
33769769 2021. Plasmapheresis Efficiency in Coronavirus Disease 2019: More Related to What You Add and Not What You Take Away?
33731635 2021. Is "Mega-Dose" IV Vitamin C Required for Septic and Critical Coronavirus Disease 2019 Patients?
33591008 2021. The Surviving Sepsis Campaign: Research Priorities for Coronavirus Disease 2019 in Critical Illness.
33685299 2021. Lactoferrin: an overview of its main functions, immunomodulatory and antimicrobial role, and clinical significance.
33645486 2021. Integrated Nutritional Supports for Diabetic Patients during COVID-19 Infection: A Comprehensive Review.
33797367 2021. Novel Pulmonary Delivery of Antiviral Drugs for Treating COVID-19 in Patients with Parkinson's Disease.
33588727 2021. Small-molecule antiviral agents in ongoing clinical trials for COVID-19.
33781188 2021. Protein-ligand Docking Simulations with AutoDock4 Focused on the Main Protease of SARS-CoV-2.
33550959 2021. Natural Products as Potential Agents Against SARS-CoV and SARS-CoV-2.
33563148 2021. Nucleoside Inhibitors of Coronaviruses.

33691249 2021. Fluoxetine as an anti-inflammatory therapy in SARS-CoV-2 infection.
33662680 2021. Flavonoids against the SARS-CoV-2 induced inflammatory storm.
33732744 2021. Both Chloroquine and Lopinavir/Ritonavir Are Ineffective for COVID-19 Treatment and Combined Worsen the Pathology: A Single-Center Experience with Severely Ill Patients.
33728324 2021. Immunoinformatics and Molecular Docking Studies Predicted Potential Multiepitope-Based Peptide Vaccine and Novel Compounds against Novel SARS-CoV-2 through Virtual Screening.
33708993 2021. Impact of Ethnicity and Underlying Comorbidity on COVID-19 Inhospital Mortality: An Observational Study in Abu Dhabi, UAE.
33564683 2021. Comparison of Immune Response between SARS, MERS, and COVID-19 Infection, Perspective on Vaccine Design and Development.
33731494 2021. Antiviral Efficacy of Pralatrexate against SARS-CoV-2.
33557097 2021. In Silico Screening of Natural Products Isolated from Mexican Herbal Medicines against COVID-19.
33671652 2021. Screening and Molecular Modeling Evaluation of Food Peptides to Inhibit Key Targets of COVID-19 Virus.
33671255 2021. Multivalent Display of SARS-CoV-2 Spike (RBD Domain) of COVID-19 to Nanomaterial, Protein Ferritin Nanocages.
33676041 2021. Molecular designing, crystal structure determination and in silico screening of copper(II) complexes bearing 8-hydroxyquinoline derivatives as anti-COVID-19.
33667900 2021. Discovery of novel inhibitors against main protease (Mpro) of SARS-CoV-2 via virtual screening and biochemical evaluation.
33753260 2021. SARS-CoV-2 main protease inhibition by compounds isolated from Luffa cylindrica using molecular docking.
33689873 2021. Application of niclosamide and analogs as small molecule inhibitors of Zika virus and SARS-CoV-2 infection.
33662537 2021. Design, synthesis and biological evaluation of 2-aminoquinazolin-4(3H)-one derivatives as potential SARS-CoV-2 and MERS-CoV treatments.
33775840 2021. Identification of non-covalent SARS-CoV-2 main protease inhibitors by a virtual screen of commercially available drug-like compounds.
33711743 2021. Evaluation of potential anti-RNA-dependent RNA polymerase (RdRP) drugs against the newly emerged model of COVID-19 RdRP using computational methods.
33585808 2021. An update to monoclonal antibody as therapeutic option against COVID-19.
33590853 2021. In vitro selection of an RNA aptamer yields an interleukin-6/interleukin-6 receptor interaction inhibitor.
33624754 2021. Knowing and combating the enemy: a brief review on SARS-CoV-2 and computational approaches applied to the discovery of drug candidates.
33746182 2021. COVID-19 vaccine research focusses on safety, efficacy, immunoinformatics, and vaccine production and delivery: a bibliometric analysis based on VOSviewer.
33612990 2021. Coronavirus-Replikation: Mechanismus und Inhibition durch Remdesivir.
33612989 2021. COR-101, ein menschlicher Antikorper gegen COVID-19.
33629351 2021. Efficacy of mesenchymal stromal cells and cellular products in improvement of symptoms for COVID-19 and similar lung diseases.
33547723 2021. COVID-19 vaccines for rapid global impact.
33560402 2021. Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19.
33621948 2021. Effectiveness of convalescent plasma in Indian patients with COVID-19.
33789273 2021. Convalescent Blood: Current Perspective on the Efficacy of a Legacy Approach in COVID-19 Treatment.
33721869 2021. Should the Therapeutic Apheresis Method Be Added to Treatment in the COVID-19 Outbreak?
33771096 2021. In silico comparative study of SARS-CoV-2 proteins and antigenic proteins in BCG, OPV, MMR and other vaccines: evidence of a possible putative protective effect.
33711981 2021. Repurposing novel therapeutic candidate drugs for coronavirus disease-19 based on protein-protein interaction network analysis.
33531083 2021. De novo design and bioactivity prediction of SARS-CoV-2 main protease inhibitors using recurrent neural network-based transfer learning.
33765919 2021. Vaccinomic approach for novel multi epitopes vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
33673818 2021. Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India.
33761870 2021. Efficacy and safety of Levamisole treatment in clinical presentations of non-hospitalized patients with COVID-19: a double-blind, randomized, controlled trial.
33706794 2021. Impact of previous exposure to systemic corticosteroids on unfavorable outcome in patients hospitalized for COVID-19.
33618696 2021. Proposal of selective wedge instillation of pulmonary surfactant for COVID-19 pneumonia based on computational fluid dynamics simulation.
33785004 2021. Protective role of intravesical BCG in COVID-19 severity.
33541971 2021. Steroid harms if given early in COVID-19 viraemia.
33622757 2021. COVID-19 cardiac injury and the use of colchicine.
33558355 2021. Examination of patient characteristics and hydroxychloroquine use based on the US Food and Drug Administration's recommendation: a cross-sectional analysis in New York.
33664123 2021. Association between influenza vaccination and hospitalisation or all-cause mortality in people with COVID-19: a retrospective cohort study.
33662986 2021. Desarrollo de vacunas contra el SARS-CoV-2.
33564122 2021. Allogeneic stem cell transplantation in acute leukemia patients after COVID-19 infection.
33823270 2021. Covid-19 vaccine and autoimmunity: Awakening the sleeping dragon.
33768222 2021. Single dose of a mRNA SARS-CoV-2 vaccine is associated with lower nasopharyngeal viral load among nursing home residents with asymptomatic COVID-19.
33749746 2021. Remdesivir: An antiviral still seeking a raison d'etre.
33819571 2021. Fourteen-day survival among older adults with severe infection with severe acute respiratory syndrome coronavirus 2 treated with corticosteroid: a cohort study.
33813110 2021. Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial.
33705574 2021. Vaccines: Underlying Principles of Design and Testing.
33624299 2021. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.
33722106 2021. Adjunctive intravenous immunoglobulins (IVIg) for moderate-severe COVID-19: emerging therapeutic roles.
33810947 2021. Serum IP-10 and IL-7 levels are associated with disease severity of coronavirus disease 2019.
33593661 2021. Granulocyte macrophage colony-stimulating factor has come of age: From a vaccine adjuvant to antiviral immunotherapy.
33814294 2021. Letter to the Editor in response to article: Hypocalcemia is associated with severe COVID-19: A systematic review and meta-analysis (Martha et al.).
33823331 2021. Impact of the vitamin D deficiency on COVID-19 infection and mortality in Asian countries.
33802453 2021. Comparative Assessment of Sera from Individuals after S-Gene RNA-Based SARS-CoV-2 Vaccination with Spike-Protein-Based and Nucleocapsid-Based Serological Assays.
33804914 2021. Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines.
33588980 2021. Exploration of Association Between Respiratory Vaccinations With Infection and Mortality Rates of COVID-19.
33820650 2021. The Covid-19 infection: An opportunity to develop systematic vitamin D supplementation in psychiatry.
33819636 2021. Vitamin D Sufficiency and COVID-19: Is Vitamin D Binding Protein (and Its Polymorphism) the Missing Link?
33819635 2021. Authors' Reply: Vitamin D Sufficiency and COVID-19: Is Vitamin D Binding Protein (and Its Polymorphism) the Missing Link?
33769268 2021. Biological drugs in paediatric COVID-19 infection: what patients, which drug, how much and how long.
33635229 2021. The safety profile of hydroxychloroquine: major cutaneous and extracutaneous adverse events.
33527123 2021. On Setting Expectations for a Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine.
33782318 2021. 18F-FDG-Avid Lymph Nodes After COVID-19 Vaccination on 18F-FDG PET/CT.
33782299 2021. Axillary Lymph Nodes Hypermetabolism After BNT162b2 mRNA COVID-19 Vaccination in Cancer Patients Undergoing 18F-FDG PET/CT: A Cohort Study.
33661194 2021. COVID-19 Vaccine-Related Local FDG Uptake.
33661193 2021. COVID-19 Vaccination Manifesting as Incidental Lymph Nodal Uptake on 18F-FDG PET/CT.
33661192 2021. FDG PET Findings Post-COVID Vaccinations: Signs of the Times?
33795589 2021. DOTATATE -Avid Bilateral Axilla and Subpectoral Lymphadenopathy Induced From COVID-19 mRNA Vaccination Visualized on PET/CT.
33591026 2021. COVID-19 mRNA Vaccination-Induced Lymphadenopathy Mimics Lymphoma Progression on FDG PET/CT.
33793179 2021. Emergency Use Authorization for Bamlanivimab in Mild to Moderate COVID-19: Implications for CNS Practice.
33793172 2021. Emergency Use Authorization for Bamlanivimab in Mild to Moderate COVID-19: Implications for Clinical Nurse Specialist Practice.
33534255 2021. COVID-19 Vaccine: Development, Testing, and Distribution.
33534247 2021. COVID-19 Vaccine: Development, Testing, and Distribution.
33759449 2021. Drugs in COVID-19 Clinical Trials: Predicting Transporter-Mediated Drug-Drug Interactions Using In Vitro Assays and Real-World Data.
33792037 2021. Effect of Corticosteroids on Mortality in Hospitalized COVID-19 Patients Not Receiving Invasive Mechanical Ventilation.
33769172 2021. Toxicity resulting from colchicine used to treat COVID-19 patients: a new challenge for clinical toxicologists.
33786990 2021. Adverse Drug Event Risk Assessment by the Virtual Addition of COVID-19 Repurposed Drugs to Medicare and Commercially Insured Patients' Drug Regimens: A Drug Safety Simulation Study.
33786981 2021. In vitro safety "clinical trial" of the cardiac liability of drug polytherapy.
33724440 2021. Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease.
33765340 2021. Contested effects and chaotic policies: the 2020 story of (hydroxy) chloroquine for treating COVID-19.
33734435 2021. Interleukin-6 blocking agents for treating COVID-19: a living systematic review.
33538665 2021. An Urgent Industrial Scheme both for Total Synthesis, and for Pharmaceutical Analytical Analysis of Umifenovir as an Anti-Viral API for Treatment of COVID-19.
33563150 2021. Targeting Viral RNA-Dependent RNA Polymerases as an Antiviral Therapy.
33605848 2021. Advances of Inorganic Materials in the Detection and Therapeutic Uses Against Coronaviruses.
33602071 2021. Viral Envelope Membrane: A Special Entry Pathway and a Promising Drug Target.
33622224 2021. SARS-CoV-2 proteins: Are they useful as targets for COVID-19 drugs and vaccines?
33535951 2021. Molecular Elucidation and Therapeutic Targeting for combating COVID19: Current Scenario and Future Prospective.
33602083 2021. Phyto-compounds from a rather poisonous plant, Strychnos nux-vomica, show high potency against SARS-CoV-2 RNA-dependent RNA polymerase.
33587365 2021. Coronavirus disease 2019 pandemic and alterations of body composition.
33629969 2021. Host-directed therapies for COVID-19.
33749558 2021. Herbal Medicine in Fighting Against COVID-19: New Battle with an Old Weapon.
33530904 2021. BCG Vaccination Program mitigates COVID19 Related Mortality: A Reality check.
33593256 2021. Unravelling The Immune Modulatory Effect Of Indian Spices To Impede The Transmission Of Covid-19: A Promising Approach.
33719967 2021. Tocilizumab: From Rheumatic Diseases to COVID-19.
33550966 2021. The Computational Intervention of Macrolide Antibiotics in the Treatment of COVID-19.
33591423 2021. mRNA-Based Vaccines and Mode of Action.
33751756 2021. Chitin-lipid interactions and the potential relationship between Demodex and SARS-CoV-2.
33547204 2021. Association Between DPP-4 Inhibitors and COVID-19-Related Outcomes Among Patients With Type 2 Diabetes.
33663970 2021. Reply to letter of Davie et al. regarding the article: "Vitamin D concentrations and COVID-19 infection in UK Biobank" (Hastie et al.).
33652503 2021. Potential mechanisms of action of convalescent plasma in COVID-19.
33820581 2021. Roll out of COVID-19 vaccination in India: A SWOT analysis.
33817811 2021. Crocetin and related oxygen diffusion-enhancing compounds: Review of chemical synthesis, pharmacology, clinical development, and novel therapeutic applications.
33581321 2021. A new horizon for the old antibacterial drug clofoctol.
33770833 2021. CYP2D6 and CYP3A4 variants influence the risk and outcome of COVID-19 infection among rheumatoid arthritis patients maintained on hydroxychloroquine.
33757133 2021. Famotidine Repurposing for Novel Corona Virus Disease of 2019: A Systematic Review.
33726658 2021. The Biochemical Parameters and Vitamin D Levels in ICU Patients with Covid-19: A Cross-Sectional Study.
33725359 2021. Response to: COVID-19 re-infection. Vaccinated individuals as a potential source of transmission.
33675065 2021. Janus kinase signaling as risk factor and therapeutic target for severe SARS-CoV-2 infection.
33772778 2021. A single subcutaneous or intranasal immunization with adenovirus-based SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice.

33685635 2021. Putative antiviral effects of propofol in COVID-19.
33795925 2020. Neprilysin Inhibitors and Angiotensin(1-7) in COVID-19.
33609410 2021. Repurposing of thalidomide and its derivatives for the treatment of SARS-coV-2 infections: Hints on molecular action.
33608891 2021. Dexamethasone use and mortality in hospitalized patients with coronavirus disease 2019: A multicentre retrospective observational study.
33580602 2021. Postvaccination anaphylaxis and mRNA-based SARS-CoV-2 vaccines-Much ado about nothing?
33685770 2021. Plant products in reducing spread of coronavirus infection (COVID-19).
33685772 2021. Supraclavicular lymphadenopathy following COVID-19 vaccination: an incre<iframe src="http://www.kidney.de/amapp.php?a=g presentation to the two-week wait neck lump clinic?
33761533 2021. SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study.
33640910 2021. Berberine reduces circulating inflammatory mediators in patients with severe COVID-19.
33594349 2021. Bell's Palsy after second dose of Pfizer COVID-19 vaccination in a patient with history of recurrent Bell's palsy.
33527097 2021. Clozapine, neutropenia and Covid-19: should clinicians be concerned? 3 months report.
33612882 2021. Immunonutrition in perioperative care of COVID-19 patients: an old weapon for a new disease?
33621543 2021. Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19.
33729394 2021. Immunity, virus evolution, and effectiveness of SARS-CoV-2 vaccines.
33623995 2021. A molecular modelling approach for identifying antiviral selenium-containing heterocyclic compounds that inhibit the main protease of SARS-CoV-2: an in silico investigation.
33592108 2021. Data science in unveiling COVID-19 pathogenesis and diagnosis: evolutionary origin to drug repurposing.
33583943 2021. Le vaccin a ARN pour la COVID-19 - quel risque allergique ?
33674059 2021. Vaccination anti COVID-19 pour les personnes souffrant de cancer : un imperatif medical et ethique.
33741139 2021. Nous devons respecter le schema vaccinal anti-SARS-CoV-2 sans decalage chez les patients atteints de cancer sous traitement.
33663776 2021. Repositionnement des antineoplasiques utilises en hematologie dans le traitement du COVID-19.
33788116 2021. Antiviral Drug Ivermectin at Nanomolar Concentrations Inhibits Glycine-Induced Chloride Current in Rat Hippocampal Neurons.
33727782 2021. In silico identification of compounds from Nigella sativa seed oil as potential inhibitors of SARS-CoV-2 targets.
33642851 2021. Importance of immunoglobulin therapy for COVID-19 patients with lymphocytopenia.
33564223 2021. A proposed insight into the anti-viral potential of metallic nanoparticles against novel coronavirus disease-19 (COVID-19).
33654695 2020. Gut, metabolism and nutritional Support for COVID-19: Experiences from China.
33727379 2021. COVID-19 vaccine fast facts.
33727376 2021. Medication use during COVID-19: Review of recent evidence.
33689451 2021. Ribavirin shows antiviral activity against SARS-CoV-2 and downregulates the activity of TMPRSS2 and the expression of ACE2 in vitro.
33688374 2021. Effect of Hydroxychloroquine and Azithromycin on QT Interval Prolongation and Other Cardiac Arrhythmias in COVID-19 Confirmed Patients.
33747583 2021. Targeting Cytokine Storm in COVID-19: A Role of Online Hemodiafiltration with Asymmetric Cellulose Triacetate in Maintenance Hemodialysis Patients-A Report of 10 Cases.
33577765 2021. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection.
33740443 2021. Messenger RNA vaccines against SARS-CoV-2.
33773105 2021. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein.
33761326 2021. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2.
33743213 2021. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.
33756110 2021. The antigenic anatomy of SARS-CoV-2 receptor binding domain.
33691139 2021. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection.
33667349 2021. Extremely potent human monoclonal antibodies from COVID-19 convalescent patients.
33792836 2021. Piece of the puzzle: Remdesivir disassembles the multimeric SARS-CoV-2 RNA-dependent RNA polymerase complex.
33766136 2021. Functional analysis of SARS-CoV-2 proteins in Drosophila identifies Orf6-induced pathogenic effects with Selinexor as an effective treatment.
33766124 2021. Characterization of SARS-CoV-2 proteins reveals Orf6 pathogenicity, subcellular localization, host interactions and attenuation by Selinexor.
33640032 2021. Ginkgolic acid and anacardic acid are specific covalent inhibitors of SARS-CoV-2 cysteine proteases.
33762578 2021. Inhibition of HECT E3 ligases as potential therapy for COVID-19.
33723251 2021. Plasma IL-6 levels following corticosteroid therapy as an indicator of ICU length of stay in critically ill COVID-19 patients.
33731711 2020. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro.
33723226 2020. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2.
33789084 2021. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite.
33705704 2021. Virus vaccines: proteins prefer prolines.
33592168 2021. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies.
33535027 2021. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization.
33789085 2021. SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera.
33705729 2021. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines.
33657424 2021. Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies.
33580169 2021. Ferritin nanoparticle-based SARS-CoV-2 RBD vaccine induces a persistent antibody response and long-term memory in mice.
33731916 2021. Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice.
33664486 2021. Systematic profiling of SARS-CoV-2-specific IgG epitopes at amino acid resolution.
33633321 2021. Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies.
33662255 2021. Use of convalescent serum reduces severity of COVID-19 in nonhuman primates.
33545052 2021. Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2.
33784499 2021. Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication.
33778788 2021. A comprehensive analysis and resource to use CRISPR-Cas13 for broad-spectrum targeting of RNA viruses.
33754147 2021. A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques.
33820686 2021. Lessons from pathophysiology: Use of individualized combination treatments with immune interventional agents to tackle severe respiratory failure in patients with COVID-19.
33812315 2021. Structure-based drug design of an inhibitor of the SARS-CoV-2 (COVID-19) main protease using free software: A tutorial for students and scientists.
33823185 2021. Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PL(PRO) and 3CL(PRO) proteases.
33539819 2021. SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study.
33755985 2021. Flight hormones as therapeutic target for novel Coronavirus infectious disease.
33755983 2021. Early combination treatment with existing HIV antivirals: an effective treatment for COVID-19?
33755951 2021. Hyperlipidemia management during the COVID-19 pandemic: PCSK9 inhibitors to enhance the antiviral action of interferon.
33755949 2021. Reply Letter - "Safety and efficacy of oral lopinavir/ritonavir in pediatric patients with coronavirus disease: a nationwide comparative analysis".
33823179 2021. Evidence that Maackia amurensis seed lectin (MASL) exerts pleiotropic actions on oral squamous cells with potential to inhibit SARS-CoV-2 infection and COVID-19 disease progression.
33593200 2021. Coronavirus helicases: attractive and unique targets of antiviral drug-development and therapeutic patents.
33781166 2021. System for administering and monitoring hydroxychloroquine prophylaxis for COVID-19 in accordance with a national advisory: preliminary experience of a tertiary care institute in India.
33759682 2021. Low pH Hypromellose (Taffix) nasal powder spray could reduce SARS-CoV-2 infection rate post mass-gathering event at a highly endemic community: an observational prospective open label user survey.
33739215 2021. Vitamin D and immuno-pathology of COVID-19: many interactions but uncertain therapeutic benefits.
33792473 2021. Perspective: the nose and the stomach play a critical role in the NZACE2-Patari (modified ACE2) drug treatment project of SARS-CoV-2 infection.
33706626 2021. Compounds of plants with activity against SARS-CoV-2 targets.
33787439 2021. Is SARS-CoV-2 vaccination safe and effective for elderly individuals with neurodegenerative diseases?
33822489 2021. iPSC screening for drug repurposing identifies anti-RNA virus agents modulating host cell susceptibility.
33823228 2021. Recent efforts for drug identification from phytochemicals against SARS-CoV-2: Exploration of the chemical space to identify druggable leads.
33818582 2021. SARS-CoV-2 vaccine development and how Brazil is contributing.
33822042 2021. Pan-selectin inhibitors as potential therapeutics for COVID-19 treatment: in silico screening study.
33820678 2021. COVID-19 vaccine challenges: What have we learned so far and what remains to be done?
33764160 2021. Stage III Hypertension in Patients After mRNA-Based SARS-CoV-2 Vaccination.
33818480 2021. Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis.
33818476 2021. Inactivation of SARS-CoV-2 by gamma irradiation.
33818475 2021. Prediction of potential small interfering RNA molecules for silencing of the spike gene of SARS-CoV-2.
33818472 2021. Chloroquine nasal drops in asymptomatic & mild COVID-19: An exploratory randomized clinical trial.
33818470 2021. Drug repurposing for identification of potential inhibitors against SARS-CoV-2 spike receptor-binding domain: An in silico approach.
33818467 2021. Use of convalescent plasma for COVID-19 in India: A review & practical guidelines.
33563353 2021. Impact of coronavirus disease 2019 (COVID-19) vaccination program on healthcare worker infections in an academic hospital.
33780551 2021. Clinical predictors of SARS-CoV-2 neutralizing antibody titers in COVID-19 convalescents: Implications for convalescent plasma donor recruitment.
33608444 2021. Information on COVID-19 vaccines and vaccinations.
33611530 2020. Amiodarone as a possible therapy for coronavirus infection.
33757336 2021. COVID-19: Antiviral agents and enzyme inhibitors/receptor blockers in development.
33719819 2021. Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials.
33620014 2021. Convalescent plasma and hyperimmune globulin therapy in COVID-19.
33769888 2021. Exploring the room for repurposed hydroxychloroquine to impede COVID-19: toxicities and multipronged combination approaches with pharmaceutical insights.
33749491 2021. Inhaled vaccine delivery in the combat against respiratory viruses: a 2021 overview of recent developments and implications for COVID-19.
33749932 2021. A small molecule compound berberine as an orally active therapeutic candidate against COVID-19 and SARS: A computational and mechanistic study.
33617964 2021. Saponins: Extraction, bio-medicinal properties and way forward to anti-viral representatives.
33658420 2021. THE PECULIARITY OF COVID- 19 GENOME AND THE CORONAVIRUS RNA TRANSLATION PROCESS AS APOTENTIAL TARGET FOR ETIOTROPIC MEDICATIONSWITH ADENINE AND OTHER NUCLEOTIDE ANALOGUES (REVIEW).
33822348 2021. Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH.
33618380 2021. Severe Acute Thromboinflammation: Case Report of Individualized Homeopathic Treatment.
33567460 2021. Clinical Characteristics and Remedy Profiles of Patients with COVID-19: A Retrospective Cohort Study.
33544528 2021. COVID-19 and nutritional deficiency: a review of existing knowledge.
33687303 2021. Research trends in COVID-19 vaccine: a bibliometric analysis.
33769207 2021. BCG vaccination potential for COVID-19: an analytical approach.
33545014 2021. Coronavirus (SARS-CoV-2): a systematic review for potential vaccines.
33544024 2021. Anticipated reduction in COVID-19 mortality due to population-wide BCG vaccination: evidence from Germany.
33687847 2021. CoronaPep: An Anti-coronavirus Peptide Generation Tool.
33779464 2021. B Cell Response to Vaccination.

33649747 2021. Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters.
33782529 2021. Structure-based development of three- and four-antibody cocktails against SARS-CoV-2 via multiple mechanisms.
33731853 2021. Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies.
33629254 2021. CIGB-258, a peptide derived from human heat-shock protein 60, decreases hyperinflammation in COVID-19 patients.
33650894 2021. Mesenchymal Stromal Cell-Based Therapy: A Promising Approach for Severe COVID-19.
33673459 2021. Upregulation of the Renin-Angiotensin System Pathways and SARS-CoV-2 Infection: The Rationale for the Administration of Zinc-Chelating Agents in COVID-19 Patients.
33540625 2021. Thymoquinone: A Tie-Breaker in SARS-CoV2-Infected Cancer Patients?
33609497 2021. Testing of the inhibitory effects of loratadine and desloratadine on SARS-CoV-2 spike pseudotyped virus viropexis.
33776550 2021. Make it clean, make it safe: A review on virus elimination via adsorption.
33762883 2021. Inhalable nanovaccine with biomimetic coronavirus structure to trigger mucosal immunity of respiratory tract against COVID-19.
33776065 2021. In silico studies on stilbenolignan analogues as SARS-CoV-2 Mpro inhibitors.
33716308 2021. Inhibition of interferon-stimulated gene 15 and lysine 48-linked ubiquitin binding to the SARS-CoV-2 papain-like protease by small molecules: In silico studies.
33716307 2021. Biological perspective of thiazolide derivatives against Mpro and MTase of SARS-CoV-2: Molecular docking, DFT and MD simulation investigations.
33623170 2021. Identification of high affinity and low molecular alternatives of boceprevir against SARS-CoV-2 main protease: A virtual screening approach.
33558778 2021. QSAR study of unsymmetrical aromatic disulfides as potent avian SARS-CoV main protease inhibitors using quantum chemical descriptors and statistical methods.
33756475 2021. Targeting Microbiome: An Alternative Strategy for Fighting SARS-CoV-2 Infection.
33540487 2021. An Androsterone-H2 @C60 hybrid: Synthesis, Properties and Molecular Docking Simulations with SARS-Cov-2.
33549598 2021. Should Antipyretics Be Used to Relieve Acute Adverse Events Related to COVID-19 Vaccines?
33621601 2021. Progesterone in Addition to Standard of Care vs Standard of Care Alone in the Treatment of Men Hospitalized With Moderate to Severe COVID-19: A Randomized, Controlled Pilot Trial.
33528745 2021. Thoughts on Traditional Chinese Medicine Treatment of Novel Coronavirus Pneumonia Based on Two Cases.
33544289 2021. Promising Antiviral Molecules from Ayurvedic Herbs and Spices against COVID-19.
33534076 2021. Effects of Chinese Medicine on Symptoms, Syndrome Evolution, and Lung Inflammation Absorption in COVID-19 Convalescent Patients during 84-Day Follow-up after Hospital Discharge: A Prospective Cohort and Nested Case-Control Study.
33618736 2021. Traditional Chinese herbal medicine-potential therapeutic application for the treatment of COVID-19.
33617183 2020. Statins as candidate therapeutic agents for coronavirus disease 2019 (COVID-19).
33555601 2021. Just the facts: updates in COVID-19 therapeutics.
33709361 2021. CJEM journal club: corticosteroids use for critically ill COVID-19 patients.
33534117 2021. Is dexamethasone an effective treatment for severe COVID-19 patients: Journal Club review.
33687984 2021. Vaccination for COVID-19: Is it important and what should you know about it?
33648932 2021. Anaphylaxis to vaccinations: A review of the literature and evaluation of the COVID-19 mRNA vaccinations.
33597176 2021. Monoclonal antibodies for treating COVID-19.
33648989 2021. Vascular Normalization to Improve Treatment of COVID-19: Lessons from Treatment of Cancer.
33628060 2021. A Phthalocyanine Derivate Mouthwash to Gargling/Rinsing as an Option to Reduce Clinical Symptoms of COVID-19: Case Series.
33754328 2021. Can mRNA Vaccines Turn the Tables During the COVID-19 Pandemic? Current Status and Challenges.
33666256 2021. COVID-19 vaccination and patients with psoriasis under biologics: real-life evidence on safety and effectiveness from Italian vaccinated healthcare workers.
33555252 2021. Vaccination against SARS-CoV-2 in patients with rheumatic diseases: doubts and perspectives.
33635218 2021. High-dose glucocorticoids pulse-therapy for beta-coronaviridae pneumonia: a systematic literature review and case-series of Coronavirus disease-2019.
33628750 2021. Current updates and research on plant-based vaccines for coronavirus disease 2019.
33628749 2021. A review on the advancements in the development of vaccines to combat coronavirus disease 2019.
33548200 2021. What Gastroenterologists Should Know About COVID-19 Vaccines.
33684527 2021. Mesenchymal stem cell alongside exosomes as a novel cell-based therapy for COVID-19: A review study.
33693610 2021. Impressive boosting of anti-S1/S2 IgG production in COVID-19-experienced patients after the first shot of the BNT162b2 mRNA COVID-19 Vaccine.
33693552 2021. Are some COVID vaccines better than others? Interpreting and comparing estimates of efficacy in trials of COVID-19 vaccines.
33693607 2021. Trends in Prescribing of Antibiotics and Drugs Investigated for COVID-19 Treatment in U.S. Nursing Home Residents During the COVID-19 Pandemic.
33639622 2021. How to test SARS-CoV-2 vaccines ethically even after one is available.
33630997 2021. Reduced Vitamin K Status and Coronavirus Disease 2019: An Epiphenomenon of Impaired Kidney Function?
33654337 2021. SAFETY PROFILE OF TREATMENTS ADMINISTERED IN COVID 19 INFECTION IN PREGNANT WOMEN.
33762401 2021. SARS-CoV-2 infection despite vaccination: an under-reported COVID-19 cohort.
33593830 2021. Perspective: Vitamin D supplementation prevents rickets and acute respiratory infections when given as daily maintenance but not as intermittent bolus: implications for COVID-19.
33705848 2021. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis - Author's reply.
33705849 2021. A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel.
33549765 2021. Re: 'Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis' by Tleyjeh et al.
33647441 2021. Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns.
33564204 2021. Convalescent Plasma for Infectious Diseases: Historical Framework and Use in COVID-19.
33631509 2021. Can pulse steroid therapy increase the risk of infection by COVID-19 in patients with multiple sclerosis?
33745749 2021. Vitamin D deficiency in critically ill COVID-19 ARDS patients.
33745628 2021. The prevalence of malnutrition and analysis of related factors among adult patients with the Coronavirus Disease 2019 (COVID 19) in a tertiary government hospital: The MalnutriCoV study.
33745598 2021. Evaluation of vitamin D levels in COVID-19 patients referred to Labafinejad hospital in Tehran and its relationship with disease severity and mortality.
33745593 2021. Are history of dietary intake and food habits of patients with clinical symptoms of COVID 19 different from healthy controls? A case-control study.
33745572 2021. Trajectories of eating behavior during COVID-19 lockdown: Longitudinal analyses of 22,374 adults.
33745566 2021. Healthy nutritional behavior during COVID-19 lockdown: A cross-sectional study.
33782830 2021. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor.
33641159 2021. Systematic Review and Patient-Level Meta-Analysis of SARS-CoV-2 Viral Dynamics to Model Response to Antiviral Therapies.
33547636 2021. Neglecting Plasma Protein Binding in COVID-19 Patients Leads to a Wrong Interpretation of Lopinavir Overexposure.
33529354 2021. Real-World Evidence for Assessing Pharmaceutical Treatments in the Context of COVID-19.
33798755 2021. Predictive analysis of COVID-19 eradication with vaccination in India, Brazil, and U.S.A.
33819681 2021. Immunogenicity and antigenicity based T-cell and B-cell epitopes identification from conserved regions of 10664 SARS-CoV-2 genomes.
33783508 2021. Safety of Tofacitinib in the COVID-19 Pandemic-Enough Is Not Enough.
33772572 2021. Development of COVID-19 vaccines utilizing gene therapy technology.
33812260 2021. The effect of tocilizumab on COVID-19 patient mortality: A systematic review and meta-analysis of randomized controlled trials.
33803339 2021. Approaches to Nutritional Screening in Patients with Coronavirus Disease 2019 (COVID-19).
33801651 2021. A Rapid Review of COVID-19 Vaccine Prioritization in the U.S.: Alignment between Federal Guidance and State Practice.
33809918 2021. Linear B-Cell Epitope Prediction for In Silico Vaccine Design: A Performance Review of Methods Available via Command-Line Interface.
33808940 2021. Identification of Anti-Severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Oxysterol Derivatives In Vitro.
33808574 2021. Dietary and Protective Factors to Halt or Mitigate Progression of Autoimmunity, COVID-19 and Its Associated Metabolic Diseases.
33802761 2021. Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence.
33802729 2021. SARS-CoV-2 Entry Related Viral and Host Genetic Variations: Implications on COVID-19 Severity, Immune Escape, and Infectivity.
33804129 2021. Metal-Bound Methisazone; Novel Drugs Targeting Prophylaxis and Treatment of SARS-CoV-2, a Molecular Docking Study.
33802169 2021. A Novel Computational Approach for the Discovery of Drug Delivery System Candidates for COVID-19.
33797236 2021. Stealth Fluorescence Labeling for Live Microscopy Imaging of mRNA Delivery.
33792713 2021. Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU-authors' response.
33758946 2021. Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials.
33784944 2021. Design and synthesis of novel phe-phe hydroxyethylene derivatives as potential coronavirus main protease inhibitors.
33645490 2021. COVID-19: Potential Repurposing Drugs.
33602078 2021. Natural Derived Nasal Spray; a Proposed Approach for COVID-19 Disease Control.
33573449 2021. Effects of tocilizumab versus hemoadsorption combined with tocilizumab in patients with SARS-CoV-2 pneumonia: Preliminary results.
33624584 2021. Bioequivalence study of two favipiravir tablet formulations in healthy male subjects.
33624583 2021. Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: A pilot retrospective study.
33605875 2021. COVID-19 double whammy - Vaccine and variants.
33763939 2021. Investigation of SARS-CoV-2 RNA in milk produced by women with COVID-19 and follow-up of their infants: A preliminary study.
33759318 2021. Effect of COVID-19 medications on corrected QT interval and induction of torsade de pointes: Results of a multicenter national survey.
33743543 2021. Investigation of the disease process and drug combinations in patients with suspected/confirmed COVID-19 using favipiravir.
33797849 2021. Detectable respiratory SARS-CoV-2 RNA is associated with low vitamin D levels and high social deprivation.
33752299 2021. Does therapeutic drug monitoring of hydroxychloroquine improve treatment outcome in intensive care unit patients with COVID-19?
33682604 2021. Exploring the rationale for thermotherapy in COVID-19.
33822495 2021. Chaga Medicinal Mushroom Inonotus obliquus (Agaricomycetes) Terpenoids May Interfere with SARS-CoV-2 Spike Protein Recognition of the Host Cell: A Molecular Docking Study.
33725395 2021. The effect of Chinese herbal medicine on digestive system and liver functions should not be neglected in COVID-19: An updated systematic review and meta-analysis.
33749986 2021. Identification of mutation resistance coldspots for targeting the SARS-CoV2 main protease.
33691499 2021. Mycobacterium vaccae Nebulization in the Treatment of COVID-19: A Randomized, Double-Blind, Placebo-Controlled Trial.
33596158 2021. l-Cysteine Stimulates the Effect of Vitamin D on Inhibition of Oxidative Stress, IL-8, and MCP-1 Secretion in High Glucose Treated Monocytes.
33768521 2021. Immunogenicity of the BNT162b2 vaccine in frail or disabled nursing home residents: COVID-A study.
33762353 2021. SARS-CoV-2 Vaccines in Kidney Transplant Recipients: Will They Be Safe and Effective and How Will We Know?
33526471 2021. A Novel Soluble ACE2 Variant with Prolonged Duration of Action Neutralizes SARS-CoV-2 Infection in Human Kidney Organoids.
33527804 2021. Itolizumab Treatment for Cytokine Release Syndrome in Moderate to Severe Acute Respiratory Distress Syndrome Due to COVID-19: Clinical Outcomes, A Retrospective Study.
33594850 2021. In silico approach: docking study of oxindole derivatives against the main protease of COVID-19 and its comparison with existing therapeutic agents.
33594843 2021. Evidence that Ginkgo Biloba could use in the influenza and coronavirus COVID-19 infections.
33682642 2021. Finding potent inhibitors against SARS-CoV-2 main protease through virtual screening, ADMET, and molecular dynamics simulation studies.
33682639 2021. Binding and inhibitory effect of ravidasvir on 3CL(pro) of SARS-CoV-2: a molecular docking, molecular dynamics and MM/PBSA approach.
33682633 2021. Structural insight into the binding interactions of NTPs and nucleotide analogues to RNA dependent RNA polymerase of SARS-CoV-2.
33682632 2021. Structure-based virtual screening, molecular dynamics and binding affinity calculations of some potential phytocompounds against SARS-CoV-2.
33682606 2021. Flavonoids as potential therapeutics against novel coronavirus disease-2019 (nCOVID-19).
33663346 2021. Metadynamics-based enhanced sampling protocol for virtual screening: case study for 3CLpro protein for SARS-CoV-2.
33764269 2021. Isatin-based virtual high throughput screening, molecular docking, DFT, QM/MM, MD and MM-PBSA study of novel inhibitors of SARS-CoV-2 main protease.

33751280 2021. A practical approach for vaccinations including COVID-19 in autoimmune/autoinflammatory rheumatic diseases: a non-systematic review.
33579547 2021. The COVID-19 mRNA Vaccines and the Pandemic: Do They Represent the Beginning of the End or the End of the Beginning?
33549310 2021. A Critical Appraisal of the Effects of Anesthetics on Immune-system Modulation in Critically Ill Patients With COVID-19.
33641562 2021. Safety and effectiveness concerns of lopinavir/ritonavir in COVID-19 affected patients: a retrospective series.
33728279 2021. Prevalence of thyroid dysfunction in patients with COVID-19: a systematic review.
33732459 2021. Antibodies to neutralising epitopes synergistically block the interaction of the receptor-binding domain of SARS-CoV-2 to ACE 2.
33635001 2021. Bromelain inhibits SARS-CoV-2 infection via targeting ACE-2, TMPRSS2, and spike protein.
33634996 2021. Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial.
33634979 2021. Ring vaccination of COVID-19 vaccines in medium- and high-risk areas of countries with low incidence of SARS-CoV-2 infection.
33620150 2021. Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off-label in the first wave of COVID-19.
33606912 2021. Virtual screening FDA approved drugs against multiple targets of SARS-CoV-2.
33606894 2021. Mortality, viral clearance, and other clinical outcomes of hydroxychloroquine in COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials.
33595145 2021. Bamlanivimab for treatment of COVID-19 in solid organ transplant recipients: Early single-center experience.
33535811 2021. COVID-19 vaccine trials: The use of active controls and non-inferiority studies.
33530721 2021. An ethics framework for consolidating and prioritizing COVID-19 clinical trials.
33787678 2021. COVID-19 and Thromboinflammation: Is There a Role for Statins?
33692091 2021. Tocilizumab for hospitalized patients with COVID-19.
33552306 2021. Deep Learning-Based Potential Ligand Prediction Framework for COVID-19 with Drug-Target Interaction Model.
33564211 2021. Nano-size dependence in the adsorption by the SARS-CoV-2 spike protein over gold colloid.
33795896 2020. COVID-19: The Ivermectin African Enigma.
33564093 2021. Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU from SARS-CoV-2.
33627795 2021. Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy.
33580154 2021. Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection.
33551714 2021. Critical roles of TLRs on the polarization of mesenchymal stem cells for cell therapy of viral infections: a notice for COVID-19 treatment.
33677227 2021. Docking-based virtual screening studies aiming at the covalent inhibition of SARS-CoV-2 M(Pro) by targeting the cysteine 145.
33751995 2021. Structural insights on the interaction potential of natural leads against major protein targets of SARS-CoV-2: Molecular modelling, docking and dynamic simulation studies.
33721736 2021. Deep learning model for virtual screening of novel 3C-like protease enzyme inhibitors against SARS coronavirus diseases.
33705994 2021. A hijack mechanism of Indian SARS-CoV-2 isolates for relapsing contemporary antiviral therapeutics.
33535144 2021. Analogue discovery of safer alternatives to HCQ and CQ drugs for SAR-CoV-2 by computational design.
33662683 2021. Targeting multiple conformations of SARS-CoV2 Papain-Like Protease for drug repositioning: An in-silico study.
33662681 2021. Network pharmacology and RNA-sequencing reveal the molecular mechanism of Xuebijing injection on COVID-19-induced cardiac dysfunction.
33777333 2021. Specific epitopes form extensive hydrogen-bonding networks to ensure efficient antibody binding of SARS-CoV-2: Implications for advanced antibody design.
33680350 2021. COVID-19 pandemic: Can zinc supplementation provide an additional shield against the infection?
33680348 2021. Antioxidants and pentoxifylline as coadjuvant measures to standard therapy to improve prognosis of patients with pneumonia by COVID-19.
33552444 2021. Current concepts in the development of therapeutics against human and animal coronavirus diseases by targeting NP.
33619460 2021. Covid-19 treatment: Investigation on the phytochemical constituents of Vernonia amygdalina as potential Coronavirus-2 inhibitors.
33553857 2021. Screening possible drug molecules for Covid-19. The example of vanadium (III/IV/V) complex molecules with computational chemistry and molecular docking.
33532671 2021. From genomes to molecular dynamics - A bottom up approach in extrication of SARS CoV-2 main protease inhibitors.
33557911 2021. Carboxypeptidase B blocks ex vivo activation of the anaphylatoxin-neutrophil extracellular trap axis in neutrophils from COVID-19 patients.
33786440 2021. New Decade, Old Debate: Blocking the Cytokine Pathways in Infection-Induced Cytokine Cascade.
33817660 2021. Early Tocilizumab Dosing Is Associated With Improved Survival in Critically Ill Patients Infected With Severe Acute Respiratory Syndrome Coronavirus-2.
33660966 2021. Could fluvoxamine keep COVID-19 patients out of hospitals and intensive care units?
33786251 2021. Purpuric Rash and Thrombocytopenia After the mRNA-1273 (Moderna) COVID-19 Vaccine.
33717715 2021. Predictors of Mortality Amongst Tocilizumab Administered COVID-19 Asian Indians: A Predictive Study From a Tertiary Care Centre.
33786231 2021. Lymphadenopathy Associated With the COVID-19 Vaccine.
33633920 2021. Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial.
33758714 2021. Neurological Complications of COVID-19: Guillain-Barre Syndrome Following Pfizer COVID-19 Vaccine.
33643746 2021. Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial - Biochemical).
33532161 2020. The History of Methylprednisolone, Ascorbic Acid, Thiamine, and Heparin Protocol and I-MASK+ Ivermectin Protocol for COVID-19.
33686365 2021. Developmental Status of the Potential Vaccines for the Mitigation of the COVID-19 Pandemic and a Focus on the Effectiveness of the Pfizer-BioNTech and Moderna mRNA Vaccines.
33582901 2021. Corticosteroids Treatment of Patients with Coronavirus Disease 2019: A Propensity Score Matching Study.
33680715 2021. Determination of Potential Drug Candidate Molecules of the Hypericum perforatum for COVID-19 Treatment.
33619447 2021. Efficacy and Safety of New and Emerging Drugs for COVID-19: Favipiravir and Dexamethasone.
33773396 2021. Glycyrrhizin prevents SARS-CoV-2 S1 and Orf3a induced high mobility group box 1 (HMGB1) release and inhibits viral replication.
33714693 2021. The conundrum of current anti-SARS-CoV-2 vaccines.
33776206 2021. Taming of Covid-19: potential and emerging application of mesenchymal stem cells.
33797339 2021. COVID19-inhibitory activity of withanolides involves targeting of the host cell surface receptor ACE2: insights from computational and biochemical assays.
33784094 2021. Lead Discovery of SARS-CoV-2 Main Protease Inhibitors through Covalent Docking-Based Virtual Screening.
33821020 2021. Cytotoxicity, anti-microbial studies of M(II)-dithiocarbamate complexes, and molecular docking study against SARS COV2 RNA-dependent RNA polymerase.
33822770 2021. SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63.
33808205 2021. Effects of Different Dialysis Strategies on Inflammatory Cytokine Profile in Maintenance Hemodialysis Patients with COVID-19: A Randomized Trial.
33805760 2021. Angiotensin-(1-7)-A Potential Remedy for AKI: Insights Derived from the COVID-19 Pandemic.
33798667 2021. The dawn of mRNA vaccines: The COVID-19 case.
33818731 2021. Retrospective analysis of vitamin D status on inflammatory markers and course of the disease in patients with COVID-19 infection.
33813013 2021. Antiviral effect of fufang yinhua jiedu (FFYH) granules against influenza A virus through regulating the inflammatory responses by TLR7/MyD88 signaling pathway.
33811961 2021. BNT 13b2 Pfizer vaccine protects against SARS-CoV-2 respiratory mucosal colonization even after prolonged exposure to positive family members.
33811939 2021. Reactogenicity, safety and antibody response, after one and two doses of mRNA-1273 in seronegative and seropositive healthcare workers.
33761582 2021. Super-rapid race for saving lives by developing COVID-19 vaccines.
33743557 2021. Special issue on COVID-19 data integration opportunities and vaccine development strategies.
33759703 2021. A computational study on active constituents of Habb-ul-aas and Tabasheer as inhibitors of SARS-CoV-2 main protease.
33759690 2021. In silico screening of therapeutic potentials from Strychnos nux-vomica against the dimeric main protease (M(pro)) structure of SARS-CoV-2.
33749547 2021. Evaluation of the effects of chlorhexidine and several flavonoids as antiviral purposes on SARS-CoV-2 main protease: molecular docking, molecular dynamics simulation studies.
33749545 2021. On the search for COVID-19 therapeutics: identification of potential SARS-CoV-2 main protease inhibitors by virtual screening, pharmacophore modeling and molecular dynamics.
33749538 2021. Phylogenic analysis of coronavirus genome and molecular studies on potential anti-COVID-19 agents from selected FDA-approved drugs.
33749528 2021. Repurposing of anticancer phytochemicals for identifying potential fusion inhibitor for SARS-CoV-2 using molecular docking and molecular dynamics (MD) simulations.
33749496 2021. Cyanobacterial natural products as sources for antiviral drug discovery against COVID-19.
33734021 2021. Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection.
33719855 2021. Potentiality of Moringa oleifera against SARS-CoV-2: identified by a rational computer aided drug design method.
33706683 2021. Potential inhibitors of angiotensin converting enzyme 2 receptor of COVID-19 by Corchorus olitorius Linn using docking, molecular dynamics, conceptual DFT investigation and pharmacophore mapping.
33715598 2021. A rational design of a multi-epitope vaccine against SARS-CoV-2 which accounts for the glycan shield of the spike glycoprotein.
33715595 2021. Black tea bioactives as inhibitors of multiple targets of SARS-CoV-2 (3CLpro, PLpro and RdRp): a virtual screening and molecular dynamic simulation study.
33715592 2021. In silico drug designing for COVID-19: an approach of high-throughput virtual screening, molecular, and essential dynamics simulations.
33554747 2021. Targeting the N-terminal domain of the RNA-binding protein of the SARS-CoV-2 with high affinity natural compounds to abrogate the protein-RNA interaction: a molecular dynamics study.
33645457 2021. Targeting allosteric pockets of SARS-CoV-2 main protease M(pro).
33625318 2021. 4-acetamido-3-nitrobenzoic acid - structural, quantum chemical studies, ADMET and molecular docking studies of SARS-CoV2.
33618628 2021. Investigation of the inhibitory activity of some dietary bioactive flavonoids against SARS-CoV-2 using molecular dynamics simulations and MM-PBSA calculations.
33618621 2021. Structural stability predictions and molecular dynamics simulations of RBD and HR1 mutations associated with SARS-CoV-2 spike glycoprotein.
33615998 2021. In silico evaluation of isatin-based derivatives with RNA-dependent RNA polymerase of the novel coronavirus SARS-CoV-2.
33586620 2021. Whole proteome screening and identification of potential epitopes of SARS-CoV-2 for vaccine design-an immunoinformatic, molecular docking and molecular dynamics simulation accelerated robust strategy.
33810774 2021. In silico inquest reveals the efficacy of Cannabis in the treatment of post-Covid-19 related neurodegeneration.
33648025 2021. Rapid development of a de novo convalescent plasma program in response to a global pandemic: A large southeastern U.S. blood center's experience.
33768612 2021. QT prolongation associated with hydroxychloroquine and protease inhibitors in COVID-19.
33650415 2021. The Effect of Tocilizumab on Inflammatory Markers in Survivors and Non-survivors of Severe COVID-19.
33787192 2021. The effects of combination of Zingiber officinale and Echinacea on alleviation of clinical symptoms and hospitalization rate of suspected COVID-19 outpatients: a randomized controlled trial.
33544526 2021. Preventive aspect of ayurveda and yoga towards newly emerging disease COVID-19.
33713492 2021. Drug repositioning to target NSP15 protein on SARS-CoV-2 as possible COVID-19 treatment.
33638924 2021. Herpes zoster following inactivated COVID-19 vaccine: A coexistence or coincidence?
33682615 2021. Trace Minerals, Vitamins and Nutraceuticals in Prevention and Treatment of COVID-19.
33594938 2021. Potential Efficacy of Nutrient Supplements for Treatment or Prevention of COVID-19.
33683080 2021. Coronavirus Vaccination Adverse Reactions and the Role of the Dermatologist.
33528149 2020. The Relevance of Vitamin D Supplementation for People of Color in the Era of COVID-19.
33783873 2021. Skin manifestations of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers. 'COVID-arm': a clinical and histological characterization.
33783855 2021. Extraordinary claims without extraordinary evidence: controversy on anti-androgen therapy for COVID-19.
33783017 2021. Persistent maculopapular rash after the first dose of Pfizer-BioNTech COVID-19 vaccine.
33780556 2021. Vaccination against SARS-CoV-2 and psoriasis: the three things every dermatologist should know.
33725406 2021. Prompt onset of Rowell's syndrome following the first BNT162b2 SARS-CoV-2 vaccination.
33617431 2021. Early and Significant Reduction in C-Reactive Protein Levels After Corticosteroid Therapy Is Associated With Reduced Mortality in Patients With COVID-19.
33576702 2021. Letter to the editor: COVID-19 Vaccines and Breastfeeding.
33735530 2021. A UK survey of nutritional care pathways for patients with COVID-19 prior to and post-hospital stay.
33632000 2021. A Comparison of Methylprednisolone and Dexamethasone in Intensive Care Patients With COVID-19.
33621130 2021. Perspectives on Targeting IL-6 as a Potential Therapeutic Strategy for COVID-19.
33822418 2021. Reply letter to: Inhibition of SARS-CoV-2 replication using calcineurin inhibitors: Are concentrations required clinically achievable?

33560802 2021. Morbilliform rash after administration of Pfizer-BioNTech COVID-19 mRNA vaccine.
33744398 2021. Increased mortality risk associated with statins in the CORONADO study.
33752274 2021. Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19.
33662839 2021. Metformin is associated with lower hospitalizations, mortality and severe coronavirus infection among elderly medicare minority patients in 8 states in USA.
33662837 2021. COVID-19 vaccination in patients with diabetes mellitus: Current concepts, uncertainties and challenges.
33528920 2021. Use of dipeptidyl peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study.
33606909 2021. Meta-analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodium-glucose co-transporter-2 inhibitors: Implications for the COVID-19 pandemic.
33594475 2021. The disproportionate excess mortality risk of COVID-19 in younger people with diabetes warrants vaccination prioritisation.
33625613 2021. Does Famotidine Reduce the Risk of Progression to Severe Disease, Death, and Intubation for COVID-19 Patients? A Systemic Review and Meta-Analysis.
33625612 2021. More Than Just Heartburn: Does Famotidine Effectively Treat Patients with COVID-19?
33535388 2021. Targeting NSP16 Methyltransferase for the Broad-Spectrum Clinical Management of Coronaviruses: Managing the Next Pandemic.
33689074 2021. Thermovaccination: Thermoheliox as an Immune Response Stimulant. Kinetics of Antibodies and C-Reactive Protein Synthesis in Coronaviral Infection.
33694083 2021. Advances in vaccine delivery systems against viral infectious diseases.
33762818 2021. Potential Anti-Coronavirus Agents and the Pharmacologic Mechanisms.
33737804 2021. Withanone from Withania somnifera Attenuates SARS-CoV-2 RBD and Host ACE2 Interactions to Rescue Spike Protein Induced Pathologies in Humanized Zebrafish Model.
33692615 2021. Beware of Steroid-Induced Avascular Necrosis of the Femoral Head in the Treatment of COVID-19-Experience and Lessons from the SARS Epidemic.
33612572 2021. Multidrug treatment for COVID-19.
33775925 2021. Diabetes, inflammation, and the adiponectin paradox: Therapeutic targets in SARS-CoV-2.
33609782 2021. Inflammation control and improvement of cognitive function in COVID-19 infections: is there a role for kynurenine 3-monooxygenase inhibition?
33609783 2021. Developing new drugs that activate the protective arm of the renin-angiotensin system as a potential treatment for respiratory failure in COVID-19 patients.
33683968 2021. In quest of a new therapeutic approach in COVID-19: the endocannabinoid system.
33666902 2021. Safety Consequences of Off-Label Drugs Used for COVID-19.
33683637 2021. BNT162b2 mRNA COVID-19 Vaccine: First Approval.
33782908 2021. Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry.
33638807 2021. MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19.
33643421 2021. The race to a COVID-19 vaccine: opportunities and challenges in development and distribution.
33569736 2021. Pharmacotherapy Management for COVID-19 and Cardiac Safety: A Data Mining Approach for Pharmacovigilance Evidence from the FDA Adverse Event Reporting System (FAERS).
33780993 2021. SARS-CoV-2-Impfungen - Was muss der Nephrologe wissen?
33676899 2021. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity.
33752131 2021. COVID19 therapeutics: Expanding the antiviral arsenal.
33752127 2021. Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial.
33681731 2021. Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial.
33615206 2021. Clinical outcomes of different therapeutic options for COVID-19 in two Chinese case cohorts: A propensity-score analysis.
33589884 2021. Can existing unrelated vaccines boost a COVID-19 vaccine prime?
33558858 2021. Is ivermectin ready to be part of a public health policy for COVID-19 prophylaxis?
33787663 2021. Use of mouthwashes in the management of COVID-19 patients in intensive care units: recommendations and current evidence.
33682678 2021. An open label trial of anakinra to prevent respiratory failure in COVID-19.
33691606 2021. Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates.
33691601 2021. The preclinical inhibitor GS441524 in combination with GC376 efficaciously inhibited the proliferation of SARS-CoV-2 in the mouse respiratory tract.
33560940 2021. The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor.
33555988 2021. A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques.
33538646 2021. Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection.
33649739 2021. Potential Applications of Conducting Polymers to Reduce Secondary Bacterial Infections among COVID-19 Patients: a Review.
33744444 2021. Vitamin D and Its Potential Benefit for the COVID-19 Pandemic.
33705975 2021. Association of Vitamin D Status With Hospital Morbidity and Mortality in Adult Hospitalized Patients With COVID-19.
33738708 2021. Hypovitaminosis D and the endocrine phenotype of COVID-19.
33585705 2021. Therapeutic plasma exchange for persistent encephalopathy associated with Covid-19.
33741148 2021. Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency - Three consecutive cases and review of the literature.
33691157 2021. Selenium (Se) plays a key role in the biological effects of some viruses: Implications for COVID-19.
33809879 2021. Prevention of Covid-19 Infection and Related Complications by Ozonized Oils.
33821145 2021. COVID-19: Filling the Many Knowledge Gaps and Supporting Evidence-Based Vaccination.
33530857 2021. Trajectory of individual immunity and vaccination required for SARS-CoV-2 community immunity: a conceptual investigation.
33821691 2021. Medicolegal consequences of altered COVID-19 vaccine administration.
33772577 2021. Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2.
33627390 2021. Effect of an Adenovirus-Vectored Universal Influenza Virus Vaccine on Pulmonary Pathophysiology in a Mouse Model.
33555305 2021. Outpatient Dietary Management of Electrolyte Disorders During COVID-19: Food as Medicine.
33821223 2021. Timing of COVID-19 Vaccine in the Setting of Anti-CD20 Therapy: A Primer for Nephrologists.
33676614 2021. Single-dose Oxford-AstraZeneca COVID-19 vaccine followed by a 12-week booster.
33798498 2021. Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence?
33798499 2021. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.
33798464 2021. Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England.
33798462 2021. Can glucose-lowering drugs affect the prognosis of COVID-19 in patients with type 2 diabetes?
33811822 2021. COVID-19 vaccines for patients with haematological conditions.
33733767 2021. Weinreb Amide Approach to the Practical Synthesis of a Key Remdesivir Intermediate.
33634692 2021. Practical Remdesivir Synthesis through One-Pot Organocatalyzed Asymmetric (S)-P-Phosphoramidation.
33817870 2021. The precautionary principle, the AstraZeneca COVID-19 vaccine and mixed messaging.
33625085 2021. Favorable Outcome of COVID-19 Infection in a Pediatric Cancer Patient Receiving an Anti-PD-L1/Anti-CTLA-4 Combination.
33620123 2021. Acute and chronic inflammatory neuropathies and COVID-19 vaccines: Practical recommendations from the task force of the Italian Peripheral Nervous System Association (ASNP).
33779758 2021. Isatis indigotica: a review of phytochemistry, pharmacological activities and clinical applications.
33759631 2021. Interleukin-6 Antagonists: Lessons From Cytokine Release Syndrome to the Therapeutic Application in Severe COVID-19 Infection.
33736526 2021. Tocilizumab for the Critically Ill With Severe COVID-19: A Community Hospital Case Series.
33719698 2021. A Review of the Evidence for Corticosteroids in COVID-19.
33622090 2021. Remdesivir for the Treatment of COVID-19: A Need for Combined In Vivo and In Vitro Studies to Evaluate the Efficacy.
33760611 2021. Unveiling the Molecular Structure of Antimalarial Drugs Chloroquine and Hydroxychloroquine in Solution through Analysis of (1)H NMR Chemical Shifts.
33759236 2021. Melatonin multifaceted pharmacological actions on melatonin receptors converging to abrogate COVID-19.
33758126 2021. The Potential Role of Radiogenomics in Precision Medicine for COVID-19.
33783953 2021. A case report of acquired hemophilia following COVID-19 vaccine.
33789993 2021. The Physiological TMPRSS2 Inhibitor HAI-2 Alleviates SARS-CoV-2 Infection.
33692215 2021. Cryo-EM structure of S-Trimer, a subunit vaccine candidate for COVID-19.
33720292 2021. Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients.
33739374 2021. Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination.
33544136 2021. Monoclonal Antibodies for COVID-19.
33635310 2021. Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.
33566091 2021. Experts Discuss COVID-19-Vaccine Doses, Virus Variants, and More.
33533893 2021. Necessity of 2 Doses of the Pfizer and Moderna COVID-19 Vaccines.
33724312 2021. Helping Manufacturers Navigate Novel Coronavirus Variants.
33595641 2021. Vitamin D3 to Treat COVID-19: Different Disease, Same Answer.
33595634 2021. Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial.
33576785 2021. Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021.
33818592 2021. Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines.
33620389 2021. Locating COVID-19 Monoclonal Antibody Therapies.
33729423 2021. COVID-19 Vaccines vs Variants-Determining How Much Immunity Is Enough.
33662101 2021. Approaches for Optimal Use of Different COVID-19 Vaccines: Issues of Viral Variants and Vaccine Efficacy.
33635317 2021. SARS-CoV-2 Vaccines.
33704352 2021. Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.
33683290 2021. Acute Allergic Reactions to mRNA COVID-19 Vaccines.
33646285 2021. The Johnson & Johnson Vaccine for COVID-19.
33662102 2021. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial.
33646292 2021. Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2.
33818614 2021. Tocilizumab in Treatment for Patients With COVID-19.
33818612 2021. Tocilizumab in Treatment for Patients With COVID-19.
33818610 2021. Tocilizumab in Treatment for Patients With COVID-19-Reply.
33818607 2021. Tocilizumab in Treatment for Patients With COVID-19-Reply.
33818593 2021. Tocilizumab in Treatment for Patients With COVID-19.
33538761 2021. Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Nasopharyngeal Viral Load in Patients With COVID-19: A Randomized Clinical Trial.
33797950 2021. Is It Safe to Use Long-Acting G-CSF for Febrile Neutropenia Prophylaxis in COVID-19 Pandemic?
33793342 2021. Primary Prophylaxis With Biosimilar Filgrastim for Patients at Intermediate Risk for Febrile Neutropenia: A Cost-Effectiveness Analysis.
33728687 2021. Nutrition care practice patterns for patients with COVID-19-A preliminary report.
33694246 2021. Modified minimal-contact COVID-19 workflow allows for safe, remote parenteral nutrition prescribing in non-critically ill patients.
33734044 2021. Hydroxychloroquine in patients with novel coronavirus infection (COVID-19): a case-control study.
33734043 2021. Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study.
33798465 2021. Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials.

33651292 2021. Correlation between polio immunization coverage and overall morbidity and mortality for COVID-19: an epidemiological study.
33722335 2021. Association between live childhood vaccines and COVID-19 outcomes: a national-level analysis.
33816594 2021. A double-blind randomised controlled trial of protein supplementation to enhance exercise capacity in COPD during pulmonary rehabilitation: a pilot study.
33573712 2021. Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021.
33727943 2021. Phytochemicals of Rhus spp. as Potential Inhibitors of the SARS-CoV-2 Main Protease: Molecular Docking and Drug-Likeness Study.
33680061 2021. The Hydroalcoholic Extract of Uncaria tomentosa (Cat's Claw) Inhibits the Infection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) In Vitro.
33763230 2021. Mismatch: a comparative study of vitamin D status in British-Bangladeshi migrants.
33732462 2021. Conflicts over calcium and the treatment of COVID-19.
33746666 2021. A review on function and side effects of systemic corticosteroids used in high-grade COVID-19 to prevent cytokine storms.
33628162 2021. Insights into the actions of angiotensin-1 receptor (AT1R) inverse agonists: Perspectives and implications in COVID-19 treatment.
33628159 2021. All-cause mortality among patients treated with repurposed antivirals and antibiotics for COVID-19 in Mexico City: A real-world observational study.
33542677 2020. Ivermectin: Panacea or true promise for COVID-19.
33622217 2021. Mesenchymal Stem Cell-Derived Extracellular Vesicles: Promising Treatment for COVID-19 Pandemic.
33605203 2021. Feasibility of Convalescent Plasma Therapy in Kidney Transplant Recipients With Severe COVID-19: A Single-Center Prospective Cohort Study.
33544007 2021. PDE3-inhibitor enoximone prevented mechanical ventilation in patients with SARS-CoV-2 pneumonia.
33790994 2021. Severe acute respiratory syndrome coronavirus 2 ORF3a induces the expression of ACE2 in oral and pulmonary epithelial cells and the food supplement Vita Deyun((R)) diminishes this effect.
33747178 2021. Acidic preconditioning reduces lipopolysaccharide-induced acute lung injury by upregulating the expression of angiotensin-converting enzyme 2.
33603870 2021. Multifactorial expression of IL-6 with update on COVID-19 and the therapeutic strategies of its blockade (Review).
33603836 2021. Recombinant interleukin-2 stimulates lymphocyte recovery in patients with severe COVID-19.
33732293 2021. Anti-infection mechanism of phosphodiesterase-5 inhibitors and their roles in coronavirus disease 2019 (Review).
33732292 2021. Immunoregulatory therapy strategies that target cytokine storms in patients with COVID-19 (Review).
33724123 2021. Does hydroxychloroquine still have any role in the COVID-19 pandemic?
33586566 2021. Concomitant use of dexamethasone and tetracyclines: a potential therapeutic option for the management of severe COVID-19 infection?
33733058 2021. Sialylation of host proteins as targetable risk factor for COVID-19 susceptibility and spreading: A hypothesis.
33577131 2021. Associations of essential and toxic metals/metalloids in whole blood with both disease severity and mortality in patients with COVID-19.
33566370 2021. A pressor dose of angiotensin II has no influence on the angiotensin-converting enzyme 2 and other molecules associated with SARS-CoV-2 infection in mice.
33621437 2021. The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVID-19 infection.
33722600 2021. Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update.
33794307 2021. The effects of some essential and toxic metals/metalloids in COVID-19: A review.
33640537 2021. Inflammation, immunity and potential target therapy of SARS-COV-2: A total scale analysis review.
33592201 2021. Glossary of phytoconstituents: Can these be repurposed against SARS CoV-2? A quick in silico screening of various phytoconstituents from plant Glycyrrhiza glabra with SARS CoV-2 main protease.
33578926 2021. Fruits and Vegetables in the Management of Underlying Conditions for COVID-19 High-Risk Groups.
33718452 2021. Single-Cell Transcriptome Analysis Decipher New Potential Regulation Mechanism of ACE2 and NPs Signaling Among Heart Failure Patients Infected With SARS-CoV-2.
33681310 2021. Case Report: Hyperbilirubinemia in Gilbert Syndrome Attenuates Covid-19-Induced Metabolic Disturbances.
33791293 2021. Coronavirus-Induced Host Cubic Membranes and Lipid-Related Antiviral Therapies: A Focus on Bioactive Plasmalogens.
33718360 2021. SARS-CoV-2-Specific Memory T Lymphocytes From COVID-19 Convalescent Donors: Identification, Biobanking, and Large-Scale Production for Adoptive Cell Therapy.
33659247 2021. Mesenchymal Stromal Cell-Derived Extracellular Vesicles in Lung Diseases: Current Status and Perspectives.
33634100 2020. Human Dental Pulp Stem Cells Modulate Cytokine Production in vitro by Peripheral Blood Mononuclear Cells From Coronavirus Disease 2019 Patients.
33614627 2020. Targeting Lipid Rafts as a Strategy Against Coronavirus.
33796489 2021. Predictive Analysis of the Neutralization Activity in Convalescent Plasmas From COVID-19 Recovered Patients in Zhejiang Province, China, January-March, 2020.
33732682 2020. Evaluation of Annona muricata Acetogenins as Potential Anti-SARS-CoV-2 Agents Through Computational Approaches.
33614597 2020. In silico Exploration of Inhibitors for SARS-CoV-2's Papain-Like Protease.
33614592 2020. In Silico Study of Coumarins and Quinolines Derivatives as Potent Inhibitors of SARS-CoV-2 Main Protease.
33585398 2020. Microsecond MD Simulation and Multiple-Conformation Virtual Screening to Identify Potential Anti-COVID-19 Inhibitors Against SARS-CoV-2 Main Protease.
33553109 2020. Computational Characterizations of the Interactions Between the Pontacyl Violet 6R and Exoribonuclease as a Potential Drug Target Against SARS-CoV-2.
33815295 2021. The Efficacy and Potential Mechanisms of Metformin in the Treatment of COVID-19 in the Diabetics: A Systematic Review.
33716989 2021. Vitamin D Association With Macrophage-Derived Cytokines in Polycystic Ovary Syndrome: An Enhanced Risk of COVID-19 Infection?
33664772 2021. Perspectives About Modulating Host Immune System in Targeting SARS-CoV-2 in India.
33815368 2021. Efficacy and Effect of Inhaled Adenosine Treatment in Hospitalized COVID-19 Patients.
33777055 2021. Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results.
33777030 2021. Induction of Potent and Durable Neutralizing Antibodies Against SARS-CoV-2 Using a Receptor Binding Domain-Based Immunogen.
33777024 2021. Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment.
33821251 2021. Tackling the pillars of ageing to fight COVID-19.
33812495 2021. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors.
33676592 2021. IL-6 blockade for COVID-19: a global scientific call to arms.
33676590 2021. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial.
33676589 2021. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial.
33806274 2021. Therapeutic Potential of EGCG, a Green Tea Polyphenol, for Treatment of Coronavirus Diseases.
33805385 2021. In Vitro Evaluation of the Activity of Terpenes and Cannabidiol against Human Coronavirus E229.
33803014 2021. Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey.
33802763 2021. Effects and Safety of Convalescent Plasma Administration in a Group of Polish Pediatric Patients with COVID-19: A Case Series.
33814087 2021. Vitamin D and COVID-19.
33823371 2021. Endotheliitis, endothelin, and endothelin receptor blockers in COVID-19.
33799158 2021. Methylene blue: Subduing the post COVID-19 blues!
33801645 2021. The Role of Nutrition in the COVID-19 Pandemic.
33804603 2021. Ketogenic Diet as a Preventive and Supportive Care for COVID-19 Patients.
33803015 2021. COVID-19: Role of Nutrition and Supplementation.
33799985 2021. In Vitro Effects of Doxycycline on Replication of Feline Coronavirus.
33804294 2021. Differential Effects of Antiseptic Mouth Rinses on SARS-CoV-2 Infectivity In Vitro.
33799977 2021. Association between Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) and Reduced Risk of Death in COVID-19 Patients: A Retrospective Cohort Study.
33807743 2021. Rapamycin: Drug Repurposing in SARS-CoV-2 Infection.
33806331 2021. Repurposing of Some Natural Product Isolates as SARS-COV-2 Main Protease Inhibitors via In Vitro Cell Free and Cell-Based Antiviral Assessments and Molecular Modeling Approaches.
33807248 2021. Potent Antiviral Activity against HSV-1 and SARS-CoV-2 by Antimicrobial Peptoids.
33808025 2021. Development and Characterization of Inhaled Ethanol as a Novel Pharmacological Strategy Currently Evaluated in a Phase II Clinical Trial for Early-Stage SARS-CoV-2 Infection.
33802215 2021. Interaction of Remdesivir with Clinically Relevant Hepatic Drug Uptake Transporters.
33811957 2021. Traditional Chinese Medicine (TCM) in the treatment of COVID-19 and other viral infections: Efficacies and mechanisms.
33799224 2021. Association between use of Qingfei Paidu Tang and mortality in hospitalized patients with COVID-19: A national retrospective registry study.
33810568 2021. Synthesis and Characterization of a Minophosphonate Containing Chitosan Polymer Derivatives: Investigations of Cytotoxic Activity and in Silico Study of SARS-CoV-19.
33810527 2021. Niclosamide-Clay Intercalate Coated with Nonionic Polymer for Enhanced Bioavailability toward COVID-19 Treatment.
33705727 2021. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial.
33705726 2021. Adjuvantation helps to optimise COVID-19 vaccine candidate.
33676591 2021. COVID-19 and inhaled corticosteroids-another piece in an expanding puzzle.
33684947 2021. Allergische Reaktionen auf COVID-19-Impfungen - Was HNO-Arzte wissen sollten - Teil 1: Immunologische Grundlagen von Allergien auf Impfstoffe, Immunmechanismen von allergischen und pseudoallergischen Reaktionen; Teil 2: Charakteristika der mRNA-Impfstoffe BNT162b2- und mRNA-1273 zur Prophylaxe von COVID-19 und assoziierte Immunphanomene; Teil 3: Praktische Aspekte der Prophylaxe, Diagnostik und Therapie von Allergien auf COVID-19-Impfstoffe.
33729089 2021. Convalescent hyperimmune plasma in patients with hematologic malignancies and severe COVID-19 infections.
33742475 2021. Plain (1) H nuclear magnetic resonance analysis streamlines the quality control of antiviral favipiravir and congeneric World Health Organization essential medicines.
33574017 2021. Magnesium therapeutic potential against Covid-19: Could it be an "All-in-one" therapy?
33678604 2020. Dysmagnesemia in Covid-19 cohort patients: prevalence and associated factors.
33613817 2021. Efficacy of Traditional Chinese Medicine on COVID-19: Two Case Reports.
33613815 2021. Medical Acupuncture as a Treatment for Novel COVID-19-Related Respiratory Distress: Personal Experience from a Frontline Anesthesiologist.
33613814 2021. Properties of the Novel Chinese Herbal Medicine Formula Qu Du Qiang Fei I Hao Fang Warrant Further Research to Determine Its Clinical Efficacy in COVID-19 Treatment.
33563156 2021. Coumarins and Quinolones as Effective Multiple Targeted Agents Versus Covid-19: An in Silico Study.
33666909 2021. Treating COVID-19 Acute Severe Hypoxemic Respiratory Failure: First Case Report Utilizing Dexamethasone, Remdesivir, and Convalescent Plasma in Operation Inherent Resolve.
33684922 2021. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies in Neonatal Cord Blood After Vaccination in Pregnancy.
33583812 2020. Review: Herbs, Immunity and nCOVID-19: Old performers in new Pandemic.
33769223 2021. SUMO: a novel target for anti-coronavirus therapy.
33579813 2021. Remestemcel-L Therapy for COVID-19-Associated Multisystem Inflammatory Syndrome in Children.
33772933 2021. QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis.
33722710 2021. Resveratrol-mediated attenuation of superantigen-driven acute respiratory distress syndrome is mediated by microbiota in the lungs and gut.
33714279 2021. A hypothesis: Bitter taste receptors as a therapeutic target for the clinical symptoms of SARS-CoV-2.
33711090 2021. Covalent and non-covalent binding free energy calculations for peptidomimetic inhibitors of SARS-CoV-2 main protease.
33688867 2021. 1'-Ribose cyano substitution allows Remdesivir to effectively inhibit nucleotide addition and proofreading during SARS-CoV-2 viral RNA replication.
33713539 2021. Corticosteroids and pulmonary rehabilitation reducing long-term morbidity in a patient with post-COVID-19 pneumonitis: A case study.
33786876 2021. Flavonoids as potential phytotherapeutics to combat cytokine storm in SARS-CoV-2.
33778996 2021. Greater celandine (Chelidonium majus L.) for COVID-19: A twenty-case series.
33759279 2021. Plant-derived chemicals as potential inhibitors of SARS-CoV-2 main protease (6LU7), a virtual screening study.
33822421 2021. Silibinin as potential tool against SARS-Cov-2: In silico spike receptor-binding domain and main protease molecular docking analysis, and in vitro endothelial protective effects.
33817867 2021. Phyto-pharmacological perspective of Silymarin: A potential prophylactic or therapeutic agent for COVID-19, based on its promising immunomodulatory, anti-coagulant and anti-viral property.
33797123 2021. In silico approach of secondary metabolites from Brazilian herbal medicines to search for potential drugs against SARS-CoV-2.
33711848 2021. COVID-19-Impfungen bei Biologika-Therapie von Asthma bronchiale.
33583332 2021. Hydroxychloroquine Sulfate Related Hypoglycemia In A Non-Diabetic COVID-19 Patient: A Case Report and Literature Review.
33795478 2021. Clofazimine: another potential magic bullet for the treatment of COVID-19?
33591652 2021. [The role of supplying population with vitamin D in conditions of COVID-19 pandemic: foreign publications review].

33767711 2021. Editorial: Immune Responses to Persistent or Recurrent Antigens: Implications for Immunological Memory and Immunotherapy.
33767706 2021. The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic.
33763085 2021. Vitamin D in Corona Virus Disease 2019 (COVID-19) Related Multisystem Inflammatory Syndrome in Children (MIS-C).
33763077 2021. The BCG Vaccine for COVID-19: First Verdict and Future Directions.
33746945 2021. Upregulated IL-6 Indicates a Poor COVID-19 Prognosis: A Call for Tocilizumab and Convalescent Plasma Treatment.
33732258 2021. A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation.
33717181 2021. Microbiota Modulation of the Gut-Lung Axis in COVID-19.
33717077 2021. A Proteome-Wide Immunoinformatics Tool to Accelerate T-Cell Epitope Discovery and Vaccine Design in the Context of Emerging Infectious Diseases: An Ethnicity-Oriented Approach.
33679771 2021. High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China.
33679770 2021. Anti-SARS-CoV-2 Antibodies Within IVIg Preparations: Cross-Reactivities With Seasonal Coronaviruses, Natural Autoimmunity, and Therapeutic Implications.
33643316 2021. The Immunopathology of COVID-19 and the Cannabis Paradigm.
33643308 2021. Immunomodulatory Effects of Azithromycin Revisited: Potential Applications to COVID-19.
33613573 2021. The Relevance of a Physical Active Lifestyle and Physical Fitness on Immune Defense: Mitigating Disease Burden, With Focus on COVID-19 Consequences.
33643285 2020. VISTA: A Target to Manage the Innate Cytokine Storm.
33633726 2020. Activation of the Cholinergic Anti-Inflammatory Pathway as a Novel Therapeutic Strategy for COVID-19.
33613542 2020. Update on Antiviral Strategies Against COVID-19: Unmet Needs and Prospects.
33584672 2020. Indicator Regularized Non-Negative Matrix Factorization Method-Based Drug Repurposing for COVID-19.
33584668 2020. Induction of SARS-CoV-2 Protein S-Specific CD8+ T Cells in the Lungs of gp96-Ig-S Vaccinated Mice.
33569053 2020. Could Perturbation of Gut Microbiota Possibly Exacerbate the Severity of COVID-19 via Cytokine Storm?
33687643 2021. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial.
33816521 2021. Combination of Angiotensin (1-7) Agonists and Convalescent Plasma as a New Strategy to Overcome Angiotensin Converting Enzyme 2 (ACE2) Inhibition for the Treatment of COVID-19.
33816515 2021. Case Report: Administration of Amniotic Fluid-Derived Nanoparticles in Three Severely Ill COVID-19 Patients.
33777973 2021. COVID-19 Therapy: Could a Copper Derivative of Chlorophyll a Be Used to Treat Lymphopenia Associated With Severe Symptoms of SARS-CoV-2 Infection?
33768100 2021. D-Limonene Is a Potential Monoterpene to Inhibit PI3K/Akt/IKK-alpha/NF-kappaB p65 Signaling Pathway in Coronavirus Disease 2019 Pulmonary Fibrosis.
33718411 2021. COVID-19 and Risk of Acute Ischemic Stroke and Acute Lung Injury in Patients With Type II Diabetes Mellitus: The Anti-inflammatory Role of Metformin.
33718395 2021. Glucocorticoids Should Be Used With Caution in Patients With SARS-CoV-2.
33681257 2021. An Open Label Trial to Assess Safety of Losartan for Treating Worsening Respiratory Illness in COVID-19.
33644099 2021. Furin Expression in Patients With Psoriasis-A Patient Cohort Endangered to SARS-COV2?
33634148 2021. Adverse Outcomes Associated With Corticosteroid Use in Critical COVID-19: A Retrospective Multicenter Cohort Study.
33614688 2021. Decreased Mortality Rate Among COVID-19 Patients Prescribed Statins: Data From Electronic Health Records in the US.
33585529 2021. Effect of Convalescent Plasma in Critically Ill Patients With COVID-19: An Observational Study.
33585519 2020. Commentary: Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused.
33585508 2020. Mortality Benefit of Remdesivir in COVID-19: A Systematic Review and Meta-Analysis.
33553219 2020. Can GPR4 Be a Potential Therapeutic Target for COVID-19?
33537320 2020. Vitamin C and COVID-19.
33746908 2020. Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2.
33763450 2021. Emerging Therapeutic Approaches to Combat COVID-19: Present Status and Future Perspectives.
33718434 2021. Drug Repurposing Strategy (DRS): Emerging Approach to Identify Potential Therapeutics for Treatment of Novel Coronavirus Infection.
33659275 2021. Molecular Mechanisms Behind Anti SARS-CoV-2 Action of Lactoferrin.
33628764 2020. New Insights Into Potential Benefits of Bioactive Compounds of Bee Products on COVID-19: A Review and Assessment of Recent Research.
33614709 2020. Therapeutic Strategies in the Management of COVID-19.
33569392 2020. Elucidating the Interactions Between Heparin/Heparan Sulfate and SARS-CoV-2-Related Proteins-An Important Strategy for Developing Novel Therapeutics for the COVID-19 Pandemic.
33542917 2020. In silico Screening of Natural Compounds as Potential Inhibitors of SARS-CoV-2 Main Protease and Spike RBD: Targets for COVID-19.
33816542 2021. The Looming Effects of Estrogen in Covid-19: A Rocky Rollout.
33748170 2021. Negative Association Between Mediterranean Diet Adherence and COVID-19 Cases and Related Deaths in Spain and 23 OECD Countries: An Ecological Study.
33634160 2021. Plant-Derived Food Grade Substances (PDFGS) Active Against Respiratory Viruses: A Systematic Review of Non-clinical Studies.
33553234 2020. The Burden of Malnutrition and Fatal COVID-19: A Global Burden of Disease Analysis.
33708752 2020. Case Report: Use of Anakinra in Multisystem Inflammatory Syndrome During COVID-19 Pandemic.
33815126 2021. Repurposing Anti-Malaria Phytomedicine Artemisinin as a COVID-19 Drug.
33790785 2021. Evaluation of the Current Therapeutic Approaches for COVID-19: A Systematic Review and a Meta-analysis.
33776767 2021. Modeling of SARS-CoV-2 Treatment Effects for Informed Drug Repurposing.
33767626 2021. Anti-IL5 Drugs in COVID-19 Patients: Role of Eosinophils in SARS-CoV-2-Induced Immunopathology.
33767623 2021. The Anti-inflammatory Effect of the Tricyclic Antidepressant Clomipramine and Its High Penetration in the Brain Might Be Useful to Prevent the Psychiatric Consequences of SARS-CoV-2 Infection.
33767619 2021. Plant Products as Inhibitors of Coronavirus 3CL Protease.
33762960 2021. Aripiprazole as a Candidate Treatment of COVID-19 Identified Through Genomic Analysis.
33762954 2021. An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?
33716752 2021. Discovering Potential RNA Dependent RNA Polymerase Inhibitors as Prospective Drugs Against COVID-19: An in silico Approach.
33716745 2021. The Potential Therapeutic Effect of RNA Interference and Natural Products on COVID-19: A Review of the Coronaviruses Infection.
33716737 2021. In silico Analyses of Immune System Protein Interactome Network, Single-Cell RNA Sequencing of Human Tissues, and Artificial Neural Networks Reveal Potential Therapeutic Targets for Drug Repurposing Against COVID-19.
33692695 2021. Drug Repurposing and Polypharmacology to Fight SARS-CoV-2 Through Inhibition of the Main Protease.
33584318 2021. Mitochondria Are Potential Targets for the Development of New Drugs Against Neutrophilic Inflammation in Severe Pneumonia Including COVID-19.
33815095 2020. A Scoping Insight on Potential Prophylactics, Vaccines and Therapeutic Weaponry for the Ongoing Novel Coronavirus (COVID-19) Pandemic- A Comprehensive Review.
33776751 2020. A Retrospective Study on the Use of Chinese Patent Medicine in 24 Medical Institutions for COVID-19 in China.
33746739 2020. Molecular Mechanism of Action of Repurposed Drugs and Traditional Chinese Medicine Used for the Treatment of Patients Infected With COVID-19: A Systematic Scoping Review.
33737877 2020. Repurposing Treatment of Wernicke-Korsakoff Syndrome for Th-17 Cell Immune Storm Syndrome and Neurological Symptoms in COVID-19: Thiamine Efficacy and Safety, In-Vitro Evidence and Pharmacokinetic Profile.
33737875 2020. Indian Medicinal Plants and Formulations and Their Potential Against COVID-19-Preclinical and Clinical Research.
33732148 2020. Yindan Jiedu Granules, a Traditional Chinese Medicinal Formulation, as a Potential Treatment for Coronavirus Disease 2019.
33716728 2020. Prospective: Evolution of Chinese Medicine to Treat COVID-19 Patients in China.
33716720 2020. Chinese Herbal Medicine Used With or Without Conventional Western Therapy for COVID-19: An Evidence Review of Clinical Studies.
33708124 2020. Targeting Neurological Manifestations of Coronaviruses by Candidate Phytochemicals: A Mechanistic Approach.
33708112 2020. Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2.
33708109 2020. Calming the Storm: Natural Immunosuppressants as Adjuvants to Target the Cytokine Storm in COVID-19.
33692684 2020. Rational Drug Repurposing: Focus on Lysosomotropism, Targets in Disease Process, Drug Profile, and Pulmonary Tissue Accumulation in SARS-CoV-2 Infection/COVID-19.
33679384 2020. Potential Natural Products Against Respiratory Viruses: A Perspective to Develop Anti-COVID-19 Medicines.
33658931 2020. Phytochemicals: Potential Therapeutic Interventions Against Coronavirus-Associated Lung Injury.
33658924 2020. Cytotoxicity Evaluation of Chloroquine and Hydroxychloroquine in Multiple Cell Lines and Tissues by Dynamic Imaging System and Physiologically Based Pharmacokinetic Model.
33643034 2020. Development of a Physiologically Based Pharmacokinetic Model for Hydroxychloroquine and Its Application in Dose Optimization in Specific COVID-19 Patients.
33643033 2020. Modalities and Mechanisms of Treatment for Coronavirus Disease 2019.
33628169 2020. COVIEdb: A Database for Potential Immune Epitopes of Coronaviruses.
33613282 2020. Several FDA-Approved Drugs Effectively Inhibit SARS-CoV-2 Infection in vitro.
33597888 2020. Potency, Safety, and Pharmacokinetic Profiles of Potential Inhibitors Targeting SARS-CoV-2 Main Protease.
33584306 2020. HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons.
33584285 2020. Protective Effect of Arbidol Against Pulmonary Fibrosis and Sepsis in Mice.
33584268 2020. Perspectives of Antidiabetic Drugs in Diabetes With Coronavirus Infections.
33584267 2020. Nasal Delivery of Hesperidin/Chitosan Nanoparticles Suppresses Cytokine Storm Syndrome in a Mouse Model of Acute Lung Injury.
33574761 2020. Commentary: Paracetamol-Induced Glutathione Consumption: Is There a Link With Severe COVID-19 Illness?
33574756 2020. Potential of Immune-Related Therapy in COVID-19.
33542685 2020. Statins as Adjuvant Therapy for COVID-19 to Calm the Stormy Immunothrombosis and Beyond.
33636368 2021. Micronized / ultramicronized palmitoylethanolamide (PEA) as natural neuroprotector against COVID-19 inflammation.
33787891 2021. COVID-19 vaccination-associated myelitis.
33642133 2021. VitaminD supplementation for the prevention and treatment of COVID-19: a position statement from the Spanish Society of Geriatrics and Gerontology.
33817742 2020. Letter to the Editor: Boron enhances the antiviral activity of the curcumin against SARS-CoV-2.
33795718 2021. Molecular dynamics and in silico mutagenesis on the reversible inhibitor-bound SARS-CoV-2 main protease complexes reveal the role of lateral pocket in enhancing the ligand affinity.
33602867 2021. SARS-CoV-2 M(pro) inhibitors with antiviral activity in a transgenic mouse model.
33688062 2021. Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes.
33618635 2021. Mesenchymal Stem Cell Derived-Exosomes as Effective Factors in Reducing Cytokine Storm Symptoms of COVID-19.
33636424 2021. Imagining the COVID-19 pandemic through the minds of 9-11 years old: findings from an art exhibition in India.
33725726 2021. The Theoretical Value of Whole-Lung Irradiation for COVID-19 Pneumonia: A Reasonable and Safe Solution until Targeted Treatments are Developed.
33687358 2021. L'elogio dell'incertezza: una revisione sistematica living per valutare l'efficacia e la sicurezza dei trattamenti farmacologici per pazienti affetti da covid-19.
33687352 2021. Vaccino contro la covid-19: una questione aperta.
33631907 2020. Infeccion diseminada por vacuna con bacilo de Calmette-Guerin y coinfeccion por SARS-CoV-2 en paciente con deficiencia de la subunidad beta1 del receptor de IL-12.
33694220 2021. Effects of chloroquine or hydroxychloroquine treatment on non-SARS-CoV2 viral infections: A systematic review of clinical studies.
33566918 2020. Transfusion de plasma convaleciente de pacientes con COVID-19.
33566898 2020. Dioxido de cloro y derivados del cloro para prevenir o tratar la COVID-19: revision sistematica.
33739711 2020. Hydroxychloroquine dans le Covid et liberte de prescription.
33551422 2021. [Successful steroid pulse therapy for COVID-19 associated respiratory failure initially mimicking bortezomib-induced lung injury].
33620985 2020. inverted question markEl plasma convaleciente es un tratamiento alternativo para pacientes con Covid-19?
33632917 2021. COVAX Statement on WHO emergency use listing for AstraZeneca/Oxford COVID-19 vaccine.
33632915 2021. Is chloroquine or hydroxychloroquine useful in treating people with COVID-19, or in preventing infection in people who have been exposed to the virus?
33795510 2021. WHO adds Janssen vaccine to list of safe and effective emergency tools against COVID-19.
33820835 2021. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates.
33674471 2021. WHO's treatment megatrial is at a standstill.

33686419 2021. Exclusion of pregnant and lactating women from COVID-19 vaccine trials: a missed opportunity.
33569601 2021. Re-purposed antiviral drugs without a purpose in COVID-19: a valuable lesson for clinicians.
33770576 2021. SARS-CoV-2 vaccines for cancer patients: a call to action.
33743480 2021. SARS-CoV-2 vaccines for cancer patients treated with immunotherapies: Recommendations from the French society for ImmunoTherapy of Cancer (FITC).
33393082 2021. Sustaining efficient immune functions with regular physical exercise in the COVID-19 era and beyond.
33742158 2021. Comments on nutritional recommendations for CoVID-19 quarantine.
33660020 2021. Repositioning HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors for the treatment of SARS-CoV-2 infection and COVID-19.
33532896 2021. The effect of tocilizumab on mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials.
33634346 2021. External validity of phase III trials on vaccines against SARS-CoV-2 to a middle-aged and elderly Western European population.
33649879 2021. COVID-19 vaccine acceptance among pregnant women and mothers of young children: results of a survey in 16 countries.
33627476 2021. Does timing matter on tocilizumab administration? Clinical, analytical and radiological outcomes in COVID-19.
33619027 2021. The European COVID-19 drugs calculation tool: an aid for the estimation of the drugs needed during the SARS-CoV 2 pandemic.
33576494 2021. High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2.
33552315 2021. The preventive effect of Xuebijing injection against cytokine storm for severe patients with COVID-19: A prospective randomized controlled trial.
33581979 2021. Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies.
33746777 2021. Practical Recommendations Relevant to the Use of Resistance Training for COVID-19 Survivors.
33574769 2021. Targeting Endolysosomal Two-Pore Channels to Treat Cardiovascular Disorders in the Novel COronaVIrus Disease 2019.
33584335 2020. The Impact of Polyphenols-Based Diet on the Inflammatory Profile in COVID-19 Elderly and Obese Patients.
33551833 2020. CSF3 Is a Potential Drug Target for the Treatment of COVID-19.
33719281 2021. Cinnamon and Hop Extracts as Potential Immunomodulators for Severe COVID-19 Cases.
33664752 2020. Carvacrol, a Plant Metabolite Targeting Viral Protease (M(pro)) and ACE2 in Host Cells Can Be a Possible Candidate for COVID-19.
33584747 2020. Development of Plant-Produced Recombinant ACE2-Fc Fusion Protein as a Potential Therapeutic Agent Against SARS-CoV-2.
33821255 2021. Use of SGLT-2 inhibitor in COVID-19: A cautionary tale.
33821254 2021. A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential.
33799535 2021. The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients.
33807988 2021. Targeting the DEAD-Box RNA Helicase eIF4A with Rocaglates-A Pan-Antiviral Strategy for Minimizing the Impact of Future RNA Virus Pandemics.
33806624 2021. SARS-CoV-2 Disease Adjuvant Therapies and Supplements Breakthrough for the Infection Prevention.
33810287 2021. Lactiplantibacillus plantarum as a Potential Adjuvant and Delivery System for the Development of SARS-CoV-2 Oral Vaccines.
33804162 2021. COVID-19: Insights into Potential Vaccines.
33792313 2021. Role of Hydrogen Bonds in Formation of Co-amorphous Valsartan/Nicotinamide Compositions of High Solubility and Durability with Anti-hypertension and Anti-COVID-19 Potential.
33823303 2021. A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice.
33800013 2021. Structure-Based Virtual Screening Identifies Multiple Stable Binding Sites at the RecA Domains of SARS-CoV-2 Helicase Enzyme.
33807773 2021. SARS-CoV-2 Main Protease Active Site Ligands in the Human Metabolome.
33808054 2021. The Inhibitory Effects of Plant Derivate Polyphenols on the Main Protease of SARS Coronavirus 2 and Their Structure-Activity Relationship.
33805419 2021. Accelerated Repurposing and Drug Development of Pulmonary Hypertension Therapies for COVID-19 Treatment Using an AI-Integrated Biosimulation Platform.
33810416 2021. Molecular Basis of the Therapeutical Potential of Clove (Syzygium aromaticum L.) and Clues to Its Anti-COVID-19 Utility.
33809963 2021. Medicinal Plants, Phytochemicals, and Herbs to Combat Viral Pathogens Including SARS-CoV-2.
33801151 2021. Identification of Potential SARS-CoV-2 Main Protease and Spike Protein Inhibitors from the Genus Aloe: An In Silico Study for Drug Development.
33800977 2021. Natural Products from Medicinal Plants with Anti-Human Coronavirus Activities.
33802860 2021. Is PF-00835231 a Pan-SARS-CoV-2 Mpro Inhibitor? A Comparative Study.
33799871 2021. Receptor-Based Pharmacophore Modeling in the Search for Natural Products for COVID-19 M(pro).
33794595 2021. The initial experience of COVID-19 vaccination from a tertiary care centre of India.
33755376 2021. SARS-CoV-2 Infection after Vaccination in Health Care Workers in California.
33755373 2021. BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers.
33755375 2021. Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine.
33755374 2021. Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center.
33725432 2021. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.
33691060 2021. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine.
33807206 2021. Pea Protein Nanoemulsion Effectively Stabilizes Vitamin D in Food Products: A Potential Supplementation during the COVID-19 Pandemic.
33795671 2021. Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors.
33795856 2021. Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination.
33597220 2021. Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets.
33766944 2021. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection.
33646996 2021. FDA authorizes Pfizer-BioNTech COVID-19 vaccine.
33739278 2021. L'ARN polymerase COVID-19 - Le talon d'Achille du SARS-CoV-2.
33687881 2021. The situation of small molecules targeting key proteins to combat SARS-CoV-2: Synthesis, metabolic pathway, mechanism of action, and potential therapeutic applications.
33797374 2021. Effectiveness of Azithromycin as add-on Therapy in COVID-19 Management.
33663367 2021. Recent Advance in Natural Products with Antiviral Activities.
33573545 2021. S.A.R.S Covid-19 A Medicinal Chemistry Approach.
33550970 2021. Coronavirus (COVID -19): Chemical entities of biological interest.
33535950 2021. Natural substances and semisynthetic derivatives as potential alternative products against SARS-CoV-2.
33655830 2021. Treatment approaches for COVID-19: A critical review.
33632095 2021. Elucidating the drug repurposing spectra of COVID-19 with its analogues SARS and MERS.
33596800 2021. A review on Remdesivir: A broad-spectrum antiviral molecule for possible COVID-19 treatment.
33568033 2021. Glycyrrhizin as a Potential Treatment for the Novel Coronavirus (COVID-19).
33787066 2021. An Integrative in silico Drug Repurposing Approach for Identification of Potential Inhibitors of SARS-CoV-2 Main Protease.
33657301 2021. Audio Interview: A New SARS-CoV-2 Vaccine and a New Look at Treatment.
33596347 2021. Delayed Second Dose versus Standard Regimen for Covid-19 Vaccination.
33567188 2021. Hydroxychloroquine in Hospitalized Patients with Covid-19. Reply.
33567187 2021. Hydroxychloroquine in Hospitalized Patients with Covid-19.
33534968 2021. Monoclonal Antibody for Patients with Covid-19. Reply.
33534967 2021. Monoclonal Antibody for Patients with Covid-19.
33730461 2021. Audio Interview: Efficacy of Current Covid-19 Vaccines against Variant Viruses.
33567190 2021. Maintaining Safety with SARS-CoV-2 Vaccines. Reply.
33567189 2021. Maintaining Safety with SARS-CoV-2 Vaccines.
33626259 2021. Audio Interview: The Real-World Effectiveness of Covid-19 Vaccination.
33822494 2021. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19.
33596351 2021. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. Reply.
33596350 2021. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
33596349 2021. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
33596348 2021. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
33657288 2021. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. Reply.
33657287 2021. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. Reply.
33657286 2021. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.
33536629 2021. Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents.
33623157 2021. Biological activity-based modeling identifies antiviral leads against SARS-CoV-2.
33796820 2021. A deep learning framework for high-throughput mechanism-driven phenotype compound screening and its application to COVID-19 drug repurposing.
33782619 2021. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine.
33772244 2021. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies.
33795870 2021. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2.
33664494 2021. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies.
33654292 2021. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.
33558724 2021. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera.
33769143 2021. Chlorogenic acid, a natural product as potential inhibitor of COVID-19: virtual screening experiment based on network pharmacology and molecular docking.
33707753 2021. FDA authorizes first single-shot COVID-19 vaccine.
33633370 2021. Trends in COVID-19 therapeutic clinical trials.
33674802 2021. Structural basis for inhibition of the SARS-CoV-2 RNA polymerase by suramin.
33780970 2021. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma.
33767445 2021. Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice.
33727703 2021. Clofazimine broadly inhibits coronaviruses including SARS-CoV-2.
33706364 2021. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.
33772237 2021. Coronapod: the Oxford-AstraZeneca COVID vaccine - what you need to know.
33767467 2021. Latest results put Oxford-AstraZeneca COVID vaccine back on track.
33742175 2021. Coronapod: Why COVID antibody treatments may not be the answer.
33654255 2021. J&J's single-dose COVID vaccine raises hopes for faster rollout.
33712752 2021. COVID antibody treatments show promise for preventing severe disease.
33654298 2021. Some antibodies can dampen antiviral defences in people with severe COVID.
33623151 2021. Why COVID vaccines are so difficult to compare.
33561864 2021. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801.
33526898 2021. J&J's one-shot COVID vaccine offers hope for faster protection.
33811258 2021. Coronapod: How to define rare COVID vaccine side effects.
33707257 2021. Vaccine efficacy probable against COVID-19 variants.

33639344 2021. A new class of alpha-ketoamide derivatives with potent anticancer and anti-SARS-CoV-2 activities.
33618158 2021. Protease targeted COVID-19 drug discovery: What we have learned from the past SARS-CoV inhibitors?
33609889 2021. Synthetic and medicinal perspective of quinolines as antiviral agents.
33588180 2021. Discovery and structural optimization of 3-O-beta-chacotriosyl oleanane-type triterpenoids as potent entry inhibitors of SARS-CoV-2 virus infections.
33573699 2021. Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial.
33537632 2020. Breastfeeding during the COVID-19 pandemic.
33675368 2021. COVID-19 vaccine as a cause for unilateral lymphadenopathy detected by 18F-FDG PET/CT in a patient affected by melanoma.
33661328 2021. Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F]Choline PET/CT-not only an FDG finding.
33774684 2021. Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [(18)F]FDG PET-CT and relevance to study interpretation.
33638003 2021. COVID-19 vaccination induced axillary nodal uptake on [18F]FDG PET/CT.
33585950 2021. A key role for vitamin D binding protein in COVID-19?
33576843 2021. Reply to: A key role for vitamin D binding protein in COVID-19?
33788001 2021. The association between vitamin D levels and the clinical severity and inflammation markers in pediatric COVID-19 patients: single-center experience from a pandemic hospital.
33617948 2021. In silico identification of available drugs targeting cell surface BiP to disrupt SARS-CoV-2 binding and replication: Drug repurposing approach.
33775827 2021. In-silico screening for identification of potential inhibitors against SARS-CoV-2 transmembrane serine protease 2 (TMPRSS2).
33667455 2021. Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19.
33639193 2021. Brief review on repurposed drugs and vaccines for possible treatment of COVID-19.
33722593 2021. COVID-19 and IL-6: Why vitamin D (probably) helps but tocilizumab might not.
33607104 2021. No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial.
33549577 2021. Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis.
33545161 2021. Chloroquine: Autophagy inhibitor, antimalarial, bitter taste receptor agonist in fight against COVID-19, a reality check?
33580785 2021. The strange case of hydroxychloroquine and COVID-19.
33623975 2020. QTc-interval prolongation and increased risk of sudden cardiac death associated with hydroxychloroquine.
33624070 2020. Amiodarone in COVID-19: let's not forget its potential for pulmonary toxicity.
33585912 2021. The hydroxychloroquine debate: a therapeutic dilemma for general practitioners.
33542051 2021. Genetic polymorphisms, vitamin D binding protein and vitamin D deficiency in COVID-19.
33795322 2021. Inhaled corticosteroids downregulate SARS-CoV-2-related genes in COPD: results from a RCT.
33602862 2021. Reply: Is high-dose glucocorticoid beneficial in COVID-19?
33574071 2021. Corticosteroids in COVID-19: one size does not fit all.
33568526 2021. Corticosteroids for CAP, influenza and COVID-19: when, how and benefits or harm?
33577063 2021. Effect of glucocorticoid therapy on the prognosis of patients with severe and critical COVID-19: a single-center retrospective cohort study.
33577009 2021. Molecular exploration of combinational therapy of orlistat with metformin prevents the COVID-19 consequences in obese diabetic patients.
33660833 2021. The interplay between vitamin D and COVID-19: protective or bystander?
33629336 2021. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
33716536 2021. High-Dose Vitamin C Infusion for the Treatment of Covid-19: Beware of Paraben Intoxication.
33769252 2021. Robust antibody responses in 70-80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021.
33706861 2021. Acute onset supraclavicular lymphadenopathy coinciding with intramuscular mRNA vaccination against COVID-19 may be related to vaccine injection technique, Spain, January and February 2021.
33663646 2021. Incidence of COVID-19 in patients exposed to chloroquine and hydroxychloroquine: results from a population-based prospective cohort in Catalonia, Spain, 2020.
33748066 2021. The Impact of Vitamin D Level on COVID-19 Infection: Systematic Review and Meta-Analysis.
33553096 2020. Vitamin D Deficiency as an Important Biomarker for the Increased Risk of Coronavirus (COVID-19) in People From Black and Asian Ethnic Minority Groups.
33778086 2021. Ethnomedicinal herbs in African traditional medicine with potential activity for the prevention, treatment, and management of coronavirus disease 2019.
33754123 2021. Therapeutic role of corticosteroids in COVID-19: a systematic review of registered clinical trials.
33576273 2021. Targeting the SARS-CoV-2 3CL(pro) and NO/cGMP/PDE5 pathway in COVID-19: a commentary on PDE5 inhibitors.
33590764 2021. De novo design of new chemical entities for SARS-CoV-2 using artificial intelligence.
33709775 2021. COVID-19 pneumonia: do not leave the corticosteroids behind!
33569984 2021. Dual targeting of Toll-like receptor 4 and angiotensin-converting enzyme 2: a proposed approach to SARS-CoV-2 treatment.
33538178 2021. The right immune-modulation at the right time: thymosin alpha1 for prevention of severe COVID-19 in cancer patients.
33705746 2021. The associations between pharmacological gastric acid suppression and adverse outcomes in patients with COVID-19.
33609504 2021. Lack of Consistent Associations Between Pharmacologic Gastric Acid Suppression and Adverse Outcomes in Patients With Coronavirus Disease 2019: Meta-Analysis of Observational Studies.
33814381 2021. COVAX Statement on WHO emergency use listing for AstraZeneca/Oxford COVID-19 vaccine.
33814379 2021. Is chloroquine or hydroxychloroquine useful in treating people with COVID-19, or in preventing infection in people who have been exposed to the virus?
33795636 2021. Antimicrobial peptide DP7 with potential activity against SARS coronavirus infections.
33810926 2021. COVID-19 Vaccines Based on Adenovirus Vectors.
33814228 2021. The role of multiple SARS-CoV-2 viral antigens in a vaccine-induced integrated immune response.
33810907 2021. Are vaccines against COVID-19 tailored to the most vulnerable people?
33807818 2021. SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines.
33807579 2021. Allergic Reactions to Current Available COVID-19 Vaccinations: Pathophysiology, Causality, and Therapeutic Considerations.
33806646 2021. COVID-19 Vaccine Failure in a Patient with Multiple Sclerosis on Ocrelizumab.
33802467 2021. Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies.
33805473 2021. Immunogenicity and Neutralizing Activity Comparison of SARS-CoV-2 Spike Full-Length and Subunit Domain Proteins in Young Adult and Old-Aged Mice.
33804981 2021. Soluble Spike DNA Vaccine Provides Long-Term Protective Immunity against SARS-CoV-2 in Mice and Nonhuman Primates.
33810026 2021. Potent Neutralization Antibodies Induced by a Recombinant Trimeric Spike Protein Vaccine Candidate Containing PIKA Adjuvant for COVID-19.
33801380 2021. SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response.
33808708 2021. Opportunities for Refinement of Non-Human Primate Vaccine Studies.
33809002 2021. COVID-19 Vaccine Roll-Out in South Africa and Zimbabwe: Urgent Need to Address Community Preparedness, Fears and Hesitancy.
33799505 2021. Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19.
33802086 2021. COVID-19 Vaccines in the Pipeline, Are Antibodies Adequate?
33801926 2021. Simultaneous CD8(+) T-Cell Immune Response against SARS-Cov-2 S, M, and N Induced by Endogenously Engineered Extracellular Vesicles in Both Spleen and Lungs.
33801831 2021. Correlates of Vaccine-Induced Protection against SARS-CoV-2.
33800528 2021. Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19.
33800932 2021. The Combination of Bromelain and Acetylcysteine (BromAc) Synergistically Inactivates SARS-CoV-2.
33807957 2021. Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection.
33807839 2021. Target Product Profile Analysis of COVID-19 Vaccines in Phase III Clinical Trials and Beyond: An Early 2021 Perspective.
33807769 2021. Antiviral Activity of the Propylamylatin(TM) Formula against the Novel Coronavirus SARS-CoV-2 In Vitro Using Direct Injection and Gas Assays in Virus Suspensions.
33807592 2021. Pharmacogenetics Approach for the Improvement of COVID-19 Treatment.
33808275 2021. In Vitro Antiviral Activities of Salinomycin on Porcine Epidemic Diarrhea Virus.
33597779 2021. COVID vaccines and safety: what the research says.
33795861 2021. Why is it so hard to investigate the rare side effects of COVID vaccines?
33762708 2021. What scientists do and don't know about the Oxford-AstraZeneca COVID vaccine.
33567448 2021. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.
33737735 2020. Daily briefing: The five questions that scientists hunting a coronavirus vaccine must answer.
33723024 2021. Reader Response: A Prospective Study of Neurologic Disorders in Hospitalized Patients With COVID-19 in New York City.
33722093 2021. Needlestick Injuries Among Healthcare Workers Administering COVID-19 Vaccinations in the United States.
33811162 2021. X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease.
33574203 2021. Single-domain antibodies make a difference.
33555845 2021. Comparison of Associations between Glucocorticoids Treatment and Mortality in COVID-19 Patients and SARS Patients: A Systematic Review and Meta-Analysis.
33715385 2021. Research Progress of Mesenchymal Stem Cell Therapy for Severe COVID-19.
33720635 2021. [BCG, muramylpeptides, trained immunity (part II): a low molecular weight alternative to multicomponent bacterial immunostimulants for prevention of respiratory infections during a pandemic].
33720613 2020. [The role of vitamin D in seasonal acute respiratory viral infections and COVID-19].
33720612 2020. [Umifenovir and coronavirus infections: a review of research results and clinical practice].
33720607 2020. [Administration of the immunomodulatory drug aminodihydrophthalazinedione sodium for prevention of progression pneumonia induced COVID-19].
33720594 2020. [BCG, muramylpeptides, trained immunity (part I): linkages in the light of the COVID-19 pandemic].
33720587 2020. [Experience of olokizumab use in COVID-19 patients].
33641131 2020. Our Best Shot: Texas Physicians Help Find Safe, Effective COVID-19 Vaccines.
33677827 2021. Sulodexide in the Treatment of Patients with Early Stages of COVID-19: A Randomized Controlled Trial.
33749020 2021. Deterrents in recruitment of COVID-19 convalescent plasma donors: Experience from a hospital-based blood centre in India.
33784412 2021. Convalescent plasma treatment of critically ill intensive care COVID-19 patients.
33734448 2021. A trend of dropping anti-SARS-CoV-2 plaque reduction neutralization test titers over time in Canadian convalescent plasma donors.
33723852 2021. COVID-19 convalescent plasma; time for "goal directed therapy"?
33760230 2021. Personalized collection of plasma from healthy donors: A randomized controlled trial of a novel technology-enabled nomogram.
33715160 2021. Brief report: Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.
33728702 2021. Adoptive transfer of ex vivo expanded SARS-CoV-2-specific cytotoxic lymphocytes: A viable strategy for COVID-19 immunosuppressed patients?
33560728 2021. Safety of the First Dose of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients.
33724242 2021. Casirivimab-Imdevimab for Treatment of COVID-19 in Solid Organ Transplant Recipients: an Early Experience.
33741844 2021. Kidney Transplant Recipients Rarely Show an Early Antibody Response Following the First COVID-19 Vaccine Administration.
33724250 2021. SARS-CoV-2 Vaccination and Solid Organ Transplant Patients: Data Needed to Inform Safety and Efficacy.
33612766 2020. Could antiseptic gargling prevent COVID-19?
33734065 2021. [SARS-CoV-2 vaccines].
33734074 2021. [Vaccination immunology in SARS-CoV-2].
33734524 2021. Benefits and potential harms of COVID-19 vaccination during pregnancy: evidence summary for patient counseling.
33648028 2021. Physiologic and biochemical rationale for treating COVID-19 patients with hyperbaric oxygen.
33810902 2021. The safety of BCG revaccination: A systematic review.

33737124 2021. Epidemiological transcriptomic data supports BCG protection in viral diseases including COVID-19.
33549712 2021. The use of mesenchymal stem cells in the process of treatment and tissue regeneration after recovery in patients with Covid-19.
33596123 2021. Adjusting extracellular pH to prevent entry of SARS-CoV-2 into human cells.
33722288 2021. SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription.
33569701 2021. The impact of immuno-aging on SARS-CoV-2 vaccine development.
33627051 2021. Making a COVID-19 vaccine that works for everyone: ensuring equity and inclusivity in clinical trials.
33688588 2021. COVID-19 vaccines: implementation, limitations and opportunities.
33669357 2021. The Effect of Chair-Based Exercise on Physical Function in Older Adults: A Systematic Review and Meta-Analysis.
33671943 2021. Global Impact of COVID-19 on Weight and Weight-Related Behaviors in the Adult Population: A Scoping Review.
33726557 2021. A review: Mechanism of action of antiviral drugs.
33746095 2021. Interim estimates in null models of COVID-19 vaccine effectiveness.
33746092 2021. A case of COVID-19 diagnosed with favipiravir-induced drug fever based on a positive drug-induced lymphocyte stimulation test.
33647517 2021. A shorter symptom onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis.
33794380 2021. Bacille Calmette-Guerin (BCG) vaccine and potential cross-protection against SARS-CoV-2 infection - Assumptions, knowns, unknowns and need for developing an accurate scientific evidence base.
33540128 2021. Remdesivir and systemic corticosteroids for the treatment of COVID-19: A Bayesian re-analysis.
33737128 2021. The effect of tocilizumab, anakinra and prednisolone on antibody response to SARS-CoV-2 in patients with COVID-19: A prospective cohort study with multivariate analysis of factors affecting the antibody response.
33713817 2021. Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study.
33652065 2021. COVID-19 vaccines: Global challenges and prospects forum recommendations.
33647515 2021. Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: A single-center retrospective study.
33636357 2021. Less severe course of COVID-19 is associated with elevated levels of antibodies against seasonal human coronaviruses OC43 and HKU1 (HCoV OC43, HCoV HKU1).
33609773 2021. Tocilizumab treatment in critically ill patients with COVID-19: A retrospective observational study.
33607305 2021. Convalescent plasma treatment is associated with lower mortality and better outcomes in high-risk COVID-19 patients - propensity-score matched case-control study.
33607304 2021. The role of ibrutinib in COVID-19 hyperinflammation: A case report.
33601033 2021. Letter to the editor on "Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial" by Udwadia et al.
33601032 2021. Response to the comments received on article "Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial" by Udwadia et al.
33592340 2021. Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study.
33592338 2021. Prioritizing second-generation SARS-CoV-2 vaccines through low-dosage challenge studies.
33578014 2021. Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico.
33578007 2021. The effect of probiotics on respiratory tract infection with special emphasis on COVID-19: Systemic review 2010-20.
33746604 2021. A network pharmacology based approach for predicting active ingredients and potential mechanism of Lianhuaqingwen capsule in treating COVID-19.
33746581 2021. Systematic elucidation of the mechanism of Jingyin granule in the treatment of Novel Coronavirus (COVID-19) Pneumonia via Network Pharmacology.
33628091 2021. Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome.
33532356 2021. A single dose of in situ gel formulation of antimalarial drug chloroquine phosphate as a sustained prophylactic candidate for COVID-19.
33552658 2021. Approved mRNA Vaccines for SARS-CoV-2.
33556464 2021. Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia.
33711496 2021. A Cost-Effectiveness Evaluation of Hospitalizations, Fatalities, and Economic Outcomes Associated with Universal Versus Anaphylaxis Risk-Stratified COVID-19 Vaccination Strategies.
33766582 2021. Nonirritant concentrations for skin testing with SARS-CoV-2 mRNA vaccine.
33529722 2021. The COVID-19 Pandemic in 2021: Avoiding Overdiagnosis of Anaphylaxis Risk While Safely Vaccinating the World.
33817690 2021. Toxicity of herbal medications suggested as treatment for COVID-19: A narrative review.
33605826 2021. An Evaluation of Serum 25-Hydroxy Vitamin D Levels in Patients with COVID-19 in New York City.
33600292 2021. Low Vitamin D Status at Admission as a Risk Factor for Poor Survival in Hospitalized Patients With COVID-19: An Italian Retrospective Study.
33713605 2021. Unilateral Lymphadenopathy After COVID-19 Vaccination: A Practical Management Plan for Radiologists Across Specialties.
33546986 2021. Summary of adverse drug events for hydroxychloroquine, azithromycin, and chloroquine during the COVID-19 pandemic.
33561203 2021. Comment on: Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU.
33559270 2021. Soybean-associated endophytic fungi as potential source for anti-COVID-19 metabolites supported by docking analysis.
33776210 2021. Docking and in silico toxicity assessment of Arthrospira compounds as potential antiviral agents against SARS-CoV-2.
33600286 2021. Dexamethasone and transdehydroandrosterone significantly reduce pulmonary epithelial cell injuries associated with mechanical ventilation.
33577360 2021. Montelukast in hospitalized patients diagnosed with COVID-19.
33746457 2021. Modulation of neutrophil (dys)function by Ayurvedic herbs and its potential influence on SARS-CoV-2 infection.
33727768 2021. Ayurveda co-interventions have supported complete recovery in Severe COVID- 19 infection with a Chest Severity Score 18/25: A Case Report.
33548227 2021. How glycobiology can help us treat and beat the COVID-19 pandemic.
33639165 2021. Glucosylceramide synthase inhibitors prevent replication of SARS-CoV-2 and Influenza virus.
33571675 2021. Drug repurposing for COVID-19 via knowledge graph completion.
33645443 2021. A potential peptide inhibitor of SARS-CoV-2 S and human ACE2 complex.
33612076 2021. Identification of the binding interactions of some novel antiviral compounds against Nsp1 protein from SARS-CoV-2 (COVID-19) through high throughput screening.
33525993 2021. Impact of dimerization and N3 binding on molecular dynamics of SARS-CoV and SARS-CoV-2 main proteases.
33599180 2021. In silico prediction of SARS-CoV-2 main protease and polymerase inhibitors: 3D-Pharmacophore modelling.
33596787 2021. Metabolomic profiling of three Araucaria species, and their possible potential role against COVID-19.
33590806 2021. Repurposing drugs and identification of inhibitors of integral proteins (spike protein and main protease) of SARS-CoV-2.
33583350 2021. Anti-HIV-drug and phyto-flavonoid combination against SARS-CoV-2: a molecular docking-simulation base assessment.
33583328 2021. In silico identification and validation of natural antiviral compounds as potential inhibitors of SARS-CoV-2 methyltransferase.
33565387 2021. Artificially expanded genetic information systems (AEGISs) as potent inhibitors of the RNA-dependent RNA polymerase of the SARS-CoV-2.
33526003 2021. Flavonol morin targets host ACE2, IMP-alpha, PARP-1 and viral proteins of SARS-CoV-2, SARS-CoV and MERS-CoV critical for infection and survival: a computational analysis.
33619888 2021. Blue photobiomodulation LED therapy impacts SARS-CoV-2 by limiting its replication in Vero cells.
33762863 2021. Correlation of Automated Chemiluminescent Method with Enzyme-Linked Immunosorbent Assay (ELISA) Antibody Titers in Convalescent COVID-19 Plasma Samples: Development of Rapid, Cost-Effective Semi-Quantitative Diagnostic Methods.
33673216 2021. Sinus Bradycardia Associated with Remdesivir Treatment in COVID-19: A Case Report and Literature Review.
33619758 2021. Tetracycline as an inhibitor to the SARS-CoV-2.
33768214 2021. Possible Therapeutic Use of Natural Compounds Against COVID-19.
33655751 2021. Biostructural Models for the Binding of Nucleoside Analogs to SARS-CoV-2 RNA-Dependent RNA Polymerase.
33619962 2021. Shedding Light on the Inhibitory Mechanisms of SARS-CoV-1/CoV-2 Spike Proteins by ACE2-Designed Peptides.
33538596 2021. Targeting SARS-CoV-2 M3CLpro by HCV NS3/4a Inhibitors: In Silico Modeling and In Vitro Screening.
33734704 2021. Macrolides May Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Entry into Cells: A Quantitative Structure Activity Relationship Study and Experimental Validation.
33756448 2021. Development and validation of a simple, selective, and sensitive LC-MS/MS assay for the quantification of remdesivir in human plasma.
33544910 2021. Efficacy of convalescent plasma therapy for COVID-19: A systematic review and meta-analysis.
33616257 2021. A matched cohort study of convalescent plasma therapy for COVID-19.
33587767 2021. Donor tolerability of convalescent plasma donation.
33578448 2021. The use of therapeutic plasma exchange as adjunctive therapy in the treatment of coronavirus disease 2019: A critical appraisal of the current evidence.
33536704 2021. Smell/Taste alteration in COVID-19 may reflect zinc deficiency.
33560344 2021. Association of Metformin with Susceptibility to COVID-19 in People with Type 2 Diabetes.
33575003 2021. Is there scientific evidence of the mouthwashes effectiveness in reducing viral load in Covid-19? A systematic review.
33763778 2021. Interferon-beta Therapy in a Patient with Incontinentia Pigmenti and Autoantibodies against Type I IFNs Infected with SARS-CoV-2.
33547548 2021. A Patient with X-Linked Agammaglobulinemia and COVID-19 Infection Treated with Remdesivir and Convalescent Plasma.
33611660 2021. Resolution of Persistent COVID-19 After Convalescent Plasma in a Patient with B Cell Aplasia.
33616813 2021. Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia.
33621214 2021. SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities.
33571169 2021. Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality.
33726984 2021. Association between antecedent statin use and severe disease outcomes in COVID-19: A retrospective study with propensity score matching.
33669218 2021. The Rheumatology Drugs for COVID-19 Management: Which and When?
33672805 2021. Effects of Methylprednisolone on Ventilator-Free Days in Mechanically Ventilated Patients with Acute Respiratory Distress Syndrome and COVID-19: A Retrospective Study.
33578922 2021. The Use of Antiviral Agents against SARS-CoV-2: Ineffective or Time and Age Dependent Result? A Retrospective, Observational Study among COVID-19 Older Adults.
33645763 2021. Repurposing functional inhibitors of acid sphingomyelinase (fiasmas): an opportunity against SARS-CoV-2 infection?
33638257 2021. Safety of tocilizumab in COVID-19 pregnant women and their newborn: A retrospective study.
33543766 2021. PEG That Reaction: A Case Series of Allergy to Polyethylene Glycol.
33552429 2021. Remdesivir in a pregnant patient with COVID-19 pneumonia.
33810356 2021. In Vitro Assessment of the Antiviral Activity of Ketotifen, Indomethacin and Naproxen, Alone and in Combination, against SARS-CoV-2.
33804989 2021. Amantadine Inhibits SARS-CoV-2 In Vitro.
33804957 2021. NSP16 2'-O-MTase in Coronavirus Pathogenesis: Possible Prevention and Treatments Strategies.
33807095 2021. Blockers of the SARS-CoV-2 3a Channel Identified by Targeted Drug Repurposing.
33706965 2021. Melatonin and healthy aging.
33683065 2021. [Interferon gamma in the treatment of patients with moderate COVID-19].
33533219 2020. [The use of viral RNA polymerase inhibitors in combination with a fusion inhibitor in the treatment of patients with COVID-19: hypothesis].
33772791 2021. Lessons learned in the collection of convalescent plasma during the COVID-19 pandemic.
33745163 2021. High-titre anti-SARS-CoV-2 convalescent plasma donation after donors' vaccination.
33734455 2021. Impact of pathogen reduction methods on immunological properties of the COVID-19 convalescent plasma.
33730761 2021. Understanding the role of therapeutic plasma exchange in COVID-19: preliminary guidance and practices.
33794556 2021. COVID-19 convalescent plasma therapy: hit fast, hit hard!
33798303 2021. [Observation of therapeutic effect on coronavirus disease 2019 with insomnia in treatment with baduanjin and auricular point sticking therapy].
33645139 2021. [Treatment strategy and thought on classical herbal formulae for coronavirus disease 2019].
33548966 2021. [Progress in the development of coronavirus disease 2019 vaccine].
33729129 2021. [Evaluation of the effects of immunotherapy and mesenchymal stem cells transplantation in the treatment of critically ill coronavirus disease 2019 patients].
33541491 2020. [Clinical efficacy and safety of different antiviral regimens in patients with coronavirus disease 2019].
33730835 2021. [Research study on nucleic acid testing of hemostatic stickers used and the surface of the recipients' hands after the inoculation of inactivated SARS-CoV-2 vaccine].

33631468 2021. Good nutrition critical to prevent Covid 19 mortality.
33817388 2021. Prediction of potential inhibitors of SARS-CoV-2 using 3D-QSAR, molecular docking modeling and ADMET properties.
33748511 2021. Use of vitamin/zinc supplements, medicinal plants, and immune boosting drinks during COVID-19 pandemic: A pilot study from Benha city, Egypt.
33748510 2021. Evaluation of flavonoids as 2019-nCoV cell entry inhibitor through molecular docking and pharmacological analysis.
33732940 2021. Discovery of Clioquinol and analogues as novel inhibitors of Severe Acute Respiratory Syndrome Coronavirus 2 infection, ACE2 and ACE2 - Spike protein interaction in vitro.
33693066 2021. Structural analogues of existing anti-viral drugs inhibit SARS-CoV-2 RNA dependent RNA polymerase: A computational hierarchical investigation.
33688584 2021. The study of antiviral drugs targeting SARS-CoV-2 nucleocapsid and spike proteins through large-scale compound repurposing.
33532640 2021. Potential compounds from several Indonesian plants to prevent SARS-CoV-2 infection: A mini-review of SARS-CoV-2 therapeutic targets.
33655086 2021. Antiviral and immunomodulatory activity of curcumin: A case for prophylactic therapy for COVID-19.
33655082 2021. Exploring existing drugs: proposing potential compounds in the treatment of COVID-19.
33615017 2021. Prospects of nutritional interventions in the care of COVID-19 patients.
33585706 2021. Can Echinacea be a potential candidate to target immunity, inflammation, and infection - The trinity of coronavirus disease 2019.
33553708 2021. Recent updates in the clinical trials of therapeutic monoclonal antibodies targeting cytokine storm for the management of COVID-19.
33623886 2021. SARS-CoV-2 Vaccines in Patients With Multiple Myeloma.
33817558 2021. CHALLENGES IN THE PRODUCTION OF COVID19 CONVALESCENT PLASMA - ANALYSIS OF DONOR RECRUITMENT.
33778377 2021. Suggested guidelines for convalescent plasma therapy for the treatment of COVID-19.
33577086 2021. AASLD Expert Panel Consensus Statement: Vaccines to Prevent COVID-19 Infection in Patients with Liver Disease.
33790052 2021. Optimising vitamin D levels in patients with COVID-19.
33677814 2021. COVID-19 vaccines: rapid development, implications, challenges and future prospects.
33527306 2021. mTOR inhibition: a double-edged sword in patients with COVID-19?
33640208 2021. Administration of high titer convalescent anti-SARS-CoV-2 plasma: From donor selection to monitoring recipient outcomes.
33632561 2021. Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade.
33577681 2021. Integration of genetically regulated gene expression and pharmacological library provides therapeutic drug candidates.
33567446 2021. Potential Interplay between Nrf2, TRPA1, and TRPV1 in Nutrients for the Control of COVID-19.
33526960 2021. Presence of antibodies against SARS-CoV-2 spike protein in bovine whey IgG enriched fraction.
33715009 2021. Interleukin-6: From arthritis to CAR-T cell therapy and COVID-19.
33571745 2021. Immune response scenario and vaccine development for SARS-CoV-2 infection.
33765614 2021. The potential for Lactoferrin to reduce SARS-CoV-2 induced cytokine storm.
33735712 2021. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia.
33714884 2021. The role of probiotics in coronavirus disease-19 infection in Wuhan: A retrospective study of 311 severe patients.
33631512 2021. Serum cytokine levels of COVID-19 patients after 7 days of treatment with Favipiravir or Kaletra.
33582019 2021. Efficacy and safety of convalescent plasma therapy in severe COVID-19 patients with acute respiratory distress syndrome.
33571819 2021. Leflunomide an immunomodulator with antineoplastic and antiviral potentials but drug-induced liver injury: A comprehensive review.
33540249 2021. Interferon-based therapies in COVID-19.
33714420 2021. Balanced evaluation of preliminary data on a candidate COVID-19 hydroxychloroquine treatment.
33596459 2021. Effect of hydroxychloroquine and azithromycin on the viral clearance of SARS-CoV-2: response to Herve Seligmann.
33722657 2021. Timing and dosage may be the key in the realisation of hydroxychloroquine + azithromycin treatment benefit in Covid-19 elderly patients.
33731132 2021. How COVID-19 lockdown and reopening affected daily steps: evidence based on 164,630 person-days of prospectively collected data from Shanghai, China.
33607132 2021. Underscoring the immense potential of chitosan in fighting a wide spectrum of viruses: A plausible molecule against SARS-CoV-2?
33794238 2021. A review on antiviral and immunomodulatory polysaccharides from Indian medicinal plants, which may be beneficial to COVID-19 infected patients.
33766591 2021. A review on the interaction of nucleoside analogues with SARS-CoV-2 RNA dependent RNA polymerase.
33385461 2021. Development of new vaccine target against SARS-CoV2 using envelope (E) protein: An evolutionary, molecular modeling and docking based study.
33716131 2021. Exploitation of polyphenols and proteins using nanoencapsulation for anti-viral and brain boosting properties - Evoking a synergistic strategy to combat COVID-19 pandemic.
33421473 2021. Denovo designing, retro-combinatorial synthesis, and molecular dynamics analysis identify novel antiviral VTRM1.1 against RNA-dependent RNA polymerase of SARS CoV2 virus.
33548314 2021. Epigallocatechin-3-gallate, an active ingredient of Traditional Chinese Medicines, inhibits the 3CLpro activity of SARS-CoV-2.
33548321 2021. Targeting C-terminal Helical bundle of NCOVID19 Envelope (E) protein.
33767597 2021. Evaluation and characterization of HSPA5 (GRP78) expression profiles in normal individuals and cancer patients with COVID-19.
33390829 2021. Current advances in the development of SARS-CoV-2 vaccines.
33447763 2020. Cardiovascular medications and regulation of COVID-19 receptors expression.
33751323 2021. Sodium-glucose co-transporter 2 inhibitors in COVID-19: meeting at the crossroads between heart, diabetes and infectious diseases.
33555131 2021. The association between micronutrient and hemogram values and prognostic factors in COVID-19 patients: A single-center experience from Turkey.
33550688 2021. Therapeutic efficacy, mechanical ventilation, length of hospital stay, and mortality rate in severe COVID-19 patients treated with tocilizumab.
33650165 2021. Androgens and women: COVID-19 outcomes in women with acne vulgaris, polycystic ovarian syndrome, and hirsutism.
33419015 2021. Is It Time for Sports and Health in the Era of Covid-19 Pandemic?
33668304 2021. Cardiac Rehabilitation Based on the Walking Test and Telerehabilitation Improved Cardiorespiratory Fitness in People Diagnosed with Coronary Heart Disease during the COVID-19 Pandemic.
33668262 2021. A Pandemic within the Pandemic? Physical Activity Levels Substantially Decreased in Countries Affected by COVID-19.
33576451 2021. Pineal hormone melatonin as an adjuvant treatment for COVID19 (Review).
33576441 2021. Determining available strategies for prevention and therapy: Exploring COVID19 from the perspective of ACE2 (Review).
33537824 2021. Potential immunomodulatory effects of vitamin D in the prevention of severe coronavirus disease 2019: An ally for Latin America (Review).
33573283 2021. Pseudo-Dipeptide Bearing alpha,alpha-Difluoromethyl Ketone Moiety as Electrophilic Warhead with Activity against Coronaviruses.
33530554 2021. Mediterranean Diet for the Prevention of Gestational Diabetes in the Covid-19 Era: Implications of Il-6 In Diabesity.
33572480 2021. Human Milk Antibodies Against S1 and S2 Subunits from SARS-CoV-2, HCoV-OC43, and HCoV-229E in Mothers with A Confirmed COVID-19 PCR, Viral SYMPTOMS, and Unexposed Mothers.
33572274 2021. Understanding Viral Infection Mechanisms and Patient Symptoms for the Development of COVID-19 Therapeutics.
33557278 2021. Comparison of Antiviral Activity of Gemcitabine with 2'-Fluoro-2'-Deoxycytidine and Combination Therapy with Remdesivir against SARS-CoV-2.
33557253 2021. Predicting Potential SARS-COV-2 Drugs-In Depth Drug Database Screening Using Deep Neural Network Framework SSnet, Classical Virtual Screening and Docking.
33671104 2021. Nutraceuticals in the Prevention of Viral Infections, including COVID-19, among the Pediatric Population: A Review of the Literature.
33669738 2021. Computational Selectivity Assessment of Protease Inhibitors against SARS-CoV-2.
33671463 2021. Opportunities, Challenges and Pitfalls of Using Cannabidiol as an Adjuvant Drug in COVID-19.
33669456 2021. Adjunctive Nutraceutical Therapies for COVID-19.
33669167 2021. Phosphodiesterase Inhibitors in Acute Lung Injury: What Are the Perspectives?
33671877 2021. Neutralizing Human Antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 Isolated from a Human Synthetic Fab Phage Display Library.
33668523 2021. Bioactive Alkaloids from Genus Aspergillus: Mechanistic Interpretation of Their Antimicrobial and Potential SARS-CoV-2 Inhibitory Activity Using Molecular Modelling.
33673372 2021. Platelet Lysate Nebulization Protocol for the Treatment of COVID-19 and Its Sequels: Proof of Concept and Scientific Rationale.
33670304 2021. Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19.
33688191 2021. New Acaciin-Loaded Self-Assembled Nanofibers as M(Pro) Inhibitors Against BCV as a Surrogate Model for SARS-CoV-2.
33746660 2021. In-Silico Drug Designing of Spike Receptor with Its ACE2 Receptor and Nsp10/Nsp16 MTase Complex Against SARS-CoV-2.
33781885 2021. BRD4 targeting nanotherapy prevents lipopolysaccharide induced acute respiratory distress syndrome.
33540028 2021. Self-injectable extended release formulation of Remdesivir (SelfExRem): A potential formulation alternative for COVID-19 treatment.
33484917 2021. Visualizing the spatial localization of ciclesonide and its metabolites in rat lungs after inhalation of 1-mum aerosol of ciclesonide by desorption electrospray ionization-time of flight mass spectrometry imaging.
33785968 2021. Distance based and bond additive topological indices of certain repurposed antiviral drug compounds tested for treating COVID-19.
33612855 2020. Topological indices and QSPR/QSAR analysis of some antiviral drugs being investigated for the treatment of COVID-19 patients.
33677049 2021. Low-Dose Radiation Therapy for Severe COVID-19 Pneumonia: A Randomized Double-Blind Study.
33677050 2021. COVID-19 Vaccine-Induced Radiation Recall Phenomenon.
33722770 2021. Low Doses of Radiation Increase the Immunosuppressive Profile of Lung Macrophages During Viral Infection and Pneumonia.
33688993 2021. Potential role for interferon gamma in the treatment of recurrent ventilator-acquired pneumonia in patients with COVID-19: a hypothesis.
33694056 2021. Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID19 pneumonia and moderate hyperinflammation. A retrospective cohort study: reply.
33547620 2021. Timing of corticosteroids impacts mortality in hospitalized COVID-19 patients.
33598871 2021. Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID19 pneumonia and moderate hyperinflammation. A retrospective cohort study: comment.
33687691 2021. Deep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccine.
33635496 2021. Adverse drug reactions in SARS-CoV-2 hospitalised patients: a case-series with a focus on drug-drug interactions-reply.
33583886 2021. Drug Fever Due to Favipiravir Administration for the Treatment of a COVID-19 Patient.
33580823 2021. Allergische Reaktionen auf COVID-19-Impfstoffe - Evidenz und praxisorientiertes Vorgehen.
33560450 2021. Impfstoffentwicklung zur Pravention von COVID-19 - Teil 2.
33788135 2021. Vigilance regarding immune thrombocytopenic purpura after COVID-19 vaccine.
33710481 2021. COVID-19 pandemic: vaccine and new monoclonal antibodies, point of view.
33598881 2021. The role of taurine derivatives in the putative therapy of COVID-19-induced inflammation.
33639626 2021. Mechanisms of COVID-19 Entry into the Cell: Potential Therapeutic Approaches Based on Virus Entry Inhibition in COVID-19 Patients with Underlying Diseases.
33639625 2021. Relationship between Bacillus Calmette Guerin Vaccination Policy and Coronavirus Disease-2019 (COVID-19) Incidence.
33787513 2021. Does prior immunization with measles, mumps, and rubella vaccines contribute to the antibody response to COVID-19 antigens?
33603991 2020. The efficacy of remdesivir in coronavirus disease 2019 (COVID-19): a systematic review.
33680028 2020. Approaches for the Treatment of SARS-CoV-2 Infection: A Pharmacologic View and Literature Review.
33708724 2020. Selected Micronutrients: An Option to Boost Immunity against COVID-19 and Prevent Adverse Pregnancy Outcomes in Pregnant Women: A Narrative Review.
33708723 2020. Convalescent Plasma in the Treatment of Severe COVID-19: A Systematic Review and Meta-Analysis.
33681723 2021. Targeting androgen regulation of TMPRSS2 and ACE2 as a therapeutic strategy to combat COVID-19.
33665567 2021. A computational framework of host-based drug repositioning for broad-spectrum antivirals against RNA viruses.
33585804 2021. Transcriptomic profiling of SARS-CoV-2 infected human cell lines identifies HSP90 as target for COVID-19 therapy.
33817567 2021. Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment.
33748696 2021. Learning from HIV-1 to predict the immunogenicity of T cell epitopes in SARS-CoV-2.
33723528 2021. Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation.
33734623 2021. Peripheral Facial Nerve Palsy Following BNT162b2 (COVID-19) Vaccination.
33639998 2021. Breastfeeding and COVID-19 vaccination: position statement of the Italian scientific societies.
33588905 2021. Could nutritional supplements act as therapeutic adjuvants in COVID-19?

33764850 2021. Probiotics reduce self-reported symptoms of upper respiratory tract infection in overweight and obese adults: should we be considering probiotics during viral pandemics?
33651911 2021. Vaccination against COVID-19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders.
33647634 2021. Older adults' activity destinations before and during COVID-19 restrictions: From a variety of activities to mostly physical exercise close to home.
33623809 2021. Characteristics of the First 102 Severe COVID-19 Cases Treated With Convalescent Plasma or Tocilizumab or Both in Al-Nahdha Hospital, Oman.
33651967 2021. beta-glucans: wide-spectrum immune-balancing food-supplement-based enteric (beta-WIFE) vaccine adjuvant approach to COVID-19.
33577374 2021. Immunotherapies and immunomodulatory approaches in clinical trials - a mini review.
33606594 2021. Phylodynamic analysis in the understanding of the current COVID-19 pandemic and its utility in vaccine and antiviral design and assessment.
33536584 2021. Estrogen receptors are linked to angiotensin-converting enzyme 2 (ACE2), ADAM metallopeptidase domain 17 (ADAM-17), and transmembrane protease serine 2 (TMPRSS2) expression in the human atrium: insights into COVID-19.
33596958 2021. Unanticipated efficacy of SARS-CoV-2 vaccination in older adults.
33728100 2021. COVID-19 Antiviral and Treatment Candidates: Current Status.
33728098 2021. Ongoing Clinical Trials of Vaccines to Fight against COVID-19 Pandemic.
33728097 2021. Current Status of COVID-19 Vaccine Development: Focusing on Antigen Design and Clinical Trials on Later Stages.
33631118 2021. A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs.
33557591 2021. Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma.
33753964 2021. Wild Sambucus nigra L. from north-east edge of the species range: A valuable germplasm with inhibitory capacity against SARS-CoV2 S-protein RBD and hACE2 binding in vitro.
33714413 2021. HCQ prophylaxis in COVID-19 did not show any QTc prolongation in Healthcare workers.
33814589 2021. Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study.
33814753 2021. Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review.
33551585 2021. Association of Vitamin D Status with COVID-19 Infection and Mortality in the Asia Pacific region: A Cross-Sectional Study.
33613002 2021. Trace Elements as Immunoregulators in SARS-CoV-2 and Other Viral Infections.
33623187 2020. Prospects of Vaccine against COVID-19.
33790504 2021. Tocilizumab: An Effective Therapy for Severely and Critically Ill COVID-19 Patients.
33790498 2021. Tocilizumab in COVID-19: Is the Temptation Worthwhile?
33707911 2021. Painful Blisters of Left Hand Following Extravasation of Remdesivir Infusion in COVID-19.
33746378 2021. Efficacy and Safety of Convalescent Plasma for COVID-19: A Systematic Review and Meta-analysis.
33781656 2021. The efficacy and safety of hydroxychloroquine (HCQ) in treatment of COVID19 -a systematic review and meta-analysis.
33533733 2021. Use of convalescent plasma for COVID-19 in India: A review & practical guidelines.
33595460 2021. Vitamin D supplementation in diabetic retinopathy in the era of COVID-19.
33614469 2021. Otorhinolaryngological Manifestations and Its Management in COVID 19 Patients.
33666200 2020. Efficacy and safety of steroid therapy in COVID-19: A rapid systematic review and Meta-analysis.
33666199 2020. Antiviral effect of amiodarone and its possible role in COVID-19: An appraisal.
33641858 2021. A review: Epidemiology, pathogenesis and prospect in developing vaccines for novel Coronavirus (COVID-19).
33641831 2021. BCG vaccination induced protection from COVID-19.
33706819 2021. Extensive environmental contamination and prolonged severe acute respiratory coronavirus-2 (SARS CoV-2) viability in immunosuppressed recent heart transplant recipients with clinical and virologic benefit with remdesivir.
33642866 2021. Inhibition of ACE2 Expression by Ascorbic Acid Alone and its Combinations with Other Natural Compounds.
33620019 2021. Corticosteroids and tocilizumab reduce in-hospital mortality in severe COVID-19 pneumonia: a retrospective study in a Spanish hospital.
33748805 2021. Mosaic vaccination schedule: An unexpected card to play against SARS-CoV-2?
33681861 2021. COVID-19 vaccines: Frequently asked questions and updated answers.
33585830 2021. BCG vaccination and COVID-19: Was flattening the curve just an illusion?
33731163 2021. Efficacy of the combination of modern medicine and traditional Chinese medicine in pulmonary fibrosis arising as a sequelae in convalescent COVID-19 patients: a randomized multicenter trial.
33726861 2021. Human coronaviruses and therapeutic drug discovery.
33532909 2021. Computational and Experimental Studies Reveal That Thymoquinone Blocks the Entry of Coronaviruses Into In Vitro Cells.
33738764 2021. Evaluating Clinical Efficacy of Antiviral Therapy for COVID-19: A Surrogate Endpoint Approach.
33790587 2021. BCG Vaccine-Induced Trained Immunity and COVID-19: Protective or Bystander?
33774178 2021. Molecular characterization of interactions between the D614G variant of SARS-CoV-2 S-protein and neutralizing antibodies: A computational approach.
33704465 2021. Barriers to Administering Vaccines in Inflammatory Bowel Disease Centers.
33740066 2021. Association of alpha-1-antitrypsin deficiency with vitamin D status: who is most at risk of getting severe COVID-19?
33608746 2021. Pharmacological mechanism of immunomodulatory agents for the treatment of severe cases of COVID-19 infection.
33751358 2021. A Dual Target-Directed Single Domain-Based Fusion Protein Against Interleukin-6 Receptor Decelerate Experimental Arthritis Progression Via Modulating JNK Expression.
33715284 2021. COVID-19-vaccinated plasma treatment for COVID-19 patients?
33649734 2021. Repurposing FDA-approved drugs to fight COVID-19 using in silico methods: Targeting SARS-CoV-2 RdRp enzyme and host cell receptors (ACE2, CD147) through virtual screening and molecular dynamic simulations.
33623816 2021. Evaluation of drug repositioning by molecular docking of pharmaceutical resources available in the Brazilian healthcare system against SARS-CoV-2.
33594342 2021. Identification of potential antivirals against SARS-CoV-2 using virtual screening method.
33553571 2021. The screening and evaluation of potential clinically significant HIV drug combinations against the SARS-CoV-2 virus.
33531865 2021. Aurintricarboxylic acid and its metal ion complexes in comparative virtual screening versus Lopinavir and Hydroxychloroquine in fighting COVID-19 pandemic: Synthesis and characterization.
33589845 2021. Are vanadium complexes druggable against the main protease M(pro) of SARS-CoV-2? - A computational approach.

33992805 2021. A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19.
33333292 2021. Synergistic and Antagonistic Drug Combinations against SARS-CoV-2.
33984520 2021. Plant-derived exosomal microRNAs inhibit lung inflammation induced by exosomes SARS-CoV-2 Nsp12.
34007862 2021. Engineering mesenchymal stromal cells with neutralizing and anti-inflammatory capability against SARS-CoV-2 infection.
34072087 2021. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
34070140 2021. Prioritisation of Compounds for 3CL(pro) Inhibitor Development on SARS-CoV-2 Variants.
33916461 2021. In Silico Mining of Terpenes from Red-Sea Invertebrates for SARS-CoV-2 Main Protease (M(pro)) Inhibitors.
33947107 2021. The Potency of Seaweed Sulfated Polysaccharides for the Correction of Hemostasis Disorders in COVID-19.
33946802 2021. Antiviral Properties of the NSAID Drug Naproxen Targeting the Nucleoprotein of SARS-CoV-2 Coronavirus.
33921378 2021. Molecular Dynamic Simulation Search for Possible Amphiphilic Drug Discovery for Covid-19.
33921289 2021. Efficacy of Phytochemicals Derived from Avicennia officinalis for the Management of COVID-19: A Combined In Silico and Biochemical Study.
33942600 2021. Lipid-lowering therapy in high cardiovascular risk patients during COVID-19 pandemic: keep focused on the target.
33947804 2021. Dietary Supplements and Nutraceuticals under Investigation for COVID-19 Prevention and Treatment.
34040779 2021. Effects of cytokine blocking agents on hospital mortality in patients admitted to ICU with acute respiratory distress syndrome by SARS-CoV-2 infection: retrospective cohort study.
33306283 2021. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.
33356051 2021. A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19.
33332779 2021. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.
33332778 2021. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.
33289973 2021. A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19.
32706531 2021. The RECOVERY Platform.
33264557 2021. A Large, Simple Trial Leading to Complex Questions.
33264556 2021. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.
33963705 2021. [Salvianolic acid B and its magnesium salt inhibit SARS-CoV-2 infection of Vero-E6 cells by blocking spike protein-mediated membrane fusion].
33846686 2021. Lung-selective 25-hydroxycholesterol nanotherapeutics as a suppressor of COVID-19-associated cytokine storm.
34069866 2021. Unveiling the Potential Role of Nanozymes in Combating the COVID-19 Outbreak.
33982600 2021. Aerosolized nanoliposomal carrier of remdesivir: an effective alternative for COVID-19 treatment in vitro.
34045486 2021. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection.
34031399 2021. Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives.
33919991 2021. L-Carnitine Tartrate Downregulates the ACE2 Receptor and Limits SARS-CoV-2 Infection.
33924387 2021. Impact of COVID-19 Pandemic on Serum Vitamin D Level among Infants and Toddlers: An Interrupted Time Series Analysis and before-and-after Comparison.
33921297 2021. Does Evidence Exist to Blunt Inflammatory Response by Nutraceutical Supplementation during COVID-19 Pandemic? An Overview of Systematic Reviews of Vitamin D, Vitamin C, Melatonin, and Zinc.
33916257 2021. Vitamin C in the Treatment of COVID-19.
33916087 2021. Consequences of the COVID-19 Syndemic for Nutritional Health: A Systematic Review.
33895559 2021. Clinical efficacy of eucaloric ketogenic nutrition in the COVID-19 cytokine storm: A retrospective analysis of mortality and intensive care unit admission.
33321395 2021. An exploratory study of selenium status in healthy individuals and in patients with COVID-19 in a south Indian population: The case for adequate selenium status.
34014806 2021. The Relationship between COVID-19 Severity and Bacillus Calmette-Guerin (BCG)/ Mycobacterium tuberculosis exposure history in healthcare workers: a multi-center study.
33969249 2021. Alpha 1 Antitrypsin is an Inhibitor of the SARS-CoV-2-Priming Protease TMPRSS2.
34064210 2021. Dolosigranulum pigrum Modulates Immunity against SARS-CoV-2 in Respiratory Epithelial Cells.
34069460 2021. Strong Inhibitory Activity and Action Modes of Synthetic Maslinic Acid Derivative on Highly Pathogenic Coronaviruses: COVID-19 Drug Candidate.
34021797 2021. Favipiravir use in children with COVID-19 and acute kidney injury: is it safe?
33947420 2021. Severe COVID-19 in pediatric age: an update on the role of the anti-rheumatic agents.
33981493 2021. A molecular dynamics simulation study of the ACE2 receptor with screened natural inhibitors to identify novel drug candidate against COVID-19.
33954061 2021. Natural resources to control COVID-19: could lactoferrin amend SARS-CoV-2 infectivity?
33954055 2021. Identification of a novel inhibitor of SARS-CoV-2 3CL-PRO through virtual screening and molecular dynamics simulation.
34000327 2021. Review of antiviral peptides for use against zoonotic and selected non-zoonotic viruses.
34086487 2021. Pharmacogenomic considerations for repurposing of dexamethasone as a potential drug against SARS-CoV-2 infection.
34073502 2021. Immunotherapeutic Efficacy of IgY Antibodies Targeting the Full-Length Spike Protein in an Animal Model of Middle East Respiratory Syndrome Coronavirus Infection.
34069716 2021. Hydrotalcite-Niclosamide Nanohybrid as Oral Formulation towards SARS-CoV-2 Viral Infections.
34064831 2021. Tenofovir, Another Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection.
33801579 2021. Comprehensive and Rapid Quality Evaluation Method for the Ayurvedic Medicine Divya-Swasari-Vati Using Two Analytical Techniques: UPLC/QToF MS and HPLC-DAD.
33917573 2021. Ultramicronized Palmitoylethanolamide (um-PEA): A New Possible Adjuvant Treatment in COVID-19 patients.
33917313 2021. Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods.
33921724 2021. Phytochemicals from Plant Foods as Potential Source of Antiviral Agents: An Overview.
33924395 2021. Identification of Anti-SARS-CoV-2 Compounds from Food Using QSAR-Based Virtual Screening, Molecular Docking, and Molecular Dynamics Simulation Analysis.
34070725 2021. A Review of Repurposed Cancer Drugs in Clinical Trials for Potential Treatment of COVID-19.
34073500 2021. A Dry Powder Platform for Nose-to-Brain Delivery of Dexamethasone: Formulation Development and Nasal Deposition Studies.
34073456 2021. Biomedical Text Link Prediction for Drug Discovery: A Case Study with COVID-19.
34071116 2021. Lipophilicity, Pharmacokinetic Properties, and Molecular Docking Study on SARS-CoV-2 Target for Betulin Triazole Derivatives with Attached 1,4-Quinone.
33916409 2021. Tackling Immune Pathogenesis of COVID-19 through Molecular Pharmaceutics.
33918313 2021. A COVID-19 Drug Repurposing Strategy through Quantitative Homological Similarities Using a Topological Data Analysis-Based Framework.
33919660 2021. Drug Repurposing for COVID-19 Treatment by Integrating Network Pharmacology and Transcriptomics.
33315210 2021. Hospital Length of Stay for Patients with Severe COVID-19: Implications for Remdesivir's Value.
34075294 2021. Tocilizumab cost effective in reducing COVID-19-related deaths.
33948076 2021. Remdesivir cost effective for severe COVID-19 in China.
34052981 2021. The application of in silico experimental model in the assessment of ciprofloxacin and levofloxacin interaction with main SARS-CoV-2 targets: S-, E- and TMPRSS2 proteins, RNA-dependent RNA polymerase and papain-like protease (PLpro)-preliminary molecular docking analysis.
34085181 2021. Use of glucocorticoids and azithromycin in the therapy of COVID-19.
33970450 2021. Rifampicin and Letermovir as potential repurposed drug candidate for COVID-19 treatment: insights from an in-silico study.
33880743 2021. Role of pirfenidone in TGF-beta pathways and other inflammatory pathways in acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection: a theoretical perspective.
33359911 2021. Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19.
34089865 2021. Remdesivir in moderate to severe COVID-19: A matter of time?
33369210 2021. Targeting host cell proteases as a potential treatment strategy to limit the spread of SARS-CoV-2 in the respiratory tract.
33910199 2021. Utilizing Artificial Intelligence to Manage COVID-19 Scientific Evidence Torrent with Risklick AI: A Critical Tool for Pharmacology and Therapy Development.
33892181 2021. Antimicrobial photodynamic therapy with hypocrellin B against SARS-CoV-2 infection?
33838311 2021. Robust antimicrobial photodynamic therapy with curcumin-poly (lactic-co-glycolic acid) nanoparticles against COVID-19: A preliminary in vitro study in Vero cell line as a model.
33836277 2021. Photodynamic therapy with curcumin for combating SARS-CoV-2.
33836276 2021. Focused role of nanoparticles against COVID-19: Diagnosis and treatment.
33369281 2021. Might proton pump or sodium-hydrogen exchanger inhibitors be of value to ameliorate SARs-CoV-2 pathophysiology?
34093097 2021. Plant-derived lignans as potential antiviral agents: a systematic review.
34054380 2021. Flavonoids are promising safe therapy against COVID-19.
33867898 2021. Brazilian essential oils as source for the discovery of new anti-COVID-19 drug: a review guided by in silico study.
33376043 2021. Lycorine, a non-nucleoside RNA dependent RNA polymerase inhibitor, as potential treatment for emerging coronavirus infections.
34033999 2021. Sulforaphane inhibits the expression of interleukin-6 and interleukin-8 induced in bronchial epithelial IB3-1 cells by exposure to the SARS-CoV-2 Spike protein.
34029937 2021. Corilagin prevents SARS-CoV-2 infection by targeting RBD-ACE2 binding.
33961621 2021. Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes.
34061844 2021. Vitamin D and COVID-19 susceptibility and severity in the COVID-19 Host Genetics Initiative: A Mendelian randomization study.
34029332 2021. COVID-19 and helminth infection: Beyond the Th1/Th2 paradigm.
34061842 2021. Ivermectin as a potential treatment for COVID-19?
34106964 2021. Lack of efficacy of hydroxychloroquine and azithromycin in patients hospitalized for COVID-19 pneumonia: A retrospective study.
34106944 2021. Identification and evaluation of the inhibitory effect of Prunella vulgaris extract on SARS-coronavirus 2 virus entry.
34081722 2021. Inhaled corticosteroids do not adversely impact outcomes in COVID-19 positive patients with COPD: An analysis of Cleveland Clinic's COVID-19 registry.
34048457 2021. Avian antibodies (IgY) targeting spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inhibit receptor binding and viral replication.
34043733 2021. Molecular dynamics analysis of N-acetyl-D-glucosamine against specific SARS-CoV-2's pathogenicity factors.
34033648 2021. Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia.
34015003 2021. DPP-4 inhibitors may improve the mortality of coronavirus disease 2019: A meta-analysis.
34010326 2021. Unraveling the unbinding pathways of SARS-CoV-2 Papain-like proteinase known inhibitors by Supervised Molecular Dynamics simulation.
34010282 2021. Available medications used as potential therapeutics for COVID-19: What are the known safety profiles in pregnancy.
34003827 2021. Computational designing of a peptide that potentially blocks the entry of SARS-CoV, SARS-CoV-2 and MERS-CoV.
33989354 2021. Targeted antiviral treatment using non-ionizing radiation therapy for SARS-CoV-2 and viral pandemics preparedness: Technique, methods and practical notes for clinical application.
33984041 2021. Natural plant products as potential inhibitors of RNA dependent RNA polymerase of Severe Acute Respiratory Syndrome Coronavirus-2.
33974624 2021. Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients.
33914780 2021. Risk factors for COVID-19 mortality: The effect of convalescent plasma administration.
33886614 2021. High-throughput screening of the ReFRAME, Pandemic Box, and COVID Box drug repurposing libraries against SARS-CoV-2 nsp15 endoribonuclease to identify small-molecule inhibitors of viral activity.
33882090 2021. The proportion and effect of corticosteroid therapy in patients with COVID-19 infection: A systematic review and meta-analysis.
33831046 2021. What about tocilizumab? A retrospective study from a NYC Hospital during the COVID-19 outbreak.
34003853 2021. Interactions of SARS-CoV-2 envelope protein with amilorides correlate with antiviral activity.
33836016 2021. Mutations derived from horseshoe bat ACE2 orthologs enhance ACE2-Fc neutralization of SARS-CoV-2.
34048156 2021. An asymptomatic course of SARS-CoV-2 infection in a patient with 3 different neoplasms and treated with bortezomib: a coincidence or new therapeutic possibility?
34020813 2021. Influenza and pneumococcal vaccinations are not associated to COVID-19 outcomes among patients admitted to a university hospital.
33341305 2021. BCG vaccine: Worrying proposal for COVID-19.
34071430 2021. Lymphopenia in COVID-19: gammadelta T Cells-Based Therapeutic Opportunities.
34073559 2021. The Relevance of Monoclonal Antibodies in the Treatment of COVID-19.
34065294 2021. The Association between Influenza Vaccination and COVID-19 and Its Outcomes: A Systematic Review and Meta-Analysis of Observational Studies.

34086221 2021. Rekonvaleszenten-Plasma mildert COVID-19-Verlauf bei Alteren.
34086220 2021. Ivermectin gegen Hakenwurm - und Coronavirus?
33904080 2021. Budesonid verhindert bei COVID-19 Ubergang zu schwerem Verlauf.
33840851 2021. Use of Convalescent Plasma in the Management of COVID-19.
34023987 2021. Targeting the intestinal TMPRSS2 protease to prevent SARS-CoV-2 entry into enterocytes-prospects and challenges.
33358936 2021. Nanobodies, the potent agents to detect and treat the Coronavirus infections: A systematic review.
33961167 2021. Identification of phytocompounds from Houttuynia cordata Thunb. as potential inhibitors for SARS-CoV-2 replication proteins through GC-MS/LC-MS characterization, molecular docking and molecular dynamics simulation.
34008129 2021. Meticulous assessment of natural compounds from NPASS database for identifying analogue of GRL0617, the only known inhibitor for SARS-CoV2 papain-like protease (PLpro) using rigorous computational workflow.
33856591 2021. Identification of potential plant-based inhibitor against viral proteases of SARS-CoV-2 through molecular docking, MM-PBSA binding energy calculations and molecular dynamics simulation.
33844135 2021. Structure-based identification of SARS-CoV-2 main protease inhibitors from anti-viral specific chemical libraries: an exhaustive computational screening approach.
33825097 2021. Identifying structural-functional analogue of GRL0617, the only well-established inhibitor for papain-like protease (PLpro) of SARS-CoV2 from the pool of fungal metabolites using docking and molecular dynamics simulation.
33837893 2021. Investigation of angucycline compounds as potential drug candidates against SARS Cov-2 main protease using docking and molecular dynamic approaches.
34068970 2021. Targeting Multiple Signal Transduction Pathways of SARS-CoV-2: Approaches to COVID-19 Therapeutic Candidates.
34064568 2021. Role of Resveratrol in Prevention and Control of Cardiovascular Disorders and Cardiovascular Complications Related to COVID-19 Disease: Mode of Action and Approaches Explored to Increase Its Bioavailability.
34068579 2021. In Silico Studies of Some Isoflavonoids as Potential Candidates against COVID-19 Targeting Human ACE2 (hACE2) and Viral Main Protease (M(pro)).
34062737 2021. Olive-Derived Triterpenes Suppress SARS COV-2 Main Protease: A Promising Scaffold for Future Therapeutics.
33918595 2021. Native Structure-Based Peptides as Potential Protein-Protein Interaction Inhibitors of SARS-CoV-2 Spike Protein and Human ACE2 Receptor.
33917694 2021. Algae-Derived Bioactive Molecules for the Potential Treatment of SARS-CoV-2.
33976229 2021. A SARS-CoV-2 antibody curbs viral nucleocapsid protein-induced complement hyperactivation.
33976198 2021. A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes.
34083527 2021. Drug repurposing screens identify chemical entities for the development of COVID-19 interventions.
33837182 2021. GCG inhibits SARS-CoV-2 replication by disrupting the liquid phase condensation of its nucleocapsid protein.
33863887 2021. Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model.
33859192 2021. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials.
33273742 2021. Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets.
33977847 2021. Computational and experimental insights on the interaction of artemisinin, dihydroartemisinin and chloroquine with SARS-CoV-2 spike protein receptor-binding domain (RBD).
33875867 2021. Neutralizing monoclonal antibodies for treatment of COVID-19.
33850327 2021. Is IL-6 a key cytokine target for therapy in COVID-19?
33961065 2021. Current understanding on molecular drug targets and emerging treatment strategy for novel coronavirus-19.
33948424 2021. Inhibitory effect of anti-HIV compounds extracted from Indian medicinal plants to retard the replication and transcription process of SARS-CoV-2: an insight from molecular docking and MD-simulation studies.
33842188 2021. Binding ability of arginine, citrulline, N-acetyl citrulline and thiocitrulline with SARS COV-2 main protease using molecular docking studies.
34026229 2021. Convalescent plasma therapy as a conventional trick for treating COVID-19: a systematic review and meta-analysis study.
33976895 2021. A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019.
33851074 2021. ICU admission rates in Istanbul following the addition of favipiravir to the national COVID-19 treatment protocol.
33829849 2021. Hypothesis regarding the connections between severe COVID-19 in children and nutrition: a narrative review.
34034769 2021. Nutritional screening based on objective indices at admission predicts in-hospital mortality in patients with COVID-19.
34020679 2021. The impact of vitamin D supplementation on body fat mass in elite male collegiate athletes.
33838992 2021. Statin and outcomes of coronavirus disease 2019 (COVID-19): A systematic review, meta-analysis, and meta-regression.
33308994 2021. Determinants of vitamin D activation in patients with acute coronary syndromes and its correlation with inflammatory markers.
33341894 2021. Potential benefits of dietary seaweeds as protection against COVID-19.
34064534 2021. Emergent Drug and Nutrition Interactions in COVID-19: A Comprehensive Narrative Review.
34072977 2021. Relation of Serum Copper Status to Survival in COVID-19.
34064175 2021. Calcifediol Treatment and Hospital Mortality Due to COVID-19: A Cohort Study.
34064053 2021. The Impact of Nutrition on the COVID-19 Pandemic and the Impact of the COVID-19 Pandemic on Nutrition.
34069656 2021. Mediterranean Diet and SARS-COV-2 Infection: Is There Any Association? A Proof-of-Concept Study.
34069412 2021. COVID-19 Disease Severity and Death in Relation to Vitamin D Status among SARS-CoV-2-Positive UAE Residents.
34068374 2021. Selenium as a Bioactive Micronutrient in the Human Diet and Its Cancer Chemopreventive Activity.
34068142 2021. Human Milk from Previously COVID-19-Infected Mothers: The Effect of Pasteurization on Specific Antibodies and Neutralization Capacity.
34068656 2021. Micronutrients Deficiency, Supplementation and Novel Coronavirus Infections-A Systematic Review and Meta-Analysis.
33800961 2021. In the Age of Viral Pandemic, Can Ingredients Inspired by Human Milk and Infant Nutrition Be Repurposed to Support the Immune System?
33807280 2021. Feasibility of Vitamin C in the Treatment of Post Viral Fatigue with Focus on Long COVID, Based on a Systematic Review of IV Vitamin C on Fatigue.
33801745 2021. Vitamin C: From Bench to Bedside.
33947070 2021. Oral and Topical Vitamin D, Sunshine, and UVB Phototherapy Safely Control Psoriasis in Patients with Normal Pretreatment Serum 25-Hydroxyvitamin D Concentrations: A Literature Review and Discussion of Health Implications.
33925932 2021. Vitamin D Status in Adolescents during COVID-19 Pandemic: A Cross-Sectional Comparative Study.
33925783 2021. Nutritional Interventions for COVID-19: A Role for Carnosine?
33880395 2021. Ivermectin against COVID-19: The unprecedented consequences in Latin America.
34102081 2021. Exploring the therapeutic potential of forkhead box O for outfoxing COVID-19.
33732750 2021. Cost-effectiveness of Remdesivir and Dexamethasone for COVID-19 Treatment in South Africa.
34036116 2021. Debating the Role of Vitamin D in COVID-19 - An interview with Dr. David Meltzer.
33880393 2021. A Case of Severe Acute Respiratory Syndrome Coronavirus 2 Treatment With Remdesivir in a Hepatitis C-Coinfected Patient Resulting in Temporary Viral Control and Posttreatment Flare.
33879509 2021. A nutraceutical strategy for downregulating TGFbeta signalling: prospects for prevention of fibrotic disorders, including post-COVID-19 pulmonary fibrosis.
33875563 2021. Anti-inflammatory activity of ivermectin in late-stage COVID-19 may reflect activation of systemic glycine receptors.
33869781 2021. COVID-19 severity in relation to sociodemographics and vitamin D use.
33364433 2021. Additional baricitinib loading dose improves clinical outcome in COVID-19.
33995792 2021. Probiotics potentials in mitigating coronavirus disease (COVID-19) pandemic.
33869886 2021. Impact of montelukast as add on treatment to the novel coronavirus pneumonia (COVID-19): protocol for an investigator-initiated open labeled randomized controlled pragmatic trial.
33842834 2021. Computational molecular docking and virtual screening revealed promising SARS-CoV-2 drugs.
33859954 2021. Positive Therapeutic Role of Selected Foods and Plant on Ailments with a Trend Towards COVID-19: A Review.
33894123 2021. Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021).
34006644 2021. Old vaccines for new infections: Exploiting innate immunity to control COVID-19 and prevent future pandemics.
33906951 2021. Network medicine framework for identifying drug-repurposing opportunities for COVID-19.
33893175 2021. Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice.
33303654 2021. A data-driven approach to identify risk profiles and protective drugs in COVID-19.
34031627 2021. Teletherapie - eine innovative Therapiemoglichkeit (auch) fur altere Menschen.
33915202 2021. Lipid homeostasis and mevalonate pathway in COVID-19: Basic concepts and potential therapeutic targets.
33967350 2021. Future antiviral polymers by plasma processing.
33864621 2021. High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors.
33852951 2021. An efficient system to generate truncated human angiotensin converting enzyme 2 (hACE2) capable of binding RBD and spike protein of SARS-CoV2.
33840006 2021. Milk Peptides as Novel Multi-Targeted Therapeutic Candidates for SARS-CoV2.
33290940 2021. Anti-viral properties of antipsychotic medications in the time of COVID-19.
33357253 2021. Evaluation of dietary supplement, functional food and herbal medicine use by dietitians during the COVID-19 pandemic.
33259924 2021. Scope of adjuvant therapy using roflumilast, a PDE-4 inhibitor against COVID-19.
34023513 2021. Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19.
33933611 2021. Endothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19.
33284977 2021. Successful treatment of COVID-19 with colchicine in a kidney transplant recipient.
33972885 2021. Effectiveness and feasibility of convalescent blood transfusion to reduce COVID-19 fatality ratio.
33996135 2021. Cardiac TdP risk stratification modelling of anti-infective compounds including chloroquine and hydroxychloroquine.
34089436 2021. Tocilizumab effects in COVID-19 pneumonia: role of CT texture analysis in quantitative assessment of response to therapy.
33932453 2021. Nrf2 activation putatively mediates clinical benefits of low-dose radiotherapy in COVID-19 pneumonia and acute respiratory distress syndrome (ARDS): Novel mechanistic considerations.
33360293 2021. Hydroxychloroquine can potentially interfere with immune function in COVID-19 patients: Mechanisms and insights.
33988482 2021. Treatment of COVID-19 by stage: any space left for mesenchymal stem cell therapy?
33992585 2021. Complementary and alternative medicines use in COVID-19: A global perspective on practice, policy and research.
33932822 2021. Virucidal and antiviral effects of Thymus vulgaris essential oil on feline coronavirus.
34102594 2021. Extracorporeal cytokine hemadsorption in severe COVID-19 respiratory failure.
34087610 2021. Beneficial effects of inhaled surfactant in patients with COVID-19-associated acute respiratory distress syndrome.
33832495 2021. Letter to the editor: Vitamin D levels in acute illness and clinical severity in COVID-19 patients.
33907666 2021. Triazole, imidazole, and thiazole-based compounds as potential agents against coronavirus.
33829722 2021. Tocilizumab reduces the risk of ICU admission and mortality in patients with SARS-CoV-2 infection.
33982984 2021. Experience with the use of siltuximab in patients with SARS-CoV-2 infection.
34095859 2021. Protocol for constructing large size human antibody heavy chain variable domain (VH) library and selection of SARS-CoV-2 neutralizing antibody domains.
34078447 2021. The immune modulatory effects of umbilical cord-derived mesenchymal stromal cells in severe COVID-19 pneumonia.
33851324 2021. Targeting the PANoptosome with miRNA Loaded Mesenchymal Stem Cell Derived Extracellular Vesicles; a New Path to Fight Against the Covid-19?
34035820 2021. Mesenchymal Stem Cells and COVID-19: Cure, Prevention, and Vaccination.
34102020 2021. Umbilical cord mesenchymal stromal cells as critical COVID-19 adjuvant therapy: A randomized controlled trial.
34008922 2021. Advances in mesenchymal stem cell therapy for immune and inflammatory diseases: Use of cell-free products and human pluripotent stem cell-derived mesenchymal stem cells.
33867777 2021. The binding mechanism of ivermectin and levosalbutamol with spike protein of SARS-CoV-2.
33930306 2021. A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro.
33898692 2021. Ivermectin & COVID-19: Let's keep a One Health perspective.
33889481 2021. Indoor air quality improvement in COVID-19 pandemic: Review.
34010429 2021. Supplementation of the population during the COVID-19 pandemic with vitamins and micronutrients - how much evidence is needed?
33962652 2021. Repurposing existing medications for coronavirus disease 2019: protocol for a rapid and living systematic review.
33813870 2021. Translation, Adaptation, and Validation of Chronic Kidney Disease Self-Management and Knowledge Instruments for People at Pre-Dialysis Stage in the Arab World.

34009133 2021. Notes From the Field: The Combined Effects of Tocilizumab and Remdesivir in a Patient With Severe COVID-19 and Cytokine Release Syndrome.
33825689 2021. Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis.
34032815 2021. Mobile App-Reported Use of Traditional Medicine for Maintenance of Health in India During the COVID-19 Pandemic: Cross-sectional Questionnaire Study.
33997535 2021. Osmotic Tubulopathy in a Patient With COVID-19 Treated With Remdesivir.
33900614 2021. Tocilizumab bor overvagas i tidigt skede av svar covid-19.
34000257 2021. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.
34000255 2021. Convalescent plasma in patients hospitalised with COVID-19.
33933206 2021. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
33933194 2021. Tocilizumab in COVID-19: some clarity amid controversy.
33545097 2021. Azithromycin, RECOVERY, and the power of large, simple trials.
34106642 2021. High-dose vitamin C intravenous infusion in the treatment of patients with COVID-19: A protocol for systematic review and meta-analysis.
34087822 2021. Retinal toxicity caused by hydroxychloroquine in patients with systemic lupus erythematosus: A case report.
33832097 2021. The relationship between nutritional status and the prognosis of COVID-19: A retrospective analysis of 63 patients.
33879697 2021. The effect of traditional Chinese medicine treatment for post-viral olfactory dysfunction: A protocol for systematic review and meta-analysis.
33879694 2021. The therapeutic effect and safety of the drugs for COVID-19: A systematic review and meta-analysis.
33996501 2021. Design of advanced siRNA therapeutics for the treatment of COVID-19.
32482538 2021. Propuesta de uso de anakinra en el distres respiratorio agudo secundario a COVID-19.
33967357 2021. Effects of Anacardic Acid Monoene on the Respiratory System of Mice Submitted to Acute Respiratory Distress Syndrome.
33317261 2021. COVID-19 and Acute Respiratory Distress Syndrome. Impact of corticosteroid treatment and predictors of poor outcome.
33902254 2021. Plitidepsina, un inhibidor del factor de elongacion celular eEF1a y molnupiravir un analogo del ribonucleosido citidina, dos nuevos compuestos quimicos con intensa actividad frente al SARS-CoV-2.
34007141 2021. Prevalence du COVID-19 chez les patients atteints de rhumatismes inflammatoires chroniques traites par biotherapies ou inhibiteurs des JAK : une etude basee sur la population au cours des deux premiers mois de l'epidemie de COVID-19 en Italie.
33875975 2021. Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases.
34089357 2021. COVID-19 in patients with gout on colchicine.
34028704 2021. The Rise and Fall of Hydroxychloroquine with the COVID-19 Pandemic: Narrative Review of Selected Data.
33895812 2021. Comment on: Gudu T, Stober C, Cope AP et al. Baricitinib set to join the Covid-19 therapeutic arsenal? Rheumatology (Oxford). 2021;60:1585-1587.
33856453 2021. Risk of COVID-19 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional DMARDs in Italy.
34092840 2021. Chemical constituents from coconut waste and their in silico evaluation as potential antiviral agents against SARS-CoV-2.
34046177 2021. Vitamin D regulation of the immune system and its implications for COVID-19: A mini review.
33824652 2021. Role of almitrine bismesylate in managing refractory hypoxemia in COVID19 acute respiratory distress syndrome.
33897263 2021. Research and effectiveness of anti-viral drugs against COVID-19; global public intervention to prevent coronavirus and to improve human health.
33935562 2021. Therapeutic development by repurposing drugs targeting SARS-CoV-2 spike protein interactions by simulation studies.
33835053 2021. Nutrition and the microbiota post-COVID-19.
33850422 2021. Calming the inflammatory storm in severe COVID-19 infections: Role of biologics- A narrative review.
34039613 2021. Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses.
33958322 2021. Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11.
33318880 2021. Protoporphyrin IX and verteporfin potently inhibit SARS-CoV-2 infection in vitro and in a mouse model expressing human ACE2.
34010139 2021. A diamidobenzimidazole STING agonist protects against SARS-CoV-2 infection.
33958613 2021. Rapid development of neutralizing and diagnostic SARS-COV-2 mouse monoclonal antibodies.
33953295 2021. Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model.
33953223 2021. Network pharmacology approach to decipher signaling pathways associated with target proteins of NSAIDs against COVID-19.
34040117 2021. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials.
34040048 2021. A method for the rational selection of drug repurposing candidates from multimodal knowledge harmonization.
34040046 2021. Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2.
34031435 2021. Integrative web-based analysis of omics data for study of drugs against SARS-CoV-2.
34021229 2021. Corticosteroids for hospitalized patients with mild to critically-ill COVID-19: a multicenter, retrospective, propensity score-matched study.
34017029 2021. Impact of daily high dose oral vitamin D therapy on the inflammatory markers in patients with COVID 19 disease.
34012108 2021. A super-potent tetramerized ACE2 protein displays enhanced neutralization of SARS-CoV-2 virus infection.
34006961 2021. Implementing a method for engineering multivalency to substantially enhance binding of clinical trial anti-SARS-CoV-2 antibodies to wildtype spike and variants of concern proteins.
33986405 2021. Repurposing potential of posaconazole and grazoprevir as inhibitors of SARS-CoV-2 helicase.
33986382 2021. Exploring antibody repurposing for COVID-19: beyond presumed roles of therapeutic antibodies.
33986351 2021. In silico analysis suggests the RNAi-enhancing antibiotic enoxacin as a potential inhibitor of SARS-CoV-2 infection.
33976287 2021. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease.
33972631 2021. Development and characterization of two equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19.
34099831 2021. A metabolic modeling approach reveals promising therapeutic targets and antiviral drugs to combat COVID-19.
34099745 2021. Hydroxychloroquine plus standard of care compared with standard of care alone in COVID-19: a meta-analysis of randomized controlled trials.
34088975 2021. Regulation of the acetylcholine/alpha7nAChR anti-inflammatory pathway in COVID-19 patients.
34075090 2021. Targeting of the CD80/86 proinflammatory axis as a therapeutic strategy to prevent severe COVID-19.
33574416 2021. Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2.
33824382 2021. Distinct SARS-CoV-2 antibody reactivity patterns in coronavirus convalescent plasma revealed by a coronavirus antigen microarray.
33931664 2021. A SARS-CoV-2 (COVID-19) biological network to find targets for drug repurposing.
33927258 2021. The dimer-monomer equilibrium of SARS-CoV-2 main protease is affected by small molecule inhibitors.
33907251 2021. An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients.
33907209 2021. A computational approach to aid clinicians in selecting anti-viral drugs for COVID-19 trials.
33893337 2021. Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either Dexamethasone or Tocilizumab.
33888840 2021. CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge.
33888738 2021. Nanoparticle composite TPNT1 is effective against SARS-CoV-2 and influenza viruses.
33883570 2021. Evidence of a dysregulated vitamin D endocrine system in SARS-CoV-2 infected patient's lung cells.
33863950 2021. Reconcile the debate over protective effects of BCG vaccine against COVID-19.
33850241 2021. Development of a chiral HPLC method for the separation and quantification of hydroxychloroquine enantiomers.
33850184 2021. Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial.
34091342 2021. Transformation of antiviral ribavirin during ozone/PMS intensified disinfection amid COVID-19 pandemic.
34030377 2021. Can pharmaceutical drugs used to treat Covid-19 infection leads to human health risk? A hypothetical study to identify potential risk.
33360321 2021. A systematic review of the infectious complications of colchicine and the use of colchicine to treat infections.
33973446 2021. [Optimization of expression conditions and determination the proteolytic activity of codon-optimized SARS-CoV-2 main protease in Escherichia coli].
34052830 2021. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease.
34023849 2021. SARS-CoV-2 nanobodies 2.0.
34006835 2021. Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein-ACE2 interaction.
34001849 2021. Safety and efficacy of meplazumab in healthy volunteers and COVID-19 patients: a randomized phase 1 and an exploratory phase 2 trial.
33994545 2021. Protein kinase CK2: a potential therapeutic target for diverse human diseases.
33972500 2021. Lenalidomide downregulates ACE2 protein abundance to alleviate infection by SARS-CoV-2 spike protein conditioned pseudoviruses.
34075025 2021. Identification of proteasome and caspase inhibitors targeting SARS-CoV-2 M(pro).
33837193 2021. FcgammaRIIb blockage: a promising immunotherapy target for severe COVID-19.
33895786 2021. An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19.
33895782 2021. Berbamine inhibits SARS-CoV-2 infection by compromising TRPMLs-mediated endolysosomal trafficking of ACE2.
33895772 2021. Proteome-wide epitope mapping identifies a resource of antibodies for SARS-CoV-2 detection and neutralization.
34078171 2021. Application of a High-Content Screening Assay Utilizing Primary Human Lung Fibroblasts to Identify Antifibrotic Drugs for Rapid Repurposing in COVID-19 Patients.
33874769 2021. A High-Throughput Radioactivity-Based Assay for Screening SARS-CoV-2 nsp10-nsp16 Complex.
33898925 2021. Repositioned Drugs for COVID-19-the Impact on Multiple Organs.
33875977 2021. Old Treatment for a New Disease: Can Rectal Ozone Insufflation Be Used for COVID-19 Management? A Case Report.
33870092 2021. A 3-Case Series of Autoimmune Haemolytic Anaemia and COVID-19: Is Plasma Exchange an Alternative?
33989977 2021. Tuning the Computational Evaluation of Spectroscopic, ELF, LOL, NCI analysis and Molecular Docking of Novel Anti COVID-19 Molecule 4-Dimethylamino Pyridinium 3, 5-Dichlorosalicylate.
34098482 2021. Computational details of molecular structure, spectroscopic properties, topological studies and SARS-Cov-2 enzyme molecular docking simulation of substituted triazolo pyrimidine thione heterocycles.
33333412 2021. Experimental design approach for development of spectrofluorimetric method for determination of favipiravir; a potential therapeutic agent against COVID-19 virus: Application to spiked human plasma.
34093778 2021. Potential role of Nigella sativa supplementation with physical activity in prophylaxis and treatment of COVID-19: a contemporary review.
33971318 2021. Locally harvested Covid-19 convalescent plasma could probably help combat the geographically determined SARS-CoV-2 viral variants.
33358868 2021. Strategies to DAMPen COVID-19-mediated lung and systemic inflammation and vascular injury.
33378571 2021. A retrospective matched cohort single-center study evaluating outcomes of COVID-19 and the impact of immunomodulation on COVID-19-related cytokine release syndrome in solid organ transplant recipients.
33316396 2021. Reply to Lebeaux D, Revest M. No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin.
34054222 2021. Potential protective mechanisms of green tea polyphenol EGCG against COVID-19.
33867130 2021. Therapeutic Potential of Targeting Plasminogen Activator Inhibitor-1 in COVID-19.
33910614 2021. Natural tannin extracts supplementation for COVID-19 patients (TanCOVID): a structured summary of a study protocol for a randomized controlled trial.
33874981 2021. A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial.
33845867 2021. Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial.
34015868 2021. Efficacy and Safety of Azithromycin for the Treatment of COVID-19: A Systematic Review and Meta-analysis.
34078038 2021. The Effect of the Timing of Dexamethasone Administration in Patients with COVID-19 Pneumonia.
34038993 2021. Dexamethasone and COVID-19 in a Developing Country: Appropriate Use?
33853308 2021. Agir COVID-19 enfeksiyonunda tosilizumab'in etkinligi: Guncel calismalarin derlemes.
33969238 2021. Randomized controlled trials of remdesivir in hospitalized coronavirus disease 2019 patients: A meta-analysis.
34092050 2021. History repeats itself: Horse originated Hyperimmune sera production against SARS CoV-2.
33878858 2021. Pulse Steroid Treatment for Hospitalized Adults with COVID-19.
33918368 2021. Deep Transfer Learning Approach for Automatic Recognition of Drug Toxicity and Inhibition of SARS-CoV-2.
33918301 2021. Glycyrrhizin Effectively Inhibits SARS-CoV-2 Replication by Inhibiting the Viral Main Protease.

33318996 2021. Longitudinal melanonychia and skin hyperpigmentation associated with hydroxychloroquine therapy.
34009353 2021. Reassessing the Association of Vitamin D Level With SARS-CoV-2 Seropositivity.
34009346 2021. Assessment of the Association of Vitamin D Level With SARS-CoV-2 Seropositivity Among Working-Age Adults.
33885775 2021. Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The TOGETHER Randomized Clinical Trial.
33880453 2021. Commentary: Therapeutic plasma exchange in COVID-19 pediatric patients: Is there a role?
34100005 2021. Combining immunomodulators and antivirals for COVID-19 - Authors' reply.
34100004 2021. Combining immunomodulators and antivirals for COVID-19.
34100001 2021. Convalescent plasma transfusion for pregnant patients with COVID-19.
33870260 2021. Getting hands on a drug for Covid-19: Inhaled and Intranasal Niclosamide.
33842908 2021. A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19.
34015326 2021. Immunotherapy in COVID-19: why, who, and when?
33930329 2021. Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context.
33872590 2021. Interleukin-6: obstacles to targeting a complex cytokine in critical illness.
34090608 2021. Repurposing drugs for treatment of COVID-19.
34000236 2021. Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial.
34000235 2021. Cytokine adsorption during ECMO for COVID-19-related ARDS.
33991509 2021. Inhaled budesonide for early treatment of COVID-19 - Authors' reply.
33991508 2021. Inhaled budesonide for early treatment of COVID-19.
33991507 2021. Inhaled budesonide for early treatment of COVID-19.
33991506 2021. Inhaled budesonide for early treatment of COVID-19.
33844998 2021. Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19.
33844996 2021. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial.
33341157 2021. Remdesivir for COVID-19 in Europe: will it provide value for money?
34051878 2021. Exploiting an early immunological window of opportunity in COVID-19.
34051877 2021. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial.
33997800 2021. Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study.
33997799 2021. Non-steroidal anti-inflammatory drug use in COVID-19.
33349815 2021. Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform.
34031531 2021. Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19.
33990684 2021. JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis.
34002026 2021. Systematic review and meta-analysis of tocilizumab in persons with coronavirus disease-2019 (COVID-19).
34063766 2021. Strategies for the Production of Soluble Interferon-Alpha Consensus and Potential Application in Arboviruses and SARS-CoV-2.
33919577 2021. The Three Pillars of COVID-19 Convalescent Plasma Therapy.
33358906 2021. Targeting inflammatory cytokine storm to fight against COVID-19 associated severe complications.
33925791 2021. Micronutrients in Sepsis and COVID-19: A Narrative Review on What We Have Learned and What We Want to Know in Future Trials.
33950993 2021. Off-label tocilizumab and adjuvant iron chelator effectiveness in a group of severe COVID-19 pneumonia patients: A single center experience.
33950951 2021. A case report of COVID-19 in refractory myasthenia: Outcome with remdesivir and dexamethasone.
34032734 2021. Efficacy and safety of Lianhuaqingwen for mild or moderate coronavirus disease 2019: A meta-analysis of randomized controlled trials.
34032722 2021. No evidence of tocilizumab treatment efficacy for severe to critical SARS-CoV2 infected patients: Results from a retrospective controlled multicenter study.
34011029 2021. Corticosteroid therapy for COVID-19: A systematic review and meta-analysis of randomized controlled trials.
34011026 2021. Efficacy and safety of Xuanfei Baidu granules for treating COVID-19: A protocol for systematic review and meta-analysis.
34011025 2021. Efficacy of traditional herbal medicine for psychological sequelae in COVID-19 survivors: A protocol for systematic review and meta-analysis.
34106658 2021. Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2.
34056571 2021. Anti-viral treatment for SARS-CoV-2 infection: A race against time amidst the ongoing pandemic.
33301775 2021. Reply to Vitamin D deficiency in COVID-19: mixing up cause and consequence.
33920813 2021. Serum Zinc, Copper, and Other Biometals Are Associated with COVID-19 Severity Markers.
33888152 2021. Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment.
33933603 2021. Promising role of defensins peptides as therapeutics to combat against viral infection.
33932547 2021. Astemizole as a drug to inhibit the effect of SARS-COV-2 in vitro.
34033891 2021. Phytochemicals present in Indian ginseng possess potential to inhibit SARS-CoV-2 virulence: A molecular docking and MD simulation study.
33984466 2021. Molecular scaffolds from mother nature as possible lead compounds in drug design and discovery against coronaviruses: A landscape analysis of published literature and molecular docking studies.
34022374 2021. Lipopeptide-based pan-CoV fusion inhibitors potently inhibit HIV-1 infection.
33824542 2021. Eco-friendly UPLC-MS/MS analysis of possible add-on therapy for COVID-19 in human plasma: Insights of greenness assessment.
33916747 2021. A Study of 3CLpros as Promising Targets against SARS-CoV and SARS-CoV-2.
33925715 2021. Next-Generation Probiotics and Their Metabolites in COVID-19.
33921971 2021. Baicalein and Baicalin Inhibit SARS-CoV-2 RNA-Dependent-RNA Polymerase.
33920489 2021. A Phase II Study on the Use of Convalescent Plasma for the Treatment of Severe COVID-19- A Propensity Score-Matched Control Analysis.
33331748 2021. Extracorporeal immune modulation in COVID-19 induced immune dysfunction and secondary infections: the role of oXiris(R) membrane.
33823571 2021. Concomitant use of surfactant and extra-corporeal membrane oxygenation for COVID-19 in an 8-year-old boy.
33856141 2021. A TGF - beta2 enriched formula as an oral nutritional supplement for hospitalized COVID-19 patients.
34060731 2021. Preventive effects of Pycnogenol(R) on cardiovascular risk factors (including endothelial function) and microcirculation in subjects recovering from coronavirus disease 2019 (COVID-19).
33995692 2021. Eau tonique et quinine - un cocktail de bicentenaire servi en pleine effervescence.
34019535 2021. METHYLENE BLUE FOR TREATMENT OF HOSPITALIZED COVID-19 PATIENTS: A RANDOMIZED, CONTROLLED, OPEN-LABEL CLINICAL TRIAL, PHASE 2.
33870077 2021. Treatment of a Critically Ill COVID-19 Patient with the Seraph 100 Microbind Affinity Filter.
33995989 2021. Treatment with eltrombopag of severe immune thrombocytopenia and hemolytic anemia associated with COVID-19 pneumonia: a case report.
33854571 2021. Influence of colchicine prescription in COVID-19-related hospital admissions: a survival analysis.
33953559 2021. Chloroquine and Hydroxychloroquine for the Prevention and Treatment of COVID-19: A Fiction, Hope or Hype? An Updated Review.
33995653 2021. The therapeutic potential of inorganic polyphosphate: A versatile physiological polymer to control coronavirus disease (COVID-19).
33886017 2021. Insights into SARS-CoV-2: Medicinal Chemistry Approaches to Combat Its Structural and Functional Biology.
34058295 2021. Computational and experimental studies on the inhibitory mechanism of hydroxychloroquine on hERG.
34045121 2021. Convalescent plasma to treat COVID-19: Following the Argentinian lead.
33994107 2021. Preparedness and activities of the anti-SARS-CoV-2 convalescent plasma bank in the Veneto region (Italy): An organizational model for future emergencies.
33994106 2021. Efficacy of convalescent plasma therapy in severe COVID-19 patients.
33962885 2021. Effects on mortality of early vs late administration of convalescent plasma in the treatment of Covid-19.
33931359 2021. COVID19 immune plasma donation after vaccination: pros and cons.
33896671 2021. Plasma exchange followed by convalescent plasma transfusion in COVID-19 patients.
34102319 2021. Covid-19 convalescent plasma therapy: Analyzing the factors that led to its failure in India.
33965621 2021. Convalescent Plasma Therapy in the management of COVID-19 patients-The newer dimensions.
33931305 2021. Early and persistent viral clearance in COVID-19 patients treated with convalescent plasma.
33901641 2021. COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?
33895379 2021. Psychological assessment and lived experiences of recovered COVID-19 patients who presented for convalescent plasma donation.
33839301 2021. What convalescent plasma in treating severe acute respiratory infections of viral aetiology can hint for COVID-19? Evidence from a meta-analysis.
33839300 2021. Bioethical perspective of convalescent plasma therapy for COVID-19: A systematic review.
33887552 2021. Exploring the utility of extracellular vesicles in ameliorating viral infection-associated inflammation, cytokine storm and tissue damage.
34034765 2021. Benefits of treatment with favipiravir in hospitalized patients for COVID-19: a retrospective observational case-control study.
34020680 2021. Intravenous immunoglobulin-based adjuvant therapy for severe COVID-19: a single-center retrospective cohort study.
34019233 2021. Anti-SARS-CoV-2 IgY Isolated from Egg Yolks of Hens Immunized with Inactivated SARS-CoV-2 for Immunoprophylaxis of COVID-19.
33370597 2021. Repurposing of renin inhibitors as SARS-COV-2 main protease inhibitors: A computational study.
34052578 2021. Azelastine inhibits viropexis of SARS-CoV-2 spike pseudovirus by binding to SARS-CoV-2 entry receptor ACE2.
34090962 2021. The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models.
33359190 2021. Tmprss2 specific miRNAs as promising regulators for SARS-CoV-2 entry checkpoint.
33333102 2021. A retrospective comparison of drugs against COVID-19.
33845063 2021. Quantifying the effect of trypsin and elastase on in vitro SARS-CoV infections.
34099981 2021. Assessment of nitric oxide (NO) potential to mitigate COVID-19 severity.
33842675 2021. Potential combination therapy using twenty phytochemicals from twenty plants to prevent SARS- CoV-2 infection: An in silico Approach.
33842673 2021. Phytochemicals as potential drug candidates for targeting SARS CoV 2 proteins, an in silico study.
33948452 2021. Direct acting anti-hepatitis C combinations as potential COVID-19 protease inhibitors.
33869672 2021. Molecular docking and ADMET studies of Allium cepa, Azadirachta indica and Xylopia aethiopica isolates as potential anti-viral drugs for Covid-19.
34073401 2021. Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon.
34070524 2021. Noble Metal Organometallic Complexes Display Antiviral Activity against SARS-CoV-2.
34071034 2021. GABAA-Receptor Agonists Limit Pneumonitis and Death in Murine Coronavirus-Infected Mice.
34067381 2021. Remdesivir for Early COVID-19 Treatment of High-Risk Individuals Prior to or at Early Disease Onset-Lessons Learned.
34063247 2021. Scutellaria barbata D. Don Inhibits the Main Proteases (M(pro) and TMPRSS2) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.
34069827 2021. Aptamer BC 007's Affinity to Specific and Less-Specific Anti-SARS-CoV-2 Neutralizing Antibodies.
34069206 2021. Compelling Evidence for the Activity of Antiviral Peptides against SARS-CoV-2.
34068686 2021. The Repurposed Drugs Suramin and Quinacrine Cooperatively Inhibit SARS-CoV-2 3CL(pro) In Vitro.
33918958 2021. Screening of FDA-Approved Drugs Using a MERS-CoV Clinical Isolate from South Korea Identifies Potential Therapeutic Options for COVID-19.
33918914 2021. Broad-Spectrum Antiviral Activity of 3D8, a Nucleic Acid-Hydrolyzing Single-Chain Variable Fragment (scFv), Targeting SARS-CoV-2 and Multiple Coronaviruses In Vitro.
33918670 2021. Quinine Inhibits Infection of Human Cell Lines with SARS-CoV-2.
33918615 2021. The Photosensitizer Octakis(cholinyl)zinc Phthalocyanine with Ability to Bind to a Model Spike Protein Leads to a Loss of SARS-CoV-2 Infectivity In Vitro When Exposed to Far-Red LED.
33916927 2021. Neutralizing Antibody Therapeutics for COVID-19.
33946304 2021. Inhibitors of Protein Glycosylation Are Active against the Coronavirus Severe Acute Respiratory Syndrome Coronavirus SARS-CoV-2.

33340994 2021. Reducing transmission of SARS-CoV-2 with intranasal prophylaxis.
33997737 2021. Complement inhibition in severe COVID-19 - Blocking C5a seems to be key.
33937736 2021. Complement inhibition in severe COVID-19 - Blocking C5a seems to be key: Author's reply.
33903855 2021. Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.
33870149 2021. RBD-specific polyclonal F(ab )2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial.
33886937 2021. Convalescent plasma therapy in COVID-19 critically ill patients during advanced phases of clinical trials and their preliminary results.
34085928 2021. Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality.
34057039 2021. Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants.
33847245 2021. Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus.
33999367 2021. Vitamin D in the Covid-19 era: a review with recommendations from a G.I.O.S.E.G. expert panel.
33858814 2021. Malnutrition and nutrition support in COVID-19: The results of a nutrition support protocol.
34031634 2021. Nanozymes to fight the COVID-19 and future pandemics.
33841038 2021. An in silico approach to target RNA-dependent RNA polymerase of COVID-19 with naturally occurring phytochemicals.
33934306 2021. In silico screening of potent bioactive compounds from honeybee products against COVID-19 target enzymes.
33344687 2021. Recent case studies on the use of ozone to combat coronavirus: Problems and perspectives.
33957025 2021. Effectiveness of hydrogen peroxide as auxiliary treatment for hospitalized COVID-19 patients in Brazil: preliminary results of a randomized double-blind clinical trial.
34021807 2021. Mouthrinses against SARS-CoV-2: anti-inflammatory effectivity and a clinical pilot study.
33870079 2021. Cytosorb treatment in severe COVID-19 cardiac and pulmonary disease.
33982133 2021. Plasma concentrations of remdesivir metabolite in a critical COVID-19 patient needing continuous venovenous haemodialysis.
33966929 2021. Convalescent plasma in the management of COVID-19 pneumonia.
34023738 2021. A cyclic peptide inhibitor of the SARS-CoV-2 main protease.
33894564 2021. Phenoxazine nucleoside derivatives with a multiple activity against RNA and DNA viruses.
34054314 2021. Prophylactic effects of probiotics on respiratory viruses including COVID-19: a review.
34068930 2021. A Review of the Role of Micronutrients and Bioactive Compounds on Immune System Supporting to Fight against the COVID-19 Disease.
33347987 2021. The role of NO in COVID-19 and potential therapeutic strategies.
34017865 2021. In silico Exploration of Interactions Between Potential COVID-19 Antiviral Treatments and the Pore of the hERG Potassium Channel-A Drug Antitarget.
33969013 2021. Iloprost in COVID-19: The Rationale of Therapeutic Benefit.
33928083 2021. Acceleration of Translational Mesenchymal Stromal Cell Therapy Through Consistent Quality GMP Manufacturing.
33981629 2021. Fluticasone Propionate Suppresses Poly(I:C)-Induced ACE2 in Primary Human Nasal Epithelial Cells.
33968808 2021. Could Nutraceutical Approaches Possibly Attenuate the Cytokine Storm in COVID-19 Patients?
34041221 2021. Pharmacophore Modelling-Based Drug Repurposing Approaches for SARS-CoV-2 Therapeutics.
34017819 2021. Molecular Docking and Dynamics Simulation Revealed the Potential Inhibitory Activity of ACEIs Against SARS-CoV-2 Targeting the hACE2 Receptor.
33865880 2021. Antiviral strategies should focus on stimulating the biosynthesis of heparan sulfates, not their inhibition.
33316266 2021. Repurposing of histone deacetylase inhibitors: A promising strategy to combat pulmonary fibrosis promoted by TGF-beta signalling in COVID-19 survivors.
33310043 2021. Screened antipsychotic drugs inhibit SARS-CoV-2 binding with ACE2 in vitro.
33865879 2021. Therapeutic potential of mesenchymal stem cells in multiple organs affected by COVID-19.
34050796 2021. Tocilizumab in Hospitalized Patients with COVID-19: A Meta Analysis of Randomized Controlled Trials.
33942765 2021. Plasma therapy in COVID-19: All that glitters is not gold.
34024246 2021. Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies.
33958972 2021. Ivermectin and COVID-19.
33922914 2021. Dieckol and Its Derivatives as Potential Inhibitors of SARS-CoV-2 Spike Protein (UK Strain: VUI 202012/01): A Computational Study.
33921174 2021. Inhibition of SARS-CoV-2 Virus Entry by the Crude Polysaccharides of Seaweeds and Abalone Viscera In Vitro.
34094885 2021. Phenolic compounds as promising drug candidates against COVID-19 - An integrated molecular docking and dynamics simulation study.
33308613 2021. Immune-boosting role of vitamins D, C, E, zinc, selenium and omega-3 fatty acids: Could they help against COVID-19?
33958066 2021. In Reply-Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis.
33958065 2021. Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis.
33958057 2021. The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis.
33958056 2021. A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19: The Mayo Clinic Model.
34060334 2021. Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes.
33906927 2021. ColdZyme Maintains Integrity in SARS-CoV-2-Infected Airway Epithelia.
33879585 2021. Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma.
33307107 2021. Decreased serum levels of the inflammaging marker miR-146a are associated with clinical non-response to tocilizumab in COVID-19 patients.
34083071 2021. Efecto de la adicion de bemiparina y cefepime al tratamiento habitual en el paciente oncologico con infeccion por SARS-CoV-2.
34059357 2021. Prolongacion del intervalo QT en pacientes geriatricos bajo tratamiento por la infeccion por SARS-CoV-2: estudio OCTA-COVID.
33308853 2021. Incidencia de la COVID-19 en pacientes en tratamiento cronico con hidroxicloroquina.
33308854 2021. Cuestiones por resolver en el tratamiento con glucocorticoides de la infeccion COVID-19.
34056111 2021. Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation.
33846702 2021. The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review.
33878626 2021. Application of intravenous immunoglobulin (IVIG) to modulate inflammation in critical COVID-19 - A theoretical perspective.
33848919 2021. Role of NLRP3 inflammasome in COVID-19 and periodontitis: Possible protective effect of melatonin.
34102600 2021. A tale of two diseases: Sarcoidosis, COVID-19 and new therapeutic options with dual RAS inhibition and tetanus-diphtheria vaccine.
34098463 2021. Decorin as a possible strategy for the amelioration of COVID-19.
33360447 2021. Closing the portal to SARS-CoV-2 cellular entry: May open newer avenues....
33341328 2021. Does tetanus vaccination contribute to reduced severity of the COVID-19 infection?
33341032 2021. Methylene blue in covid-19.
33333472 2021. Statins and PCSK9 inhibitors: What is their role in coronavirus disease 2019?
33308938 2021. Inhaled milrinone for sick COVID-19 cohort: A pathophysiology driven hypothesis!
33308935 2021. Combating hypoxemia in COVID-19 patients with a natural oxygen carrier, HEMO2Life(R) (M101).
33867175 2021. Terapia combinada de tocilizumab y corticoides en la enfermedad grave por SARS-CoV-2.
33985821 2021. Dexametasona en COVID-19: inverted question markun medicamento para todos?
33277927 2021. Drug repurposing approach to combating coronavirus: Potential drugs and drug targets.
33828895 2021. BCG Protection Against COVID-19: Is it Reality or Illusion?
33967626 2021. Recombinant Human Thymosin Beta-4 Protects against Mouse Coronavirus Infection.
33974610 2021. Monoclonal Antibodies vs COVID-19: Eduardo Ojito-Magaz MS General Director, Molecular Immunology Center.
33974608 2021. An Experience with Cuban Biotech's Nasalferon to Prevent SARS-COV-2 Infections in International Travelers and their Contacts.
33906157 2021. Una nueva alternativa: terapia con plasma de convalecientes, posible antidoto en tiempos de COVID-19.
33906156 2021. Terapia con plasma de convalecientes en pacientes COVID-19.
34098567 2021. Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants.
33978988 2021. Malnutrition is associated with hyperinflammation and immunosuppression in COVID-19 patients: A prospective observational study.
34109257 2021. In Silico Evaluation of Cyclophilin Inhibitors as Potential Treatment for SARS-CoV-2.
34110959 2021. Possible therapeutic effects of Nigella sativa and its thymoquinone on COVID-19.
33835512 2021. Use of Remdesivir in Myasthenia gravis and COVID-19.
33860587 2021. The effect of propolis plus Hyoscyamus niger L. methanolic extract on clinical symptoms in patients with acute respiratory syndrome suspected to COVID-19: A clinical trial.
33979464 2021. Efficacy and safety of Xiyanping injection in the treatment of COVID-19: A multicenter, prospective, open-label and randomized controlled trial.
33928690 2021. New perspectives on natural flavonoids on COVID-19-induced lung injuries.
34111204 2021. Simulated sunlight decreases the viability of SARS-CoV-2 in mucus.
34111191 2021. Combination of (interferon beta-1b, lopinavir/ritonavir and ribavirin) versus favipiravir in hospitalized patients with non-critical COVID-19: A cohort study.
34103373 2021. Sofosbuvir with daclatasvir and the outcomes of patients with COVID-19: a systematic review and meta-analysis with GRADE assessment.
33973262 2021. ACE2-based decoy receptors for SARS coronavirus 2.
33893649 2021. Tackling Covid-19 using disordered-to-order transition of residues in the spike protein upon angiotensin-converting enzyme 2 binding.
34074129 2021. Wharton's Jelly Mesenchymal Stem Cell-Derived Extracellular Vesicles Reduce SARS-CoV2-Induced Inflammatory Cytokines Under High Glucose and Uremic Toxin Conditions.
34089033 2021. Antibody-laden nasal spray could provide COVID protection - and treatment.
33827113 2021. Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia.
34082438 2021. Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants.
33932964 2021. The possibilities of using the effects of ozone therapy in neurology.
33368619 2021. Association Between Low Zinc Levels and Severity of Acute Respiratory Distress Syndrome by New Coronavirus SARS-CoV-2.
33858237 2021. Coronavirus management and control: Nutrition and alternative medicines.
33847299 2021. Neonates With SARS-CoV-2 Infection and Pulmonary Disease Safely Treated With Remdesivir.
33902077 2021. Novel Treatment of Infant With COVID-19 With the Sialidase Fusion Protein, DAS181.
33967228 2021. Safety and Antibody Kinetics of COVID-19 Convalescent Plasma for the Treatment of Moderate to Severe Cases of SARS-CoV-2 Infection in Pediatric Patients.
33316149 2021. The influence of the genetic background of the host on vitamin D deficiency in children with COVID-19.
33289321 2021. Tracing the path of inhaled nitric oxide: Biological consequences of protein nitrosylation.
33883243 2021. Compassionate Use of Remdesivir in Children With Severe COVID-19.
33964992 2021. Inhibition effects of eight anti-coronavirus drugs on glycosides metabolism and glycosidases in human gut microflora.
34009028 2021. Photodynamic Therapy and Photobiomodulation on Oral Lesion in Patient with Coronavirus Disease 2019: A Case Report.
33876086 2021. A crystallography-based investigation of weak interactions for drug design against COVID-19.
34008647 2021. Antiviral drug design based on the opening mechanism of spike glycoprotein in SARS-CoV-2.
34110678 2021. Therapeutic targets of natural products for the management of cardiovascular symptoms of coronavirus disease 2019.
33929758 2021. Andrographis paniculata (Burm. F) Wall ex Nees: Antiviral properties.
33882609 2021. Die Behandlung eines Patienten mit ausgepragtem Zytokinsturm bei schwerer COVID-19-Pneumonie unter Einsatz von Hamoadsorption in Kombination mit der Gabe von Tocilizumab.
33307968 2021. The Coronavirus Pandemic: A Pitfall or a Fast Track for Validating Cell Therapy Products?
34044609 2021. Human Umbilical Cord Mesenchymal Stromal Cell Treatment of Severe COVID-19 Patients: A 3-Month Follow-Up Study Following Hospital Discharge.

33888522 2021. Genetic polymorphisms, vitamin D binding protein and vitamin D deficiency in COVID-19.
34083403 2021. Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19-a randomised double-blinded placebo-controlled trial.
33361100 2021. Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial.
33303541 2021. Vitamin D status and seroconversion for COVID-19 in UK healthcare workers.
34002840 2021. Intravenous ozonized saline therapy as prophylaxis for healthcare workers (HCWs) in a dedicated COVID-19 hospital in India - A retrospective study.
33829465 2021. Therapeutic potential of N-acetyl cysteine (NAC) in preventing cytokine storm in COVID-19: review of current evidence.
33829464 2021. SARS-CoV-2 infection and H1N1 vaccination: does a relationship between the two factors really exist? A retrospective analysis of a territorial cohort in Ferrara, Italy.
33829431 2021. Comment on safety and efficacy of oral lopinavir/ritonavir in pediatric patients with coronavirus disease: a nationwide comparative analysis.
33829430 2021. Ozone therapy may be an option for COVID-19 patients.
33877683 2021. Dantrolene repurposed to treat sepsis or septic shock and COVID-19 patients.
33877681 2021. Prediction of potential therapeutic drugs against SARS-CoV-2 by using Connectivity Map based on transcriptome data.
34009333 2021. Modelling sudden cardiac death risks factors in patients with coronavirus disease of 2019: the hydroxychloroquine and azithromycin case.
33996744 2021. Pomegranate Peel Extract as an Inhibitor of SARS-CoV-2 Spike Binding to Human ACE2 Receptor (in vitro): A Promising Source of Novel Antiviral Drugs.
33889562 2021. Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main Protease.
33868174 2021. New Roles for Vitamin D Superagonists: From COVID to Cancer.
34093569 2021. Can Resveratrol-Inhaled Formulations Be Considered Potential Adjunct Treatments for COVID-19?
34093548 2021. Nasopharyngeal Type-I Interferon for Immediately Available Prophylaxis Against Emerging Respiratory Viral Infections.
34054866 2021. Intestinal Microbiota-A Promising Target for Antiviral Therapy?
34054808 2021. Human Surfactant Protein D Binds Spike Protein and Acts as an Entry Inhibitor of SARS-CoV-2 Pseudotyped Viral Particles.
34046038 2021. Case Report: Successful Response to Intravenous Immunoglobulin and Steroid Pulses in a Renal Transplant Recipient With Severe Covid-19 Disease and Associated Acute Allograft Failure.
34040614 2021. Vitamin C May Increase the Recovery Rate of Outpatient Cases of SARS-CoV-2 Infection by 70%: Reanalysis of the COVID A to Z Randomized Clinical Trial.
34025650 2021. Anti-TNF-alpha agents Modulate SARS-CoV-2 Receptors and Increase the Risk of Infection Through Notch-1 Signaling.
34012456 2021. Regulation of Tissue Immune Responses by Local Glucocorticoids at Epithelial Barriers and Their Impact on Interorgan Crosstalk.
34012436 2021. Case Report: Convalescent Plasma Achieves SARS-CoV-2 Viral Clearance in a Patient With Persistently High Viral Replication Over 8 Weeks Due to Severe Combined Immunodeficiency (SCID) and Graft Failure.
33995424 2021. Commentary: Mesenchymal Stem Cells: A New Piece in the Puzzle of COVID-19 Treatment.
33995420 2021. High Levels of Common Cold Coronavirus Antibodies in Convalescent Plasma Are Associated With Improved Survival in COVID-19 Patients.
33995419 2021. Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation.
33995361 2021. Mini-Factor H Modulates Complement-Dependent IL-6 and IL-10 Release in an Immune Cell Culture (PBMC) Model: Potential Benefits Against Cytokine Storm.
33968017 2021. Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery.
33897692 2021. Case Report: Interferon-gamma Restores Monocytic Human Leukocyte Antigen Receptor (mHLA-DR) in Severe COVID-19 With Acquired Immunosuppression Syndrome.
33868305 2021. Commentary: The Long History of Vitamin C: From Prevention of the Common Cold to Potential Aid in the Treatment of COVID-19.
33859652 2021. Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities.
33841439 2021. Revisiting Pleiotropic Effects of Type I Interferons: Rationale for Its Prophylactic and Therapeutic Use Against SARS-CoV-2.
33833758 2021. Bovine Coronavirus Immune Milk Against COVID-19.
33909259 2021. Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections.
33909260 2021. Effects of Shuanghuanglian oral liquids on patients with COVID-19: a randomized, open-label, parallel-controlled, multicenter clinical trial.
34026798 2021. Phytochemical Moieties From Indian Traditional Medicine for Targeting Dual Hotspots on SARS-CoV-2 Spike Protein: An Integrative in-silico Approach.
34026778 2021. Vagus Nerve Stimulation: A Potential Adjunct Therapy for COVID-19.
33968969 2021. Efficacy Evaluation of Thymosin Alpha 1 in Non-severe Patients With COVID-19: A Retrospective Cohort Study Based on Propensity Score Matching.
33968948 2021. The Use of the Anticoagulant Heparin and Corticosteroid Dexamethasone as Prominent Treatments for COVID-19.
33937285 2021. Management of SARS-CoV-2 Infection: Key Focus in Macrolides Efficacy for COVID-19.
33898477 2021. Mortality Benefit of Convalescent Plasma in COVID-19: A Systematic Review and Meta-Analysis.
33889590 2021. Assessment of the Safety and Therapeutic Benefits of Convalescent Plasma in COVID-19 Treatment: A Systematic Review and Meta-Analysis.
34054782 2021. Therapeutic Potential of Exploiting Autophagy Cascade Against Coronavirus Infection.
33995308 2021. Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor in vitro.
33967984 2021. Computational Simulations Identified Marine-Derived Natural Bioactive Compounds as Replication Inhibitors of SARS-CoV-2.
34079818 2021. An Integrated Computational and Experimental Approach to Identifying Inhibitors for SARS-CoV-2 3CL Protease.
34055887 2021. Current Strategies of Antiviral Drug Discovery for COVID-19.
34046428 2021. Synthesis and Cytotoxic Activity of Novel Indole Derivatives and Their in silico Screening on Spike Glycoprotein of SARS-CoV-2.
34041263 2021. Prospective Role of Peptide-Based Antiviral Therapy Against the Main Protease of SARS-CoV-2.
34026833 2021. A Strategy Based on Loop Analysis to Develop Peptide Epitopes: Application to SARS-CoV-2 Spike Protein.
33937333 2021. Administration Timing and Efficacy of Tocilizumab in Patients With COVID-19 and Elevated IL-6.
33912587 2021. Inhibition of SARS-CoV-2 3CL M(pro) by Natural and Synthetic Inhibitors: Potential Implication for Vaccine Production Against COVID-19.
33898520 2021. Structure-Based Virtual Screening to Identify Novel Potential Compound as an Alternative to Remdesivir to Overcome the RdRp Protein Mutations in SARS-CoV-2.
33869283 2021. A Multifunctional Peptide From Bacillus Fermented Soybean for Effective Inhibition of SARS-CoV-2 S1 Receptor Binding Domain and Modulation of Toll Like Receptor 4: A Molecular Docking Study.
34054418 2021. Vitamin D, Depressive Symptoms, and Covid-19 Pandemic.
33927594 2021. Selective Vagus Nerve Stimulation as a Therapeutic Approach for the Treatment of ARDS: A Rationale for Neuro-Immunomodulation in COVID-19 Disease.
34095193 2021. Encapsulated Food Products as a Strategy to Strengthen Immunity Against COVID-19.
33855042 2021. Low Serum 25-hydroxyvitamin D (Vitamin D) Level Is Associated With Susceptibility to COVID-19, Severity, and Mortality: A Systematic Review and Meta-Analysis.
34093195 2021. A Large Impact of Obesity on the Disposition of Ivermectin, Moxidectin and Eprinomectin in a Canine Model: Relevance for COVID-19 Patients.
34079462 2021. Marine Sponge is a Promising Natural Source of Anti-SARS-CoV-2 Scaffold.
34054557 2021. Synergy Between Vitamin D and Sex Hormones in Respiratory Functionality of Patients Affected by COVID-19.
34054532 2021. Multi-Omics Approach in the Identification of Potential Therapeutic Biomolecule for COVID-19.
34054522 2021. Broad Anti-Viral Capacities of Lian-Hua-Qing-Wen Capsule and Jin-Hua-Qing-Gan Granule and Rational use Against COVID-19 Based on Literature Mining.
34054510 2021. beta-Caryophyllene, A Natural Dietary CB2 Receptor Selective Cannabinoid can be a Candidate to Target the Trinity of Infection, Immunity, and Inflammation in COVID-19.
34025433 2021. Curcumin as a Potential Treatment for COVID-19.
34025406 2021. The Anti-Viral and Anti-Inflammatory Properties of Edible Bird's Nest in Influenza and Coronavirus Infections: From Pre-Clinical to Potential Clinical Application.
34025393 2021. The Rise and Fall of Chloroquine/Hydroxychloroquine as Compassionate Therapy of COVID-19.
34017257 2021. Strategy, Progress, and Challenges of Drug Repurposing for Efficient Antiviral Discovery.
34017249 2021. The Cholinergic Drug Pyridostigmine Alleviates Inflammation During LPS-Induced Acute Respiratory Distress Syndrome.
34012398 2021. Comparative Effectiveness of Pharmacological Interventions for Covid-19: A Systematic Review and Network Meta-Analysis.
34012395 2021. A Survey Among Italian Physicians During COVID-19 Outbreak. Could Bacillus Calmette-Guerin Vaccine Be Effective Against SARS-CoV2?
34012391 2021. Natural Products Modulating Angiotensin Converting Enzyme 2 (ACE2) as Potential COVID-19 Therapies.
34012390 2021. Withania somnifera (L.) Dunal: Opportunity for Clinical Repurposing in COVID-19 Management.
33995094 2021. Pelargonium Extract EPs 7630 in the Treatment of Human Corona Virus-Associated Acute Respiratory Tract Infections - A Secondary Subgroup-Analysis of an Open-Label, Uncontrolled Clinical Trial.
33995078 2021. Edible and Herbal Plants for the Prevention and Management of COVID-19.
33995062 2021. Profiling Ribonucleotide and Deoxyribonucleotide Pools Perturbed by Remdesivir in Human Bronchial Epithelial Cells.
33995053 2021. Intermittent Hypoxic Preconditioning: A Potential New Powerful Strategy for COVID-19 Rehabilitation.
33986661 2021. Potential Mechanism Prediction of Herbal Medicine for Pulmonary Fibrosis Associated with SARS-CoV-2 Infection Based on Network Analysis and Molecular Docking.
33981235 2021. Phytochemicals as Potential Therapeutics for SARS-CoV-2-Induced Cardiovascular Complications: Thrombosis and Platelet Perspective.
33981229 2021. Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome.
33981214 2021. Therapeutic Potentials of Antiviral Plants Used in Traditional African Medicine With COVID-19 in Focus: A Nigerian Perspective.
33967777 2021. Pleiotropic Effects of Tetracyclines in the Management of COVID-19: Emerging Perspectives.
33967773 2021. High Dose Intravenous Vitamin C for Preventing The Disease Aggravation of Moderate COVID-19 Pneumonia. A Retrospective Propensity Matched Before-After Study.
33967755 2021. No Efficacy of the Combination of Lopinavir/Ritonavir Plus Hydroxychloroquine Versus Standard of Care in Patients Hospitalized With COVID-19: A Non-Randomized Comparison.
33959018 2021. Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19.
33953674 2021. Giloy Ghanvati (Tinospora cordifolia (Willd.) Hook. f. and Thomson) Reversed SARS-CoV-2 Viral Spike-Protein Induced Disease Phenotype in the Xenotransplant Model of Humanized Zebrafish.
33953673 2021. Hydroxychloroquine Increased Anxiety-Like Behaviors and Disrupted the Expression of Some Related Genes in the Mouse Brain.
33935717 2021. Na(+)/K(+)-ATPase as a Target of Cardiac Glycosides for the Treatment of SARS-CoV-2 Infection.
33912048 2021. Commentary: Use of Cannabinoids to Treat Acute Respiratory Distress Syndrome and Cytokine Storm Associated With Coronavirus Disease-2019.
33912041 2021. Phytoconstituents, In Vitro Anti-Infective Activity of Buddleja indica Lam., and In Silico Evaluation of its SARS-CoV-2 Inhibitory Potential.
33912030 2021. Repurposing Chloroquine Against Multiple Diseases With Special Attention to SARS-CoV-2 and Associated Toxicity.
33897423 2021. 1,2,3,4,6-Pentagalloyl Glucose, a RBD-ACE2 Binding Inhibitor to Prevent SARS-CoV-2 Infection.
33841165 2021. Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.
33841143 2021. Medicinal Plants in COVID-19: Potential and Limitations.
33833683 2021. COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms.
33828481 2021. Fever and Antipyretic Supported by Traditional Chinese Medicine: A Multi-Pathway Regulation.
34093219 2021. Can Vitamin D Deficiency Increase the Susceptibility to COVID-19?
34054572 2021. The Cholinergic and ACE-2-Dependent Anti-Inflammatory Systems in the Lung: New Scenarios Emerging From COVID-19.
34077600 2021. Efficacy and safety of azithromycin in Covid-19 patients: A systematic review and meta-analysis of randomized clinical trials.
33882179 2021. Tocilizumab in COVID-19 pneumonia: Practical proposals based on a narrative review of randomised trials.
33999135 2021. Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a systematic review and meta-analysis.
33872387 2021. Interactions between SARS coronavirus 2 papain-like protease and immune system: A potential drug target for the treatment of COVID-19.
34035117 2021. Complement control for COVID-19.
33915006 2021. Feasibility and safety of remdesivir in SARS-CoV2 infected renal transplant recipients: A retrospective cohort from a developing nation.
34046618 2021. Recent advances in the discovery of potent RNA-dependent RNA-polymerase (RdRp) inhibitors targeting viruses.
34046603 2021. Identification of LASSBio-1945 as an inhibitor of SARS-CoV-2 main protease (M(PRO)) through in silico screening supported by molecular docking and a fragment-based pharmacophore model.
33944732 2021. Ivermectin for COVID-19: Promising but not yet conclusive.
33944756 2021. A qualitative analysis of seven ivermectin formulations in South Africa.
34011224 2021. Robust classification-based molecular modelling of diverse chemical entities as potential SARS-CoV-2 3CL(pro) inhibitors: theoretical justification in light of experimental evidences.
34010142 2021. Pharmacological activation of STING blocks SARS-CoV-2 infection.
34081820 2021. Initial experience of bamlanivimab monotherapy use in solid organ transplant recipients.

33345848 2021. Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel.
34015316 2021. Evaluation of Th1 and Th2 mediated cellular and humoral immunity in patients with COVID-19 following the use of melatonin as an adjunctive treatment.
34004207 2021. Role of leukotriene pathway and montelukast in pulmonary and extrapulmonary manifestations of Covid-19: The enigmatic entity.
34015317 2021. Azithromycin: Immunomodulatory and antiviral properties for SARS-CoV-2 infection.
34104202 2021. Alkaloids as Potential Phytochemicals against SARS-CoV-2: Approaches to the Associated Pivotal Mechanisms.
34040501 2021. Selenium to selenoproteins - role in COVID-19.
33302737 2021. Protease-activated receptor 1 as a potential therapeutic target for COVID-19.
33899542 2021. Manipulation of genes could inhibit SARS-CoV-2 infection that causes COVID-19 pandemics.
33310152 2021. Metformin in acute respiratory distress syndrome: An opinion.
34035463 2021. Platycodin D, a natural component of Platycodon grandiflorum, prevents both lysosome- and TMPRSS2-driven SARS-CoV-2 infection by hindering membrane fusion.
33968179 2021. Efficiency of antiviral treatment in COVID-19.
33835886 2021. A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19.
33703986 2021. Considerations of the effects of commonly investigated drugs for COVID-19 in the cholesterol synthesis pathway.
33857397 2021. TLR4 as a therapeutic target for respiratory and neurological complications of SARS-CoV-2.
34015985 2021. Corticosteroids in SARS-COV2 infection: certainties and uncertainties in clinical practice.
33844613 2021. Antimicrobial peptides and other peptide-like therapeutics as promising candidates to combat SARS-CoV-2.
33823733 2021. Efficacy and safety of Tocilizumab in severe and critical COVID-19: A Systematic Review and Meta-Analysis.
33962524 2021. Antiviral treatment selection for SARS-CoV-2 pneumonia.
34015243 2021. Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations.
34046165 2021. Is butyrate a natural alternative to dexamethasone in the management of CoVID-19?
33968364 2021. Identifying potential drug targets and candidate drugs for COVID-19: biological networks and structural modeling approaches.
33763201 2021. Optimal use of tocilizumab for severe and critical COVID-19: a systematic review and meta-analysis.
33879541 2021. Rationales and uncertainties for aspirin use in COVID-19: a narrative review.
33894315 2021. Discovery of naturally occurring inhibitors against SARS-CoV-2 3CL(pro) from Ginkgo biloba leaves via large-scale screening.
33995121 2021. Proteomics and Machine Learning Approaches Reveal a Set of Prognostic Markers for COVID-19 Severity With Drug Repurposing Potential.
34054909 2021. Plant-Produced Receptor-Binding Domain of SARS-CoV-2 Elicits Potent Neutralizing Responses in Mice and Non-human Primates.
33315181 2021. Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: randomized control trial in Singapore.
34061787 2021. Vitamin D plasma levels in patients with COVID-19: a case series.
33325523 2021. Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry.
33860869 2021. Induction of Exaggerated Cytokine Production in Human Peripheral Blood Mononuclear Cells by a Recombinant SARS-CoV-2 Spike Glycoprotein S1 and Its Inhibition by Dexamethasone.
34075339 2021. Computational prediction of nimbanal as potential antagonist of respiratory syndrome coronavirus.
34075338 2021. Structural insights and inhibition mechanism of TMPRSS2 by experimentally known inhibitors Camostat mesylate, Nafamostat and Bromhexine hydrochloride to control SARS-coronavirus-2: A molecular modeling approach.
34028468 2021. The journey of antimalarial drugs against SARS-CoV-2: Review article.
33846694 2021. Computational prediction of potential siRNA and human miRNA sequences to silence orf1ab associated genes for future therapeutics against SARS-CoV-2.
33363251 2021. Computational and network pharmacology analysis of bioflavonoids as possible natural antiviral compounds in COVID-19.
33352565 2021. Spices to Control COVID-19 Symptoms: Yes, but Not Only....
33833556 2021. Preliminary Exploration of Setting the Disease Severity Score in the Nutritional Risk Screening of Patients with Severe Novel Coronavirus Pneumonia by Applying NRS2002.
33864917 2021. Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial.
33848675 2021. A call to caution when hydroxychloroquine is given to elderly patients with COVID-19.
34052406 2021. Determinants of the protective effect of glucocorticoids on mortality in hospitalized patients with COVID-19: Insights from the Cardio-COVID-Italy multicenter study.
34048887 2021. Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: An interventional study.
33930480 2021. Lung Cancer and Heart Disease Risks Associated With Low-Dose Pulmonary Radiotherapy to COVID-19 Patients With Different Background Risks.
33957219 2021. Low dose radiation therapy for severe COVID-19 pneumonia: a randomized double-blind study.
33340603 2021. Immunomodulatory Low-Dose Whole-Lung Radiation for Patients with Coronavirus Disease 2019-Related Pneumonia.
33309910 2021. Clinician Attitudes to Using Low-Dose Radiation Therapy to Treat COVID-19 Lung Disease.
33840973 2021. Sudarshan Kriya Yoga: A Breath of Hope during COVID-19 Pandemic.
33960271 2021. Tuberculosis vaccine BCG: the magical effect of the old vaccine in the fight against the COVID-19 pandemic.
33876268 2021. Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis.
34057560 2021. Time for tocilizumab in COVID-19?
34019122 2021. Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials.
33846824 2021. Camostat mesylate therapy in critically ill patients with COVID-19 pneumonia.
34035806 2021. Severity and Mortality Associated with Steroid Use among Patients with COVID-19: A Systematic Review and Meta-Analysis.
34037928 2021. High-dose steroids for the treatment of severe COVID-19: comment.
33876321 2021. High-dose steroids for the treatment of severe COVID-19: a new therapeutic tool?
33856664 2021. High-dose steroids for the treatment of severe COVID-19.
33837906 2021. A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm.
33355896 2021. Adverse drug reactions in SARS-CoV-2 hospitalised patients: a case-series with a focus on drug-drug interactions.
33328409 2021. Severe Coronavirus Disease 2019 That Recovered from Respiratory Failure by Treatment That Included High-dose Intravenous Immunoglobulin.
33847768 2021. Antikorpertherapie bei Patienten mit COVID-19.
33902268 2021. Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19.
34083855 2021. Hypothetical Protective Effects of Crocin Carotenoid against Coronavirus-Induced Organ Damage: The Possible Role of the NF-kappaB Signaling Pathway.
34083848 2021. A Narrative Review of a Pulmonary Aerosolized Formulation or a Nasal Drop Using Sera Containing Neutralizing Antibodies Collected from COVID-19-Recovered Patients as a Probable Therapy for COVID-19.
33937725 2021. Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice.
33913665 2021. Ultraviolet radiation, vitamin D, and COVID-19.
33860009 2021. Molecular optimization, docking, and dynamic simulation profiling of selective aromatic phytochemical ligands in blocking the SARS-CoV-2 S protein attachment to ACE2 receptor: an in silico approach of targeted drug designing.
34015930 2021. Epigallocatechin Gallate Inhibits the Uridylate-Specific Endoribonuclease Nsp15 and Efficiently Neutralizes the SARS-CoV-2 Strain.
33358557 2021. Commercial immunoglobulin products contain cross-reactive but not neutralizing antibodies against SARS-CoV-2.
33852936 2021. C5aR inhibition of nonimmune cells suppresses inflammation and maintains epithelial integrity in SARS-CoV-2-infected primary human airway epithelia.
34018723 2021. NMR Based SARS-CoV-2 Antibody Screening.
33832492 2021. The use of medicinal plants to prevent COVID-19 in Nepal.
33902620 2021. Contested or complementary healing paradigms? Women's narratives of COVID-19 remedies in Mwanza, Tanzania.
34102269 2021. Active components in Ephedra sinica stapf disrupt the interaction between ACE2 and SARS-CoV-2 RBD: Potent COVID-19 therapeutic agents.
34029640 2021. Positive effects of Lianhuaqingwen granules in COVID-19 patients: A retrospective study of 248 cases.
33831468 2021. In silico analysis of the potential mechanism of a preventive Chinese medicine formula on coronavirus disease 2019.
34057365 2021. Add-on Ayurveda Treatment for Early Stage COVID-19: A Single Center Retrospective Cohort Study From Gujarat, India.
33871567 2021. SARS-CoV-2 spike therapeutic antibodies in the age of variants.
34041139 2021. Hydroxychloroquine: A review of its safety and efficacy in COVID-19.
33838985 2021. Combined intravenous immunoglobulin and baricitinib treatment for severe COVID-19 with rhabdomyolysis: A case report.
34074579 2021. Assessing efficacy of antiviral therapy for COVID-19 patients: A case study on remdesivir with bayesian synthesis design and multistate analysis.
33897833 2021. Promising role of curcumin against viral diseases emphasizing COVID-19 management: A review on the mechanistic insights with reference to host-pathogen interaction and immunomodulation.
34055047 2021. Virgin coconut oil is effective in lowering C-reactive protein levels among suspect and probable cases of COVID-19.
33987794 2021. The Association Between Convalescent Plasma Treatment and Survival of Patients with COVID-19.
33904037 2021. Reply to the Letter to Editor by Lacout and colleagues: Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis.
34052520 2021. Epigallocatechin-3-gallate (EGCG): a potential molecule for the development of therapeutics against emerging SARS-CoV-1, MERS-CoV and SARS-CoV-2 coronaviruses.
33359936 2021. Treatment of a case of COVID-19 by intravenous immunoglobulin.
33307274 2021. Remdesivir for the treatment of coronavirus COVID-19: A meta-analysis of randomised controlled trials.
34055580 2021. Comparative retrospective open-label study of ayurvedic medicines and their combination with allopathic drugs on asymptomatic and mildly-symptomatic COVID-19 patients.
33865974 2021. Oral antiseptics against coronavirus: in-vitro and clinical evidence.
33298617 2021. Repurposed Tocilizumab in Patients with Severe COVID-19.
33837054 2021. IL-6 modulation for COVID-19: the right patients at the right time?
34029628 2021. Secukinumab in severe COVID-19 pneumonia: Does it have a clinical impact?
34052239 2021. Remdesivir treatment and transient bradycardia in patients with coronavirus diseases 2019 (COVID-19).
33992687 2021. Clinical efficacy of nitric oxide nasal spray (NONS) for the treatment of mild COVID-19 infection.
34020215 2021. Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials.
33341481 2021. Impact of repurposed drugs on the symptomatic COVID-19 patients.
34045883 2021. Fat-Soluble Vitamins and the Current Global Pandemic of COVID-19: Evidence-Based Efficacy from Literature Review.
33833542 2021. Anti-Inflammatory and Antiviral Osmotic Polymeric Film to Treat Covid-19 Early-Stage Infection.
33983065 2021. Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial.
33906526 2021. Oxygen saturation improved with nitrate-based nutritional formula in patients with COVID-19.
33349611 2021. Treatment of pulmonary fibrosis in one convalescent patient with corona virus disease 2019 by oral traditional Chinese medicine decoction: A case report.
33847265 2021. COVID-19 and TEN treated with IVIG and Total plasma exchange. Simultaneous systemic treatment for both diseases.
34105382 2021. Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania.
34054244 2021. Reviewing the Ethical Concerns of the Convalescent Plasma Therapy in COVID-19.
34010403 2021. Tocilizumab in the treatment of COVID-19 - a meta-analysis.
33989420 2021. Corticosteroids for treating mild COVID-19: Opening the floodgates of therapeutic misadventure.
33988903 2021. Graphene Oxide Nanosheets Interact and Interfere with SARS-CoV-2 Surface Proteins and Cell Receptors to Inhibit Infectivity.
33874878 2021. Probiotics/ prebiotics in viral respiratory infections: implication for emerging pathogens.
34009761 2021. Inefficacite de l'ivermectine sur les symptomes de Covid-19 leger.
33881236 2021. Covid-19 - vitamine D - traitement de l'osteoporose.
34083449 2021. Fe-S cofactors in the SARS-CoV-2 RNA-dependent RNA polymerase are potential antiviral targets.
34103349 2021. Senolytics reduce coronavirus-related mortality in old mice.
33843825 2021. Intrapleural Steroid Instillation for Critically Ill Patients With Covid-19 Severe Adult Respiratory Distress Syndrome.

34020394 2021. Insights on the mechanisms of action of ozone in the medical therapy against COVID-19.
34020392 2021. Intragastric and atomized administration of canagliflozin inhibit inflammatory cytokine storm in lipopolysaccharide-treated sepsis in mice: A potential COVID-19 treatment.
34015598 2021. Clinical outcomes of patients with mild COVID-19 following treatment with hydroxychloroquine in an outpatient setting.
33984718 2021. A pilot study for treatment of COVID-19 patients in moderate stage using intravenous administration of ozonized saline as an adjuvant treatment-registered clinical trial.
33882442 2021. Immunopharmacological perspective on zinc in SARS-CoV-2 infection.
33310665 2021. Ozone therapy for patients with COVID-19 pneumonia: Preliminary report of a prospective case-control study.
33348292 2021. Interferon-inducer antivirals: Potential candidates to combat COVID-19.
33338863 2021. Convalescent plasma may be a possible treatment for COVID-19: A systematic review.
33930705 2021. The role of vitamin D in reducing SARS-CoV-2 infection: An update.
33838224 2021. Therapeutic plasma exchange in patients with life-threatening COVID-19: a randomised controlled clinical trial.
33370568 2021. Plasma exchange in the treatment of complex COVID-19-related critical illness: controversies and perspectives.
33338559 2021. Early clinical outcomes with tocilizumab for severe COVID-19: a two-centre retrospective study.
33321211 2021. Reply to 'Low-dose hydroxychloroquine therapy and lower mortality in hospitalized patients with COVID-19: association does not mean causality'.
33609720 2021. Reply to "The perceived efficacy of hydroxychloroquine in observational studies: the results of the confounding effects of 'goals of care'".
33609717 2021. Perceived efficacy of hydroxychloroquine in observational studies: Results of the confounding effect of "goals of care".
34048833 2021. Classification, structure and mechanism of antiviral polysaccharides derived from edible and medicinal fungus.
33930442 2021. Chitin and chitosan as tools to combat COVID-19: A triple approach.
33915212 2021. Heparin: A simplistic repurposing to prevent SARS-CoV-2 transmission in light of its in-vitro nanomolar efficacy.
33901557 2021. Identification of Vitamin K3 and its analogues as covalent inhibitors of SARS-CoV-2 3CL(pro).
34051259 2021. Ethyl cellulose coated sustained release aspirin spherules for treating COVID-19: DOE led rapid optimization using arbitrary interface; applicable for emergency situations.
33309661 2021. Ritonavir may inhibit exoribonuclease activity of nsp14 from the SARS-CoV-2 virus and potentiate the activity of chain terminating drugs.
33907519 2021. In silico structure-based discovery of a SARS-CoV-2 main protease inhibitor.
33907517 2021. Hydroxychloroquine/Chloroquine as Therapeutics for COVID-19: Truth under the Mystery.
34000267 2021. Administration of Bamlanivimab to Skilled Nursing Facility Residents During a COVID-19 Outbreak, January-February 2021, Arizona.
33895839 2021. COVID-19 Trial Graph: A Linked Graph for COVID-19 Clinical Trials.
33880524 2021. In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19.
33712855 2021. Usage experience of remdesivir for SARS-CoV-2 infection in a patient with chronic cirrhosis of Child-Pugh class C.
33338232 2021. Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial.
33976504 2021. Potential for supportive Ayurvedic care in hypoxemic COVID-19 patients.
34054248 2021. "Standalone Ayurvedic Intervention with Home Quarantine in COVID-19 - Outcomes of Clinical Practice".
34054247 2021. Immune status determined as per guidelines of Ayurveda found associated with clinical outcomes of COVID-19 disease - Results of a cross-sectional pilot study.
34054246 2021. Evaluation of potency of the selected bioactive molecules from Indian medicinal plants with M(Pro) of SARS-CoV-2 through in silico analysis.
34024691 2021. A case series sharing novel experience of treating viral pandemic cases of morbid, mid aged, mild, moderate & severe grade with only Ayurvedic Medicines.
33654345 2021. In silico evaluation of the compounds of the ayurvedic drug, AYUSH-64, for the action against the SARS-CoV-2 main protease.
33897204 2021. A Randomized open label parallel group pilot study to evaluate efficacy of Ayurveda interventions in the management of Asymptomatic and Mild COVID-19 patients-Experiences of a Lucknow based Level 2 hospital of Uttar Pradesh, India.
34082895 2021. Significance of AYUSH: India's first line of defence against COVID-19.
33989635 2021. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template.
33895135 2021. Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells.
33891947 2021. Repression of transcription by the glucocorticoid receptor: A parsimonious model for the genomics era.
34052441 2021. Machine learning enabled identification of potential SARS-CoV-2 3CLpro inhibitors based on fixed molecular fingerprints and Graph-CNN neural representations.
33856612 2021. A COVID moonshot: assessment of ligand binding to the SARS-CoV-2 main protease by saturation transfer difference NMR spectroscopy.
33950784 2021. Mechanistic insights into the inhibitory activity of FDA approved ivermectin against SARS-CoV-2: old drug with new implications.
33949286 2021. Quantum biochemistry, molecular docking, and dynamics simulation revealed synthetic peptides induced conformational changes affecting the topology of the catalytic site of SARS-CoV-2 main protease.
33949279 2021. Antivirals virtual screening to SARS-CoV-2 non-structural proteins.
33939590 2021. In silico identification and validation of triarylchromones as potential inhibitor against main protease of severe acute respiratory syndrome coronavirus 2.
34033727 2021. How to face COVID-19: proposed treatments based on remdesivir and hydroxychloroquine in the presence of zinc sulfate. Docking/DFT/POM structural analysis.
34032180 2021. Virtual screening of quinoline derived library for SARS-COV-2 targeting viral entry and replication.
34018907 2021. Proposition of a new allosteric binding site for potential SARS-CoV-2 3CL protease inhibitors by utilizing molecular dynamics simulations and ensemble docking.
34014150 2021. Marine algal antagonists targeting 3CL protease and spike glycoprotein of SARS-CoV-2: a computational approach for anti-COVID-19 drug discovery.
33998954 2021. A large-scale computational screen identifies strong potential inhibitors for disrupting SARS-CoV-2 S-protein and human ACE2 interaction.
33988079 2021. Repurposing of the herbal formulations: molecular docking and molecular dynamics simulation studies to validate the efficacy of phytocompounds against SARS-CoV-2 proteins.
33988066 2021. Target SARS-CoV-2: theoretical exploration on clinical suitability of certain drugs.
33998950 2021. Computational basis of SARS-CoV 2 main protease inhibition: an insight from molecular dynamics simulation based findings.
33970798 2021. A higher flexibility at the SARS-CoV-2 main protease active site compared to SARS-CoV and its potentialities for new inhibitor virtual screening targeting multi-conformers.
34062110 2021. Chemical system biology approach to identify multi-targeting FDA inhibitors for treating COVID-19 and associated health complications.
34060418 2021. Molecular modeling of potent novel sulfonamide derivatives as non-peptide small molecule anti-COVID 19 agents.
33826483 2021. Identification of doxorubicin as a potential therapeutic against SARS-CoV-2 (COVID-19) protease: a molecular docking and dynamics simulation studies.
33896392 2021. Combined use of the hepatitis C drugs and amentoflavone could interfere with binding of the spike glycoprotein of SARS-CoV-2 to ACE2: the results of a molecular simulation study.
33879035 2021. The in silico mechanism of hVKOR interaction with acetaminophen and its metabolite, as well as N-acetyl cysteine: caution on application in COVID-19 patients.
33847241 2021. Inhibition of SARS-CoV-2 main protease: a repurposing study that targets the dimer interface of the protein.
33843474 2021. Elucidation of the inhibitory activity of ivermectin with host nuclear importin alpha and several SARS-CoV-2 targets.
34068104 2021. Effect of Hydroxychloroquine on QTc in Patients Diagnosed with COVID-19: A Systematic Review and Meta-Analysis.
34028178 2021. Targeting the glycans: A paradigm for host-targeted and COVID-19 drug design.
33336936 2021. Mortality and pre-hospitalization use of low-dose aspirin in COVID-19 patients with coronary artery disease.
33829781 2021. Benchmark of Popular Free Energy Approaches Revealing the Inhibitors Binding to SARS-CoV-2 Mpro.
34047191 2021. Benchmarking the Ability of Common Docking Programs to Correctly Reproduce and Score Binding Modes in SARS-CoV-2 Protease Mpro.
34052564 2021. Development and validation of a sensitive, fast and simple LC-MS / MS method for the quantitation of favipiravir in human serum.
33310480 2021. Cell membrane chromatography for the analysis of the interaction between chloroquine and hydroxychloroquine with ACE2 receptors.
34101091 2021. Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-beta.
34009544 2021. Neutralizing Autoantibodies to Type I Interferons in COVID-19 Convalescent Donor Plasma.
33844653 2021. Structure-based phylogeny identifies avoralstat as a TMPRSS2 inhibitor that prevents SARS-CoV-2 infection in mice.
33974559 2021. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19.
33306484 2021. BCG vaccination in health care providers and the protection against COVID-19.
33320842 2021. Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates.
33994121 2021. Statins in COVID-19 infection: A rehash of old themes or truly a new hope?
34071293 2021. Vitamin D Levels in COVID-19 Outpatients from Western Mexico: Clinical Correlation and Effect of Its Supplementation.
34070628 2021. Role of Iron Chelation and Protease Inhibition of Natural Products on COVID-19 Infection.
34069355 2021. Targeting the Complement Cascade in the Pathophysiology of COVID-19 Disease.
34068847 2021. Convalescent Plasma Efficacy in Life-Threatening COVID-19 Patients Admitted to the ICU: A Retrospective Cohort Study.
33918563 2021. Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6.
33917093 2021. Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19.
33916281 2021. Statin Use Is Associated with a Decreased Risk of Mortality among Patients with COVID-19.
33915784 2021. Adjunctive Use of Statins for COVID-19.
33992179 2021. Drug repurposing of selective serotonin reuptake inhibitors: Could these drugs help fight COVID-19 and save lives?
34007812 2021. Favipiravir-induced Liver Injury in Patients with Coronavirus Disease 2019.
34007810 2021. Rapid Recovery in COVID-19 Patients with Chronic Hepatitis B Virus Infection Treated with Tenofovir Disoproxil Fumarate.
34027204 2021. Interleukin-13 as a target to alleviate severe coronavirus disease 2019 and restore lung homeostasis.
33889318 2021. Experimental therapies under investigation for COVID-19.
33887951 2021. Testing the efficacy of tocilizumab in patients with COVID-19 pneumonia.
33622611 2021. Cheap and simple, could it get even cooler? Mild hypothermia and COVID-19.
33583631 2021. Successful use of mild therapeutic hypothermia as compassionate treatment for severe refractory hypoxemia in COVID-19.
33884425 2021. The impact of vedolizumab on COVID-19 outcomes among adult IBD patients in the SECURE-IBD registry.
33331120 2021. Is metformin a miracle or a menace in COVID-19 patients with type 2 diabetes?
33816359 2021. Vitamin D and COVID-19: is there a role?
33816358 2021. Dipeptidyl peptidase 4 (DPP4) inhibitor and outcome from coronavirus disease 2019 (COVID-19) in diabetic patients: a systematic review, meta-analysis, and meta-regression.
33649708 2021. The pulmonary route as a way to drug repositioning in COVID-19 therapy.
33617141 2021. Hydroxychloroquine-induced acute generalized exanthematous pustulosis: an adverse reaction to keep in mind during COVID-19 pandemic.
33688540 2021. Review of investigational drugs for coronavirus disease 2019.
34075313 2021. Innovative electrochemical sensor for the precise determination of the new antiviral COVID-19 treatment Favipiravir in the presence of coadministered drugs.
33353811 2021. Utility of Hypertonic Saline and Diazepam in COVID-19-Related Hydroxychloroquine Toxicity.
33840080 2021. Vitamin D and Vitamin D binding protein: the inseparable duo in COVID-19.
34053008 2021. Risks of potential drug-drug interactions in COVID-19 patients treated with corticosteroids: a single-center experience.
33980119 2021. Flavonoids as inhibitors of human neutrophil elastase.
34044222 2021. A literature review on beneficial role of vitamins and trace elements: Evidence from published clinical studies.
34026584 2021. Calendulaglycoside A Showing Potential Activity Against SARS-CoV-2 Main Protease: Molecular Docking, Molecular Dynamics, and SAR Studies.
34099976 2021. In-silico evaluation of bioactive compounds from tea as potential SARS-CoV-2 nonstructural protein 16 inhibitors.
33868970 2021. Virtual screening by targeting proteolytic sites of furin and TMPRSS2 to propose potential compounds obstructing the entry of SARS-CoV-2 virus into human host cells.
33778462 2021. Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab.
33971907 2021. Therapeutic mechanisms of mesenchymal stem cells in acute respiratory distress syndrome reveal potentials for Covid-19 treatment.
33781275 2021. The effect of omega-3 fatty acid supplementation on clinical and biochemical parameters of critically ill patients with COVID-19: a randomized clinical trial.
33902635 2021. Vitamin D status of Arab Gulf residents screened for SARS-CoV-2 and its association with COVID-19 infection: a multi-centre case-control study.
33888147 2021. MSC-derived exosomes carrying a cocktail of exogenous interfering RNAs an unprecedented therapy in era of COVID-19 outbreak.

34026595 2021. Virucidal effect of povidone iodine on COVID-19 in the nasopharynx: an open-label randomized clinical trial.
34099209 2021. Is the tuberculosis vaccine BCG an alternative weapon for developing countries to defeat COVID-19?
33985598 2021. Surveillance of adverse drug events associated with tocilizumab in hospitalized veterans with coronavirus disease 2019 (COVID-19) to inform patient safety and pandemic preparedness.
33974479 2021. Remdesivir for coronavirus disease 2019 (COVID-19): a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials.
34024240 2021. A short course of corticosteroids reduces the risk of mechanical ventilation and death in patients with moderate to severe COVID 19 pneumonia: results of a retrospective monocentric cohort.
34001244 2021. Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis.
33874998 2021. Effectiveness of potential antiviral treatments in COVID-19 transmission control: a modelling study.
34067822 2021. Remdesivir Treatment for COVID 19 in Pregnant Patients with Moderate to Severe Symptoms: Serial Case Report.
33928532 2021. A Response to: Letter to the Editor Regarding Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort.
33914266 2021. Letter to the Editor Regarding Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study.
33826106 2021. Pharmacokinetic and Pharmacodynamic Evaluation of Ravulizumab in Adults with Severe Coronavirus Disease 2019.
34040397 2021. Network Analysis of Herbs Recommended for the Treatment of COVID-19.
33880043 2021. The Role for Tocilizumab in COVID-19 Patients: Reflections on Monza Cohort Data.
34089909 2021. Designing an effective therapeutic siRNA to silence RdRp gene of SARS-CoV-2.
34052418 2021. Pathomechanisms, therapeutic targets and potent inhibitors of some beta-coronaviruses from bench-to-bedside.
33907516 2021. Glucocorticoids are double-edged sword in the treatment of COVID-19 and cancers.
33907515 2021. Developing effective siRNAs to reduce the expression of key viral genes of COVID-19.
33907512 2021. Development and application of therapeutic antibodies against COVID-19.
33332726 2021. Dexamethasone vs COVID-19: An experimental study in line with the preliminary findings of a large trial.
33300221 2021. Repurposing of some anti-infective drugs for COVID-19 treatment: A surveillance study supported by an in silico investigation.
34064793 2021. Does Trypsin Oral Spray (Viruprotect((R))/ColdZyme((R))) Protect against COVID-19 and Common Colds or Induce Mutation? Caveats in Medical Device Regulations in the European Union.
33801759 2021. Vitamin D Levels Are Reduced at the Time of Hospital Admission in Sicilian SARS-CoV-2-Positive Patients.
33924038 2021. Impact of COVID-19 Lockdown on Sun Exposure of UK Office Workers.
33919644 2021. COVID-19 Severity and Neonatal BCG Vaccination among Young Population in Taiwan.
33359949 2021. No clinical benefit in mortality associated with hydroxychloroquine treatment in patients with COVID-19.
33940189 2021. Does vitamin D serum level affect prognosis of COVID-19 patients?
33901652 2021. COVID-19 chemoprevention.
33892191 2021. Serum Calcium and Vitamin D levels: Correlation with severity of COVID-19 in hospitalized patients in Royal Hospital, Oman.
34087484 2021. Hydroxychloroquine as a primary prophylactic agent against SARS-CoV-2 infection: A cohort study.
33878462 2021. Effect of Ammonium Chloride in addition to standard of care in outpatients and hospitalized COVID-19 patients: A randomized clinical trial.
33333254 2021. Thalidomide combined with short-term low-dose glucocorticoid therapy for the treatment of severe COVID-19: A case-series study.
33333252 2021. Tocilizumab in the treatment of critical COVID-19 pneumonia: A retrospective cohort study of mechanically ventilated patients.
33333250 2021. A high-throughput drug screening strategy against coronaviruses.
33316389 2021. An umbrella review of systematic reviews with meta-analyses evaluating positive and negative outcomes of Hydroxychloroquine and chloroquine therapy.
33310109 2021. Response to "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients".
33310107 2021. Response to correspondence concerning: "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients".
33310106 2021. More gastro-intestinal adverse events in non-ICU hospitalised COVID-19 patients treated with chloroquine versus hydroxychloroquine.
34066560 2021. Probiotics, Photobiomodulation, and Disease Management: Controversies and Challenges.
34073529 2021. Could Histamine H1 Receptor Antagonists Be Used for Treating COVID-19?
34067243 2021. Possible Beneficial Actions of Caffeine in SARS-CoV-2.
34063964 2021. Existing Drugs Considered as Promising in COVID-19 Therapy.
34065735 2021. Immunological Aspects of SARS-CoV-2 Infection and the Putative Beneficial Role of Vitamin-D.
33917321 2021. Corticosteroids for COVID-19 Therapy: Potential Implications on Tuberculosis.
33920709 2021. COVID-19: Direct and Indirect Mechanisms of Statins.
33920748 2021. Pharmacological Modulators of Autophagy as a Potential Strategy for the Treatment of COVID-19.
33921228 2021. SARS-CoV-2 Papain-Like Protease Potential Inhibitors-In Silico Quantitative Assessment.
33867899 2021. In Silico Identification of Multi-target Anti-SARS-CoV-2 Peptides from Quinoa Seed Proteins.
33850482 2021. Identification of Potential Peptide Inhibitors of ACE-2 Target of SARS-CoV-2 from Buckwheat & Quinoa.
33880115 2021. Potential Antioxidative, Anti-inflammatory and Immunomodulatory Effects of Ghrelin, an Endogenous Peptide from the Stomach in SARS-CoV2 Infection.
33373651 2021. Sofosbuvir/daclatasvir in the treatment of COVID-19 infection: A meta-analysis.
33902990 2021. Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients.
33814353 2021. Two cases of novel coronavirus infection (COVID-19) with transient viral elevation using semi-quantitative real-time reverse transcription PCR and symptom relapse after completion of 10 days of favipiravir treatment.
33956648 2021. Nutritional status is closely related to the severity of COVID-19: a multi-center retrospective study.
33367731 2021. Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potential Therapeutic.
33885811 2021. Excessive Matrix Metalloproteinase-1 and Hyperactivation of Endothelial Cells Occurred in COVID-19 Patients and Were Associated With the Severity of COVID-19.
33961695 2021. beta-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells.
33866129 2021. Aminoglycosides as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study on FDA-approved antiviral and anti-infection agents.
33857725 2021. Recent knowledge in favor of remdesivir (GS-5734) as a therapeutic option for the COVID-19 infections.
33848890 2021. Essential oils as an effective alternative for the treatment of COVID-19: Molecular interaction analysis of protease (M(pro)) with pharmacokinetics and toxicological properties.
33984091 2021. A Novel Report on the Compassionate Use of Baricitinib in Treating a Pediatric Patient With Severe Symptoms of COVID-19 Infection.
33877845 2021. Betulonic Acid Derivatives Interfering with Human Coronavirus 229E Replication via the nsp15 Endoribonuclease.
34081439 2021. Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy.
33929200 2021. Supercoiling Structure-Based Design of a Trimeric Coiled-Coil Peptide with High Potency against HIV-1 and Human beta-Coronavirus Infection.
33872498 2021. Design, Synthesis, and Biological Evaluation of Peptidomimetic Aldehydes as Broad-Spectrum Inhibitors against Enterovirus and SARS-CoV-2.
34026588 2021. Molecular Docking Analysis of Anti-Severe Acute Respiratory Syndrome-Coronavirus 2 Ligands against Spike Glycoprotein and the 3-Chymotrypsin-Like Protease.
34090821 2021. Good response of low-dose steroid in a patient with COVID-19 pneumonia and autoimmune disease.
33373642 2021. Adverse effects of hydroxychloroquine and azithromycin on contractility and arrhythmogenicity revealed by human engineered cardiac tissues.
33333424 2021. Effect of nelfinavir stereoisomers on coronavirus main protease: Molecular docking, molecular dynamics simulation and MM/GBSA study.
33798836 2021. Rutin and flavone analogs as prospective SARS-CoV-2 main protease inhibitors: In silico drug discovery study.
33933885 2021. Modelling studies reveal the importance of the C-terminal inter motif loop of NSP1 as a promising target site for drug discovery and screening of potential phytochemicals to combat SARS-CoV-2.
33892297 2021. In silico approach for identifying natural lead molecules against SARS-COV-2.
33994607 2021. Inhibition of SARS-CoV-2 reproduction using Boswellia carterii: A theoretical study.
33746318 2021. Structural investigations, quantum mechanical studies on proton and metal affinity and biological activity predictions of selpercatinib.
33846661 2021. Construction, petro-collecting/dispersing capacities, antimicrobial activity, and molecular docking study of new cationic surfactant-sulfonamide conjugates.
34031621 2021. Molecular basis of the new COVID-19 target neuropilin-1 in complex with SARS-CoV-2 S1 C-end rule peptide and small-molecule antagonists.
33903781 2021. Charge-transfer chemistry of azithromycin, the antibiotic used worldwide to treat the coronavirus disease (COVID-19). Part III: A green protocol for facile synthesis of complexes with TCNQ, DDQ, and TFQ acceptors.
33879934 2021. Structurally modified compounds of hydroxychloroquine, remdesivir and tetrahydrocannabinol against main protease of SARS-CoV-2, a possible hope for COVID-19: Docking and molecular dynamics simulation studies.
33963942 2021. Analysis of natural compounds against the activity of SARS-CoV-2 NSP15 protein towards an effective treatment against COVID-19: a theoretical and computational biology approach.
34057647 2021. Plausible blockers of Spike RBD in SARS-CoV2-molecular design and underlying interaction dynamics from high-level structural descriptors.
33864532 2021. Multi-conformation representation of Mpro identifies promising candidates for drug repurposing against COVID-19.
33903779 2021. Synthesis, X-ray crystal structure, IR and Raman spectroscopic analysis, quantum chemical computational and molecular docking studies on hydrazone-pyridine compound: As an insight into the inhibitor capacity of main protease of SARS-CoV2.
33903778 2021. In search of RdRp and Mpro inhibitors against SARS CoV-2: Molecular docking, molecular dynamic simulations and ADMET analysis.
33903777 2021. New alpha-Hydrazinophosphonic acid: Synthesis, characterization, DFT study and in silico prediction of its potential inhibition of SARS-CoV-2 main protease.
33967344 2021. Screening of cryptogamic secondary metabolites as putative inhibitors of SARS-CoV-2 main protease and ribosomal binding domain of spike glycoprotein by molecular docking and molecular dynamics approaches.
33967343 2021. In silico detection of inhibitor potential of Passiflora compounds against SARS-Cov-2(Covid-19) main protease by using molecular docking and dynamic analyses.
34007088 2021. Design and synthesis of pyrazolone-based compounds as potent blockers of SARS-CoV-2 viral entry into the host cells.
34054142 2021. DFT, molecular docking and molecular dynamics simulation studies on some newly introduced natural products for their potential use against SARS-CoV-2.
34031619 2021. Chemical reactivities and molecular docking studies of parthenolide with the main protease of HEP-G2 and SARS-CoV-2.
33846658 2021. Synthesis, antimicrobial activity, density functional modelling and molecular docking with COVID-19 main protease studies of benzoxazole derivative: 2-(p-chloro-benzyl)-5-[3-(4-ethly-1-piperazynl) propionamido]-benzoxazole.
33840836 2021. The identification of novel inhibitors of human angiotensin-converting enzyme 2 and main protease of Sars-Cov-2: A combination of in silico methods for treatment of COVID-19.
33840835 2021. Rational design of flavonoid based potential inhibitors targeting SARS-CoV 3CL protease for the treatment of COVID-19.
33867575 2021. Molecular insights of hyaluronic acid-hydroxychloroquine conjugate as a promising drug in targeting SARS-CoV-2 viral proteins.
33928494 2021. Screening for inhibitory effects of crude drugs on furin-like enzymatic activities.
33352046 2021. Natural Products with Potential to Treat RNA Virus Pathogens Including SARS-CoV-2.
33844528 2021. Anti-SARS-CoV-2 Activity of Andrographis paniculata Extract and Its Major Component Andrographolide in Human Lung Epithelial Cells and Cytotoxicity Evaluation in Major Organ Cell Representatives.
33884222 2021. Chemo-Preventive Effect of Vegetables and Fruits Consumption on the COVID-19 Pandemic.
33949642 2021. Letter to the Editor: Challenges Providing Nutrition Care during the COVID-19 Pandemic: Canadian Dietitian Perspectives.
33367467 2021. A Correlation Analysis between the Nutritional Status and Prognosis of COVID-19 Patients.
33306130 2021. Severe Acute Respiratory Syndrome Coronavirus-2 Pneumonia in a Newborn Treated With Remdesivir and Coronavirus Disease 2019 Convalescent Plasma.
33842018 2021. Reducing SARS-CoV-2 pathological protein activity with small molecules.
34084043 2021. Hydroxychloroquine and Chloroquine in Prophylaxis and Treatment of COVID-19: What Is Known?
33831737 2021. A novel LC-MS/MS method for determination of the potential antiviral candidate favipiravir for the emergency treatment of SARS-CoV-2 virus in human plasma: Application to a bioequivalence study in Egyptian human volunteers.
34048671 2021. Lopinavir/Ritonavir for COVID-19: a Systematic Review and Meta-Analysis.
34048669 2021. Safety and Efficacy of Remdesivir for the Treatment of COVID-19: A Systematic Review and Meta-Analysis.
34048668 2021. Role of OATP4C1 in Renal Handling of Remdesivir and its Nucleoside Analog GS-441524: The First Approved Drug for Patients with COVID-19.
33939951 2021. Clinical Outcomes of COVID-19 Patients Treated with Convalescent Plasma or Remdesivir Alone and in Combination at a Community Hospital in California's Central Valley.
33912505 2020. Evaluation of the Prescribed Drugs to Elderly in a Tertiary Healthcare Center for Possible Drug Interactions with Investigational Drugs for COVID-19 Treatment.
34091026 2021. The relationship between 25(OH) vitamin D levels and COVID-19 onset and disease course in Spanish patients.
33864925 2021. Learning from previous methodological pitfalls to propose well-designed trials on vitamin D in COVID-19.
34059065 2021. Exosomes contribution in COVID-19 patients' treatment.
33853637 2021. Dodging COVID-19 infection: low expression and localization of ACE2 and TMPRSS2 in multiple donor-derived lines of human umbilical cord-derived mesenchymal stem cells.
33968608 2021. The face mask-touching behavior during the COVID-19 pandemic: Observational study of public transportation users in the greater Paris region: The French-mask-touch study.

34033406 2021. Tocilizumab
34033367 2021. Coronavirus (COVID-19) Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT)
34033365 2021. Monoclonal Antibody Therapy For High-Risk Coronavirus (COVID 19) Patients With Mild To Moderate Disease Presentations
34097371 2021. Coronavirus Disease 2019 (COVID-19) Emergency Use Authorizations (EUAs)
34009769 2020. Science Brief: COVID-19 Vaccines and Vaccination
34014630 2012. Covid-19 Drugs
34014629 2012. Covid-19 Vaccines
34014628 2012. Covid-19 Monoclonal Antibodies: Monoclonal Antibodies to SARS-CoV-2
31643344 2012. Baricitinib
33835300 2021. Next-Generation COVID-19 Vaccines Should Take Efficiency of Distribution into Consideration.
33985872 2021. Lymphadenopathy Following COVID-19 Vaccination: Imaging Findings Review.
33930273 2021. Glycyrrhizic Acid Nanoparticles as Antiviral and Anti-inflammatory Agents for COVID-19 Treatment.
33378177 2021. Cracking the Chloroquine Conundrum: The Application of Defective UiO-66 Metal-Organic Framework Materials to Prevent the Onset of Heart Defects-In Vivo and In Vitro.
34075346 2021. Simeprevir Potently Suppresses SARS-CoV-2 Replication and Synergizes with Remdesivir.
34075345 2021. Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines.
34075344 2021. Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines.
34056095 2021. Synthetic Siglec-9 Agonists Inhibit Neutrophil Activation Associated with COVID-19.
34056089 2021. Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine.
34056083 2021. A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development.
33979123 2021. Small-Molecule Inhibitors of the Coronavirus Spike: ACE2 Protein-Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2.
33849267 2021. Human Cathelicidin Inhibits SARS-CoV-2 Infection: Killing Two Birds with One Stone.
33876632 2021. Antibody Affinity Governs the Inhibition of SARS-CoV-2 Spike/ACE2 Binding in Patient Serum.
33854700 2021. Intriguing Antiviral Modified Nucleosides: A Retrospective View into the Future Treatment of COVID-19.
33850605 2021. Structural Insights into Plasticity and Discovery of Remdesivir Metabolite GS-441524 Binding in SARS-CoV-2 Macrodomain.
33373194 2021. Uncovering Flexible Active Site Conformations of SARS-CoV-2 3CL Proteases through Protease Pharmacophore Clusters and COVID-19 Drug Repurposing.
34056406 2021. Artificial Intelligence-Guided De Novo Molecular Design Targeting COVID-19.
34056192 2021. Progress Toward a Large-Scale Synthesis of Molnupiravir (MK-4482, EIDD-2801) from Cytidine.
33855277 2021. Synergistic Inhibition of SARS-CoV-2 Replication Using Disulfiram/Ebselen and Remdesivir.
33855276 2021. Tissue-Specific Proteomics Analysis of Anti-COVID-19 Nucleoside and Nucleotide Prodrug-Activating Enzymes Provides Insights into the Optimization of Prodrug Design and Pharmacotherapy Strategy.
33855275 2021. Repurposing Quinoline and Artemisinin Antimalarials as Therapeutics for SARS-CoV-2: Rationale and Implications.
34018145 2021. Acute disseminated encephalomyelitis-like presentation after an inactivated coronavirus vaccine.
34002386 2021. Neurological side effects of COVID-19 vaccines are rare.
34002379 2021. SARS-CoV-2 vaccines are not free of neurological side effects.
34002130 2021. SARS-CoV-2 cell entry and targeted antiviral development.
33850275 2021. The challenges and opportunities of traditional Chinese medicines against COVID-19: a way out from a network perspective.
33931765 2021. Pharmacokinetics-based identification of pseudoaldosterogenic compounds originating from Glycyrrhiza uralensis roots (Gancao) after dosing LianhuaQingwen capsule.
33907306 2021. A multi-targeting drug design strategy for identifying potent anti-SARS-CoV-2 inhibitors.
33350096 2021. SARS-CoV-2 effects on the renin-angiotensin-aldosterone system, therapeutic implications.
34012162 2021. Familiar dermatologic drugs as therapies for COVID-19.
33880039 2021. Chemoinformatic Analysis of Psychotropic and Antihistaminic Drugs in the Light of Experimental Anti-SARS-CoV-2 Activities.
33359141 2021. COVID-19 vaccines: The status and perspectives in delivery points of view.
33340620 2021. Non-viral COVID-19 vaccine delivery systems.
33316346 2021. Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection.
33309815 2021. Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy.
34060150 2021. Formulation of a Composite Nasal Spray Enabling Enhanced Surface Coverage and Prophylaxis of SARS-COV-2.
34022675 2021. Role of the early short-course corticosteroids treatment in ARDS caused by COVID-19: A single-center, retrospective analysis.
33966265 2021. Antifibrotics for COVID-19 related lung fibrosis: Agents with benefits?
33966262 2021. The relationship between the severity and mortality of SARS-CoV-2 infection and 25-hydroxyvitamin D concentration - a metaanalysis.
33966260 2021. A clinical profile and factors associated with severity of the disease among Polish patients hospitalized due to COVID-19 - an observational study.
33881163 2021. Pulmonary thromboembolism post-COVID convalescent plasma therapy: adding fuel to a smoldering fire!
33871042 2021. Timing of Anti-viral therapy in COVID-19: Key to success.
33850691 2021. Nitric Oxide to Fight Viral Infections.
34075554 2021. Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era.
34028041 2021. Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: Don't give up on the second dose!
33948956 2021. BNT162b2 mRNA COVID-19 vaccine induces antibodies of broader cross-reactivity than natural infection, but recognition of mutant viruses is up to 10-fold reduced.
33837568 2021. Silencing of SARS-CoV-2 with modified siRNA-peptide dendrimer formulation.
33993490 2021. Caspases and therapeutic potential of caspase inhibitors in moderate-severe SARS CoV2 infection and long COVID.
34020451 2021. Influence of vitamin D status on hospital length of stay and prognosis in hospitalized patients with moderate to severe COVID-19: a multicenter prospective cohort study.
34057236 2021. SARS-CoV-2 vaccination induces breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria on complement inhibitor.
33837984 2021. Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine.
34057243 2021. Covid-19 vaccination in patients with multiple myeloma: Focus on immune response.
33939851 2021. Hemolytic crisis due to Covid-19 vaccination in a woman with cold agglutinin disease.
33738273 2020. Anti-Infective, Anti-Inflammatory, and Immunomodulatory Properties of Breast Milk Factors for the Protection of Infants in the Pandemic From COVID-19.
34095323 2021. Potent phytochemicals against COVID-19 infection from phyto-materials used as antivirals in complementary medicines: a review.
34099962 2021. Druggability of cavity pockets within SARS-CoV-2 spike glycoprotein and pharmacophore-based drug discovery.
34055031 2021. Tocilizumab in the treatment of coronavirus disease 2019 pneumonia: real-world data from a case series.
33891952 2021. Reply.
33340538 2021. Potential Biases in Studies of Acid-Suppressing Drugs and COVID-19 Infection.
34045093 2021. Due to their anti-inflammatory, antioxidant and neurotrophic properties, second-generation antipsychotics are suitable in patients with schizophrenia and COVID-19.
33346100 2021. Recognition of plausible therapeutic agents to combat COVID-19: An omics data based combined approach.
33887367 2021. Inferring molecular mechanisms of dexamethasone therapy in severe COVID-19 from existing transcriptomic data.
34073716 2021. Genome-Scale Metabolic Model of Infection with SARS-CoV-2 Mutants Confirms Guanylate Kinase as Robust Potential Antiviral Target.
33321203 2021. A computational approach to design potential siRNA molecules as a prospective tool for silencing nucleocapsid phosphoprotein and surface glycoprotein gene of SARS-CoV-2.
33937567 2021. Investigator initiated clinical trial of remdesivir for the treatment of COVID-19 in Japan.
33987628 2021. Inclusion of Cephalexin in COVID-19 Treatment Combinations May Prevent Lung Involvement in Mild Infections: A Case Report with Pharmacological Genomics Perspective.
34104701 2021. Potential Role of Vitamins and Zinc on Acute Respiratory Infections Including Covid-19.
34026493 2021. Remdesivir-induced symptomatic bradycardia in the treatment of COVID-19 disease.
34007917 2021. Saffron: A potential drug-supplement for severe acute respiratory syndrome coronavirus (COVID) management.
33824915 2021. Design and identification of novel annomontine analogues against SARS-CoV-2: An in-silico approach.
33903854 2021. Convalescent plasma therapy - a silver lining for COVID-19 management?
33905094 2021. Role of Statins in Coronavirus-Related Disease (COVID-19): A Retrospective Cohort Study in Northern Italy.
33974497 2021. Perspectives on the use and risk of adverse events associated with cytokine-storm targeting antibodies and challenges associated with development of novel monoclonal antibodies for the treatment of COVID-19 clinical cases.
33913801 2021. Impact of influenza vaccination on the risk of SARS-CoV-2 infection in a middle-aged group of people.
33836142 2021. Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant.
33834387 2021. MyD88 and beyond: a perspective on MyD88-targeted therapeutic approach for modulation of host immunity.
34018464 2021. Anti-IgE monoclonal antibodies as potential treatment in COVID-19.
34015982 2021. Tranilast: a potential anti-Inflammatory and NLRP3 inflammasome inhibitor drug for COVID-19.
34057871 2021. Promising drug repurposing approach targeted for cytokine storm implicated in SARS-CoV-2 complications.
33906375 2021. Cytokine storm modulation in COVID-19: a proposed role for vitamin D and DPP-4 inhibitor combination therapy (VIDPP-4i).
33842191 2021. Computational screening of FDA approved drugs of fungal origin that may interfere with SARS-CoV-2 spike protein activation, viral RNA replication, and post-translational modification: a multiple target approach.
33842190 2021. In search of drugs to alleviate suppression of the host's innate immune responses against SARS-CoV-2 using a molecular modeling approach.
34045820 2021. Second-degree Heart Block Caused by Itolizumab-induced Infusion Reaction in COVID-19.
34045817 2021. Off-label Use of Itolizumab in Patients with COVID-19 ARDS: Our Clinical Experience in a Dedicated COVID Center.
34045812 2021. Evidence for Chloroquine/Hydroxychloroquine in the Treatment of COVID-19.
33846691 2021. Povidone Iodine (PVP-I) Oro-Nasal Spray: An Effective Shield for COVID-19 Protection for Health Care Worker (HCW), for all.
33973204 2021. Challenges of Cellular Therapy During the COVID-19 Pandemic.
33973199 2021. The COVID-19 Vaccine Landscape.
33973198 2021. Photobiomodulation and Antiviral Photodynamic Therapy in COVID-19 Management.
33973197 2021. Dietary Supplements for COVID-19.
33973196 2021. Nutrition and Immunity in COVID-19.
33973194 2021. Immune-Based Therapy for COVID-19.
33861442 2021. Possible Mechanisms and Special Clinical Considerations of Curcumin Supplementation in Patients with COVID-19.
33993131 2021. Safety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV.
34009000 2021. Frequency and Characteristics of Nodal and Deltoid FDG and 11C-Choline Uptake on PET Imaging Performed After COVID-19 Vaccination.
33980347 2021. Is nutraceutical supplementation appropriate for COVID-19 management?
33357261 2021. The war on infectious diseases: COVID-19 vaccines and the public: Challenges and solutions.
33373323 2021. Time to Enhance Immunity via Functional Foods and Supplements: Hope for SARS-CoV-2 Outbreak.
33891569 2021. Neem (Azadirachta Indica A. Juss) Capsules for Prophylaxis of COVID-19 Infection: A Pilot, Double-Blind, Randomized Controlled Trial.
34060795 2021. Case Report: Thrombotic Thrombocytopenia after COVID-19 Janssen Vaccination.
33853498 2021. Potential Role of Gut Microbiota in Traditional Chinese Medicine against COVID-19.
34047304 2021. Adverse Events After SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease.
33982938 2021. Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients.

34038639 2021. Quinoline and Quinazoline Derivatives Inhibit Viral RNA Synthesis by SARS-CoV-2 RdRp.
33988136 2021. Implications of Interleukin-6 (IL-6)-blockade for severe COVID-19 infection in patients with Multiple Myeloma.
33898162 2021. Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and OGAI.
33962863 2021. Allergy to COVID-19 vaccines: A current update.
33842829 2021. COVID-19 vaccination of patients with allergies and type-2 inflammation with concurrent antibody therapy (biologicals) - A Position Paper of the German Society of Allergology and Clinical Immunology (DGAKI) and the German Society for Applied Allergology (AeDA).
33316045 2021. Chloroquine- and Hydroxychloroquine-Induced Cardiomyopathy: A Case Report and Brief Literature Review.
33994051 2021. COVID-19 vaccine adverse reactions bring patients to emergency departments.
33980419 2021. Thrombotic Thrombocytopenic Purpura after Ad26.COV2-S Vaccination.
34062319 2021. Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines.
34059386 2021. Extending the clinical spectrum of thrombotic thrombocytopenic syndrome attributable to adenovirus-based vaccines for Covid-19.
33348222 2021. Safety and efficacy of hydroxychloroquine in 152 outpatients with confirmed COVID-19: A pilot observational study.
33896653 2021. Thymosin a1 use is not associated with reduced COVID-19 mortality.
33847737 2021. Safety of Tenofovir Disoproxil Fumarate (TDF) for Pregnant Women facing the COVID-19 Pandemic.
33950198 2021. Peripheral infiltration of remdesivir in 3 patients with COVID-19: Case series and discussion.
33955454 2021. Pharmacy leadership, expertise imperative for successful COVID-19 vaccine rollout.
34023417 2021. Relapse of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine.
33839200 2021. Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine.
34019949 2021. Clinically Significant COVID-19 Following SARS-CoV-2 Vaccination in Kidney Transplant Recipients.
33992727 2021. An Additional Case of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine.
34059207 2021. Virucidal mouth rinses for patients during the coronavirus disease 2019 outbreak.
33894177 2021. Targeting Runt-Related Transcription Factor 1 Prevents Pulmonary Fibrosis and Reduces Expression of Severe Acute Respiratory Syndrome Coronavirus 2 Host Mediators.
33949212 2021. The effect of estrogen in coronavirus disease 2019.
33566663 2021. Enhancing the WHO's Proposed Framework for Distributing COVID-19 Vaccines Among Countries.
32955926 2021. Role of IL-6 in Severe Inflammation.
34085760 2021. Postvaccination SARS-CoV-2 infections among skilled nursing facility residents and staff members - Chicago, Illinois, December 2020-March 2021.
34080285 2021. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus: Not alarming, but should be taken gravely.
34058052 2021. Impaired anti-SARS-CoV-2 humoral and cellular immune response induced by Pfizer-BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patients.
34043872 2021. Severe consequences of COVID-19 infection among vaccinated kidney transplant recipients.
34036720 2021. Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients.
33866672 2021. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus.
33864722 2021. Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients.
33829628 2021. The future of SARS-CoV-2 vaccines in transplant recipients: To be determined.
33890410 2021. COVID-19 infection in solid organ transplant recipients after SARS-CoV-2 vaccination.
33950300 2021. Human cell receptors: potential drug targets to combat COVID-19.
33995537 2021. EVOLUCION DEL INTERVALO QTC EN PACIENTES CON INFECCION SARS-COV-2 TRATADOS CON FARMACOS ANTIVIRALES( lozenge).
33946037 2021. SARS-CoV-2 vaccination efficacy on hospitalisation and variants.
33895471 2021. COVID-19 vaccines surveillance in France: a global response to a major national challenge.
34033927 2021. Oxford-AstraZeneca COVID-19 vaccine-induced cerebral venous thrombosis and thrombocytopaenia: A missed opportunity for a rapid return of experience.
33901708 2021. SARS-CoV-2 vaccination efficacy on hospitalisation and variants.
33867032 2021. First electrochemical evaluation of favipiravir used as an antiviral option in the treatment of COVID-19: A study of its enhanced voltammetric determination in cationic surfactant media using a boron-doped diamond electrode.
33350010 2021. A Ligand Selection Strategy Identifies Chemical Probes Targeting the Proteases of SARS-CoV-2.
33860605 2021. Polysulfates Block SARS-CoV-2 Uptake through Electrostatic Interactions.
33915014 2021. Supramolecular Cylinders Target Bulge Structures in the 5' UTR of the RNA Genome of SARS-CoV-2 and Inhibit Viral Replication.
34022388 2021. Seroconversion after coronavirus disease 2019 vaccination in patients with immune deficiency.
33838338 2021. Disproportionality analysis of anaphylactic reactions after vaccination with messenger RNA coronavirus disease 2019 vaccines in the United States.
33962029 2021. Risk of allergic reaction in patients with atopic disease and recent coronavirus disease 2019 vaccination.
34020659 2021. Repurposing of antibiotics for clinical management of COVID-19: a narrative review.
34030782 2021. Idiopathic Thrombocytopenic Purpura and the Moderna Covid-19 Vaccine.
33349491 2021. Do Systemic Corticosteroids Reduce Mortality in Critically Ill Adult Patients With COVID-19?
33940219 2021. COVID-19 vaccine-induced immune thrombotic thrombocytopenia: An emerging cause of splanchnic vein thrombosis.
34057642 2021. Impact of dexamethasone on the incidence of ventilator-associated pneumonia and blood stream infections in COVID-19 patients requiring invasive mechanical ventilation: a multicenter retrospective study.
33956361 2021. The impact of hydroxychloroquine-azithromycin combination on Tpeak-to-end and Tpeak-to-end/QT ratio during a short treatment course.
34035003 2021. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease.
33903110 2021. Overcoming Culture Restriction for SARS-CoV-2 in Human Cells Facilitates the Screening of Compounds Inhibiting Viral Replication.
34097489 2021. Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In Vitro.
34042319 2021. Use of Tofacitinib in the Context of COVID-19 Vaccination: Comment on the American College of Rheumatology Clinical Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases.
34042308 2021. Reply.
33857328 2021. Can ketone bodies inactivate coronavirus spike protein? The potential of biocidal agents against SARS-CoV-2.
33938041 2021. Vitamin E at a high dose as an anti-ferroptosis drug and not just a supplement for COVID-19 treatment.
33338375 2021. Could Simultaneous Nasal and Oral Irrigation Be a Nontherapeutic Tool against SARS-CoV-2?
33860219 2021. Toward the Next-Generation COVID-19 Vaccines That Circumvent Antigenic Drift while Defusing Viral Infection.
33860218 2021. SARS-CoV-2 Glycosylation Suggests That Vaccines Should Have Adopted the S1 Subunit as Antigen.
33308005 2021. Bail-out extracorporeal membrane oxygenation for hydroxychloroquine intoxication: a warning for COVID-19 health-care givers.
34008482 2021. Ethical reflections on Covid-19 vaccines.
33428805 2021. Ruxolitinib in adult patients with secondary hemophagocytic lymphohistiocytosis.
33350698 2021. Remdesivir in The Treatment of COVID-19.
33350691 2021. Remdesivir Approved to Treat COVID-19 Amid Controversy.
33932943 2021. COVID-19 Vaccine Considerations during Pregnancy and Lactation.
34014798 2021. Interleukin-6 Inhibition Reduces Neuronal Injury In A Murine Model of Ventilator-Induced Lung Injury.
33961754 2021. Therapeutic Application of Alpha-1 Antitrypsin in COVID-19.
33852488 2021. Arrhythmias in Patients With Coronavirus Disease 2019 Treated With Hydroxychloroquine and/or Azithromycin.
34010161 2021. Tocilizumab-Associated Cecal Perforation in COVID-19 Pneumonia.
33346946 2021. Arterial abnormalities identified in kidneys transplanted into children during the COVID-19 pandemic.
33998136 2021. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus: No cause for alarm.
34019051 2021. Green and sensitive spectrofluorimetric determination of Remdesivir, an FDA approved SARS-CoV-2 candidate antiviral; application in pharmaceutical dosage forms and spiked human plasma.
33369927 2021. Is Aspirin Effective in Preventing Intensive Care Unit Admission in Patients With Coronavirus Disease 2019 Pneumonia?
34018416 2021. A Possible Case of Hypertensive Crisis With Intracranial Haemorrhage After an mRNA Anti-COVID-19 Vaccine.
34004274 2021. Primary care provider-reported prevalence of vaccine and polyethylene glycol allergy in Canada.
33939483 2021. In South Africa, a 2-dose Oxford/AZ vaccine did not prevent mild to moderate COVID-19 (cases mainly B.1.351 variant).
34058104 2021. In COVID-19, tocilizumab reduces all-cause mortality at 28 d.
34058103 2021. In patients hospitalized with COVID-19, adding azithromycin to usual care did not reduce 28-d mortality.
34049853 2021. SARS-COV-2 vaccination after stem cell transplantation for scleroderma.
34031032 2021. High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases.
34031031 2021. Correspondence on 'Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'.
33958323 2021. SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response.
33985941 2021. Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry by Rosenbaum et al.
33903096 2021. Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'.
33903095 2021. Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study by Kaklamanos et al.
33883160 2021. Correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine'.
34001511 2021. Nodosome Inhibition as a Novel Broad-Spectrum Antiviral Strategy against Arboviruses, Enteroviruses, and SARS-CoV-2.
33972256 2021. Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study.
34033288 2021. Reasons to avoid vitamin D deficiency during COVID-19 pandemic.
34011777 2021. [MANAGEMENT, DIAGNOSIS, AND TREATMENT OF SEVERE ALLERGIC REACTIONS INCLUDING ANAPHYLAXIS TO COVID-19 VACCINE].
33881925 2021. Letter by Carmona et al Regarding Article, "Beneficial Effect of Statins in COVID-19-Related Outcomes-Brief Report: a National Population-Based Cohort Study".
33377184 2021. Polymyxin B hemoperfusion in coronavirus disease 2019 patients with endotoxic shock: Case series from EUPHAS2 registry.
33340765 2021. In vitro display evolution of IL-6R-binding unnatural peptides ribosomally initiated and cyclized with m-(chloromethyl)benzoic acid.
34077310 2021. Identifying the molecular targets and mechanisms of xuebijing injection for the treatment of COVID-19 via network parmacology and molecular docking.
33858291 2021. Can algae contribute to the war with Covid-19?
33962976 2021. Covid-19: Sputnik vaccine rockets, thanks to Lancet boost.
33958384 2021. Covid-19: Sputnik vaccine rockets, thanks to Lancet boost.
33952506 2021. Thromboembolism and the Oxford-AstraZeneca vaccine.
33952443 2021. Covid-19: Two doses of Pfizer vaccine are "highly effective" against infection, hospital admission, and death, study finds.
33952439 2021. Covid-19: Vaccines will be tested against variants of concern after pound29m funding boost from UK government.
34049897 2021. Suspend intellectual property rights for covid-19 vaccines.
34045236 2021. Covid-19: Pfizer-BioNTech vaccine is "likely" responsible for deaths of some elderly patients, Norwegian review finds.
34039569 2021. Covid-19: Variants are spreading in countries with low vaccination rates.
34035010 2021. Covid-19: Are high rates of B.1.617.2 linked to vaccine hesitancy?
34006591 2021. Covid-19 vaccines: In the rush for regulatory approval, do we need more data?
34006531 2021. Covid-19: Most UK adults had antibodies after one dose of AstraZeneca or Pfizer vaccine, data suggest.
34001499 2021. Antivirals against SARS-CoV-2 by autumn?
33980548 2021. Covid-19: Fever, chills, and aches more common when AstraZeneca and Pfizer vaccines are mixed, early data show.
34074627 2021. On the road to Recovery-the world's biggest covid-19 treatment trial.

33978844 2021. Convalescent plasma therapy and mortality in COVID-19 patients admitted to the ICU: a prospective observational study.
34029488 2021. Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case Series.
34029487 2021. Safety and Immunogenicity of Anti-SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants.
34029484 2021. Symptoms After COVID-19 Vaccination in Patients With Persistent Symptoms After Acute Infection: A Case Series.
33844575 2021. A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated.
34094533 2021. Convalescent plasma as a treatment modality for Coronavirus Disease 2019 in Indonesia: A case reports.
33932508 2021. Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors.
33932501 2021. Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients.
33894725 2021. Efficacy and safety of Reduning injection in the treatment of COVID-19: a randomized, multicenter clinical study.
33849115 2021. Comparison of the antiviral effect of Arbidol and Chloroquine in treating COVID-19.
33894736 2021. A narrative review of COVID-19: magnesium isoglycyrrhizinate as a potential adjuvant treatment.
33832291 2021. Investigation into molecular mechanisms and high-frequency core TCM for pulmonary fibrosis secondary to COVID-19 based on network pharmacology and data mining.
33958324 2021. SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases.
33987222 2021. Day-90 survival in critically-ill patients with COVID-19 and hydroxychloroquine: a propensity analysis.
34066998 2021. Cnicin as an Anti-SARS-CoV-2: An Integrated In Silico and In Vitro Approach for the Rapid Identification of Potential COVID-19 Therapeutics.
33918619 2021. Potential Roles for Probiotics in the Treatment of COVID-19 Patients and Prevention of Complications Associated with Increased Antibiotic Use.
33920366 2021. Sinapic Acid Suppresses SARS CoV-2 Replication by Targeting Its Envelope Protein.
34069726 2021. Effects of Antioxidant Vitamins, Curry Consumption, and Heavy Metal Levels on Metabolic Syndrome with Comorbidities: A Korean Community-Based Cross-Sectional Study.
34069549 2021. The Efficacy of Antioxidant Oral Supplements on the Progression of COVID-19 in Non-Critically Ill Patients: A Randomized Controlled Trial.
33922049 2021. Can Prophylactic High Flow of Humidified and Warmed Filtered Air Improve Survival from Bacterial Pneumonia and SARS-CoV-2 in Elderly Individuals? The Role of Surfactant Protein A.
33894278 2021. A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase.
33872675 2021. Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CL(pro).
34010661 2021. Virucidal and antiviral activity of astodrimer sodium against SARS-CoV-2 in vitro.
33309540 2021. Antiviral activity against Middle East Respiratory Syndrome coronavirus by Montelukast, an anti-asthma drug.
33826068 2021. RNAi Technology and Investigation on Possible Vaccines to Combat SARS-CoV-2 Infection.
33959781 2021. Process development and scale-up optimization of the SARS-CoV-2 receptor binding domain-based vaccine candidate, RBD219-N1C1.
33950278 2021. Potential role of IFN-alpha in COVID-19 patients and its underlying treatment options.
33876282 2021. Potential "biopeptidal" therapeutics for severe respiratory syndrome coronaviruses: a review of antiviral peptides, viral mechanisms, and prospective needs.
33883784 2021. Antiviral peptides from aquatic organisms: Functionality and potential inhibitory effect on SARS-CoV-2.
33358224 2021. Posibilidad de sesgo en estudio retrospectivo de ivermectina para COVID-19.
33994631 2021. Smoker, Former Smoker and COVID-19: Nicotine Does Not Protect Against SARS-CoV-2.
33836322 2021. Nutritional determinants and COVID-19 outcomes of older patients with COVID-19: A systematic review.
32972773 2021. Status of Remdesivir: Not Yet Beyond Question!
32948379 2021. Response to: Status of Remdesivir: Not Yet Beyond Question!
34025857 2021. Virtual screening for small molecular non-covalent binders of the SARS-CoV-2 main protease.
34025855 2021. Could amantadine interfere with COVID-19 vaccines based on the LNP-mRNA platform?
34025827 2021. Improved COVID-19 ICU admission and mortality outcomes following treatment with statins: a systematic review and meta-analysis.
33747262 2021. Game of "crowning" season 8: RAS and reproductive hormones in COVID-19 - can we end this viral series?
33950349 2021. Investigation of potential inhibitor properties of ethanolic propolis extracts against ACE-II receptors for COVID-19 treatment by molecular docking study.
34047940 2021. COVID-19 and pulmonary fibrosis: therapeutics in clinical trials, repurposing, and potential development.
33893998 2021. Phytochemistry and pharmacological activity of the genus artemisia.
34059544 2021. Secondary immune thrombocytopenia supposedly attributable to COVID-19 vaccination.
33990984 2021. Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia.
33982806 2021. Interferon-alpha-2b aerosol inhalation is associated with improved clinical outcomes in patients with coronavirus disease-2019.
33855727 2021. Economic evaluation of remdesivir for the treatment of severe COVID-19 patients in China under different scenarios.
33847002 2021. SARS-CoV-2 mutations: A strain on efficacy of neutralizing monoclonal antibodies?
33982284 2021. Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease.
33904168 2021. Chilblain lesions after COVID-19 mRNA vaccine.
33904157 2021. Pityriasis rosea-like eruption after Pfizer-BioNTech COVID-19 vaccination.
33893637 2021. Pernio after COVID-19 vaccination.
34097311 2021. Management of a patient with a rare congenital limb malformation syndrome after SARS-CoV-2 vaccine-induced thrombosis and thrombocytopenia (VITT).
34085278 2021. Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia.
34075578 2021. Exacerbation of immune thrombocytopenia following COVID-19 vaccination.
34036570 2021. AZD1222 vaccine-related coagulopathy and thrombocytopenia without thrombosis in a young female.
33934330 2021. Immune thrombocytopenic purpura after SARS-CoV-2 vaccine.
34044900 2021. Plant stanol esters might optimise the immune response and improve the SARS-CoV-2/COVID-19 vaccine efficacy in overweight and obese subjects.
33977890 2021. Vitamin D status of children with Paediatric Inflammatory Multisystem Syndrome Temporally associated with Severe acute respiratory syndrome coronavirus 2 (PIMS-TS).
34096487 2021. Beyond probiotic legend: ESSAP gut microbiota health score to delineate SARS-COV-2 infection severity.
34061355 2021. Therapeutic potential of megadose vitamin C to reverse organ dysfunction in sepsis and COVID-19.
33825201 2021. Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro.
34058750 2021. Quercetin for COVID-19 and DENGUE co-infection: a potential therapeutic strategy of targeting critical host signal pathways triggered by SARS-CoV-2 and DENV.
34036326 2021. A multi-modal data harmonisation approach for discovery of COVID-19 drug targets.
33993214 2021. Structure-based drug repurposing against COVID-19 and emerging infectious diseases: methods, resources and discoveries.
34081143 2021. A transferable deep learning approach to fast screen potential antiviral drugs against SARS-CoV-2.
34089044 2021. Infectious disease mRNA vaccines and a review on epitope prediction for vaccine design.
33831281 2021. Annual influenza vaccination effect on the susceptibility to COVID-19 infection.
33949124 2021. Atomistic De-novo Inhibitor Generation-Guided Drug Repurposing for SARS-CoV-2 Spike Protein with Free-Energy Validation by Well-Tempered Metadynamics.
33894099 2021. Computational design and modeling of nanobodies toward SARS-CoV-2 receptor binding domain.
34008627 2021. Discovery of SARS-CoV-2 main protease inhibitors using a synthesis-directed de novo design model.
34002456 2021. Metal Complexes as Antiviral Agents for SARS-CoV-2.
33348462 2021. Action of Dipeptidyl Peptidase-4 Inhibitors on SARS-CoV-2 Main Protease.
34092298 2021. Chemical profiling of Huashi Baidu prescription, an effective anti-COVID-19 TCM formula, by UPLC-Q-TOF/MS.
33825239 2021. Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine.
33969530 2021. COVID-19 vaccines do not trigger psoriasis flares in patients with psoriasis treated with apremilast.
34081806 2021. COVID-19 vaccine-induced Stevens-Johnson syndrome.
34080223 2021. Radiation recall dermatitis triggered by inactivated COVID-19 vaccine.
33835617 2021. Ribonucleic acid COVID-19 vaccine-associated cutaneous adverse drug events: a case series of two patients.
33896010 2021. Ivermectin in dermatology: why it 'mite' be useless against COVID-19.
34061349 2021. Human CD4(+) T cells specific for dominant epitopes of SARS-CoV-2 Spike and Nucleocapsid proteins with therapeutic potential.
33836994 2021. What do we know about China's covid-19 vaccines?
33827801 2021. Incarcerated people should be prioritised for covid-19 vaccination.
33931384 2021. Covid-19: Most people admitted to hospital after vaccination were infected before immunity could develop, research shows.
33883164 2021. Covid-19: Unusual blood clots are "very rare side effect" of Janssen vaccine, says EMA.
33863757 2021. Covid-19: Risk of cerebral blood clots from disease is 10 times that from vaccination, study finds.
33858846 2021. Covid-19: Single dose of Pfizer or AstraZeneca vaccine produces strong antibody response in over 80s.
33853865 2021. Thrombosis after covid-19 vaccination.
33849903 2021. Covid-19: Moderna and Novavax vaccines to be tested in mixing vaccines trial.
33849900 2021. Covid-19: EU investigates four reports of blood clots after Janssen vaccine.
33849893 2021. Covid-19: Chinese vaccines may need changes to improve efficacy, admits official.
33846162 2021. Covid-19: Rare immune response may cause clots after AstraZeneca vaccine, say researchers.
33846122 2021. Reporting of AstraZeneca studies may have caused vaccine reservations.
33846115 2021. Covid-19: Budesonide shortens recovery time in patients not admitted to hospital, study finds.
33888547 2021. Misleading clinical evidence and systematic reviews on ivermectin for COVID-19.
33871897 2021. Pharmacovigilance-based drug repurposing: The search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections.
33993472 2021. Ivermectin in the management of a scabies outbreak in a long-term care facility.
34045261 2021. Regional lymphadenopathy following COVID-19 vaccination: considerations for primary care management.
33355153 2021. Vitamin D and COVID-19 in older age: evidence versus expectations.
33314018 2021. Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies.
33336562 2021. Determinants of physical activity among adults in the United Kingdom during the COVID-19 pandemic: The DUK-COVID study.
33372846 2021. Considerations for COVID-19 Vaccination in Lactation.
33372839 2021. President's Corner: Introduction to ABM's Statement on Considerations for COVID-19 Vaccination in Lactation.
33990347 2021. Blood Cancers Diminish Response to COVID-19 Vaccine.
33318035 2021. How Cancer Vaccine Tech Shaped COVID Response.
33331360 2021. A novel STING agonist for cancer immunotherapy and a SARS-CoV-2 vaccine adjuvant.
34009959 2021. Safety of mRNA-Based Vaccines for SARS CoV-2.
33325938 2021. Biocatalytic routes to anti-viral agents and their synthetic intermediates.
33350032 2021. Ferritin as a Platform for Creating Antiviral Mosaic Nanocages: Prospects for Treating COVID-19.
34061468 2021. Poly-l-lysine Glycoconjugates Inhibit DC-SIGN-mediated Attachment of Pandemic Viruses.
33970560 2021. An Androsterone-H2 @C60 hybrid: Synthesis, Properties and Molecular Docking Simulations with SARS-Cov-2.
33875170 2021. Comprehensive profiling and characterization of the absorbed components and metabolites in mice serum and tissues following oral administration of Qing-Fei-Pai-Du decoction by UHPLC-Q-Exactive-Orbitrap HRMS.
33838087 2021. Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series.
33914926 2021. A flare of pre-existing erythema multiforme following BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine.

33535790 2021. Beneficial Effect of Statins in COVID-19-Related Outcomes-Brief Report: A National Population-Based Cohort Study.
34007828 2021. Skin testing with Pfizer SARS-CoV-2 vaccine and PEG 2000.
33793439 2021. Topical Ocular Povidone-Iodine as an Adjunctive Preventative Practice in the Era of COVID-19.
33360711 2021. Finding Horcrux of psychiatric symptoms in COVID-19: Deficiencies of amino acids and vitamin D.
34059849 2021. Immunising older Australians: Pre-COVID-19 vaccine perspectives from general practice training.
33911335 2021. ChAdOx1-S vaccine for prevention of COVID-19.
33911334 2021. BNT162b2 vaccine for prevention of COVID-19.
33326855 2021. Combined Anakinra and Ruxolitinib treatment to rescue extremely ill COVID-19 patients: A pilot study.
34026905 2021. Can trace element supplementations (Cu, Se, and Zn) enhance human immunity against COVID-19 and its new variants?
33773923 2021. Maternal vaccines-safety in pregnancy.
33965331 2021. Uptake of vaccination in pregnancy.
34056140 2021. Accommodating receptor flexibility and free energy calculation to reduce false positive binders in the discovery of natural products blockers of SARS-COV-2 spike RBD-ACE2 interface.
33364445 2021. Analysis of non-structural proteins, NSPs of SARS-CoV-2 as targets for computational drug designing.
33309272 2021. Identification of antiviral antihistamines for COVID-19 repurposing.
33872570 2021. Discovery of a AHR pelargonidin agonist that counter-regulates Ace2 expression and attenuates ACE2-SARS-CoV-2 interaction.
34082041 2021. Essential sufficiency of zinc, omega-3 polyunsaturated fatty acids, vitamin D and magnesium for prevention and treatment of COVID-19, diabetes, cardiovascular diseases, lung diseases and cancer.
33951913 2021. Self-Assembling Nanoparticle Vaccines Displaying the Receptor Binding Domain of SARS-CoV-2 Elicit Robust Protective Immune Responses in Rhesus Monkeys.
33356169 2021. Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2.
33888980 2021. Prediction of Anti-COVID 19 Therapeutic Power of Medicinal Moroccan Plants Using Molecular Docking.
34062724 2021. Molecular Docking and Dynamics Simulation Study of Hyrtios erectus Isolated Scalarane Sesterterpenes as Potential SARS-CoV-2 Dual Target Inhibitors.
33910079 2021. PEGylated nanoparticle albumin-bound steroidal ginsenoside derivatives ameliorate SARS-CoV-2-mediated hyper-inflammatory responses.
33360781 2021. 4-Aminoquinoline compounds from the Spanish flu to COVID-19.
33894625 2021. Resveratrol-zinc nanoparticles or pterostilbene-zinc: Potential COVID-19 mono and adjuvant therapy.
33866132 2021. Babaodan controls excessive immune responses and may represent a cytokine-targeted agent suitable for COVID-19 treatment.
33848774 2021. Will curcumin nanosystems be the next promising antiviral alternatives in COVID-19 treatment trials?
33360048 2021. Could natural products modulate early inflammatory responses, preventing acute respiratory distress syndrome in COVID-19-confirmed patients?
34052565 2021. Main protease inhibitors and drug surface hotspots for the treatment of COVID-19: A drug repurposing and molecular docking approach.
34051617 2021. Theobroma cacao L. compounds: Theoretical study and molecular modeling as inhibitors of main SARS-CoV-2 protease.
34095308 2021. Virtual Screening of Phytochemicals by Targeting HR1 Domain of SARS-CoV-2 S Protein: Molecular Docking, Molecular Dynamics Simulations, and DFT Studies.
34066608 2021. Methodical Design of Viral Vaccines Based on Avant-Garde Nanocarriers: A Multi-Domain Narrative Review.
34063015 2021. Association of Calcitriol Supplementation with Reduced COVID-19 Mortality in Patients with Chronic Kidney Disease: A Population-Based Study.
34067609 2021. Predicting COVID-19-Comorbidity Pathway Crosstalk-Based Targets and Drugs: Towards Personalized COVID-19 Management.
33918402 2021. Rutin Is a Low Micromolar Inhibitor of SARS-CoV-2 Main Protease 3CLpro: Implications for Drug Design of Quercetin Analogs.
33919584 2021. Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro.
33372165 2021. COVID-19 Vaccine: Critical Questions with Complicated Answers.
34071582 2021. Binding of SARS-CoV Covalent Non-Covalent Inhibitors to the SARS-CoV-2 Papain-Like Protease and Ovarian Tumor Domain Deubiquitinases.
34071060 2021. Attacking COVID-19 Progression Using Multi-Drug Therapy for Synergetic Target Engagement.
34069869 2021. Povidone-Iodine Attenuates Viral Replication in Ocular Cells: Implications for Ocular Transmission of RNA Viruses.
33946644 2021. Computational Identification of Potential Anti-Inflammatory Natural Compounds Targeting the p38 Mitogen-Activated Protein Kinase (MAPK): Implications for COVID-19-Induced Cytokine Storm.
33921886 2021. SARS-CoV-2 M(pro): A Potential Target for Peptidomimetics and Small-Molecule Inhibitors.
33919870 2021. Molecular Simulation-Based Investigation of Highly Potent Natural Products to Abrogate Formation of the nsp10-nsp16 Complex of SARS-CoV-2.
33862474 2021. Novel inhibitors of the main protease enzyme of SARS-CoV-2 identified via molecular dynamics simulation-guided in vitro assay.
33975232 2021. Synthesis, molecular docking, and in silico ADMET studies of 4-benzyl-1-(2,4,6-trimethyl-benzyl)-piperidine: Potential Inhibitor of SARS-CoV2.
33915460 2021. Ebsulfur and Ebselen as highly potent scaffolds for the development of potential SARS-CoV-2 antivirals.
33831697 2021. Identification of SARS-CoV-2 viral entry inhibitors using machine learning and cell-based pseudotyped particle assay.
33957246 2021. Identification of non-covalent 3C-like protease inhibitors against severe acute respiratory syndrome coronavirus-2 via virtual screening of a Korean compound library.
33984473 2021. Promising anti-SARS-CoV-2 drugs by effective dual targeting against the viral and host proteases.
33940136 2021. Exploring the potential of novel phenolic compounds as potential therapeutic candidates against SARS-CoV-2, using quantum chemistry, molecular docking and dynamic studies.
33887440 2021. Development of ciclesonide analogues that block SARS-CoV-2 RNA replication.
34089978 2021. A computational evaluation of targeted oxidation strategy (TOS) for potential inhibition of SARS-CoV-2 by disulfiram and analogues.
33962341 2021. Proposal of novel natural inhibitors of severe acute respiratory syndrome coronavirus 2 main protease: Molecular docking and ab initio fragment molecular orbital calculations.
33935291 2021. Gaseous Nitric Oxide and Dinitrosyl Iron Complexes with Thiol-Containing Ligands as Potential Medicines that Can Relieve COVID-19.
33342929 2021. Efficacy of early hydroxychloroquine treatment in preventing COVID-19 pneumonia aggravation, the experience from Shanghai, China.
33994673 2021. SARS-CoV-PL(pro)-Inhibitoren als mogliche Breitspektrum-Virostatika.
33666158 2021. Methylprednisolone as rescue therapy after tocilizumab failure in patients with severe COVID-19 pneumonia.
34050731 2021. Neutralization heterogeneity of United Kingdom and South-African SARS-CoV-2 variants in BNT162b2-vaccinated or convalescent COVID-19 healthcare workers.
34036334 2021. It is time to determine Tocilizumab place in COVID-19.
34015087 2021. Circulating SARS-CoV-2 Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients.
33999992 2021. Cost-effectiveness of tocilizumab in severe COVID-19: to see or not to see.
33999127 2021. The effectiveness of the TWO-DOSE BNT162b2 vaccine: analysis of real-world data.
33993265 2021. Reduced BNT162b2 mRNA vaccine response in SARS-CoV-2-naive nursing home residents.
33993228 2021. BNT162b2 mRNA vaccination did not prevent an outbreak of SARS COV-2 variant 501Y.V2 in an elderly nursing home but reduced transmission and disease severity.
33989390 2021. Immediate reactions following the first dose of the SARS-CoV2 mRNA vaccines do not preclude second dose administration.
34091665 2021. Adverse Outcomes Associated with SARS-CoV-2 variant B.1.351 Infection in Vaccinated Residents of a Long Term Care Home, Ontario, Canada.
34091664 2021. Early Monoclonal Antibody Administration Can Reduce Both Hospitalizations and Mortality in High-Risk Outpatients with COVID-19.
34086881 2021. Incidence and Characteristics of Delayed Injection Site Reaction to the mRNA-1273 SARS-CoV2 Vaccine (Moderna) in a Cohort of Hospital Employees.
33735520 2021. Pentoxifylline or theophylline use in hospitalized COVID-19 patients requiring oxygen support.
34057814 2021. Potential benefit of vitamin d supplementation in people with respiratory illnesses, during the Covid-19 pandemic.
33982445 2021. A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID-19.
34041932 2021. COVID-19 vaccine trials: The potential for "hybrid" analyses.
34029238 2021. Keratoplasty Rejection After the BNT162b2 messenger RNA Vaccine.
34091550 2021. Vaccine allergy: evidence to consider for COVID-19 vaccines.
34090785 2021. Antiphospholipid antibodies and risk of post-COVID-19 vaccination thrombophilia: The straw that breaks the camel's back?
33940227 2021. Hepatobiliary Adverse Drug Reactions Associated With Remdesivir: The WHO International Pharmacovigilance Study.
32761148 2021. Hydroxychloroquine Failure: The End Does Not Justify the Means.
34079995 2021. The potential declining efficacy of the ChAdOx1 nCoV-19 vaccine(AZD1222) on inoculators with NSAIDs intake.
34045299 2021. mRNA COVID-19 Vaccine for People with Kidney Failure.
34031182 2021. Antibody Response to mRNA-1273 SARS-CoV-2 Vaccine in Hemodialysis Patients with and without Prior COVID-19.
33824157 2021. Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis.
33883486 2021. False-Positive Axillary Lymph Nodes on FDG PET/CT Resulting From COVID-19 Immunization.
34024569 2021. Can an anti-inflammatory diet be effective in preventing or treating viral respiratory diseases? A systematic narrative review.
33340409 2021. Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database.
34029377 2021. Vitamin D supplementation for the treatment of COVID-19: a living systematic review.
34013969 2021. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
34077341 2021. Identification of Generalized Peptide Regions for Designing Vaccine Effective for All Significant Mutated Strains of SARS-CoV-2.
34077664 2021. Vaccines for COVID-19: An Overview.
33951604 2021. Exploring the effectiveness of the TSR-based protein 3-D structural comparison method for protein clustering, and structural motif identification and discovery of protein kinases, hydrolases, and SARS-CoV-2's protein via the application of amino acid grouping.
34049307 2021. Using Nonheparin Anticoagulant to Treat a Near-Fatal Case With Multiple Venous Thrombotic Lesions During ChAdOx1 nCoV-19 Vaccination-Related Vaccine-Induced Immune Thrombotic Thrombocytopenia.
34034298 2021. Increased Glucocorticoid Receptor Alpha Expression and Signaling in Critically Ill Coronavirus Disease 2019 Patients.
34049310 2021. Glucocorticoid-Glucocorticoid Receptor Response to Severe Acute Respiratory Syndrome Coronavirus 2.
33870924 2021. Convalescent Plasma and Coronavirus Disease 2019: Time for Reassessment.
33870923 2021. Severe Acute Respiratory Syndrome Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019 Infected Hospitalized Patients in New York: A Double-Blind Randomized Trial.
34024199 2021. Lopinavir/Ritonavir: A Review of Analytical Methodologies for the Drug Substances, Pharmaceutical Formulations and Biological Matrices.
33949929 2021. Machine Learning in Discovery of New Antivirals and Optimization of Viral Infections Therapy.
34042026 2021. Interfering with Host Proteases in SARS-CoV-2 Entry as a Promising Therapeutic Strategy.
34042025 2021. COVID-19: The significance of platelets, mitochondria, vitamin D, serotonin and the gut microbiota.
33992054 2021. Structural Basis for the Understanding of Entry Inhibitors Against SARS Viruses.
33881969 2021. SARS-CoV-2 Entry inhibitors targeting virus-ACE2 or virus-TMPRSS2 interactions.
33982651 2021. To vaccinate or not to vaccinate; that is the question! (New insights on COVID-19 Vaccination).
34077352 2021. Evaluation of Dual Inhibitory Effect of Anagliptin, Ramipril, and Lisinopril on Angiotensin-Converting Enzyme and DPP-4 Activities.
33829974 2021. C-Phycocyanin-derived Phycocyanobilin as a Potential Nutraceutical Approach for Major Neurodegenerative Disorders and COVID-19-induced Damage to the Nervous System.
34074880 2021. Coronavirus disease 2019 vaccination in transplant recipients.
33990506 2021. Coronavirus disease 2019, vitamin D and kidney function.
34097590 2021. Identification of novel drug candidates for the inhibition of catalytic cleavage activity of coronavirus 3CL-like protease enzyme.
33882805 2021. Potential Candidates against COVID-19 Targeting RNA-Dependent RNA Polymerase: A Comprehensive Review.
33845735 2021. Olive oil consumption can prevent non-communicable diseases and COVID-19 : Review.
34009111 2021. Viral Diseases and Natural Products: Prospects in COVID-19 Treatment (Part II).
33308117 2021. Chloroquine Analogs: An Overview of Natural and Synthetic Quinolines as Broad Spectrum Antiviral Agents.
33302855 2021. Anti-malarial Drugs are Not Created Equal for SARS-CoV-2 Treatment: A Computational Analysis Evidence.
34028347 2021. Azithromycin Use in COVID-19 Patients: Implications on the Antimicrobial Resistance.
33970846 2021. The Effect of Recombinant Human Interferon Alpha Nasal Drops to Prevent COVID-19 Pneumonia for Medical Staff in an Epidemic Area.
33851937 2021. Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines and Cutaneous Adverse Reactions: A Review.

33314794 2021. Computational drug repurposing study of the RNA binding domain of SARS-CoV-2 nucleocapsid protein with antiviral agents.
34002690 2021. Revisiting vitamin D status and supplementation for in-patients with intellectual and developmental disability in the North of England, UK.
33988688 2021. Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2.
33861303 2021. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.
33945618 2021. COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria.
33945605 2021. A flow cytometric assay to detect platelet-activating antibodies in VITT after ChAdOx1 nCov-19 vaccination.
33861315 2021. Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose.
33857940 2021. Endotoxin Adsorbent Therapy in Severe COVID-19 Pneumonia.
34059190 2021. Position paper on the use of COVID-19 convalescent plasma: an update.
33832440 2021. Common low complexity regions for SARS-CoV-2 and human proteomes as potential multidirectional risk factor in vaccine development.
33962573 2021. Impact of high dose of baricitinib in severe COVID-19 pneumonia: a prospective cohort study in Bangladesh.
33947344 2021. Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients.
34058989 2021. Effects of early corticosteroid use in patients with severe coronavirus disease 2019.
34044777 2021. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis.
34011281 2021. Association between fatality rate of COVID-19 and selenium deficiency in China.
34006228 2021. Lack of association between vitamin D insufficiency and clinical outcomes of patients with COVID-19 infection.
33863281 2021. Methylene blue photochemical treatment as a reliable SARS-CoV-2 plasma virus inactivation method for blood safety and convalescent plasma therapy for COVID-19.
33838657 2021. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial.
33952445 2021. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study.
34035040 2021. Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study.
33985964 2021. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study.
33980718 2021. Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study.
33975825 2021. Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study.
33903131 2021. Prophylaxis against covid-19: living systematic review and network meta-analysis.
33762295 2021. Lateral ST-elevation myocardial infarction after donation of COVID-19 convalescent plasma in a naive donor.
33888484 2021. Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1.
34049903 2021. Association between vitamin D supplementation or serum vitamin D level and susceptibility to SARS-CoV-2 infection or COVID-19 including clinical course, morbidity and mortality outcomes? A systematic review.
33574155 2021. Safety and feasibility of using acellular sterile filtered amniotic fluid as a treatment for patients with COVID-19: protocol for a randomised, double-blinded, placebo-controlled clinical trial.
33853806 2021. Multicentre randomised double-blinded placebo-controlled trial of favipiravir in adults with mild COVID-19.
33358041 2021. Does opioid substitution treatment have a protective effect on the clinical manifestations of COVID-19? Comment on Br J Anaesth 2020; 125: e382-3.
33769875 2021. COVID-19 vaccination: intramuscular injection technique.
33910885 2021. Characteristics of endothelial corneal transplant rejection following immunisation with SARS-CoV-2 messenger RNA vaccine.
33947605 2021. COVID-19 vaccination and low cervical lymphadenopathy in the two week neck lump clinic - a follow up audit.
34075664 2021. Exacerbation of subacute cutaneous lupus erythematosus following vaccination with BNT162b2 mRNA vaccine.
34033207 2021. Tumor necrosis factor inhibitors are associated with a decreased risk of COVID-19-associated hospitalization in patients with psoriasis-A population-based cohort study.
34031953 2021. Local reactions to the second dose of the BNT162 COVID-19 vaccine.
33955644 2021. Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine.
34038246 2021. Reckoning gamma-Glutamyl-S-allylcysteine as a potential main protease (m(pro)) inhibitor of novel SARS-CoV-2 virus identified using docking and molecular dynamics simulation.
33960002 2021. TWIRLS, a knowledge-mining technology, suggests a possible mechanism for the pathological changes in the human host after coronavirus infection via ACE2.
33847382 2021. Potential antiviral activity of isorhamnetin against SARS-CoV-2 spike pseudotyped virus in vitro.
34089595 2021. Do Anti-androgens Have Potential as Therapeutics for COVID-19?
33928745 2021. COVID-19: vaccination problems.
34001753 2021. Theoretical Framework for Retrospective Studies of the Effectiveness of SARS-CoV-2 Vaccines.
33987882 2021. COVID-19 vaccine-associated immune thrombosis and thrombocytopenia (VITT): Diagnostic and therapeutic recommendations for a new syndrome.
34092488 2021. Thrombosis with Thrombocytopenia Syndrome associated with viral vector COVID-19 vaccines.
34090750 2021. SARS-CoV-2 vaccine-induced cerebral venous thrombosis.
34058925 2021. How can we accelerate COVID-19 vaccine discovery?
34088250 2021. NSAIDs/nitazoxanide/azithromycin repurposed for COVID-19: potential mitigation of the cytokine storm interleukin-6 amplifier via immunomodulatory effects.
34078215 2021. COVID-19 pandemic: SARS-CoV-2 specific vaccines and challenges, protection via BCG trained immunity, and clinical trials.
34092166 2021. Reported adverse effects following COVID-19 vaccination at a tertiary care hospital, focus on cerebral venous sinus thrombosis (CVST).
34004056 2021. Disruption of disulfides within RBD of SARS-CoV-2 spike protein prevents fusion and represents a target for viral entry inhibition by registered drugs.
34058321 2021. Nrf2 activator PB125(R) as a carnosic acid-based therapeutic agent against respiratory viral diseases, including COVID-19.
34027650 2021. Phytotherapy for treatment of cytokine storm in COVID-19.
33973280 2021. COVID-19 in DMARD-treated patients with inflammatory rheumatic diseases: Insights from an analysis of the World Health Organization pharmacovigilance database.
33369768 2021. Remdesivir potently inhibits carboxylesterase-2 through covalent modifications: signifying strong drug-drug interactions.
33829614 2021. Delirium triggered by COVID-19 vaccine in an elderly patient.
34085396 2021. Acute kidney injury secondary to chlorine dioxide use for COVID-19 prevention.
34033528 2021. COVID-19 vaccine platforms: Delivering on a promise?
33966665 2021. Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in asymptomatic vaccinated healthcare workers.
33928831 2021. Drug delivery of amoxicillin molecule as a suggested treatment for covid-19 implementing functionalized mesoporous SBA-15 with aminopropyl groups.
33818031 2021. Drugs intervention study in COVID-19 management.
33378773 2021. Development of a Physiologically-Based Pharmacokinetic (PBPK) Model of Nebulized Hydroxychloroquine for Pulmonary Delivery to COVID-19 Patients.
33890267 2021. A Concept for the Reduction of Mucosal SARS-CoV-2 Load using Hypochloric Acid Solutions.
33931565 2021. COVID-19 vaccination in pregnancy.
34061008 2021. Revisiting the antiviral efficacy of terpenoids: Plausible adjunct therapeutics for novel SARS-CoV-2?
34057409 2021. Physicians' opinions on the necessity of COVID-19 vaccination in patients with epilepsy.
32725108 2021. End-stage heart failure secondary to low-dose hydroxychloroquine treatment.
33878713 2021. Pigs Don't Fly and You Cannot Expect Absolutely Safe COVID-19 Vaccines (But You Should Expect a Fair Compensation).
33963635 2021. Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients - a prospective cohort study.
34031153 2021. Petechial skin rash associated with CoronaVac vaccination: first cutaneous side effect report before phase 3 results.
33990390 2021. Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19.
34083222 2021. Benefit versus toxicity risk of digoxin in patients with COVID-19.
33832918 2021. Electronic monitoring of potential adverse drug events related to lopinavir/ritonavir and hydroxychloroquine during the first wave of COVID-19.
33930196 2021. JAK inhibitors: Ten years after.
33832827 2021. Safety of treatment with chloroquine and hydroxychloroquine: A ten-year systematic review and meta-analysis.
33966314 2021. SARS-CoV-2 vaccine-related neurological complications need large collaborative studies, not single case reports or small descriptive series.
33843287 2021. Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: A case report.
33886388 2021. Immunomodulatory extracellular vesicles: an alternative to cell therapy for COVID-19.
33957833 2021. Machine learning techniques applied to the drug design and discovery of new antivirals: a brief look over the past decade.
33307875 2021. Are academia-pharma partnerships essential for novel drug discovery in the time of the COVID-19 pandemic?
33345645 2021. Can drug repurposing strategies be the solution to the COVID-19 crisis?
33874829 2021. The role of IL-6 and IL-6 blockade in COVID-19.
33331197 2021. The COVID-19 pandemic: a target for surfactant therapy?
33858268 2021. Effects of select dietary supplements on the prevention and treatment of viral respiratory tract infections: a systematic review of randomized controlled trials.
33945381 2021. Does methylprednisolone reduce the mortality risk in hospitalized COVID-19 patients? A meta-analysis of randomized control trials.
33853488 2021. Progress in research on the S protein as the target of COVID-19 vaccines.
33350389 2021. Supplementation en vitamine D et Covid-19 : consensus d'experts et recommandations.
33860513 2021. Consensus Recommendations for Intramuscular COVID-19 Vaccination in Patients with Hemophilia.
34034356 2021. Analysis of Homeopathic Genus Epidemicus for COVID-19 Patients in Spain.
33348417 2021. COVID-19 Pneumonia: A Potential Role of Homeopathy.
33930904 2021. Homeopathic Remedies in COVID-19: Prognostic Factor Research.
33853178 2021. Clinical Repurposing of Medicines is Intrinsic to Homeopathy: Research Initiatives on COVID-19 in India.
33853177 2021. Antimonium Tartaricum as a Possible Homeopathic Prophylactic Remedy in the COVID-19 Epidemic.
34005841 2021. Association between vitamin D level and prognostic factors among patients infected with SARS-CoV-2.
33998533 2021. A review of monoclonal antibodies in COVID-19: Role in immunotherapy, vaccine development and viral detection.
33858231 2021. Current Update on Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development with a Special Emphasis on Gene Therapy Viral Vector Design and Construction for Vaccination.
34033732 2021. Reactive arthritis after COVID-19 vaccination.
34032555 2021. Guillain-Barre syndrome should be monitored upon mass vaccination against SARS-CoV-2.
33857399 2021. Countries with high deaths due to flu and tuberculosis demonstrate lower COVID-19 mortality: roles of vaccinations.
34015240 2021. Acute relapse and poor immunization following COVID-19 vaccination in a rituximab-treated multiple sclerosis patient.
33377817 2021. The association of previous influenza vaccination and coronavirus disease-2019.
34081583 2021. LUNAR :Drug Screening for Novel Coronavirus Based on Representation Learning Graph Convolutional Network.
33914685 2021. Detection of Binding Sites on SARS-CoV-2 Spike Protein Receptor-Binding Domain by Molecular Dynamics Simulations in Mixed Solvents.
33941025 2021. Interplay of Anti-Viral Vaccines with Biologic Agents and Immunomodulators in Individuals with Autoimmune and Autoinflammatory Diseases.
33830864 2021. Better, Faster, Stronger: mRNA Vaccines Show Promise for Influenza Vaccination in Older Adults.
33955564 2021. A century of BCG: Impact on tuberculosis control and beyond.
34057870 2021. Repurposing metformin for covid-19 complications in patients with type 2 diabetes and insulin resistance.
34032546 2021. Neuroprotective role of camphor against ciprofloxacin induced depression in rats: modulation of Nrf-2 and TLR4.
33356684 2021. Different aspects of convalescent plasma therapy for COVID-19 treatment; a critical review.
34047261 2021. A short review on key role of plants and their extracts in boosting up immune response to combat COVID-19.

33313690 2021. COVID-19 vaccine and Guillain-Barre syndrome: let's not leap to associations.
33857630 2021. Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination - A report of two UK cases.
33842899 2021. Boosting nitric oxide in stress and respiratory infection: Potential relevance for asthma and COVID-19.
33355812 2021. COVID-19 and Methylene Blue.
33866350 2021. Is acupuncture effective in the treatment of COVID-19 related symptoms? Based on bioinformatics/network topology strategy.
33839760 2021. Bioinformatics and machine learning approach identifies potential drug targets and pathways in COVID-19.
33839740 2021. SMMPPI: a machine learning-based approach for prediction of modulators of protein-protein interactions and its application for identification of novel inhibitors for RBD:hACE2 interactions in SARS-CoV-2.
34009266 2021. DeepImmuno: deep learning-empowered prediction and generation of immunogenic peptides for T-cell immunity.
34009288 2021. Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19.
33416848 2021. SARS-CoV-2 3D database: understanding the coronavirus proteome and evaluating possible drug targets.
33875896 2021. COVID-19 vaccin et anaphylaxie.
33902920 2021. La vaccination anti-COVID-19 et patients atteints de cancer : etat de l'art et synthese des recommandations.
33902918 2021. Vaccination contre la COVID-19 des patients atteints de cancer solide : revue et preconisations d'un inter-groupe oncologique francais (CGO, TNCD, UNICANCER).
34025112 2021. Serial computed tomography findings of Coronavirus disease 2019 (COVID-19) pneumonia treated with favipiravir and steroid therapy: report of 11 cases.
33947599 2021. Timing of COVID-19 vaccination in the major burns patient.
33903009 2021. Radiotherapie de faible dose pour la pneumopathie covid-19 : rationnel biologique et revue de la litterature.
34090218 2021. COVID-19 patients' sera induce epithelial mesenchymal transition in cancer cells.
33910715 2021. Sulfobutylether-beta-cyclodextrin-enabled antiviral remdesivir: Characterization of electrospun- and lyophilized formulations.
34015720 2021. Marine sulfated polysaccharides as potential antiviral drug candidates to treat Corona Virus disease (COVID-19).
33927910 2021. Vitamin D Deficiency Rickets and COVID-19 Pandemic.
33836156 2021. TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation.
34087172 2021. Tackling COVID-19 with neutralizing monoclonal antibodies.
34051873 2021. A traditional medicine, respiratory detox shot (RDS), inhibits the infection of SARS-CoV, SARS-CoV-2, and the influenza A virus in vitro.
33979649 2021. Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2.
34031383 2021. Targeting novel LSD1-dependent ACE2 demethylation domains inhibits SARS-CoV-2 replication.
33894127 2021. A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection.
33359760 2021. Effects of vitamin D on macrophages and myeloid-derived suppressor cells (MDSCs) hyperinflammatory response in the lungs of COVID-19 patients.
33958745 2021. Identification and characterization of a monoclonal antibody blocking the SARS-CoV-2 spike protein-ACE2 interaction.
34059790 2021. Fludarabine inhibits type I interferon-induced expression of the SARS-CoV-2 receptor angiotensin-converting enzyme 2.
33984267 2021. Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture.
33852916 2021. Hypoxic and pharmacological activation of HIF inhibits SARS-CoV-2 infection of lung epithelial cells.
34074163 2021. Combined Use of Tocilizumab and Mesenchymal Stromal Cells in the Treatment of Severe Covid-19: Case Report.
33845643 2021. Recent Findings on Cell-Based Therapies for COVID19-Related Pulmonary Fibrosis.
34067054 2021. The Discovery of Naringenin as Endolysosomal Two-Pore Channel Inhibitor and Its Emerging Role in SARS-CoV-2 Infection.
34068958 2021. Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae?
33917481 2021. Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19.
33946869 2021. Remdesivir and Ledipasvir among the FDA-Approved Antiviral Drugs Have Potential to Inhibit SARS-CoV-2 Replication.
33887223 2021. Potent toxic effects of Taroxaz-104 on the replication of SARS-CoV-2 particles.
33991505 2021. A novel nano therapeutic using convalescent plasma derived exosomal (CP(Exo)) for COVID-19: A combined hyperactive immune modulation and diagnostics.
33974898 2021. Elucidating of oxidative distress in COVID-19 and methods of its prevention.
34007086 2021. Antiviral nucleoside analogs.
34007082 2021. Modeling the binding of protoporphyrin IX, verteporfin, and chlorin e6 to SARS-CoV-2 proteins.
33850334 2021. In silico investigation of potential small molecule inhibitors of the SARS-CoV-2 nsp10-nsp16 methyltransferase complex.
33362291 2021. Unraveling the origin of interactions of hydroxychloroquine with the receptor-binding domain of SARS-CoV-2 in aqueous medium.
34024911 2021. Non-competitive interactions between hydroxychloroquine and azithromycin: Systematic density functional, molecular dynamics, and docking calculations.
33994552 2021. Low rotational barriers for the most dynamically active methyl groups in the proposed antiviral drugs for treatment of SARS-CoV-2, apilimod and tetrandrine.
33994655 2021. An insight into the inhibitory mechanism of phytochemicals and FDA-approved drugs on the ACE2-Spike complex of SARS-CoV-2 using computational methods.
34025012 2021. Discovery of (E)-N-(4-cyanobenzylidene)- 6-fluoro- 3-hydroxypyrazine-2 -carboxamide (cyanorona-20): the first potent and specific anti-COVID-19 drug.
34010501 2021. Computational Approaches to Discover Novel Natural Compounds for SARS-CoV-2 Therapeutics.
33965141 2021. Questioning Tocilizumab Use in Hospitalized Patients With Coronavirus Disease 2019.
33965138 2021. Standard Dose Ivermectin for COVID-19.
33965137 2021. Remarks About Retrospective Analysis of Ivermectin Effectiveness on Coronavirus Disease 2019 (ICON Study).
33965134 2021. Corticosteroid Plus Tocilizumab in COVID-19: When Two Is Better Than One.
33965120 2021. One Size Does Not Fit All: Moving Towards a Personalized Approach for Steroids in COVID-19.
33316235 2021. Corticosteroid Therapy Is Associated With Improved Outcome in Critically Ill Patients With COVID-19 With Hyperinflammatory Phenotype.
34021998 2021. Etoposide for Cytokine Storm Because of Coronavirus Disease 2019.
34031814 2021. Chinese Medicine Rescues Acute Respiratory Dyspnea Syndrome Caused by COVID-19: A Case Report.
34018412 2021. Thrombotic Events in COVID-19: Inquires About the Deleterious Procoagulant Effect of Corticosteroid Therapy.
33999204 2021. COVID-19 Vaccination in Patients With Inflammatory Bowel Disease and History of Reaction to Injectable Therapies.
33878754 2021. Spices and COVID-19.
34047498 2021. Olfactory dysfunction after coronavirus disease 2019 (COVID-19) vaccination.
34080261 2021. Promising effects of atorvastatin on mortality and need for mechanical ventilation in patients with severe COVID-19; a retrospective cohort study.
33971067 2021. Effectiveness of ozone therapy in addition to conventional treatment on mortality in patients with COVID-19.
34089534 2021. COVID-19 vaccines and nanomedicine.
33998677 2021. Recurrent varicella following SARS-CoV-2 vaccination with BNT162b2.
33900629 2021. Acral chilblain-like lesions following inactivated SARS-CoV-2 vaccination.
33855706 2021. Cutaneous reaction to BNT162b2 mRNA COVID-19 vaccine.
33928638 2021. Leukocytoclastic vasculitis flare following the COVID-19 vaccine.
34037266 2021. The use of cow dung and urine to cure COVID-19 in India: A public health concern.
33973379 2021. Recommendations for COVID-19 vaccination in people with rheumatic disease: Developed by the Singapore Chapter of Rheumatologists.
34075419 2021. Concordance between the results of randomized and non-randomized interventional clinical trials assessing the efficacy of drugs for COVID-19: a cross-sectional study.
34075418 2021. Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2.
34037760 2021. Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial.
33973313 2021. Drug-induced organ injury in coronavirus disease 2019 pharmacotherapy: Mechanisms and challenges in differential diagnosis and potential protective strategies.
34001719 2021. Could Dapagliflozin Attenuate COVID-19 Progression in High-Risk Patients With or Without Diabetes? Behind DARE-19 Concept.
33993519 2021. Recombinant CD137-Fc, its synthesis, and applications for improving the immune system functions, such as tumor immunotherapy and to reduce the inflammation due to the novel coronavirus.
34097036 2021. Calcifediol treatment and COVID-19-related outcomes.
33959987 2021. Medication safety in a pandemic: A multicentre point prevalence study of QTc monitoring of hydroxychloroquine for COVID-19.
33870531 2021. Baricitinib: From Rheumatoid Arthritis to COVID-19.
34008285 2021. Could isotretinoin be a protective agent against COVID-19?: A dermatologist perspective.
33978291 2021. Yellow-white fluorescence on the nails: A novel finding of Favipiravir used for the treatment of COVID-19.
34074197 2021. Is carbonic anhydrase inhibition useful as a complementary therapy of Covid-19 infection?
33817822 2021. Immunomodulatory and anti-inflammatory potential of crocin in COVID-19 treatment.
33913803 2021. Effective in vitro inactivation of SARS-CoV-2 by commercially available mouthwashes.
33891534 2021. Investigative study into whether an insect repellent has virucidal activity against SARS-CoV-2.
33830908 2021. The green tea catechin epigallocatechin gallate inhibits SARS-CoV-2 infection.
34054274 2021. Will Remdesivir Reshape Cardiovascular Practice in COVID 19 Era?
33998306 2021. Successful use of CytoSorb in a Covid-19 patient with secondary septic shock due to a sacral decubitus infection.
33862126 2021. Insulin fast-dissolving film for intranasal delivery via olfactory region, a promising approach for the treatment of anosmia in COVID-19 patients: Design, in-vitro characterization and clinical evaluation.
33332179 2021. Reply to: regarding: 'the risk of induced cancer and ischemic heart disease following low dose lung irradiation for COVID-19: estimation based on a virtual case'.
33320755 2021. Low-dose radiotherapy (LD-RT) for COVID-19-induced pneumopathy: a worth considering approach.
33320738 2021. Regarding: "the risk of induced cancer and ischemic heart disease following low dose lung irradiation for COVID-19: estimation based on a virtual case".
33301368 2021. Could Dietary Factors Reduce COVID-19 Mortality Rates? Moderating the Inflammatory State.
33211596 2021. Intravenous sulforhodamine B reduces alveolar surface tension, improves oxygenation, and reduces ventilation injury in a respiratory distress model.
33934592 2021. SARS-CoV-2 infection versus the body immune defenses: the role of immune responses and mechanism of action of dexamethasone.
33904269 2021. Monoclonal antibody therapy in COVID-19.
33896155 2021. Antibodies for COVID-19 - which, when and how long?
33982533 2021. Glycyrrhizin for topical use and prophylaxis of COVID-19: an interesting pharmacological perspective.
33947317 2021. The non-specific antiviral activity of polysulfates to fight SARS-CoV-2, its mutants and viruses with cationic spikes.
33970805 2021. Medicinal plant compounds as promising inhibitors of coronavirus (COVID-19) main protease: an in silico study.
33685364 2021. An in-silico approach to identify the potential hot spots in SARS-CoV-2 spike RBD to block the interaction with ACE2 receptor.
33826484 2021. Computational exploration of natural peptides targeting ACE2.
33928870 2021. In a search for potential drug candidates for combating COVID-19: computational study revealed salvianolic acid B as a potential therapeutic targeting 3CLpro and spike proteins.
33908318 2021. Cameroonian medicinal plants as potential candidates of SARS-CoV-2 inhibitors.
33372280 2021. Immunomodulatory effects of nanocurcumin on Th17 cell responses in mild and severe COVID-19 patients.
33368439 2021. Real-world prevalence and consequences of potential drug-drug interactions in the first-wave COVID-19 treatments.
33350472 2021. Amantadine for COVID-19.
33843779 2021. Antibodies: Friends, Foes, or Both? Lessons From COVID-19 for the Rheumatologist.
33962499 2021. Herbal supplement (Combi-5) in the management of COVID 19 individual with mild to moderate symptoms: a case report.
33915020 2021. Evaluation of the frequency and intensity of favipiravir-associated yellow-green fluorescence in lunulae, hair, and face.
33977807 2021. Lactoferrin for Mental Health: Neuro-Redox Regulation and Neuroprotective Effects across the Blood-Brain Barrier with Special Reference to Neuro-COVID-19.
33760271 2021. Study on the mechanism of active components of Liupao tea on 3CL(pro) based on HPLC-DAD fingerprint and molecular docking technique.

34084491 2021. Corticosteroid therapy for 2019-nCoV-infected patients: A case series of eight mechanically ventilated patients.
33936671 2021. Response to pegylated interferon in a COVID-19-positive elderly woman with primary myelofibrosis treated with ruxolitinib.
33972060 2021. Is the BCG vaccine a useful tool against COVID-19?
33997476 2021. The predictors of high titer of anti-SARS-CoV-2 antibody of convalescent plasma donors.
33969237 2021. The use of Janus Kinase inhibitors in hospitalized patients with COVID-19: Systematic review and meta-analysis.
33845194 2021. The microbiota-mediated dietary and nutritional interventions for COVID-19.
33838340 2021. Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products.
33956936 2021. Combination therapy with tocilizumab and dexamethasone cost-effectively reduces Coronavirus disease 2019 mortality.
32588884 2021. Influence of Corticosteroid Dose on Viral Shedding Duration in Patients With COVID-19.
33905481 2021. Vaccinated and convalescent donor-derived SARS-CoV-2-specific T cells as adoptive immunotherapy for high-risk COVID-19 patients.
33861337 2021. Impact of convalescent plasma therapy on SARS CoV-2 antibody profile in COVID-19 patients.
33846730 2021. Real-World Experience of Bamlanivimab for COVID-19: A Case-Control Study.
33953913 2021. Treatment for severe COVID-19 with a biomimetic sorbent haemoperfusion device in patients on haemodialysis.
33479100 2021. Vitamin D.
33355217 2021. Effectiveness of early treatment of lopinavir-ritonavir in patients with severe COVID-19: a case series.
34048876 2021. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-beta-1a and hydroxychloroquine in hospitalized patients with COVID-19.
34044151 2021. Use of an antiviral mouthwash as a barrier measure in the SARS-CoV-2 transmission in adults with asymptomatic to mild COVID-19: a multicentre, randomized, double-blind controlled trial.
34020032 2021. Intravenous immunoglobulin treatment for patients with severe COVID-19: a retrospective multicentre study.
33878505 2021. Patient-blood management for COVID19 convalescent plasma therapy: relevance of affinity and donor-recipient differences in concentration of neutralizing antibodies.
33915284 2021. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update.
33316402 2021. Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: a population-based cohort study.
34084692 2021. Effectiveness of convalescent plasma therapy in a patient with severe COVID-19-associated acute kidney injury.
33933296 2021. Polydatin and COVID-19.
33933295 2021. Nutritional risk at hospital admission is associated with prolonged length of hospital stay in old patients with COVID-19.
33933299 2021. Influence of foods and nutrients on COVID-19 recovery: A multivariate analysis of data from 170 countries using a generalized linear model.
33933297 2021. Early caloric deficit is associated with a higher risk of death in invasive ventilated COVID-19 patients.
33933298 2021. Region-specific COVID-19 risk scores and nutritional status of a high-risk population based on individual vulnerability assessment in the national survey data.
33353766 2021. Different barriers to nutritional therapy among critically-ill patients with COVID-19.
33349484 2021. The differential roles of zinc in immune responses and their potential implications in antiviral immunity against SARS-CoV-2.
34049750 2021. Nutritional status in post SARS-Cov2 rehabilitation patients.
33934925 2021. Mediterranean diet and the risk of COVID-19 in the 'Seguimiento Universidad de Navarra' cohort.
34024561 2021. Safety and tolerance of enteral nutrition in COVID-19 critically ill patients, a retrospective study.
34024545 2021. Strengthening the immunity of the Swiss population with micronutrients: A narrative review and call for action.
34024544 2021. Energy expenditure and feeding practices and tolerance during the acute and late phase of critically ill COVID-19 patients.
34024543 2021. The validity of the global leadership initiative on malnutrition criteria for diagnosing malnutrition in critically ill patients with COVID-19: A prospective cohort study.
34024542 2021. Poor nutritional status, risk of sarcopenia and nutrition related complaints are prevalent in COVID-19 patients during and after hospital admission.
34024527 2021. Serum vitamin D, calcium, and zinc levels in patients with COVID-19.
34024521 2021. Outcomes of nutritionally at-risk Coronavirus Disease 2019 (COVID 19) patients admitted in a tertiary government hospital: A follow-up study of the MalnutriCoV study.
34024518 2021. Influence of nutritional status on clinical outcomes among hospitalized patients with COVID-19.
34024514 2021. Glucose-6-phosphate dehydrogenase inhibitor for treatment of severe COVID-19: Polydatin.
34024511 2021. Prevalence and outcomes of malnutrition among hospitalized COVID-19 patients: A systematic review and meta-analysis.
33864625 2021. Comment on "Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6".
33864624 2021. Authors' Reply to Cattaneo et al.: "Comment on: Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin6".
33956042 2021. Patient safety recommendations and management in patients with COVID-19 pneumonia suspicion: a retrospective study.
34052007 2021. Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-blind, Randomized, Controlled Clinical Trial.
34049725 2021. SARS-CoV-2 Monoclonal Antibodies in Children: Ethical Considerations.
34026115 2021. Dynamics of antibodies to SARS-CoV-2 in convalescent plasma donors.
34013493 2021. Saving time in the radiotherapy procedures for COVID-19 pneumonia treatment. A single-institution experience.
34008772 2021. Efficacy and safety of umbilical cord mesenchymal stem cells for the treatment of patients with COVID-19.
33824151 2021. Le remdesivir chez les patients atteints de la COVID-19.
33866523 2021. Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies.
33838582 2021. Antiviral zinc oxide nanoparticles mediated by hesperidin and in silico comparison study between antiviral phenolics as anti-SARS-CoV-2.
34079039 2021. JAK inhibitors dampen activation of interferon-stimulated transcription of ACE2 isoforms in human airway epithelial cells.
33893388 2021. Structure and function analysis of a potent human neutralizing antibody CA521(FALA) against SARS-CoV-2.
33995820 2021. Therapeutic application of light and electromagnetic fields to reduce hyper-inflammation triggered by COVID-19.
33839522 2021. Traditional Chinese exercise potential role as prevention and adjuvant therapy in patients with COVID-19.
33989861 2021. Adjunctive homeopathic treatment of hospitalized COVID-19 patients (COVIHOM): A retrospective case series.
34091029 2021. Therapeutic effects and safety of oral Chinese patent medicine for COVID-19: A rapid systematic review and meta-analysis of randomized controlled trials.
33984653 2021. Designing potential siRNA molecule for the nucleocapsid(N) gene silencing of different SARS-CoV-2 strains of Bangladesh: Computational approach.
33845430 2021. The role of human C5a as a non-genomic target in corticosteroid therapy for management of severe COVID19.
33360831 2021. A computational drug repurposing approach in identifying the cephalosporin antibiotic and anti-hepatitis C drug derivatives for COVID-19 treatment.
33352458 2021. Identification of FDA approved drugs and nucleoside analogues as potential SARS-CoV-2 A1pp domain inhibitor: An in silico study.
33915361 2021. Promising phytochemicals of traditional Himalayan medicinal plants against putative replication and transmission targets of SARS-CoV-2 by computational investigation.
33895457 2021. Identification of potential antiviral compounds against SARS-CoV-2 structural and non structural protein targets: A pharmacoinformatics study of the CAS COVID-19 dataset.
33894500 2021. Screening of potent phytochemical inhibitors against SARS-CoV-2 protease and its two Asian mutants.
33862305 2021. Virtual screening of peptides with high affinity for SARS-CoV-2 main protease.
33845270 2021. Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning.
34090015 2021. Screening of natural compounds from Cyperus rotundus Linn against SARS-CoV-2 main protease (M(pro)): An integrated computational approach.
34020130 2021. The interaction of the bioflavonoids with five SARS-CoV-2 proteins targets: An in silico study.
34020129 2021. QSAR modeling and pharmacoinformatics of SARS coronavirus 3C-like protease inhibitors.
34015671 2021. Facilitating SARS CoV-2 RNA-Dependent RNA polymerase (RdRp) drug discovery by the aid of HCV NS5B palm subdomain binders: In silico approaches and benchmarking.
33915479 2021. Dual targeting of cytokine storm and viral replication in COVID-19 by plant-derived steroidal pregnanes: An in silico perspective.
33990955 2021. Vitamin D and COVID-19: Role of ACE2, age, gender, and ethnicity.
33951210 2021. Maternal selenium status plays a crucial role on clinical outcomes of pregnant women with COVID-19 infection.
33942327 2021. Feasibility of convalescent plasma therapy in severe COVID-19 patients with persistent SARS-CoV-2 viremia.
33913549 2021. Decreased in-hospital mortality associated with aspirin administration in hospitalized patients due to severe COVID-19.
33851732 2021. Targeting the viral-entry facilitators of SARS-CoV-2 as a therapeutic strategy in COVID-19.
33788302 2021. Hypothesis of zinc ascorbate as best zinc ionophore for raising antiviral resistance against Covid-19.
34076901 2021. Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled study.
33856708 2021. Interferon beta-1b for patients with moderate to severe COVID-19 in the inflammatory phase of the disease.
33792956 2021. Different incidences of acute kidney injury (AKI) and outcomes in COVID-19 patients with and without non-azithromycin antibiotics: A retrospective study.
33788273 2021. Remdesivir for the treatment of COVID-19 in pregnancy.
33755218 2021. Use of chlorhexidine to eradicate oropharyngeal SARS-CoV-2 in COVID-19 patients.
33710631 2021. Assessment of the role of zinc in the prevention of COVID-19 infections and mortality: A retrospective study in the Asian and European population.
33675235 2021. The role of teicoplanin in the treatment of SARS-CoV-2 infection: A retrospective study in critically ill COVID-19 patients (Tei-COVID study).
33982105 2021. The Role of Nutrition in COVID-19 Susceptibility and Severity of Disease: A Systematic Review.
33982128 2021. Low Circulating Vitamin D in Intensive Care Unit-Admitted COVID-19 Patients as a Predictor of Negative Outcomes.
33938523 2021. Receptor-binding Domain Severe Acute Respiratory Syndrome Coronavirus 2-specific Antibodies in Human Milk From Mothers With Coronavirus Disease 2019 Polymerase Chain Reaction or With Symptoms Suggestive of Coronavirus Disease 2019.
33980583 2021. Characterization of the SARS-CoV-2 Neutralization Potential of COVID-19-Convalescent Donors.
33860730 2021. From nicotine to the cholinergic anti-inflammatory reflex - Can nicotine alleviate the dysregulated inflammation in COVID-19?
34085075 2021. Nanoparticle-mediated surfactant therapy in patients with severe COVID-19: a perspective.
33539089 2021. Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
33775096 2021. Antimalarial Quinacrine and Chloroquine Lose Their Activity by Decreasing Cationic Amphiphilic Structure with a Slight Decrease in pH.
33891389 2021. Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors.
33835812 2021. Prodrugs of a 1'-CN-4-Aza-7,9-dideazaadenosine C-Nucleoside Leading to the Discovery of Remdesivir (GS-5734) as a Potent Inhibitor of Respiratory Syncytial Virus with Efficacy in the African Green Monkey Model of RSV.
33689397 2021. Plant Metabolites as Antiviral Preparations Against Coronaviruses.
32926302 2021. Hydroxychloroquine Overdose: What Are the Exact Roles of Diazepam and Potassium Infusion?
34061377 2021. Inhibitory effect on SARS-CoV-2 infection of neferine by blocking Ca(2+) -dependent membrane fusion.
33314173 2021. Administration of intravenous immunoglobulin in the treatment of COVID-19: A review of available evidence.
33336811 2021. Respiratory syndrome coronavirus-2 response: Microbiota as lactobacilli could make the difference.
33372690 2021. Rebuttal to overinterpretation of the antiviral results for human coronavirus 229E relative to severe acute respiratory syndrome coronavirus-2 by Rowpar Pharmaceuticals.
33368412 2021. Co-infection of malaria and early clearance of SARS-CoV-2 in healthcare workers.
33325032 2021. The safety of remdesivir for COVID-19 patients.
33314219 2021. mTOR inhibition in COVID-19: A commentary and review of efficacy in RNA viruses.
33314166 2021. The association between the level of serum 25(OH) vitamin D, obesity, and underlying diseases with the risk of developing COVID-19 infection: A case-control study of hospitalized patients in Tehran, Iran.
33980349 2021. A Combined Molecular Docking and Density Functional Theory Nuclear Magnetic Resonance Study of Trans-Dehydrocrotonin Interacting with COVID-19 Main Protease and Severe Acute Respiratory Syndrome Coronavirus 2 3C-Like Protease.
33560122 2021. Axial Chiral Binaphthoquinone and Perylenequinones from the Stromata of Hypocrella bambusae Are SARS-CoV-2 Entry Inhibitors.
33934125 2021. Is Hydroxychloroquine with Azithromycin a Good Combination in COVID-19 Compared to Hydroxychloroquine Alone from Cardiac Perspective? A Systematic Review and Meta-Analysis.
33906514 2021. The Rise and Fall of Hydroxychloroquine and Chloroquine in COVID-19.
33882724 2021. Treatment of Severe Hypertriglyceridemia With Insulin Infusions in Severe COVID-19: A Case Series.
33853438 2021. Probable Interaction Between Warfarin and the Combination of Remdesivir With Dexamethasone for Coronavirus Disease 2019 (COVID-19) Treatment: A 2 Case Report.
33302762 2021. A Response to the Recommendations for Using Dexamethasone for the Treatment of COVID-19: The Dark Side of Dexamethasone.

33903133 2021. Bradycardia associated with remdesivir therapy for COVID-19 in a 59-year-old man.
34055238 2021. Prediction of repurposed drugs for Coronaviruses using artificial intelligence and machine learning.
34002118 2021. Computational optimization of angiotensin-converting enzyme 2 for SARS-CoV-2 Spike molecular recognition.
33936562 2021. Resources and computational strategies to advance small molecule SARS-CoV-2 discovery: Lessons from the pandemic and preparing for future health crises.
33841751 2021. Identification of multipotent drugs for COVID-19 therapeutics with the evaluation of their SARS-CoV2 inhibitory activity.
33312453 2021. Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses.
34074458 2021. The link between vitamin D and COVID-19.
34074457 2021. Response to the letter to the editor: "The link between Vitamin D and COVID-19".
34074339 2021. Hemofiltration with the Seraph((R)) 100 Microbind((R)) Affinity filter decreases SARS-CoV-2 nucleocapsid protein in critically ill COVID-19 patients.
34036275 2021. Cytokine Blockade in Coronavirus Disease 2019: Keeping an Open Mind.
33834168 2021. In Vitro-Administered Dexamethasone Suppresses T Cell Function With Reversal by Interleukin-7 in Coronavirus Disease 2019.
33986957 2021. The Use of Dornase Alfa in the Management of COVID-19-Associated Adult Respiratory Distress Syndrome.
33981518 2021. Clinical Impact of the Early Use of Monoclonal Antibody LY-CoV555 (Bamlanivimab) on Mortality and Hospitalization Among Elderly Nursing Home Patients: A Multicenter Retrospective Study.
33936897 2021. Clearing the Fog: Is Hydroxychloroquine Effective in Reducing Coronavirus Disease-2019 Progression? A Randomized Controlled Trial.
33564538 2021. Safety and Efficacy of Low-Dose Corticosteroids in Patients With Non-severe Coronavirus Disease 2019: A Retrospective Cohort Study.
34035996 2021. Azithromycin in the Successful Management of COVID-19: A Family Physician's Perspective.
33890544 2021. Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis.
33877545 2021. A Network Pharmacology Study to Uncover the Multiple Molecular Mechanism of the Chinese Patent Medicine Toujiequwen Granules in the Treatment of Corona Virus Disease 2019 (COVID-19).
33948913 2021. Keeping a Balance During the Pandemic: a Narrative Review on the Important Role of Micronutrients in Preventing Infection and Reducing Complications of COVID-19.
33835432 2021. A Mechanistic Link Between Selenium and Coronavirus Disease 2019 (COVID-19).
33323712 2021. Editorial: COVID-19 in older persons: the role of nutrition.
34052732 2021. Remdesivir for the treatment of Covid-19: the value of biochemical studies.
34029993 2021. Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection.
33907665 2021. Indomethacin: Can It Counteract Bradykinin Effects in COVID-19 Patients?
33926774 2021. Perspectives on anti-IL-1 inhibitors as potential therapeutic interventions for severe COVID-19.
33333393 2021. Experience of using tocilizumab for treatment in Indonesian patients with severe COVID-19.
33992887 2021. COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon.
34053857 2021. Mesenchymal stromal cell therapy for coronavirus disease 2019: which? when? and how much?
33898670 2021. Design and manufacturability data on additively manufactured solutions for COVID-19.
33869690 2021. Data on the docking of phytoconstituents of betel plant and matcha green tea on SARS-CoV-2.
33855133 2021. Dataset of AMBER force field parameters of drugs, natural products and steroids for simulations using GROMACS.
33404148 2021. Fluorescence of nails and hair on Wood's lamp examination in Covid pandemic; undefined effect of Favipiravir in humans.
33354849 2021. Tetracyclines in COVID-19 patients quarantined at home: Literature evidence supporting real-world data from a multicenter observational study targeting inflammatory and infectious dermatoses.
33838614 2021. Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) - A systematic review, meta-analysis, and meta-regression.
33319454 2021. Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study.
33310173 2021. Association of metformin with mortality or ARDS in patients with COVID-19 and type 2 diabetes: A retrospective cohort study.
33947009 2021. Dolutegravir Plus Lamivudine Two-Drug Regimen: Safety, Efficacy and Diagnostic Considerations for Its Use in Real-Life Clinical Practice-A Refined Approach in the COVID-19 Era.
34025036 2021. Theoretical investigation of favipiravir antiviral drug based on fullerene and boron nitride nanocages.
33919780 2021. Potential Effects of Melatonin and Micronutrients on Mitochondrial Dysfunction during a Cytokine Storm Typical of Oxidative/Inflammatory Diseases.
33867892 2021. Possible Potential Effects of Honey and Its Main Components Against Covid-19 Infection.
33976534 2021. Thymoquinone: A Promising Natural Compound with Potential Benefits for COVID-19 Prevention and Cure.
34048893 2021. High-throughput screening assays for SARS-CoV-2 drug development: Current status and future directions.
33309533 2021. Potential SARS-CoV-2 main protease inhibitors.
33892145 2021. Web resources facilitate drug discovery in treatment of COVID-19.
33128226 2021. Tutankhamun's Antimalarial Drug for Covid-19.
33864232 2021. Safety and Efficacy of Ivermectin and Doxycycline Monotherapy and in Combination in the Treatment of COVID-19: A Scoping Review.
34047956 2021. Comment on: "Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry".
33828607 2021. The effect of azoximer bromide (Polyoxidonium(R)) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study.
34097570 2021. A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351.
34074219 2021. 501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro.
33993282 2021. The Challenging but Imperative Path to Monoclonal Antibody Use Against COVID-19 for a Small Overseas Military Hospital.
33993281 2021. Bamlanivimab Use in a Military Treatment Facility.
33904240 2021. Targeting SARS-CoV-2 Spike Protein/ACE2 Protein-Protein Interactions: a Computational Study.
34018687 2021. In silico Studies on the Interaction between Mpro and PLpro From SARS-CoV-2 and Ebselen, its Metabolites and Derivatives.
33963053 2021. Targeting the Conserved Stem Loop 2 Motif in the SARS-CoV-2 Genome.
33910954 2021. Inhibitors of Coronavirus 3CL Proteases Protect Cells from Protease-Mediated Cytotoxicity.
33963054 2021. ILRUN Downregulates ACE2 Expression and Blocks Infection of Human Cells by SARS-CoV-2.
33961002 2021. Precision Medicine for COVID-19: Phenotype Anarchy or Promise Realized?
33306087 2021. An EUA for Bamlanivimab-A Monoclonal Antibody for COVID-19.
34081086 2021. Could Statins Do More Than Lower Cholesterol in Patients With COVID-19?
34081075 2021. Bamlanivimab for Prevention of COVID-19.
34081073 2021. Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial.
34028504 2021. Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19: A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial.
33914069 2021. Regarding Use of Povidone Iodine to Reduce Nasopharyngeal Viral Load in Patients With COVID-19.
33914066 2021. Regarding Use of Povidone Iodine to Reduce Nasopharyngeal Viral Load in Patients With COVID-19-Reply.
34087041 2021. Synthesis, comparative in vitro antibacterial, antioxidant and UV fluorescence studies of bis indole Schiff bases and molecular docking with ct-DNA and SARS-CoV-2 M(pro).
33958069 2021. In Reply - Safety of Convalescent Plasma Transfusion.
33958067 2021. Safety of Convalescent Plasma Transfusion.
33976099 2021. Fluvoxamine for COVID-19?
33830966 2021. An EUA for bamlanivimab and etesevimab for COVID-19.
33212200 2021. An updated and comprehensive review of the antiviral potential of essential oils and their chemical constituents with special focus on their mechanism of action against various influenza and coronaviruses.
33845740 2021. A therapeutic journey of potential drugs against COVID-19.
33355053 2021. Repurposed Antiviral Drugs for the Treatment of COVID-19: Syntheses, Mechanism of Infection and Clinical Trials.
33280595 2021. Synthetic and Semi-synthetic Drugs as a Promising Therapeutic Option for the Treatment of COVID-19.
33844232 2021. Antikorper-Duo verhindert schwere COVID-19-Verlaufe.
33328281 2021. Relevance of the Bruton Tyrosine Kinase as a Target for COVID-19 Therapy.
33945284 2021. siRNA Therapeutics for the Therapy of COVID-19 and Other Coronaviruses.
33356050 2021. Tocilizumab in Covid-19. Reply.
33356049 2021. Tocilizumab in Covid-19.
33378611 2021. Neutralizing Antibody LY-CoV555 for Outpatient Covid-19. Reply.
33378610 2021. Neutralizing Antibody LY-CoV555 for Outpatient Covid-19.
33826817 2021. Preparing for the Future - Nanobodies for Covid-19?
33900318 2021. Inhibition mechanism and hot-spot prediction of nine potential drugs for SARS-CoV-2 M(pro) by large-scale molecular dynamic simulations combined with accurate binding free energy calculations.
33986543 2021. Tocilizumab for the treatment of severe COVID-19.
33837377 2021. Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19.
33949277 2021. Molecular docking of compounds from Clinacanthus nutans extract detected by GC-MS analysis with the SARS-CoV-2 main protease and ACE2 protein.
33949276 2021. Potential of (Citrus nobilis Lour x Citrus deliciosa Tenora) metabolites on COVID-19 virus main protease supported by in silico analysis.
33949266 2021. Can nutraceuticals assist treatment and improve covid-19 symptoms?
34027770 2021. Natural metabolites from the soft coral Nephthea sp. as potential SARS-CoV-2 main protease inhibitors.
33864035 2021. RECOVERY 1 year on: a rare success in the COVID-19 clinical trial landscape.
33981021 2021. Structural basis for broad coronavirus neutralization.
33963326 2021. International COVID-19 trial to restart with focus on immune responses.

TempP

Aktuelle Version vom 15. September 2021, 13:56 Uhr

Meine Werkzeuge

Namensräume

Varianten

Ansichten

Aktionen

Suche

Navigation

Werkzeuge

@@ Zeile 135: / Zeile 135: @@
 {{tp|p=33052207|t=2020. Remdesivir : forme inhalee en pediatrie.|pdf=|usr=024}}
 {{tp|p=32842641|t=2020. Plant-Derived Nutraceuticals and Immune System Modulation: An Evidence-Based Overview.|pdf=|usr=024}}
+{{tp|p=33515005|t=2021. Habitual use of vitamin D supplements and risk of coronavirus disease 2019 (COVID-19) infection: a prospective study in UK Biobank.|pdf=|usr=025}}
+{{tp|p=33399201|t=2021. Hospital-Based Donor Recruitment and Predonation Serologic Testing for COVID-19 Convalescent Plasma.|pdf=|usr=025}}
+{{tp|p=33399186|t=2021. Importance of the Lipid-Bound Character of Vitamin D Binding Protein in the Evaluation of Vitamin D Status in COVID-19 Patients.|pdf=|usr=025}}
+{{tp|p=33483744|t=2021. Developing statewide remdesivir use criteria.|pdf=|usr=025}}
+{{tp|p=33493729|t=2021. The outcome of fluticasone nasal spray on anosmia and triamcinolone oral paste in dysgeusia in COVID-19 patients.|pdf=|usr=025}}
+{{tp|p=33410395|t=2021. COVID-19 and Corticosteroids: Unfamiliar but Potentially Fatal Infections That Can Arise following Short-Course Steroid Treatment.|pdf=|usr=025}}
+{{tp|p=33508271|t=2021. Validation of LC-MS/MS methods for determination of remdesivir and its metabolites GS-441524 and GS-704277 in acidified human plasma and their application in COVID-19 related clinical studies.|pdf=|usr=025}}
+{{tp|p=33469977|t=2021. Molecular Simulations suggest Vitamins, Retinoids and Steroids as Ligands of the Free Fatty Acid Pocket of the SARS-CoV-2 Spike Protein.|pdf=|usr=025}}
+{{tp|p=33464672|t=2021. Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine.|pdf=|usr=025}}
+{{tp|p=33387615|t=2021. Monitoring neutrophil-to-lymphocyte ratio in patients with coronavirus disease 2019 receiving tocilizumab.|pdf=|usr=025}}
+{{tp|p=33420963|t=2021. Pilot trial of high-dose vitamin C in critically ill COVID-19 patients.|pdf=|usr=025}}
+{{tp|p=33395345|t=2021. Speed Versus Efficacy: Quantifying Potential Tradeoffs in COVID-19 Vaccine Deployment.|pdf=|usr=025}}
+{{tp|p=33395339|t=2021. A Public Health COVID-19 Vaccination Strategy to Maximize the Health Gains for Every Single Vaccine Dose.|pdf=|usr=025}}
+{{tp|p=33460347|t=2021. SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn.|pdf=|usr=025}}
+{{tp|p=33456770|t=2021. Protease inhibitor GC376 for COVID-19: Lessons learned from feline infectious peritonitis.|pdf=|usr=025}}
+{{tp|p=33520220|t=2021. When to call it off: Defining the role of low-dose corticosteroids in thwarting the progression of non-severe COVID-19.|pdf=|usr=025}}
+{{tp|p=33489115|t=2021. Remdesivir therapy in patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials.|pdf=|usr=025}}
+{{tp|p=33440983|t=2021. Antiviral treatment in COVID-19: which is the most promising?-a narrative review.|pdf=|usr=025}}
+{{tp|p=33381234|t=2020. Low-dose radiation therapy for coronavirus disease-2019 pneumonia: Is it time to look beyond apprehensions?|pdf=|usr=025}}
+{{tp|p=33440681|t=2021. Viroinformatics-Based Analysis of SARS-CoV-2 Core Proteins for Potential Therapeutic Targets.|pdf=|usr=025}}
+{{tp|p=33401749|t=2021. Role of Melatonin on Virus-Induced Neuropathogenesis-A Concomitant Therapeutic Strategy to Understand SARS-CoV-2 Infection.|pdf=|usr=025}}
+{{tp|p=33515606|t=2021. Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development.|pdf=|usr=025}}
+{{tp|p=33444702|t=2021. Inhibition of coronavirus infection by a synthetic STING agonist in primary human airway system.|pdf=|usr=025}}
+{{tp|p=33422611|t=2021. The rocaglate CR-31-B (-) inhibits SARS-CoV-2 replication at non-cytotoxic, low nanomolar concentrations in vitro and ex vivo.|pdf=|usr=025}}
+{{tp|p=33512610|t=2021. Apoptosis induced by SARS-CoV-2: can we target it?|pdf=|usr=025}}
+{{tp|p=33512650|t=2021. Strong Binding of Leupeptin with TMPRSS2 Protease May Be an Alternative to Camostat and Nafamostat for SARS-CoV-2 Repurposed Drug: Evaluation from Molecular Docking and Molecular Dynamics Simulations.|pdf=|usr=025}}
+{{tp|p=33519322|t=2021. Drug repositioning based on similarity constrained probabilistic matrix factorization: COVID-19 as a case study.|pdf=|usr=025}}
+{{tp|p=33485847|t=2021. Pharmacoinformatics approach based identification of potential Nsp15 endoribonuclease modulators for SARS-CoV-2 inhibition.|pdf=|usr=025}}
+{{tp|p=33483203|t=2020. Reply to "Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19".|pdf=|usr=025}}
+{{tp|p=33389097|t=2021. Safety of lymphocytes immunotherapy during the COVID-19 outbreak in Wuhan, China.|pdf=|usr=025}}
+{{tp|p=33485639|t=2020. New COVID-19 Vaccines, Its Cost and Shelf Life: A Cost Effectiveness Analysis.|pdf=|usr=025}}
+{{tp|p=33380359|t=2020. COVID-19 Vaccines: New Developments and the Road Ahead.|pdf=|usr=025}}
+{{tp|p=33459817|t=2021. Addressing the potential role of curcumin in the prevention of COVID-19 by targeting the Nsp9 replicase protein through molecular docking.|pdf=|usr=025}}
+{{tp|p=33398691|t=2021. Role of specialized pro-resolving lipid mediators and their receptors in virus infection: a promising therapeutic strategy for SARS-CoV-2 cytokine storm.|pdf=|usr=025}}
+{{tp|p=33492523|t=2021. Efficacy of favipiravir in COVID-19 treatment: a multi-center randomized study.|pdf=|usr=025}}
+{{tp|p=33457430|t=2021. Chemical profiling of selected Ayurveda formulations recommended for COVID-19.|pdf=|usr=025}}
+{{tp|p=33483287|t=2021. Hydroxychloroquine for the treatment of COVID-19 and its potential cardiovascular toxicity: Hero or villain?|pdf=|usr=025}}
+{{tp|p=33454058|t=2021. The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease.|pdf=|usr=025}}
+{{tp|p=33388129|t=2021. Remdesivir: From Ebola to COVID-19.|pdf=|usr=025}}
+{{tp|p=33387885|t=2021. In silico study of the potential interactions of 4'-acetamidechalcones with protein targets in SARS-CoV-2.|pdf=|usr=025}}
+{{tp|p=33477032|t=2021. ATP biphasically modulates LLPS of SARS-CoV-2 nucleocapsid protein and specifically binds its RNA-binding domain.|pdf=|usr=025}}
+{{tp|p=33515531|t=2021. PDE4 inhibition as a therapeutic strategy for improvement of pulmonary dysfunctions in Covid-19 and cigarette smoking.|pdf=|usr=025}}
+{{tp|p=33482149|t=2021. Biochemical features and mutations of key proteins in SARS-CoV-2 and their impacts on RNA therapeutics.|pdf=|usr=025}}
+{{tp|p=33439253|t=2021. Antivirals that target the host IMPalpha/beta1-virus interface.|pdf=|usr=025}}
+{{tp|p=33469510|t=2021. A domain-based vaccine construct against SARS-CoV-2, the causative agent of COVID-19 pandemic: development of self-amplifying mRNA and peptide vaccines.|pdf=|usr=025}}
+{{tp|p=33381848|t=2020. FBA reveals guanylate kinase as a potential target for antiviral therapies against SARS-CoV-2.|pdf=|usr=025}}
+{{tp|p=33409924|t=2021. Olfactory Disturbances as Presenting Manifestation Among Egyptian Patients with COVID-19: Possible Role of Zinc.|pdf=|usr=025}}
+{{tp|p=33513850|t=2021. Promising Extracellular Vesicle-Based Vaccines against Viruses, Including SARS-CoV-2.|pdf=|usr=025}}
+{{tp|p=33508618|t=2021. The direct evidence and mechanism of traditional Chinese medicine treatment of COVID-19.|pdf=|usr=025}}
+{{tp|p=33486202|t=2021. Human endeavor for anti-SARS-CoV-2 pharmacotherapy: A major strategy to fight the pandemic.|pdf=|usr=025}}
+{{tp|p=33378989|t=2021. Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size.|pdf=|usr=025}}
+{{tp|p=33486212|t=2021. Impact of virus genetic variability and host immunity for the success of COVID-19 vaccines.|pdf=|usr=025}}
+{{tp|p=33454595|t=2021. The role of iron in the pathogenesis of COVID-19 and possible treatment with lactoferrin and other iron chelators.|pdf=|usr=025}}
+{{tp|p=33426074|t=2020. Molecular Insights into the MAPK Cascade during Viral Infection: Potential Crosstalk between HCQ and HCQ Analogues.|pdf=|usr=025}}
+{{tp|p=33424013|t=2021. Discovery of New Fusion Inhibitor Peptides against SARS-CoV-2 by Targeting the Spike S2 Subunit.|pdf=|usr=025}}
+{{tp|p=33430299|t=2021. Bioactive Terpenes and Their Derivatives as Potential SARS-CoV-2 Proteases Inhibitors from Molecular Modeling Studies.|pdf=|usr=025}}
+{{tp|p=33445810|t=2021. Cytokines and Chemokines in SARS-CoV-2 Infections-Therapeutic Strategies Targeting Cytokine Storm.|pdf=|usr=025}}
+{{tp|p=33396926|t=2020. Potential Medicinal Plants for the Treatment of Dengue Fever and Severe Acute Respiratory Syndrome-Coronavirus.|pdf=|usr=025}}
+{{tp|p=33450541|t=2021. Broad-spectrum antivirals of protoporphyrins inhibit the entry of highly pathogenic emerging viruses.|pdf=|usr=025}}
+{{tp|p=33515918|t=2021. Potential inhibitors interacting in Neuropilin-1 to develop an adjuvant drug against COVID-19, by molecular docking.|pdf=|usr=025}}
+{{tp|p=33458647|t=2021. Review of pharmacologic and immunologic agents in the management of COVID-19.|pdf=|usr=025}}
+{{tp|p=33390423|t=2021. Tetracycline plus macrolide: A potential therapeutic regimen for COVID-19?|pdf=|usr=025}}
+{{tp|p=33390384|t=2021. Latest updates on COVID-19 vaccines.|pdf=|usr=025}}
+{{tp|p=33443562|t=2021. Vaccinations in CLL: implications for COVID-19.|pdf=|usr=025}}
+{{tp|p=33478471|t=2021. Allergen fragrance molecules: a potential relief for COVID-19.|pdf=|usr=025}}
+{{tp|p=33446136|t=2021. Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study.|pdf=|usr=025}}
+{{tp|p=33430799|t=2021. JAK-inhibitor and type I interferon ability to produce favorable clinical outcomes in COVID-19 patients: a systematic review and meta-analysis.|pdf=|usr=025}}
+{{tp|p=33413329|t=2021. Computational analysis to repurpose drugs for COVID-19 based on transcriptional response of host cells to SARS-CoV-2.|pdf=|usr=025}}
+{{tp|p=33482902|t=2021. A pilot trial of human amniotic fluid for the treatment of COVID-19.|pdf=|usr=025}}
+{{tp|p=33472855|t=2021. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial.|pdf=|usr=025}}
+{{tp|p=33419750|t=2021. Successful treatment of severe COVID-19 pneumonia and hyperinflammatory syndrome with tocilizumab.|pdf=|usr=025}}
+{{tp|p=33509890|t=2021. Convalescent plasma for COVID-19 complicated by ARDS due to TRALI.|pdf=|usr=025}}
+{{tp|p=33472840|t=2021. Effect of micronutrient supplements on influenza and other respiratory tract infections among adults: a systematic review and meta-analysis.|pdf=|usr=025}}
+{{tp|p=33504571|t=2021. Does vitamin D supplementation prevent SARS-CoV-2 infection in military personnel? Review of the evidence.|pdf=|usr=025}}
+{{tp|p=33521556|t=2020. Micronutrient deficiencies in patients with COVID-19: how metabolomics can contribute to their prevention and replenishment.|pdf=|usr=025}}
+{{tp|p=33521536|t=2020. Responsibility for vitamin D supplementation of elderly care home residents in England: falling through the gap between medicine and food.|pdf=|usr=025}}
+{{tp|p=33441373|t=2021. Rationale for azithromycin in COVID-19: an overview of existing evidence.|pdf=|usr=025}}
+{{tp|p=33483637|t=2021. Oral side effects of COVID-19 vaccine.|pdf=|usr=025}}
+{{tp|p=33454964|t=2021. Oral ivermectin for a scabies outbreak in a long-term care facility: potential value in preventing COVID-19 and associated mortality.|pdf=|usr=025}}
+{{tp|p=33524158|t=2021. Convalescent plasma for COVID-19 - encouraging signals of efficacy.|pdf=|usr=025}}
+{{tp|p=33482025|t=2021. Early mortality benefit with COVID-19 convalescent plasma: a matched control study.|pdf=|usr=025}}
+{{tp|p=33504378|t=2021. Optimising COVID-19 vaccine efficacy by ensuring nutritional adequacy.|pdf=|usr=025}}
+{{tp|p=33468263|t=2021. Vitamin A in resistance to and recovery from infection: relevance to SARS-CoV2.|pdf=|usr=025}}
+{{tp|p=33518836|t=2021. Helmet mask and tocilizumab for a patient with hemophagocytic lymphohistiocytosis syndrome and COVID-19: a case report.|pdf=|usr=025}}
+{{tp|p=33497434|t=2021. Identifying anti-coronavirus peptides by incorporating different negative datasets and imbalanced learning strategies.|pdf=|usr=025}}
+{{tp|p=33480398|t=2021. DrugRepV: a compendium of repurposed drugs and chemicals targeting epidemic and pandemic viruses.|pdf=|usr=025}}
+{{tp|p=33461215|t=2021. Ligand-based approach for predicting drug targets and for virtual screening against COVID-19.|pdf=|usr=025}}
+{{tp|p=33406222|t=2021. Exploration of natural compounds with anti-SARS-CoV-2 activity via inhibition of SARS-CoV-2 Mpro.|pdf=|usr=025}}
+{{tp|p=33406218|t=2021. A comprehensive drug repurposing study for COVID19 treatment: novel putative dihydroorotate dehydrogenase inhibitors show association to serotonin-dopamine receptors.|pdf=|usr=025}}
+{{tp|p=33497123|t=2021. Monoclonal Antibodies Receive EUA to Treat Mild to Moderate COVID-19.|pdf=|usr=025}}
+{{tp|p=33517757|t=2021. Clozapine Intoxication in COVID-19.|pdf=|usr=025}}
+{{tp|p=33439703|t=2021. The Need for Novel Approaches in Assessing the Value of COVID-19 Vaccines.|pdf=|usr=025}}
+{{tp|p=33416244|t=2020. Effects of Hydroxychloroquine With or Without Azithromycin on QT Interval in COVID-19: A Systematic Review. Electrophysiology Collaborative Consortium for Meta-analysis-Electram Investigators.|pdf=|usr=025}}
+{{tp|p=33481405|t=2021. Aspirin in Coronavirus Disease 2019-Related Acute Respiratory Distress Syndrome: An Old, Low-Cost Therapy With a Strong Rationale.|pdf=|usr=025}}
+{{tp|p=33395337|t=2021. WHO recommends corticosteroids for patients with severe or critical COVID-19.|pdf=|usr=025}}
+{{tp|p=33395331|t=2021. In severe COVID-19, adding lopinavir-ritonavir to usual care did not improve mortality at 28 days.|pdf=|usr=025}}
+{{tp|p=33524290|t=2021. The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 >/=7 days after the 2nd dose.|pdf=|usr=025}}
+{{tp|p=33524282|t=2021. In inpatients with COVID-19, none of remdesivir, hydroxychloroquine, lopinavir, or interferon beta-1a differed from standard care for in-hospital mortality.|pdf=|usr=025}}
+{{tp|p=33524280|t=2021. Tocilizumab did not reduce hypoxemic respiratory failure or death in hospitalized patients with COVID-19.|pdf=|usr=025}}
+{{tp|p=33509798|t=2021. Response to: 'Correspondence on 'Anti-inflammatory therapy for COVID-19 infection: the case for colchicine'' by Perricone et al.|pdf=|usr=025}}
+{{tp|p=33509794|t=2021. Correspondence on 'Anti-inflammatory therapy for COVID-19 infection: the case for colchicine'.|pdf=|usr=025}}
+{{tp|p=33504481|t=2021. Correspondence on 'Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome'.|pdf=|usr=025}}
+{{tp|p=33504480|t=2021. Response to: 'Correspondence on 'Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome'' by Kawada.|pdf=|usr=025}}
+{{tp|p=33452005|t=2021. Correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine'.|pdf=|usr=025}}
+{{tp|p=33459727|t=2020. Adverse effects, pharmacological interactions, and cardiovascular drugs in COVID-19 treatment.|pdf=|usr=025}}
+{{tp|p=33472834|t=2021. Covid-19: Arthritis drug trial for severe illness is stopped early after increase in deaths.|pdf=|usr=025}}
+{{tp|p=33446489|t=2021. Covid-19: Convalescent plasma may cut deaths in patients not on ventilation, study indicates.|pdf=|usr=025}}
+{{tp|p=33436419|t=2021. How the Oxford-AstraZeneca covid-19 vaccine was made.|pdf=|usr=025}}
+{{tp|p=33455917|t=2021. Cyclosporine: hope for severe COVID-19?|pdf=|usr=025}}
+{{tp|p=33401333|t=2021. COVID-19 and the revival of passive immunization: Antibody therapy for inhibiting SARS-CoV-2 and preventing host cell infection: IUPHAR review: 31.|pdf=|usr=025}}
+{{tp|p=33512003|t=2021. Neurological risks and benefits of cytokine-based treatments in coronavirus disease 2019: from preclinical to clinical evidence.|pdf=|usr=025}}
+{{tp|p=33502877|t=2021. Are clarithromycin, azithromycin and their analogues effective in the treatment of COVID19?|pdf=|usr=025}}
+{{tp|p=33521606|t=2021. Antiviral activity of sulfated polysaccharides from marine algae and its application in combating COVID-19: Mini review.|pdf=|usr=025}}
+{{tp|p=33481336|t=2021. Generation of enzymatically competent SARS-CoV-2 decoy receptor ACE2-Fc in glycoengineered Nicotiana benthamiana.|pdf=|usr=025}}
+{{tp|p=33430659|t=2021. Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors.|pdf=|usr=025}}
+{{tp|p=33513419|t=2021. Potential effect of Maxing Shigan decoction against coronavirus disease 2019 (COVID-19) revealed by network pharmacology and experimental verification.|pdf=|usr=025}}
+{{tp|p=33485971|t=2021. Dissecting the novel mechanism of reduning injection in treating Coronavirus Disease 2019 (COVID-19) based on network pharmacology and experimental verification.|pdf=|usr=025}}
+{{tp|p=33485973|t=2021. Chinese herbal medicine: Fighting SARS-CoV-2 infection on all fronts.|pdf=|usr=025}}
+{{tp|p=33514385|t=2021. Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein.|pdf=|usr=025}}
+{{tp|p=33426604|t=2021. ACE-2-interacting Domain of SARS-CoV-2 (AIDS) Peptide Suppresses Inflammation to Reduce Fever and Protect Lungs and Heart in Mice: Implications for COVID-19 Therapy.|pdf=|usr=025}}
+{{tp|p=33403500|t=2021. Pharmacotherapeutics of SARS-CoV-2 Infections.|pdf=|usr=025}}
+{{tp|p=33491033|t=2021. Impact of Serum 25(OH) Vitamin D Level on Mortality in Patients with COVID-19 in Turkey.|pdf=|usr=025}}
+{{tp|p=33491026|t=2021. Editorial: COVID19 Vaccination in Frail People. Lots of Hope and Some Questions.|pdf=|usr=025}}
+{{tp|p=33398242|t=2021. Potential therapeutic approaches of microRNAs for COVID-19: Challenges and opportunities.|pdf=|usr=025}}
+{{tp|p=33456225|t=2020. A brief outlook on the current emerging trends of COVID 19 vaccines.|pdf=|usr=025}}
+{{tp|p=33388760|t=2021. Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of COVID-19 in Children and Adolescents.|pdf=|usr=025}}
+{{tp|p=33495677|t=2021. Comments on potential re-purposing of medicines against high-altitude illnesses towards SARS-CoV2: possibilities and pitfalls.|pdf=|usr=025}}
+{{tp|p=33472369|t=2021. ACE-2-Derived Biomimetic Peptides for the Inhibition of Spike Protein of SARS-CoV-2.|pdf=|usr=025}}
+{{tp|p=33439850|t=2021. Diet, Nutrition, Obesity, and Their Implications for COVID-19 Mortality: Development of a Marginalized Two-Part Model for Semicontinuous Data.|pdf=|usr=025}}
+{{tp|p=33437926|t=2021. A Call to Action: "Low-Dose Radiation May Help Cure COVID-19..." [Taps Mic] "...Is This Thing On?"|pdf=|usr=025}}
+{{tp|p=33437924|t=2021. Low-Dose Radiation Therapy for COVID-19: Promises and Pitfalls.|pdf=|usr=025}}
+{{tp|p=33390434|t=2020. Increased secondary infection in COVID-19 patients treated with steroids in New York City.|pdf=|usr=025}}
+{{tp|p=33485468|t=2021. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial.|pdf=|usr=025}}
+{{tp|p=33485467|t=2021. Optimism and caution for an inactivated COVID-19 vaccine.|pdf=|usr=025}}
+{{tp|p=33493450|t=2021. Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial.|pdf=|usr=025}}
+{{tp|p=33493449|t=2021. The right place for IL-1 inhibition in COVID-19.|pdf=|usr=025}}
+{{tp|p=33484632|t=2021. Realising the potential of SARS-CoV-2 vaccines-a long shot?|pdf=|usr=025}}
+{{tp|p=33460572|t=2021. Assessing the importance of interleukin-6 in COVID-19 - Authors' reply.|pdf=|usr=025}}
+{{tp|p=33460569|t=2021. Assessing the importance of interleukin-6 in COVID-19.|pdf=|usr=025}}
+{{tp|p=33461387|t=2021. Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies.|pdf=|usr=025}}
+{{tp|p=33476632|t=2021. Protective effect of Rosuvastatin on Azithromycin induced cardiotoxicity in a rat model.|pdf=|usr=025}}
+{{tp|p=33513400|t=2021. Cardiovascular protective properties of oxytocin against COVID-19.|pdf=|usr=025}}
+{{tp|p=33402630|t=2021. Is there a role for inhaled ciclesonide in the treatment of COVID-19?|pdf=|usr=025}}
+{{tp|p=33513822|t=2021. Caged Dexamethasone/Quercetin Nanoparticles, Formed of the Morphogenetic Active Inorganic Polyphosphate, are Strong Inducers of MUC5AC.|pdf=|usr=025}}
+{{tp|p=33413833|t=2021. Inverse Relationship of Maximal Exercise Capacity to Hospitalization Secondary to Coronavirus Disease 2019.|pdf=|usr=025}}
+{{tp|p=33413825|t=2021. Micro-Thrombosis, Perfusion Defects, and Worsening Oxygenation in COVID-19 Patients: A Word of Caution on the Use of Convalescent Plasma.|pdf=|usr=025}}
+{{tp|p=33413824|t=2021. In Reply - Micro-Thrombosis, Perfusion Defects, and Worsening Oxygenation in COVID-19 Patients: A Word of Caution on the Use of Convalescent Plasma.|pdf=|usr=025}}
+{{tp|p=33419872|t=2021. Pneumococcal Conjugate Vaccine Protection against Coronavirus-Associated Pneumonia Hospitalization in Children Living with and without HIV.|pdf=|usr=025}}
+{{tp|p=33468703|t=2021. Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses In Vitro.|pdf=|usr=025}}
+{{tp|p=33424100|t=2020. Physical Activity Outdoors as an Alternative to Lockdown: the Three Cs Strategy.|pdf=|usr=025}}
+{{tp|p=33388144|t=2021. Reaccion transfusional a plasma hiperinmune en pacientes con infeccion grave por COVID-19.|pdf=|usr=025}}
+{{tp|p=33380371|t=2021. Efectividad de los glucocorticoides en pacientes hospitalizados por neumonia grave por SARS-CoV-2.|pdf=|usr=025}}
+{{tp|p=33392390|t=2021. Relationship between MMR vaccination and severity of Covid-19 infection. Survey among primary care physicians.|pdf=|usr=025}}
+{{tp|p=33422363|t=2021. Tackling the COVID-19 "cytokine storm" with microRNA mimics directly targeting the 3'UTR of pro-inflammatory mRNAs.|pdf=|usr=025}}
+{{tp|p=33385879|t=2021. Phenylmethimazole is a candidate drug for the treatment of severe forms of coronavirus disease 2019 (COVID-19) as well as other virus-induced "cytokines storm".|pdf=|usr=025}}
+{{tp|p=33385878|t=2021. The plausible mechanisms of tramadol for treatment of COVID-19.|pdf=|usr=025}}
+{{tp|p=33485026|t=2021. Daylight is critical to preserve 5-methoxytryptophol levels in suspected and confirmed COVID-19 patients.|pdf=|usr=025}}
+{{tp|p=33482620|t=2021. Fecal microbiota transplantation for COVID-19; a potential emerging treatment strategy.|pdf=|usr=025}}
+{{tp|p=33460992|t=2021. Scientific hypothesis and rational pharmacological for the use of sacubitril/valsartan in cardiac damage caused by COVID-19.|pdf=|usr=025}}
+{{tp|p=33421690|t=2021. Platelet hyperactivity in COVID-19: Can the tomato extract Fruitflow(R) be used as an antiplatelet regime?|pdf=|usr=025}}
+{{tp|p=33505216|t=2021. Exploring the Pivotal Immunomodulatory and Anti-Inflammatory Potentials of Glycyrrhizic and Glycyrrhetinic Acids.|pdf=|usr=025}}
+{{tp|p=33481741|t=2020. La bioseguridad de las vacunas anti-COVID-19.|pdf=|usr=025}}
+{{tp|p=33481727|t=2020. Plasma de convalecientes como terapia para la neumonia por COVID-19 grave.|pdf=|usr=025}}
+{{tp|p=33429732|t=2021. Anti-IL6 treatment of serious COVID-19 disease: A monocentric retrospective experience.|pdf=|usr=025}}
+{{tp|p=33453392|t=2021. Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening pipeline and in-vitro validation assays.|pdf=|usr=025}}
+{{tp|p=33482357|t=2021. Could targeting immunometabolism be a way to control the burden of COVID-19 infection?|pdf=|usr=025}}
+{{tp|p=33430200|t=2021. Intravenous Immunoglobulins at the Crossroad of Autoimmunity and Viral Infections.|pdf=|usr=025}}
+{{tp|p=33451069|t=2021. Development of Coronavirus Treatments Using Neutralizing Antibodies.|pdf=|usr=025}}
+{{tp|p=33402220|t=2021. SARS-CoV-2: vaccines in the pandemic era.|pdf=|usr=025}}
+{{tp|p=33464512|t=2021. Anaphylaxie-Risiko bei der COVID-19-Impfung: Empfehlungen fur das praktische Management.|pdf=|usr=025}}
+{{tp|p=33507892|t=2021. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Moderna COVID-19 Vaccine - United States, December 21, 2020-January 10, 2021.|pdf=|usr=025}}
+{{tp|p=33444297|t=2021. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020.|pdf=|usr=025}}
+{{tp|p=33382675|t=2021. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Moderna COVID-19 Vaccine - United States, December 2020.|pdf=|usr=025}}
+{{tp|p=33464543|t=2021. Cell-Based High-Throughput Screening Protocol for Discovering Antiviral Inhibitors Against SARS-COV-2 Main Protease (3CLpro).|pdf=|usr=025}}
+{{tp|p=33400086|t=2021. COVID-19: inflammatory responses, structure-based drug design and potential therapeutics.|pdf=|usr=025}}
+{{tp|p=33400085|t=2021. First structure-activity relationship analysis of SARS-CoV-2 virus main protease (Mpro) inhibitors: an endeavor on COVID-19 drug discovery.|pdf=|usr=025}}
+{{tp|p=33398633|t=2021. Identification of novel inhibitors of angiotensin-converting enzyme 2 (ACE-2) receptor from Urtica dioica to combat coronavirus disease 2019 (COVID-19).|pdf=|usr=025}}
+{{tp|p=33389560|t=2021. CoViTris2020 and ChloViD2020: a striking new hope in COVID-19 therapy.|pdf=|usr=025}}
+{{tp|p=33389441|t=2021. The anti-HCV, Sofosbuvir, versus the anti-EBOV Remdesivir against SARS-CoV-2 RNA dependent RNA polymerase in silico.|pdf=|usr=025}}
+{{tp|p=33492566|t=2021. Computational assessment of saikosaponins as adjuvant treatment for COVID-19: molecular docking, dynamics, and network pharmacology analysis.|pdf=|usr=025}}
+{{tp|p=33389440|t=2021. Designing of peptide aptamer targeting the receptor-binding domain of spike protein of SARS-CoV-2: an in silico study.|pdf=|usr=025}}
+{{tp|p=33503834|t=2021. Antiviral Activity of Jamaican Medicinal Plants and Isolated Bioactive Compounds.|pdf=|usr=025}}
+{{tp|p=33467029|t=2021. Natural and Nature-Derived Products Targeting Human Coronaviruses.|pdf=|usr=025}}
+{{tp|p=33466743|t=2021. Cheminformatics-Based Identification of Potential Novel Anti-SARS-CoV-2 Natural Compounds of African Origin.|pdf=|usr=025}}
+{{tp|p=33500564|t=2021. The lung-gut axis during viral respiratory infections: the impact of gut dysbiosis on secondary disease outcomes.|pdf=|usr=025}}
+{{tp|p=33471984|t=2021. Monoclonal Antibodies to Disrupt Progression of Early Covid-19 Infection.|pdf=|usr=025}}
+{{tp|p=33440088|t=2021. Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine.|pdf=|usr=025}}
+{{tp|p=33440086|t=2021. (A Little) Clarity on Convalescent Plasma for Covid-19.|pdf=|usr=025}}
+{{tp|p=33406353|t=2021. Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults.|pdf=|usr=025}}
+{{tp|p=33391623|t=2020. Manganese nanodepot augments host immune response against coronavirus.|pdf=|usr=025}}
+{{tp|p=33418136|t=2021. iRGD conjugated nimbolide liposomes protect against endotoxin induced acute respiratory distress syndrome.|pdf=|usr=025}}
+{{tp|p=33510133|t=2021. A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication.|pdf=|usr=025}}
+{{tp|p=33483491|t=2021. A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses.|pdf=|usr=025}}
+{{tp|p=33473140|t=2021. Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape.|pdf=|usr=025}}
+{{tp|p=33473130|t=2021. The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery.|pdf=|usr=025}}
+{{tp|p=33446655|t=2021. SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice.|pdf=|usr=025}}
+{{tp|p=33436624|t=2021. Mechanism of SARS-CoV-2 polymerase stalling by remdesivir.|pdf=|usr=025}}
+{{tp|p=33436577|t=2021. A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein.|pdf=|usr=025}}
+{{tp|p=33436573|t=2021. Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity.|pdf=|usr=025}}
+{{tp|p=33431876|t=2021. Development and structural basis of a two-MAb cocktail for treating SARS-CoV-2 infections.|pdf=|usr=025}}
+{{tp|p=33431856|t=2021. Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry.|pdf=|usr=025}}
+{{tp|p=33432129|t=2021. Immune readouts from the Oxford COVID-19 vaccine.|pdf=|usr=025}}
+{{tp|p=33394134|t=2021. NF-kappaB signalling as a pharmacological target in COVID-19: potential roles for IKKbeta inhibitors.|pdf=|usr=025}}
+{{tp|p=33416933|t=2021. Chloroquine/hydroxychloroquine: an inflammasome inhibitor in severe COVID-19?|pdf=|usr=025}}
+{{tp|p=33443616|t=2021. Efficacy of synthetic glucocorticoids in COVID-19 endothelites.|pdf=|usr=025}}
+{{tp|p=33425362|t=2021. Oral probiotics in coronavirus disease 2019: connecting the gut-lung axis to viral pathogenesis, inflammation, secondary infection and clinical trials.|pdf=|usr=025}}
+{{tp|p=33495468|t=2021. Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters.|pdf=|usr=025}}
+{{tp|p=33495451|t=2021. The double-sided effects of Mycobacterium Bovis bacillus Calmette-Guerin vaccine.|pdf=|usr=025}}
+{{tp|p=33435521|t=2021. Magnesium in Infectious Diseases in Older People.|pdf=|usr=025}}
+{{tp|p=33498631|t=2021. Protective Effects of Lactoferrin against SARS-CoV-2 Infection In Vitro.|pdf=|usr=025}}
+{{tp|p=33466642|t=2021. Effectiveness of In-Hospital Cholecalciferol Use on Clinical Outcomes in Comorbid COVID-19 Patients: A Hypothesis-Generating Study.|pdf=|usr=025}}
+{{tp|p=33419325|t=2020. Nutritional and Behavioral Approaches to Body Composition and Low-Grade Chronic Inflammation Management for Older Adults in the Ordinary and COVID-19 Times.|pdf=|usr=025}}
+{{tp|p=33412367|t=2021. Prospective options of algae-derived nutraceuticals as supplements to combat COVID-19 and human coronavirus diseases.|pdf=|usr=025}}
+{{tp|p=33456092|t=2021. COVID-19: Analysis of Drug Repositioning Practice.|pdf=|usr=025}}
+{{tp|p=33445955|t=2021. Repurposing drugs during the COVID-19 pandemic and beyond.|pdf=|usr=025}}
+{{tp|p=33430081|t=2021. Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection.|pdf=|usr=025}}
+{{tp|p=33419184|t=2021. Immunogenicity of Multiple Doses of pDNA Vaccines against SARS-CoV-2.|pdf=|usr=025}}
+{{tp|p=33455739|t=2021. Inmunomodulacion mediante CONVEHY(R) para COVID-19: de la tormenta al anticiclon de citoquinas.|pdf=|usr=025}}
+{{tp|p=33493900|t=2021. Carrying out pseudo dual nucleic acid detection from sample to visual result in a polypropylene bag with CRISPR/Cas12a.|pdf=|usr=025}}
+{{tp|p=33419743|t=2021. Covid-19: Arthritis drugs improve survival in intensive care patients, shows study.|pdf=|usr=025}}
+{{tp|p=33408068|t=2021. Covid-19 vaccination: What's the evidence for extending the dosing interval?|pdf=|usr=025}}
+{{tp|p=33514589|t=2021. Incre<iframe src="http://www.kidney.de/amapp.php?a=g recruitment into covid-19 trials.|pdf=|usr=025}}
+{{tp|p=33428504|t=2021. Formulation and stability study of hydroxychloroquine sulfate oral suspensions.|pdf=|usr=025}}
+{{tp|p=33497594|t=2021. The Potential Role of Photobiomodulation in Long COVID-19 Patients Rehabilitation.|pdf=|usr=025}}
+{{tp|p=33476998|t=2021. Predictive value of the prognostic nutritional index for the severity of coronavirus disease 2019.|pdf=|usr=025}}
+{{tp|p=33450678|t=2021. Micronutrients and bioactive substances: Their potential roles in combating COVID-19.|pdf=|usr=025}}
+{{tp|p=33421827|t=2021. Sarcopenia: An underlying treatment target during the COVID-19 pandemic.|pdf=|usr=025}}
+{{tp|p=33418230|t=2021. Increased risk for COVID-19 in patients with vitamin D deficiency.|pdf=|usr=025}}
+{{tp|p=33426364|t=2021. Friend or foe? ACE2 inhibitors and GLP-1R agonists in COVID-19 treatment.|pdf=|usr=025}}
+{{tp|p=33408570|t=2020. Hydroxychloroquine Use in Patients With COVID-19: A Brief Perspective on Current Clinical Trials.|pdf=|usr=025}}
+{{tp|p=33426262|t=2021. Matched cohort study on the efficacy of tocilizumab in patients with COVID-19.|pdf=|usr=025}}
+{{tp|p=33506065|t=2021. Thymosin Alpha 1 Mitigates Cytokine Storm in Blood Cells From Coronavirus Disease 2019 Patients.|pdf=|usr=025}}
+{{tp|p=33425070|t=2020. BCG Vaccine does not Protect Against COVID-19.|pdf=|usr=025}}
+{{tp|p=33456654|t=2020. Use of tocilizumab in a patient with severe COVID-19 in a Teaching Hospital in Ghana: a case report.|pdf=|usr=025}}
+{{tp|p=33456653|t=2020. Promotion of unproved and potential dangerous measures in fighting COVID-19 pandemic: urgent need for vigilant appropriate public communication and generation of scientific evidence.|pdf=|usr=025}}
+{{tp|p=33425157|t=2020. A review of COVID-19 vaccines in development: 6 months into the pandemic.|pdf=|usr=025}}
+{{tp|p=33480519|t=2021. Why two doses of the BNT162b2 mRNA Covid-19 vaccine? A different strategy to speed up the vaccination process: single-dose of the BNT162b2 mRNA Covid-19 and other vaccines.|pdf=|usr=025}}
+{{tp|p=33504008|t=2021. Identification of 37 Heterogeneous Drug Candidates for Treatment of COVID-19 via a Rational Transcriptomics-Based Drug Repurposing Approach.|pdf=|usr=025}}
+{{tp|p=33477294|t=2021. COVID-19-The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection.|pdf=|usr=025}}
+{{tp|p=33435273|t=2021. Interactions of Potential Anti-COVID-19 Compounds with Multispecific ABC and OATP Drug Transporters.|pdf=|usr=025}}
+{{tp|p=33437147|t=2021. Effects on LOS may not justify cost of remdesivir for severe COVID-19.|pdf=|usr=025}}
+{{tp|p=33389725|t=2021. Ivermectin as a potential drug for treatment of COVID-19: an in-sync review with clinical and computational attributes.|pdf=|usr=025}}
+{{tp|p=33389724|t=2021. SARS-CoV-2 therapeutics: how far do we stand from a remedy?|pdf=|usr=025}}
+{{tp|p=33421347|t=2021. Drug-drug interactions with candidate medications used for COVID-19 treatment: An overview.|pdf=|usr=025}}
+{{tp|p=33515763|t=2021. A combination of phototherapy modalities for extensive lip lesions in a patient with SARS-CoV-2 infection.|pdf=|usr=025}}
+{{tp|p=33422697|t=2021. Can photodynamic therapy be repurposed to treat oral lesions of COVID-19?|pdf=|usr=025}}
+{{tp|p=33463909|t=2021. 17beta-estradiol reduces SARS-CoV-2 infection in vitro.|pdf=|usr=025}}
+{{tp|p=33485605|t=2020. Herbal immune-boosters: Substantial warriors of pandemic Covid-19 battle.|pdf=|usr=025}}
+{{tp|p=33380375|t=2020. Phytopharmaceuticals mediated Furin and TMPRSS2 receptor blocking: can it be a potential therapeutic option for Covid-19?|pdf=|usr=025}}
+{{tp|p=33419674|t=2020. Effects and safety of herbal medicines among community-dwelling residents during COVID-19 pandemic: A large prospective, randomized controlled trial (RCT).|pdf=|usr=025}}
+{{tp|p=33495692|t=2021. Localized Plasmonic Photothermal Therapy as a Life-saving Treatment Paradigm for Hospitalized COVID-19 Patients.|pdf=|usr=025}}
+{{tp|p=33382685|t=2020. A novel virtual screening procedure identifies Pralatrexate as inhibitor of SARS-CoV-2 RdRp and it reduces viral replication in vitro.|pdf=|usr=025}}
+{{tp|p=33395417|t=2021. Zinc against COVID-19? Symptom surveillance and deficiency risk groups.|pdf=|usr=025}}
+{{tp|p=33507958|t=2021. High-dose corticosteroid pulse therapy increases the survival rate in COVID-19 patients at risk of hyper-inflammatory response.|pdf=|usr=025}}
+{{tp|p=33497420|t=2021. Temporal development and neutralising potential of antibodies against SARS-CoV-2 in hospitalised COVID-19 patients: An observational cohort study.|pdf=|usr=025}}
+{{tp|p=33493227|t=2021. Screening, simulation, and optimization design of small molecule inhibitors of the SARS-CoV-2 spike glycoprotein.|pdf=|usr=025}}
+{{tp|p=33481950|t=2021. Serum Amyloid P inhibits single stranded RNA-induced lung inflammation, lung damage, and cytokine storm in mice.|pdf=|usr=025}}
+{{tp|p=33444408|t=2021. Quercetin as a potential treatment for COVID-19-induced acute kidney injury: Based on network pharmacology and molecular docking study.|pdf=|usr=025}}
+{{tp|p=33417604|t=2021. Computational drug repurposing strategy predicted peptide-based drugs that can potentially inhibit the interaction of SARS-CoV-2 spike protein with its target (humanACE2).|pdf=|usr=025}}
+{{tp|p=33411791|t=2021. Therapeutic plasma exchange for coronavirus disease-2019 triggered cytokine release syndrome; a retrospective propensity matched control study.|pdf=|usr=025}}
+{{tp|p=33406138|t=2021. The efficacy and safety of hydroxychloroquine for COVID-19 prophylaxis: A systematic review and meta-analysis of randomized trials.|pdf=|usr=025}}
+{{tp|p=33382734|t=2020. The use of methylprednisolone in COVID-19 patients: A propensity score matched retrospective cohort study.|pdf=|usr=025}}
+{{tp|p=33465165|t=2021. Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is attenuated by TMPRSS2.|pdf=|usr=025}}
+{{tp|p=33382547|t=2021. Remdesivir-based therapy improved the recovery of patients with COVID-19 in the multicenter, real-world SARSTer study.|pdf=|usr=025}}
+{{tp|p=33481361|t=2020. Polymers with antiviral properties: A brief review.|pdf=|usr=025}}
+{{tp|p=33481360|t=2020. Focus on COVID-19: Antiviral polymers in drugs and vaccines.|pdf=|usr=025}}
+{{tp|p=33452205|t=2021. Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection.|pdf=|usr=025}}
+{{tp|p=33390763|t=2021. Rapid determination of remdesivir (SARS-CoV-2 drug) in human plasma for therapeutic drug monitoring in COVID-19-Patients.|pdf=|usr=025}}
+{{tp|p=33516093|t=2021. Blood omega-3 fatty acids and death from COVID-19: A pilot study.|pdf=|usr=025}}
+{{tp|p=33420956|t=2021. Pan-coronavirus fusion inhibitors as the hope for today and tomorrow.|pdf=|usr=025}}
+{{tp|p=33387249|t=2021. In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors.|pdf=|usr=025}}
+{{tp|p=33392622|t=2021. Fluvoxamine, melatonin and COVID-19.|pdf=|usr=025}}
+{{tp|p=33465426|t=2021. Antihistamines and azithromycin as a treatment for COVID-19 on primary health care - A retrospective observational study in elderly patients.|pdf=|usr=025}}
+{{tp|p=33489300|t=2020. Vitamin D and COVID-19: evidence and recommendations for supplementation.|pdf=|usr=025}}
+{{tp|p=33415646|t=2021. Potential Role of Zinc in the COVID-19 Disease Process and its Probable Impact on Reproduction.|pdf=|usr=025}}
+{{tp|p=33461535|t=2021. Surfactant therapy for COVID-19 related ARDS: a retrospective case-control pilot study.|pdf=|usr=025}}
+{{tp|p=33399672|t=2020. Corticoides para el tratamiento de COVID-19.|pdf=|usr=025}}
+{{tp|p=33388902|t=2021. Colchicine as an adjunct to heparin for prophylaxis of venous thromboembolism in patients with COVID-19.|pdf=|usr=025}}
+{{tp|p=33386447|t=2021. COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases.|pdf=|usr=025}}
+{{tp|p=33447107|t=2021. Effects of Vitamin D on COVID-19 Infection and Prognosis: A Systematic Review.|pdf=|usr=025}}
+{{tp|p=33458569|t=2021. Re-reading ACT, BCG, and Low COVID-19 in Africa.|pdf=|usr=025}}
+{{tp|p=33503560|t=2021. Molecular structure, NBO analysis of the hydrogen-bonded interactions, spectroscopic (FT-IR, FT-Raman), drug likeness and molecular docking of the novel anti COVID-2 molecule (2E)-N-methyl-2-[(4-oxo-4H-chromen-3-yl)methylidene]-hydrazinecarbothioamide (Dimer) - quantum chemical approach.|pdf=|usr=025}}
+{{tp|p=33514427|t=2021. Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series.|pdf=|usr=025}}
+{{tp|p=33511519|t=2021. Mesenchymal Stem Cell-Derived Extracellular Vesicles Carrying miRNA as a Potential Multi Target Therapy to COVID-19: an In Silico Analysis.|pdf=|usr=025}}
+{{tp|p=33511518|t=2021. Stem Cell Therapy Potency in Personalizing Severe COVID-19 Treatment.|pdf=|usr=025}}
+{{tp|p=33432484|t=2021. Proposed Mechanisms of Targeting COVID-19 by Delivering Mesenchymal Stem Cells and Their Exosomes to Damaged Organs.|pdf=|usr=025}}
+{{tp|p=33423157|t=2021. Stem Cells as Potential Therapeutics and Targets for Infection by COVID19 - Special Issue on COVID19 in Stem Cell Reviews and Reports.|pdf=|usr=025}}
+{{tp|p=33415541|t=2021. Dimethyl Fumarate Can Enhance the Potential Therapeutic Effects of Epidermal Neural Crest Stem Cells in COVID-19 Patients.|pdf=|usr=025}}
+{{tp|p=33414832|t=2020. Human Mesenchymal Stem Cells: The Present Alternative for High-Incidence Diseases, Even SARS-Cov-2.|pdf=|usr=025}}
+{{tp|p=33400390|t=2021. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial.|pdf=|usr=025}}
+{{tp|p=33502567|t=2021. COVID-19 pneumonia treated with ultra-low doses of radiotherapy (ULTRA-COVID study): a single institution report of two cases.|pdf=|usr=025}}
+{{tp|p=33437137|t=2021. Combination and tricombination therapy to destabilize the structural integrity of COVID-19 by some bioactive compounds with antiviral drugs: insights from molecular docking study.|pdf=|usr=025}}
+{{tp|p=33382449|t=2020. Early experimental COVID-19 therapies: associations with length of hospital stay, mortality and related costs.|pdf=|usr=025}}
+{{tp|p=33408775|t=2021. The 2020 race towards SARS-CoV-2 specific vaccines.|pdf=|usr=025}}
+{{tp|p=33391531|t=2021. Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of in vitro, in vivo, and clinical trials.|pdf=|usr=025}}
+{{tp|p=33391497|t=2021. Rapid design and development of CRISPR-Cas13a targeting SARS-CoV-2 spike protein.|pdf=|usr=025}}
+{{tp|p=33433109|t=2021. Kortikosteroider til sykehjemspasienter med covid-19?|pdf=|usr=025}}
+{{tp|p=33428032|t=2021. Reviews on Biological Activity, Clinical Trial and Synthesis Progress of Small Molecules for the Treatment of COVID-19.|pdf=|usr=025}}
+{{tp|p=33484708|t=2021. Chloroquine may induce endothelial injury through lysosomal dysfunction and oxidative stress.|pdf=|usr=025}}
+{{tp|p=33425684|t=2021. Nicotinic cholinergic system and COVID-19: In silico evaluation of nicotinic acetylcholine receptor agonists as potential therapeutic interventions.|pdf=|usr=025}}
+{{tp|p=33478889|t=2021. A look-back at convalescent plasma to treat COVID-19.|pdf=|usr=025}}
+{{tp|p=33461918|t=2021. New generation of vaccines and convalescent plasma therapy for management of CoV-2: Perspectives from the UK and potential deployment in the current global pandemic.|pdf=|usr=025}}
+{{tp|p=33388249|t=2021. The use of convalescent plasma for pediatric patients with SARS-CoV-2: A systematic literature review.|pdf=|usr=025}}
+{{tp|p=33462569|t=2021. The Intersection of Photopheresis and COVID-19 Vaccination.|pdf=|usr=025}}
+{{tp|p=33515686|t=2021. Could shear stress mimetics delay complications in COVID-19?|pdf=|usr=025}}
+{{tp|p=33424125|t=2021. Polysaccharides obtained from natural edible sources and their role in modulating the immune system: Biologically active potential that can be exploited against COVID-19.|pdf=|usr=025}}
+{{tp|p=33446406|t=2021. Slaying SARS-CoV-2 One (Single-domain) Antibody at a Time.|pdf=|usr=025}}
+{{tp|p=33505872|t=2021. Antiviral drugs against severe acute respiratory syndrome coronavirus 2 infection triggering the coronavirus disease-19 pandemic.|pdf=|usr=025}}
+{{tp|p=33441235|t=2021. Anaphylactic reactions to novel mRNA SARS-CoV-2/COVID-19 vaccines.|pdf=|usr=025}}
+{{tp|p=33478794|t=2021. Immunoinformatics prediction of overlapping CD8(+) T-cell, IFN-gamma and IL-4 inducer CD4(+) T-cell and linear B-cell epitopes based vaccines against COVID-19 (SARS-CoV-2).|pdf=|usr=025}}
+{{tp|p=33478787|t=2021. Immuno-informatics approach for B-cell and T-cell epitope based peptide vaccine design against novel COVID-19 virus.|pdf=|usr=025}}
+{{tp|p=33429880|t=2021. Current State of the First COVID-19 Vaccines.|pdf=|usr=025}}
+{{tp|p=33406785|t=2021. SARS-CoV-2/COVID-19 Vaccines: The Promises and the Challenges Ahead.|pdf=|usr=025}}
+{{tp|p=33513693|t=2021. COVID-19 Infection and Previous BCG Vaccination Coverage in the Ecuadorian Population.|pdf=|usr=025}}
+{{tp|p=33499326|t=2021. Optimising Vaccine Dose in Inoculation against SARS-CoV-2, a Multi-Factor Optimisation Modelling Study to Maximise Vaccine Safety and Efficacy.|pdf=|usr=025}}
+{{tp|p=33494530|t=2021. Delivery of mRNA Vaccine against SARS-CoV-2 Using a Polyglucin:Spermidine Conjugate.|pdf=|usr=025}}
+{{tp|p=33494381|t=2021. Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses.|pdf=|usr=025}}
+{{tp|p=33478109|t=2021. Nanomaterial Delivery Systems for mRNA Vaccines.|pdf=|usr=025}}
+{{tp|p=33440794|t=2021. Who Is Really at Risk for Anaphylaxis Due to COVID-19 Vaccine?|pdf=|usr=025}}
+{{tp|p=33440640|t=2021. SARS-CoV-2 Spike Protein Elicits Cell Signaling in Human Host Cells: Implications for Possible Consequences of COVID-19 Vaccines.|pdf=|usr=025}}
+{{tp|p=33396667|t=2020. Plant-Based Drugs and Vaccines for COVID-19.|pdf=|usr=025}}
+{{tp|p=33394351|t=2020. Human Monoclonal Antibodies: On the Menu of Targeted Therapeutics Against COVID-19.|pdf=|usr=025}}
+{{tp|p=33421743|t=2021. Network analysis and molecular mapping for SARS-CoV-2 to reveal drug targets and repurposing of clinically developed drugs.|pdf=|usr=025}}
+{{tp|p=33387788|t=2021. Dexamethasone inhibits SARS-CoV-2 spike pseudotyped virus viropexis by binding to ACE2.|pdf=|usr=025}}
+{{tp|p=33503819|t=2021. Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188.|pdf=|usr=025}}
+{{tp|p=33498923|t=2021. Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CL(pro) Inhibitors.|pdf=|usr=025}}
+{{tp|p=33477902|t=2021. Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies.|pdf=|usr=025}}
+{{tp|p=33477376|t=2021. Quinacrine, an Antimalarial Drug with Strong Activity Inhibiting SARS-CoV-2 Viral Replication In Vitro.|pdf=|usr=025}}
+{{tp|p=33466921|t=2021. Domains and Functions of Spike Protein in Sars-Cov-2 in the Context of Vaccine Design.|pdf=|usr=025}}
+{{tp|p=33451132|t=2021. Systematic Search for SARS-CoV-2 Main Protease Inhibitors for Drug Repurposing: Ethacrynic Acid as a Potential Drug.|pdf=|usr=025}}
+{{tp|p=33396343|t=2020. Lead SARS-CoV-2 Candidate Vaccines: Expectations from Phase III Trials and Recommendations Post-Vaccine Approval.|pdf=|usr=025}}
+{{tp|p=33396594|t=2020. PSGL-1 Inhibits the Incorporation of SARS-CoV and SARS-CoV-2 Spike Glycoproteins into Pseudovirions and Impairs Pseudovirus Attachment and Infectivity.|pdf=|usr=025}}
+{{tp|p=33396578|t=2020. Interferon-alpha2b Treatment for COVID-19 Is Associated with Improvements in Lung Abnormalities.|pdf=|usr=025}}
+{{tp|p=33425204|t=2021. Efficacy of broccoli and glucoraphanin in COVID-19: From hypothesis to proof-of-concept with three experimental clinical cases.|pdf=|usr=025}}
+{{tp|p=33386950|t=2021. COVID-19 and BCG: where's the challenge?|pdf=|usr=025}}
+{{tp|p=33438061|t=2021. Impfung gegen SARS-CoV-2 bei entzundlich rheumatischen Erkrankungen : Empfehlungen der DGRh fur Arzte und Patienten.|pdf=|usr=025}}
+{{tp|p=33440401|t=2021. Convergent evidence for the antiviral effects of several FDA-approved phenothiazine antipsychotics against SARS-CoV-2 and other coronaviruses.|pdf=|usr=025}}
+{{tp|p=33386025|t=2021. Identifying the natural polyphenol catechin as a multi-targeted agent against SARS-CoV-2 for the plausible therapy of COVID-19: an integrated computational approach.|pdf=|usr=025}}
+{{tp|p=33456058|t=2021. Les vaccins a ARN anti-COVID-19.|pdf=|usr=025}}
+{{tp|p=33495684|t=2021. Luteolin and abyssinone II as potential inhibitors of SARS-CoV-2: an in silico molecular modeling approach in battling the COVID-19 outbreak.|pdf=|usr=025}}
+{{tp|p=33503163|t=2021. Reacoes adversas a medicamentos em pacientes com COVID-19 no Brasil: analise das notificacoes espontaneas do sistema de farmacovigilancia brasileiro.|pdf=|usr=025}}
+{{tp|p=33404925|t=2021. Promising Therapy for Heart Failure in Patients with Severe COVID-19: Calming the Cytokine Storm.|pdf=|usr=025}}
+{{tp|p=33387252|t=2021. QTc Prolongation in COVID-19 Patients Using Chloroquine.|pdf=|usr=025}}
+{{tp|p=33425407|t=2020. The Safe Administration of Remdesivir in a Patient with Acute Kidney Injury Requiring Hemodialysis.|pdf=|usr=025}}
+{{tp|p=33425279|t=2020. Plasmapheresis with corticosteroids and antiviral: a life-saving treatment for severe cases of Covid 19.|pdf=|usr=025}}
+{{tp|p=33425262|t=2020. A brief review of the latest pharmacological treatments of COVID-19.|pdf=|usr=025}}
+{{tp|p=33479399|t=2021. COVID-19 vaccines: where we stand and challenges ahead.|pdf=|usr=025}}
+{{tp|p=33421384|t=2021. The Neutrophil-to-Lymphocyte Ratio Determines Clinical Efficacy of Corticosteroid Therapy in Patients with COVID-19.|pdf=|usr=025}}
+{{tp|p=33488836|t=2021. Engineered Aptamers for Enhanced COVID-19 Theranostics.|pdf=|usr=025}}
+{{tp|p=33521696|t=2021. Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency.|pdf=|usr=025}}
+{{tp|p=33473156|t=2021. Dalbavancin: novel candidate for COVID-19 treatment.|pdf=|usr=025}}
+{{tp|p=33522308|t=2021. Estrogen and Androgen Receptor Inhibitors: Unexpected Allies in the Fight Against COVID-19.|pdf=|usr=025}}
+{{tp|p=33502716|t=2021. Effective treatment with Tocilizumab in a COVID-19 patient on maintenance hemodialysis: A case report.|pdf=|usr=025}}
+{{tp|p=33462575|t=2021. Mass spectrometry reveals potential of beta-lactams as SARS-CoV-2 M(pro) inhibitors.|pdf=|usr=025}}
+{{tp|p=33424029|t=2021. Synthetic strategies for pyrrolo[2,1-f][1,2,4]triazine: the parent moiety of antiviral drug remdesivir.|pdf=|usr=025}}
+{{tp|p=33519023|t=2021. Molecular modeling evaluation of the binding effect of five protease inhibitors to COVID-19 main protease.|pdf=|usr=025}}
+{{tp|p=33518774|t=2021. Exploring the new potential antiviral constituents of Moringa oliefera for SARS-COV-2 pathogenesis: An in silico molecular docking and dynamic studies.|pdf=|usr=025}}
+{{tp|p=33518775|t=2020. Identification of potential inhibitors of SARS-CoV-2 main protease from Aloe vera compounds: A molecular docking study.|pdf=|usr=025}}
+{{tp|p=33518858|t=2020. Structure features of peptide-type SARS-CoV main protease inhibitors: Quantitative structure activity relationship study.|pdf=|usr=025}}
+{{tp|p=33453180|t=2021. A Reserve System for the Equitable Allocation of a Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine.|pdf=|usr=025}}
+{{tp|p=33493441|t=2021. Surfactant for the Treatment of ARDS in a Patient With Coronavirus Disease 2019.|pdf=|usr=025}}
+{{tp|p=33422222|t=2021. Zinc and Coronavirus Disease 2019: Causal or Casual Association?|pdf=|usr=025}}
+{{tp|p=33420601|t=2021. Chinese Medicine in Fighting against Covid-19: Role and Inspiration.|pdf=|usr=025}}
+{{tp|p=33489151|t=2021. Tocilizumab-induced cytomegalovirus colitis in a patient with COVID-19.|pdf=|usr=025}}
+{{tp|p=33521390|t=2021. Antivirals for COVID-19: A critical review.|pdf=|usr=025}}
+{{tp|p=33486146|t=2021. Unilateral axillary Adenopathy in the setting of COVID-19 vaccine.|pdf=|usr=025}}
+{{tp|p=33429060|t=2021. Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to "potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases".|pdf=|usr=025}}
+{{tp|p=33515458|t=2021. Absence of vaccine-enhanced disease with unexpected positive protection against SARS-CoV-2 by inactivated vaccine given within three days of virus challenge in Syrian hamster model.|pdf=|usr=025}}
+{{tp|p=33515255|t=2021. The Olympiad of SARS-CoV-2 vaccinology: Fundamentals to Complement Technical Frontiers.|pdf=|usr=025}}
+{{tp|p=33515253|t=2021. Tocilizumab in COVID-19: Give it time!|pdf=|usr=025}}
+{{tp|p=33515252|t=2021. The impact of vaccination on COVID-19 outbreaks in the United States.|pdf=|usr=025}}
+{{tp|p=33503230|t=2021. The case against delaying SARS-CoV-2 mRNA vaccine boosting doses.|pdf=|usr=025}}
+{{tp|p=33503229|t=2021. Antioxidant therapy in COVID-19: The crucial role of early treatment and antioxidant typology.|pdf=|usr=025}}
+{{tp|p=33502467|t=2021. Accelerate COVID-19 Vaccine Rollout by Delaying the Second Dose of mRNA Vaccines.|pdf=|usr=025}}
+{{tp|p=33493302|t=2021. Making sense of contradictory evidence in Covid-19 trials.|pdf=|usr=025}}
+{{tp|p=33402859|t=2020. Early Experience With Methylprednisolone on SARS-CoV-2 Infection in the African American Population, a Retrospective Analysis.|pdf=|usr=025}}
+{{tp|p=33476807|t=2021. Prophylaxis for COVID-19: a systematic review.|pdf=|usr=025}}
+{{tp|p=33380357|t=2020. Association between iron status and the risk of adverse outcomes in COVID-19.|pdf=|usr=025}}
+{{tp|p=33487301|t=2021. Nutritional status assessment in patients with Covid-19 after discharge from the intensive care unit.|pdf=|usr=025}}
+{{tp|p=33487263|t=2021. Anthropometric assessment in ambulatory nutrition amid the COVID-19 pandemic: Possibilities for the remote and in-person care.|pdf=|usr=025}}
+{{tp|p=33402269|t=2021. Optimal Timing for COVID-19 Vaccination in Oncology Patients Receiving Chemotherapy?|pdf=|usr=025}}
+{{tp|p=33501997|t=2021. Physiologically-Based Pharmacokinetic Modeling of Remdesivir and Its Metabolites to Support Dose Selection for the Treatment of Pediatric Patients With COVID-19.|pdf=|usr=025}}
+{{tp|p=33406317|t=2021. Rationale for Effective Prophylaxis Against COVID-19 Through Simultaneous Blockade of Both Endosomal and Non-Endosomal SARS-CoV-2 Entry into Host Cell.|pdf=|usr=025}}
+{{tp|p=33520676|t=2021. Spectroscopic investigation on the affinity of SARS-CoV-2 spike protein to gold nano-particles.|pdf=|usr=025}}
+{{tp|p=33520528|t=2020. High Dose Steroid Therapy to Prevent Severe Hypoxia in COVID-19 Patients: A Potential Solution for Low Resource Clinical Setting.|pdf=|usr=025}}
+{{tp|p=33486832|t=2021. Exacerbation of psoriasis following hydroxychloroquine in a patient with suspected COVID-19.|pdf=|usr=025}}
+{{tp|p=33406308|t=2021. Cutaneous manifestations of COVID-19: An unusual presentation with edematous plaques and pruritic, erythematous papules, and comment on the role of bradykinin storm and its therapeutic implications.|pdf=|usr=025}}
+{{tp|p=33403227|t=2020. Drug Repurposing for Prevention and Treatment of COVID-19: A Clinical Landscape.|pdf=|usr=025}}
+{{tp|p=33402882|t=2020. Effectiveness of Convalescent Plasma Therapy for COVID-19 Patients in Hunan, China.|pdf=|usr=025}}
+{{tp|p=33496060|t=2021. Targeting cyclooxygenase enzyme for the adjuvant COVID-19 therapy.|pdf=|usr=025}}
+{{tp|p=33499310|t=2021. The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of COVID-19.|pdf=|usr=025}}
+{{tp|p=33494244|t=2021. Exercise, Immune System, Nutrition, Respiratory and Cardiovascular Diseases during COVID-19: A Complex Combination.|pdf=|usr=025}}
+{{tp|p=33451007|t=2021. Favipiravir in Therapy of Viral Infections.|pdf=|usr=025}}
+{{tp|p=33447309|t=2020. COVID-19 and Possible Pharmacological Preventive Options.|pdf=|usr=025}}
+{{tp|p=33426360|t=2020. Anti-tumor necrosis factor agents and COVID-19: A word of caution.|pdf=|usr=025}}
+{{tp|p=33450319|t=2021. Development of nanoparticle-delivery systems for antiviral agents: A review.|pdf=|usr=025}}
+{{tp|p=33439960|t=2021. Critical analysis on the use of cholecalciferol as a COVID-19 intervention: a narrative review.|pdf=|usr=025}}
+{{tp|p=33424398|t=2021. In silico evaluation of flavonoids as effective antiviral agents on the spike glycoprotein of SARS-CoV-2.|pdf=|usr=025}}
+{{tp|p=33424377|t=2021. Probiotics, prebiotics, and COVID-19 infection: A review article.|pdf=|usr=025}}
+{{tp|p=33457042|t=2021. A large-scale transcriptional study reveals inhibition of COVID-19 related cytokine storm by traditional chinese medicines.|pdf=|usr=025}}
+{{tp|p=33471276|t=2021. Evaluation of the efficacy and safety of hydroxychloroquine in comparison with chloroquine in moderate and severe patients with COVID-19.|pdf=|usr=025}}
+{{tp|p=33441564|t=2021. Ontological modeling and analysis of experimentally or clinically verified drugs against coronavirus infection.|pdf=|usr=025}}
+{{tp|p=33420186|t=2021. ABBV-744 as a potential inhibitor of SARS-CoV-2 main protease enzyme against COVID-19.|pdf=|usr=025}}
+{{tp|p=33483539|t=2021. First principle simulation of coated hydroxychloroquine on Ag, Au and Pt nanoparticles.|pdf=|usr=025}}
+{{tp|p=33479401|t=2021. Catechin and curcumin interact with S protein of SARS-CoV2 and ACE2 of human cell membrane: insights from computational studies.|pdf=|usr=025}}
+{{tp|p=33479261|t=2021. Autumn COVID-19 surge dates in Europe correlated to latitudes, not to temperature-humidity, pointing to vitamin D as contributing factor.|pdf=|usr=025}}
+{{tp|p=33446817|t=2021. Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages.|pdf=|usr=025}}
+{{tp|p=33441985|t=2021. Contact residue contributions to interaction energies between SARS-CoV-1 spike proteins and human ACE2 receptors.|pdf=|usr=025}}
+{{tp|p=33441909|t=2021. Corticosteroid treatment has no effect on hospital mortality in COVID-19 patients.|pdf=|usr=025}}
+{{tp|p=33436985|t=2021. Antiviral activity of lambda-carrageenan against influenza viruses and severe acute respiratory syndrome coronavirus 2.|pdf=|usr=025}}
+{{tp|p=33436946|t=2021. The association of Coronavirus Disease-19 mortality and prior bacille Calmette-Guerin vaccination: a robust ecological analysis using unsupervised machine learning.|pdf=|usr=025}}
+{{tp|p=33425427|t=2020. Potential of Plant Bioactive Compounds as SARS-CoV-2 Main Protease (M(pro)) and Spike (S) Glycoprotein Inhibitors: A Molecular Docking Study.|pdf=|usr=025}}
+{{tp|p=33514688|t=2021. Constrained surfaces: promising therapeutic targets for COVID-19 determined by systematically mutational analysis.|pdf=|usr=025}}
+{{tp|p=33423577|t=2021. A High-Throughput RNA Displacement Assay for Screening SARS-CoV-2 nsp10-nsp16 Complex toward Developing Therapeutics for COVID-19.|pdf=|usr=025}}
+{{tp|p=33457315|t=2020. The Many Faces of Covid-19: Organizing Pneumonia (OP) Pattern HRCT Features.|pdf=|usr=025}}
+{{tp|p=33504502|t=2021. Covid-19 controversies: the tocilizumab chapter.|pdf=|usr=025}}
+{{tp|p=33500251|t=2021. Covid-19: Moderna plans booster doses to counter variants.|pdf=|usr=025}}
+{{tp|p=33483332|t=2021. Covid-19: Reports from Israel suggest one dose of Pfizer vaccine could be less effective than expected.|pdf=|usr=025}}
+{{tp|p=33381648|t=2020. Letter to the Editor: Possible Drug-Drug Interactions Between Cannabinoids and Candidate COVID-19 Drugs.|pdf=|usr=025}}
+{{tp|p=33445938|t=2020. Ročni obdobi, vitamin D a COVID-19.|pdf=|usr=025}}
+{{tp|p=33386649|t=2021. Novel quantitative structure-activity relationship model to predict activities of natural products against COVID-19.|pdf=|usr=025}}
+{{tp|p=33443248|t=2021. Synthesis and immunological evaluation of synthetic peptide based anti-SARS-CoV-2 vaccine candidates.|pdf=|usr=025}}
+{{tp|p=33524090|t=2021. Antiviral drug discovery: preparing for the next pandemic.|pdf=|usr=025}}
+{{tp|p=33434052|t=2021. DAMPening Mortality in COVID-19: Therapeutic Insights From Basic Cardiometabolic Studies on S100A8/A9.|pdf=|usr=025}}
+{{tp|p=33394522|t=2021. Clinical manifestations and impact on daily life of allergy to polyethylene glycol (PEG) in ten patients.|pdf=|usr=025}}
+{{tp|p=33480877|t=2021. Convalescent Plasma: Education and Administration Implications.|pdf=|usr=025}}
+{{tp|p=33480870|t=2021. COVID-19 Vaccines: Preparing for Vaccination in the Context of Clinical Oncology Care.|pdf=|usr=025}}
+{{tp|p=33410139|t=2021. Nonspecific Binding Considerations in the Rational Design and Development of Small Molecule COVID-19 Therapeutics.|pdf=|usr=025}}
+{{tp|p=33410134|t=2021. Mechanistic Modeling of SARS-CoV-2 and Other Infectious Diseases and the Effects of Therapeutics.|pdf=|usr=025}}
+{{tp|p=33480424|t=2021. Host cell glutamine metabolism as a potential antiviral target.|pdf=|usr=025}}
+{{tp|p=33404204|t=2021. Hybrid physiologically-based pharmacokinetic model for remdesivir: Application to SARS-CoV-2.|pdf=|usr=025}}
+{{tp|p=33404133|t=2021. Chloroquine and hydroxychloroquine provoke arrhythmias at concentrations higher than those clinically used to treat COVID-19: A simulation study.|pdf=|usr=025}}
+{{tp|p=33403775|t=2021. Compassionate use of ruxolitinib in patients with SARS-Cov-2 infection not on mechanical ventilation: Short-term effects on inflammation and ventilation.|pdf=|usr=025}}
+{{tp|p=33441063|t=2021. Deep learning in the quest for compound nomination for fighting COVID-19.|pdf=|usr=025}}
+{{tp|p=33509001|t=2021. The nutritional status of the elderly patient infected with COVID-19: the forgotten risk factor?|pdf=|usr=025}}
+{{tp|p=33504301|t=2021. Phenylbenzopyrone of flavonoids as a potential scaffold to prevent SARS-CoV-2 replication by inhibiting its MPRO main protease.|pdf=|usr=025}}
+{{tp|p=33459226|t=2021. Therapeutic agents against COVID-19 with clinical evidence.|pdf=|usr=025}}
+{{tp|p=33459225|t=2021. Natural agents modulating ACE-2: A review of compounds with potential against SARS-CoV-2 infections.|pdf=|usr=025}}
+{{tp|p=33430748|t=2021. In silico Prediction and Designing of Potential siRNAs to be Used as Antivirals Against SARS-CoV-2.|pdf=|usr=025}}
+{{tp|p=33430746|t=2021. Natural Products, a Potential Therapeutic Modality in Management and Treatment of nCoV-19 Infection: Preclinical and Clinical based Evidence.|pdf=|usr=025}}
+{{tp|p=33388014|t=2021. Use of Natural Compounds as a potential therapeutic agent against COVID-19.|pdf=|usr=025}}
+{{tp|p=33438550|t=2021. Regenerative Medicine Approaches in COVID -19 Pneumonia.|pdf=|usr=025}}
+{{tp|p=33463470|t=2021. An Updated Review on Betacoronavirus Viral Entry Inhibitors: Learning from Past Discoveries to Advance COVID-19 Drug Discovery.|pdf=|usr=025}}
+{{tp|p=33497492|t=2021. A finding associated with favipiravir-associated photosensitivity: Yellow-green fluorescence in the lunulae, scalp, and face.|pdf=|usr=025}}
+{{tp|p=33517789|t=2021. Study on mechanism of matrine in treatment of COVID-19 combined with liver injury by network pharmacology and molecular docking technology.|pdf=|usr=025}}
+{{tp|p=33401328|t=2021. Efficacy and Safety of Tocilizumab for Coronavirus Disease 2019 (Covid-19) Patients: A Systematic Review and Meta-analysis.|pdf=|usr=025}}
+{{tp|p=33513649|t=2021. Steroide in der Infektionsmedizin.|pdf=|usr=025}}
+{{tp|p=33459251|t=2021. The Role of Nutrition during the COVID-19 Pandemic: What We Know.|pdf=|usr=025}}
+{{tp|p=33520579|t=2021. Screening of potent drug inhibitors against SARS-CoV-2 RNA polymerase: an in silico approach.|pdf=|usr=025}}
+{{tp|p=33500874|t=2021. Perspective on therapeutic and diagnostic potential of camel nanobodies for coronavirus disease-19 (COVID-19).|pdf=|usr=025}}
+{{tp|p=33457176|t=2021. Factual insights of the allosteric inhibition mechanism of SARS-CoV-2 main protease by quercetin: an in silico analysis.|pdf=|usr=025}}
+{{tp|p=33457172|t=2021. Designing a next generation multi-epitope based peptide vaccine candidate against SARS-CoV-2 using computational approaches.|pdf=|usr=025}}
+{{tp|p=33457171|t=2021. In silico docking analysis revealed the potential of phytochemicals present in Phyllanthus amarus and Andrographis paniculata, used in Ayurveda medicine in inhibiting SARS-CoV-2.|pdf=|usr=025}}
+{{tp|p=33417425|t=2021. Early Returns on Small Molecule Therapeutics for SARS-CoV-2.|pdf=|usr=025}}
+{{tp|p=33479570|t=2021. Influence of 4'-Substitution on the Activity of Gemcitabine and Its ProTide Against VZV and SARS-CoV-2.|pdf=|usr=025}}
+{{tp|p=33480671|t=2021. Design of SARS-CoV-2 hFc-Conjugated Receptor-Binding Domain mRNA Vaccine Delivered via Lipid Nanoparticles.|pdf=|usr=025}}
+{{tp|p=33464829|t=2021. Rapid Development of SARS-CoV-2 Spike Protein Receptor-Binding Domain Self-Assembled Nanoparticle Vaccine Candidates.|pdf=|usr=025}}
+{{tp|p=33398250|t=2020. Structure-Based Virtual Screening and Biochemical Validation to Discover a Potential Inhibitor of the SARS-CoV-2 Main Protease.|pdf=|usr=025}}
+{{tp|p=33456449|t=2021. Complexity analysis of cold chain transportation in a vaccine supply chain considering activity inspection and time-delay.|pdf=|usr=025}}
+{{tp|p=33422546|t=2021. Advances in gene-based vaccine platforms to address the COVID-19 pandemic.|pdf=|usr=025}}
+{{tp|p=33421475|t=2021. Recombinant protein vaccines, a proven approach against coronavirus pandemics.|pdf=|usr=025}}
+{{tp|p=33400957|t=2021. Self-assembled mRNA vaccines.|pdf=|usr=025}}
+{{tp|p=33428995|t=2021. Nanocarrier vaccines for SARS-CoV-2.|pdf=|usr=025}}
+{{tp|p=33482248|t=2021. SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?|pdf=|usr=025}}
+{{tp|p=33465451|t=2021. In silico T cell epitope identification for SARS-CoV-2: Progress and perspectives.|pdf=|usr=025}}
+{{tp|p=33491915|t=2021. Broad-Spectrum Antiviral Agents Based on Multivalent Inhibitors of Viral Infectivity.|pdf=|usr=025}}
+{{tp|p=33458958|t=2021. Next-Generation Vaccines: Nanoparticle-Mediated DNA and mRNA Delivery.|pdf=|usr=025}}
+{{tp|p=33520645|t=2021. Vitamin-D and COVID-19: time for the profession to take a stand.|pdf=|usr=025}}
+{{tp|p=33520646|t=2020. The potential contribution of traditional, complementary and integrative treatments in acute viral respiratory tract infections: Rapid Reviews in response to the COVID-19 pandemic.|pdf=|usr=025}}
+{{tp|p=33439972|t=2021. Western Dietary Pattern Antioxidant Intakes and Oxidative Stress: Importance During the SARS-CoV-2/COVID-19 Pandemic.|pdf=|usr=025}}
+{{tp|p=33471354|t=2021. A review of Ciclesonide in COVID-19. Still a long way to go.|pdf=|usr=025}}
+{{tp|p=33393643|t=2020. Clinical outcome, viral response and safety profile of chloroquine in COVID-19 patients - initial experience.|pdf=|usr=025}}
+{{tp|p=33465050|t=2021. Fighting the storm: could novel anti-TNFalpha and anti-IL-6 C. sativa cultivars tame cytokine storm in COVID-19?|pdf=|usr=025}}
+{{tp|p=33489449|t=2020. TaibUVID nutritional supplements help rapid cure of COVID-19 infection and rapid reversion to negative nasopharyngeal swab PCR: for better public prophylaxis and treatment of COVID-19 pandemic.|pdf=|usr=025}}
+{{tp|p=33415017|t=2020. Tannic acid suppresses SARS-CoV-2 as a dual inhibitor of the viral main protease and the cellular TMPRSS2 protease.|pdf=|usr=025}}
+{{tp|p=33417877|t=2021. Meta-Analysis of the Effect of Aspirin on Mortality in COVID-19.|pdf=|usr=025}}
+{{tp|p=33489475|t=2020. Perspectives: potential therapeutic approach with inhalation of ACE2-derived peptides for SARS-CoV-2 infection.|pdf=|usr=025}}
+{{tp|p=33502950|t=2021. Soluble ACE2 as a potential therapy for COVID-19.|pdf=|usr=025}}
+{{tp|p=33404354|t=2021. Exploring the link between vitamin D and clinical outcomes in COVID-19.|pdf=|usr=025}}
+{{tp|p=33404365|t=2021. Remote ischemic conditioning for acute respiratory distress syndrome in COVID-19.|pdf=|usr=025}}
+{{tp|p=33496642|t=2020. Potential role for nitazoxanide in treating SARS-CoV-2 infection.|pdf=|usr=025}}
+{{tp|p=33437355|t=2020. Role of azithromycin in antiviral treatment: enhancement of interferon-dependent antiviral pathways and mitigation of inflammation may rely on inhibition of the MAPK cascade?|pdf=|usr=025}}
+{{tp|p=33397585|t=2021. Mesenchymal stromal cells to fight SARS-CoV-2: Taking advantage of a pleiotropic therapy.|pdf=|usr=025}}
+{{tp|p=33484986|t=2021. Potential beneficial role of probiotics on the outcome of COVID-19 patients: An evolving perspective.|pdf=|usr=025}}
+{{tp|p=33390567|t=2021. Analytical methods for the determination of remdesivir as a promising antiviral candidate drug for the COVID-19 pandemic.|pdf=|usr=025}}
+{{tp|p=33385574|t=2021. Why do we lack a specific magic anti-COVID-19 drug? Analyses and solutions.|pdf=|usr=025}}
+{{tp|p=33422991|t=2021. Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice.|pdf=|usr=025}}
+{{tp|p=33418497|t=2021. Understanding the pharmacokinetics of Favipiravir: Implications for treatment of influenza and COVID-19.|pdf=|usr=025}}
+{{tp|p=33495752|t=2021. The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial.|pdf=|usr=025}}
+{{tp|p=33521339|t=2021. Multiple sclerosis, B cell therapy, and the COVID-19 vaccine.|pdf=|usr=025}}
+{{tp|p=33520331|t=2020. The Scientific Foundation of Chinese Herbal Medicine against COVID-19.|pdf=|usr=025}}
+{{tp|p=33472816|t=2021. Is it safe to use remdesivir in combination with a combined p-glycoprotein and CYP3A4 inhibitor?|pdf=|usr=025}}
+{{tp|p=33520016|t=2021. COVID-19, prevention and treatment with herbal medicine in the herbal markets of Sale Prefecture, North-Western Morocco.|pdf=|usr=025}}
+{{tp|p=33520014|t=2021. Two pronged approach for prevention and therapy of COVID-19 (Sars-CoV-2) by a multi-targeted herbal drug, a component of ayurvedic decoction.|pdf=|usr=025}}
+{{tp|p=33520015|t=2020. Analysis of the mechanism of Shufeng Jiedu capsule prevention and treatment for COVID-19 by network pharmacology tools.|pdf=|usr=025}}
+{{tp|p=33524687|t=2021. RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic.|pdf=|usr=025}}
+{{tp|p=33508085|t=2021. Is COVID-19 lockdown associated with vitamin D deficiency?|pdf=|usr=025}}
+{{tp|p=33506949|t=2021. Quinacrine as a potential treatment for COVID-19 virus infection.|pdf=|usr=025}}
+{{tp|p=33506948|t=2021. Safety and efficacy of oral lopinavir/ritonavir in pediatric patients with coronavirus disease: a nationwide comparative analysis.|pdf=|usr=025}}
+{{tp|p=33506946|t=2021. Remdesivir as a broad-spectrum antiviral drug against COVID-19.|pdf=|usr=025}}
+{{tp|p=33504238|t=2021. Tocilizumab for the treatment of COVID-19.|pdf=|usr=025}}
+{{tp|p=33475441|t=2021. SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19.|pdf=|usr=025}}
+{{tp|p=33499687|t=2021. Clinical course of severe patients with COVID-19 treated with tocilizumab: report from a cohort study in Spain.|pdf=|usr=025}}
+{{tp|p=33435759|t=2021. Immunoinformatics-guided designing and in silico analysis of epitope-based polyvalent vaccines against multiple strains of human coronavirus (HCoV).|pdf=|usr=025}}
+{{tp|p=33435774|t=2021. COVID-19 vaccine: where are we now and where should we go?|pdf=|usr=025}}
+{{tp|p=33443475|t=2021. Remdesivir y reduccion de mortalidad en pacientes con COVID-19: analisis sistematizado de subgrupos de los ensayos clinicos.|pdf=|usr=025}}
+{{tp|p=33449359|t=2021. Dynamics and electrostatics define an allosteric druggable site within the receptor-binding domain of SARS-CoV-2 spike protein.|pdf=|usr=025}}
+{{tp|p=33520970|t=2020. Perinatal Cells: A Promising COVID-19 Therapy?|pdf=|usr=025}}
+{{tp|p=33520943|t=2020. In silico Analysis Revealed Potential Anti-SARS-CoV-2 Main Protease Activity by the Zonulin Inhibitor Larazotide Acetate.|pdf=|usr=025}}
+{{tp|p=33521056|t=2020. In vitro Dissolution Profile at Different Biological pH Conditions of Hydroxychloroquine Sulfate Tablets Is Available for the Treatment of COVID-19.|pdf=|usr=025}}
+{{tp|p=33521032|t=2020. Predictive Value of Prognostic Nutritional Index on COVID-19 Severity.|pdf=|usr=025}}
+{{tp|p=33472895|t=2021. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting.|pdf=|usr=025}}
+{{tp|p=33462654|t=2021. Impfempfehlungen der Standigen Impfkommission (STIKO) : Impfungen bei Immundefizienz und Impfung gegen COVID-19.|pdf=|usr=025}}
+{{tp|p=33482433|t=2021. Is prognostic nutritional index a predictive marker for estimating all-cause in-hospital mortality in COVID-19 patients with cardiovascular risk factors?|pdf=|usr=025}}
+{{tp|p=33467131|t=2021. Can Optimum Solar Radiation Exposure or Supplemented Vitamin D Intake Reduce the Severity of COVID-19 Symptoms?|pdf=|usr=025}}
+{{tp|p=33524396|t=2021. Potent mouse monoclonal antibodies that block SARS-CoV-2 infection.|pdf=|usr=025}}
+{{tp|p=33416020|t=2021. Searching for potential drugs against SARS-CoV-2 through virtual screening on several molecular targets.|pdf=|usr=025}}
+{{tp|p=33413032|t=2021. Identification of potential SARS-CoV-2 M(pro) inhibitors integrating molecular docking and water thermodynamics.|pdf=|usr=025}}
+{{tp|p=33403946|t=2021. In silico design of multi-epitope-based peptide vaccine against SARS-CoV-2 using its spike protein.|pdf=|usr=025}}
+{{tp|p=33509045|t=2021. Applying high throughput and comprehensive immunoinformatics approaches to design a trivalent subunit vaccine for induction of immune response against emerging human coronaviruses SARS-CoV, MERS-CoV and SARS-CoV-2.|pdf=|usr=025}}
+{{tp|p=33491579|t=2021. Molecular basis for the repurposing of histamine H2-receptor antagonist to treat COVID-19.|pdf=|usr=025}}
+{{tp|p=33491569|t=2021. RNA dependent RNA polymerase (RdRp) as a drug target for SARS-CoV2.|pdf=|usr=025}}
+{{tp|p=33427102|t=2021. ACE2-derived peptides interact with the RBD domain of SARS-CoV-2 spike glycoprotein, disrupting the interaction with the human ACE2 receptor.|pdf=|usr=025}}
+{{tp|p=33474735|t=2021. AAMC Discusses Monoclonal Antibody Therapeutics for SARS-CoV-2 Infection.|pdf=|usr=025}}
+{{tp|p=33511638|t=2021. Potential COVID-19 Therapeutic Agents and Vaccines: An Evidence-Based Review.|pdf=|usr=025}}
+{{tp|p=33491508|t=2021. Scutellaria baicalensis extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease in vitro.|pdf=|usr=025}}
+{{tp|p=33442304|t=2021. Experimental Pharmacotherapy for COVID-19: The Latest Advances.|pdf=|usr=025}}
+{{tp|p=33391636|t=2020. Extracellular vesicles containing ACE2 efficiently prevent infection by SARS-CoV-2 Spike protein-containing virus.|pdf=|usr=025}}
+{{tp|p=33458853|t=2021. Potential health benefits of zinc supplementation for the management of COVID-19 pandemic.|pdf=|usr=025}}
+{{tp|p=33380377|t=2020. Vaccine efficacy against COVID-19: A foresight on the host-associated factors.|pdf=|usr=025}}
+{{tp|p=33519145|t=2021. Evaluating the potency of Sulawesi propolis compounds as ACE-2 inhibitors through molecular docking for COVID-19 drug discovery preliminary study.|pdf=|usr=025}}
+{{tp|p=33519144|t=2021. Probiotic lactobacilli: Can be a remediating supplement for pandemic COVID-19. A review.|pdf=|usr=025}}
+{{tp|p=33464639|t=2021. Role of vitamin D in regulating COVID-19 severity-An immunological perspective.|pdf=|usr=025}}
+{{tp|p=33523654|t=2021. Remdesivir Metabolite GS-441524 Effectively Inhibits SARS-CoV-2 Infection in Mouse Models.|pdf=|usr=025}}
+{{tp|p=33512007|t=2021. Vitamin D deficiency is associated with COVID-19 positivity and severity of the disease.|pdf=|usr=025}}
+{{tp|p=33503267|t=2021. Oxygen-ozone autohemotherapy against COVID-19 needs to fit highly experienced, customized, and standardized protocols to succeed.|pdf=|usr=025}}
+{{tp|p=33475170|t=2021. Zinc treatment of outpatient COVID-19: A retrospective review of 28 consecutive patients.|pdf=|usr=025}}
+{{tp|p=33475167|t=2021. Targeting SARS-CoV-2 viral proteases as a therapeutic strategy to treat COVID-19.|pdf=|usr=025}}
+{{tp|p=33511655|t=2021. Early remdesivir treatment in COVID-19: Why wait another day?|pdf=|usr=025}}
+{{tp|p=33448426|t=2021. Clinical efficacy of Methylprednisolone and the combined use of Lopinavir/Ritonavir with Arbidol in treatment of Coronavirus Disease 2019.|pdf=|usr=025}}
+{{tp|p=33493301|t=2021. Available drugs and supplements for rapid deployment for treatment of COVID-19.|pdf=|usr=025}}
+{{tp|p=33516966|t=2021. A potential solution to avoid overdose of mixed drugs in the event of Covid-19: Nanomedicine at the heart of the Covid-19 pandemic.|pdf=|usr=025}}
+{{tp|p=33518856|t=2021. A computational approach for the screening of potential antiviral compounds against SARS-CoV-2 protease: Ionic liquid vs herbal and natural compounds.|pdf=|usr=025}}
+{{tp|p=33518854|t=2021. Charge-transfer chemistry of azithromycin, the antibiotic used worldwide to treat the coronavirus disease (COVID-19). Part II: Complexation with several pi-acceptors (PA, CLA, CHL).|pdf=|usr=025}}
+{{tp|p=33395259|t=2021. Antiviral Activity of 7-Substituted 7-Deazapurine Ribonucleosides, Monophosphate Prodrugs, and Triphoshates against Emerging RNA Viruses.|pdf=|usr=025}}
+{{tp|p=33468299|t=2021. Vacina para a COVID-19: Da Teoria a Pratica.|pdf=|usr=025}}
+{{tp|p=33523540|t=2021. Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series.|pdf=|usr=025}}
+{{tp|p=33504509|t=2021. Is sitagliptin effective for the treatment of COVID-19?|pdf=|usr=025}}
+{{tp|p=33386655|t=2021. Primary prevention of COVID-19: Advocacy for vaccination from a neurological perspective.|pdf=|usr=025}}
+{{tp|p=33423554|t=2021. SARS-CoV-2 protein drug targets landscape: a potential pharmacological insight view for the new drug development.|pdf=|usr=025}}
+{{tp|p=33400393|t=2021. Overview of antiviral drug candidates targeting coronaviral 3C-like main proteases.|pdf=|usr=025}}
+{{tp|p=33448695|t=2020. Vitamin D to prevent COVID-19: recommendations for the design of clinical trials.|pdf=|usr=025}}
+{{tp|p=33491580|t=2021. Immunomodulatory and anti-cytokine therapeutic potential of curcumin and its derivatives for treating COVID-19 - a computational modeling.|pdf=|usr=025}}
+{{tp|p=33491573|t=2021. Exploring potential inhibitor of SARS-CoV2 replicase from FDA approved drugs using insilico drug discovery methods.|pdf=|usr=025}}
+{{tp|p=33459176|t=2021. Molecular docking and simulation studies of natural compounds of Vitex negundo L. against papain-like protease (PL(pro)) of SARS CoV-2 (coronavirus) to conquer the pandemic situation in the world.|pdf=|usr=025}}
+{{tp|p=33459174|t=2021. Withanolides from Withania somnifera as an immunity booster and their therapeutic options against COVID-19.|pdf=|usr=025}}
+{{tp|p=33433137|t=2021. Pandemic aspect of dexamethasone: Molecular mechanisms and clinical application.|pdf=|usr=025}}
+{{tp|p=33504214|t=2021. A Psoriatic Patient-Based Survey on the Understanding of the Use of Vaccines While on Biologics During the COVID-19 Pandemic.|pdf=|usr=025}}
+{{tp|p=33507143|t=2021. Targeting novel structural and functional features of coronavirus protease nsp5 (3CL(pro), M(pro)) in the age of COVID-19.|pdf=|usr=025}}
+{{tp|p=33386773|t=2021. SARS-CoV-2 nucleocapsid protein intranasal inoculation induces local and systemic T cell responses in mice.|pdf=|usr=025}}
+{{tp|p=33426632|t=2021. COVID-19 vaccination in immunocompromised patients.|pdf=|usr=025}}
+{{tp|p=33503192|t=2021. Antiviral activity of Brazilian Green Propolis extract against SARS-CoV-2 (Severe Acute Respiratory Syndrome - Coronavirus 2) infection: case report and review.|pdf=|usr=025}}
+{{tp|p=33504561|t=2021. Pregnancy, breastfeeding and the SARS-CoV-2 vaccine: an ethics-based framework for shared decision-making.|pdf=|usr=025}}
+{{tp|p=33408097|t=2021. Remdesivir for patients with COVID-19.|pdf=|usr=025}}
+{{tp|p=33473151|t=2021. Identification of 3-chymotrypsin like protease (3CLPro) inhibitors as potential anti-SARS-CoV-2 agents.|pdf=|usr=025}}
+{{tp|p=33505639|t=2021. Spontaneous binding of potential COVID-19 drugs (Camostat and Nafamostat) to human serine protease TMPRSS2.|pdf=|usr=025}}
+{{tp|p=33398234|t=2021. Computational design of SARS-CoV-2 spike glycoproteins to increase immunogenicity by T cell epitope engineering.|pdf=|usr=025}}
+{{tp|p=33391634|t=2021. Exploiting cheminformatic and machine learning to navigate the available chemical space of potential small molecule inhibitors of SARS-CoV-2.|pdf=|usr=025}}
+{{tp|p=33391633|t=2021. Computational modelling supports that dengue virus envelope antibodies can bind to SARS-CoV-2 receptor binding sites: Is pre-exposure to dengue virus protective against COVID-19 severity?|pdf=|usr=025}}
+{{tp|p=33422642|t=2021. Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials.|pdf=|usr=025}}
+{{tp|p=33495742|t=2021. Pragmatic, open-label, single-center, randomized, phase II clinical trial to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus in patients with severe pneumonia secondary to COVID-19: The TACROVID trial protocol.|pdf=|usr=025}}
+{{tp|p=33397463|t=2021. Early corticosteroids are associated with lower mortality in critically ill patients with COVID-19: a cohort study.|pdf=|usr=025}}
+{{tp|p=33490955|t=2021. Tocilizumab in Coronavirus Disease 2019-Related Critical Illness: A Propensity Matched Analysis.|pdf=|usr=025}}
+{{tp|p=33437559|t=2021. Influenza Vaccination Quality Improvement as a Model for COVID-19 Prophylaxis.|pdf=|usr=025}}
+{{tp|p=33425565|t=2021. The Flu Vaccination May Have a Protective Effect on the Course of COVID-19 in the Pediatric Population: When Does Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Meet Influenza?|pdf=|usr=025}}
+{{tp|p=33409034|t=2020. Treatment Experience With Inhaled Corticosteroids in Combination with Remdesivir and Dexamethasone Among COVID-19 Patients Admitted to a Rural Community Hospital: A Case Series.|pdf=|usr=025}}
+{{tp|p=33409026|t=2020. The Role of Vitamin C as Adjuvant Therapy in COVID-19.|pdf=|usr=025}}
+{{tp|p=33510989|t=2020. Tocilizumab for COVID-19 Acute Respiratory Distress Syndrome: Outcomes Assessment Using the WHO Ordinal Scale.|pdf=|usr=025}}
+{{tp|p=33489621|t=2020. Is There any Additional Benefit of Multiple Doses of Tocilizumab in COVID-19 Patients?|pdf=|usr=025}}
+{{tp|p=33475900|t=2021. Hydroxychloroquine and COVID-19: a Rheumatologist's Take on the Lessons Learned.|pdf=|usr=025}}
+{{tp|p=33409442|t=2020. COVID-19 and Telenutrition: Remote Consultation in Clinical Nutrition Practice.|pdf=|usr=025}}
+{{tp|p=33390762|t=2021. Exogenous pulmonary surfactant: A review focused on adjunctive therapy for severe acute respiratory syndrome coronavirus 2 including SP-A and SP-D as added clinical marker.|pdf=|usr=025}}
+{{tp|p=33403480|t=2021. Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor.|pdf=|usr=025}}
+{{tp|p=33457366|t=2020. Treatment of Crimean-Congo Haemorrhagic Fever by Favipiravir in a Patient with Novel Coronavirus Co-Infection.|pdf=|usr=025}}
+{{tp|p=33415491|t=2021. A novel approach to managing COVID-19 patients; results of lopinavir plus doxycycline cohort.|pdf=|usr=025}}
+{{tp|p=33439342|t=2021. A novel approach to managing COVID-19 patients: results of lopinavir plus doxycycline cohort-authors' reply.|pdf=|usr=025}}
+{{tp|p=33404753|t=2021. Remdesivir for COVID-19 pneumonia: still undecided, but it might all be about adequate timing.|pdf=|usr=025}}
+{{tp|p=33452110|t=2021. A prospective, observational study to evaluate adverse drug reactions in patients with COVID-19 treated with remdesivir or hydroxychloroquine: a preliminary report.|pdf=|usr=025}}
+{{tp|p=33425074|t=2021. Network pharmacology-based analysis of Zukamu granules for the treatment of COVID-19.|pdf=|usr=025}}
+{{tp|p=33423905|t=2021. Flying higher than politics: The goal of preventive medicine at the time of the COVID-19 pandemic.|pdf=|usr=025}}
+{{tp|p=33486200|t=2021. The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2.|pdf=|usr=025}}
+{{tp|p=33483798|t=2021. Severe sinus bradycardia associated with Remdesivir in a child with severe SARS-CoV-2 infection.|pdf=|usr=025}}
+{{tp|p=33464367|t=2021. Severe sinus bradycardia associated with remdesivir in a child with severe SARS-COV-2 infection-reply.|pdf=|usr=025}}
+{{tp|p=33428898|t=2021. Dexamethasone: Therapeutic potential, risks, and future projection during COVID-19 pandemic.|pdf=|usr=025}}
+{{tp|p=33387467|t=2021. Unraveling the mechanism of arbidol binding and inhibition of SARS-CoV-2: Insights from atomistic simulations.|pdf=|usr=025}}
+{{tp|p=33482181|t=2021. A review of potential suggested drugs for coronavirus disease (COVID-19) treatment.|pdf=|usr=025}}
+{{tp|p=33497607|t=2021. Repositioning of histamine H1 receptor antagonist: Doxepin inhibits viropexis of SARS-CoV-2 Spike pseudovirus by blocking ACE2.|pdf=|usr=025}}
+{{tp|p=33509962|t=2021. Is high-dose glucocorticoid beneficial in COVID-19?|pdf=|usr=025}}
+{{tp|p=33511068|t=2020. Extraordinary Survival Benefits of Severe and Critical Patients with COVID-19 by Immune Modulators: The Outcome of a Clinical Trial in Bangladesh.|pdf=|usr=025}}
+{{tp|p=33381197|t=2020. Screening for a Potential Therapeutic Agent from the Herbal Formula in the 4(th) Edition of the Chinese National Guidelines for the Initial-Stage Management of COVID-19 via Molecular Docking.|pdf=|usr=025}}
+{{tp|p=33500777|t=2020. Option-based guarantees to accelerate urgent, high-risk vaccines: a new market-shaping approach.|pdf=|usr=025}}
+{{tp|p=33495727|t=2021. Polyphenols as promising biologically active substances for preventing SARS-CoV-2: A review with research evidence and underlying mechanisms.|pdf=|usr=025}}
+{{tp|p=33418408|t=2021. An in-silico evaluation of different bioactive molecules of tea for their inhibition potency against non structural protein-15 of SARS-CoV-2.|pdf=|usr=025}}
+{{tp|p=33412235|t=2021. Promising phytochemicals of traditional Indian herbal steam inhalation therapy to combat COVID-19 - An in silico study.|pdf=|usr=025}}
+{{tp|p=33435315|t=2021. Probiotic Effects against Virus Infections: New Weapons for an Old War.|pdf=|usr=025}}
+{{tp|p=33475983|t=2021. Does herbal therapy for COVID-19 have implications for forensic practice?|pdf=|usr=025}}
+{{tp|p=33469529|t=2020. Nitric Oxide Rele<iframe src="http://www.kidney.de/amapp.php?a=g Hydrogel Nanoparticles Decreases Epithelial Cell Injuries Associated With Airway Reopening.|pdf=|usr=025}}
+{{tp|p=33426009|t=2020. Investigating the Potential for Ultraviolet Light to Modulate Morbidity and Mortality From COVID-19: A Narrative Review and Update.|pdf=|usr=025}}
+{{tp|p=33392268|t=2020. Thromboinflammation and COVID-19: The Role of Exercise in the Prevention and Treatment.|pdf=|usr=025}}
+{{tp|p=33469541|t=2020. Combating COVID-19 With Mesenchymal Stem/Stromal Cell Therapy: Promise and Challenges.|pdf=|usr=025}}
+{{tp|p=33384971|t=2020. NOX-Dependent Signaling Dysregulation in Severe COVID-19: Clues to Effective Treatments.|pdf=|usr=025}}
+{{tp|p=33381464|t=2020. What Can Cellular Redox, Iron, and Reactive Oxygen Species Suggest About the Mechanisms and Potential Therapy of COVID-19?|pdf=|usr=025}}
+{{tp|p=33425850|t=2020. Computational Prediction of Potential Inhibitors of the Main Protease of SARS-CoV-2.|pdf=|usr=025}}
+{{tp|p=33488592|t=2020. Rapid GMP-Compliant Expansion of SARS-CoV-2-Specific T Cells From Convalescent Donors for Use as an Allogeneic Cell Therapy for COVID-19.|pdf=|usr=025}}
+{{tp|p=33424848|t=2020. COVID-19: Coronavirus Vaccine Development Updates.|pdf=|usr=025}}
+{{tp|p=33424838|t=2020. The Artificial-Liver Blood-Purification System Can Effectively Improve Hypercytokinemia for COVID-19.|pdf=|usr=025}}
+{{tp|p=33408715|t=2020. Akt-Fas to Quell Aberrant T Cell Differentiation and Apoptosis in Covid-19.|pdf=|usr=025}}
+{{tp|p=33391285|t=2020. A Potent SARS-CoV-2 Neutralizing Human Monoclonal Antibody That Reduces Viral Burden and Disease Severity in Syrian Hamsters.|pdf=|usr=025}}
+{{tp|p=33425942|t=2020. Humidified Warmed CO2 Treatment Therapy Strategies Can Save Lives With Mitigation and Suppression of SARS-CoV-2 Infection: An Evidence Review.|pdf=|usr=025}}
+{{tp|p=33415116|t=2020. The Need for Antiviral Drugs for Pandemic Coronaviruses From a Global Health Perspective.|pdf=|usr=025}}
+{{tp|p=33490110|t=2020. Molecular Docking and Molecular Dynamics Aided Virtual Search of OliveNet Directory for Secoiridoids to Combat SARS-CoV-2 Infection and Associated Hyperinflammatory Responses.|pdf=|usr=025}}
+{{tp|p=33425995|t=2020. Exploring the Potential of Carbon Dots to Combat COVID-19.|pdf=|usr=025}}
+{{tp|p=33425994|t=2020. Molecular Docking Studies on the Anti-viral Effects of Compounds From Kabasura Kudineer on SARS-CoV-2 3CL(pro).|pdf=|usr=025}}
+{{tp|p=33392263|t=2020. The Leukotriene Receptor Antagonist Montelukast as a Potential COVID-19 Therapeutic.|pdf=|usr=025}}
+{{tp|p=33392261|t=2020. Identification of Potential Inhibitors of 3CL Protease of SARS-CoV-2 From ZINC Database by Molecular Docking-Based Virtual Screening.|pdf=|usr=025}}
+{{tp|p=33381519|t=2020. Potential Mechanisms for Traditional Chinese Medicine in Treating Airway Mucus Hypersecretion Associated With Coronavirus Disease 2019.|pdf=|usr=025}}
+{{tp|p=33505983|t=2020. Oral Bacteriotherapy in Patients With COVID-19: A Retrospective Cohort Study.|pdf=|usr=025}}
+{{tp|p=33385008|t=2020. Probiotics as a Weapon in the Fight Against COVID-19.|pdf=|usr=025}}
+{{tp|p=33489899|t=2020. COVID-19: High-JAKing of the Inflammatory "Flight" by Ruxolitinib to Avoid the Cytokine Storm.|pdf=|usr=025}}
+{{tp|p=33447586|t=2020. Complement Inhibition in Severe COVID-19 Acute Respiratory Distress Syndrome.|pdf=|usr=025}}
+{{tp|p=33442386|t=2020. Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic.|pdf=|usr=025}}
+{{tp|p=33424586|t=2020. Autophagy Modulation in Lymphocytes From COVID-19 Patients: New Therapeutic Target in SARS-COV-2 Infection.|pdf=|usr=025}}
+{{tp|p=33390999|t=2020. Commentary: Does Lithium Deserve a Place in the Treatment Against COVID-19? A Preliminary Observational Study in Six Patients, Case Report.|pdf=|usr=025}}
+{{tp|p=33390994|t=2020. COVID-19 Disease and Vitamin D: A Mini-Review.|pdf=|usr=025}}
+{{tp|p=33390974|t=2020. Hydroxychloroquine as a Chemoprophylactic Agent for COVID-19: A Clinico-Pharmacological Review.|pdf=|usr=025}}
+{{tp|p=33390967|t=2020. Repurposing Approved Drugs for Guiding COVID-19 Prophylaxis: A Systematic Review.|pdf=|usr=025}}
+{{tp|p=33390952|t=2020. Potential Simultaneous Inhibitors of Angiotensin-Converting Enzyme 2 and Transmembrane Protease, Serine 2.|pdf=|usr=025}}
+{{tp|p=33390948|t=2020. The Large Action of Chlorpromazine: Translational and Transdisciplinary Considerations in the Face of COVID-19.|pdf=|usr=025}}
+{{tp|p=33384605|t=2020. Current Evidence of Interleukin-6 Signaling Inhibitors in Patients With COVID-19: A Systematic Review and Meta-Analysis.|pdf=|usr=025}}
+{{tp|p=33505321|t=2020. Stimulating the Resolution of Inflammation Through Omega-3 Polyunsaturated Fatty Acids in COVID-19: Rationale for the COVID-Omega-F Trial.|pdf=|usr=025}}
+{{tp|p=33424618|t=2020. The Effects of Displacing Sedentary Behavior With Two Distinct Patterns of Light Activity on Health Outcomes in Older Adults (Implications for COVID-19 Quarantine).|pdf=|usr=025}}
+{{tp|p=33490659|t=2021. Can limonene be a possible candidate for evaluation as an agent or adjuvant against infection, immunity, and inflammation in COVID-19?|pdf=|usr=025}}
+{{tp|p=33462562|t=2021. Traditional foods with their constituent's antiviral and immune system modulating properties.|pdf=|usr=025}}
+{{tp|p=33458435|t=2021. In silico validation of potent phytochemical orientin as inhibitor of SARS-CoV-2 spike and host cell receptor GRP78 binding.|pdf=|usr=025}}
+{{tp|p=33421583|t=2021. Impact of colchicine on mortality in patients with COVID-19: A meta-analysis.|pdf=|usr=025}}
+{{tp|p=33473017|t=2021. Chloroquine nasal drops in asymptomatic & mild COVID-19: An exploratory randomized clinical trial.|pdf=|usr=025}}
+{{tp|p=33448317|t=2021. Vitamin D, zinc and glutamine: Synergistic action with OncoTherad immunomodulator in interferon signaling and COVID19 (Review).|pdf=|usr=025}}
+{{tp|p=33491759|t=2021. Immune-checkpoint inhibitors from cancer to COVID19: A promising avenue for the treatment of patients with COVID19 (Review).|pdf=|usr=025}}
+{{tp|p=33523564|t=2021. Emerging COVID-19 vaccines: A rheumatology perspective.|pdf=|usr=025}}
+{{tp|p=33517559|t=2021. Adverse drug reactions in SARS-COV-2 hospitalised patients: a case series with a focus on drug-drug interactions-comment.|pdf=|usr=025}}
+{{tp|p=33521604|t=2021. Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model.|pdf=|usr=025}}
+{{tp|p=33388478|t=2020. mRNA Vaccines to Prevent COVID-19 Disease and Reported Allergic Reactions: Current Evidence and Suggested Approach.|pdf=|usr=025}}
+{{tp|p=33524876|t=2021. COVID-19 convalescent plasma composition and immunological effects in severe patients.|pdf=|usr=025}}
+{{tp|p=33519133|t=2021. An Open Clinical Evaluation Of Selected Siddha Regimen In Expediting The Management Of Covid-19 -A Randomized Controlled Study.|pdf=|usr=025}}
+{{tp|p=33519134|t=2020. Pathophysiology of COVID-19 and Host centric approaches of Ayurveda.|pdf=|usr=025}}
+{{tp|p=33518853|t=2021. Computational study on peptidomimetic inhibitors against SARS-CoV-2 main protease.|pdf=|usr=025}}
+{{tp|p=33518802|t=2021. In silico assessment and sonochemical synthesis of 2-alkynyl 3-chloropyrazines as prospective ligands for SARS-CoV-2.|pdf=|usr=025}}
+{{tp|p=33518801|t=2021. Molecular docking identification for the efficacy of some zinc complexes with chloroquine and hydroxychloroquine against main protease of COVID-19.|pdf=|usr=025}}
+{{tp|p=33518803|t=2021. Inhibitory capacity of chloroquine against SARS-COV-2 by effective binding with angiotensin converting enzyme-2 receptor: An insight from molecular docking and MD-simulation studies.|pdf=|usr=025}}
+{{tp|p=33493479|t=2021. Safety and Pharmacokinetic Assessments of a Novel Ivermectin Nasal Spray Formulation in a Pig Model.|pdf=|usr=025}}
+{{tp|p=33523655|t=2021. Retrained Generic Antibodies Can Recognize SARS-CoV-2.|pdf=|usr=025}}
+{{tp|p=33508197|t=2021. On Drug-Membrane Permeability of Antivirals for SARS-CoV-2.|pdf=|usr=025}}
+{{tp|p=33439735|t=2021. Butyrate Regulates COVID-19-Relevant Genes in Gut Epithelial Organoids From Normotensive Rats.|pdf=|usr=025}}
+{{tp|p=33406943|t=2021. Statins as an adjunctive therapy for COVID-19: the biological and clinical plausibility.|pdf=|usr=025}}
+{{tp|p=33390092|t=2021. The impact of probiotics on interactions within the microbiota-gut-lung triad in COVID-19.|pdf=|usr=025}}
+{{tp|p=33435749|t=2021. Dietary supplements, vitamins and minerals as potential interventions against viruses: Perspectives for COVID-19.|pdf=|usr=025}}
+{{tp|p=33488303|t=2020. Opportunities for Health Promotion: Highlighting Herbs and Spices to Improve Immune Support and Well-being.|pdf=|usr=025}}
+{{tp|p=33500022|t=2021. Molecular Docking of Azithromycin, Ritonavir, Lopinavir, Oseltamivir, Ivermectin and Heparin Interacting with Coronavirus Disease 2019 Main and Severe Acute Respiratory Syndrome Coronavirus-2 3C-Like Proteases.|pdf=|usr=025}}
+{{tp|p=33510536|t=2021. COVID-19 Vaccine Development to Vaccination.|pdf=|usr=025}}
+{{tp|p=33509969|t=2021. LETTER TO THE EDITOR: ON POTENTIAL USE OF RADIOLABELED ANTIBODIES FOR IMAGING AND TREATMENT OF COVID-19.|pdf=|usr=025}}
+{{tp|p=33483330|t=2021. COVID-19 Vaccination: An Overview and Education Tool for Nuclear Medicine Technologists.|pdf=|usr=025}}
+{{tp|p=33455524|t=2021. Clinical Consideration of Glucocorticoids in COVID-19.|pdf=|usr=025}}
+{{tp|p=33447376|t=2020. Effects of rapid recruitment and dissemination on Covid-19 mortality: the RECOVERY trial.|pdf=|usr=025}}
+{{tp|p=33447372|t=2020. Computational screening for potential drug candidates against the SARS-CoV-2 main protease.|pdf=|usr=025}}
+{{tp|p=33519469|t=2020. Inhibition of SARS-CoV-2 by Highly Potent Broad-Spectrum Anti-Coronaviral Tylophorine-Based Derivatives.|pdf=|usr=025}}
+{{tp|p=33519467|t=2020. 3-Hydroxyphthalic Anhydride-Modified Chicken Ovalbumin as a Potential Candidate Inhibits SARS-CoV-2 Infection by Disrupting the Interaction of Spike Protein With Host ACE2 Receptor.|pdf=|usr=025}}
+{{tp|p=33519463|t=2020. TLR9 and COVID-19: A Multidisciplinary Theory of a Multifaceted Therapeutic Target.|pdf=|usr=025}}
+{{tp|p=33519460|t=2020. Methylene Blue Inhibits the SARS-CoV-2 Spike-ACE2 Protein-Protein Interaction-a Mechanism that can Contribute to its Antiviral Activity Against COVID-19.|pdf=|usr=025}}
+{{tp|p=33519449|t=2020. A Review on Plant Bioactive Compounds and Their Modes of Action Against Coronavirus Infection.|pdf=|usr=025}}
+{{tp|p=33490124|t=2020. The Strategy of Boosting the Immune System Under the COVID-19 Pandemic.|pdf=|usr=025}}
+{{tp|p=33457429|t=2021. Compounds of Citrus medica and Zingiber officinale for COVID-19 inhibition: in silico evidence for cues from Ayurveda.|pdf=|usr=025}}
+{{tp|p=33415989|t=2021. Can natural products stop the SARS-CoV-2 virus? A docking and molecular dynamics study of a natural product database.|pdf=|usr=025}}
+{{tp|p=33404263|t=2020. Existing antiviral options against SARS-CoV-2 replication in COVID-19 patients.|pdf=|usr=025}}
+{{tp|p=33432269|t=2020. Exploring the effect of ritonavir and TMC-310911 on SARS-CoV-2 and SARS-CoV main proteases: potential from a molecular perspective.|pdf=|usr=025}}
+{{tp|p=33387518|t=2021. Tacrolimus: Unlikely Harmful and Perhaps Helpful in Liver Transplant Recipients with COVID-19.|pdf=|usr=025}}
+{{tp|p=33484690|t=2021. Reply: The New Foe and Old Friends: Are We Ready for Microbiota-based Therapeutics in Treating COVID-19 Patients?|pdf=|usr=025}}
+{{tp|p=33453230|t=2021. Reply.|pdf=|usr=025}}
+{{tp|p=33388317|t=2020. Letter to the editor: Famotidine and mortality in COVID-19.|pdf=|usr=025}}
+{{tp|p=33387529|t=2020. Famotidine and COVID-19.|pdf=|usr=025}}
+{{tp|p=33487665|t=2021. COVID-19 Treatment: Drug Safety Prior to Conception and During Pregnancy and Breastfeeding.|pdf=|usr=025}}
+{{tp|p=33428154|t=2021. Screening druggable targets and predicting therapeutic drugs for COVID-19 via integrated bioinformatics analysis.|pdf=|usr=025}}
+{{tp|p=33413610|t=2021. An integrated in silico immuno-genetic analytical platform provides insights into COVID-19 serological and vaccine targets.|pdf=|usr=025}}
+{{tp|p=33482326|t=2021. Transcriptome network analyses in human coronavirus infections suggest a rational use of immunomodulatory drugs for COVID-19 therapy.|pdf=|usr=025}}
+{{tp|p=33412759|t=2020. Druggability for COVID-19: in silico discovery of potential drug compounds against nucleocapsid (N) protein of SARS-CoV-2.|pdf=|usr=025}}
+{{tp|p=33432441|t=2021. PI3K/AKT signaling pathway: a possible target for adjuvant therapy in COVID-19.|pdf=|usr=025}}
+{{tp|p=33386081|t=2021. Network machine learning maps phytochemically rich "Hyperfoods" to fight COVID-19.|pdf=|usr=025}}
+{{tp|p=33426490|t=2021. Editorial Comment to Successful recovery from coronavirus disease 2019 in a living kidney transplant recipient using low-dose methylprednisolone.|pdf=|usr=025}}
+{{tp|p=33465283|t=2021. Efficacy of canakinumab in mild or severe COVID-19 pneumonia.|pdf=|usr=025}}
+{{tp|p=33418320|t=2021. BCG immunomodulation: From the 'hygiene hypothesis' to COVID-19.|pdf=|usr=025}}
+{{tp|p=33492637|t=2021. A review of COVID-19 convalescent plasma use in COVID-19 with focus on proof of efficacy.|pdf=|usr=025}}
+{{tp|p=33397150|t=2021. An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases.|pdf=|usr=025}}
+{{tp|p=33432283|t=2021. Evaluation of certain medicinal plants compounds as new potential inhibitors of novel corona virus (COVID-19) using molecular docking analysis.|pdf=|usr=025}}
+{{tp|p=33425648|t=2021. In silico investigation of saponins and tannins as potential inhibitors of SARS-CoV-2 main protease (M(pro)).|pdf=|usr=025}}
+{{tp|p=33425647|t=2021. Designing a conserved peptide-based subunit vaccine against SARS-CoV-2 using immunoinformatics approach.|pdf=|usr=025}}
+{{tp|p=33437070|t=2020. Hyperbaric oxygen therapy: Can it be a novel supportive therapy in COVID-19?|pdf=|usr=025}}
+{{tp|p=33495676|t=2021. COVID-19 and Gut Microbiota: A Potential Connection.|pdf=|usr=025}}
+{{tp|p=33384519|t=2020. Evaluating the Efficacy and Safety of the Existing Repurposed Pharmacological Agents for Treating COVID-19: A Meta-analysis and Systematic Review of Clinical Trials.|pdf=|usr=025}}
+{{tp|p=33384506|t=2020. A Retrospective Observational Study of Hypoxic COVID-19 Patients Treated with Immunomodulatory Drugs in a Tertiary Care Hospital.|pdf=|usr=025}}
+{{tp|p=33384504|t=2020. Immunomodulation and COVID-19: Is There a Winning Combination?|pdf=|usr=025}}
+{{tp|p=33446983|t=2020. Intravenous Immunoglobulin may Reverse Multisystem Inflammation in COVID-19 Pneumonitis and Guillain-Barre Syndrome.|pdf=|usr=025}}
+{{tp|p=33424043|t=2021. Restoring Good Health in Elderly with Diverse Gut Microbiome and Food Intake Restriction to Combat COVID-19.|pdf=|usr=025}}
+{{tp|p=33390627|t=2020. Recent Clinical Trials on Natural Products and Traditional Chinese Medicine Combating the COVID-19.|pdf=|usr=025}}
+{{tp|p=33469896|t=2021. BCG Vaccination Protection Against COVID-19: Correspondence.|pdf=|usr=025}}
+{{tp|p=33484407|t=2021. The Efficacy and Safety of Hydroxychloroquine in Patients with COVID-19: A Multicenter National Retrospective Cohort.|pdf=|usr=025}}
+{{tp|p=33500636|t=2021. Review on Up-to-Date Status of Candidate Vaccines for COVID-19 Disease.|pdf=|usr=025}}
+{{tp|p=33422682|t=2021. Identification of SARS-CoV-2 CTL epitopes for development of a multivalent subunit vaccine for COVID-19.|pdf=|usr=025}}
+{{tp|p=33495884|t=2021. Worldwide inverse correlation between Bacille Calmette-Guerin (BCG) immunization and COVID-19 mortality.|pdf=|usr=025}}
+{{tp|p=33389708|t=2021. Remdesivir in Coronavirus Disease 2019 (COVID-19) treatment: a review of evidence.|pdf=|usr=025}}
+{{tp|p=33521241|t=2021. Manipulated bio antimicrobial peptides from probiotic bacteria as proposed drugs for COVID-19 disease.|pdf=|usr=025}}
+{{tp|p=33457495|t=2021. In silico exploration of novel protease inhibitors against coronavirus 2019 (COVID-19).|pdf=|usr=025}}
+{{tp|p=33521757|t=2021. Structural Basis of SARS-CoV-2 Polymerase Inhibition by Favipiravir.|pdf=|usr=025}}
+{{tp|p=33524979|t=2021. Principles and Challenges in anti-COVID-19 Vaccine Development.|pdf=|usr=025}}
+{{tp|p=33476982|t=2021. Ozone therapy for the treatment of COVID-19 pneumonia: A scoping review.|pdf=|usr=025}}
+{{tp|p=33450596|t=2021. Different characteristics of critical COVID-19 and thinking of treatment strategies in non-elderly and elderly severe adult patients.|pdf=|usr=025}}
+{{tp|p=33429331|t=2021. The immune response and immune evasion characteristics in SARS-CoV, MERS-CoV, and SARS-CoV-2: Vaccine design strategies.|pdf=|usr=025}}
+{{tp|p=33418248|t=2021. Could cilostazol be beneficial in COVID-19 treatment? Thinking about phosphodiesterase-3 as a therapeutic target.|pdf=|usr=025}}
+{{tp|p=33412395|t=2021. Combination therapy of IFNbeta1 with lopinavir-ritonavir, increases oxygenation, survival and discharging of sever COVID-19 infected inpatients.|pdf=|usr=025}}
+{{tp|p=33421928|t=2021. Safety and efficacy of ozone therapy in mild to moderate COVID-19 patients: A phase 1/11 randomized control trial (SEOT study).|pdf=|usr=025}}
+{{tp|p=33515687|t=2021. Chloroquine for treatment of COVID-19 results in subtherapeutic exposure and prolonged QTc intervals.|pdf=|usr=025}}
+{{tp|p=33476734|t=2021. Reply to the letter to the editor "Azithromycin, treatment in COVID-19".|pdf=|usr=025}}
+{{tp|p=33476733|t=2021. Azithromycin, a questionable treatment for COVID-19.|pdf=|usr=025}}
+{{tp|p=33400975|t=2021. Passive immunization and its rebirth in the era of the COVID-19 pandemic.|pdf=|usr=025}}
+{{tp|p=33408033|t=2021. Clinical efficacy and safety profile of hydroxychloroquine and azithromycin against COVID-19.|pdf=|usr=025}}
+{{tp|p=33408032|t=2021. Advanced statistical methods and designs for clinical trials for COVID-19.|pdf=|usr=025}}
+{{tp|p=33408031|t=2021. Response to the use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.|pdf=|usr=025}}
+{{tp|p=33408029|t=2021. Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes.|pdf=|usr=025}}
+{{tp|p=33408028|t=2021. Response to advances statistical methods and designs for clinical trials for COVID-19.|pdf=|usr=025}}
+{{tp|p=33408027|t=2021. Response to effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.|pdf=|usr=025}}
+{{tp|p=33408026|t=2021. Uncertain effects of hydroxychloroquine and azithromycin on SARS-Cov-2 viral load.|pdf=|usr=025}}
+{{tp|p=33408025|t=2021. Safety profile of hydroxychloroquine and azithromycin combined treatment in COVID-19 patients.|pdf=|usr=025}}
+{{tp|p=33408024|t=2021. Letter to the editor about "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".|pdf=|usr=025}}
+{{tp|p=33408022|t=2021. Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial.|pdf=|usr=025}}
+{{tp|p=33408021|t=2021. Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".|pdf=|usr=025}}
+{{tp|p=33408020|t=2021. Use of hydroxychloroquine in combination with azithromycin for patients with COVID-19 is not supported by recent literature.|pdf=|usr=025}}
+{{tp|p=33408019|t=2021. Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a meta-analysis.|pdf=|usr=025}}
+{{tp|p=33408018|t=2021. Doxycycline as an Alternative to Azithromycin in Elderly Patients.|pdf=|usr=025}}
+{{tp|p=33408017|t=2021. Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.|pdf=|usr=025}}
+{{tp|p=33405321|t=2021. Efficacy and safety of OM-85 in paediatric recurrent respiratory tract infections which could have a possible protective effect on COVID-19 pandemic: A meta-analysis.|pdf=|usr=025}}
+{{tp|p=33417696|t=2021. Temporal Analysis of Serial Donations Reveals Decrease in Neutralizing Capacity and Justifies Revised Qualifying Criteria for Coronavirus Disease 2019 Convalescent Plasma.|pdf=|usr=025}}
+{{tp|p=33411937|t=2021. Coronavirus Disease 2019 Convalescent Plasma and the Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer.|pdf=|usr=025}}
+{{tp|p=33433587|t=2021. Nature and dimensions of the systemic hyper-inflammation and its attenuation by convalescent plasma in severe COVID-19.|pdf=|usr=025}}
+{{tp|p=33511686|t=2021. Tocilizumab in COVID-19 interstitial pneumonia.|pdf=|usr=025}}
+{{tp|p=33520685|t=2021. Mushroom-derived bioactive compounds potentially serve as the inhibitors of SARS-CoV-2 main protease: An in silico approach.|pdf=|usr=025}}
+{{tp|p=33520684|t=2021. Analyzing the potential therapeutic mechanism of Huashi Baidu Decoction on severe COVID-19 through integrating network pharmacological methods.|pdf=|usr=025}}
+{{tp|p=33520683|t=2021. Anti-COVID-19 drug candidates: A review on potential biological activities of natural products in the management of new coronavirus infection.|pdf=|usr=025}}
+{{tp|p=33520682|t=2021. Molecular docking analysis of rutin reveals possible inhibition of SARS-CoV-2 vital proteins.|pdf=|usr=025}}
+{{tp|p=33521616|t=2021. Disruption of CCR5 signaling to treat COVID-19-associated cytokine storm: Case series of four critically ill patients treated with leronlimab.|pdf=|usr=025}}
+{{tp|p=33480414|t=2021. From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?|pdf=|usr=025}}
+{{tp|p=33516648|t=2021. Role of Famotidine and Other Acid Reflux Medications for SARS-CoV-2: A Pilot Study.|pdf=|usr=025}}
+{{tp|p=33521397|t=2021. Integrating Integrins: A New Way to Increase Our COVID-19 Armamentarium?|pdf=|usr=025}}
+{{tp|p=33518628|t=2021. Inactivation of SARS-CoV-2 by Catechins from Green Tea.|pdf=|usr=025}}
+{{tp|p=33518623|t=2021. Nasopharyngeal SARS-CoV-2 Viral Load Response among COVID-19 Patients Receiving Favipiravir.|pdf=|usr=025}}
+{{tp|p=33524312|t=2021. Next-generation COVID-19 vaccines: here come the proteins.|pdf=|usr=025}}
+{{tp|p=33524311|t=2021. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial.|pdf=|usr=025}}
+{{tp|p=33521772|t=2021. Metformin and risk of mortality in patients hospitalised with COVID-19: a retrospective cohort analysis.|pdf=|usr=025}}
+{{tp|p=33521771|t=2021. Metformin: an inexpensive and effective treatment in people with diabetes and COVID-19?|pdf=|usr=025}}
+{{tp|p=33521768|t=2020. Tackling immunosenescence to improve COVID-19 outcomes and vaccine response in older adults.|pdf=|usr=025}}
+{{tp|p=33521732|t=2021. COVID-19 vaccines: the pandemic will not end overnight.|pdf=|usr=025}}
+{{tp|p=33463480|t=2021. The Role of Justicia Adhatoda as prophylaxis for COVID-19 - Analysis based on docking study.|pdf=|usr=025}}
+{{tp|p=33493866|t=2021. Ergosterol peroxide exhibits antiviral and immunomodulatory abilities against porcine deltacoronavirus (PDCoV) via suppression of NF-kappaB and p38/MAPK signaling pathways in vitro.|pdf=|usr=025}}
+{{tp|p=33414160|t=2021. Insight into vaccine development for Alpha-coronaviruses based on structural and immunological analyses of spike proteins.|pdf=|usr=025}}
+{{tp|p=33414159|t=2021. COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice.|pdf=|usr=025}}
+{{tp|p=33468542|t=2021. The time for COVID-19 vaccination.|pdf=|usr=025}}
+{{tp|p=33441348|t=2021. Non-steroidal anti-inflammatory drugs dampen the cytokine and antibody response to SARS-CoV-2 infection.|pdf=|usr=025}}
+{{tp|p=33507218|t=2021. SARS-CoV-2 Vaccines and the Growing Threat of Viral Variants.|pdf=|usr=025}}
+{{tp|p=33404587|t=2021. Sorting Out Whether Vitamin D Deficiency Raises COVID-19 Risk.|pdf=|usr=025}}
+{{tp|p=33464336|t=2021. Effect of Discontinuing vs Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial.|pdf=|usr=025}}
+{{tp|p=33404585|t=2021. Problems With Paying People to Be Vaccinated Against COVID-19.|pdf=|usr=025}}
+{{tp|p=33475702|t=2021. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine.|pdf=|usr=025}}
+{{tp|p=33475716|t=2021. Neutralizing Monoclonal Antibody for Mild to Moderate COVID-19.|pdf=|usr=025}}
+{{tp|p=33475701|t=2021. Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.|pdf=|usr=025}}
+{{tp|p=33512398|t=2021. Can We Protect Pregnant Women and Young Infants From COVID-19 Through Maternal Immunization?|pdf=|usr=025}}
+{{tp|p=33515791|t=2021. Hydroxychloroquine in systemic and autoimmune diseases: Where are we now?|pdf=|usr=025}}
+{{tp|p=33444566|t=2021. Vitamin D and COVID-19: why the controversy?|pdf=|usr=025}}
+{{tp|p=33392487|t=2021. Cyclosporine A and COVID19 - The COQUIMA cohort - Author's reply.|pdf=|usr=025}}
+{{tp|p=33392485|t=2021. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of an open-label, Phase 1 clinical trial.|pdf=|usr=025}}
+{{tp|p=33385129|t=2021. Cyclosporine A and COVID-19 - The COQUIMA cohort.|pdf=|usr=025}}
+{{tp|p=33385128|t=2021. Cyclosporine A and COVID19 - The COQUIMA cohort.|pdf=|usr=025}}
+{{tp|p=33385124|t=2021. Prioritizing incarcerated populations for COVID-19 vaccination and vaccine trials.|pdf=|usr=025}}
+{{tp|p=33471720|t=2020. Considerations for Gut Microbiota and Probiotics in Patients with Diabetes Amidst the Covid-19 Pandemic: A Narrative Review.|pdf=|usr=025}}
+{{tp|p=33380209|t=2020. Vitamin D Status and COVID-19 Clinical Outcomes in Hospitalized Patients.|pdf=|usr=025}}
+{{tp|p=33452994|t=2021. Patients hospitalized with COVID-19 have low levels of 25-hydroxyvitamin D.|pdf=|usr=025}}
+{{tp|p=33413989|t=2020. Efficacy and safety of hydroxychloroquine in healthcare professionals with mild SARS-CoV-2 infection: Prospective, non-randomized trial.|pdf=|usr=025}}
+{{tp|p=33401173|t=2021. A novel screening strategy of anti-SARS-CoV-2 drugs via blocking interaction between Spike RBD and ACE2.|pdf=|usr=025}}
+{{tp|p=33387537|t=2021. Urinary trace elements in association with disease severity and outcome in patients with COVID-19.|pdf=|usr=025}}
+{{tp|p=33447984|t=2021. Hydroxychloroquine in COVID-19: therapeutic promises, current status, and environmental implications.|pdf=|usr=025}}
+{{tp|p=33427370|t=2021. A systematic review of experimental evidence for antiviral effects of ivermectin and an in silico analysis of ivermectin's possible mode of action against SARS-CoV-2.|pdf=|usr=025}}
+{{tp|p=33520339|t=2020. Lifestyle factors in the prevention of COVID-19.|pdf=|usr=025}}
+{{tp|p=33387629|t=2021. Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine.|pdf=|usr=025}}
+{{tp|p=33408016|t=2021. Can we use hydroxychloroquine to treat COVID-19 now?|pdf=|usr=025}}
+{{tp|p=33408015|t=2021. Response to uncertain effect of hydroxychloroquine and azithromycin on SARS-CoV-2 viral load.|pdf=|usr=025}}
+{{tp|p=33408014|t=2021. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial revisited.|pdf=|usr=025}}
+{{tp|p=33515771|t=2021. Efficacy of ribavirin and interferon-alpha therapy for hospitalized patients with COVID-19: A multicenter, retrospective cohort study.|pdf=|usr=025}}
+{{tp|p=33493690|t=2021. A short discussion about the SARS-CoV-2 mRNA-1273 vaccine.|pdf=|usr=025}}
+{{tp|p=33476760|t=2021. Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19.|pdf=|usr=025}}
+{{tp|p=33401034|t=2021. Low vitamin D status is associated with coronavirus disease 2019 outcomes: a systematic review and meta-analysis.|pdf=|usr=025}}
+{{tp|p=33385581|t=2021. Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study.|pdf=|usr=025}}
+{{tp|p=33434674|t=2021. Efficacy evaluation of intravenous immunoglobulin in non-severe patients with COVID-19: A retrospective cohort study based on propensity score matching.|pdf=|usr=025}}
+{{tp|p=33437199|t=2021. Clinical characteristics and impacts of traditional Chinese medicine treatment on the convalescents of COVID-19.|pdf=|usr=025}}
+{{tp|p=33390810|t=2021. DCs-based therapies: potential strategies in severe SARS-CoV-2 infection.|pdf=|usr=025}}
+{{tp|p=33390800|t=2021. Perspective Adjunctive Therapies for COVID-19: Beyond Antiviral Therapy.|pdf=|usr=025}}
+{{tp|p=33416113|t=2021. Unraveling the roles of vitamin D status and melanin during Covid19 (Review).|pdf=|usr=025}}
+{{tp|p=33498909|t=2021. Membrane Microvesicles as Potential Vaccine Candidates.|pdf=|usr=025}}
+{{tp|p=33488318|t=2021. Could Dermaseptin Analogue be a Competitive Inhibitor for ACE2 Towards Binding with Viral Spike Protein Causing COVID19?: Computational Investigation.|pdf=|usr=025}}
+{{tp|p=33427662|t=2020. Immunomodulatory Low-Dose Whole-Lung Radiation for Patients with COVID-19-Related Pneumonia.|pdf=|usr=025}}
+{{tp|p=33460304|t=2020. Your help is needed in the fight against COVID-19: Please contribute to the COVID-19 Global Rheumatology Alliance Registry.|pdf=|usr=025}}
+{{tp|p=33487035|t=2021. The coronavirus disease (COVID-19) - A supportive approach with selected micronutrients.|pdf=|usr=025}}
+{{tp|p=33425283|t=2021. Ayurvedic metal nanoparticles could be novel antiviral agents against SARS-CoV-2.|pdf=|usr=025}}
+{{tp|p=33488306|t=2020. The Long Haul of COVID-19 Recovery: Immune Rejuvenation versus Immune Support.|pdf=|usr=025}}
+{{tp|p=33507321|t=2021. The ten reasons why corticosteroid therapy reduces mortality in severe COVID-19. Author's reply.|pdf=|usr=025}}
+{{tp|p=33388793|t=2021. Ten reasons why corticosteroid therapy reduces mortality in severe COVID-19.|pdf=|usr=025}}
+{{tp|p=33398609|t=2021. COVID-19 treatment options: a difficult journey between failed attempts and experimental drugs.|pdf=|usr=025}}
+{{tp|p=33400161|t=2021. The need for a correct oxygen-ozone autohemotherapy (O3-AHT) in patients with mild to moderate COVID-19 pneumonia.|pdf=|usr=025}}
+{{tp|p=33400157|t=2021. Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study.|pdf=|usr=025}}
+{{tp|p=33390490|t=2021. Immediate Amelioration of Severe Respiratory Distress in Sjogren's Syndrome with COVID-19 Treated with a Single Dose of Off-label Tocilizumab.|pdf=|usr=025}}
+{{tp|p=33409846|t=2021. Active vitamin D supplementation and COVID-19 infections: review.|pdf=|usr=025}}
+{{tp|p=33409844|t=2021. Step zero: optimising nutrition for physical and mental health wellbeing during COVID-19.|pdf=|usr=025}}
+{{tp|p=33433843|t=2021. Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks?|pdf=|usr=025}}
+{{tp|p=33490902|t=2021. High-throughput rational design of the remdesivir binding site in the RdRp of SARS-CoV-2: implications for potential resistance.|pdf=|usr=025}}
+{{tp|p=33426509|t=2021. A multi-pronged approach targeting SARS-CoV-2 proteins using ultra-large virtual screening.|pdf=|usr=025}}
+{{tp|p=33443334|t=2021. Convalescent Whole Blood Donors Screening Strategies for Providing Efficient and Safe COVID-19 Survivors' Plasma and Other Blood Components.|pdf=|usr=025}}
+{{tp|p=33425697|t=2020. The coronavirus disease 2019 main protease inhibitor from Andrographis paniculata (Burm. f) Ness.|pdf=|usr=025}}
+{{tp|p=33485650|t=2021. mRNA COVID-19 vaccine is well tolerated in patients with cutaneous and systemic mastocytosis with mast cell activation symptoms and anaphylaxis.|pdf=|usr=025}}
+{{tp|p=33482251|t=2021. An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology.|pdf=|usr=025}}
+{{tp|p=33440213|t=2021. Chronic hydroxychloroquine therapy and COVID-19 outcomes: A retrospective case-control analysis.|pdf=|usr=025}}
+{{tp|p=33492492|t=2021. Molecular docking studies of some selected gallic acid derivatives against five non-structural proteins of novel coronavirus.|pdf=|usr=025}}
+{{tp|p=33524316|t=2021. SARS-CoV-2 evolution and vaccines: cause for concern?|pdf=|usr=025}}
+{{tp|p=33521656|t=2021. Divergent effects of acute versus chronic glucocorticoids in COVID-19.|pdf=|usr=025}}
+{{tp|p=33521667|t=2021. Hydroxychloroquine in the prevention of COVID-19 mortality.|pdf=|usr=025}}
+{{tp|p=33521676|t=2021. Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19 - Authors' reply.|pdf=|usr=025}}
+{{tp|p=33521675|t=2021. Genetic IL-6R variants and therapeutic inhibition of IL-6 receptor signalling in COVID-19.|pdf=|usr=025}}
+{{tp|p=33521674|t=2021. Efficacy matters: broadening complement inhibition in COVID-19.|pdf=|usr=025}}
+{{tp|p=33521673|t=2021. Efficacy matters: broadening complement inhibition in COVID-19 - Authors' reply.|pdf=|usr=025}}
+{{tp|p=33521663|t=2020. Mavrilimumab for severe COVID-19 - Authors' reply.|pdf=|usr=025}}
+{{tp|p=33521662|t=2020. Mavrilimumab for severe COVID-19.|pdf=|usr=025}}
+{{tp|p=33521661|t=2020. Mavrilimumab for severe COVID-19.|pdf=|usr=025}}
+{{tp|p=33521660|t=2020. Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment.|pdf=|usr=025}}
+{{tp|p=33521666|t=2020. GM-CSF in the treatment of COVID-19: a new conductor in the pathogenesis of cytokine storm?|pdf=|usr=025}}
+{{tp|p=33491234|t=2021. A Narrative Review of Pharmacologic Treatments for COVID-19: Safety Considerations and Ototoxicity.|pdf=|usr=025}}
+{{tp|p=33459118|t=2021. Antibodies to watch in 2021.|pdf=|usr=025}}
+{{tp|p=33520672|t=2021. FDA Recommended Potent Drugs against Covid-19: Insight through Molecular Docking.|pdf=|usr=025}}
+{{tp|p=33521747|t=2021. A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice.|pdf=|usr=025}}
+{{tp|p=33521295|t=2021. Unresolved questions about the treatment of COVID-19 with corticosteroids.|pdf=|usr=025}}
+{{tp|p=33521297|t=2020. Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection.|pdf=|usr=025}}
+{{tp|p=33521304|t=2020. Tocilizumab plus glucocorticoids in severe and critically COVID-19 patients. A single center experience.|pdf=|usr=025}}
+{{tp|p=33521302|t=2020. Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia.|pdf=|usr=025}}
+{{tp|p=33521623|t=2021. AI drug discovery screening for COVID-19 reveals zafirlukast as a repurposing candidate.|pdf=|usr=025}}
+{{tp|p=33520634|t=2021. Tocilizumab administration in COVID-19 patients: Water on the fire or gasoline?|pdf=|usr=025}}
+{{tp|p=33460213|t=2021. What coronavirus 3C-like protease tells us: From structure, substrate selectivity, to inhibitor design.|pdf=|usr=025}}
+{{tp|p=33519030|t=2020. Nutricion y pandemia de la COVID-19.|pdf=|usr=025}}
+{{tp|p=33524563|t=2021. Inhibitory efficiency of potential drugs against SARS-CoV-2 by blocking human angiotensin converting enzyme-2: Virtual screening and molecular dynamics study.|pdf=|usr=025}}
+{{tp|p=33520405|t=2021. Small interfering RNA: a tailored approach to explore the therapeutic potential in COVID-19.|pdf=|usr=025}}
+{{tp|p=33523609|t=2021. Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19.|pdf=|usr=025}}
+{{tp|p=33509749|t=2021. [Mechanism and material basis of Lianhua Qingwen capsule for improving clinical cure rate of COVID-19: a study based on network pharmacology and molecular docking technology].|pdf=|usr=025}}
+{{tp|p=33497482|t=2021. Germicidal UV Sources and Systems(dagger).|pdf=|usr=025}}
+{{tp|p=33438214|t=2021. Bare-bulb Upper-Room Germicidal Ultraviolet-C (GUV) Indoor Air Disinfection for COVID-19(dagger).|pdf=|usr=025}}
+{{tp|p=33511704|t=2021. Spices and herbs: Potential antiviral preventives and immunity boosters during COVID-19.|pdf=|usr=025}}
+{{tp|p=33452734|t=2021. Exploring the treatment of COVID-19 with Yinqiao powder based on network pharmacology.|pdf=|usr=025}}
+{{tp|p=33448101|t=2021. In silico and in vitro evaluation of kaempferol as a potential inhibitor of the SARS-CoV-2 main protease (3CLpro).|pdf=|usr=025}}
+{{tp|p=33524017|t=2021. A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease.|pdf=|usr=025}}
+{{tp|p=33524041|t=2021. Metabolomic/lipidomic profiling of COVID-19 and individual response to tocilizumab.|pdf=|usr=025}}
+{{tp|p=33427193|t=2021. Nutritional knowledge, attitude and behaviours regarding Coronavirus Disease 2019 among residents of Gonabad, Iran.|pdf=|usr=025}}
+{{tp|p=33416888|t=2021. Rapid recovery of taste and smell in a patient with SARS-CoV-2 following convalescent plasma therapy.|pdf=|usr=025}}
+{{tp|p=33482671|t=2021. Allergische Reaktionen auf COVID-19-Impfungen - Was HNO-Arzte wissen sollten - Teil 1: Allgemeine Aspekte von Allergien auf Impfstoffe, immunologische Grundlagen von Allergien auf Impfstoffe, Immunmechanismen von allergischen und pseudoallergischen Reaktionen, Teil 2: Charakteristiken der mRNA-Impfstoffe BNT162b2 und mRNA-1273 zur Prophylaxe von COVID-19 und assoziierte Immunphanomene, Teil 3: Praktische Aspekte der Prophylaxe, Diagnostik und Therapie von Allergien auf COVID-19-Impfstoffe.|pdf=|usr=025}}
+{{tp|p=33524996|t=2021. Allergische Reaktionen auf COVID-19-Impfungen - Was HNO-Arzte wissen sollten - Teil 1: Allgemeine Aspekte von Allergien auf Impfstoffe, immunologische Grundlagen von Allergien auf Impfstoffe, Immunmechanismen von allergischen und pseudoallergischen Reaktionen; Teil 2: Charakteristiken der mRNA-Impfstoffe BNT162b2 und mRNA-1273 zur Prophylaxe von COVID-19, weitere Impfstoff-Kandidaten und assoziierte Immunphanomene; Teil 3: Praktische Aspekte der Prophylaxe, Diagnostik und Therapie von Allergien auf COVID-19-Impfstoffe.|pdf=|usr=025}}
+{{tp|p=33429407|t=2020. Timing of remdesivir for COVID-19.|pdf=|usr=025}}
+{{tp|p=33443491|t=2020. Remdesivir (Veklury) for COVID-19.|pdf=|usr=025}}
+{{tp|p=33443490|t=2020. An EUA for bamlanivimab - a monoclonal antibody for COVID-19.|pdf=|usr=025}}
+{{tp|p=33451175|t=2020. An EUA for baricitinib (Olumiant) for COVID-19.|pdf=|usr=025}}
+{{tp|p=33451174|t=2020. An EUA for casirivimab and imdevimab for COVID-19.|pdf=|usr=025}}
+{{tp|p=33393116|t=2021. Therapeutic targets and potential agents for the treatment of COVID-19.|pdf=|usr=025}}
+{{tp|p=33382060|t=2020. Terapias celulares para el COVID-19: Una revision sistematica viva.|pdf=|usr=025}}
+{{tp|p=33397236|t=2021. A mini review on emerging targets and Approaches for the synthesis of Anti-Viral compounds: In perspective to COVID-19.|pdf=|usr=025}}
+{{tp|p=33405340|t=2021. QSAR Modeling of SARS-CoV M(pro) Inhibitors Identifies Sufugolix, Cenicriviroc, Proglumetacin, and other Drugs as Candidates for Repurposing against SARS-CoV-2.|pdf=|usr=025}}
+{{tp|p=33513050|t=2021. How IvIg Can Mitigate Covid-19 Disease: A Symmetrical Immune Network Model.|pdf=|usr=025}}
+{{tp|p=33400280|t=2020. Standardized 25-Hydroxyvitamin D Measurements in Parkinson's Disease Patients With COVID-19.|pdf=|usr=025}}
+{{tp|p=33400277|t=2020. Reply to: Standardized 25-Hydroxyvitamin D Measurements in Parkinson's Disease Patients With COVID-19.|pdf=|usr=025}}
+{{tp|p=33432224|t=2021. Hunt for improved monoclonals against coronavirus gathers pace.|pdf=|usr=025}}
+{{tp|p=33432247|t=2021. A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent.|pdf=|usr=025}}
+{{tp|p=33494096|t=2021. Global absence and targeting of protective immune states in severe COVID-19.|pdf=|usr=025}}
+{{tp|p=33514888|t=2021. How to redesign COVID vaccines so they protect against variants.|pdf=|usr=025}}
+{{tp|p=33510489|t=2021. Novavax offers first evidence that COVID vaccines protect people against variants.|pdf=|usr=025}}
+{{tp|p=33471372|t=2021. Extreme Exposure to Filtered Far-UVC: A Case Study.|pdf=|usr=025}}
+{{tp|p=33389761|t=2021. Oral nano-curcumin formulation efficacy in management of mild to moderate hospitalized coronavirus disease-19 patients: An open label nonrandomized clinical trial.|pdf=|usr=025}}
+{{tp|p=33507610|t=2021. Phytotherapeutic options for the treatment of COVID-19: A concise viewpoint.|pdf=|usr=025}}
+{{tp|p=33452160|t=2021. Vitamin D and COVID-19: causal factor or bystander?|pdf=|usr=025}}
+{{tp|p=33434117|t=2021. Vitamin D Deficiency and Low Serum Calcium as Predictors of Poor Prognosis in Patients with Severe COVID-19.|pdf=|usr=025}}
+{{tp|p=33487918|t=2020. Convalescent plasma therapy in COVID 19: Every dark cloud has a silver lining.|pdf=|usr=025}}
+{{tp|p=33413968|t=2021. 'BhAVI-23'-A spice-herb based dietary infusion possessing in-vitro anti-viral potential.|pdf=|usr=025}}
+{{tp|p=33491541|t=2021. Drivers of Infectious Disease Seasonality: Potential Implications for COVID-19.|pdf=|usr=025}}
+{{tp|p=33495424|t=2020. The prognosis and short-term efficacy of corticosteroid therapy for COVID-19 patients.|pdf=|usr=025}}
+{{tp|p=33397223|t=2021. Virtual screening of curcumin and its analogs against the spike surface glycoprotein of SARS-CoV-2 and SARS-CoV.|pdf=|usr=025}}
+{{tp|p=33397209|t=2021. Molecular mechanism of inhibition of COVID-19 main protease by beta-adrenoceptor agonists and adenosine deaminase inhibitors using in silico methods.|pdf=|usr=025}}
+{{tp|p=33478342|t=2021. In silico evaluation of lapachol derivatives binding to the Nsp9 of SARS-CoV-2.|pdf=|usr=025}}
+{{tp|p=33475021|t=2021. In silico study indicates antimalarials as direct inhibitors of SARS-CoV-2-RNA dependent RNA polymerase.|pdf=|usr=025}}
+{{tp|p=33459192|t=2021. An in silico analysis of Ibuprofen enantiomers in high concentrations of sodium chloride with SARS-CoV-2 main protease.|pdf=|usr=025}}
+{{tp|p=33459182|t=2021. Identification of 1,2,3-triazole-phthalimide derivatives as potential drugs against COVID-19: a virtual screening, docking and molecular dynamic study.|pdf=|usr=025}}
+{{tp|p=33446077|t=2021. Prospecting for Cressa cretica to treat COVID-19 via in silico molecular docking models of the SARS-CoV-2.|pdf=|usr=025}}
+{{tp|p=33446058|t=2021. Bacillus species; a potential source of anti-SARS-CoV-2 main protease inhibitors.|pdf=|usr=025}}
+{{tp|p=33438525|t=2021. Enfuvirtide, an HIV-1 fusion inhibitor peptide, can act as a potent SARS-CoV-2 fusion inhibitor: an in silico drug repurposing study.|pdf=|usr=025}}
+{{tp|p=33427588|t=2021. Predictive medicinal metabolites from Momordica dioica against comorbidity related proteins of SARS-CoV-2 infections.|pdf=|usr=025}}
+{{tp|p=33382023|t=2020. Fisetin 8-C-glucoside as entry inhibitor in SARS CoV-2 infection: molecular modelling study.|pdf=|usr=025}}
+{{tp|p=33382021|t=2020. Virtual repurposing of ursodeoxycholate and chenodeoxycholate as lead candidates against SARS-Cov2-Envelope protein: A molecular dynamics investigation.|pdf=|usr=025}}
+{{tp|p=33423911|t=2021. Successful Management of COVID-19 With Adalimumab in a Post-Coronary Artery Bypass Graft Surgery Patient.|pdf=|usr=025}}
+{{tp|p=33426541|t=2020. Potentials of Interferons and Hydroxychloroquine for the Prophylaxis and Early Treatment of COVID-19.|pdf=|usr=025}}
+{{tp|p=33468620|t=2021. Ipomoeassin-F inhibits the in vitro biogenesis of the SARS-CoV-2 spike protein and its host cell membrane receptor.|pdf=|usr=025}}
+{{tp|p=33474624|t=2021. C1 Esterase Inhibition: Targeting Multiple Systems in COVID-19.|pdf=|usr=025}}
+{{tp|p=33458752|t=2020. Relationship Between Dietary Variety and Frailty in Older Japanese Women During the Period of Restriction on Outings Due to COVID-19.|pdf=|usr=025}}
+{{tp|p=33476835|t=2021. Convalescent plasma: Alternative or promising therapy?|pdf=|usr=025}}
+{{tp|p=33460844|t=2021. Hydroxychloroquine serum concentrations in non-critical care patients infected with SARS-CoV-2.|pdf=|usr=025}}
+{{tp|p=33385588|t=2021. Antiviral activity of interferon-based combination therapy in critically ill patients with COVID-19: Preliminary observations.|pdf=|usr=025}}
+{{tp|p=33441177|t=2021. Observations on the use of Bruton's tyrosine kinase inhibitors in SAR-CoV-2 and cancer.|pdf=|usr=025}}
+{{tp|p=33426096|t=2020. Cellular and Molecular Immunology Approaches for the Development of Immunotherapies against the New Coronavirus (SARS-CoV-2): Challenges to Near-Future Breakthroughs.|pdf=|usr=025}}
+{{tp|p=33402301|t=2021. Suspected cholestatic liver injury induced by favipiravir in a patient with COVID-19.|pdf=|usr=025}}
+{{tp|p=33493919|t=2021. Identification of potential SARS-CoV-2 entry inhibitors by targeting the interface region between the spike RBD and human ACE2.|pdf=|usr=025}}
+{{tp|p=33493917|t=2021. The growing complexity of COVID-19 drug and vaccine candidates: challenges and critical transitions.|pdf=|usr=025}}
+{{tp|p=33486372|t=2021. Bioinformatics prediction of B and T cell epitopes within the spike and nucleocapsid proteins of SARS-CoV2.|pdf=|usr=025}}
+{{tp|p=33509217|t=2021. Anti-inflammatory potential of Quercetin in COVID-19 treatment.|pdf=|usr=025}}
+{{tp|p=33447071|t=2021. Understanding COVID-19 Pandemic: Molecular Mechanisms and Potential Therapeutic Strategies. An Evidence-Based Review.|pdf=|usr=025}}
+{{tp|p=33414643|t=2020. Calcio-Herbal Medicine Divya-Swasari-Vati Ameliorates SARS-CoV-2 Spike Protein-Induced Pathological Features and Inflammation in Humanized Zebrafish Model by Moderating IL-6 and TNF-alpha Cytokines.|pdf=|usr=025}}
+{{tp|p=33433387|t=2021. Excipients as Potential Agents of Anaphylaxis in Vaccines: Analyzing the Formulations of Currently Authorized COVID-19 Vaccines.|pdf=|usr=025}}
+{{tp|p=33393485|t=2021. The Century of mRNA Vaccines: COVID-19 Vaccines and Allergy.|pdf=|usr=025}}
+{{tp|p=33432258|t=2021. Quantum chemical studies on molecular structure, AIM, ELF, RDG and antiviral activities of hybrid hydroxychloroquine in the treatment of COVID-19: Molecular docking and DFT calculations.|pdf=|usr=025}}
+{{tp|p=33390681|t=2021. Computational investigations of three main drugs and their comparison with synthesized compounds as potent inhibitors of SARS-CoV-2 main protease (M(pro)): DFT, QSAR, molecular docking, and in silico toxicity analysis.|pdf=|usr=025}}
+{{tp|p=33463095|t=2021. The Impact of the Coronavirus Disease-2019 Pandemic on Childhood Obesity and Vitamin D Status.|pdf=|usr=025}}
+{{tp|p=33425294|t=2020. Computational Biology Analysis of COVID-19 Receptor-Binding Domains: A Target Site for Indocyanine Green Through Antimicrobial Photodynamic Therapy.|pdf=|usr=025}}
+{{tp|p=33425284|t=2020. Application of Laser Blue Light With a Wavelength of 405 nm in the Treatment of Patients With the Virus COVID-19.|pdf=|usr=025}}
+{{tp|p=33500211|t=2021. Can hydroxychloroquine be protective against COVID-19-associated thrombotic events ?|pdf=|usr=025}}
+{{tp|p=33390633|t=2021. Charge-transfer chemistry of azithromycin, the antibiotic used worldwide to treat the coronavirus disease (COVID-19). Part I: Complexation with iodine in different solvents.|pdf=|usr=025}}
+{{tp|p=33390634|t=2021. Excited-state electronic properties, structural studies, noncovalent interactions, and inhibition of the novel severe acute respiratory syndrome coronavirus 2 proteins in Ripretinib by first-principle simulations.|pdf=|usr=025}}
+{{tp|p=33500591|t=2021. Probing CAS database as prospective antiviral agents against SARS-CoV-2 main protease.|pdf=|usr=025}}
+{{tp|p=33390613|t=2021. Synthesis of novel indolo[3,2-c]isoquinoline derivatives bearing pyrimidine, piperazine rings and their biological evaluation and docking studies against COVID-19 virus main protease.|pdf=|usr=025}}
+{{tp|p=33424034|t=2021. Pyrrolo[2,3-b]quinoxalines in attenuating cytokine storm in COVID-19: their sonochemical synthesis and in silico / in vitro assessment.|pdf=|usr=025}}
+{{tp|p=33457350|t=2020. Waiting for Godot: A cross sectional survey based analysis of the hydroxychloroquine prophylaxis strategy against COVID-19 in India.|pdf=|usr=025}}
+{{tp|p=33493945|t=2021. Inositol and vitamin D may naturally protect human reproduction and women undergoing assisted reproduction from Covid-19 risk.|pdf=|usr=025}}
+{{tp|p=33437230|t=2021. In-silico analysis of the inhibition of the SARS-CoV-2 main protease by some active compounds from selected African plants.|pdf=|usr=025}}
+{{tp|p=33443088|t=2021. Identification of SARS-CoV-2 Nucleocapsid and Spike T-Cell Epitopes for Assessing T-Cell Immunity.|pdf=|usr=025}}
+{{tp|p=33497729|t=2021. Antiviral activity of bioactive phytocompounds against coronavirus: An update.|pdf=|usr=025}}
+{{tp|p=33417058|t=2021. A case of shock after 10 days systemic corticosteroid therapy for COVID-19.|pdf=|usr=025}}
+{{tp|p=33478708|t=2021. Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19.|pdf=|usr=025}}
+{{tp|p=33427208|t=2021. Dissecting strategies to tune the therapeutic potential of SARS-CoV-2-specific monoclonal antibody CR3022.|pdf=|usr=025}}
+{{tp|p=33476300|t=2021. Treatment of severe COVID-19 with convalescent plasma in Bronx, NYC.|pdf=|usr=025}}
+{{tp|p=33520251|t=2021. Chloroquine and COVID-19: role as a bitter taste receptor agonist?|pdf=|usr=025}}
+{{tp|p=33518950|t=2020. Can vitamin D offer protection against the coronavirus?|pdf=|usr=025}}
+{{tp|p=33494567|t=2021. Vitamin D in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) patients with non-invasive ventilation support.|pdf=|usr=025}}
+{{tp|p=33520633|t=2021. In-silico drug repurposing study: Amprenavir, enalaprilat, and plerixafor, potential drugs for destabilizing the SARS-CoV-2 S-protein-angiotensin-converting enzyme 2 complex.|pdf=|usr=025}}
+{{tp|p=33520632|t=2021. Biflavonoid as potential 3-chymotrypsin-like protease (3CLpro) inhibitor of SARS-Coronavirus.|pdf=|usr=025}}
+{{tp|p=33518780|t=2021. inverted question markEs la nutricion el factor de riesgo olvidado en la infeccion por COVID-19?|pdf=|usr=025}}
+{{tp|p=33519022|t=2021. Principales desafios del desequilibrio electrolitico en pacientes geriatricos con COVID-19 y riesgo de prolongacion del intervalo QT.|pdf=|usr=025}}
+{{tp|p=33382930|t=2020. Mega doses of retinol: A possible immunomodulation in Covid-19 illness in resource-limited settings.|pdf=|usr=025}}
+{{tp|p=33515320|t=2021. SARS-CoV-2 vaccines and autoimmune diseases amidst the COVID-19 crisis.|pdf=|usr=025}}
+{{tp|p=33502499|t=2021. Baricitinib set to join the Covid-19 therapeutic arsenal?|pdf=|usr=025}}
+{{tp|p=33519274|t=2021. Fighting against the second wave of COVID-19: Can honeybee products help protect against the pandemic?|pdf=|usr=025}}
+{{tp|p=33519272|t=2021. In-silico network-based analysis of drugs used against COVID-19: Human well-being study.|pdf=|usr=025}}
+{{tp|p=33519276|t=2021. In silico prediction and experimental validation of siRNAs targeting ORF1ab of MERS-CoV in Vero cell line.|pdf=|usr=025}}
+{{tp|p=33519275|t=2021. Potential bangle (Zingiber montanum J.Konig) rhizome extract as a supplement to prevent and reduce symptoms of Covid-19.|pdf=|usr=025}}
+{{tp|p=33519339|t=2021. Safety and Efficacy of Convalescent Plasma for Severe COVID-19: Interim Report of a Multicenter Phase II Study from Saudi Arabia.|pdf=|usr=025}}
+{{tp|p=33519336|t=2021. Convalescent Plasma in COVID-19: To what Degree should Clinicians Rely on Currently Available Data?|pdf=|usr=025}}
+{{tp|p=33397677|t=2021. Stereotypic neutralizing VH antibodies against SARS-CoV-2 spike protein receptor binding domain in patients with COVID-19 and healthy individuals.|pdf=|usr=025}}
+{{tp|p=33514629|t=2021. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera.|pdf=|usr=025}}
+{{tp|p=33495306|t=2021. Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A.|pdf=|usr=025}}
+{{tp|p=33495308|t=2021. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19.|pdf=|usr=025}}
+{{tp|p=33495307|t=2021. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody.|pdf=|usr=025}}
+{{tp|p=33436526|t=2021. Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape.|pdf=|usr=025}}
+{{tp|p=33436524|t=2021. Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice.|pdf=|usr=025}}
+{{tp|p=33516820|t=2021. Edible plant-derived exosomal microRNAs: Exploiting a cross-kingdom regulatory mechanism for targeting SARS-CoV-2.|pdf=|usr=025}}
+{{tp|p=33483756|t=2021. Cardiotoxic Potential of Hydroxychloroquine, Chloroquine and Azithromycin in Adult Human Primary Cardiomyocytes.|pdf=|usr=025}}
+{{tp|p=33518427|t=2021. COVID-19 neutralizing antibody-based therapies in humoral immune deficiencies: A narrative review.|pdf=|usr=025}}
+{{tp|p=33518428|t=2021. WITHDRAWN: New Generation of vaccines and convalescent plasma therapy for management of CoV-2: Perspectives from the UK and potential deployment in the current global pandemic.|pdf=|usr=025}}
+{{tp|p=33458811|t=2021. COVID-19 convalescent plasma donor characteristics, product disposition, and comparison with standard apheresis donors.|pdf=|usr=025}}
+{{tp|p=33448402|t=2021. Neutralizing activity to SARS-CoV-2 of convalescent and control plasma used in a randomized controlled trial.|pdf=|usr=025}}
+{{tp|p=33521322|t=2021. Statins in patients with COVID-19: a retrospective cohort study in Iranian COVID-19 patients.|pdf=|usr=025}}
+{{tp|p=33523551|t=2021. Clinical course of severe COVID19 treated with tocilizumab and antivirals post-allogeneic stem cell transplant with extensive chronic GVHD.|pdf=|usr=025}}
+{{tp|p=33519087|t=2021. Review article: Probiotics, prebiotics and dietary approaches during COVID-19 pandemic.|pdf=|usr=025}}
+{{tp|p=33519086|t=2020. Food policy, nutrition and nutraceuticals in the prevention and management of COVID-19: Advice for healthcare professionals.|pdf=|usr=025}}
+{{tp|p=33522946|t=2021. High-dose vitamin D versus placebo to prevent complications in COVID-19 patients: A structured summary of a study protocol for a randomised controlled trial (CARED-TRIAL).|pdf=|usr=025}}
+{{tp|p=33516600|t=2021. Recombinant SARS-CoV-2 RBD with a built in T helper epitope induces strong neutralization antibody response.|pdf=|usr=025}}
+{{tp|p=33524990|t=2021. BNT162b vaccines protect rhesus macaques from SARS-CoV-2.|pdf=|usr=025}}
+{{tp|p=33481519|t=2021. Corticosteroids in the Management of Pregnant Patients With Coronavirus Disease (COVID-19).|pdf=|usr=025}}
+{{tp|p=33481518|t=2021. Corticosteroids in the Management of Pregnant Patients With Coronavirus Disease (COVID-19).|pdf=|usr=025}}
+{{tp|p=33411888|t=2021. Monte Carlo Simulation of SARS-CoV-2 Radiation-Induced Inactivation for Vaccine Development.|pdf=|usr=025}}
+{{tp|p=33401979|t=2021. Using in silico modelling and FRET-based assays in the discovery of novel FDA-approved drugs as inhibitors of MERS-CoV helicase.|pdf=|usr=025}}
+{{tp|p=33423931|t=2021. Copper in infectious disease: Using both sides of the penny.|pdf=|usr=025}}
+{{tp|p=33482680|t=2021. Protective Effects of Statins Administration in European and North American Patients Infected with COVID-19: A Meta-analysis.|pdf=|usr=025}}
+{{tp|p=33443365|t=2021. H2S As A Therapeutic Adjuvant Against COVID-19: Why and How?|pdf=|usr=025}}
+{{tp|p=33448169|t=2020. [Mechanism and intervention of mucosal immune regulation based on "lung and large intestine being interior-exteriorly related" theory of traditional Chinese medicine].|pdf=|usr=025}}
+{{tp|p=33415866|t=2020. [Effect of moxibustion on clinical symptoms, peripheral inflammatory indexes and T lymphocyte subsets in COVID-19 patients].|pdf=|usr=025}}
+{{tp|p=33496147|t=2020. [Potential therapies for COVID-19 cardiovascular complications using artemisinin and its derivatives intervene based on its cardiovascular protection].|pdf=|usr=025}}
+{{tp|p=33463485|t=2020. [Effectiveness of convalescent plasma for treatment of coronavirus disease 2019 patients].|pdf=|usr=025}}
+{{tp|p=33623472|t=2021. Corona-Cov-2 (COVID-19) and ginseng: Comparison of possible use in COVID-19 and influenza.|pdf=|usr=026}}
+{{tp|p=33657907|t=2021. A cross-sectional study of physical activity behaviour and associations with wellbeing during the UK coronavirus lockdown.|pdf=|usr=026}}
+{{tp|p=33640005|t=2021. COVID-19 vaccines for patients with cancer: benefits likely outweigh risks.|pdf=|usr=026}}
+{{tp|p=33563499|t=2021. EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients.|pdf=|usr=026}}
+{{tp|p=33816085|t=2021. Appropriate use of essential oils and their components in the management of upper respiratory tract symptoms in patients with COVID-19.|pdf=|usr=026}}
+{{tp|p=33774141|t=2021. Rapid decrease of SARS-CoV-2 circulation in a large Italian hospital six weeks after the start of the immunization program.|pdf=|usr=026}}
+{{tp|p=33547169|t=2021. IL-1 Receptor Antagonist Anakinra in the Treatment of COVID-19 Acute Respiratory Distress Syndrome: A Retrospective, Observational Study.|pdf=|usr=026}}
+{{tp|p=33763494|t=2021. Hydroxychloroquine Effects on TLR Signalling: Underexposed but Unneglectable in COVID-19.|pdf=|usr=026}}
+{{tp|p=33745918|t=2021. IL-6 inhibition in the treatment of COVID-19: A meta-analysis and meta-regression.|pdf=|usr=026}}
+{{tp|p=33549625|t=2021. Early clinical experience with imatinib in COVID-19: Searching for a dual effect.|pdf=|usr=026}}
+{{tp|p=33716109|t=2021. Short durations of corticosteroids for hospitalised COVID-19 patients are associated with a high readmission rate.|pdf=|usr=026}}
+{{tp|p=33582204|t=2021. Early Lopinavir/ritonavir does not reduce mortality in COVID-19 patients: Results of a large multicenter study.|pdf=|usr=026}}
+{{tp|p=33577902|t=2021. Oral corticoid, aspirin, anticoagulant, colchicine, and furosemide to improve the outcome of hospitalized COVID-19 patients - the COCAA-COLA cohort study.|pdf=|usr=026}}
+{{tp|p=33639176|t=2021. In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy.|pdf=|usr=026}}
+{{tp|p=33678548|t=2021. Efficacy and safety of hydroxychloroquine/chloroquine against SARS-CoV-2 infection: A systematic review and meta-analysis.|pdf=|usr=026}}
+{{tp|p=33676844|t=2021. A retrospective analysis of clinical efficacy of ribavirin in adults hospitalized with severe COVID-19.|pdf=|usr=026}}
+{{tp|p=33690202|t=2021. The influence of vitamin-C intake on blood glucose measurements in COVID-19 pandemic.|pdf=|usr=026}}
+{{tp|p=33715012|t=2021. Comment on: Nature and Dimensions of the Systemic Hyper-inflammation and Its Attenuation by Convalescent Plasma in Severe COVID-19.|pdf=|usr=026}}
+{{tp|p=33585890|t=2021. A Phase II Safety and Efficacy Study on Prognosis of Moderate Pneumonia in Coronavirus Disease 2019 Patients With Regular Intravenous Immunoglobulin Therapy.|pdf=|usr=026}}
+{{tp|p=33725725|t=2021. Rapidly Incre<iframe src="http://www.kidney.de/amapp.php?a=g SARS-CoV-2 Neutralization by Intravenous Immunoglobulins Produced from Plasma Collected During the 2020 Pandemic.|pdf=|usr=026}}
+{{tp|p=33535239|t=2021. Lessons From Bacille Calmette-Guerin for SARS-CoV-2 Vaccine Candidates.|pdf=|usr=026}}
+{{tp|p=33647555|t=2021. The find of COVID-19 vaccine: Challenges and opportunities.|pdf=|usr=026}}
+{{tp|p=33647553|t=2021. Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir.|pdf=|usr=026}}
+{{tp|p=33751982|t=2021. COVID-19 infection, inception and immunity: Observations and recommendations in the light of vitamin D?|pdf=|usr=026}}
+{{tp|p=33743371|t=2021. Combating COVID-19: The role of drug repurposing and medicinal plants.|pdf=|usr=026}}
+{{tp|p=33776469|t=2021. Evaluation of Adjunctive Photobiomodulation (PBMT) for COVID-19 Pneumonia via Clinical Status and Pulmonary Severity Indices in a Preliminary Trial.|pdf=|usr=026}}
+{{tp|p=33758527|t=2021. Coronil, a Tri-Herbal Formulation, Attenuates Spike-Protein-Mediated SARS-CoV-2 Viral Entry into Human Alveolar Epithelial Cells and Pro-Inflammatory Cytokines Production by Inhibiting Spike Protein-ACE-2 Interaction.|pdf=|usr=026}}
+{{tp|p=33679136|t=2021. The Implications of Zinc Therapy in Combating the COVID-19 Global Pandemic.|pdf=|usr=026}}
+{{tp|p=33574690|t=2021. Analysis of the Effect of Proton-Pump Inhibitors on the Course of COVID-19.|pdf=|usr=026}}
+{{tp|p=33583756|t=2021. Early therapeutic interventions of traditional Chinese medicine in COVID-19 patients: A retrospective cohort study.|pdf=|usr=026}}
+{{tp|p=33547011|t=2021. Impact of the COVID-19 pandemic on intention to use traditional Chinese medicine: A cross-sectional study based on the theory of planned behavior.|pdf=|usr=026}}
+{{tp|p=33663244|t=2021. Mesenchymal Stem Cell Therapy for Severe COVID-19 ARDS.|pdf=|usr=026}}
+{{tp|p=33634528|t=2021. Inhibition of SARS-CoV-2 replication using calcineurin inhibitors: are concentrations required clinically achievable?|pdf=|usr=026}}
+{{tp|p=33648905|t=2021. Safety of New mRNA Vaccines Against COVID-19 in Severely Allergic Patients.|pdf=|usr=026}}
+{{tp|p=33574015|t=2021. Delving Into COVID-19 Vaccination-Induced Anaphylaxis: Are mRNA Vaccines Safe in Mast Cell Disorders?|pdf=|usr=026}}
+{{tp|p=33558797|t=2021. Combined docking methods and molecular dynamics to identify effective antiviral 2, 5-diaminobenzophenonederivatives against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33531790|t=2021. Enhanced production of camptothecin by immobilized callus of Ophiorrhiza mungos and a bioinformatic insight into its potential antiviral effect against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33686812|t=2021. Estimating Baseline Incidence of Conditions Potentially Associated with Vaccine Adverse Events: a Call for Surveillance System Using the Korean National Health Insurance Claims Data.|pdf=|usr=026}}
+{{tp|p=33783147|t=2021. COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases: Clinical Guidance of the Korean College of Rheumatology.|pdf=|usr=026}}
+{{tp|p=33754512|t=2021. Clinical and Virologic Effectiveness of Remdesivir Treatment for Severe Coronavirus Disease 2019 (COVID-19) in Korea: a Nationwide Multicenter Retrospective Cohort Study.|pdf=|usr=026}}
+{{tp|p=33559409|t=2021. What We Do Know and Do Not Yet Know about COVID-19 Vaccines as of the Beginning of the Year 2021.|pdf=|usr=026}}
+{{tp|p=33627186|t=2021. The use of integrative therapy based on Yoga and Ayurveda in the treatment of a high-risk case of COVID-19/SARS-CoV-2 with multiple comorbidities: a case report.|pdf=|usr=026}}
+{{tp|p=33755450|t=2021. Direct Observation of Protonation State Modulation in SARS-CoV-2 Main Protease upon Inhibitor Binding with Neutron Crystallography.|pdf=|usr=026}}
+{{tp|p=33560998|t=2021. Artificial Intelligence-Aided Precision Medicine for COVID-19: Strategic Areas of Research and Development.|pdf=|usr=026}}
+{{tp|p=33638553|t=2021. Interaction effects between angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and steroid or antiviral therapies in COVID-19: A population-based study.|pdf=|usr=026}}
+{{tp|p=33629384|t=2021. A pilot double-blind safety and feasibility randomized controlled trial of high-dose intravenous zinc in hospitalized COVID-19 patients.|pdf=|usr=026}}
+{{tp|p=33620107|t=2021. Potential remdesivir-related transient bradycardia in patients with coronavirus disease 2019 (COVID-19).|pdf=|usr=026}}
+{{tp|p=33590901|t=2021. Effect of a combination of nitazoxanide, ribavirin, and ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19.|pdf=|usr=026}}
+{{tp|p=33590886|t=2021. Comment on Hadadi et al., Does recombinant human erythropoietin administration in critically ill COVID-19 patients have miraculous therapeutic effects? J. Med. Virol. 2020; 92:915-918.|pdf=|usr=026}}
+{{tp|p=33580518|t=2021. Three salvianolic acids inhibit 2019-nCoV spike pseudovirus viropexis by binding to both its RBD and receptor ACE2.|pdf=|usr=026}}
+{{tp|p=33527424|t=2021. SARS-CoV-2-specific humoral and cellular immunity in two renal transplants and two hemodialysis patients treated with convalescent plasma.|pdf=|usr=026}}
+{{tp|p=33666253|t=2021. In vitro activity of itraconazole against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33666250|t=2021. Efficacy of corticosteroid in patients with COVID-19: A multi-center retrospective study and meta-analysis.|pdf=|usr=026}}
+{{tp|p=33666244|t=2021. Is a single dose of mRNA vaccine sufficient for COVID-19 survivors?|pdf=|usr=026}}
+{{tp|p=33666241|t=2021. Vitamin D axis status and the severity of COVID-19.|pdf=|usr=026}}
+{{tp|p=33656189|t=2021. Letter to Editor in response to the article "Vitamin D insufficiency as a potential culprit in critical COVID-19 patients".|pdf=|usr=026}}
+{{tp|p=33580540|t=2021. Outpatient metformin use is associated with reduced severity of COVID-19 disease in adults with overweight or obesity.|pdf=|usr=026}}
+{{tp|p=33527314|t=2021. Raloxifene as a treatment option for viral infections.|pdf=|usr=026}}
+{{tp|p=33746189|t=2021. Clinical Effect of Traditional Chinese Medicine Shenhuang Granule in Critically Ill Patients with COVID-19: A Single-Centered, Retrospective, Observational Study.|pdf=|usr=026}}
+{{tp|p=33632620|t=2021. Low blood zinc concentrations in patients with poor clinical outcome during SARS-CoV-2 infection: is there a need to supplement with zinc COVID-19 patients?|pdf=|usr=026}}
+{{tp|p=33623736|t=2020. COVID-19 and Phosphodiesterase Enzyme Type 5 Inhibitors.|pdf=|usr=026}}
+{{tp|p=33623735|t=2020. Hydroxychloroquine Toxicity Management: A Literature Review in COVID-19 Era.|pdf=|usr=026}}
+{{tp|p=33775667|t=2021. Engineered Ultra-High Affinity Synthetic Antibodies for SARS-CoV-2 Neutralization and Detection.|pdf=|usr=026}}
+{{tp|p=33753053|t=2021. Platforms for Personalized Polytherapeutics Discovery in COVID-19.|pdf=|usr=026}}
+{{tp|p=33693723|t=2021. What makes (hydroxy)chloroquine ineffective against COVID-19: insights from cell biology.|pdf=|usr=026}}
+{{tp|p=33556646|t=2021. Interaction of small molecules with the SARS-CoV-2 papain-like protease: In silico studies and in vitro validation of protease activity inhibition using an enzymatic inhibition assay.|pdf=|usr=026}}
+{{tp|p=33684603|t=2021. Ensemble-based screening of natural products and FDA-approved drugs identified potent inhibitors of SARS-CoV-2 that work with two distinct mechanisms.|pdf=|usr=026}}
+{{tp|p=33647752|t=2021. Pinpointing the potential hits for hindering interaction of SARS-CoV-2 S-protein with ACE2 from the pool of antiviral phytochemicals utilizing molecular docking and molecular dynamics (MD) simulations.|pdf=|usr=026}}
+{{tp|p=33612899|t=2021. Rational design of potent anti-COVID-19 main protease drugs: An extensive multi-spectrum in silico approach.|pdf=|usr=026}}
+{{tp|p=33753950|t=2021. Binding and drug displacement study of colchicine and bovine serum albumin in presence of azithromycin using multispectroscopic techniques and molecular dynamic simulation.|pdf=|usr=026}}
+{{tp|p=33641023|t=2021. Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (M(pro)) of SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33583954|t=2021. Computational search for drug repurposing to identify potential inhibitors against SARS-COV-2 using Molecular Docking, QTAIM and IQA methods in viral Spike protein - Human ACE2 interface.|pdf=|usr=026}}
+{{tp|p=33526951|t=2021. 5-((1H-imidazol-1-yl)methyl)quinolin-8-ol as potential antiviral SARS-CoV-2 candidate: Synthesis, crystal structure, Hirshfeld surface analysis, DFT and molecular docking studies.|pdf=|usr=026}}
+{{tp|p=33612858|t=2021. "Identification of Nafamostat and VR23 as COVID-19 drug candidates by targeting 3CL(pro) and PL(pro)."|pdf=|usr=026}}
+{{tp|p=33603214|t=2021. Ensuring continued progress for development of COVID-19 therapeutics in children.|pdf=|usr=026}}
+{{tp|p=33680575|t=2021. DisCoVering potential candidates of RNAi-based therapy for COVID-19 using computational methods.|pdf=|usr=026}}
+{{tp|p=33615115|t=2021. Stapled ACE2 peptidomimetics designed to target the SARS-CoV-2 spike protein do not prevent virus internalization.|pdf=|usr=026}}
+{{tp|p=33676968|t=2021. Antiviral peptides against Coronaviridae family: A review.|pdf=|usr=026}}
+{{tp|p=33816211|t=2021. Hydroxychloroquine in the prophylaxis of COVID 19: A survey of safety on the healthcare workers in India.|pdf=|usr=026}}
+{{tp|p=33660201|t=2021. Nanoparticle-Mediated Cytoplasmic Delivery of Messenger RNA Vaccines: Challenges and Future Perspectives.|pdf=|usr=026}}
+{{tp|p=33668390|t=2021. Evaluation of the Antiviral Activity of Sitagliptin-Glatiramer Acetate Nano-Conjugates against SARS-CoV-2 Virus.|pdf=|usr=026}}
+{{tp|p=33572332|t=2021. Conjugation of Mannans to Enhance the Potency of Liposome Nanoparticles for the Delivery of RNA Vaccines.|pdf=|usr=026}}
+{{tp|p=33562240|t=2021. Therapeutic Potential of Mesenchymal Stem Cells and Their Products in Lung Diseases-Intravenous Administration versus Inhalation.|pdf=|usr=026}}
+{{tp|p=33652894|t=2021. Repurposing of Sitagliptin- Melittin Optimized Nanoformula against SARS-CoV-2: Antiviral Screening and Molecular Docking Studies.|pdf=|usr=026}}
+{{tp|p=33668969|t=2021. Drug Repurposing in the COVID-19 Era: Insights from Case Studies Showing Pharmaceutical Peculiarities.|pdf=|usr=026}}
+{{tp|p=33688154|t=2021. WTP for COVID-19 vaccine in Chile.|pdf=|usr=026}}
+{{tp|p=33564224|t=2021. COVID-19 vaccination predicted to be cost effective in USA.|pdf=|usr=026}}
+{{tp|p=33759544|t=2021. Predictive association of ABCB1 C3435T genetic polymorphism with the efficacy or safety of lopinavir and ritonavir in COVID-19 patients.|pdf=|usr=026}}
+{{tp|p=33542445|t=2021. Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs.|pdf=|usr=026}}
+{{tp|p=33779964|t=2021. The association between the use of ivermectin and mortality in patients with COVID-19: a meta-analysis.|pdf=|usr=026}}
+{{tp|p=33666864|t=2021. Perspectives on glucocorticoid treatment for COVID-19: a systematic review.|pdf=|usr=026}}
+{{tp|p=33625686|t=2021. Evaluation of effects of chronic nasal steroid use on rhinological symptoms of COVID-19 with SNOT-22 questionnaire.|pdf=|usr=026}}
+{{tp|p=33608850|t=2021. In-hospital use of statins is associated with a reduced risk of mortality in coronavirus-2019 (COVID-19): systematic review and meta-analysis.|pdf=|usr=026}}
+{{tp|p=33604795|t=2021. Amantadine in the prevention of clinical symptoms caused by SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33781873|t=2021. Understanding the heart-brain axis response in COVID-19 patients: A suggestive perspective for therapeutic development.|pdf=|usr=026}}
+{{tp|p=33710753|t=2021. Hemoadsorption eliminates remdesivir from the circulation: Implications for the treatment of COVID-19.|pdf=|usr=026}}
+{{tp|p=33687995|t=2021. Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics.|pdf=|usr=026}}
+{{tp|p=33662449|t=2021. SARS-CoV-2 and other coronaviruses negatively influence mitochondrial quality control: beneficial effects of melatonin.|pdf=|usr=026}}
+{{tp|p=33601001|t=2021. A systematic review of photodynamic therapy as an antiviral treatment: Potential guidance for dealing with SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33564274|t=2021. Quantum mechanical studies of the adsorption of Remdesivir, as an effective drug for treatment of COVID-19, on the surface of pristine, COOH-functionalized and S-, Si- and Al- doped carbon nanotubes.|pdf=|usr=026}}
+{{tp|p=33580917|t=2021. Breastfeeding importance and its therapeutic potential against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33527774|t=2021. Lingonberry polyphenols: Potential SARS-CoV-2 inhibitors as nutraceutical tools?|pdf=|usr=026}}
+{{tp|p=33685739|t=2021. Out-patient physiotherapy service delivery post COVID-19: opportunity for a re-set and a new normal?|pdf=|usr=026}}
+{{tp|p=33637412|t=2021. Effect and safety of Chinese herbal medicine granules in patients with severe coronavirus disease 2019 in Wuhan, China: a retrospective, single-center study with propensity score matching.|pdf=|usr=026}}
+{{tp|p=33593628|t=2021. Toxicity as prime selection criterion among SARS-active herbal medications.|pdf=|usr=026}}
+{{tp|p=33596494|t=2021. Randomized placebo-controlled pilot clinical trial on the efficacy of ayurvedic treatment regime on COVID-19 positive patients.|pdf=|usr=026}}
+{{tp|p=33587321|t=2021. Oroxylin A is a severe acute respiratory syndrome coronavirus 2-spiked pseudotyped virus blocker obtained from Radix Scutellariae using angiotensin-converting enzyme II/cell membrane chromatography.|pdf=|usr=026}}
+{{tp|p=33564969|t=2021. Glucocorticoid use in patients with adrenal insufficiency following administration of the COVID-19 vaccine: a pituitary society statement.|pdf=|usr=026}}
+{{tp|p=33673316|t=2021. COVID-19 Crisis: How Can Plant Biotechnology Help?|pdf=|usr=026}}
+{{tp|p=33647008|t=2021. Success of prophylactic antiviral therapy for SARS-CoV-2: Predicted critical efficacies and impact of different drug-specific mechanisms of action.|pdf=|usr=026}}
+{{tp|p=33544720|t=2021. SAveRUNNER: A network-based algorithm for drug repurposing and its application to COVID-19.|pdf=|usr=026}}
+{{tp|p=33657114|t=2021. Early versus deferred anti-SARS-CoV-2 convalescent plasma in patients admitted for COVID-19: A randomized phase II clinical trial.|pdf=|usr=026}}
+{{tp|p=33620862|t=2021. COVID (SARS-COV-2) Vaccine|pdf=|usr=026}}
+{{tp|p=33666876|t=2021. Vitamin D deficiency, secondary hyperparathyroidism and respiratory insufficiency in hospitalized patients with COVID-19.|pdf=|usr=026}}
+{{tp|p=33685335|t=2021. In silico identification of novel SARS-COV-2 2'-O-methyltransferase (nsp16) inhibitors: structure-based virtual screening, molecular dynamics simulation and MM-PBSA approaches.|pdf=|usr=026}}
+{{tp|p=33641565|t=2021. Exposure of human intestinal epithelial cells and primary human hepatocytes to trypsin-like serine protease inhibitors with potential antiviral effect.|pdf=|usr=026}}
+{{tp|p=33605108|t=2021. The Role of Convalescent Plasma and Tocilizumab in the Management of COVID-19 Infection: A Cohort of 110 Patients from a Tertiary Care Hospital in Oman.|pdf=|usr=026}}
+{{tp|p=33605118|t=2021. A Case Series of Severe Hospitalized COVID-19 Patients Treated with Tocilizumab and Glucocorticoids: A Report from Saudi Arabian Hospital.|pdf=|usr=026}}
+{{tp|p=33631276|t=2021. Evaluating the Traditional Chinese Medicine (TCM) Officially Recommended in China for COVID-19 Using Ontology-Based Side-Effect Prediction Framework (OSPF) and Deep Learning.|pdf=|usr=026}}
+{{tp|p=33716085|t=2021. Artemisia annua L. extracts inhibit the in vitro replication of SARS-CoV-2 and two of its variants.|pdf=|usr=026}}
+{{tp|p=33529638|t=2021. Efficacy and safety assessment of severe COVID-19 patients with Chinese medicine: A retrospective case series study at early stage of the COVID-19 epidemic in Wuhan, China.|pdf=|usr=026}}
+{{tp|p=33587756|t=2021. European Task Force on Atopic Dermatitis: position on vaccination of adult patients with atopic dermatitis against COVID-19 (SARS-CoV-2) being treated with systemic medication and biologics.|pdf=|usr=026}}
+{{tp|p=33752263|t=2021. Risk of severe allergic reactions to COVID-19 vaccines among patients with allergic skin diseases - practical recommendations. A position statement of ETFAD with external experts.|pdf=|usr=026}}
+{{tp|p=33650226|t=2021. Insights into Sars-CoV-2 vaccination in patients with chronic plaque psoriasis on systemic treatments.|pdf=|usr=026}}
+{{tp|p=33787349|t=2021. Licorice: A Potential Herb in Overcoming SARS-CoV-2 Infections.|pdf=|usr=026}}
+{{tp|p=33554423|t=2021. Role of vitamin D in COVID-19 infections and deaths.|pdf=|usr=026}}
+{{tp|p=33786534|t=2021. News About the Extracellular Vesicles from Mesenchymal Stem Cells: Functions, Therapy and Protection from COVID-19.|pdf=|usr=026}}
+{{tp|p=33772438|t=2021. Chronotherapy in COVID-19 Disease.|pdf=|usr=026}}
+{{tp|p=33711156|t=2021. Impact of systemic corticosteroids on mortality in older adults with critical COVID-19 pneumonia.|pdf=|usr=026}}
+{{tp|p=33678903|t=2021. Inhibitory efficacy of RNA virus drugs against SARS-CoV-2 proteins: An extensive study.|pdf=|usr=026}}
+{{tp|p=33814612|t=2021. Unmasking of crucial structural fragments for coronavirus protease inhibitors and its implications in COVID-19 drug discovery.|pdf=|usr=026}}
+{{tp|p=33758509|t=2021. Corticosteroids Use in Pregnant Women with COVID-19: Recommendations from Available Evidence.|pdf=|usr=026}}
+{{tp|p=33544324|t=2021. A Role for Extracellular Vesicles in SARS-CoV-2 Therapeutics and Prevention.|pdf=|usr=026}}
+{{tp|p=33534108|t=2021. Repurposing of Tetracyclines for COVID-19 Neurological and Neuropsychiatric Manifestations: A Valid Option to Control SARS-CoV-2-Associated Neuroinflammation?|pdf=|usr=026}}
+{{tp|p=33721079|t=2021. Neurology and vaccinations: considerations in the context of COVID-19/SARS-COV-2.|pdf=|usr=026}}
+{{tp|p=33537898|t=2021. Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19.|pdf=|usr=026}}
+{{tp|p=33638680|t=2021. Negative anti-SARS-CoV-2 S antibody response following Pfizer SARS-CoV-2 vaccination in a patient on ocrelizumab.|pdf=|usr=026}}
+{{tp|p=33611630|t=2021. Bell's palsy following COVID-19 vaccination.|pdf=|usr=026}}
+{{tp|p=33692301|t=2021. Physical compatibility of nafamostat with analgesics, sedatives, and muscle relaxants for coronavirus disease treatment.|pdf=|usr=026}}
+{{tp|p=33693698|t=2021. Risk of Malnutrition Is Common in Patients with Coronavirus Disease 2019 (COVID-19) in Wuhan, China: A Cross-sectional Study.|pdf=|usr=026}}
+{{tp|p=33575730|t=2021. Malnutrition Prolongs the Hospitalization of Patients with COVID-19 Infection: A Clinical Epidemiological Analysis.|pdf=|usr=026}}
+{{tp|p=33643836|t=2021. Virucidal activity of oral care products against SARS-CoV-2 in vitro.|pdf=|usr=026}}
+{{tp|p=33527524|t=2021. Reported orofacial adverse effects of COVID-19 vaccines: The knowns and the unknowns.|pdf=|usr=026}}
+{{tp|p=33716511|t=2021. Recommendations and Guidance for Steroid Injection Therapy and COVID-19 Vaccine Administration from the American Society of Pain and Neuroscience (ASPN).|pdf=|usr=026}}
+{{tp|p=33649442|t=2021. Previous viral symptoms and individual mothers influenced the leveled duration of human milk antibodies cross-reactive to S1 and S2 subunits from SARS-CoV-2, HCoV-229E, and HCoV-OC43.|pdf=|usr=026}}
+{{tp|p=33578937|t=2021. Statin Therapy and the Risk of COVID-19: A Cohort Study of the National Health Insurance Service in South Korea.|pdf=|usr=026}}
+{{tp|p=33782640|t=2021. The potential of miRNA-based therapeutics in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection: a review.|pdf=|usr=026}}
+{{tp|p=33552628|t=2021. Accurate and sensitive determination of hydroxychloroquine sulfate used on COVID-19 patients in human urine, serum and saliva samples by GC-MS.|pdf=|usr=026}}
+{{tp|p=33549875|t=2021. Vitamin C supplementation is necessary for patients with coronavirus disease: An ultra-high-performance liquid chromatography-tandem mass spectrometry finding.|pdf=|usr=026}}
+{{tp|p=33548872|t=2021. Simultaneous quantification of seven repurposed COVID-19 drugs remdesivir (plus metabolite GS-441524), chloroquine, hydroxychloroquine, lopinavir, ritonavir, favipiravir and azithromycin by a two-dimensional isotope dilution LC-MS/MS method in human serum.|pdf=|usr=026}}
+{{tp|p=33688448|t=2021. Potential therapeutic and pharmacological strategies for SARS-CoV2.|pdf=|usr=026}}
+{{tp|p=33793885|t=2021. Propolis antiviral and immunomodulatory activity: a review and perspectives for COVID-19 treatment.|pdf=|usr=026}}
+{{tp|p=33684397|t=2021. Insilico drug repurposing using FDA approved drugs against Membrane protein of SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33657325|t=2021. An Active Site Inhibitor Induces Conformational Penalties for ACE2 Recognition by the Spike Protein of SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33577324|t=2021. Kobophenol A Inhibits Binding of Host ACE2 Receptor with Spike RBD Domain of SARS-CoV-2, a Lead Compound for Blocking COVID-19.|pdf=|usr=026}}
+{{tp|p=33776343|t=2021. Structure-based inhibitor screening of natural products against NSP15 of SARS-CoV-2 revealed thymopentin and oleuropein as potent inhibitors.|pdf=|usr=026}}
+{{tp|p=33667055|t=2021. Elevated clozapine levels and toxic effects after SARS-CoV-2 vaccination.|pdf=|usr=026}}
+{{tp|p=33703870|t=2021. COVID-19 infection causes a reduction in neutrophil counts in patients taking clozapine.|pdf=|usr=026}}
+{{tp|p=33589559|t=2021. Rethinking Physical Activity Promotion During the COVID-19 Pandemic: Focus on a 24-hour Day.|pdf=|usr=026}}
+{{tp|p=33775882|t=2021. Physical activity and its relationship with COVID-19 cases and deaths: Analysis of U.S. counties.|pdf=|usr=026}}
+{{tp|p=33775818|t=2021. Therapeutic and prognostic role of vitamin D for COVID-19 infection: A systematic review and meta-analysis of 43 observational studies.|pdf=|usr=026}}
+{{tp|p=33569200|t=2021. Hydroxychloroquine and chloroquine for treatment of coronavirus disease 19 (COVID-19): a systematic review and meta-analysis of randomized and non-randomized controlled trials.|pdf=|usr=026}}
+{{tp|p=33615209|t=2021. Benefits of early aggressive immunomodulatory therapy (tocilizumab and methylprednisolone) in COVID-19: Single center cohort study of 685 patients.|pdf=|usr=026}}
+{{tp|p=33789686|t=2021. Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis.|pdf=|usr=026}}
+{{tp|p=33635318|t=2021. What can we learn from COVID-19 vaccine R&D in China? A discussion from a public policy perspective.|pdf=|usr=026}}
+{{tp|p=33620081|t=2021. 'Blue toes' following vaccination with the BNT162b2 mRNA COVID-19 vaccine.|pdf=|usr=026}}
+{{tp|p=33663198|t=2021. Can we use mesenchymal stem cell transplantation for COVID-19 patients in puerperium period?|pdf=|usr=026}}
+{{tp|p=33573494|t=2021. The evolving use of hyperbaric oxygen therapy during the COVID-19 pandemic.|pdf=|usr=026}}
+{{tp|p=33748377|t=2021. "COVID arm": A reaction to the Moderna vaccine.|pdf=|usr=026}}
+{{tp|p=33782672|t=2021. Regression of Coronary Aneurysms With Intravenous Immunoglobulins and Steroids for COVID-19 Adult Multisystem Inflammatory Syndrome.|pdf=|usr=026}}
+{{tp|p=33760094|t=2021. Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19.|pdf=|usr=026}}
+{{tp|p=33739433|t=2021. Association of Vitamin D Levels, Race/Ethnicity, and Clinical Characteristics With COVID-19 Test Results.|pdf=|usr=026}}
+{{tp|p=33774074|t=2021. The link between COVID-19 and VItamin D (VIVID): A systematic review and meta-analysis.|pdf=|usr=026}}
+{{tp|p=33639316|t=2021. Multi-targeting approach for nsp3, nsp9, nsp12 and nsp15 proteins of SARS-CoV-2 by Diosmin as illustrated by molecular docking and molecular dynamics simulation methodologies.|pdf=|usr=026}}
+{{tp|p=33729874|t=2021. Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity.|pdf=|usr=026}}
+{{tp|p=33744495|t=2021. COVID-19 Vaccine Decisions: Considering the Choices and Opportunities.|pdf=|usr=026}}
+{{tp|p=33776146|t=2021. Green micellar solvent-free HPLC and spectrofluorimetric determination of favipiravir as one of COVID-19 antiviral regimens.|pdf=|usr=026}}
+{{tp|p=33572117|t=2021. Fluoxetine Can Inhibit SARS-CoV-2 In Vitro.|pdf=|usr=026}}
+{{tp|p=33668694|t=2021. Antiviral Activity of Vacuolar ATPase Blocker Diphyllin against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33688701|t=2021. Statin therapy is associated with less ICU admissions in COVID-19 patients. A preliminary analysis of the current observations.|pdf=|usr=026}}
+{{tp|p=33709676|t=2021. The administration of S. salivarius K12 to children may reduce the rate of SARS-CoV-2 infection.|pdf=|usr=026}}
+{{tp|p=33661860|t=2021. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Janssen COVID-19 Vaccine - United States, February 2021.|pdf=|usr=026}}
+{{tp|p=33793460|t=2021. Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight U.S. Locations, December 2020-March 2021.|pdf=|usr=026}}
+{{tp|p=33551490|t=2021. COVID-19 Convalescent Plasma: from donation to treatment - A Systematic Review & Single Center Experience.|pdf=|usr=026}}
+{{tp|p=33750821|t=2021. Cross-linking peptide and repurposed drugs inhibit both entry pathways of SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33785743|t=2021. Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial.|pdf=|usr=026}}
+{{tp|p=33658497|t=2021. Immunogenicity of prime-boost protein subunit vaccine strategies against SARS-CoV-2 in mice and macaques.|pdf=|usr=026}}
+{{tp|p=33654090|t=2021. Immunogenicity and protective efficacy of inactivated SARS-CoV-2 vaccine candidate, BBV152 in rhesus macaques.|pdf=|usr=026}}
+{{tp|p=33741945|t=2021. Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model.|pdf=|usr=026}}
+{{tp|p=33741941|t=2021. Alpha-1 antitrypsin inhibits TMPRSS2 protease activity and SARS-CoV-2 infection.|pdf=|usr=026}}
+{{tp|p=33731724|t=2021. A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies.|pdf=|usr=026}}
+{{tp|p=33707427|t=2021. SARS-CoV-2 neutralizing human recombinant antibodies selected from pre-pandemic healthy donors binding at RBD-ACE2 interface.|pdf=|usr=026}}
+{{tp|p=33649323|t=2021. S-Trimer, a COVID-19 subunit vaccine candidate, induces protective immunity in nonhuman primates.|pdf=|usr=026}}
+{{tp|p=33558541|t=2021. Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide.|pdf=|usr=026}}
+{{tp|p=33547300|t=2021. Efficacy and tolerability of bevacizumab in patients with severe Covid-19.|pdf=|usr=026}}
+{{tp|p=33536425|t=2021. A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33637713|t=2021. Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19.|pdf=|usr=026}}
+{{tp|p=33531496|t=2021. Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors.|pdf=|usr=026}}
+{{tp|p=33589624|t=2021. Causal network models of SARS-CoV-2 expression and aging to identify candidates for drug repurposing.|pdf=|usr=026}}
+{{tp|p=33568665|t=2021. Potential health and economic impacts of dexamethasone treatment for patients with COVID-19.|pdf=|usr=026}}
+{{tp|p=33542537|t=2021. COVID-19 vaccines: acting on the evidence.|pdf=|usr=026}}
+{{tp|p=33785883|t=2021. Antibody responses to SARS-CoV-2 infection are attenuated in infliximab-treated patients with IBD.|pdf=|usr=026}}
+{{tp|p=33564149|t=2021. Targeting autoantibodies in COVID-19.|pdf=|usr=026}}
+{{tp|p=33674759|t=2021. COVID-19 vaccines: modes of immune activation and future challenges.|pdf=|usr=026}}
+{{tp|p=33658707|t=2021. Are COVID-19 vaccines safe in pregnancy?|pdf=|usr=026}}
+{{tp|p=33558753|t=2021. COVID-19 vaccines and kidney disease.|pdf=|usr=026}}
+{{tp|p=33587164|t=2021. Interferon-beta offers promising avenues to COVID-19 treatment: a systematic review and meta-analysis of clinical trial studies.|pdf=|usr=026}}
+{{tp|p=33640181|t=2021. Consenso multidisciplinar sobre la valoracion y el tratamiento nutricional y dietetico en pacientes con enfermedad renal cronica e infeccion por SARS-CoV-2. Consenso de nutricion en enfermedad renal cronica e infeccion por SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33693778|t=2021. Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases.|pdf=|usr=026}}
+{{tp|p=33786291|t=2021. In silico studies of selected multi-drug targeting against 3CLpro and nsp12 RNA-dependent RNA-polymerase proteins of SARS-CoV-2 and SARS-CoV.|pdf=|usr=026}}
+{{tp|p=33585155|t=2021. Exploring the active constituents of Oroxylum indicum in intervention of novel coronavirus (COVID-19) based on molecular docking method.|pdf=|usr=026}}
+{{tp|p=33527083|t=2021. To stress or not to stress: Brain-behavior-immune interaction may weaken or promote the immune response to SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33555604|t=2021. COVID-19 mRNA vaccines (Pfizer-BioNTech and Moderna) in patients with multiple sclerosis: a statement by a working group convened by the Section of Multiple Sclerosis and Neuroimmunology of the Polish Neurological Society.|pdf=|usr=026}}
+{{tp|p=33411196|t=2021. Acupuncture helps to regain the consciousness of a COVID-19 patient complicated with hypoxic-ischemic encephalopathy: a case report.|pdf=|usr=026}}
+{{tp|p=33760858|t=2021. Reduced mortality in COVID-19 patients treated with colchicine: Results from a retrospective, observational study.|pdf=|usr=026}}
+{{tp|p=33750975|t=2021. DNA vaccine candidate encoding SARS-CoV-2 spike proteins elicited potent humoral and Th1 cell-mediated immune responses in mice.|pdf=|usr=026}}
+{{tp|p=33735271|t=2021. A comprehensive SARS-CoV-2 genomic analysis identifies potential targets for drug repurposing.|pdf=|usr=026}}
+{{tp|p=33730088|t=2021. COVID-19 Evidence Accelerator: A parallel analysis to describe the use of Hydroxychloroquine with or without Azithromycin among hospitalized COVID-19 patients.|pdf=|usr=026}}
+{{tp|p=33730022|t=2021. Immuno-informatics design of a multimeric epitope peptide based vaccine targeting SARS-CoV-2 spike glycoprotein.|pdf=|usr=026}}
+{{tp|p=33725021|t=2021. Knowledge of medical professionals, their practices, and their attitudes toward traditional Chinese medicine for the prevention and treatment of coronavirus disease 2019: A survey in Sichuan, China.|pdf=|usr=026}}
+{{tp|p=33667247|t=2021. Development and validation of an LC-MS/MS method for determination of hydroxychloroquine, its two metabolites, and azithromycin in EDTA-treated human plasma.|pdf=|usr=026}}
+{{tp|p=33674391|t=2021. COVID-19 Drugs Chloroquine and Hydroxychloroquine, but Not Azithromycin and Remdesivir, Block hERG Potassium Channels.|pdf=|usr=026}}
+{{tp|p=33658349|t=2021. Potent Neutralization of SARS-CoV-2 by Hetero-bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain.|pdf=|usr=026}}
+{{tp|p=33622961|t=2021. A comparative analysis of SARS-CoV-2 antivirals characterizes 3CL(pro) inhibitor PF-00835231 as a potential new treatment for COVID-19.|pdf=|usr=026}}
+{{tp|p=33551489|t=2021. Magnesium and Vitamin D Deficiency as a Potential Cause of Immune Dysfunction, Cytokine Storm and Disseminated Intravascular Coagulation in covid-19 patients.|pdf=|usr=026}}
+{{tp|p=33551236|t=2021. The need for precision nutrition, genetic variation and resolution in Covid-19 patients.|pdf=|usr=026}}
+{{tp|p=33620659|t=2021. Glucose-6-phosphate dehydrogenase deficiency and hydroxychloroquine in the COVID-19 era: a mini review.|pdf=|usr=026}}
+{{tp|p=33625681|t=2021. Bioinformatics Analysis of SARS-CoV-2 to Approach an Effective Vaccine Candidate Against COVID-19.|pdf=|usr=026}}
+{{tp|p=33722265|t=2021. Clinical and immunological effects of mRNA vaccines in malignant diseases.|pdf=|usr=026}}
+{{tp|p=33632261|t=2021. mRNA vaccine for cancer immunotherapy.|pdf=|usr=026}}
+{{tp|p=33593376|t=2021. mRNA vaccine: a potential therapeutic strategy.|pdf=|usr=026}}
+{{tp|p=33631104|t=2021. Remdesivir is a delayed translocation inhibitor of SARS-CoV-2 replication.|pdf=|usr=026}}
+{{tp|p=33604809|t=2021. Role of vitamin D in treating COVID-19-associated coagulopathy: problems and perspectives.|pdf=|usr=026}}
+{{tp|p=33587232|t=2021. Therapeutic opportunities of edible antiviral plants for COVID-19.|pdf=|usr=026}}
+{{tp|p=33675510|t=2021. Exploring naphthyl derivatives as SARS-CoV papain-like protease (PLpro) inhibitors and its implications in COVID-19 drug discovery.|pdf=|usr=026}}
+{{tp|p=33786727|t=2021. Pharmacoinformatics-based identification of transmembrane protease serine-2 inhibitors from Morus Alba as SARS-CoV-2 cell entry inhibitors.|pdf=|usr=026}}
+{{tp|p=33765239|t=2021. In silico evaluation of potential inhibitory activity of remdesivir, favipiravir, ribavirin and galidesivir active forms on SARS-CoV-2 RNA polymerase.|pdf=|usr=026}}
+{{tp|p=33582935|t=2021. Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19.|pdf=|usr=026}}
+{{tp|p=33571463|t=2021. Allergic Reactions and Anaphylaxis to LNP-Based COVID-19 Vaccines.|pdf=|usr=026}}
+{{tp|p=33723514|t=2021. In vitro characterization of engineered red blood cells as viral traps against HIV-1 and SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33573318|t=2021. COVID-19 Prophylaxis Efforts Based on Natural Antiviral Plant Extracts and Their Compounds.|pdf=|usr=026}}
+{{tp|p=33573088|t=2021. In Silico Study of Polyunsaturated Fatty Acids as Potential SARS-CoV-2 Spike Protein Closed Conformation Stabilizers: Epidemiological and Computational Approaches.|pdf=|usr=026}}
+{{tp|p=33525415|t=2021. Chloroquine and Hydroxychloroquine Interact Differently with ACE2 Domains Reported to Bind with the Coronavirus Spike Protein: Mediation by ACE2 Polymorphism.|pdf=|usr=026}}
+{{tp|p=33525411|t=2021. Computational Determination of Potential Multiprotein Targeting Natural Compounds for Rational Drug Design Against SARS-COV-2.|pdf=|usr=026}}
+{{tp|p=33530467|t=2021. Current Updates on Naturally Occurring Compounds Recognizing SARS-CoV-2 Druggable Targets.|pdf=|usr=026}}
+{{tp|p=33562030|t=2021. Therapeutic Potential of Resveratrol in COVID-19-Associated Hemostatic Disorders.|pdf=|usr=026}}
+{{tp|p=33557115|t=2021. Combining Different Docking Engines and Consensus Strategies to Design and Validate Optimized Virtual Screening Protocols for the SARS-CoV-2 3CL Protease.|pdf=|usr=026}}
+{{tp|p=33669054|t=2021. Propolis, Bee Honey, and Their Components Protect against Coronavirus Disease 2019 (COVID-19): A Review of In Silico, In Vitro, and Clinical Studies.|pdf=|usr=026}}
+{{tp|p=33668085|t=2021. EGCG, a Green Tea Catechin, as a Potential Therapeutic Agent for Symptomatic and Asymptomatic SARS-CoV-2 Infection.|pdf=|usr=026}}
+{{tp|p=33672163|t=2021. Therapeutic Intervention of COVID-19 by Natural Products: A Population-Specific Survey Directed Approach.|pdf=|usr=026}}
+{{tp|p=33672721|t=2021. Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease.|pdf=|usr=026}}
+{{tp|p=33669720|t=2021. In Silico Screening of the DrugBank Database to Search for Possible Drugs against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33668428|t=2021. Nucleoside Analogs and Nucleoside Precursors as Drugs in the Fight against SARS-CoV-2 and Other Coronaviruses.|pdf=|usr=026}}
+{{tp|p=33578831|t=2021. Field-Template, QSAR, Ensemble Molecular Docking, and 3D-RISM Solvation Studies Expose Potential of FDA-Approved Marine Drugs as SARS-CoVID-2 Main Protease Inhibitors.|pdf=|usr=026}}
+{{tp|p=33590551|t=2021. The double-edged sword of systemic corticosteroid therapy in viral pneumonia: A case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis.|pdf=|usr=026}}
+{{tp|p=33556628|t=2021. FN3-based monobodies selective for the receptor binding domain of the SARS-CoV-2 spike protein.|pdf=|usr=026}}
+{{tp|p=33657299|t=2021. Baricitinib Therapy in Covid-19 Pneumonia - An Unmet Need Fulfilled.|pdf=|usr=026}}
+{{tp|p=33631066|t=2021. Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia.|pdf=|usr=026}}
+{{tp|p=33631065|t=2021. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.|pdf=|usr=026}}
+{{tp|p=33631064|t=2021. Interleukin-6 Receptor Inhibition in Covid-19 - Cooling the Inflammatory Soup.|pdf=|usr=026}}
+{{tp|p=33626250|t=2021. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting.|pdf=|usr=026}}
+{{tp|p=33657292|t=2021. Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33815564|t=2021. Role of nanotechnology behind the success of mRNA vaccines for COVID-19.|pdf=|usr=026}}
+{{tp|p=33758593|t=2021. Engineering a self-navigated MnARK nanovaccine for inducing potent protective immunity against novel coronavirus.|pdf=|usr=026}}
+{{tp|p=33753982|t=2021. 2D MXenes with antiviral and immunomodulatory properties: A pilot study against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33753282|t=2021. Cerium oxide nanoparticle delivery of microRNA-146a for local treatment of acute lung injury.|pdf=|usr=026}}
+{{tp|p=33662593|t=2021. Synthesis and immunogenicity assessment of a gold nanoparticle conjugate for the delivery of a peptide from SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33815808|t=2021. Computational insights of phytochemical-driven disruption of RNA-dependent RNA polymerase-mediated replication of coronavirus: a strategic treatment plan against coronavirus disease 2019.|pdf=|usr=026}}
+{{tp|p=33580031|t=2020. Insights into the use of mesenchymal stem cells in COVID-19 mediated acute respiratory failure.|pdf=|usr=026}}
+{{tp|p=33785745|t=2021. Replicating bacterium-vectored vaccine expressing SARS-CoV-2 Membrane and Nucleocapsid proteins protects against severe COVID-19-like disease in hamsters.|pdf=|usr=026}}
+{{tp|p=33767200|t=2021. The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization.|pdf=|usr=026}}
+{{tp|p=33741993|t=2021. Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease.|pdf=|usr=026}}
+{{tp|p=33741992|t=2021. Human endogenous retrovirus-enveloped baculoviral DNA vaccines against MERS-CoV and SARS-CoV2.|pdf=|usr=026}}
+{{tp|p=33619260|t=2021. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates.|pdf=|usr=026}}
+{{tp|p=33526776|t=2021. Piglet immunization with a spike subunit vaccine enhances disease by porcine epidemic diarrhea virus.|pdf=|usr=026}}
+{{tp|p=33580085|t=2020. Universal coronavirus vaccines: the time to start is now.|pdf=|usr=026}}
+{{tp|p=33580049|t=2020. Certainty of success: three critical parameters in coronavirus vaccine development.|pdf=|usr=026}}
+{{tp|p=33580061|t=2020. The outbreak of SARS-CoV-2 pneumonia calls for viral vaccines.|pdf=|usr=026}}
+{{tp|p=33580080|t=2020. Applying lessons from the Ebola vaccine experience for SARS-CoV-2 and other epidemic pathogens.|pdf=|usr=026}}
+{{tp|p=33580058|t=2020. Plasma-based COVID-19 treatments in low- and middle-income nations pose a high risk of an HIV epidemic.|pdf=|usr=026}}
+{{tp|p=33580068|t=2020. Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19.|pdf=|usr=026}}
+{{tp|p=33580044|t=2020. COVID-19 vaccines: breaking record times to first-in-human trials.|pdf=|usr=026}}
+{{tp|p=33549288|t=2021. Herbal Medication to Enhance or Modulate Viral Infections.|pdf=|usr=026}}
+{{tp|p=33667020|t=2021. Nutrition Support in Patients With Acute Respiratory Distress Syndrome COVID-19.|pdf=|usr=026}}
+{{tp|p=33651909|t=2021. Early Enteral Nutrition in Mechanically Ventilated Patients With COVID-19 Infection.|pdf=|usr=026}}
+{{tp|p=33549452|t=2021. Excessive vitamin B12 and poor outcome in COVID-19 pneumonia.|pdf=|usr=026}}
+{{tp|p=33549427|t=2021. Nutrition and the Covid-19 pandemic: Three factors with high impact on community health.|pdf=|usr=026}}
+{{tp|p=33592454|t=2021. Probiotics: A potential immunomodulator in COVID-19 infection management.|pdf=|usr=026}}
+{{tp|p=33570583|t=2021. Nutritional perspectives for the prevention and mitigation of COVID-19.|pdf=|usr=026}}
+{{tp|p=33573173|t=2021. Phytonutrient and Nutraceutical Action against COVID-19: Current Review of Characteristics and Benefits.|pdf=|usr=026}}
+{{tp|p=33573169|t=2021. Micronutrients, Phytochemicals and Mediterranean Diet: A Potential Protective Role against COVID-19 through Modulation of PAF Actions and Metabolism.|pdf=|usr=026}}
+{{tp|p=33525447|t=2021. Vitamin D Supplementation to Prevent COVID-19 Infections and Deaths-Accumulating Evidence from Epidemiological and Intervention Studies Calls for Immediate Action.|pdf=|usr=026}}
+{{tp|p=33572045|t=2021. Low Zinc Levels at Admission Associates with Poor Clinical Outcomes in SARS-CoV-2 Infection.|pdf=|usr=026}}
+{{tp|p=33557013|t=2021. Diagnostic and Pharmacological Potency of Creatine in Post-Viral Fatigue Syndrome.|pdf=|usr=026}}
+{{tp|p=33652653|t=2021. Notable Developments for Vitamin D Amid the COVID-19 Pandemic, but Caution Warranted Overall: A Narrative Review.|pdf=|usr=026}}
+{{tp|p=33668240|t=2021. Vitamin D and Lung Outcomes in Elderly COVID-19 Patients.|pdf=|usr=026}}
+{{tp|p=33671491|t=2021. The Antiviral Properties of Human Milk: A Multitude of Defence Tools from Mother Nature.|pdf=|usr=026}}
+{{tp|p=33611766|t=2021. Roux-en-Y Gastric Bypass Downregulates Angiotensin-Converting Enzyme 2 (ACE2) Gene Expression in Subcutaneous White Adipose Tissue: A Putative Protective Mechanism Against Severe COVID-19.|pdf=|usr=026}}
+{{tp|p=33537364|t=2021. Tocilizumab for the Treatment of COVID-19 Among Hospitalized Patients: A Matched Retrospective Cohort Analysis.|pdf=|usr=026}}
+{{tp|p=33628858|t=2021. Is There Still a Place for Tocilizumab in Coronavirus Disease 2019?|pdf=|usr=026}}
+{{tp|p=33628857|t=2021. Impact of Interleukin-6 Receptor Blockade With Tocilizumab on Cardiac Injury in Patients With COVID-19: A Retrospective Cohort Study.|pdf=|usr=026}}
+{{tp|p=33623808|t=2021. Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19.|pdf=|usr=026}}
+{{tp|p=33604400|t=2021. Matched Cohort Study of Convalescent COVID-19 Plasma Treatment in Severely or Life Threateningly Ill COVID-19 Patients.|pdf=|usr=026}}
+{{tp|p=33556157|t=2021. Real-World Inpatient Use of Medications Repurposed for Coronavirus Disease 2019 in United States Hospitals, March-May 2020.|pdf=|usr=026}}
+{{tp|p=33553472|t=2021. A First Draft of the History of Treating Coronavirus Disease 2019: Use of Repurposed Medications in United States Hospitals.|pdf=|usr=026}}
+{{tp|p=33553467|t=2021. Cytokine and Chemokine Levels in Coronavirus Disease 2019 Convalescent Plasma.|pdf=|usr=026}}
+{{tp|p=33741691|t=2021. Melatonin may decrease risk for and aid treatment of COVID-19 and other RNA viral infections.|pdf=|usr=026}}
+{{tp|p=33778162|t=2021. Judicious use of low-dosage corticosteroids for non-severe COVID-19: A case report.|pdf=|usr=026}}
+{{tp|p=33717367|t=2020. Novel and Controversial Therapies in COVID-19.|pdf=|usr=026}}
+{{tp|p=33675508|t=2021. Ophthalmological Considerations for COVID-19 Vaccination in Patients with Inflammatory Eye Diseases and Autoimmune Disorders.|pdf=|usr=026}}
+{{tp|p=33628371|t=2021. Oxidative Imbalance as a Crucial Factor in Inflammatory Lung Diseases: Could Antioxidant Treatment Constitute a New Therapeutic Strategy?|pdf=|usr=026}}
+{{tp|p=33691012|t=2021. Feasibility of the vaccine development for SARS-CoV-2 and other viruses using the shell disorder analysis.|pdf=|usr=026}}
+{{tp|p=33691011|t=2021. SARS-CoV-2 Drug Discovery based on Intrinsically Disordered Regions.|pdf=|usr=026}}
+{{tp|p=33605425|t=2021. Do Corticosteroid Injections for the Treatment of Pain Influence the Efficacy of mRNA COVID-19 Vaccines?|pdf=|usr=026}}
+{{tp|p=33623607|t=2020. Psychiatric side effects of chloroquine in COVID-19 patients: two case reports.|pdf=|usr=026}}
+{{tp|p=33623604|t=2020. Cochrane corner: convalescent plasma or hyperimmune immunoglobulin for people with COVID-19.|pdf=|usr=026}}
+{{tp|p=33534822|t=2021. Rational design of multi epitope-based subunit vaccine by exploring MERS-COV proteome: Reverse vaccinology and molecular docking approach.|pdf=|usr=026}}
+{{tp|p=33765086|t=2021. Sieve analysis to understand how SARS-CoV-2 diversity can impact vaccine protection.|pdf=|usr=026}}
+{{tp|p=33765062|t=2021. Inactivated rabies virus vectored SARS-CoV-2 vaccine prevents disease in a Syrian hamster model.|pdf=|usr=026}}
+{{tp|p=33657135|t=2021. A high-affinity RBD-targeting nanobody improves fusion partner's potency against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33571304|t=2021. Multi-clonal SARS-CoV-2 neutralization by antibodies isolated from severe COVID-19 convalescent donors.|pdf=|usr=026}}
+{{tp|p=33644964|t=2021. The essential role of a physiatrist in recommending a COVID-19 vaccine.|pdf=|usr=026}}
+{{tp|p=33589486|t=2021. Inadvertent subcutaneous injection of COVID-19 vaccine.|pdf=|usr=026}}
+{{tp|p=33770348|t=2021. The Role of Mucosal Immunity and Recombinant Probiotics in SARS-CoV2 Vaccine Development.|pdf=|usr=026}}
+{{tp|p=33537958|t=2021. Systematic Network and Meta-analysis on the Antiviral Mechanisms of Probiotics: A Preventive and Treatment Strategy to Mitigate SARS-CoV-2 Infection.|pdf=|usr=026}}
+{{tp|p=33597253|t=2021. Bepridil is potent against SARS-CoV-2 in vitro.|pdf=|usr=026}}
+{{tp|p=33688035|t=2021. One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower respiratory tract infection.|pdf=|usr=026}}
+{{tp|p=33688034|t=2021. A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike.|pdf=|usr=026}}
+{{tp|p=33568500|t=2021. Reply to Ma and Wang: Reliability of various in vitro activity assays on SARS-CoV-2 main protease inhibitors.|pdf=|usr=026}}
+{{tp|p=33526596|t=2021. Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP.|pdf=|usr=026}}
+{{tp|p=33766889|t=2021. Generation of SARS-CoV-2 reporter replicon for high-throughput antiviral screening and testing.|pdf=|usr=026}}
+{{tp|p=33636189|t=2021. Targeting SARS-CoV-2 Nsp3 macrodomain structure with insights from human poly(ADP-ribose) glycohydrolase (PARG) structures with inhibitors.|pdf=|usr=026}}
+{{tp|p=33770364|t=2021. Understanding the phase separation characteristics of nucleocapsid protein provides a new therapeutic opportunity against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33586288|t=2021. Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naive human antibody library.|pdf=|usr=026}}
+{{tp|p=33771367|t=2021. Vaccination for COVID-19: benchmarks in public health and virus transmission.|pdf=|usr=026}}
+{{tp|p=33743214|t=2021. Vaccines for COVID-19: learning from ten phase II trials to inform clinical and public health vaccination programmes.|pdf=|usr=026}}
+{{tp|p=33685998|t=2021. SARS-CoV-2 vaccines in patients with SLE.|pdf=|usr=026}}
+{{tp|p=33627228|t=2021. Liquen plano en una paciente tras SARS-CoV-2 tratado con lopinavir/ritonavir.|pdf=|usr=026}}
+{{tp|p=33593637|t=2021. Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection.|pdf=|usr=026}}
+{{tp|p=33622529|t=2021. Glucocorticoides solos versus tocilizumab solo o glucocorticoides mas tocilizumab en pacientes con neumonia grave por SARS-CoV-2 e inflamacion moderada.|pdf=|usr=026}}
+{{tp|p=33715841|t=2021. Tocilizumab en el paciente con COVID-19.|pdf=|usr=026}}
+{{tp|p=33778159|t=2021. Lichen planus after SARS-CoV-2 infection treated with lopinavir/ritonavir.|pdf=|usr=026}}
+{{tp|p=33589878|t=2021. Transfusion reaction to hyperimmune plasma in patients with severe COVID-19 infection.|pdf=|usr=026}}
+{{tp|p=33585689|t=2021. Effectiveness of glucocorticoids in patients hospitalized for severe SARS-CoV-2 pneumonia.|pdf=|usr=026}}
+{{tp|p=33686372|t=2021. Indication of glucocorticoid pulses for patients with SARS-CoV-2 infection.|pdf=|usr=026}}
+{{tp|p=33763598|t=2021. Tocilizumab in patients infected by SARS-CoV2.|pdf=|usr=026}}
+{{tp|p=33817623|t=2021. Network bioinformatics analysis provides insight into drug repurposing for COVID-19.|pdf=|usr=026}}
+{{tp|p=33780778|t=2021. Anticholinergic drugs versus preprocedural mouth rinses for reduction of SARS-CoV-2 load in dental aerosols.|pdf=|usr=026}}
+{{tp|p=33780777|t=2021. Aminoglycosides and their potential as SARS-CoV-2 antivirals.|pdf=|usr=026}}
+{{tp|p=33735762|t=2021. Clofazimine: A potential therapeutic option for severe COVID-19.|pdf=|usr=026}}
+{{tp|p=33730601|t=2021. Etoricoxib may inhibit cytokine storm to treat COVID-19.|pdf=|usr=026}}
+{{tp|p=33571758|t=2021. Antihistamine and cationic amphiphilic drugs, old molecules as new tools against the COVID-19?|pdf=|usr=026}}
+{{tp|p=33561624|t=2021. The potential use of lactate blockers for the prevention of COVID-19 worst outcome, insights from exercise immunology.|pdf=|usr=026}}
+{{tp|p=33549964|t=2021. Airways to heaven: Caution needed when exercising during COVID-19.|pdf=|usr=026}}
+{{tp|p=33529978|t=2021. Could diet and exercise reduce risk of COVID-19 syndemic?|pdf=|usr=026}}
+{{tp|p=33657458|t=2021. Autism Spectrum Disorder patients may be susceptible to COVID-19 disease due to deficiency in melatonin.|pdf=|usr=026}}
+{{tp|p=33647606|t=2021. Old drug, new Trick? The rationale for the treatment of COVID-19 with activated protein C.|pdf=|usr=026}}
+{{tp|p=33640714|t=2021. Can bilirubin nanomedicine become a hope for the management of COVID-19?|pdf=|usr=026}}
+{{tp|p=33636587|t=2021. COVID-19, colchicine and glycemia.|pdf=|usr=026}}
+{{tp|p=33636586|t=2021. COVID-19-related arrhythmias and the possible effects of ranolazine.|pdf=|usr=026}}
+{{tp|p=33621842|t=2021. Pulmonary lipid modulation: A possible therapeutic target for SARS-CoV-2 infection.|pdf=|usr=026}}
+{{tp|p=33607405|t=2021. A genetic insight into vitamin D binding protein and COVID-19.|pdf=|usr=026}}
+{{tp|p=33744019|t=2021. Corticosteroids in COVID-19: A double-edged sword - a retrospective study.|pdf=|usr=026}}
+{{tp|p=33816370|t=2020. Efficacy and safety of chloroquine and hydroxychloroquine for COVID-19: A comprehensive evidence synthesis of clinical, animal, and in vitro studies.|pdf=|usr=026}}
+{{tp|p=33571171|t=2021. Risk Factors of Coronavirus Disease 2019-Related Mortality and Optimal Treatment Regimens: A Retrospective Study.|pdf=|usr=026}}
+{{tp|p=33776574|t=2021. Corticosteroid Pulses for Hospitalized Patients with COVID-19: Effects on Mortality.|pdf=|usr=026}}
+{{tp|p=33673527|t=2021. Antiviral and Immunomodulation Effects of Artemisia.|pdf=|usr=026}}
+{{tp|p=33673004|t=2021. Natural Products and Nutrients against Different Viral Diseases: Prospects in Prevention and Treatment of SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33655919|t=2021. Oral high dose vitamin D for the treatment of diabetic patients with COVID-19: A protocol for systematic review and meta-analysis.|pdf=|usr=026}}
+{{tp|p=33761696|t=2021. Role of tocilizumab for concomitant systemic fungal infection in severe COVID-19 patient: Case report.|pdf=|usr=026}}
+{{tp|p=33725851|t=2021. Low-dose oral hydroxychloroquine led to impaired vision in a child with renal failure: Case report and literature review.|pdf=|usr=026}}
+{{tp|p=33530261|t=2021. Arbidol combined with the Chinese medicine Lianhuaqingwen capsule versus arbidol alone in the treatment of COVID-19.|pdf=|usr=026}}
+{{tp|p=33578548|t=2021. Effect of low-dose aspirin on mortality and viral duration of the hospitalized adults with COVID-19.|pdf=|usr=026}}
+{{tp|p=33623561|t=2020. Immunity, parasites, genetics and sex hormones: contributors to mild inflammatory responses in COVID-19?|pdf=|usr=026}}
+{{tp|p=33623551|t=2020. An alert on the incautious use of herbal medicines by sub-Saharan African populations to fight against the COVID-19.|pdf=|usr=026}}
+{{tp|p=33573530|t=2021. Use of hydroxychloroquine and chloroquine in patients with COVID-19: a meta-analysis of randomized clinical trials.|pdf=|usr=026}}
+{{tp|p=33682640|t=2021. Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection.|pdf=|usr=026}}
+{{tp|p=33573221|t=2021. Potential SARS-CoV-2 Immune Correlates of Protection in Infection and Vaccine Immunization.|pdf=|usr=026}}
+{{tp|p=33669635|t=2021. Hypothiocyanite and Hypothiocyanite/Lactoferrin Mixture Exhibit Virucidal Activity In Vitro against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33671315|t=2021. Chloroquine and Hydroxychloroquine: Efficacy in the Treatment of the COVID-19.|pdf=|usr=026}}
+{{tp|p=33621264|t=2021. Development and validation of a prediction model for tocilizumab failure in hospitalized patients with SARS-CoV-2 infection.|pdf=|usr=026}}
+{{tp|p=33621254|t=2021. Retrospective analysis of 426 donors of a convalescent collective after mild COVID-19.|pdf=|usr=026}}
+{{tp|p=33606790|t=2021. Observational study of haloperidol in hospitalized patients with COVID-19.|pdf=|usr=026}}
+{{tp|p=33606702|t=2021. A Bayesian reanalysis of the effects of hydroxychloroquine and azithromycin on viral carriage in patients with COVID-19.|pdf=|usr=026}}
+{{tp|p=33596235|t=2021. Mapping major SARS-CoV-2 drug targets and assessment of druggability using computational fragment screening: Identification of an allosteric small-molecule binding site on the Nsp13 helicase.|pdf=|usr=026}}
+{{tp|p=33596218|t=2021. Iota-carrageenan neutralizes SARS-CoV-2 and inhibits viral replication in vitro.|pdf=|usr=026}}
+{{tp|p=33592050|t=2021. Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study.|pdf=|usr=026}}
+{{tp|p=33571320|t=2021. Development and evaluation of inhalable composite niclosamide-lysozyme particles: A broad-spectrum, patient-adaptable treatment for coronavirus infections and sequalae.|pdf=|usr=026}}
+{{tp|p=33727066|t=2021. Sequential doxycycline and colchicine combination therapy in Covid-19: The salutary effects.|pdf=|usr=026}}
+{{tp|p=33643864|t=2021. mRNA Vaccines for COVID-19: A Simple Explanation.|pdf=|usr=026}}
+{{tp|p=33677593|t=2021. The potential risks of delaying the second vaccine dose during the SARS-CoV-2 pandemic.|pdf=|usr=026}}
+{{tp|p=33486522|t=2021. Vitamin D supplementation, COVID-19 and disease severity: a meta-analysis.|pdf=|usr=026}}
+{{tp|p=33647971|t=2021. COVID-19 vaccine-related myositis.|pdf=|usr=026}}
+{{tp|p=33599247|t=2021. Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos.|pdf=|usr=026}}
+{{tp|p=33778667|t=2021. Axillary Lymphadenopathy After mRNA COVID-19 Vaccination.|pdf=|usr=026}}
+{{tp|p=33625301|t=2021. Evolution of Lymphadenopathy at PET/MRI after COVID-19 Vaccination.|pdf=|usr=026}}
+{{tp|p=33625299|t=2021. Adenopathy Following COVID-19 Vaccination.|pdf=|usr=026}}
+{{tp|p=33625300|t=2021. Lymphadenopathy in COVID-19 Vaccine Recipients: Diagnostic Dilemma in Oncology Patients.|pdf=|usr=026}}
+{{tp|p=33625298|t=2021. Multidisciplinary Recommendations Regarding Post-Vaccine Adenopathy and Radiologic Imaging: Radiology Scientific Expert Panel.|pdf=|usr=026}}
+{{tp|p=33723519|t=2021. Potency of Mesenchymal Stem Cell and Its Secretome in Treating COVID-19.|pdf=|usr=026}}
+{{tp|p=33542837|t=2021. Low-Level Laser Therapy in Prevention of the Development of Endothelial Dysfunction and Clinical Experience of Treatment and Rehabilitation of COVID-19 Patients.|pdf=|usr=026}}
+{{tp|p=33547007|t=2021. Sustained coronavirus disease 2019-related organizing pneumonia successfully treated with corticosteroid.|pdf=|usr=026}}
+{{tp|p=33550151|t=2021. Colchicine and SARS-CoV-2: Management of the hyperinflammatory state.|pdf=|usr=026}}
+{{tp|p=33721697|t=2021. SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity.|pdf=|usr=026}}
+{{tp|p=33552890|t=2021. COVID-19 acute respiratory distress syndrome: can iloprost have a role for the treatment?|pdf=|usr=026}}
+{{tp|p=33657448|t=2021. Use of exogenous pulmonary surfactant in acute respiratory distress syndrome (ARDS): Role in SARS-CoV-2-related lung injury.|pdf=|usr=026}}
+{{tp|p=33658032|t=2021. Circulating Vitamin D levels status and clinical prognostic indices in COVID-19 patients.|pdf=|usr=026}}
+{{tp|p=33815804|t=2021. Nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019.|pdf=|usr=026}}
+{{tp|p=33732466|t=2021. Multimodality treatment in immunocompromised patients with severe COVID-19: the role of IL-6 inhibitor, intravenous immunoglobulin, and haemoperfusion.|pdf=|usr=026}}
+{{tp|p=33619449|t=2021. An integrated virtual screening of compounds from Carica papaya leaves against multiple protein targets of SARS-Coronavirus-2.|pdf=|usr=026}}
+{{tp|p=33677945|t=2021. Vitamin D and disease severity in coronavirus disease 19 (COVID-19).|pdf=|usr=026}}
+{{tp|p=33716310|t=2021. Precaucion con el uso de dexametasona en pacientes con COVID-19 en sus fases iniciales.|pdf=|usr=026}}
+{{tp|p=33776190|t=2021. Miocarditis aguda tras administracion de vacuna BNT162b2 contra la COVID-19.|pdf=|usr=026}}
+{{tp|p=33675220|t=2021. Real-life use of remdesivir in hospitalized patients with COVID-19.|pdf=|usr=026}}
+{{tp|p=33654051|t=2021. Impacto de la COVID-19 sobre las listas de espera quirurgicas.|pdf=|usr=026}}
+{{tp|p=33399749|t=2020. Tratamientos experimentales y coronavirus.|pdf=|usr=026}}
+{{tp|p=33480368|t=2020. El dilema de COVID-19: inverted question marksangre suficiente versus plasma convaleciente?|pdf=|usr=026}}
+{{tp|p=33612319|t=2021. Chez des sujets de 16 ans et plus, est-ce que le vaccin BNT162b2, un vaccin a ARN messager contre la COVID-19, est efficace et securitaire ?|pdf=|usr=026}}
+{{tp|p=33594794|t=2021. Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects.|pdf=|usr=026}}
+{{tp|p=33666285|t=2021. Vaccines for SARS coronavirus 2 and the new normal in vaccinology.|pdf=|usr=026}}
+{{tp|p=33621405|t=2021. Current views on the potentials of convalescent plasma therapy (CPT) as Coronavirus disease 2019 (COVID-19) treatment: A systematic review and meta-analysis based on recent studies and previous respiratory pandemics.|pdf=|usr=026}}
+{{tp|p=33580566|t=2020. Background to new treatments for COVID-19, including its chronicity, through altering elements of the cytokine storm.|pdf=|usr=026}}
+{{tp|p=33764494|t=2021. Vacunacion frente al SARS-CoV-2 en pacientes con esclerosis multiple.|pdf=|usr=026}}
+{{tp|p=33710296|t=2021. COVID-19 vaccination and antirheumatic therapy.|pdf=|usr=026}}
+{{tp|p=33542047|t=2021. Beneficial effects of colchicine for moderate to severe COVID-19: a randomised, double-blinded, placebo-controlled clinical trial.|pdf=|usr=026}}
+{{tp|p=33544784|t=2020. Natural and semisynthetic candidate molecules for COVID-19 prophylaxis and treatment.|pdf=|usr=026}}
+{{tp|p=33776395|t=2021. Synthesis, Molecular Docking, In Silico ADME Predictions, and Toxicity Studies of N-Substituted-5-(4-Chloroquinolin-2-yl)-1,3,4-Thiadiazol-2-Amine Derivatives as COVID-19 Inhibitors.|pdf=|usr=026}}
+{{tp|p=33753960|t=2021. Natural product remedies for COVID-19: A focus on safety.|pdf=|usr=026}}
+{{tp|p=33614035|t=2021. Deficiency of antioxidants and increased oxidative stress in COVID-19 patients: A cross-sectional comparative study in Jigawa, Northwestern Nigeria.|pdf=|usr=026}}
+{{tp|p=33796310|t=2021. Tocilizumab and PMX-DHP have efficacy for severe COVID-19 pneumonia.|pdf=|usr=026}}
+{{tp|p=33656132|t=2021. Critical analysis on the use of cholecalciferol as a COVID-19 intervention: a narrative review.|pdf=|usr=026}}
+{{tp|p=33649700|t=2021. Screening of drug databank against WT and mutant main protease of SARS-CoV-2: Towards finding potential compound for repurposing against COVID-19.|pdf=|usr=026}}
+{{tp|p=33642896|t=2021. In silico analysis of quranic and prophetic medicinals plants for the treatment of infectious viral diseases including corona virus.|pdf=|usr=026}}
+{{tp|p=33732045|t=2021. Nano-formulation of herbo-mineral alternative medicine from linga chenduram and evaluation of antiviral efficacy.|pdf=|usr=026}}
+{{tp|p=33758570|t=2021. Structure insights of SARS-CoV-2 open state envelope protein and inhibiting through active phytochemical of ayurvedic medicinal plants from Withania somnifera.|pdf=|usr=026}}
+{{tp|p=33746538|t=2021. A comprehensive insight into the role of zinc deficiency in the renin-angiotensin and kinin-kallikrein system dysfunctions in COVID-19 patients.|pdf=|usr=026}}
+{{tp|p=33654454|t=2021. Screening of inhibitors against SARS-CoV-2 spike protein and their capability to block the viral entry mechanism: A viroinformatics study.|pdf=|usr=026}}
+{{tp|p=33551661|t=2021. Computational drug screening against the SARS-CoV-2 Saudi Arabia isolates through a multiple-sequence alignment approach.|pdf=|usr=026}}
+{{tp|p=33526965|t=2021. Identification of natural compounds as potent inhibitors of SARS-CoV-2 main protease using combined docking and molecular dynamics simulations.|pdf=|usr=026}}
+{{tp|p=33722251|t=2021. Extracorporeal cardiopulmonary resuscitation for severe chloroquine intoxication in a child - a case report.|pdf=|usr=026}}
+{{tp|p=33741598|t=2021. Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates.|pdf=|usr=026}}
+{{tp|p=33608249|t=2021. Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans.|pdf=|usr=026}}
+{{tp|p=33597251|t=2021. An engineered decoy receptor for SARS-CoV-2 broadly binds protein S sequence variants.|pdf=|usr=026}}
+{{tp|p=33547083|t=2021. A lymph node-targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33536217|t=2021. Leveraging systems biology for predicting modulators of inflammation in patients with COVID-19.|pdf=|usr=026}}
+{{tp|p=33686143|t=2021. The in-vitro effect of famotidine on sars-cov-2 proteases and virus replication.|pdf=|usr=026}}
+{{tp|p=33664446|t=2021. Polyunsaturated omega-3 fatty acids inhibit ACE2-controlled SARS-CoV-2 binding and cellular entry.|pdf=|usr=026}}
+{{tp|p=33664393|t=2021. Potential neutralizing antibodies discovered for novel corona virus using machine learning.|pdf=|usr=026}}
+{{tp|p=33576820|t=2021. Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 Infection: The COVID A to Z Randomized Clinical Trial.|pdf=|usr=026}}
+{{tp|p=33576814|t=2021. Supplements for the Treatment of Mild COVID-19-Challenging Health Beliefs With Science From A to Z.|pdf=|usr=026}}
+{{tp|p=33769311|t=2021. IgV somatic mutation of human anti-SARS-CoV-2 monoclonal antibodies governs neutralization and breadth of reactivity.|pdf=|usr=026}}
+{{tp|p=33529170|t=2021. Dromedary camels as a natural source of neutralizing nanobodies against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33571168|t=2021. Clinical and laboratory evaluation of patients with SARS-CoV-2 pneumonia treated with high-titer convalescent plasma.|pdf=|usr=026}}
+{{tp|p=33724265|t=2020. No Time to Waste: Real-World Repurposing of Generic Drugs as a Multifaceted Strategy Against COVID-19.|pdf=|usr=026}}
+{{tp|p=33666263|t=2021. Nutrition evaluation and management of critically ill patients with COVID-19 during post-intensive care rehabilitation.|pdf=|usr=026}}
+{{tp|p=33756482|t=2021. Pathophysiological Implication of Vitamin D in Diabetic Kidney Disease.|pdf=|usr=026}}
+{{tp|p=33647327|t=2021. Kidney disorders as serious adverse drug reactions of remdesivir in coronavirus disease 2019: a retrospective case-noncase study.|pdf=|usr=026}}
+{{tp|p=33775674|t=2021. Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients.|pdf=|usr=026}}
+{{tp|p=33585728|t=2021. Systematic Review of Safety and Efficacy of COVID-19 Vaccines in Patients With Kidney Disease.|pdf=|usr=026}}
+{{tp|p=33706472|t=2021. Baseline use of hydroxychloroquine or immunosuppressive drugs and the risk of coronavirus disease 2019.|pdf=|usr=026}}
+{{tp|p=33617777|t=2021. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.|pdf=|usr=026}}
+{{tp|p=33617772|t=2021. MAb for symptomatic COVID-19 in correctional facilities: an important opportunity.|pdf=|usr=026}}
+{{tp|p=33610193|t=2021. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients.|pdf=|usr=026}}
+{{tp|p=33640037|t=2021. Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine.|pdf=|usr=026}}
+{{tp|p=33705696|t=2021. (18)F-fluorodeoxyglucose PET/CT findings in a systemic inflammatory response syndrome after COVID-19 vaccine.|pdf=|usr=026}}
+{{tp|p=33676597|t=2021. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial.|pdf=|usr=026}}
+{{tp|p=33640038|t=2021. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals.|pdf=|usr=026}}
+{{tp|p=33684351|t=2021. Sex-disaggregated data in COVID-19 vaccine trials.|pdf=|usr=026}}
+{{tp|p=33545098|t=2021. Sputnik V COVID-19 vaccine candidate appears safe and effective.|pdf=|usr=026}}
+{{tp|p=33545094|t=2021. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia.|pdf=|usr=026}}
+{{tp|p=33549168|t=2021. WHO international non-proprietary names: the need to distinguish COVID-19 vaccines.|pdf=|usr=026}}
+{{tp|p=33545096|t=2021. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.|pdf=|usr=026}}
+{{tp|p=33765410|t=2021. Vaccines and SARS-CoV-2 variants: the urgent need for a correlate of protection.|pdf=|usr=026}}
+{{tp|p=33743220|t=2021. Malnutrition risk in hospitalised COVID-19 patients receiving CPAP.|pdf=|usr=026}}
+{{tp|p=33770519|t=2021. WHO International Standard for anti-SARS-CoV-2 immunoglobulin.|pdf=|usr=026}}
+{{tp|p=33665645|t=2021. The potential of rapalogs to enhance resilience against SARS-CoV-2 infection and reduce the severity of COVID-19.|pdf=|usr=026}}
+{{tp|p=33773111|t=2021. Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.|pdf=|usr=026}}
+{{tp|p=33606999|t=2021. Anti-SARS-CoV-2 antibodies in healthy donor plasma pools and IVIG products.|pdf=|usr=026}}
+{{tp|p=33548196|t=2021. Inactivated COVID-19 vaccines to make a global impact.|pdf=|usr=026}}
+{{tp|p=33548194|t=2021. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.|pdf=|usr=026}}
+{{tp|p=33639103|t=2021. Bell's palsy and SARS-CoV-2 vaccines.|pdf=|usr=026}}
+{{tp|p=33778791|t=2021. Convalescent plasma from people vaccinated after COVID-19 infection.|pdf=|usr=026}}
+{{tp|p=33817676|t=2021. Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19.|pdf=|usr=026}}
+{{tp|p=33655229|t=2021. COVID-19 drug practices risk antimicrobial resistance evolution.|pdf=|usr=026}}
+{{tp|p=33571468|t=2021. SARS-CoV-2 vaccination and phase 1 cancer clinical trials.|pdf=|usr=026}}
+{{tp|p=33556319|t=2021. Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial.|pdf=|usr=026}}
+{{tp|p=33817664|t=2021. Flare of rheumatoid arthritis after COVID-19 vaccination.|pdf=|usr=026}}
+{{tp|p=33655225|t=2021. Hydroxychloroquine treatment does not reduce COVID-19 mortality; underdosing to the wrong patients?|pdf=|usr=026}}
+{{tp|p=33655224|t=2021. Hydroxychloroquine treatment does not reduce COVID-19 mortality; underdosing to the wrong patients? - Authors' reply.|pdf=|usr=026}}
+{{tp|p=33817665|t=2021. The role of antirheumatics in patients with COVID-19.|pdf=|usr=026}}
+{{tp|p=33754144|t=2021. Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial.|pdf=|usr=026}}
+{{tp|p=33782671|t=2021. Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation.|pdf=|usr=026}}
+{{tp|p=33782670|t=2021. Interleukin-1 and interleukin-6 inhibition in patients with COVID-19 and hyperinflammation - Authors' reply.|pdf=|usr=026}}
+{{tp|p=33655222|t=2021. Type I interferon, anti-interferon antibodies, and COVID-19.|pdf=|usr=026}}
+{{tp|p=33655221|t=2021. COVID-19 cytokine storm: targeting the appropriate cytokine.|pdf=|usr=026}}
+{{tp|p=33655220|t=2021. Perspective of patients with autoimmune diseases on COVID-19 vaccination.|pdf=|usr=026}}
+{{tp|p=33655219|t=2021. Vaccination against COVID-19: Expectations and concerns of patients with autoimmune and rheumatic diseases.|pdf=|usr=026}}
+{{tp|p=33655218|t=2021. Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study.|pdf=|usr=026}}
+{{tp|p=33619736|t=2021. The effect of climbing chalk powder on the infectivity of human coronavirus OC43.|pdf=|usr=026}}
+{{tp|p=33671893|t=2021. The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19.|pdf=|usr=026}}
+{{tp|p=33636175|t=2021. Targeting RAGE to prevent SARS-CoV-2-mediated multiple organ failure: Hypotheses and perspectives.|pdf=|usr=026}}
+{{tp|p=33745895|t=2021. Effects of metformin, insulin on COVID-19 patients with pre-existed type 2 diabetes: A multicentral retrospective study.|pdf=|usr=026}}
+{{tp|p=33789145|t=2021. Nanocurcumin improves Treg cell responses in patients with mild and severe SARS-CoV2.|pdf=|usr=026}}
+{{tp|p=33781826|t=2021. Heparin prevents in vitro glycocalyx shedding induced by plasma from COVID-19 patients.|pdf=|usr=026}}
+{{tp|p=33607159|t=2021. COVID-19, cytokines, inflammation, and spices: How are they related?|pdf=|usr=026}}
+{{tp|p=33593923|t=2021. A systems-based method to repurpose marketed therapeutics for antiviral use: a SARS-CoV-2 case study.|pdf=|usr=026}}
+{{tp|p=33687000|t=2021. Anti-fibrotic therapy for the treatment of pulmonary sequelae in patients healed by COVID-19.|pdf=|usr=026}}
+{{tp|p=33686995|t=2021. Early experience with anti-interleukin-6 therapy in COVID-19 hyperinflammation.|pdf=|usr=026}}
+{{tp|p=33686972|t=2021. The link between vitamin D deficiency and COVID-19.|pdf=|usr=026}}
+{{tp|p=33666135|t=2021. Bispecific VH/Fab antibodies targeting neutralizing and non-neutralizing Spike epitopes demonstrate enhanced potency against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33566210|t=2021. Photosynthetically Controlled Spirulina, but Not Solar Spirulina, Inhibits TNF-alpha Secretion: Potential Implications for COVID-19-Related Cytokine Storm Therapy.|pdf=|usr=026}}
+{{tp|p=33670191|t=2021. New Hopes for Drugs against COVID-19 Come from the Sea.|pdf=|usr=026}}
+{{tp|p=33589849|t=2021. Preparation of cerium molybdates and their antiviral activity against bacteriophage Phi6 and SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33628136|t=2020. Why Not Encourage Physical Activity Outdoors and Inhaling Through the Uncovered Nose During the Coronavirus Lockdown?|pdf=|usr=026}}
+{{tp|p=33718003|t=2021. Encapsulation of bioactive agent (Curcumin, Moringa) in electrospun nanofibers - Some insights into recent research trends.|pdf=|usr=026}}
+{{tp|p=33816131|t=2021. Repurposing antiviral drugs on recently emerged viral infections: A review article.|pdf=|usr=026}}
+{{tp|p=33757717|t=2021. Role of vitamin D supplementation in aging patients with COVID-19.|pdf=|usr=026}}
+{{tp|p=33673930|t=2021. In Reply - Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019.|pdf=|usr=026}}
+{{tp|p=33673929|t=2021. Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019.|pdf=|usr=026}}
+{{tp|p=33549269|t=2021. Elevated Rate of HLA Antibodies in Male COVID-19 Convalescent Plasma Donors: A Risk Factor for Transfusion-Related Acute Lung Injury.|pdf=|usr=026}}
+{{tp|p=33714594|t=2021. Vitamin D Status Is Associated With In-Hospital Mortality and Mechanical Ventilation: A Cohort of COVID-19 Hospitalized Patients.|pdf=|usr=026}}
+{{tp|p=33817559|t=2021. Anti-Inflammatory treatment of COVID-19 pneumonia with tofacitinib alone or in combination with dexamethasone is safe and possibly superior to dexamethasone as a single agent in a predominantly African American cohort.|pdf=|usr=026}}
+{{tp|p=33748678|t=2021. Association Between Chronic Statin Use and 30-Day Mortality in Hospitalized Patients With COVID-19.|pdf=|usr=026}}
+{{tp|p=33585799|t=2021. Safety and Efficacy of Convalescent Plasma in Elderly COVID-19 Patients: The RESCUE Trial.|pdf=|usr=026}}
+{{tp|p=33585798|t=2021. Viral Respiratory Infections: An Ounce of Prevention Is Worth a Pound of Cure.|pdf=|usr=026}}
+{{tp|p=33785634|t=2021. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.|pdf=|usr=026}}
+{{tp|p=33653892|t=2021. Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model.|pdf=|usr=026}}
+{{tp|p=33653891|t=2021. Development of Spike Receptor-Binding Domain Nanoparticles as a Vaccine Candidate against SARS-CoV-2 Infection in Ferrets.|pdf=|usr=026}}
+{{tp|p=33653888|t=2021. Genetically Engineered Live-Attenuated Middle East Respiratory Syndrome Coronavirus Viruses Confer Full Protection against Lethal Infection.|pdf=|usr=026}}
+{{tp|p=33653885|t=2021. The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19.|pdf=|usr=026}}
+{{tp|p=33563823|t=2021. Characterization of SARS-CoV-2 RNA, Antibodies, and Neutralizing Capacity in Milk Produced by Women with COVID-19.|pdf=|usr=026}}
+{{tp|p=33531392|t=2021. Reply to Marakasova and Baranova, "MMR Vaccine and COVID-19: Measles Protein Homology May Contribute to Cross-Reactivity or to Complement Activation Protection".|pdf=|usr=026}}
+{{tp|p=33531391|t=2021. MMR Vaccine and COVID-19: Measles Protein Homology May Contribute to Cross-Reactivity or to Complement Activation Protection.|pdf=|usr=026}}
+{{tp|p=33564221|t=2021. Structural modeling and analysis of the SARS-CoV-2 cell entry inhibitor camostat bound to the trypsin-like protease TMPRSS2.|pdf=|usr=026}}
+{{tp|p=33790352|t=2021. Computational drug repurposing study elucidating simultaneous inhibition of entry and replication of novel corona virus by Grazoprevir.|pdf=|usr=026}}
+{{tp|p=33790308|t=2021. Safety and efficacy of favipiravir versus hydroxychloroquine in management of COVID-19: A randomised controlled trial.|pdf=|usr=026}}
+{{tp|p=33785846|t=2021. Ivermectin reduces in vivo coronavirus infection in a mouse experimental model.|pdf=|usr=026}}
+{{tp|p=33767276|t=2021. Risk of QT prolongation through drug interactions between hydroxychloroquine and concomitant drugs prescribed in real world practice.|pdf=|usr=026}}
+{{tp|p=33762619|t=2021. Mining of high throughput screening database reveals AP-1 and autophagy pathways as potential targets for COVID-19 therapeutics.|pdf=|usr=026}}
+{{tp|p=33737631|t=2021. Lack of association of baseline 25-hydroxyvitamin D levels with disease severity and mortality in Indian patients hospitalized for COVID-19.|pdf=|usr=026}}
+{{tp|p=33737545|t=2021. Computational evidence for nitro derivatives of quinoline and quinoline N-oxide as low-cost alternative for the treatment of SARS-CoV-2 infection.|pdf=|usr=026}}
+{{tp|p=33737523|t=2021. Prioritizing antiviral drugs against SARS-CoV-2 by integrating viral complete genome sequences and drug chemical structures.|pdf=|usr=026}}
+{{tp|p=33723270|t=2021. The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2 in human lung tissue.|pdf=|usr=026}}
+{{tp|p=33707532|t=2021. Preclinical efficacy and safety analysis of gamma-irradiated inactivated SARS-CoV-2 vaccine candidates.|pdf=|usr=026}}
+{{tp|p=33692457|t=2021. Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma.|pdf=|usr=026}}
+{{tp|p=33692386|t=2021. Blockade of SARS-CoV-2 spike protein-mediated cell-cell fusion using COVID-19 convalescent plasma.|pdf=|usr=026}}
+{{tp|p=33692377|t=2021. Drug design and repurposing with DockThor-VS web server focusing on SARS-CoV-2 therapeutic targets and their non-synonym variants.|pdf=|usr=026}}
+{{tp|p=33564039|t=2021. Histone deacetylase inhibitors suppress ACE2 and ABO simultaneously, suggesting a preventive potential against COVID-19.|pdf=|usr=026}}
+{{tp|p=33558635|t=2021. Potent neutralization of clinical isolates of SARS-CoV-2 D614 and G614 variants by a monomeric, sub-nanomolar affinity nanobody.|pdf=|usr=026}}
+{{tp|p=33547334|t=2021. An in silico deep learning approach to multi-epitope vaccine design: a SARS-CoV-2 case study.|pdf=|usr=026}}
+{{tp|p=33542325|t=2021. DNA-launched RNA replicon vaccines induce potent anti-SARS-CoV-2 immune responses in mice.|pdf=|usr=026}}
+{{tp|p=33542252|t=2021. Sensitive mass spectrometric determination of kinin-kallikrein system peptides in light of COVID-19.|pdf=|usr=026}}
+{{tp|p=33637783|t=2021. Exploratory analysis of immunization records highlights decreased SARS-CoV-2 rates in individuals with recent non-COVID-19 vaccinations.|pdf=|usr=026}}
+{{tp|p=33627767|t=2021. Identification of candidate repurposable drugs to combat COVID-19 using a signature-based approach.|pdf=|usr=026}}
+{{tp|p=33619344|t=2021. In silico detection of SARS-CoV-2 specific B-cell epitopes and validation in ELISA for serological diagnosis of COVID-19.|pdf=|usr=026}}
+{{tp|p=33794459|t=2021. Virtual screening of plant-derived compounds against SARS-CoV-2 viral proteins using computational tools.|pdf=|usr=026}}
+{{tp|p=33578259|t=2021. Potential interactions between COVID-19 vaccines and antiepileptic drugs.|pdf=|usr=026}}
+{{tp|p=33677470|t=2021. Targeting glucose metabolism for treatment of COVID-19.|pdf=|usr=026}}
+{{tp|p=33790219|t=2021. Newly synthesized M(pro) inhibitors as potential oral anti-SARS-CoV-2 agents.|pdf=|usr=026}}
+{{tp|p=33658482|t=2021. Clinical evidence of an interferon-glucocorticoid therapeutic synergy in COVID-19.|pdf=|usr=026}}
+{{tp|p=33758167|t=2021. Identification of bis-benzylisoquinoline alkaloids as SARS-CoV-2 entry inhibitors from a library of natural products.|pdf=|usr=026}}
+{{tp|p=33654055|t=2021. Study on the promotion of lymphocytes in patients with COVID-19 by broad-spectrum chemokine receptor inhibitor vMIP-II and its Mechanism of signal transmission in vitro.|pdf=|usr=026}}
+{{tp|p=33542181|t=2021. Structural basis for the inhibition of the SARS-CoV-2 main protease by the anti-HCV drug narlaprevir.|pdf=|usr=026}}
+{{tp|p=33542177|t=2021. Evaluation of the immunomodulatory effects of anti-COVID-19 TCM formulae by multiple virus-related pathways.|pdf=|usr=026}}
+{{tp|p=33619243|t=2021. Therapeutic potential of C1632 by inhibition of SARS-CoV-2 replication and viral-induced inflammation through upregulating let-7.|pdf=|usr=026}}
+{{tp|p=33612824|t=2021. Efficacy and safety of systematic corticosteroids among severe COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials.|pdf=|usr=026}}
+{{tp|p=33531462|t=2021. Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need.|pdf=|usr=026}}
+{{tp|p=33568628|t=2021. Effect of human umbilical cord-derived mesenchymal stem cells on lung damage in severe COVID-19 patients: a randomized, double-blind, placebo-controlled phase 2 trial.|pdf=|usr=026}}
+{{tp|p=33724070|t=2021. Development of a High-Throughput Screening Assay to Identify Inhibitors of the SARS-CoV-2 Guanine-N7-Methyltransferase Using RapidFire Mass Spectrometry.|pdf=|usr=026}}
+{{tp|p=33786372|t=2021. Ultraefficiently Calming Cytokine Storm Using Ti3C2T x MXene.|pdf=|usr=026}}
+{{tp|p=33778374|t=2021. Compassionate Use of Rectal Ozone (O3) in Severe COVID-19 Pneumonia: a Case-Control Study.|pdf=|usr=026}}
+{{tp|p=33748676|t=2021. On BCG Vaccine Protection from COVID-19: A Review.|pdf=|usr=026}}
+{{tp|p=33644693|t=2021. Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment.|pdf=|usr=026}}
+{{tp|p=33623865|t=2021. The Evidence for High-Titer Convalescent Plasma in SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33558862|t=2021. Ex vivo assay to evaluate the efficacy of drugs targeting sphingolipids in preventing SARS-CoV-2 infection of nasal epithelial cells.|pdf=|usr=026}}
+{{tp|p=33688491|t=2021. Placenta-derived mesenchymal stem cells (P-MSCs) for COVID-19 pneumonia-a regenerative dogma.|pdf=|usr=026}}
+{{tp|p=33691145|t=2021. Broad-Spectrum Anti-coronavirus Vaccines and Therapeutics to Combat the Current COVID-19 Pandemic and Future Coronavirus Disease Outbreaks.|pdf=|usr=026}}
+{{tp|p=33601098|t=2021. Medical progress: Stem cells as a new therapeutic strategy for COVID-19.|pdf=|usr=026}}
+{{tp|p=33550140|t=2021. Structural insights into SARS-CoV-2 infection and therapeutics development.|pdf=|usr=026}}
+{{tp|p=33648582|t=2021. Stem cells and COVID-19: are the human amniotic cells a new hope for therapies against the SARS-CoV-2 virus?|pdf=|usr=026}}
+{{tp|p=33575962|t=2021. P2Y14 Receptor as a Target for Neutrophilia Attenuation in Severe COVID-19 Cases: From Hematopoietic Stem Cell Recruitment and Chemotaxis to Thrombo-inflammation.|pdf=|usr=026}}
+{{tp|p=33575961|t=2021. Results and Prospects of Using Activator of Hematopoietic Stem Cell Differentiation in Complex Therapy for Patients with COVID-19.|pdf=|usr=026}}
+{{tp|p=33586320|t=2021. Mesenchymal stem cell immunomodulation: In pursuit of controlling COVID-19 related cytokine storm.|pdf=|usr=026}}
+{{tp|p=33527780|t=2021. Mesenchymal stromal cell delivery via an ex vivo bioreactor preclinical test system attenuates clot formation for intravascular application.|pdf=|usr=026}}
+{{tp|p=33726854|t=2021. Direct and indirect evidence of efficacy and safety of rapid exercise tests for exertional desaturation in Covid-19: a rapid systematic review.|pdf=|usr=026}}
+{{tp|p=33765902|t=2021. Clinical effectiveness of drugs in hospitalized patients with COVID-19: a systematic review and meta-analysis.|pdf=|usr=026}}
+{{tp|p=33624533|t=2021. An overview of vaccine development for COVID-19.|pdf=|usr=026}}
+{{tp|p=33664866|t=2021. MERS-CoV and SARS-CoV-2 replication can be inhibited by targeting the interaction between the viral spike protein and the nucleocapsid protein.|pdf=|usr=026}}
+{{tp|p=33558079|t=2021. Pharmacokinetics and pharmacodynamics of hydroxychloroquine in hospitalized patients with COVID-19.|pdf=|usr=026}}
+{{tp|p=33579777|t=2021. Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19.|pdf=|usr=026}}
+{{tp|p=33662796|t=2021. Recombinant ADAMTS13 reduces abnormally up-regulated von Willebrand factor in plasma from patients with severe COVID-19.|pdf=|usr=026}}
+{{tp|p=33685103|t=2021. Covid-19-vaksiner gir okt risiko for anafylaksi.|pdf=|usr=026}}
+{{tp|p=33723507|t=2021. Use of ivermectin in the treatment of Covid-19: A pilot trial.|pdf=|usr=026}}
+{{tp|p=33733663|t=2021. COVID-19 vaccines for low- and middle-income countries.|pdf=|usr=026}}
+{{tp|p=33678561|t=2021. Convalescent blood plasma (CBP) donated by recovered COVID-19 patients - A comment.|pdf=|usr=026}}
+{{tp|p=33574010|t=2021. Convalescent plasma therapy for severe Covid-19 in patients with hematological malignancies.|pdf=|usr=026}}
+{{tp|p=33637467|t=2021. Two patients with rituximab associated low gammaglobulin levels and relapsed covid-19 infections treated with convalescent plasma.|pdf=|usr=026}}
+{{tp|p=33663928|t=2021. Facts and challenges on global deployment of vaccines for the immunotherapy of the evolving SARS Cov-2 variants: What a new year, with a fast spreading South African and the most fearful Brazilian variants, as the unwanted gifts, imposing enormous crises to surmount.|pdf=|usr=026}}
+{{tp|p=33610448|t=2021. Immunotherapy for COVID-19: Evolving treatment of viral infection and associated adverse immunological reactions.|pdf=|usr=026}}
+{{tp|p=33677086|t=2021. Constraints and challenges in convalescent plasma collection amidst the Covid 19 pandemic- strategies and recommendations to overcome these.|pdf=|usr=026}}
+{{tp|p=33675992|t=2021. Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency.|pdf=|usr=026}}
+{{tp|p=33604922|t=2021. High-throughput detection of antibodies targeting the SARS-CoV-2 Spike in longitudinal convalescent plasma samples.|pdf=|usr=026}}
+{{tp|p=33604884|t=2021. A longitudinal study of convalescent plasma (CCP) donors and correlation of ABO group, initial neutralizing antibodies (nAb), and body mass index (BMI) with nAb and anti-nucleocapsid (NP) SARS-CoV-2 antibody kinetics: Proposals for better quality of CCP collections.|pdf=|usr=026}}
+{{tp|p=33590906|t=2021. Factors driving availability of COVID-19 convalescent plasma: Insights from a demand, production, and supply model.|pdf=|usr=026}}
+{{tp|p=33559248|t=2021. Impact of serological and PCR testing requirements on the selection of COVID-19 convalescent plasma donors.|pdf=|usr=026}}
+{{tp|p=33616966|t=2021. Decrease in serum antibodies to SARS-CoV-2 in convalescent plasma donors over time.|pdf=|usr=026}}
+{{tp|p=33615484|t=2021. Longitudinal analysis of SARS-CoV-2 antibodies in 8000 U.S. first-time convalescent plasma donations.|pdf=|usr=026}}
+{{tp|p=33586160|t=2021. COVID-19 convalescent plasma: Interim recommendations from the AABB.|pdf=|usr=026}}
+{{tp|p=33554362|t=2021. Selecting COVID-19 convalescent plasma for neutralizing antibody potency using a high-capacity SARS-CoV-2 antibody assay.|pdf=|usr=026}}
+{{tp|p=33633933|t=2021. Association between vaccinations and clinical manifestations in children with COVID-19.|pdf=|usr=026}}
+{{tp|p=33610763|t=2021. Caution advised when considering "Exceptional" extended or single dose COVID-19 vaccination strategies.|pdf=|usr=026}}
+{{tp|p=33578045|t=2021. AZD1222 (Covishield) vaccination for COVID-19: Experiences, challenges, and solutions in Nepal.|pdf=|usr=026}}
+{{tp|p=33549822|t=2021. Reply to Alizazgar J. Dangers of the use of hydroxychloroquine and azithromycin combination in COVID-19 patients.|pdf=|usr=026}}
+{{tp|p=33535106|t=2021. Risk of Strongyloides Hyperinfection Syndrome when prescribing dexamethasone in severe COVID-19.|pdf=|usr=026}}
+{{tp|p=33558789|t=2021. Role of food nutrients and supplementation in fighting against viral infections and boosting immunity: A review.|pdf=|usr=026}}
+{{tp|p=33785249|t=2021. Therapeutic Potential of Metformin in COVID-19: Reasoning for Its Protective Role.|pdf=|usr=026}}
+{{tp|p=33541791|t=2021. Repurposing Antimalarials to Tackle the COVID-19 Pandemic: (Trends in Parasitology 37, 8-11; 2021).|pdf=|usr=026}}
+{{tp|p=33750432|t=2021. Evaluation of the safety and efficacy of XAV-19 in patients with COVID-19-induced moderate pneumonia: study protocol for a randomized, double-blinded, placebo-controlled phase 2 (2a and 2b) trial.|pdf=|usr=026}}
+{{tp|p=33573681|t=2021. Impact of intravenous lidocaine on clinical outcomes of patients with ARDS during COVID-19 pandemia (LidoCovid): A structured summary of a study protocol for a randomised controlled trial.|pdf=|usr=026}}
+{{tp|p=33779109|t=2021. The effect of the timing of dexamethasone administration in patients with COVID-19 pneumonia.|pdf=|usr=026}}
+{{tp|p=33679150|t=2021. Comparison of clinically approved molecules on SARS-CoV-2 drug target proteins: a molecular docking study.|pdf=|usr=026}}
+{{tp|p=33726487|t=2021. Antithrombin, COVID-19, and Fresh Frozen Plasma Treatment|pdf=|usr=026}}
+{{tp|p=33726482|t=2021. The Comparison of Lopinavir/Ritonavir Combination and Favipiravir In COVID-19 Treatment.|pdf=|usr=026}}
+{{tp|p=33646106|t=2021. Use of Hydroxychloroquine in Patients with COVID-19: A Retrospective Observational Study.|pdf=|usr=026}}
+{{tp|p=33676782|t=2021. Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment.|pdf=|usr=026}}
+{{tp|p=33707061|t=2021. A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine.|pdf=|usr=026}}
+{{tp|p=33558107|t=2021. General determination of causation between Covid-19 vaccines and possible adverse events.|pdf=|usr=026}}
+{{tp|p=33640142|t=2021. Biosecurity risks associated with vaccine platform technologies.|pdf=|usr=026}}
+{{tp|p=33744042|t=2021. Natural unblinding of BCG vaccination trials.|pdf=|usr=026}}
+{{tp|p=33771389|t=2021. mRNA vaccines manufacturing: Challenges and bottlenecks.|pdf=|usr=026}}
+{{tp|p=33731271|t=2021. Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse.|pdf=|usr=026}}
+{{tp|p=33525459|t=2021. Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies.|pdf=|usr=026}}
+{{tp|p=33567790|t=2021. Exploring the Effect of Probiotics, Prebiotics, and Postbiotics in Strengthening Immune Activity in the Elderly.|pdf=|usr=026}}
+{{tp|p=33562203|t=2021. HIV mRNA Vaccines-Progress and Future Paths.|pdf=|usr=026}}
+{{tp|p=33562141|t=2021. Localized and Systemic Immune Responses against SARS-CoV-2 Following Mucosal Immunization.|pdf=|usr=026}}
+{{tp|p=33546347|t=2021. COVID-19 Vaccination: From Interesting Agent to the Patient.|pdf=|usr=026}}
+{{tp|p=33672450|t=2021. Spike S2 Subunit: The Dark Horse in the Race for Prophylactic and Therapeutic Interventions against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33670630|t=2021. COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform.|pdf=|usr=026}}
+{{tp|p=33668613|t=2021. Therapeutic Antibodies for the Treatment of Respiratory Tract Infections-Current Overview and Perspectives.|pdf=|usr=026}}
+{{tp|p=33673048|t=2021. SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond.|pdf=|usr=026}}
+{{tp|p=33670249|t=2021. Construction and Immunogenicity Comparison of Three Virus-Like Particles Carrying Different Combinations of Structural Proteins of Avian Coronavirus Infectious Bronchitis Virus.|pdf=|usr=026}}
+{{tp|p=33746069|t=2021. In silico Nigellidine (N. sativa) bind to viral spike/active-sites of ACE1/2, AT1/2 to prevent COVID-19 induced vaso-tumult/vascular-damage/comorbidity.|pdf=|usr=026}}
+{{tp|p=33638539|t=2020. Is the production of a Covid-19 vaccine using transformed Pasteurella plausible?|pdf=|usr=026}}
+{{tp|p=33781287|t=2021. Precision therapeutic targets for COVID-19.|pdf=|usr=026}}
+{{tp|p=33639976|t=2021. Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice.|pdf=|usr=026}}
+{{tp|p=33714753|t=2021. Development of a SARS-CoV-2 nucleocapsid specific monoclonal antibody.|pdf=|usr=026}}
+{{tp|p=33571798|t=2021. Exploring the efficacy of naturally occurring biflavone based antioxidants towards the inhibition of the SARS-CoV-2 spike glycoprotein mediated membrane fusion.|pdf=|usr=026}}
+{{tp|p=33660566|t=2021. Host Defence RNases as Antiviral Agents against Enveloped Single Stranded RNA Viruses.|pdf=|usr=026}}
+{{tp|p=33631219|t=2021. Protection against COVID-19 in African population: Immunology, genetics, and malaria clues for therapeutic targets.|pdf=|usr=026}}
+{{tp|p=33778130|t=2021. Vaccines and drugs under clinical trials for prevention and treatment of COVID-19.|pdf=|usr=026}}
+{{tp|p=33778129|t=2021. Computationally approached inhibition potential of Tinospora cordifolia towards COVID-19 targets.|pdf=|usr=026}}
+{{tp|p=33758772|t=2021. A molecular docking study of SARS-CoV-2 main protease against phytochemicals of Boerhavia diffusa Linn. for novel COVID-19 drug discovery.|pdf=|usr=026}}
+{{tp|p=33748347|t=2021. Respiratory delivery of favipiravir-tocilizumab combination through mucoadhesive protein-lipidic nanovesicles: prospective therapeutics against COVID-19.|pdf=|usr=026}}
+{{tp|p=33532517|t=2021. In silico virtual screening-based study of nutraceuticals predicts the therapeutic potentials of folic acid and its derivatives against COVID-19.|pdf=|usr=026}}
+{{tp|p=33572467|t=2021. Brilacidin Demonstrates Inhibition of SARS-CoV-2 in Cell Culture.|pdf=|usr=026}}
+{{tp|p=33572452|t=2021. Synthetic Messenger RNA-Based Vaccines: from Scorn to Hype.|pdf=|usr=026}}
+{{tp|p=33567520|t=2021. The Key Role of Nucleic Acid Vaccines for One Health.|pdf=|usr=026}}
+{{tp|p=33546185|t=2021. Thapsigargin Is a Broad-Spectrum Inhibitor of Major Human Respiratory Viruses: Coronavirus, Respiratory Syncytial Virus and Influenza A Virus.|pdf=|usr=026}}
+{{tp|p=33673529|t=2021. Demystifying Excess Immune Response in COVID-19 to Reposition an Orphan Drug for Down-Regulation of NF-kappaB: A Systematic Review.|pdf=|usr=026}}
+{{tp|p=33672333|t=2021. Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro.|pdf=|usr=026}}
+{{tp|p=33670023|t=2021. Rational Design of a Pan-Coronavirus Vaccine Based on Conserved CTL Epitopes.|pdf=|usr=026}}
+{{tp|p=33672785|t=2021. Recent Hydroxychloroquine Use Is Not Significantly Associated with Positive PCR Results for SARS-CoV-2: A Nationwide Observational Study in South Korea.|pdf=|usr=026}}
+{{tp|p=33669550|t=2021. Viral Vectors for COVID-19 Vaccine Development.|pdf=|usr=026}}
+{{tp|p=33671334|t=2021. Targeting the Complement Serine Protease MASP-2 as a Therapeutic Strategy for Coronavirus Infections.|pdf=|usr=026}}
+{{tp|p=33669276|t=2021. Safety and Outcomes Associated with the Pharmacological Inhibition of the Kinin-Kallikrein System in Severe COVID-19.|pdf=|usr=026}}
+{{tp|p=33669264|t=2021. Honeysuckle Aqueous Extracts Induced let-7a Suppress EV71 Replication and Pathogenesis In Vitro and In Vivo and Is Predicted to Inhibit SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33672054|t=2021. Structure-Based Identification of Natural Products as SARS-CoV-2 M(pro) Antagonist from Echinacea angustifolia Using Computational Approaches.|pdf=|usr=026}}
+{{tp|p=33670363|t=2021. Berberine and Obatoclax Inhibit SARS-Cov-2 Replication in Primary Human Nasal Epithelial Cells In Vitro.|pdf=|usr=026}}
+{{tp|p=33786383|t=2021. Hydroxychloroquine-Induced cutaneous reaction in treatment of COVID-19.|pdf=|usr=026}}
+{{tp|p=33779831|t=2021. The advantages of drug treatment with statins in patients with SARS-CoV-2 infection.|pdf=|usr=026}}
+{{tp|p=33725201|t=2021. Profiles of current COVID-19 vaccines.|pdf=|usr=026}}
+{{tp|p=33721102|t=2021. Strong correlation between prevalence of severe vitamin D deficiency and population mortality rate from COVID-19 in Europe.|pdf=|usr=026}}
+{{tp|p=33643762|t=2021. Cordifolioside: potent inhibitor against M(pro) of SARS-CoV-2 and immunomodulatory through human TGF-beta and TNF-alpha.|pdf=|usr=026}}
+{{tp|p=33585152|t=2021. Screening of JAK-STAT modulators from the antiviral plants of Indian traditional system of medicine with the potential to inhibit 2019 novel coronavirus using network pharmacology.|pdf=|usr=026}}
+{{tp|p=33552835|t=2021. Mechanistic insight into anti-COVID-19 drugs: recent trends and advancements.|pdf=|usr=026}}
+{{tp|p=33560642|t=2021. Nebulized Nitroglycerin for Coronavirus Disease 2019-Associated Acute Respiratory Distress Syndrome: A Case Report.|pdf=|usr=026}}
+{{tp|p=33623818|t=2021. Rapidly Establishing a Hospital-Based Convalescent Plasma Collection Center With the Alyx Apheresis Collection Device.|pdf=|usr=026}}
+{{tp|p=33786375|t=2021. Potent Noncovalent Inhibitors of the Main Protease of SARS-CoV-2 from Molecular Sculpting of the Drug Perampanel Guided by Free Energy Perturbation Calculations.|pdf=|usr=026}}
+{{tp|p=33786374|t=2021. Potent SARS-CoV-2 Direct-Acting Antivirals Provide an Important Complement to COVID-19 Vaccines.|pdf=|usr=026}}
+{{tp|p=33527087|t=2021. A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice.|pdf=|usr=026}}
+{{tp|p=33527086|t=2021. Modeling the Binding Mechanism of Remdesivir, Favilavir, and Ribavirin to SARS-CoV-2 RNA-Dependent RNA Polymerase.|pdf=|usr=026}}
+{{tp|p=33527085|t=2021. De Novo Discovery of High-Affinity Peptide Binders for the SARS-CoV-2 Spike Protein.|pdf=|usr=026}}
+{{tp|p=33787221|t=2021. A Clinical-Stage Cysteine Protease Inhibitor blocks SARS-CoV-2 Infection of Human and Monkey Cells.|pdf=|usr=026}}
+{{tp|p=33787218|t=2021. Novel Compounds Targeting Neuropilin Receptor 1 with Potential To Interfere with SARS-CoV-2 Virus Entry.|pdf=|usr=026}}
+{{tp|p=33783182|t=2021. Inhibition of Human Coronaviruses by Antimalarial Peroxides.|pdf=|usr=026}}
+{{tp|p=33645977|t=2021. Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses.|pdf=|usr=026}}
+{{tp|p=33570381|t=2021. Challenges for Targeting SARS-CoV-2 Proteases as a Therapeutic Strategy for COVID-19.|pdf=|usr=026}}
+{{tp|p=33793189|t=2021. Nano-Enabled COVID-19 Vaccines: Meeting the Challenges of Durable Antibody Plus Cellular Immunity and Immune Escape.|pdf=|usr=026}}
+{{tp|p=33734675|t=2021. Membrane Nanoparticles Derived from ACE2-Rich Cells Block SARS-CoV-2 Infection.|pdf=|usr=026}}
+{{tp|p=33778286|t=2021. Ethyl Pyruvate as a Potential Defense Intervention against Cytokine Storm in COVID-19?|pdf=|usr=026}}
+{{tp|p=33778258|t=2021. Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine, and Pyronaridine: In Vitro Activity against SARS-CoV-2 and Potential Mechanisms.|pdf=|usr=026}}
+{{tp|p=33644594|t=2021. Novel Development of Predictive Feature Fingerprints to Identify Chemistry-Based Features for the Effective Drug Design of SARS-CoV-2 Target Antagonists and Inhibitors Using Machine Learning.|pdf=|usr=026}}
+{{tp|p=33615173|t=2021. Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial.|pdf=|usr=026}}
+{{tp|p=33583027|t=2021. Higher vs Lower Doses of Dexamethasone in Patients with COVID-19 and Severe Hypoxia (COVID STEROID 2) trial: Protocol for a secondary Bayesian analysis.|pdf=|usr=026}}
+{{tp|p=33533477|t=2021. Nitric oxide and COVID-19: Dose, timing and how to administer it might be crucial.|pdf=|usr=026}}
+{{tp|p=33583034|t=2021. Higher vs lower doses of dexamethasone in patients with COVID-19 and severe hypoxia (COVID STEROID 2) trial: Protocol and statistical analysis plan.|pdf=|usr=026}}
+{{tp|p=33525227|t=2020. Current Perspectives of convalescent plasma therapy in COVID-19.|pdf=|usr=026}}
+{{tp|p=33525212|t=2020. Efficacy and safety of sofosbuvir/ ledipasvir in treatment of patients with COVID-19; A randomized clinical trial.|pdf=|usr=026}}
+{{tp|p=33525254|t=2020. Treatment of COVID-19 in Pregnancy with Hydroxychloroquine and Azithromycin: a case report.|pdf=|usr=026}}
+{{tp|p=33582839|t=2021. Metformin use and risk of COVID-19 among patients with type II diabetes mellitus: an NHIS-COVID-19 database cohort study.|pdf=|usr=026}}
+{{tp|p=33818411|t=2021. Convalescent Plasma Therapy for COVID-19: Lessons from SARS-CoV, MERS-CoV, and H1N1 Infection.|pdf=|usr=026}}
+{{tp|p=33527327|t=2021. Acute disseminated encephalomyelitis after severe acute respiratory syndrome coronavirus 2 vaccination: a case report.|pdf=|usr=026}}
+{{tp|p=33527456|t=2021. It's time to change the recommendations on COVID-19 and human milk donations.|pdf=|usr=026}}
+{{tp|p=33723501|t=2021. Repurposing CFDA-approved drug carrimycin as an antiviral agent against human coronaviruses, including the currently pandemic SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33614402|t=2021. Corilagin inhibits SARS-CoV-2 replication by targeting viral RNA-dependent RNA polymerase.|pdf=|usr=026}}
+{{tp|p=33642607|t=2020. COVID-19 and Oral Surgery: A narrative review of preoperative mouth rinses.|pdf=|usr=026}}
+{{tp|p=33612960|t=2021. Vitamine D et Covid-19.|pdf=|usr=026}}
+{{tp|p=33561453|t=2021. Current and prospective computational approaches and challenges for developing COVID-19 vaccines.|pdf=|usr=026}}
+{{tp|p=33539853|t=2021. Microarray patches enable the development of skin-targeted vaccines against COVID-19.|pdf=|usr=026}}
+{{tp|p=33786537|t=2021. Adsorption of SARS-CoV-2 Spike Protein S1 at Oxide Surfaces Studied by High-Speed Atomic Force Microscopy.|pdf=|usr=026}}
+{{tp|p=33615316|t=2021. Adsorption of SARS-CoV-2 Spike Protein S1 at Oxide Surfaces Studied by High-Speed Atomic Force Microscopy.|pdf=|usr=026}}
+{{tp|p=33751020|t=2021. Association of Vitamin D Status with SARS-CoV-2 Infection or COVID-19 Severity: A Systematic Review and Meta-analysis.|pdf=|usr=026}}
+{{tp|p=33783468|t=2021. Perspective: Nutritional Strategies Targeting the Gut Microbiome to Mitigate COVID-19 Outcomes.|pdf=|usr=026}}
+{{tp|p=33747847|t=2021. Nephrotoxicity of Chloroquine and Hydroxychloroquine in COVID-19 Patients.|pdf=|usr=026}}
+{{tp|p=33786369|t=2021. Drug Repurposing of Itraconazole and Estradiol Benzoate against COVID-19 by Blocking SARS-CoV-2 Spike Protein-Mediated Membrane Fusion.|pdf=|usr=026}}
+{{tp|p=33786368|t=2021. Sulfoglycodendrimer Therapeutics for HIV-1 and SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33678621|t=2021. Screening potential FDA-approved inhibitors of the SARS-CoV-2 major protease 3CL(pro) through high-throughput virtual screening and molecular dynamics simulation.|pdf=|usr=026}}
+{{tp|p=33735836|t=2021. Convalescent plasma to treat COVID-19: clinical experience and efficacy.|pdf=|usr=026}}
+{{tp|p=33638944|t=2021. The efficiency and safety of high-dose vitamin C in patients with COVID-19: a retrospective cohort study.|pdf=|usr=026}}
+{{tp|p=33581688|t=2021. Chemical composition and pharmacological mechanism of ephedra-glycyrrhiza drug pair against coronavirus disease 2019 (COVID-19).|pdf=|usr=026}}
+{{tp|p=33811756|t=2021. Beneficial effect of Arbidol in the management of COVID-19 infection.|pdf=|usr=026}}
+{{tp|p=33788172|t=2021. Severe vitamin D deficiency is not related to SARS-CoV-2 infection but may increase mortality risk in hospitalized adults: a retrospective case-control study in an Arab Gulf country.|pdf=|usr=026}}
+{{tp|p=33532128|t=2021. Metabolic Healthy Obesity, Vitamin D Status, and Risk of COVID-19.|pdf=|usr=026}}
+{{tp|p=33532123|t=2021. Low level of Vitamin C and dysregulation of Vitamin C transporter might be involved in the severity of COVID-19 Infection.|pdf=|usr=026}}
+{{tp|p=33815870|t=2021. Mesenchymal Stem Cells for the Compassionate Treatment of Severe Acute Respiratory Distress Syndrome Due to COVID 19.|pdf=|usr=026}}
+{{tp|p=33815867|t=2021. SARS-CoV-2: the "Uncensored" Truth about Its Origin and Adipose-Derived Mesenchymal Stem Cells as New Potential Immune-Modulatory Weapon.|pdf=|usr=026}}
+{{tp|p=33738381|t=2021. Progress in the risk assessment of hydroxychloroquine in frail elderly people.|pdf=|usr=026}}
+{{tp|p=33659771|t=2021. Bacillus Calmette-Guerin (BCG): the adroit vaccine.|pdf=|usr=026}}
+{{tp|p=33643776|t=2021. Severe allergic reactions after COVID-19 vaccination with the Pfizer/BioNTech vaccine in Great Britain and USA: Position statement of the German Allergy Societies: Medical Association of German Allergologists (AeDA), German Society for Allergology and Clinical Immunology (DGAKI) and Society for Pediatric Allergology and Environmental Medicine (GPA).|pdf=|usr=026}}
+{{tp|p=33657648|t=2021. Allergenic components of the mRNA-1273 vaccine for COVID-19: possible involvement of polyethylene glycol and IgG-mediated complement activation.|pdf=|usr=026}}
+{{tp|p=33722299|t=2021. COVID-19 vaccine testing & administration guidance for allergists/immunologists from the Canadian Society of Allergy and Clinical Immunology (CSACI).|pdf=|usr=026}}
+{{tp|p=33546745|t=2021. Rapid clinical recovery of a SARS-CoV-2 infected common variable immunodeficiency patient following the infusion of COVID-19 convalescent plasma.|pdf=|usr=026}}
+{{tp|p=33791156|t=2021. Screening strategy of TMPRSS2 inhibitors by FRET-based enzymatic activity for TMPRSS2-based cancer and COVID-19 treatment.|pdf=|usr=026}}
+{{tp|p=33617817|t=2021. Meta-analysis of the Effect of Colchicine on Mortality and Mechanical Ventilation in COVID-19.|pdf=|usr=026}}
+{{tp|p=33815925|t=2021. Efficacy and safety of chloroquine and hydroxychloroquine for treatment of COVID-19 patients-a systematic review and meta-analysis of randomized controlled trials.|pdf=|usr=026}}
+{{tp|p=33748918|t=2021. Treating Acute Decompensated Heart Failure in Patients with COVID-19 Using Intravenous Nitroglycerin in 5% Glutathione.|pdf=|usr=026}}
+{{tp|p=33742196|t=2021. Vitamin D and COVID-19: Can it be protective?|pdf=|usr=026}}
+{{tp|p=33714645|t=2021. Emergency department administration of COVID-19 antibody therapies: Early experience.|pdf=|usr=026}}
+{{tp|p=33821938|t=2021. COVID-19 vaccines in tribal communities save lives, preserve culture.|pdf=|usr=026}}
+{{tp|p=33791780|t=2021. Children's hospital celebrates successful COVID-19 vaccine rollout.|pdf=|usr=026}}
+{{tp|p=33798480|t=2021. Anti-severe acute respiratory syndrome coronavirus 2 antibodies induced in breast milk after Pfizer-BioNTech/BNT162b2 vaccination.|pdf=|usr=026}}
+{{tp|p=33812808|t=2021. Cord blood antibodies following maternal coronavirus disease 2019 vaccination during pregnancy.|pdf=|usr=026}}
+{{tp|p=33540139|t=2021. Coronavirus disease 2019 vaccine in pregnant women: not so far! The importance of counseling and the need for evidence-based data.|pdf=|usr=026}}
+{{tp|p=33822639|t=2021. In Silico investigation of the viroporin E as a vaccine target against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33534047|t=2021. Methylprednisolone in adults hospitalized with COVID-19 pneumonia : An open-label randomized trial (GLUCOCOVID).|pdf=|usr=026}}
+{{tp|p=33638618|t=2021. Silver nanoparticles as a potential treatment against SARS-CoV-2: A review.|pdf=|usr=026}}
+{{tp|p=33558825|t=2021. COVID-19 vaccine-associated anaphylaxis: A statement of the World Allergy Organization Anaphylaxis Committee.|pdf=|usr=026}}
+{{tp|p=33747340|t=2021. May polyethylene glycol be the cause of anaphylaxis to mRNA COVID-19 vaccines?|pdf=|usr=026}}
+{{tp|p=33728315|t=2021. Human menstrual blood-derived stem cells as immunoregulatory therapy in COVID-19: A case report and review of the literature.|pdf=|usr=026}}
+{{tp|p=33708343|t=2021. Targeting mesenchymal stem cell therapy for severe pneumonia patients.|pdf=|usr=026}}
+{{tp|p=33816150|t=2021. Are nucleotide inhibitors, already used for treating hepatitis C virus infection, a potential option for the treatment of COVID-19 compared with standard of care? A literature review.|pdf=|usr=026}}
+{{tp|p=33816149|t=2021. Bottom-up analysis of emergent properties of N-acetylcysteine as an adjuvant therapy for COVID-19.|pdf=|usr=026}}
+{{tp|p=33585175|t=2021. Emerging therapeutics in the management of COVID-19.|pdf=|usr=026}}
+{{tp|p=33691913|t=2021. Efficacy and safety of COVID-19 vaccines: a systematic review.|pdf=|usr=026}}
+{{tp|p=33606519|t=2021. Simultaneous Inhibition of SARS-CoV-2 Entry Pathways by Cyclosporine.|pdf=|usr=026}}
+{{tp|p=33738063|t=2021. Design and Structure-Activity Relationship of a Potent Furin Inhibitor Derived from Influenza Hemagglutinin.|pdf=|usr=026}}
+{{tp|p=33615193|t=2021. Glycosylation of SARS-CoV-2 Steers Evolutionary Outcomes in the Postvaccination Phase.|pdf=|usr=026}}
+{{tp|p=33615192|t=2021. Docking Prediction of Levodopa in the Receptor Binding Domain of Spike Protein of SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33615189|t=2021. Identification of Novel MicroRNAs as Promising Therapeutics for SARS-CoV-2 by Regulating the EGFR-ADAM17 Axis: An In Silico Analysis.|pdf=|usr=026}}
+{{tp|p=33792500|t=2021. Allergic reactions to COVID-19 vaccines: statement of the Belgian Society for Allergy and Clinical Immunology (BelSACI).|pdf=|usr=026}}
+{{tp|p=33547771|t=2021. Allergic Reactions to COVID-19 Vaccines: An Allergist's Perspective.|pdf=|usr=026}}
+{{tp|p=33779985|t=2021. The potential neurological effect of the COVID-19 vaccines: A review.|pdf=|usr=026}}
+{{tp|p=33710026|t=2021. Tenofovir-based PrEP for COVID-19: an untapped opportunity?|pdf=|usr=026}}
+{{tp|p=33619997|t=2021. Darunavir/Cobicistat Is Associated with Negative Outcomes in HIV-Negative Patients with Severe COVID-19 Pneumonia.|pdf=|usr=026}}
+{{tp|p=33750742|t=2021. New SARS-CoV-2 Variants Challenge Vaccines Protection.|pdf=|usr=026}}
+{{tp|p=33787294|t=2021. Reply to "Unilateral Axillary Lymphadenopathy After Coronavirus Disease (COVID-19) Vaccination".|pdf=|usr=026}}
+{{tp|p=33617289|t=2021. Unilateral Axillary Lymphadenopathy After Coronavirus Disease (COVID-19) Vaccination.|pdf=|usr=026}}
+{{tp|p=33646823|t=2021. COVID-19 Vaccination-Related Uptake on FDG PET/CT: An Emerging Dilemma and Suggestions for Management.|pdf=|usr=026}}
+{{tp|p=33543649|t=2021. Management of Unilateral Axillary Lymphadenopathy Detected on Breast MRI in the Era of Coronavirus Disease (COVID-19) Vaccination.|pdf=|usr=026}}
+{{tp|p=33624520|t=2021. Coronavirus Disease (COVID-19) Vaccination Associated Axillary Adenopathy: Imaging Findings and Follow-Up Recommendations in 23 Women.|pdf=|usr=026}}
+{{tp|p=33617288|t=2021. Mitigating the Impact of Coronavirus Disease (COVID-19) Vaccinations on Patients Undergoing Breast Imaging Examinations: A Pragmatic Approach.|pdf=|usr=026}}
+{{tp|p=33528947|t=2021. BCG immunization and COVID-19 disease association.|pdf=|usr=026}}
+{{tp|p=33528938|t=2021. Inhaled corticosteroids may have a protective effect against coronavirus infection.|pdf=|usr=026}}
+{{tp|p=33811364|t=2021. Vaccines and Allergic reactions: The past, the current COVID-19 pandemic, and future perspectives.|pdf=|usr=026}}
+{{tp|p=33811358|t=2021. Management of anaphylaxis due to COVID-19 vaccines in the elderly.|pdf=|usr=026}}
+{{tp|p=33811344|t=2021. Skin tests in urticaria/angioedema and flushing to Pfizer-BioNTech SARS-CoV-2 vaccine: Limits of intradermal testing.|pdf=|usr=026}}
+{{tp|p=33609346|t=2021. Prakriti Analysis of COVID 19 Patients: An Observational Study.|pdf=|usr=026}}
+{{tp|p=33683189|t=2021. Add-On Chinese Medicine for Coronavirus Disease 2019 (ACCORD): A Retrospective Cohort Study of Hospital Registries.|pdf=|usr=026}}
+{{tp|p=33642127|t=2021. Neuroleptic malignant syndrome following COVID-19 vaccination.|pdf=|usr=026}}
+{{tp|p=33784482|t=2021. A Recombinant Fragment of Human Surfactant Protein D Binds Spike Protein and Inhibits Infectivity and Replication of SARS-CoV-2 in Clinical Samples.|pdf=|usr=026}}
+{{tp|p=33770450|t=2021. COVID-19 and Coagulopathy.|pdf=|usr=026}}
+{{tp|p=33759735|t=2021. What Are COVID-19 Vaccines?|pdf=|usr=026}}
+{{tp|p=33590992|t=2021. "Remdesivir-Associated Pancreatitis".|pdf=|usr=026}}
+{{tp|p=33564823|t=2021. Biases in evaluating the safety and effectiveness of drugs for covid-19: designing real-world evidence studies.|pdf=|usr=026}}
+{{tp|p=33599721|t=2021. Impact of hydroxychloroquine on disease progression and ICU admissions in patients with SARS-CoV-2 infection.|pdf=|usr=026}}
+{{tp|p=33617629|t=2021. Acute and severe ribavirin-associated hyperuricemia and acute kidney injury: An underrecognized adverse effect.|pdf=|usr=026}}
+{{tp|p=33606296|t=2021. Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination.|pdf=|usr=026}}
+{{tp|p=33580970|t=2021. Familial thrombocytopenia flare-up following the first dose of mRNA-1273 Covid-19 vaccine.|pdf=|usr=026}}
+{{tp|p=33476455|t=2021. Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine.|pdf=|usr=026}}
+{{tp|p=33705721|t=2021. Bacillus Calmette-Guerin Vaccine and Nonspecific Immunity.|pdf=|usr=026}}
+{{tp|p=33667433|t=2021. Association of Pre-Admission Statin Use With Reduced In-Hospital Mortality in COVID-19.|pdf=|usr=026}}
+{{tp|p=33545113|t=2021. Inclusion of pregnant individuals among priority populations for coronavirus disease 2019 vaccination for all 50 states in the United States.|pdf=|usr=026}}
+{{tp|p=33539825|t=2021. Professionally responsible coronavirus disease 2019 vaccination counseling of obstetrical and gynecologic patients.|pdf=|usr=026}}
+{{tp|p=33529575|t=2021. The coronavirus disease 2019 vaccine in pregnancy: risks, benefits, and recommendations.|pdf=|usr=026}}
+{{tp|p=33775692|t=2021. Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study.|pdf=|usr=026}}
+{{tp|p=33727113|t=2021. Prioritization of pregnant individuals in state plans for coronavirus disease 2019 vaccination.|pdf=|usr=026}}
+{{tp|p=33621715|t=2021. Reply: Coronavirus disease 2019 vaccines in pregnancy.|pdf=|usr=026}}
+{{tp|p=33621714|t=2021. Coronavirus disease 2019 vaccines in pregnancy.|pdf=|usr=026}}
+{{tp|p=33540140|t=2021. Reply to: Coronavirus disease 2019 vaccine in pregnant women: not so far! The importance of counseling and the need for evidence-based data.|pdf=|usr=026}}
+{{tp|p=33771762|t=2021. Pregnant women's perspectives on severe acute respiratory syndrome coronavirus 2 vaccine.|pdf=|usr=026}}
+{{tp|p=33561380|t=2021. Carrageenan-containing over-the-counter nasal and oral sprays inhibit SARS-CoV-2 infection of airway epithelial cultures.|pdf=|usr=026}}
+{{tp|p=33632650|t=2021. The Benefits of Vaccinating With the First Available COVID-19 Coronavirus Vaccine.|pdf=|usr=026}}
+{{tp|p=33641268|t=2021. Allergic reactions including anaphylaxis after receipt of the first dose of Moderna COVID-19 vaccine - United States, December 21, 2020-January 10, 2021.|pdf=|usr=026}}
+{{tp|p=33641264|t=2021. Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine - United States, December 14-23, 2020.|pdf=|usr=026}}
+{{tp|p=33555140|t=2021. The advisory Committee on Immunization practices' updated interim recommendation for allocation of COVID-19 vaccine-United states, December 2020.|pdf=|usr=026}}
+{{tp|p=33720844|t=2021. Dexamethasone and COVID-19: Strategies in Low- and Middle-Income Countries to Tackle Steroid-Related Strongyloides Hyperinfection.|pdf=|usr=026}}
+{{tp|p=33774261|t=2021. COVID-19 vaccines: A race against time.|pdf=|usr=026}}
+{{tp|p=33771754|t=2021. Even vaccinated against COVID-19, we must continue to wear a mask.|pdf=|usr=026}}
+{{tp|p=33608752|t=2021. Screening and evaluation of anti-SARS-CoV-2 components from Ephedra sinica by ACE2/CMC-HPLC-IT-TOF-MS approach.|pdf=|usr=026}}
+{{tp|p=33612558|t=2021. Optimization of Analytical Procedure for In-hospital Rapid Quantification of Serum Level of Favipiravir in the Pharmacological Treatment of COVID-19.|pdf=|usr=026}}
+{{tp|p=33606889|t=2021. Re(I) Tricarbonyl Complexes as Coordinate Covalent Inhibitors for the SARS-CoV-2 Main Cysteine Protease.|pdf=|usr=026}}
+{{tp|p=33655614|t=2021. Targeting the Main Protease of SARS-CoV-2: From the Establishment of High Throughput Screening to the Design of Tailored Inhibitors.|pdf=|usr=026}}
+{{tp|p=33561300|t=2021. Aptamer Blocking Strategy Inhibits SARS-CoV-2 Virus Infection.|pdf=|usr=026}}
+{{tp|p=33775077|t=2021. Chloroquine and hydroxychloroquine - safety profile of potential COVID-19 drugs from the rheumatologist's perspective.|pdf=|usr=026}}
+{{tp|p=33781933|t=2021. Misdiagnosis of systemic allergic reactions to mRNA COVID-19 vaccines.|pdf=|usr=026}}
+{{tp|p=33775902|t=2021. Polyethylene glycol and polysorbate skin testing in the evaluation of coronavirus disease 2019 vaccine reactions: Early report.|pdf=|usr=026}}
+{{tp|p=33550776|t=2021. Review of COVID-19 Vaccines and Their Evidence in Older Adults.|pdf=|usr=026}}
+{{tp|p=33769829|t=2021. COVID-19 Vaccine: Practical Clinical Considerations.|pdf=|usr=026}}
+{{tp|p=33721523|t=2021. Correction: Remdesivir for Adults With COVID-19.|pdf=|usr=026}}
+{{tp|p=33560863|t=2021. Major Update: Remdesivir for Adults With COVID-19 : A Living Systematic Review and Meta-analysis for the American College of Physicians Practice Points.|pdf=|usr=026}}
+{{tp|p=33560862|t=2021. Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 2).|pdf=|usr=026}}
+{{tp|p=33646837|t=2021. Risk Compensation and COVID-19 Vaccines.|pdf=|usr=026}}
+{{tp|p=33721540|t=2021. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19.|pdf=|usr=026}}
+{{tp|p=33721539|t=2021. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19.|pdf=|usr=026}}
+{{tp|p=33721533|t=2021. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19.|pdf=|usr=026}}
+{{tp|p=33617726|t=2021. Web Exclusive. Annals On Call - Pregnancy, Lactation, and the COVID-19 Vaccines.|pdf=|usr=026}}
+{{tp|p=33819057|t=2021. Administration of a Second Dose of the Moderna COVID-19 Vaccine After an Immediate Hypersensitivity Reaction With the First Dose: Two Case Reports.|pdf=|usr=026}}
+{{tp|p=33620016|t=2021. Effect of a genetically engineered interferon-alpha versus traditional interferon-alpha in the treatment of moderate-to-severe COVID-19: a randomised clinical trial.|pdf=|usr=026}}
+{{tp|p=33815783|t=2021. Oxford-AstraZeneca COVID-19 vaccine (AZD1222) is ideal for resource-constrained low- and middle-income countries.|pdf=|usr=026}}
+{{tp|p=33585031|t=2021. "Tocilizumab-an option for patients with COVID-19 associated cytokine release syndrome: A single center experience", a retrospective study-original article.|pdf=|usr=026}}
+{{tp|p=33552506|t=2021. SARS-CoV-2 vaccine candidates: A beginning of the end of COVID-19 pandemic- Editorial.|pdf=|usr=026}}
+{{tp|p=33794291|t=2021. Estrogen and COVID-19: friend or foe?|pdf=|usr=026}}
+{{tp|p=33691446|t=2021. The pharmacological mechanism of Huashi Baidu Formula for the treatment of COVID-19 by combined network pharmacology and molecular docking.|pdf=|usr=026}}
+{{tp|p=33762264|t=2021. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort.|pdf=|usr=026}}
+{{tp|p=33563595|t=2021. EULAR December 2020 View points on SARS-CoV-2 vaccination in patients with RMDs.|pdf=|usr=026}}
+{{tp|p=33547062|t=2021. EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19.|pdf=|usr=026}}
+{{tp|p=33589438|t=2021. Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider.|pdf=|usr=026}}
+{{tp|p=33807320|t=2021. Clinical Efficacy of Hydroxychloroquine in Patients with COVID-19: Findings from an Observational Comparative Study in Saudi Arabia.|pdf=|usr=026}}
+{{tp|p=33809983|t=2021. Comparative Investigation of Composition, Antifungal, and Anti-Inflammatory Effects of the Essential Oil from Three Industrial Hemp Varieties from Italian Cultivation.|pdf=|usr=026}}
+{{tp|p=33558301|t=2021. Remdesivir for COVID-19: Why Not Dose Higher?|pdf=|usr=026}}
+{{tp|p=33558300|t=2021. Considering Personalized Interferon Beta Therapy for COVID-19.|pdf=|usr=026}}
+{{tp|p=33558299|t=2021. AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19.|pdf=|usr=026}}
+{{tp|p=33558296|t=2021. Plitidepsin: a Repurposed Drug for the Treatment of COVID-19.|pdf=|usr=026}}
+{{tp|p=33526482|t=2021. Kinetic Characterization and Inhibitor Screening for the Proteases Leading to Identification of Drugs against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33649117|t=2021. The anti-influenza virus drug favipiravir has little effect on replication of SARS-CoV-2 in cultured cells.|pdf=|usr=026}}
+{{tp|p=33649113|t=2021. Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33593840|t=2021. Anaphylaxis Due to Remdesivir.|pdf=|usr=026}}
+{{tp|p=33578849|t=2021. Potential Role of Antioxidant and Anti-Inflammatory Therapies to Prevent Severe SARS-Cov-2 Complications.|pdf=|usr=026}}
+{{tp|p=33535459|t=2021. Native High-Density Lipoproteins (HDL) with Higher Paraoxonase Exerts a Potent Antiviral Effect against SARS-CoV-2 (COVID-19), While Glycated HDL Lost the Antiviral Activity.|pdf=|usr=026}}
+{{tp|p=33713730|t=2021. Combined in silico and in vitro approaches identified the antipsychotic drug lurasidone and the antiviral drug elbasvir as SARS-CoV2 and HCoV-OC43 inhibitors.|pdf=|usr=026}}
+{{tp|p=33813272|t=2021. ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model.|pdf=|usr=026}}
+{{tp|p=33808612|t=2021. Changes in 25-(OH) Vitamin D Levels during the SARS-CoV-2 Outbreak: Lockdown-Related Effects and First-to-Second Wave Difference-An Observational Study from Northern Italy.|pdf=|usr=026}}
+{{tp|p=33799618|t=2021. Lymphadenopathy after BNT162b2 Covid-19 Vaccine: Preliminary Ultrasound Findings.|pdf=|usr=026}}
+{{tp|p=33801808|t=2021. Determination of the Concentration of IgG against the Spike Receptor-Binding Domain That Predicts the Viral Neutralizing Activity of Convalescent Plasma and Serum against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33800947|t=2021. Targeting MMP-Regulation of Inflammation to Increase Metabolic Tolerance to COVID-19 Pathologies: A Hypothesis.|pdf=|usr=026}}
+{{tp|p=33810129|t=2021. Antiviral Cyanometabolites-A Review.|pdf=|usr=026}}
+{{tp|p=33810011|t=2021. Deep Learning for Novel Antimicrobial Peptide Design.|pdf=|usr=026}}
+{{tp|p=33808721|t=2021. Comprehensive Virtual Screening of the Antiviral Potentialities of Marine Polycyclic Guanidine Alkaloids against SARS-CoV-2 (COVID-19).|pdf=|usr=026}}
+{{tp|p=33709491|t=2021. Synthetic Homogeneous Glycoforms of the SARS-CoV-2 Spike Receptor-Binding Domain Reveals Different Binding Profiles of Monoclonal Antibodies.|pdf=|usr=026}}
+{{tp|p=33684258|t=2021. Neutralizing Aptamers Block S/RBD-ACE2 Interactions and Prevent Host Cell Infection.|pdf=|usr=026}}
+{{tp|p=33683787|t=2021. A SARS-CoV-2 Spike Binding DNA Aptamer that Inhibits Pseudovirus Infection by an RBD-Independent Mechanism.|pdf=|usr=026}}
+{{tp|p=33735603|t=2021. A Role for Steroids in COVID-19-associated Pneumonitis at Six-Week Follow-Up?|pdf=|usr=026}}
+{{tp|p=33735602|t=2021. Reply: A Role for Steroids in COVID-19-associated Pneumonitis at Six-Week Follow-Up?|pdf=|usr=026}}
+{{tp|p=33721541|t=2021. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19.|pdf=|usr=026}}
+{{tp|p=33646836|t=2021. In high-risk adults, the Moderna vaccine had 94% efficacy against COVID-19 >/=14 d after the 2nd dose.|pdf=|usr=026}}
+{{tp|p=33646835|t=2021. In adults, the Oxford/AstraZeneca vaccine had 70% efficacy against COVID-19 >14 d after the 2nd dose.|pdf=|usr=026}}
+{{tp|p=33554941|t=2020. COVID-19 reminds us: community vitamin D deficiency.|pdf=|usr=026}}
+{{tp|p=33710649|t=2021. ANA Investigates: Neurological Complications of COVID-19 Vaccines.|pdf=|usr=026}}
+{{tp|p=33657863|t=2021. Mechanisms and Potential Roles of Glucose-Lowering Agents in COVID-19: A Review.|pdf=|usr=026}}
+{{tp|p=33757968|t=2021. Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases.|pdf=|usr=026}}
+{{tp|p=33741555|t=2021. Safety ofthefirstdose ofmRNA SARS-CoV-2vaccines inpatients with rheumatic and musculoskeletal diseases.|pdf=|usr=026}}
+{{tp|p=33607929|t=2021. N-Acetylcysteine and Hydrogen Sulfide in Coronavirus Disease 2019.|pdf=|usr=026}}
+{{tp|p=33704086|t=2020. The protease inhibitor lopinavir, boosted with ritonavir, as treatment for COVID-19: a rapid review.|pdf=|usr=026}}
+{{tp|p=33568494|t=2021. SARS-CoV-2 genome and antibodies in breastmilk: a systematic review and meta-analysis.|pdf=|usr=026}}
+{{tp|p=33740339|t=2021. No association between vitamin D status and COVID-19 infection in Sao Paulo, Brazil.|pdf=|usr=026}}
+{{tp|p=33636983|t=2021. Infliximab and Intravenous Gammaglobulin in Hospitalized Severe COVID-19 Patients in Intensive Care Unit.|pdf=|usr=026}}
+{{tp|p=33770443|t=2021. Nutraceutical management of metabolic syndrome as a palliative and a therapeutic to coronavirus disease (COVID) crisis.|pdf=|usr=026}}
+{{tp|p=33779073|t=2021. Prophylaxis of COVID-19 with Hydroxychloroquine and Chloroquine.|pdf=|usr=026}}
+{{tp|p=33728796|t=2021. American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1.|pdf=|usr=026}}
+{{tp|p=33645342|t=2021. Virus-associated ribozymes and nano carriers against COVID-19.|pdf=|usr=026}}
+{{tp|p=33786833|t=2021. SARS-CoV-2 (COVID-19) vaccination in dermatology patients on immunomodulatory and biologic agents: Recommendations from the Australasian Medical Dermatology Group.|pdf=|usr=026}}
+{{tp|p=33626309|t=2021. A clinical conundrum: clozapine and COVID-19.|pdf=|usr=026}}
+{{tp|p=33711361|t=2021. Mesenchymal stem cells: Biological characteristics and application in disease therapy.|pdf=|usr=026}}
+{{tp|p=33721722|t=2021. Wide-range direct detection of 25-hydroxyvitamin D3 using polyethylene-glycol-free gold nanorod based on LSPR aptasensor.|pdf=|usr=026}}
+{{tp|p=33797130|t=2021. Discovery of potent Covid-19 main protease inhibitors using integrated drug-repurposing strategy.|pdf=|usr=026}}
+{{tp|p=33687925|t=2021. Covid-19: Booster dose will be needed in autumn to avoid winter surge, says government adviser.|pdf=|usr=026}}
+{{tp|p=33664083|t=2021. Vitamin D and covid-19.|pdf=|usr=026}}
+{{tp|p=33658188|t=2021. Covid-19: Schedule breast screening before vaccine or 4 to 6 weeks after to avoid false positives, says guidance.|pdf=|usr=026}}
+{{tp|p=33757984|t=2021. Covid-19: variants and vaccination.|pdf=|usr=026}}
+{{tp|p=33757958|t=2021. Covid-19: Officials query data from AstraZeneca's US vaccine trial.|pdf=|usr=026}}
+{{tp|p=33753451|t=2021. Covid-19: AstraZeneca vaccine prevents 79% of symptomatic disease and 100% of severe disease, US study finds.|pdf=|usr=026}}
+{{tp|p=33653737|t=2021. Covid-19: Single dose of Pfizer and Oxford vaccines cuts risk of hospital admission by 80% in over 80s, data suggest.|pdf=|usr=026}}
+{{tp|p=33653708|t=2021. Covid-19: Where are we on vaccines and variants?|pdf=|usr=026}}
+{{tp|p=33741638|t=2021. Covid-19: AstraZeneca vaccine is not linked to increased risk of blood clots, finds European Medicine Agency.|pdf=|usr=026}}
+{{tp|p=33741559|t=2021. Covid-19: What do we know about Sputnik V and other Russian vaccines?|pdf=|usr=026}}
+{{tp|p=33711336|t=2021. Emetine suppresses SARS-CoV-2 replication by inhibiting interaction of viral mRNA with eIF4E.|pdf=|usr=026}}
+{{tp|p=33549572|t=2021. Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir.|pdf=|usr=026}}
+{{tp|p=33714660|t=2021. Influence of Cytokine Release Syndrome in Severe COVID-19 Patients Treated With Tocilizumab Over the Quantiferon TB Gold Plus Results.|pdf=|usr=026}}
+{{tp|p=33527308|t=2021. DPP4 Inhibitors and COVID-19-Holy Grail or Another Dead End?|pdf=|usr=026}}
+{{tp|p=33546870|t=2021. Immunoinformatics Approach for the Identification and Characterization of T Cell and B Cell Epitopes towards the Peptide-Based Vaccine against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33785208|t=2021. Probiotics in Prevention and Treatment of COVID-19: Current Perspective and Future Prospects.|pdf=|usr=026}}
+{{tp|p=33589286|t=2021. Bioinformatics Analysis for Screening of Therapeutic Drugs in COVID-19.|pdf=|usr=026}}
+{{tp|p=33747291|t=2021. It is time to consider an anti-inflammatory therapy based on the pathophysiology of COVID-19 infection during the right time window?|pdf=|usr=026}}
+{{tp|p=33745067|t=2021. The emerging role of probiotics as a mitigation strategy against coronavirus disease 2019 (COVID-19).|pdf=|usr=026}}
+{{tp|p=33656063|t=2021. BRAZILIAN IBD STUDY GROUP POSITION STATEMENT ON SARS-COV2 VACCINATION.|pdf=|usr=026}}
+{{tp|p=33787036|t=2021. Nutritional practice in critically ill COVID-19 patients: A multicenter ambidirectional cohort study in Wuhan and Jingzhou.|pdf=|usr=026}}
+{{tp|p=33664546|t=2021. COVID-19 vaccines - are we there yet?|pdf=|usr=026}}
+{{tp|p=33664542|t=2021. Evolving evidence for immunosuppressants in COVID-19.|pdf=|usr=026}}
+{{tp|p=33629195|t=2021. Does remote ischaemic conditioning reduce inflammation? A focus on innate immunity and cytokine response.|pdf=|usr=026}}
+{{tp|p=33782651|t=2021. Perspectives on plant flavonoid quercetin-based drugs for novel SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33527080|t=2021. Virtual screening of phytochemical compounds as potential inhibitors against SARS-CoV-2 infection.|pdf=|usr=026}}
+{{tp|p=33526326|t=2021. The protective effect of rheumatic disease agents in COVID-19.|pdf=|usr=026}}
+{{tp|p=33723524|t=2021. Virus-inspired surface-nanoengineered antimicrobial liposome: A potential system to simultaneously achieve high activity and selectivity.|pdf=|usr=026}}
+{{tp|p=33527003|t=2021. Molecular dynamics analysis of phytochemicals from Ageratina adenophora against COVID-19 main protease (M(pro)) and human angiotensin-converting enzyme 2 (ACE2).|pdf=|usr=026}}
+{{tp|p=33520034|t=2021. Therapeutic potential of medicinal plants against COVID-19: The role of antiviral medicinal metabolites.|pdf=|usr=026}}
+{{tp|p=33817352|t=2021. Repurposing of approved drugs with potential to interact with SARS-CoV-2 receptor.|pdf=|usr=026}}
+{{tp|p=33681482|t=2021. In silico investigation of potential inhibitors to main protease and spike protein of SARS-CoV-2 in propolis.|pdf=|usr=026}}
+{{tp|p=33756342|t=2021. A tissue- and gender-specific regulation of the SARS-CoV-2 receptor ACE2 by p53 in pigs.|pdf=|usr=026}}
+{{tp|p=33571909|t=2021. 5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro.|pdf=|usr=026}}
+{{tp|p=33588235|t=2021. EGCG, a green tea polyphenol, inhibits human coronavirus replication in vitro.|pdf=|usr=026}}
+{{tp|p=33722535|t=2021. Dipeptidyl peptidase 4 inhibitors: Applications in innate immunity?|pdf=|usr=026}}
+{{tp|p=33628506|t=2021. A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild to Moderate COVID-19 Infections.|pdf=|usr=026}}
+{{tp|p=33731300|t=2021. Genetic modification to design a stable yeast-expressed recombinant SARS-CoV-2 receptor binding domain as a COVID-19 vaccine candidate.|pdf=|usr=026}}
+{{tp|p=33552630|t=2021. Peptides-based vaccine against SARS-nCoV-2 antigenic fragmented synthetic epitopes recognized by T cell and beta-cell initiation of specific antibodies to fight the infection.|pdf=|usr=026}}
+{{tp|p=33532594|t=2021. IDentif.AI: Rapidly optimizing combination therapy design against severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) with digital drug development.|pdf=|usr=026}}
+{{tp|p=33795932|t=2021. The Relevance of Bioinformatics Applications in the Discovery of Vaccine Candidates and Potential Drugs for COVID-19 Treatment.|pdf=|usr=026}}
+{{tp|p=33693506|t=2021. COVID-19: disease pathways and gene expression changes predict methylprednisolone can improve outcome in severe cases.|pdf=|usr=026}}
+{{tp|p=33630276|t=2021. The Role of Diet and Supplementation of Natural Products in COVID-19 Prevention.|pdf=|usr=026}}
+{{tp|p=33574654|t=2021. Convalescent Plasma for the Treatment of Severe COVID-19.|pdf=|usr=026}}
+{{tp|p=33736953|t=2021. Phytochemicals against SARS-CoV as potential drug leads.|pdf=|usr=026}}
+{{tp|p=33727051|t=2021. Development of multi-epitope peptide-based vaccines against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33727050|t=2021. A brief review on potential application of mesenchymal stem cell and secretome in combating mortality and morbidity in COVID-19 patients.|pdf=|usr=026}}
+{{tp|p=33640332|t=2021. Exploring algae and cyanobacteria as a promising natural source of antiviral drug against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33608241|t=2021. Lopinavir/ritonavir: Repurposing an old drug for HIV infection in COVID-19 treatment.|pdf=|usr=026}}
+{{tp|p=33589377|t=2021. Neutralizing monoclonal antibodies for COVID-19 treatment and prevention.|pdf=|usr=026}}
+{{tp|p=33542545|t=2021. COVID-19, adrenal gland, glucocorticoids, and adrenal insufficiency.|pdf=|usr=026}}
+{{tp|p=33761591|t=2021. Research progress of traditional Chinese medicine against COVID-19.|pdf=|usr=026}}
+{{tp|p=33561649|t=2021. Repurposing potential of Ayurvedic medicinal plants derived active principles against SARS-CoV-2 associated target proteins revealed by molecular docking, molecular dynamics and MM-PBSA studies.|pdf=|usr=026}}
+{{tp|p=33556871|t=2021. An update review of emerging small-molecule therapeutic options for COVID-19.|pdf=|usr=026}}
+{{tp|p=33550049|t=2021. Targets and strategies for vaccine development against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33529945|t=2021. Stem cell therapy in COVID-19: Pooled evidence from SARS-CoV-2, SARS-CoV, MERS-CoV and ARDS: A systematic review.|pdf=|usr=026}}
+{{tp|p=33721754|t=2021. Antiviral activity of oleandrin and a defined extract of Nerium oleander against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33811098|t=2021. Impact of corticosteroids in hospitalised COVID-19 patients.|pdf=|usr=026}}
+{{tp|p=33792391|t=2021. Treatment of COVID-19: a review of current and prospective pharmacotherapies.|pdf=|usr=026}}
+{{tp|p=33769885|t=2021. COVID-19 vaccines and vaccine administration.|pdf=|usr=026}}
+{{tp|p=33641685|t=2021. Zinc deficiency as a possible risk factor for increased susceptibility and severe progression of Corona Virus Disease 19.|pdf=|usr=026}}
+{{tp|p=33811310|t=2021. Supplementary Therapeutic Possibilities to Alleviate Myocardial Damage Due to Microvascular Dysfunction in Coronavirus Disease 2019 (COVID-19).|pdf=|usr=026}}
+{{tp|p=33811809|t=2021. BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection.|pdf=|usr=026}}
+{{tp|p=33811811|t=2021. Drug repurposing screens reveal cell-type-specific entry pathways and FDA-approved drugs active against SARS-Cov-2.|pdf=|usr=026}}
+{{tp|p=33799966|t=2021. Mesenchymal Stem Cell-Derived Exosomes Exhibit Promising Potential for Treating SARS-CoV-2-Infected Patients.|pdf=|usr=026}}
+{{tp|p=33798507|t=2021. Role of phytoconstituents in the management of COVID-19.|pdf=|usr=026}}
+{{tp|p=33821213|t=2021. COVID-19 into Chemical Science Perspective: Chemical Preventive Measures and Drug Development.|pdf=|usr=026}}
+{{tp|p=33820462|t=2021. Circadian clock modulating small molecules repurposing as inhibitors of SARS-CoV-2 M(pro) for pharmacological interventions in COVID-19 pandemic.|pdf=|usr=026}}
+{{tp|p=33821193|t=2021. Vitamin D and COVID-19 in an immunocompromised patient with multiple comorbidities-A Case Report.|pdf=|usr=026}}
+{{tp|p=33821192|t=2021. Combination of convalescent plasma therapy and repurposed drugs to treat severe COVID-19 patient with multimorbidity.|pdf=|usr=026}}
+{{tp|p=33558274|t=2021. Covid-19: First UK vaccine safety data are "reassuring," says regulator.|pdf=|usr=026}}
+{{tp|p=33541863|t=2021. Covid-19: Israel sees new infections plummet following vaccinations.|pdf=|usr=026}}
+{{tp|p=33536232|t=2021. Covid-19: New data on Oxford AstraZeneca vaccine backs 12 week dosing interval.|pdf=|usr=026}}
+{{tp|p=33536182|t=2021. Why aren't covid-19 vaccines being manufactured in standard prefilled syringes?|pdf=|usr=026}}
+{{tp|p=33632676|t=2021. Covid-19: Pfizer BioNTech vaccine reduced cases by 94% in Israel, shows peer reviewed study.|pdf=|usr=026}}
+{{tp|p=33627357|t=2021. Optimal dosing interval for covid-19 vaccines: we need clinical trial evidence and to consider past infection.|pdf=|usr=026}}
+{{tp|p=33622695|t=2021. Behind the scenes of the Pfizer BioNTech covid-19 vaccine trial.|pdf=|usr=026}}
+{{tp|p=33619168|t=2021. Defer vaccination of people who have had covid-19.|pdf=|usr=026}}
+{{tp|p=33619037|t=2021. Covid-19: First doses of vaccines in Scotland led to a substantial fall in hospital admissions.|pdf=|usr=026}}
+{{tp|p=33531342|t=2021. Covid-19: Russian vaccine efficacy is 91.6%, show phase III trial results.|pdf=|usr=026}}
+{{tp|p=33531333|t=2021. Covid-19: People who have had infection might only need one dose of mRNA vaccine.|pdf=|usr=026}}
+{{tp|p=33574097|t=2021. Covid-19: Arthritis drug tocilizumab reduces deaths in hospitalised patients, study shows.|pdf=|usr=026}}
+{{tp|p=33526412|t=2021. Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant.|pdf=|usr=026}}
+{{tp|p=33795232|t=2021. Covid-19: Pfizer reports 100% vaccine efficacy in children aged 12 to 15.|pdf=|usr=026}}
+{{tp|p=33795218|t=2021. Covid-19: Moderna and Pfizer vaccines prevent infections as well as symptoms, CDC study finds.|pdf=|usr=026}}
+{{tp|p=33760277|t=2021. Will AstraZeneca be able to provide clinical trial data on its COVID-19 vaccine efficacy in older adults?|pdf=|usr=026}}
+{{tp|p=33763917|t=2021. Liver and kidney function in patients with Covid-19 treated with remdesivir.|pdf=|usr=026}}
+{{tp|p=33742473|t=2021. Zinc supplementation as an adjunct therapy for COVID-19: Challenges and opportunities.|pdf=|usr=026}}
+{{tp|p=33539240|t=2021. Corticosteroids, mortality and mechanical ventilation in COVID-19.|pdf=|usr=026}}
+{{tp|p=33539237|t=2021. COVID-19 vaccination in the UK: is it time to celebrate?|pdf=|usr=026}}
+{{tp|p=33632683|t=2021. COVID-19 vaccine availability: what are the side effects?|pdf=|usr=026}}
+{{tp|p=33769552|t=2021. Dual inhibition of CB1 receptors and iNOS, as a potential novel approach to the pharmacological management of acute and long COVID-19.|pdf=|usr=026}}
+{{tp|p=33729819|t=2021. Could boron-containing compounds (BCCs) be effective against SARS-CoV-2 as anti-viral agent?|pdf=|usr=026}}
+{{tp|p=33618530|t=2021. Potential therapeutic road for targeting the SARS-CoV-2 at throat.|pdf=|usr=026}}
+{{tp|p=33618529|t=2021. The relationship between vitamin D and the severity of COVID-19.|pdf=|usr=026}}
+{{tp|p=33622040|t=2021. The Canadian Society of Breast Imaging/ Canadian Association of Radiologists' Recommendations for the Management of Axillary Adenopathy in Patients With Recent COVID-19 Vaccination.|pdf=|usr=026}}
+{{tp|p=33534645|t=2021. Challenges and Opportunities for COVID-19 Vaccines in Patients with Cancer.|pdf=|usr=026}}
+{{tp|p=33740455|t=2021. Antivirals with common targets against highly pathogenic viruses.|pdf=|usr=026}}
+{{tp|p=33740454|t=2021. Novel approaches for vaccine development.|pdf=|usr=026}}
+{{tp|p=33653052|t=2021. Combination anti-coronavirus therapies based on nonlinear mathematical models.|pdf=|usr=026}}
+{{tp|p=33647240|t=2021. Low risk of the TMPRSS2 inhibitor camostat mesylate and its metabolite GBPA to act as perpetrators of drug-drug interactions.|pdf=|usr=026}}
+{{tp|p=33651072|t=2021. Targeting SARS-CoV-2 spike protein by stapled hACE2 peptides.|pdf=|usr=026}}
+{{tp|p=33719401|t=2021. Chemical and Biochemical Aspects of Molecular Hydrogen in Treating Kawasaki Disease and COVID-19.|pdf=|usr=026}}
+{{tp|p=33797868|t=2021. Inspecting the Mechanism of Fragment Hits Binding on SARS-CoV-2 M(pro) by Using Supervised Molecular Dynamics (SuMD) Simulations.|pdf=|usr=026}}
+{{tp|p=33660489|t=2021. 25-Hydroxyvitamin D concentrations in COVID-19 patients hospitalized in intensive care unit during the first wave and the second wave of the pandemic.|pdf=|usr=026}}
+{{tp|p=33554566|t=2021. Vitamin-D levels and intensive care unit outcomes of a cohort of critically ill COVID-19 patients.|pdf=|usr=026}}
+{{tp|p=33813758|t=2021. Adverse reactions to COVID-19 vaccines: A practical approach.|pdf=|usr=026}}
+{{tp|p=33719087|t=2021. Dietary deprivation during the COVID-19 pandemic producing acquired vulval zinc-deficiency dermatitis.|pdf=|usr=026}}
+{{tp|p=33577095|t=2021. The "coloring wipes" phenomenon: a peculiar skin pigmentation induced by ascorbic acid observed during lockdown.|pdf=|usr=026}}
+{{tp|p=33719081|t=2021. Colchicine treatment can improve outcomes of coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.|pdf=|usr=026}}
+{{tp|p=33684970|t=2021. Nicorandil a magic bullet or a double edged sword in critically ill COVID-19 patients?|pdf=|usr=026}}
+{{tp|p=33560913|t=2020. CRISPR-Cas13 as an Antiviral Strategy for Coronavirus Disease 2019.|pdf=|usr=026}}
+{{tp|p=33769769|t=2021. Plasmapheresis Efficiency in Coronavirus Disease 2019: More Related to What You Add and Not What You Take Away?|pdf=|usr=026}}
+{{tp|p=33731635|t=2021. Is "Mega-Dose" IV Vitamin C Required for Septic and Critical Coronavirus Disease 2019 Patients?|pdf=|usr=026}}
+{{tp|p=33591008|t=2021. The Surviving Sepsis Campaign: Research Priorities for Coronavirus Disease 2019 in Critical Illness.|pdf=|usr=026}}
+{{tp|p=33685299|t=2021. Lactoferrin: an overview of its main functions, immunomodulatory and antimicrobial role, and clinical significance.|pdf=|usr=026}}
+{{tp|p=33645486|t=2021. Integrated Nutritional Supports for Diabetic Patients during COVID-19 Infection: A Comprehensive Review.|pdf=|usr=026}}
+{{tp|p=33797367|t=2021. Novel Pulmonary Delivery of Antiviral Drugs for Treating COVID-19 in Patients with Parkinson's Disease.|pdf=|usr=026}}
+{{tp|p=33588727|t=2021. Small-molecule antiviral agents in ongoing clinical trials for COVID-19.|pdf=|usr=026}}
+{{tp|p=33781188|t=2021. Protein-ligand Docking Simulations with AutoDock4 Focused on the Main Protease of SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33550959|t=2021. Natural Products as Potential Agents Against SARS-CoV and SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33563148|t=2021. Nucleoside Inhibitors of Coronaviruses.|pdf=|usr=026}}
+{{tp|p=33691249|t=2021. Fluoxetine as an anti-inflammatory therapy in SARS-CoV-2 infection.|pdf=|usr=026}}
+{{tp|p=33662680|t=2021. Flavonoids against the SARS-CoV-2 induced inflammatory storm.|pdf=|usr=026}}
+{{tp|p=33732744|t=2021. Both Chloroquine and Lopinavir/Ritonavir Are Ineffective for COVID-19 Treatment and Combined Worsen the Pathology: A Single-Center Experience with Severely Ill Patients.|pdf=|usr=026}}
+{{tp|p=33728324|t=2021. Immunoinformatics and Molecular Docking Studies Predicted Potential Multiepitope-Based Peptide Vaccine and Novel Compounds against Novel SARS-CoV-2 through Virtual Screening.|pdf=|usr=026}}
+{{tp|p=33708993|t=2021. Impact of Ethnicity and Underlying Comorbidity on COVID-19 Inhospital Mortality: An Observational Study in Abu Dhabi, UAE.|pdf=|usr=026}}
+{{tp|p=33564683|t=2021. Comparison of Immune Response between SARS, MERS, and COVID-19 Infection, Perspective on Vaccine Design and Development.|pdf=|usr=026}}
+{{tp|p=33731494|t=2021. Antiviral Efficacy of Pralatrexate against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33557097|t=2021. In Silico Screening of Natural Products Isolated from Mexican Herbal Medicines against COVID-19.|pdf=|usr=026}}
+{{tp|p=33671652|t=2021. Screening and Molecular Modeling Evaluation of Food Peptides to Inhibit Key Targets of COVID-19 Virus.|pdf=|usr=026}}
+{{tp|p=33671255|t=2021. Multivalent Display of SARS-CoV-2 Spike (RBD Domain) of COVID-19 to Nanomaterial, Protein Ferritin Nanocages.|pdf=|usr=026}}
+{{tp|p=33676041|t=2021. Molecular designing, crystal structure determination and in silico screening of copper(II) complexes bearing 8-hydroxyquinoline derivatives as anti-COVID-19.|pdf=|usr=026}}
+{{tp|p=33667900|t=2021. Discovery of novel inhibitors against main protease (Mpro) of SARS-CoV-2 via virtual screening and biochemical evaluation.|pdf=|usr=026}}
+{{tp|p=33753260|t=2021. SARS-CoV-2 main protease inhibition by compounds isolated from Luffa cylindrica using molecular docking.|pdf=|usr=026}}
+{{tp|p=33689873|t=2021. Application of niclosamide and analogs as small molecule inhibitors of Zika virus and SARS-CoV-2 infection.|pdf=|usr=026}}
+{{tp|p=33662537|t=2021. Design, synthesis and biological evaluation of 2-aminoquinazolin-4(3H)-one derivatives as potential SARS-CoV-2 and MERS-CoV treatments.|pdf=|usr=026}}
+{{tp|p=33775840|t=2021. Identification of non-covalent SARS-CoV-2 main protease inhibitors by a virtual screen of commercially available drug-like compounds.|pdf=|usr=026}}
+{{tp|p=33711743|t=2021. Evaluation of potential anti-RNA-dependent RNA polymerase (RdRP) drugs against the newly emerged model of COVID-19 RdRP using computational methods.|pdf=|usr=026}}
+{{tp|p=33585808|t=2021. An update to monoclonal antibody as therapeutic option against COVID-19.|pdf=|usr=026}}
+{{tp|p=33590853|t=2021. In vitro selection of an RNA aptamer yields an interleukin-6/interleukin-6 receptor interaction inhibitor.|pdf=|usr=026}}
+{{tp|p=33624754|t=2021. Knowing and combating the enemy: a brief review on SARS-CoV-2 and computational approaches applied to the discovery of drug candidates.|pdf=|usr=026}}
+{{tp|p=33746182|t=2021. COVID-19 vaccine research focusses on safety, efficacy, immunoinformatics, and vaccine production and delivery: a bibliometric analysis based on VOSviewer.|pdf=|usr=026}}
+{{tp|p=33612990|t=2021. Coronavirus-Replikation: Mechanismus und Inhibition durch Remdesivir.|pdf=|usr=026}}
+{{tp|p=33612989|t=2021. COR-101, ein menschlicher Antikorper gegen COVID-19.|pdf=|usr=026}}
+{{tp|p=33629351|t=2021. Efficacy of mesenchymal stromal cells and cellular products in improvement of symptoms for COVID-19 and similar lung diseases.|pdf=|usr=026}}
+{{tp|p=33547723|t=2021. COVID-19 vaccines for rapid global impact.|pdf=|usr=026}}
+{{tp|p=33560402|t=2021. Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19.|pdf=|usr=026}}
+{{tp|p=33621948|t=2021. Effectiveness of convalescent plasma in Indian patients with COVID-19.|pdf=|usr=026}}
+{{tp|p=33789273|t=2021. Convalescent Blood: Current Perspective on the Efficacy of a Legacy Approach in COVID-19 Treatment.|pdf=|usr=026}}
+{{tp|p=33721869|t=2021. Should the Therapeutic Apheresis Method Be Added to Treatment in the COVID-19 Outbreak?|pdf=|usr=026}}
+{{tp|p=33771096|t=2021. In silico comparative study of SARS-CoV-2 proteins and antigenic proteins in BCG, OPV, MMR and other vaccines: evidence of a possible putative protective effect.|pdf=|usr=026}}
+{{tp|p=33711981|t=2021. Repurposing novel therapeutic candidate drugs for coronavirus disease-19 based on protein-protein interaction network analysis.|pdf=|usr=026}}
+{{tp|p=33531083|t=2021. De novo design and bioactivity prediction of SARS-CoV-2 main protease inhibitors using recurrent neural network-based transfer learning.|pdf=|usr=026}}
+{{tp|p=33765919|t=2021. Vaccinomic approach for novel multi epitopes vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).|pdf=|usr=026}}
+{{tp|p=33673818|t=2021. Tocilizumab improves survival in severe COVID-19 pneumonia with persistent hypoxia: a retrospective cohort study with follow-up from Mumbai, India.|pdf=|usr=026}}
+{{tp|p=33761870|t=2021. Efficacy and safety of Levamisole treatment in clinical presentations of non-hospitalized patients with COVID-19: a double-blind, randomized, controlled trial.|pdf=|usr=026}}
+{{tp|p=33706794|t=2021. Impact of previous exposure to systemic corticosteroids on unfavorable outcome in patients hospitalized for COVID-19.|pdf=|usr=026}}
+{{tp|p=33618696|t=2021. Proposal of selective wedge instillation of pulmonary surfactant for COVID-19 pneumonia based on computational fluid dynamics simulation.|pdf=|usr=026}}
+{{tp|p=33785004|t=2021. Protective role of intravesical BCG in COVID-19 severity.|pdf=|usr=026}}
+{{tp|p=33541971|t=2021. Steroid harms if given early in COVID-19 viraemia.|pdf=|usr=026}}
+{{tp|p=33622757|t=2021. COVID-19 cardiac injury and the use of colchicine.|pdf=|usr=026}}
+{{tp|p=33558355|t=2021. Examination of patient characteristics and hydroxychloroquine use based on the US Food and Drug Administration's recommendation: a cross-sectional analysis in New York.|pdf=|usr=026}}
+{{tp|p=33664123|t=2021. Association between influenza vaccination and hospitalisation or all-cause mortality in people with COVID-19: a retrospective cohort study.|pdf=|usr=026}}
+{{tp|p=33662986|t=2021. Desarrollo de vacunas contra el SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33564122|t=2021. Allogeneic stem cell transplantation in acute leukemia patients after COVID-19 infection.|pdf=|usr=026}}
+{{tp|p=33823270|t=2021. Covid-19 vaccine and autoimmunity: Awakening the sleeping dragon.|pdf=|usr=026}}
+{{tp|p=33768222|t=2021. Single dose of a mRNA SARS-CoV-2 vaccine is associated with lower nasopharyngeal viral load among nursing home residents with asymptomatic COVID-19.|pdf=|usr=026}}
+{{tp|p=33749746|t=2021. Remdesivir: An antiviral still seeking a raison d'etre.|pdf=|usr=026}}
+{{tp|p=33819571|t=2021. Fourteen-day survival among older adults with severe infection with severe acute respiratory syndrome coronavirus 2 treated with corticosteroid: a cohort study.|pdf=|usr=026}}
+{{tp|p=33813110|t=2021. Hydroxychloroquine in mild-to-moderate coronavirus disease 2019: a placebo-controlled double blind trial.|pdf=|usr=026}}
+{{tp|p=33705574|t=2021. Vaccines: Underlying Principles of Design and Testing.|pdf=|usr=026}}
+{{tp|p=33624299|t=2021. Chloroquine or hydroxychloroquine for prevention and treatment of COVID-19.|pdf=|usr=026}}
+{{tp|p=33722106|t=2021. Adjunctive intravenous immunoglobulins (IVIg) for moderate-severe COVID-19: emerging therapeutic roles.|pdf=|usr=026}}
+{{tp|p=33810947|t=2021. Serum IP-10 and IL-7 levels are associated with disease severity of coronavirus disease 2019.|pdf=|usr=026}}
+{{tp|p=33593661|t=2021. Granulocyte macrophage colony-stimulating factor has come of age: From a vaccine adjuvant to antiviral immunotherapy.|pdf=|usr=026}}
+{{tp|p=33814294|t=2021. Letter to the Editor in response to article: Hypocalcemia is associated with severe COVID-19: A systematic review and meta-analysis (Martha et al.).|pdf=|usr=026}}
+{{tp|p=33823331|t=2021. Impact of the vitamin D deficiency on COVID-19 infection and mortality in Asian countries.|pdf=|usr=026}}
+{{tp|p=33802453|t=2021. Comparative Assessment of Sera from Individuals after S-Gene RNA-Based SARS-CoV-2 Vaccination with Spike-Protein-Based and Nucleocapsid-Based Serological Assays.|pdf=|usr=026}}
+{{tp|p=33804914|t=2021. Mini-Review Discussing the Reliability and Efficiency of COVID-19 Vaccines.|pdf=|usr=026}}
+{{tp|p=33588980|t=2021. Exploration of Association Between Respiratory Vaccinations With Infection and Mortality Rates of COVID-19.|pdf=|usr=026}}
+{{tp|p=33820650|t=2021. The Covid-19 infection: An opportunity to develop systematic vitamin D supplementation in psychiatry.|pdf=|usr=026}}
+{{tp|p=33819636|t=2021. Vitamin D Sufficiency and COVID-19: Is Vitamin D Binding Protein (and Its Polymorphism) the Missing Link?|pdf=|usr=026}}
+{{tp|p=33819635|t=2021. Authors' Reply: Vitamin D Sufficiency and COVID-19: Is Vitamin D Binding Protein (and Its Polymorphism) the Missing Link?|pdf=|usr=026}}
+{{tp|p=33769268|t=2021. Biological drugs in paediatric COVID-19 infection: what patients, which drug, how much and how long.|pdf=|usr=026}}
+{{tp|p=33635229|t=2021. The safety profile of hydroxychloroquine: major cutaneous and extracutaneous adverse events.|pdf=|usr=026}}
+{{tp|p=33527123|t=2021. On Setting Expectations for a Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine.|pdf=|usr=026}}
+{{tp|p=33782318|t=2021. 18F-FDG-Avid Lymph Nodes After COVID-19 Vaccination on 18F-FDG PET/CT.|pdf=|usr=026}}
+{{tp|p=33782299|t=2021. Axillary Lymph Nodes Hypermetabolism After BNT162b2 mRNA COVID-19 Vaccination in Cancer Patients Undergoing 18F-FDG PET/CT: A Cohort Study.|pdf=|usr=026}}
+{{tp|p=33661194|t=2021. COVID-19 Vaccine-Related Local FDG Uptake.|pdf=|usr=026}}
+{{tp|p=33661193|t=2021. COVID-19 Vaccination Manifesting as Incidental Lymph Nodal Uptake on 18F-FDG PET/CT.|pdf=|usr=026}}
+{{tp|p=33661192|t=2021. FDG PET Findings Post-COVID Vaccinations: Signs of the Times?|pdf=|usr=026}}
+{{tp|p=33795589|t=2021. DOTATATE -Avid Bilateral Axilla and Subpectoral Lymphadenopathy Induced From COVID-19 mRNA Vaccination Visualized on PET/CT.|pdf=|usr=026}}
+{{tp|p=33591026|t=2021. COVID-19 mRNA Vaccination-Induced Lymphadenopathy Mimics Lymphoma Progression on FDG PET/CT.|pdf=|usr=026}}
+{{tp|p=33793179|t=2021. Emergency Use Authorization for Bamlanivimab in Mild to Moderate COVID-19: Implications for CNS Practice.|pdf=|usr=026}}
+{{tp|p=33793172|t=2021. Emergency Use Authorization for Bamlanivimab in Mild to Moderate COVID-19: Implications for Clinical Nurse Specialist Practice.|pdf=|usr=026}}
+{{tp|p=33534255|t=2021. COVID-19 Vaccine: Development, Testing, and Distribution.|pdf=|usr=026}}
+{{tp|p=33534247|t=2021. COVID-19 Vaccine: Development, Testing, and Distribution.|pdf=|usr=026}}
+{{tp|p=33759449|t=2021. Drugs in COVID-19 Clinical Trials: Predicting Transporter-Mediated Drug-Drug Interactions Using In Vitro Assays and Real-World Data.|pdf=|usr=026}}
+{{tp|p=33792037|t=2021. Effect of Corticosteroids on Mortality in Hospitalized COVID-19 Patients Not Receiving Invasive Mechanical Ventilation.|pdf=|usr=026}}
+{{tp|p=33769172|t=2021. Toxicity resulting from colchicine used to treat COVID-19 patients: a new challenge for clinical toxicologists.|pdf=|usr=026}}
+{{tp|p=33786990|t=2021. Adverse Drug Event Risk Assessment by the Virtual Addition of COVID-19 Repurposed Drugs to Medicare and Commercially Insured Patients' Drug Regimens: A Drug Safety Simulation Study.|pdf=|usr=026}}
+{{tp|p=33786981|t=2021. In vitro safety "clinical trial" of the cardiac liability of drug polytherapy.|pdf=|usr=026}}
+{{tp|p=33724440|t=2021. Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease.|pdf=|usr=026}}
+{{tp|p=33765340|t=2021. Contested effects and chaotic policies: the 2020 story of (hydroxy) chloroquine for treating COVID-19.|pdf=|usr=026}}
+{{tp|p=33734435|t=2021. Interleukin-6 blocking agents for treating COVID-19: a living systematic review.|pdf=|usr=026}}
+{{tp|p=33538665|t=2021. An Urgent Industrial Scheme both for Total Synthesis, and for Pharmaceutical Analytical Analysis of Umifenovir as an Anti-Viral API for Treatment of COVID-19.|pdf=|usr=026}}
+{{tp|p=33563150|t=2021. Targeting Viral RNA-Dependent RNA Polymerases as an Antiviral Therapy.|pdf=|usr=026}}
+{{tp|p=33605848|t=2021. Advances of Inorganic Materials in the Detection and Therapeutic Uses Against Coronaviruses.|pdf=|usr=026}}
+{{tp|p=33602071|t=2021. Viral Envelope Membrane: A Special Entry Pathway and a Promising Drug Target.|pdf=|usr=026}}
+{{tp|p=33622224|t=2021. SARS-CoV-2 proteins: Are they useful as targets for COVID-19 drugs and vaccines?|pdf=|usr=026}}
+{{tp|p=33535951|t=2021. Molecular Elucidation and Therapeutic Targeting for combating COVID19: Current Scenario and Future Prospective.|pdf=|usr=026}}
+{{tp|p=33602083|t=2021. Phyto-compounds from a rather poisonous plant, Strychnos nux-vomica, show high potency against SARS-CoV-2 RNA-dependent RNA polymerase.|pdf=|usr=026}}
+{{tp|p=33587365|t=2021. Coronavirus disease 2019 pandemic and alterations of body composition.|pdf=|usr=026}}
+{{tp|p=33629969|t=2021. Host-directed therapies for COVID-19.|pdf=|usr=026}}
+{{tp|p=33749558|t=2021. Herbal Medicine in Fighting Against COVID-19: New Battle with an Old Weapon.|pdf=|usr=026}}
+{{tp|p=33530904|t=2021. BCG Vaccination Program mitigates COVID19 Related Mortality: A Reality check.|pdf=|usr=026}}
+{{tp|p=33593256|t=2021. Unravelling The Immune Modulatory Effect Of Indian Spices To Impede The Transmission Of Covid-19: A Promising Approach.|pdf=|usr=026}}
+{{tp|p=33719967|t=2021. Tocilizumab: From Rheumatic Diseases to COVID-19.|pdf=|usr=026}}
+{{tp|p=33550966|t=2021. The Computational Intervention of Macrolide Antibiotics in the Treatment of COVID-19.|pdf=|usr=026}}
+{{tp|p=33591423|t=2021. mRNA-Based Vaccines and Mode of Action.|pdf=|usr=026}}
+{{tp|p=33751756|t=2021. Chitin-lipid interactions and the potential relationship between Demodex and SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33547204|t=2021. Association Between DPP-4 Inhibitors and COVID-19-Related Outcomes Among Patients With Type 2 Diabetes.|pdf=|usr=026}}
+{{tp|p=33663970|t=2021. Reply to letter of Davie et al. regarding the article: "Vitamin D concentrations and COVID-19 infection in UK Biobank" (Hastie et al.).|pdf=|usr=026}}
+{{tp|p=33652503|t=2021. Potential mechanisms of action of convalescent plasma in COVID-19.|pdf=|usr=026}}
+{{tp|p=33820581|t=2021. Roll out of COVID-19 vaccination in India: A SWOT analysis.|pdf=|usr=026}}
+{{tp|p=33817811|t=2021. Crocetin and related oxygen diffusion-enhancing compounds: Review of chemical synthesis, pharmacology, clinical development, and novel therapeutic applications.|pdf=|usr=026}}
+{{tp|p=33581321|t=2021. A new horizon for the old antibacterial drug clofoctol.|pdf=|usr=026}}
+{{tp|p=33770833|t=2021. CYP2D6 and CYP3A4 variants influence the risk and outcome of COVID-19 infection among rheumatoid arthritis patients maintained on hydroxychloroquine.|pdf=|usr=026}}
+{{tp|p=33757133|t=2021. Famotidine Repurposing for Novel Corona Virus Disease of 2019: A Systematic Review.|pdf=|usr=026}}
+{{tp|p=33726658|t=2021. The Biochemical Parameters and Vitamin D Levels in ICU Patients with Covid-19: A Cross-Sectional Study.|pdf=|usr=026}}
+{{tp|p=33725359|t=2021. Response to: COVID-19 re-infection. Vaccinated individuals as a potential source of transmission.|pdf=|usr=026}}
+{{tp|p=33675065|t=2021. Janus kinase signaling as risk factor and therapeutic target for severe SARS-CoV-2 infection.|pdf=|usr=026}}
+{{tp|p=33772778|t=2021. A single subcutaneous or intranasal immunization with adenovirus-based SARS-CoV-2 vaccine induces robust humoral and cellular immune responses in mice.|pdf=|usr=026}}
+{{tp|p=33685635|t=2021. Putative antiviral effects of propofol in COVID-19.|pdf=|usr=026}}
+{{tp|p=33795925|t=2020. Neprilysin Inhibitors and Angiotensin(1-7) in COVID-19.|pdf=|usr=026}}
+{{tp|p=33609410|t=2021. Repurposing of thalidomide and its derivatives for the treatment of SARS-coV-2 infections: Hints on molecular action.|pdf=|usr=026}}
+{{tp|p=33608891|t=2021. Dexamethasone use and mortality in hospitalized patients with coronavirus disease 2019: A multicentre retrospective observational study.|pdf=|usr=026}}
+{{tp|p=33580602|t=2021. Postvaccination anaphylaxis and mRNA-based SARS-CoV-2 vaccines-Much ado about nothing?|pdf=|usr=026}}
+{{tp|p=33685770|t=2021. Plant products in reducing spread of coronavirus infection (COVID-19).|pdf=|usr=026}}
+{{tp|p=33685772|t=2021. Supraclavicular lymphadenopathy following COVID-19 vaccination: an incre<iframe src="http://www.kidney.de/amapp.php?a=g presentation to the two-week wait neck lump clinic?|pdf=|usr=026}}
+{{tp|p=33761533|t=2021. SARS-CoV-2 vaccination modelling for safe surgery to save lives: data from an international prospective cohort study.|pdf=|usr=026}}
+{{tp|p=33640910|t=2021. Berberine reduces circulating inflammatory mediators in patients with severe COVID-19.|pdf=|usr=026}}
+{{tp|p=33594349|t=2021. Bell's Palsy after second dose of Pfizer COVID-19 vaccination in a patient with history of recurrent Bell's palsy.|pdf=|usr=026}}
+{{tp|p=33527097|t=2021. Clozapine, neutropenia and Covid-19: should clinicians be concerned? 3 months report.|pdf=|usr=026}}
+{{tp|p=33612882|t=2021. Immunonutrition in perioperative care of COVID-19 patients: an old weapon for a new disease?|pdf=|usr=026}}
+{{tp|p=33621543|t=2021. Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19.|pdf=|usr=026}}
+{{tp|p=33729394|t=2021. Immunity, virus evolution, and effectiveness of SARS-CoV-2 vaccines.|pdf=|usr=026}}
+{{tp|p=33623995|t=2021. A molecular modelling approach for identifying antiviral selenium-containing heterocyclic compounds that inhibit the main protease of SARS-CoV-2: an in silico investigation.|pdf=|usr=026}}
+{{tp|p=33592108|t=2021. Data science in unveiling COVID-19 pathogenesis and diagnosis: evolutionary origin to drug repurposing.|pdf=|usr=026}}
+{{tp|p=33583943|t=2021. Le vaccin a ARN pour la COVID-19 - quel risque allergique ?|pdf=|usr=026}}
+{{tp|p=33674059|t=2021. Vaccination anti COVID-19 pour les personnes souffrant de cancer : un imperatif medical et ethique.|pdf=|usr=026}}
+{{tp|p=33741139|t=2021. Nous devons respecter le schema vaccinal anti-SARS-CoV-2 sans decalage chez les patients atteints de cancer sous traitement.|pdf=|usr=026}}
+{{tp|p=33663776|t=2021. Repositionnement des antineoplasiques utilises en hematologie dans le traitement du COVID-19.|pdf=|usr=026}}
+{{tp|p=33788116|t=2021. Antiviral Drug Ivermectin at Nanomolar Concentrations Inhibits Glycine-Induced Chloride Current in Rat Hippocampal Neurons.|pdf=|usr=026}}
+{{tp|p=33727782|t=2021. In silico identification of compounds from Nigella sativa seed oil as potential inhibitors of SARS-CoV-2 targets.|pdf=|usr=026}}
+{{tp|p=33642851|t=2021. Importance of immunoglobulin therapy for COVID-19 patients with lymphocytopenia.|pdf=|usr=026}}
+{{tp|p=33564223|t=2021. A proposed insight into the anti-viral potential of metallic nanoparticles against novel coronavirus disease-19 (COVID-19).|pdf=|usr=026}}
+{{tp|p=33654695|t=2020. Gut, metabolism and nutritional Support for COVID-19: Experiences from China.|pdf=|usr=026}}
+{{tp|p=33727379|t=2021. COVID-19 vaccine fast facts.|pdf=|usr=026}}
+{{tp|p=33727376|t=2021. Medication use during COVID-19: Review of recent evidence.|pdf=|usr=026}}
+{{tp|p=33689451|t=2021. Ribavirin shows antiviral activity against SARS-CoV-2 and downregulates the activity of TMPRSS2 and the expression of ACE2 in vitro.|pdf=|usr=026}}
+{{tp|p=33688374|t=2021. Effect of Hydroxychloroquine and Azithromycin on QT Interval Prolongation and Other Cardiac Arrhythmias in COVID-19 Confirmed Patients.|pdf=|usr=026}}
+{{tp|p=33747583|t=2021. Targeting Cytokine Storm in COVID-19: A Role of Online Hemodiafiltration with Asymmetric Cellulose Triacetate in Maintenance Hemodialysis Patients-A Report of 10 Cases.|pdf=|usr=026}}
+{{tp|p=33577765|t=2021. Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection.|pdf=|usr=026}}
+{{tp|p=33740443|t=2021. Messenger RNA vaccines against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33773105|t=2021. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein.|pdf=|usr=026}}
+{{tp|p=33761326|t=2021. N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33743213|t=2021. Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity.|pdf=|usr=026}}
+{{tp|p=33756110|t=2021. The antigenic anatomy of SARS-CoV-2 receptor binding domain.|pdf=|usr=026}}
+{{tp|p=33691139|t=2021. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection.|pdf=|usr=026}}
+{{tp|p=33667349|t=2021. Extremely potent human monoclonal antibodies from COVID-19 convalescent patients.|pdf=|usr=026}}
+{{tp|p=33792836|t=2021. Piece of the puzzle: Remdesivir disassembles the multimeric SARS-CoV-2 RNA-dependent RNA polymerase complex.|pdf=|usr=026}}
+{{tp|p=33766136|t=2021. Functional analysis of SARS-CoV-2 proteins in Drosophila identifies Orf6-induced pathogenic effects with Selinexor as an effective treatment.|pdf=|usr=026}}
+{{tp|p=33766124|t=2021. Characterization of SARS-CoV-2 proteins reveals Orf6 pathogenicity, subcellular localization, host interactions and attenuation by Selinexor.|pdf=|usr=026}}
+{{tp|p=33640032|t=2021. Ginkgolic acid and anacardic acid are specific covalent inhibitors of SARS-CoV-2 cysteine proteases.|pdf=|usr=026}}
+{{tp|p=33762578|t=2021. Inhibition of HECT E3 ligases as potential therapy for COVID-19.|pdf=|usr=026}}
+{{tp|p=33723251|t=2021. Plasma IL-6 levels following corticosteroid therapy as an indicator of ICU length of stay in critically ill COVID-19 patients.|pdf=|usr=026}}
+{{tp|p=33731711|t=2020. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro.|pdf=|usr=026}}
+{{tp|p=33723226|t=2020. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33789084|t=2021. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite.|pdf=|usr=026}}
+{{tp|p=33705704|t=2021. Virus vaccines: proteins prefer prolines.|pdf=|usr=026}}
+{{tp|p=33592168|t=2021. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies.|pdf=|usr=026}}
+{{tp|p=33535027|t=2021. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization.|pdf=|usr=026}}
+{{tp|p=33789085|t=2021. SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera.|pdf=|usr=026}}
+{{tp|p=33705729|t=2021. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines.|pdf=|usr=026}}
+{{tp|p=33657424|t=2021. Robust SARS-CoV-2 infection in nasal turbinates after treatment with systemic neutralizing antibodies.|pdf=|usr=026}}
+{{tp|p=33580169|t=2021. Ferritin nanoparticle-based SARS-CoV-2 RBD vaccine induces a persistent antibody response and long-term memory in mice.|pdf=|usr=026}}
+{{tp|p=33731916|t=2021. Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice.|pdf=|usr=026}}
+{{tp|p=33664486|t=2021. Systematic profiling of SARS-CoV-2-specific IgG epitopes at amino acid resolution.|pdf=|usr=026}}
+{{tp|p=33633321|t=2021. Emerging SARS-CoV-2 variants reduce neutralization sensitivity to convalescent sera and monoclonal antibodies.|pdf=|usr=026}}
+{{tp|p=33662255|t=2021. Use of convalescent serum reduces severity of COVID-19 in nonhuman primates.|pdf=|usr=026}}
+{{tp|p=33545052|t=2021. Cross-reactivity of SARS-CoV structural protein antibodies against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33784499|t=2021. Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication.|pdf=|usr=026}}
+{{tp|p=33778788|t=2021. A comprehensive analysis and resource to use CRISPR-Cas13 for broad-spectrum targeting of RNA viruses.|pdf=|usr=026}}
+{{tp|p=33754147|t=2021. A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques.|pdf=|usr=026}}
+{{tp|p=33820686|t=2021. Lessons from pathophysiology: Use of individualized combination treatments with immune interventional agents to tackle severe respiratory failure in patients with COVID-19.|pdf=|usr=026}}
+{{tp|p=33812315|t=2021. Structure-based drug design of an inhibitor of the SARS-CoV-2 (COVID-19) main protease using free software: A tutorial for students and scientists.|pdf=|usr=026}}
+{{tp|p=33823185|t=2021. Virtual high throughput screening: Potential inhibitors for SARS-CoV-2 PL(PRO) and 3CL(PRO) proteases.|pdf=|usr=026}}
+{{tp|p=33539819|t=2021. SARS-CoV-2 entry inhibitors by dual targeting TMPRSS2 and ACE2: An in silico drug repurposing study.|pdf=|usr=026}}
+{{tp|p=33755985|t=2021. Flight hormones as therapeutic target for novel Coronavirus infectious disease.|pdf=|usr=026}}
+{{tp|p=33755983|t=2021. Early combination treatment with existing HIV antivirals: an effective treatment for COVID-19?|pdf=|usr=026}}
+{{tp|p=33755951|t=2021. Hyperlipidemia management during the COVID-19 pandemic: PCSK9 inhibitors to enhance the antiviral action of interferon.|pdf=|usr=026}}
+{{tp|p=33755949|t=2021. Reply Letter - "Safety and efficacy of oral lopinavir/ritonavir in pediatric patients with coronavirus disease: a nationwide comparative analysis".|pdf=|usr=026}}
+{{tp|p=33823179|t=2021. Evidence that Maackia amurensis seed lectin (MASL) exerts pleiotropic actions on oral squamous cells with potential to inhibit SARS-CoV-2 infection and COVID-19 disease progression.|pdf=|usr=026}}
+{{tp|p=33593200|t=2021. Coronavirus helicases: attractive and unique targets of antiviral drug-development and therapeutic patents.|pdf=|usr=026}}
+{{tp|p=33781166|t=2021. System for administering and monitoring hydroxychloroquine prophylaxis for COVID-19 in accordance with a national advisory: preliminary experience of a tertiary care institute in India.|pdf=|usr=026}}
+{{tp|p=33759682|t=2021. Low pH Hypromellose (Taffix) nasal powder spray could reduce SARS-CoV-2 infection rate post mass-gathering event at a highly endemic community: an observational prospective open label user survey.|pdf=|usr=026}}
+{{tp|p=33739215|t=2021. Vitamin D and immuno-pathology of COVID-19: many interactions but uncertain therapeutic benefits.|pdf=|usr=026}}
+{{tp|p=33792473|t=2021. Perspective: the nose and the stomach play a critical role in the NZACE2-Patari (modified ACE2) drug treatment project of SARS-CoV-2 infection.|pdf=|usr=026}}
+{{tp|p=33706626|t=2021. Compounds of plants with activity against SARS-CoV-2 targets.|pdf=|usr=026}}
+{{tp|p=33787439|t=2021. Is SARS-CoV-2 vaccination safe and effective for elderly individuals with neurodegenerative diseases?|pdf=|usr=026}}
+{{tp|p=33822489|t=2021. iPSC screening for drug repurposing identifies anti-RNA virus agents modulating host cell susceptibility.|pdf=|usr=026}}
+{{tp|p=33823228|t=2021. Recent efforts for drug identification from phytochemicals against SARS-CoV-2: Exploration of the chemical space to identify druggable leads.|pdf=|usr=026}}
+{{tp|p=33818582|t=2021. SARS-CoV-2 vaccine development and how Brazil is contributing.|pdf=|usr=026}}
+{{tp|p=33822042|t=2021. Pan-selectin inhibitors as potential therapeutics for COVID-19 treatment: in silico screening study.|pdf=|usr=026}}
+{{tp|p=33820678|t=2021. COVID-19 vaccine challenges: What have we learned so far and what remains to be done?|pdf=|usr=026}}
+{{tp|p=33764160|t=2021. Stage III Hypertension in Patients After mRNA-Based SARS-CoV-2 Vaccination.|pdf=|usr=026}}
+{{tp|p=33818480|t=2021. Safety of hydroxychloroquine in healthcare workers for COVID-19 prophylaxis.|pdf=|usr=026}}
+{{tp|p=33818476|t=2021. Inactivation of SARS-CoV-2 by gamma irradiation.|pdf=|usr=026}}
+{{tp|p=33818475|t=2021. Prediction of potential small interfering RNA molecules for silencing of the spike gene of SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33818472|t=2021. Chloroquine nasal drops in asymptomatic & mild COVID-19: An exploratory randomized clinical trial.|pdf=|usr=026}}
+{{tp|p=33818470|t=2021. Drug repurposing for identification of potential inhibitors against SARS-CoV-2 spike receptor-binding domain: An in silico approach.|pdf=|usr=026}}
+{{tp|p=33818467|t=2021. Use of convalescent plasma for COVID-19 in India: A review & practical guidelines.|pdf=|usr=026}}
+{{tp|p=33563353|t=2021. Impact of coronavirus disease 2019 (COVID-19) vaccination program on healthcare worker infections in an academic hospital.|pdf=|usr=026}}
+{{tp|p=33780551|t=2021. Clinical predictors of SARS-CoV-2 neutralizing antibody titers in COVID-19 convalescents: Implications for convalescent plasma donor recruitment.|pdf=|usr=026}}
+{{tp|p=33608444|t=2021. Information on COVID-19 vaccines and vaccinations.|pdf=|usr=026}}
+{{tp|p=33611530|t=2020. Amiodarone as a possible therapy for coronavirus infection.|pdf=|usr=026}}
+{{tp|p=33757336|t=2021. COVID-19: Antiviral agents and enzyme inhibitors/receptor blockers in development.|pdf=|usr=026}}
+{{tp|p=33719819|t=2021. Pharmacological interventions for COVID-19: a systematic review of observational studies and clinical trials.|pdf=|usr=026}}
+{{tp|p=33620014|t=2021. Convalescent plasma and hyperimmune globulin therapy in COVID-19.|pdf=|usr=026}}
+{{tp|p=33769888|t=2021. Exploring the room for repurposed hydroxychloroquine to impede COVID-19: toxicities and multipronged combination approaches with pharmaceutical insights.|pdf=|usr=026}}
+{{tp|p=33749491|t=2021. Inhaled vaccine delivery in the combat against respiratory viruses: a 2021 overview of recent developments and implications for COVID-19.|pdf=|usr=026}}
+{{tp|p=33749932|t=2021. A small molecule compound berberine as an orally active therapeutic candidate against COVID-19 and SARS: A computational and mechanistic study.|pdf=|usr=026}}
+{{tp|p=33617964|t=2021. Saponins: Extraction, bio-medicinal properties and way forward to anti-viral representatives.|pdf=|usr=026}}
+{{tp|p=33658420|t=2021. THE PECULIARITY OF COVID- 19 GENOME AND THE CORONAVIRUS RNA TRANSLATION PROCESS AS APOTENTIAL TARGET FOR ETIOTROPIC MEDICATIONSWITH ADENINE AND OTHER NUCLEOTIDE ANALOGUES (REVIEW).|pdf=|usr=026}}
+{{tp|p=33822348|t=2021. Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH.|pdf=|usr=026}}
+{{tp|p=33618380|t=2021. Severe Acute Thromboinflammation: Case Report of Individualized Homeopathic Treatment.|pdf=|usr=026}}
+{{tp|p=33567460|t=2021. Clinical Characteristics and Remedy Profiles of Patients with COVID-19: A Retrospective Cohort Study.|pdf=|usr=026}}
+{{tp|p=33544528|t=2021. COVID-19 and nutritional deficiency: a review of existing knowledge.|pdf=|usr=026}}
+{{tp|p=33687303|t=2021. Research trends in COVID-19 vaccine: a bibliometric analysis.|pdf=|usr=026}}
+{{tp|p=33769207|t=2021. BCG vaccination potential for COVID-19: an analytical approach.|pdf=|usr=026}}
+{{tp|p=33545014|t=2021. Coronavirus (SARS-CoV-2): a systematic review for potential vaccines.|pdf=|usr=026}}
+{{tp|p=33544024|t=2021. Anticipated reduction in COVID-19 mortality due to population-wide BCG vaccination: evidence from Germany.|pdf=|usr=026}}
+{{tp|p=33687847|t=2021. CoronaPep: An Anti-coronavirus Peptide Generation Tool.|pdf=|usr=026}}
+{{tp|p=33779464|t=2021. B Cell Response to Vaccination.|pdf=|usr=026}}
+{{tp|p=33649747|t=2021. Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters.|pdf=|usr=026}}
+{{tp|p=33782529|t=2021. Structure-based development of three- and four-antibody cocktails against SARS-CoV-2 via multiple mechanisms.|pdf=|usr=026}}
+{{tp|p=33731853|t=2021. Structural basis for bivalent binding and inhibition of SARS-CoV-2 infection by human potent neutralizing antibodies.|pdf=|usr=026}}
+{{tp|p=33629254|t=2021. CIGB-258, a peptide derived from human heat-shock protein 60, decreases hyperinflammation in COVID-19 patients.|pdf=|usr=026}}
+{{tp|p=33650894|t=2021. Mesenchymal Stromal Cell-Based Therapy: A Promising Approach for Severe COVID-19.|pdf=|usr=026}}
+{{tp|p=33673459|t=2021. Upregulation of the Renin-Angiotensin System Pathways and SARS-CoV-2 Infection: The Rationale for the Administration of Zinc-Chelating Agents in COVID-19 Patients.|pdf=|usr=026}}
+{{tp|p=33540625|t=2021. Thymoquinone: A Tie-Breaker in SARS-CoV2-Infected Cancer Patients?|pdf=|usr=026}}
+{{tp|p=33609497|t=2021. Testing of the inhibitory effects of loratadine and desloratadine on SARS-CoV-2 spike pseudotyped virus viropexis.|pdf=|usr=026}}
+{{tp|p=33776550|t=2021. Make it clean, make it safe: A review on virus elimination via adsorption.|pdf=|usr=026}}
+{{tp|p=33762883|t=2021. Inhalable nanovaccine with biomimetic coronavirus structure to trigger mucosal immunity of respiratory tract against COVID-19.|pdf=|usr=026}}
+{{tp|p=33776065|t=2021. In silico studies on stilbenolignan analogues as SARS-CoV-2 Mpro inhibitors.|pdf=|usr=026}}
+{{tp|p=33716308|t=2021. Inhibition of interferon-stimulated gene 15 and lysine 48-linked ubiquitin binding to the SARS-CoV-2 papain-like protease by small molecules: In silico studies.|pdf=|usr=026}}
+{{tp|p=33716307|t=2021. Biological perspective of thiazolide derivatives against Mpro and MTase of SARS-CoV-2: Molecular docking, DFT and MD simulation investigations.|pdf=|usr=026}}
+{{tp|p=33623170|t=2021. Identification of high affinity and low molecular alternatives of boceprevir against SARS-CoV-2 main protease: A virtual screening approach.|pdf=|usr=026}}
+{{tp|p=33558778|t=2021. QSAR study of unsymmetrical aromatic disulfides as potent avian SARS-CoV main protease inhibitors using quantum chemical descriptors and statistical methods.|pdf=|usr=026}}
+{{tp|p=33756475|t=2021. Targeting Microbiome: An Alternative Strategy for Fighting SARS-CoV-2 Infection.|pdf=|usr=026}}
+{{tp|p=33540487|t=2021. An Androsterone-H2 @C60 hybrid: Synthesis, Properties and Molecular Docking Simulations with SARS-Cov-2.|pdf=|usr=026}}
+{{tp|p=33549598|t=2021. Should Antipyretics Be Used to Relieve Acute Adverse Events Related to COVID-19 Vaccines?|pdf=|usr=026}}
+{{tp|p=33621601|t=2021. Progesterone in Addition to Standard of Care vs Standard of Care Alone in the Treatment of Men Hospitalized With Moderate to Severe COVID-19: A Randomized, Controlled Pilot Trial.|pdf=|usr=026}}
+{{tp|p=33528745|t=2021. Thoughts on Traditional Chinese Medicine Treatment of Novel Coronavirus Pneumonia Based on Two Cases.|pdf=|usr=026}}
+{{tp|p=33544289|t=2021. Promising Antiviral Molecules from Ayurvedic Herbs and Spices against COVID-19.|pdf=|usr=026}}
+{{tp|p=33534076|t=2021. Effects of Chinese Medicine on Symptoms, Syndrome Evolution, and Lung Inflammation Absorption in COVID-19 Convalescent Patients during 84-Day Follow-up after Hospital Discharge: A Prospective Cohort and Nested Case-Control Study.|pdf=|usr=026}}
+{{tp|p=33618736|t=2021. Traditional Chinese herbal medicine-potential therapeutic application for the treatment of COVID-19.|pdf=|usr=026}}
+{{tp|p=33617183|t=2020. Statins as candidate therapeutic agents for coronavirus disease 2019 (COVID-19).|pdf=|usr=026}}
+{{tp|p=33555601|t=2021. Just the facts: updates in COVID-19 therapeutics.|pdf=|usr=026}}
+{{tp|p=33709361|t=2021. CJEM journal club: corticosteroids use for critically ill COVID-19 patients.|pdf=|usr=026}}
+{{tp|p=33534117|t=2021. Is dexamethasone an effective treatment for severe COVID-19 patients: Journal Club review.|pdf=|usr=026}}
+{{tp|p=33687984|t=2021. Vaccination for COVID-19: Is it important and what should you know about it?|pdf=|usr=026}}
+{{tp|p=33648932|t=2021. Anaphylaxis to vaccinations: A review of the literature and evaluation of the COVID-19 mRNA vaccinations.|pdf=|usr=026}}
+{{tp|p=33597176|t=2021. Monoclonal antibodies for treating COVID-19.|pdf=|usr=026}}
+{{tp|p=33648989|t=2021. Vascular Normalization to Improve Treatment of COVID-19: Lessons from Treatment of Cancer.|pdf=|usr=026}}
+{{tp|p=33628060|t=2021. A Phthalocyanine Derivate Mouthwash to Gargling/Rinsing as an Option to Reduce Clinical Symptoms of COVID-19: Case Series.|pdf=|usr=026}}
+{{tp|p=33754328|t=2021. Can mRNA Vaccines Turn the Tables During the COVID-19 Pandemic? Current Status and Challenges.|pdf=|usr=026}}
+{{tp|p=33666256|t=2021. COVID-19 vaccination and patients with psoriasis under biologics: real-life evidence on safety and effectiveness from Italian vaccinated healthcare workers.|pdf=|usr=026}}
+{{tp|p=33555252|t=2021. Vaccination against SARS-CoV-2 in patients with rheumatic diseases: doubts and perspectives.|pdf=|usr=026}}
+{{tp|p=33635218|t=2021. High-dose glucocorticoids pulse-therapy for beta-coronaviridae pneumonia: a systematic literature review and case-series of Coronavirus disease-2019.|pdf=|usr=026}}
+{{tp|p=33628750|t=2021. Current updates and research on plant-based vaccines for coronavirus disease 2019.|pdf=|usr=026}}
+{{tp|p=33628749|t=2021. A review on the advancements in the development of vaccines to combat coronavirus disease 2019.|pdf=|usr=026}}
+{{tp|p=33548200|t=2021. What Gastroenterologists Should Know About COVID-19 Vaccines.|pdf=|usr=026}}
+{{tp|p=33684527|t=2021. Mesenchymal stem cell alongside exosomes as a novel cell-based therapy for COVID-19: A review study.|pdf=|usr=026}}
+{{tp|p=33693610|t=2021. Impressive boosting of anti-S1/S2 IgG production in COVID-19-experienced patients after the first shot of the BNT162b2 mRNA COVID-19 Vaccine.|pdf=|usr=026}}
+{{tp|p=33693552|t=2021. Are some COVID vaccines better than others? Interpreting and comparing estimates of efficacy in trials of COVID-19 vaccines.|pdf=|usr=026}}
+{{tp|p=33693607|t=2021. Trends in Prescribing of Antibiotics and Drugs Investigated for COVID-19 Treatment in U.S. Nursing Home Residents During the COVID-19 Pandemic.|pdf=|usr=026}}
+{{tp|p=33639622|t=2021. How to test SARS-CoV-2 vaccines ethically even after one is available.|pdf=|usr=026}}
+{{tp|p=33630997|t=2021. Reduced Vitamin K Status and Coronavirus Disease 2019: An Epiphenomenon of Impaired Kidney Function?|pdf=|usr=026}}
+{{tp|p=33654337|t=2021. SAFETY PROFILE OF TREATMENTS ADMINISTERED IN COVID 19 INFECTION IN PREGNANT WOMEN.|pdf=|usr=026}}
+{{tp|p=33762401|t=2021. SARS-CoV-2 infection despite vaccination: an under-reported COVID-19 cohort.|pdf=|usr=026}}
+{{tp|p=33593830|t=2021. Perspective: Vitamin D supplementation prevents rickets and acute respiratory infections when given as daily maintenance but not as intermittent bolus: implications for COVID-19.|pdf=|usr=026}}
+{{tp|p=33705848|t=2021. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis - Author's reply.|pdf=|usr=026}}
+{{tp|p=33705849|t=2021. A real-life setting evaluation of the effect of remdesivir on viral load in COVID-19 patients admitted to a large tertiary centre in Israel.|pdf=|usr=026}}
+{{tp|p=33549765|t=2021. Re: 'Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis' by Tleyjeh et al.|pdf=|usr=026}}
+{{tp|p=33647441|t=2021. Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19): a new safety concerns.|pdf=|usr=026}}
+{{tp|p=33564204|t=2021. Convalescent Plasma for Infectious Diseases: Historical Framework and Use in COVID-19.|pdf=|usr=026}}
+{{tp|p=33631509|t=2021. Can pulse steroid therapy increase the risk of infection by COVID-19 in patients with multiple sclerosis?|pdf=|usr=026}}
+{{tp|p=33745749|t=2021. Vitamin D deficiency in critically ill COVID-19 ARDS patients.|pdf=|usr=026}}
+{{tp|p=33745628|t=2021. The prevalence of malnutrition and analysis of related factors among adult patients with the Coronavirus Disease 2019 (COVID 19) in a tertiary government hospital: The MalnutriCoV study.|pdf=|usr=026}}
+{{tp|p=33745598|t=2021. Evaluation of vitamin D levels in COVID-19 patients referred to Labafinejad hospital in Tehran and its relationship with disease severity and mortality.|pdf=|usr=026}}
+{{tp|p=33745593|t=2021. Are history of dietary intake and food habits of patients with clinical symptoms of COVID 19 different from healthy controls? A case-control study.|pdf=|usr=026}}
+{{tp|p=33745572|t=2021. Trajectories of eating behavior during COVID-19 lockdown: Longitudinal analyses of 22,374 adults.|pdf=|usr=026}}
+{{tp|p=33745566|t=2021. Healthy nutritional behavior during COVID-19 lockdown: A cross-sectional study.|pdf=|usr=026}}
+{{tp|p=33782830|t=2021. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor.|pdf=|usr=026}}
+{{tp|p=33641159|t=2021. Systematic Review and Patient-Level Meta-Analysis of SARS-CoV-2 Viral Dynamics to Model Response to Antiviral Therapies.|pdf=|usr=026}}
+{{tp|p=33547636|t=2021. Neglecting Plasma Protein Binding in COVID-19 Patients Leads to a Wrong Interpretation of Lopinavir Overexposure.|pdf=|usr=026}}
+{{tp|p=33529354|t=2021. Real-World Evidence for Assessing Pharmaceutical Treatments in the Context of COVID-19.|pdf=|usr=026}}
+{{tp|p=33798755|t=2021. Predictive analysis of COVID-19 eradication with vaccination in India, Brazil, and U.S.A.|pdf=|usr=026}}
+{{tp|p=33819681|t=2021. Immunogenicity and antigenicity based T-cell and B-cell epitopes identification from conserved regions of 10664 SARS-CoV-2 genomes.|pdf=|usr=026}}
+{{tp|p=33783508|t=2021. Safety of Tofacitinib in the COVID-19 Pandemic-Enough Is Not Enough.|pdf=|usr=026}}
+{{tp|p=33772572|t=2021. Development of COVID-19 vaccines utilizing gene therapy technology.|pdf=|usr=026}}
+{{tp|p=33812260|t=2021. The effect of tocilizumab on COVID-19 patient mortality: A systematic review and meta-analysis of randomized controlled trials.|pdf=|usr=026}}
+{{tp|p=33803339|t=2021. Approaches to Nutritional Screening in Patients with Coronavirus Disease 2019 (COVID-19).|pdf=|usr=026}}
+{{tp|p=33801651|t=2021. A Rapid Review of COVID-19 Vaccine Prioritization in the U.S.: Alignment between Federal Guidance and State Practice.|pdf=|usr=026}}
+{{tp|p=33809918|t=2021. Linear B-Cell Epitope Prediction for In Silico Vaccine Design: A Performance Review of Methods Available via Command-Line Interface.|pdf=|usr=026}}
+{{tp|p=33808940|t=2021. Identification of Anti-Severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Oxysterol Derivatives In Vitro.|pdf=|usr=026}}
+{{tp|p=33808574|t=2021. Dietary and Protective Factors to Halt or Mitigate Progression of Autoimmunity, COVID-19 and Its Associated Metabolic Diseases.|pdf=|usr=026}}
+{{tp|p=33802761|t=2021. Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence.|pdf=|usr=026}}
+{{tp|p=33802729|t=2021. SARS-CoV-2 Entry Related Viral and Host Genetic Variations: Implications on COVID-19 Severity, Immune Escape, and Infectivity.|pdf=|usr=026}}
+{{tp|p=33804129|t=2021. Metal-Bound Methisazone; Novel Drugs Targeting Prophylaxis and Treatment of SARS-CoV-2, a Molecular Docking Study.|pdf=|usr=026}}
+{{tp|p=33802169|t=2021. A Novel Computational Approach for the Discovery of Drug Delivery System Candidates for COVID-19.|pdf=|usr=026}}
+{{tp|p=33797236|t=2021. Stealth Fluorescence Labeling for Live Microscopy Imaging of mRNA Delivery.|pdf=|usr=026}}
+{{tp|p=33792713|t=2021. Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU-authors' response.|pdf=|usr=026}}
+{{tp|p=33758946|t=2021. Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials.|pdf=|usr=026}}
+{{tp|p=33784944|t=2021. Design and synthesis of novel phe-phe hydroxyethylene derivatives as potential coronavirus main protease inhibitors.|pdf=|usr=026}}
+{{tp|p=33645490|t=2021. COVID-19: Potential Repurposing Drugs.|pdf=|usr=026}}
+{{tp|p=33602078|t=2021. Natural Derived Nasal Spray; a Proposed Approach for COVID-19 Disease Control.|pdf=|usr=026}}
+{{tp|p=33573449|t=2021. Effects of tocilizumab versus hemoadsorption combined with tocilizumab in patients with SARS-CoV-2 pneumonia: Preliminary results.|pdf=|usr=026}}
+{{tp|p=33624584|t=2021. Bioequivalence study of two favipiravir tablet formulations in healthy male subjects.|pdf=|usr=026}}
+{{tp|p=33624583|t=2021. Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: A pilot retrospective study.|pdf=|usr=026}}
+{{tp|p=33605875|t=2021. COVID-19 double whammy - Vaccine and variants.|pdf=|usr=026}}
+{{tp|p=33763939|t=2021. Investigation of SARS-CoV-2 RNA in milk produced by women with COVID-19 and follow-up of their infants: A preliminary study.|pdf=|usr=026}}
+{{tp|p=33759318|t=2021. Effect of COVID-19 medications on corrected QT interval and induction of torsade de pointes: Results of a multicenter national survey.|pdf=|usr=026}}
+{{tp|p=33743543|t=2021. Investigation of the disease process and drug combinations in patients with suspected/confirmed COVID-19 using favipiravir.|pdf=|usr=026}}
+{{tp|p=33797849|t=2021. Detectable respiratory SARS-CoV-2 RNA is associated with low vitamin D levels and high social deprivation.|pdf=|usr=026}}
+{{tp|p=33752299|t=2021. Does therapeutic drug monitoring of hydroxychloroquine improve treatment outcome in intensive care unit patients with COVID-19?|pdf=|usr=026}}
+{{tp|p=33682604|t=2021. Exploring the rationale for thermotherapy in COVID-19.|pdf=|usr=026}}
+{{tp|p=33822495|t=2021. Chaga Medicinal Mushroom Inonotus obliquus (Agaricomycetes) Terpenoids May Interfere with SARS-CoV-2 Spike Protein Recognition of the Host Cell: A Molecular Docking Study.|pdf=|usr=026}}
+{{tp|p=33725395|t=2021. The effect of Chinese herbal medicine on digestive system and liver functions should not be neglected in COVID-19: An updated systematic review and meta-analysis.|pdf=|usr=026}}
+{{tp|p=33749986|t=2021. Identification of mutation resistance coldspots for targeting the SARS-CoV2 main protease.|pdf=|usr=026}}
+{{tp|p=33691499|t=2021. Mycobacterium vaccae Nebulization in the Treatment of COVID-19: A Randomized, Double-Blind, Placebo-Controlled Trial.|pdf=|usr=026}}
+{{tp|p=33596158|t=2021. l-Cysteine Stimulates the Effect of Vitamin D on Inhibition of Oxidative Stress, IL-8, and MCP-1 Secretion in High Glucose Treated Monocytes.|pdf=|usr=026}}
+{{tp|p=33768521|t=2021. Immunogenicity of the BNT162b2 vaccine in frail or disabled nursing home residents: COVID-A study.|pdf=|usr=026}}
+{{tp|p=33762353|t=2021. SARS-CoV-2 Vaccines in Kidney Transplant Recipients: Will They Be Safe and Effective and How Will We Know?|pdf=|usr=026}}
+{{tp|p=33526471|t=2021. A Novel Soluble ACE2 Variant with Prolonged Duration of Action Neutralizes SARS-CoV-2 Infection in Human Kidney Organoids.|pdf=|usr=026}}
+{{tp|p=33527804|t=2021. Itolizumab Treatment for Cytokine Release Syndrome in Moderate to Severe Acute Respiratory Distress Syndrome Due to COVID-19: Clinical Outcomes, A Retrospective Study.|pdf=|usr=026}}
+{{tp|p=33594850|t=2021. In silico approach: docking study of oxindole derivatives against the main protease of COVID-19 and its comparison with existing therapeutic agents.|pdf=|usr=026}}
+{{tp|p=33594843|t=2021. Evidence that Ginkgo Biloba could use in the influenza and coronavirus COVID-19 infections.|pdf=|usr=026}}
+{{tp|p=33682642|t=2021. Finding potent inhibitors against SARS-CoV-2 main protease through virtual screening, ADMET, and molecular dynamics simulation studies.|pdf=|usr=026}}
+{{tp|p=33682639|t=2021. Binding and inhibitory effect of ravidasvir on 3CL(pro) of SARS-CoV-2: a molecular docking, molecular dynamics and MM/PBSA approach.|pdf=|usr=026}}
+{{tp|p=33682633|t=2021. Structural insight into the binding interactions of NTPs and nucleotide analogues to RNA dependent RNA polymerase of SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33682632|t=2021. Structure-based virtual screening, molecular dynamics and binding affinity calculations of some potential phytocompounds against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33682606|t=2021. Flavonoids as potential therapeutics against novel coronavirus disease-2019 (nCOVID-19).|pdf=|usr=026}}
+{{tp|p=33663346|t=2021. Metadynamics-based enhanced sampling protocol for virtual screening: case study for 3CLpro protein for SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33764269|t=2021. Isatin-based virtual high throughput screening, molecular docking, DFT, QM/MM, MD and MM-PBSA study of novel inhibitors of SARS-CoV-2 main protease.|pdf=|usr=026}}
+{{tp|p=33751280|t=2021. A practical approach for vaccinations including COVID-19 in autoimmune/autoinflammatory rheumatic diseases: a non-systematic review.|pdf=|usr=026}}
+{{tp|p=33579547|t=2021. The COVID-19 mRNA Vaccines and the Pandemic: Do They Represent the Beginning of the End or the End of the Beginning?|pdf=|usr=026}}
+{{tp|p=33549310|t=2021. A Critical Appraisal of the Effects of Anesthetics on Immune-system Modulation in Critically Ill Patients With COVID-19.|pdf=|usr=026}}
+{{tp|p=33641562|t=2021. Safety and effectiveness concerns of lopinavir/ritonavir in COVID-19 affected patients: a retrospective series.|pdf=|usr=026}}
+{{tp|p=33728279|t=2021. Prevalence of thyroid dysfunction in patients with COVID-19: a systematic review.|pdf=|usr=026}}
+{{tp|p=33732459|t=2021. Antibodies to neutralising epitopes synergistically block the interaction of the receptor-binding domain of SARS-CoV-2 to ACE 2.|pdf=|usr=026}}
+{{tp|p=33635001|t=2021. Bromelain inhibits SARS-CoV-2 infection via targeting ACE-2, TMPRSS2, and spike protein.|pdf=|usr=026}}
+{{tp|p=33634996|t=2021. Evaluation of the safety and efficacy of using human menstrual blood-derived mesenchymal stromal cells in treating severe and critically ill COVID-19 patients: An exploratory clinical trial.|pdf=|usr=026}}
+{{tp|p=33634979|t=2021. Ring vaccination of COVID-19 vaccines in medium- and high-risk areas of countries with low incidence of SARS-CoV-2 infection.|pdf=|usr=026}}
+{{tp|p=33620150|t=2021. Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off-label in the first wave of COVID-19.|pdf=|usr=026}}
+{{tp|p=33606912|t=2021. Virtual screening FDA approved drugs against multiple targets of SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33606894|t=2021. Mortality, viral clearance, and other clinical outcomes of hydroxychloroquine in COVID-19 patients: A systematic review and meta-analysis of randomized controlled trials.|pdf=|usr=026}}
+{{tp|p=33595145|t=2021. Bamlanivimab for treatment of COVID-19 in solid organ transplant recipients: Early single-center experience.|pdf=|usr=026}}
+{{tp|p=33535811|t=2021. COVID-19 vaccine trials: The use of active controls and non-inferiority studies.|pdf=|usr=026}}
+{{tp|p=33530721|t=2021. An ethics framework for consolidating and prioritizing COVID-19 clinical trials.|pdf=|usr=026}}
+{{tp|p=33787678|t=2021. COVID-19 and Thromboinflammation: Is There a Role for Statins?|pdf=|usr=026}}
+{{tp|p=33692091|t=2021. Tocilizumab for hospitalized patients with COVID-19.|pdf=|usr=026}}
+{{tp|p=33552306|t=2021. Deep Learning-Based Potential Ligand Prediction Framework for COVID-19 with Drug-Target Interaction Model.|pdf=|usr=026}}
+{{tp|p=33564211|t=2021. Nano-size dependence in the adsorption by the SARS-CoV-2 spike protein over gold colloid.|pdf=|usr=026}}
+{{tp|p=33795896|t=2020. COVID-19: The Ivermectin African Enigma.|pdf=|usr=026}}
+{{tp|p=33564093|t=2021. Tipiracil binds to uridine site and inhibits Nsp15 endoribonuclease NendoU from SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33627795|t=2021. Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy.|pdf=|usr=026}}
+{{tp|p=33580154|t=2021. Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection.|pdf=|usr=026}}
+{{tp|p=33551714|t=2021. Critical roles of TLRs on the polarization of mesenchymal stem cells for cell therapy of viral infections: a notice for COVID-19 treatment.|pdf=|usr=026}}
+{{tp|p=33677227|t=2021. Docking-based virtual screening studies aiming at the covalent inhibition of SARS-CoV-2 M(Pro) by targeting the cysteine 145.|pdf=|usr=026}}
+{{tp|p=33751995|t=2021. Structural insights on the interaction potential of natural leads against major protein targets of SARS-CoV-2: Molecular modelling, docking and dynamic simulation studies.|pdf=|usr=026}}
+{{tp|p=33721736|t=2021. Deep learning model for virtual screening of novel 3C-like protease enzyme inhibitors against SARS coronavirus diseases.|pdf=|usr=026}}
+{{tp|p=33705994|t=2021. A hijack mechanism of Indian SARS-CoV-2 isolates for relapsing contemporary antiviral therapeutics.|pdf=|usr=026}}
+{{tp|p=33535144|t=2021. Analogue discovery of safer alternatives to HCQ and CQ drugs for SAR-CoV-2 by computational design.|pdf=|usr=026}}
+{{tp|p=33662683|t=2021. Targeting multiple conformations of SARS-CoV2 Papain-Like Protease for drug repositioning: An in-silico study.|pdf=|usr=026}}
+{{tp|p=33662681|t=2021. Network pharmacology and RNA-sequencing reveal the molecular mechanism of Xuebijing injection on COVID-19-induced cardiac dysfunction.|pdf=|usr=026}}
+{{tp|p=33777333|t=2021. Specific epitopes form extensive hydrogen-bonding networks to ensure efficient antibody binding of SARS-CoV-2: Implications for advanced antibody design.|pdf=|usr=026}}
+{{tp|p=33680350|t=2021. COVID-19 pandemic: Can zinc supplementation provide an additional shield against the infection?|pdf=|usr=026}}
+{{tp|p=33680348|t=2021. Antioxidants and pentoxifylline as coadjuvant measures to standard therapy to improve prognosis of patients with pneumonia by COVID-19.|pdf=|usr=026}}
+{{tp|p=33552444|t=2021. Current concepts in the development of therapeutics against human and animal coronavirus diseases by targeting NP.|pdf=|usr=026}}
+{{tp|p=33619460|t=2021. Covid-19 treatment: Investigation on the phytochemical constituents of Vernonia amygdalina as potential Coronavirus-2 inhibitors.|pdf=|usr=026}}
+{{tp|p=33553857|t=2021. Screening possible drug molecules for Covid-19. The example of vanadium (III/IV/V) complex molecules with computational chemistry and molecular docking.|pdf=|usr=026}}
+{{tp|p=33532671|t=2021. From genomes to molecular dynamics - A bottom up approach in extrication of SARS CoV-2 main protease inhibitors.|pdf=|usr=026}}
+{{tp|p=33557911|t=2021. Carboxypeptidase B blocks ex vivo activation of the anaphylatoxin-neutrophil extracellular trap axis in neutrophils from COVID-19 patients.|pdf=|usr=026}}
+{{tp|p=33786440|t=2021. New Decade, Old Debate: Blocking the Cytokine Pathways in Infection-Induced Cytokine Cascade.|pdf=|usr=026}}
+{{tp|p=33817660|t=2021. Early Tocilizumab Dosing Is Associated With Improved Survival in Critically Ill Patients Infected With Severe Acute Respiratory Syndrome Coronavirus-2.|pdf=|usr=026}}
+{{tp|p=33660966|t=2021. Could fluvoxamine keep COVID-19 patients out of hospitals and intensive care units?|pdf=|usr=026}}
+{{tp|p=33786251|t=2021. Purpuric Rash and Thrombocytopenia After the mRNA-1273 (Moderna) COVID-19 Vaccine.|pdf=|usr=026}}
+{{tp|p=33717715|t=2021. Predictors of Mortality Amongst Tocilizumab Administered COVID-19 Asian Indians: A Predictive Study From a Tertiary Care Centre.|pdf=|usr=026}}
+{{tp|p=33786231|t=2021. Lymphadenopathy Associated With the COVID-19 Vaccine.|pdf=|usr=026}}
+{{tp|p=33633920|t=2021. Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial.|pdf=|usr=026}}
+{{tp|p=33758714|t=2021. Neurological Complications of COVID-19: Guillain-Barre Syndrome Following Pfizer COVID-19 Vaccine.|pdf=|usr=026}}
+{{tp|p=33643746|t=2021. Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial - Biochemical).|pdf=|usr=026}}
+{{tp|p=33532161|t=2020. The History of Methylprednisolone, Ascorbic Acid, Thiamine, and Heparin Protocol and I-MASK+ Ivermectin Protocol for COVID-19.|pdf=|usr=026}}
+{{tp|p=33686365|t=2021. Developmental Status of the Potential Vaccines for the Mitigation of the COVID-19 Pandemic and a Focus on the Effectiveness of the Pfizer-BioNTech and Moderna mRNA Vaccines.|pdf=|usr=026}}
+{{tp|p=33582901|t=2021. Corticosteroids Treatment of Patients with Coronavirus Disease 2019: A Propensity Score Matching Study.|pdf=|usr=026}}
+{{tp|p=33680715|t=2021. Determination of Potential Drug Candidate Molecules of the Hypericum perforatum for COVID-19 Treatment.|pdf=|usr=026}}
+{{tp|p=33619447|t=2021. Efficacy and Safety of New and Emerging Drugs for COVID-19: Favipiravir and Dexamethasone.|pdf=|usr=026}}
+{{tp|p=33773396|t=2021. Glycyrrhizin prevents SARS-CoV-2 S1 and Orf3a induced high mobility group box 1 (HMGB1) release and inhibits viral replication.|pdf=|usr=026}}
+{{tp|p=33714693|t=2021. The conundrum of current anti-SARS-CoV-2 vaccines.|pdf=|usr=026}}
+{{tp|p=33776206|t=2021. Taming of Covid-19: potential and emerging application of mesenchymal stem cells.|pdf=|usr=026}}
+{{tp|p=33797339|t=2021. COVID19-inhibitory activity of withanolides involves targeting of the host cell surface receptor ACE2: insights from computational and biochemical assays.|pdf=|usr=026}}
+{{tp|p=33784094|t=2021. Lead Discovery of SARS-CoV-2 Main Protease Inhibitors through Covalent Docking-Based Virtual Screening.|pdf=|usr=026}}
+{{tp|p=33821020|t=2021. Cytotoxicity, anti-microbial studies of M(II)-dithiocarbamate complexes, and molecular docking study against SARS COV2 RNA-dependent RNA polymerase.|pdf=|usr=026}}
+{{tp|p=33822770|t=2021. SARS-CoV-2 mRNA vaccines induce broad CD4+ T cell responses that recognize SARS-CoV-2 variants and HCoV-NL63.|pdf=|usr=026}}
+{{tp|p=33808205|t=2021. Effects of Different Dialysis Strategies on Inflammatory Cytokine Profile in Maintenance Hemodialysis Patients with COVID-19: A Randomized Trial.|pdf=|usr=026}}
+{{tp|p=33805760|t=2021. Angiotensin-(1-7)-A Potential Remedy for AKI: Insights Derived from the COVID-19 Pandemic.|pdf=|usr=026}}
+{{tp|p=33798667|t=2021. The dawn of mRNA vaccines: The COVID-19 case.|pdf=|usr=026}}
+{{tp|p=33818731|t=2021. Retrospective analysis of vitamin D status on inflammatory markers and course of the disease in patients with COVID-19 infection.|pdf=|usr=026}}
+{{tp|p=33813013|t=2021. Antiviral effect of fufang yinhua jiedu (FFYH) granules against influenza A virus through regulating the inflammatory responses by TLR7/MyD88 signaling pathway.|pdf=|usr=026}}
+{{tp|p=33811961|t=2021. BNT 13b2 Pfizer vaccine protects against SARS-CoV-2 respiratory mucosal colonization even after prolonged exposure to positive family members.|pdf=|usr=026}}
+{{tp|p=33811939|t=2021. Reactogenicity, safety and antibody response, after one and two doses of mRNA-1273 in seronegative and seropositive healthcare workers.|pdf=|usr=026}}
+{{tp|p=33761582|t=2021. Super-rapid race for saving lives by developing COVID-19 vaccines.|pdf=|usr=026}}
+{{tp|p=33743557|t=2021. Special issue on COVID-19 data integration opportunities and vaccine development strategies.|pdf=|usr=026}}
+{{tp|p=33759703|t=2021. A computational study on active constituents of Habb-ul-aas and Tabasheer as inhibitors of SARS-CoV-2 main protease.|pdf=|usr=026}}
+{{tp|p=33759690|t=2021. In silico screening of therapeutic potentials from Strychnos nux-vomica against the dimeric main protease (M(pro)) structure of SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33749547|t=2021. Evaluation of the effects of chlorhexidine and several flavonoids as antiviral purposes on SARS-CoV-2 main protease: molecular docking, molecular dynamics simulation studies.|pdf=|usr=026}}
+{{tp|p=33749545|t=2021. On the search for COVID-19 therapeutics: identification of potential SARS-CoV-2 main protease inhibitors by virtual screening, pharmacophore modeling and molecular dynamics.|pdf=|usr=026}}
+{{tp|p=33749538|t=2021. Phylogenic analysis of coronavirus genome and molecular studies on potential anti-COVID-19 agents from selected FDA-approved drugs.|pdf=|usr=026}}
+{{tp|p=33749528|t=2021. Repurposing of anticancer phytochemicals for identifying potential fusion inhibitor for SARS-CoV-2 using molecular docking and molecular dynamics (MD) simulations.|pdf=|usr=026}}
+{{tp|p=33749496|t=2021. Cyanobacterial natural products as sources for antiviral drug discovery against COVID-19.|pdf=|usr=026}}
+{{tp|p=33734021|t=2021. Antiretroviral drug activity and potential for pre-exposure prophylaxis against COVID-19 and HIV infection.|pdf=|usr=026}}
+{{tp|p=33719855|t=2021. Potentiality of Moringa oleifera against SARS-CoV-2: identified by a rational computer aided drug design method.|pdf=|usr=026}}
+{{tp|p=33706683|t=2021. Potential inhibitors of angiotensin converting enzyme 2 receptor of COVID-19 by Corchorus olitorius Linn using docking, molecular dynamics, conceptual DFT investigation and pharmacophore mapping.|pdf=|usr=026}}
+{{tp|p=33715598|t=2021. A rational design of a multi-epitope vaccine against SARS-CoV-2 which accounts for the glycan shield of the spike glycoprotein.|pdf=|usr=026}}
+{{tp|p=33715595|t=2021. Black tea bioactives as inhibitors of multiple targets of SARS-CoV-2 (3CLpro, PLpro and RdRp): a virtual screening and molecular dynamic simulation study.|pdf=|usr=026}}
+{{tp|p=33715592|t=2021. In silico drug designing for COVID-19: an approach of high-throughput virtual screening, molecular, and essential dynamics simulations.|pdf=|usr=026}}
+{{tp|p=33554747|t=2021. Targeting the N-terminal domain of the RNA-binding protein of the SARS-CoV-2 with high affinity natural compounds to abrogate the protein-RNA interaction: a molecular dynamics study.|pdf=|usr=026}}
+{{tp|p=33645457|t=2021. Targeting allosteric pockets of SARS-CoV-2 main protease M(pro).|pdf=|usr=026}}
+{{tp|p=33625318|t=2021. 4-acetamido-3-nitrobenzoic acid - structural, quantum chemical studies, ADMET and molecular docking studies of SARS-CoV2.|pdf=|usr=026}}
+{{tp|p=33618628|t=2021. Investigation of the inhibitory activity of some dietary bioactive flavonoids against SARS-CoV-2 using molecular dynamics simulations and MM-PBSA calculations.|pdf=|usr=026}}
+{{tp|p=33618621|t=2021. Structural stability predictions and molecular dynamics simulations of RBD and HR1 mutations associated with SARS-CoV-2 spike glycoprotein.|pdf=|usr=026}}
+{{tp|p=33615998|t=2021. In silico evaluation of isatin-based derivatives with RNA-dependent RNA polymerase of the novel coronavirus SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33586620|t=2021. Whole proteome screening and identification of potential epitopes of SARS-CoV-2 for vaccine design-an immunoinformatic, molecular docking and molecular dynamics simulation accelerated robust strategy.|pdf=|usr=026}}
+{{tp|p=33810774|t=2021. In silico inquest reveals the efficacy of Cannabis in the treatment of post-Covid-19 related neurodegeneration.|pdf=|usr=026}}
+{{tp|p=33648025|t=2021. Rapid development of a de novo convalescent plasma program in response to a global pandemic: A large southeastern U.S. blood center's experience.|pdf=|usr=026}}
+{{tp|p=33768612|t=2021. QT prolongation associated with hydroxychloroquine and protease inhibitors in COVID-19.|pdf=|usr=026}}
+{{tp|p=33650415|t=2021. The Effect of Tocilizumab on Inflammatory Markers in Survivors and Non-survivors of Severe COVID-19.|pdf=|usr=026}}
+{{tp|p=33787192|t=2021. The effects of combination of Zingiber officinale and Echinacea on alleviation of clinical symptoms and hospitalization rate of suspected COVID-19 outpatients: a randomized controlled trial.|pdf=|usr=026}}
+{{tp|p=33544526|t=2021. Preventive aspect of ayurveda and yoga towards newly emerging disease COVID-19.|pdf=|usr=026}}
+{{tp|p=33713492|t=2021. Drug repositioning to target NSP15 protein on SARS-CoV-2 as possible COVID-19 treatment.|pdf=|usr=026}}
+{{tp|p=33638924|t=2021. Herpes zoster following inactivated COVID-19 vaccine: A coexistence or coincidence?|pdf=|usr=026}}
+{{tp|p=33682615|t=2021. Trace Minerals, Vitamins and Nutraceuticals in Prevention and Treatment of COVID-19.|pdf=|usr=026}}
+{{tp|p=33594938|t=2021. Potential Efficacy of Nutrient Supplements for Treatment or Prevention of COVID-19.|pdf=|usr=026}}
+{{tp|p=33683080|t=2021. Coronavirus Vaccination Adverse Reactions and the Role of the Dermatologist.|pdf=|usr=026}}
+{{tp|p=33528149|t=2020. The Relevance of Vitamin D Supplementation for People of Color in the Era of COVID-19.|pdf=|usr=026}}
+{{tp|p=33783873|t=2021. Skin manifestations of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers. 'COVID-arm': a clinical and histological characterization.|pdf=|usr=026}}
+{{tp|p=33783855|t=2021. Extraordinary claims without extraordinary evidence: controversy on anti-androgen therapy for COVID-19.|pdf=|usr=026}}
+{{tp|p=33783017|t=2021. Persistent maculopapular rash after the first dose of Pfizer-BioNTech COVID-19 vaccine.|pdf=|usr=026}}
+{{tp|p=33780556|t=2021. Vaccination against SARS-CoV-2 and psoriasis: the three things every dermatologist should know.|pdf=|usr=026}}
+{{tp|p=33725406|t=2021. Prompt onset of Rowell's syndrome following the first BNT162b2 SARS-CoV-2 vaccination.|pdf=|usr=026}}
+{{tp|p=33617431|t=2021. Early and Significant Reduction in C-Reactive Protein Levels After Corticosteroid Therapy Is Associated With Reduced Mortality in Patients With COVID-19.|pdf=|usr=026}}
+{{tp|p=33576702|t=2021. Letter to the editor: COVID-19 Vaccines and Breastfeeding.|pdf=|usr=026}}
+{{tp|p=33735530|t=2021. A UK survey of nutritional care pathways for patients with COVID-19 prior to and post-hospital stay.|pdf=|usr=026}}
+{{tp|p=33632000|t=2021. A Comparison of Methylprednisolone and Dexamethasone in Intensive Care Patients With COVID-19.|pdf=|usr=026}}
+{{tp|p=33621130|t=2021. Perspectives on Targeting IL-6 as a Potential Therapeutic Strategy for COVID-19.|pdf=|usr=026}}
+{{tp|p=33822418|t=2021. Reply letter to: Inhibition of SARS-CoV-2 replication using calcineurin inhibitors: Are concentrations required clinically achievable?|pdf=|usr=026}}
+{{tp|p=33560802|t=2021. Morbilliform rash after administration of Pfizer-BioNTech COVID-19 mRNA vaccine.|pdf=|usr=026}}
+{{tp|p=33744398|t=2021. Increased mortality risk associated with statins in the CORONADO study.|pdf=|usr=026}}
+{{tp|p=33752274|t=2021. Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19.|pdf=|usr=026}}
+{{tp|p=33662839|t=2021. Metformin is associated with lower hospitalizations, mortality and severe coronavirus infection among elderly medicare minority patients in 8 states in USA.|pdf=|usr=026}}
+{{tp|p=33662837|t=2021. COVID-19 vaccination in patients with diabetes mellitus: Current concepts, uncertainties and challenges.|pdf=|usr=026}}
+{{tp|p=33528920|t=2021. Use of dipeptidyl peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study.|pdf=|usr=026}}
+{{tp|p=33606909|t=2021. Meta-analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodium-glucose co-transporter-2 inhibitors: Implications for the COVID-19 pandemic.|pdf=|usr=026}}
+{{tp|p=33594475|t=2021. The disproportionate excess mortality risk of COVID-19 in younger people with diabetes warrants vaccination prioritisation.|pdf=|usr=026}}
+{{tp|p=33625613|t=2021. Does Famotidine Reduce the Risk of Progression to Severe Disease, Death, and Intubation for COVID-19 Patients? A Systemic Review and Meta-Analysis.|pdf=|usr=026}}
+{{tp|p=33625612|t=2021. More Than Just Heartburn: Does Famotidine Effectively Treat Patients with COVID-19?|pdf=|usr=026}}
+{{tp|p=33535388|t=2021. Targeting NSP16 Methyltransferase for the Broad-Spectrum Clinical Management of Coronaviruses: Managing the Next Pandemic.|pdf=|usr=026}}
+{{tp|p=33689074|t=2021. Thermovaccination: Thermoheliox as an Immune Response Stimulant. Kinetics of Antibodies and C-Reactive Protein Synthesis in Coronaviral Infection.|pdf=|usr=026}}
+{{tp|p=33694083|t=2021. Advances in vaccine delivery systems against viral infectious diseases.|pdf=|usr=026}}
+{{tp|p=33762818|t=2021. Potential Anti-Coronavirus Agents and the Pharmacologic Mechanisms.|pdf=|usr=026}}
+{{tp|p=33737804|t=2021. Withanone from Withania somnifera Attenuates SARS-CoV-2 RBD and Host ACE2 Interactions to Rescue Spike Protein Induced Pathologies in Humanized Zebrafish Model.|pdf=|usr=026}}
+{{tp|p=33692615|t=2021. Beware of Steroid-Induced Avascular Necrosis of the Femoral Head in the Treatment of COVID-19-Experience and Lessons from the SARS Epidemic.|pdf=|usr=026}}
+{{tp|p=33612572|t=2021. Multidrug treatment for COVID-19.|pdf=|usr=026}}
+{{tp|p=33775925|t=2021. Diabetes, inflammation, and the adiponectin paradox: Therapeutic targets in SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33609782|t=2021. Inflammation control and improvement of cognitive function in COVID-19 infections: is there a role for kynurenine 3-monooxygenase inhibition?|pdf=|usr=026}}
+{{tp|p=33609783|t=2021. Developing new drugs that activate the protective arm of the renin-angiotensin system as a potential treatment for respiratory failure in COVID-19 patients.|pdf=|usr=026}}
+{{tp|p=33683968|t=2021. In quest of a new therapeutic approach in COVID-19: the endocannabinoid system.|pdf=|usr=026}}
+{{tp|p=33666902|t=2021. Safety Consequences of Off-Label Drugs Used for COVID-19.|pdf=|usr=026}}
+{{tp|p=33683637|t=2021. BNT162b2 mRNA COVID-19 Vaccine: First Approval.|pdf=|usr=026}}
+{{tp|p=33782908|t=2021. Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry.|pdf=|usr=026}}
+{{tp|p=33638807|t=2021. MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19.|pdf=|usr=026}}
+{{tp|p=33643421|t=2021. The race to a COVID-19 vaccine: opportunities and challenges in development and distribution.|pdf=|usr=026}}
+{{tp|p=33569736|t=2021. Pharmacotherapy Management for COVID-19 and Cardiac Safety: A Data Mining Approach for Pharmacovigilance Evidence from the FDA Adverse Event Reporting System (FAERS).|pdf=|usr=026}}
+{{tp|p=33780993|t=2021. SARS-CoV-2-Impfungen - Was muss der Nephrologe wissen?|pdf=|usr=026}}
+{{tp|p=33676899|t=2021. Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases and its metabolite GBPA exerts antiviral activity.|pdf=|usr=026}}
+{{tp|p=33752131|t=2021. COVID19 therapeutics: Expanding the antiviral arsenal.|pdf=|usr=026}}
+{{tp|p=33752127|t=2021. Itraconazole for COVID-19: preclinical studies and a proof-of-concept randomized clinical trial.|pdf=|usr=026}}
+{{tp|p=33681731|t=2021. Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial.|pdf=|usr=026}}
+{{tp|p=33615206|t=2021. Clinical outcomes of different therapeutic options for COVID-19 in two Chinese case cohorts: A propensity-score analysis.|pdf=|usr=026}}
+{{tp|p=33589884|t=2021. Can existing unrelated vaccines boost a COVID-19 vaccine prime?|pdf=|usr=026}}
+{{tp|p=33558858|t=2021. Is ivermectin ready to be part of a public health policy for COVID-19 prophylaxis?|pdf=|usr=026}}
+{{tp|p=33787663|t=2021. Use of mouthwashes in the management of COVID-19 patients in intensive care units: recommendations and current evidence.|pdf=|usr=026}}
+{{tp|p=33682678|t=2021. An open label trial of anakinra to prevent respiratory failure in COVID-19.|pdf=|usr=026}}
+{{tp|p=33691606|t=2021. Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates.|pdf=|usr=026}}
+{{tp|p=33691601|t=2021. The preclinical inhibitor GS441524 in combination with GC376 efficaciously inhibited the proliferation of SARS-CoV-2 in the mouse respiratory tract.|pdf=|usr=026}}
+{{tp|p=33560940|t=2021. The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor.|pdf=|usr=026}}
+{{tp|p=33555988|t=2021. A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques.|pdf=|usr=026}}
+{{tp|p=33538646|t=2021. Beneficial effect of combinational methylprednisolone and remdesivir in hamster model of SARS-CoV-2 infection.|pdf=|usr=026}}
+{{tp|p=33649739|t=2021. Potential Applications of Conducting Polymers to Reduce Secondary Bacterial Infections among COVID-19 Patients: a Review.|pdf=|usr=026}}
+{{tp|p=33744444|t=2021. Vitamin D and Its Potential Benefit for the COVID-19 Pandemic.|pdf=|usr=026}}
+{{tp|p=33705975|t=2021. Association of Vitamin D Status With Hospital Morbidity and Mortality in Adult Hospitalized Patients With COVID-19.|pdf=|usr=026}}
+{{tp|p=33738708|t=2021. Hypovitaminosis D and the endocrine phenotype of COVID-19.|pdf=|usr=026}}
+{{tp|p=33585705|t=2021. Therapeutic plasma exchange for persistent encephalopathy associated with Covid-19.|pdf=|usr=026}}
+{{tp|p=33741148|t=2021. Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency - Three consecutive cases and review of the literature.|pdf=|usr=026}}
+{{tp|p=33691157|t=2021. Selenium (Se) plays a key role in the biological effects of some viruses: Implications for COVID-19.|pdf=|usr=026}}
+{{tp|p=33809879|t=2021. Prevention of Covid-19 Infection and Related Complications by Ozonized Oils.|pdf=|usr=026}}
+{{tp|p=33821145|t=2021. COVID-19: Filling the Many Knowledge Gaps and Supporting Evidence-Based Vaccination.|pdf=|usr=026}}
+{{tp|p=33530857|t=2021. Trajectory of individual immunity and vaccination required for SARS-CoV-2 community immunity: a conceptual investigation.|pdf=|usr=026}}
+{{tp|p=33821691|t=2021. Medicolegal consequences of altered COVID-19 vaccine administration.|pdf=|usr=026}}
+{{tp|p=33772577|t=2021. Inactivated COVID-19 vaccine BBV152/COVAXIN effectively neutralizes recently emerged B.1.1.7 variant of SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33627390|t=2021. Effect of an Adenovirus-Vectored Universal Influenza Virus Vaccine on Pulmonary Pathophysiology in a Mouse Model.|pdf=|usr=026}}
+{{tp|p=33555305|t=2021. Outpatient Dietary Management of Electrolyte Disorders During COVID-19: Food as Medicine.|pdf=|usr=026}}
+{{tp|p=33821223|t=2021. Timing of COVID-19 Vaccine in the Setting of Anti-CD20 Therapy: A Primer for Nephrologists.|pdf=|usr=026}}
+{{tp|p=33676614|t=2021. Single-dose Oxford-AstraZeneca COVID-19 vaccine followed by a 12-week booster.|pdf=|usr=026}}
+{{tp|p=33798498|t=2021. Thromboembolism and the Oxford-AstraZeneca COVID-19 vaccine: side-effect or coincidence?|pdf=|usr=026}}
+{{tp|p=33798499|t=2021. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.|pdf=|usr=026}}
+{{tp|p=33798464|t=2021. Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England.|pdf=|usr=026}}
+{{tp|p=33798462|t=2021. Can glucose-lowering drugs affect the prognosis of COVID-19 in patients with type 2 diabetes?|pdf=|usr=026}}
+{{tp|p=33811822|t=2021. COVID-19 vaccines for patients with haematological conditions.|pdf=|usr=026}}
+{{tp|p=33733767|t=2021. Weinreb Amide Approach to the Practical Synthesis of a Key Remdesivir Intermediate.|pdf=|usr=026}}
+{{tp|p=33634692|t=2021. Practical Remdesivir Synthesis through One-Pot Organocatalyzed Asymmetric (S)-P-Phosphoramidation.|pdf=|usr=026}}
+{{tp|p=33817870|t=2021. The precautionary principle, the AstraZeneca COVID-19 vaccine and mixed messaging.|pdf=|usr=026}}
+{{tp|p=33625085|t=2021. Favorable Outcome of COVID-19 Infection in a Pediatric Cancer Patient Receiving an Anti-PD-L1/Anti-CTLA-4 Combination.|pdf=|usr=026}}
+{{tp|p=33620123|t=2021. Acute and chronic inflammatory neuropathies and COVID-19 vaccines: Practical recommendations from the task force of the Italian Peripheral Nervous System Association (ASNP).|pdf=|usr=026}}
+{{tp|p=33779758|t=2021. Isatis indigotica: a review of phytochemistry, pharmacological activities and clinical applications.|pdf=|usr=026}}
+{{tp|p=33759631|t=2021. Interleukin-6 Antagonists: Lessons From Cytokine Release Syndrome to the Therapeutic Application in Severe COVID-19 Infection.|pdf=|usr=026}}
+{{tp|p=33736526|t=2021. Tocilizumab for the Critically Ill With Severe COVID-19: A Community Hospital Case Series.|pdf=|usr=026}}
+{{tp|p=33719698|t=2021. A Review of the Evidence for Corticosteroids in COVID-19.|pdf=|usr=026}}
+{{tp|p=33622090|t=2021. Remdesivir for the Treatment of COVID-19: A Need for Combined In Vivo and In Vitro Studies to Evaluate the Efficacy.|pdf=|usr=026}}
+{{tp|p=33760611|t=2021. Unveiling the Molecular Structure of Antimalarial Drugs Chloroquine and Hydroxychloroquine in Solution through Analysis of (1)H NMR Chemical Shifts.|pdf=|usr=026}}
+{{tp|p=33759236|t=2021. Melatonin multifaceted pharmacological actions on melatonin receptors converging to abrogate COVID-19.|pdf=|usr=026}}
+{{tp|p=33758126|t=2021. The Potential Role of Radiogenomics in Precision Medicine for COVID-19.|pdf=|usr=026}}
+{{tp|p=33783953|t=2021. A case report of acquired hemophilia following COVID-19 vaccine.|pdf=|usr=026}}
+{{tp|p=33789993|t=2021. The Physiological TMPRSS2 Inhibitor HAI-2 Alleviates SARS-CoV-2 Infection.|pdf=|usr=026}}
+{{tp|p=33692215|t=2021. Cryo-EM structure of S-Trimer, a subunit vaccine candidate for COVID-19.|pdf=|usr=026}}
+{{tp|p=33720292|t=2021. Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients.|pdf=|usr=026}}
+{{tp|p=33739374|t=2021. Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination.|pdf=|usr=026}}
+{{tp|p=33544136|t=2021. Monoclonal Antibodies for COVID-19.|pdf=|usr=026}}
+{{tp|p=33635310|t=2021. Association of Convalescent Plasma Treatment With Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.|pdf=|usr=026}}
+{{tp|p=33566091|t=2021. Experts Discuss COVID-19-Vaccine Doses, Virus Variants, and More.|pdf=|usr=026}}
+{{tp|p=33533893|t=2021. Necessity of 2 Doses of the Pfizer and Moderna COVID-19 Vaccines.|pdf=|usr=026}}
+{{tp|p=33724312|t=2021. Helping Manufacturers Navigate Novel Coronavirus Variants.|pdf=|usr=026}}
+{{tp|p=33595641|t=2021. Vitamin D3 to Treat COVID-19: Different Disease, Same Answer.|pdf=|usr=026}}
+{{tp|p=33595634|t=2021. Effect of a Single High Dose of Vitamin D3 on Hospital Length of Stay in Patients With Moderate to Severe COVID-19: A Randomized Clinical Trial.|pdf=|usr=026}}
+{{tp|p=33576785|t=2021. Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US-December 14, 2020-January 18, 2021.|pdf=|usr=026}}
+{{tp|p=33818592|t=2021. Reactogenicity Following Receipt of mRNA-Based COVID-19 Vaccines.|pdf=|usr=026}}
+{{tp|p=33620389|t=2021. Locating COVID-19 Monoclonal Antibody Therapies.|pdf=|usr=026}}
+{{tp|p=33729423|t=2021. COVID-19 Vaccines vs Variants-Determining How Much Immunity Is Enough.|pdf=|usr=026}}
+{{tp|p=33662101|t=2021. Approaches for Optimal Use of Different COVID-19 Vaccines: Issues of Viral Variants and Vaccine Efficacy.|pdf=|usr=026}}
+{{tp|p=33635317|t=2021. SARS-CoV-2 Vaccines.|pdf=|usr=026}}
+{{tp|p=33704352|t=2021. Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.|pdf=|usr=026}}
+{{tp|p=33683290|t=2021. Acute Allergic Reactions to mRNA COVID-19 Vaccines.|pdf=|usr=026}}
+{{tp|p=33646285|t=2021. The Johnson & Johnson Vaccine for COVID-19.|pdf=|usr=026}}
+{{tp|p=33662102|t=2021. Effect of Ivermectin on Time to Resolution of Symptoms Among Adults With Mild COVID-19: A Randomized Clinical Trial.|pdf=|usr=026}}
+{{tp|p=33646292|t=2021. Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33818614|t=2021. Tocilizumab in Treatment for Patients With COVID-19.|pdf=|usr=026}}
+{{tp|p=33818612|t=2021. Tocilizumab in Treatment for Patients With COVID-19.|pdf=|usr=026}}
+{{tp|p=33818610|t=2021. Tocilizumab in Treatment for Patients With COVID-19-Reply.|pdf=|usr=026}}
+{{tp|p=33818607|t=2021. Tocilizumab in Treatment for Patients With COVID-19-Reply.|pdf=|usr=026}}
+{{tp|p=33818593|t=2021. Tocilizumab in Treatment for Patients With COVID-19.|pdf=|usr=026}}
+{{tp|p=33538761|t=2021. Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Nasopharyngeal Viral Load in Patients With COVID-19: A Randomized Clinical Trial.|pdf=|usr=026}}
+{{tp|p=33797950|t=2021. Is It Safe to Use Long-Acting G-CSF for Febrile Neutropenia Prophylaxis in COVID-19 Pandemic?|pdf=|usr=026}}
+{{tp|p=33793342|t=2021. Primary Prophylaxis With Biosimilar Filgrastim for Patients at Intermediate Risk for Febrile Neutropenia: A Cost-Effectiveness Analysis.|pdf=|usr=026}}
+{{tp|p=33728687|t=2021. Nutrition care practice patterns for patients with COVID-19-A preliminary report.|pdf=|usr=026}}
+{{tp|p=33694246|t=2021. Modified minimal-contact COVID-19 workflow allows for safe, remote parenteral nutrition prescribing in non-critically ill patients.|pdf=|usr=026}}
+{{tp|p=33734044|t=2021. Hydroxychloroquine in patients with novel coronavirus infection (COVID-19): a case-control study.|pdf=|usr=026}}
+{{tp|p=33734043|t=2021. Proactive anti-inflammatory therapy with colchicine in the treatment of advanced stages of new coronavirus infection. The first results of the COLORIT study.|pdf=|usr=026}}
+{{tp|p=33798465|t=2021. Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials.|pdf=|usr=026}}
+{{tp|p=33651292|t=2021. Correlation between polio immunization coverage and overall morbidity and mortality for COVID-19: an epidemiological study.|pdf=|usr=026}}
+{{tp|p=33722335|t=2021. Association between live childhood vaccines and COVID-19 outcomes: a national-level analysis.|pdf=|usr=026}}
+{{tp|p=33816594|t=2021. A double-blind randomised controlled trial of protein supplementation to enhance exercise capacity in COPD during pulmonary rehabilitation: a pilot study.|pdf=|usr=026}}
+{{tp|p=33573712|t=2021. Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021.|pdf=|usr=026}}
+{{tp|p=33727943|t=2021. Phytochemicals of Rhus spp. as Potential Inhibitors of the SARS-CoV-2 Main Protease: Molecular Docking and Drug-Likeness Study.|pdf=|usr=026}}
+{{tp|p=33680061|t=2021. The Hydroalcoholic Extract of Uncaria tomentosa (Cat's Claw) Inhibits the Infection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) In Vitro.|pdf=|usr=026}}
+{{tp|p=33763230|t=2021. Mismatch: a comparative study of vitamin D status in British-Bangladeshi migrants.|pdf=|usr=026}}
+{{tp|p=33732462|t=2021. Conflicts over calcium and the treatment of COVID-19.|pdf=|usr=026}}
+{{tp|p=33746666|t=2021. A review on function and side effects of systemic corticosteroids used in high-grade COVID-19 to prevent cytokine storms.|pdf=|usr=026}}
+{{tp|p=33628162|t=2021. Insights into the actions of angiotensin-1 receptor (AT1R) inverse agonists: Perspectives and implications in COVID-19 treatment.|pdf=|usr=026}}
+{{tp|p=33628159|t=2021. All-cause mortality among patients treated with repurposed antivirals and antibiotics for COVID-19 in Mexico City: A real-world observational study.|pdf=|usr=026}}
+{{tp|p=33542677|t=2020. Ivermectin: Panacea or true promise for COVID-19.|pdf=|usr=026}}
+{{tp|p=33622217|t=2021. Mesenchymal Stem Cell-Derived Extracellular Vesicles: Promising Treatment for COVID-19 Pandemic.|pdf=|usr=026}}
+{{tp|p=33605203|t=2021. Feasibility of Convalescent Plasma Therapy in Kidney Transplant Recipients With Severe COVID-19: A Single-Center Prospective Cohort Study.|pdf=|usr=026}}
+{{tp|p=33544007|t=2021. PDE3-inhibitor enoximone prevented mechanical ventilation in patients with SARS-CoV-2 pneumonia.|pdf=|usr=026}}
+{{tp|p=33790994|t=2021. Severe acute respiratory syndrome coronavirus 2 ORF3a induces the expression of ACE2 in oral and pulmonary epithelial cells and the food supplement Vita Deyun((R)) diminishes this effect.|pdf=|usr=026}}
+{{tp|p=33747178|t=2021. Acidic preconditioning reduces lipopolysaccharide-induced acute lung injury by upregulating the expression of angiotensin-converting enzyme 2.|pdf=|usr=026}}
+{{tp|p=33603870|t=2021. Multifactorial expression of IL-6 with update on COVID-19 and the therapeutic strategies of its blockade (Review).|pdf=|usr=026}}
+{{tp|p=33603836|t=2021. Recombinant interleukin-2 stimulates lymphocyte recovery in patients with severe COVID-19.|pdf=|usr=026}}
+{{tp|p=33732293|t=2021. Anti-infection mechanism of phosphodiesterase-5 inhibitors and their roles in coronavirus disease 2019 (Review).|pdf=|usr=026}}
+{{tp|p=33732292|t=2021. Immunoregulatory therapy strategies that target cytokine storms in patients with COVID-19 (Review).|pdf=|usr=026}}
+{{tp|p=33724123|t=2021. Does hydroxychloroquine still have any role in the COVID-19 pandemic?|pdf=|usr=026}}
+{{tp|p=33586566|t=2021. Concomitant use of dexamethasone and tetracyclines: a potential therapeutic option for the management of severe COVID-19 infection?|pdf=|usr=026}}
+{{tp|p=33733058|t=2021. Sialylation of host proteins as targetable risk factor for COVID-19 susceptibility and spreading: A hypothesis.|pdf=|usr=026}}
+{{tp|p=33577131|t=2021. Associations of essential and toxic metals/metalloids in whole blood with both disease severity and mortality in patients with COVID-19.|pdf=|usr=026}}
+{{tp|p=33566370|t=2021. A pressor dose of angiotensin II has no influence on the angiotensin-converting enzyme 2 and other molecules associated with SARS-CoV-2 infection in mice.|pdf=|usr=026}}
+{{tp|p=33621437|t=2021. The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVID-19 infection.|pdf=|usr=026}}
+{{tp|p=33722600|t=2021. Exploring insights of hydroxychloroquine, a controversial drug in Covid-19: An update.|pdf=|usr=026}}
+{{tp|p=33794307|t=2021. The effects of some essential and toxic metals/metalloids in COVID-19: A review.|pdf=|usr=026}}
+{{tp|p=33640537|t=2021. Inflammation, immunity and potential target therapy of SARS-COV-2: A total scale analysis review.|pdf=|usr=026}}
+{{tp|p=33592201|t=2021. Glossary of phytoconstituents: Can these be repurposed against SARS CoV-2? A quick in silico screening of various phytoconstituents from plant Glycyrrhiza glabra with SARS CoV-2 main protease.|pdf=|usr=026}}
+{{tp|p=33578926|t=2021. Fruits and Vegetables in the Management of Underlying Conditions for COVID-19 High-Risk Groups.|pdf=|usr=026}}
+{{tp|p=33718452|t=2021. Single-Cell Transcriptome Analysis Decipher New Potential Regulation Mechanism of ACE2 and NPs Signaling Among Heart Failure Patients Infected With SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33681310|t=2021. Case Report: Hyperbilirubinemia in Gilbert Syndrome Attenuates Covid-19-Induced Metabolic Disturbances.|pdf=|usr=026}}
+{{tp|p=33791293|t=2021. Coronavirus-Induced Host Cubic Membranes and Lipid-Related Antiviral Therapies: A Focus on Bioactive Plasmalogens.|pdf=|usr=026}}
+{{tp|p=33718360|t=2021. SARS-CoV-2-Specific Memory T Lymphocytes From COVID-19 Convalescent Donors: Identification, Biobanking, and Large-Scale Production for Adoptive Cell Therapy.|pdf=|usr=026}}
+{{tp|p=33659247|t=2021. Mesenchymal Stromal Cell-Derived Extracellular Vesicles in Lung Diseases: Current Status and Perspectives.|pdf=|usr=026}}
+{{tp|p=33634100|t=2020. Human Dental Pulp Stem Cells Modulate Cytokine Production in vitro by Peripheral Blood Mononuclear Cells From Coronavirus Disease 2019 Patients.|pdf=|usr=026}}
+{{tp|p=33614627|t=2020. Targeting Lipid Rafts as a Strategy Against Coronavirus.|pdf=|usr=026}}
+{{tp|p=33796489|t=2021. Predictive Analysis of the Neutralization Activity in Convalescent Plasmas From COVID-19 Recovered Patients in Zhejiang Province, China, January-March, 2020.|pdf=|usr=026}}
+{{tp|p=33732682|t=2020. Evaluation of Annona muricata Acetogenins as Potential Anti-SARS-CoV-2 Agents Through Computational Approaches.|pdf=|usr=026}}
+{{tp|p=33614597|t=2020. In silico Exploration of Inhibitors for SARS-CoV-2's Papain-Like Protease.|pdf=|usr=026}}
+{{tp|p=33614592|t=2020. In Silico Study of Coumarins and Quinolines Derivatives as Potent Inhibitors of SARS-CoV-2 Main Protease.|pdf=|usr=026}}
+{{tp|p=33585398|t=2020. Microsecond MD Simulation and Multiple-Conformation Virtual Screening to Identify Potential Anti-COVID-19 Inhibitors Against SARS-CoV-2 Main Protease.|pdf=|usr=026}}
+{{tp|p=33553109|t=2020. Computational Characterizations of the Interactions Between the Pontacyl Violet 6R and Exoribonuclease as a Potential Drug Target Against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33815295|t=2021. The Efficacy and Potential Mechanisms of Metformin in the Treatment of COVID-19 in the Diabetics: A Systematic Review.|pdf=|usr=026}}
+{{tp|p=33716989|t=2021. Vitamin D Association With Macrophage-Derived Cytokines in Polycystic Ovary Syndrome: An Enhanced Risk of COVID-19 Infection?|pdf=|usr=026}}
+{{tp|p=33664772|t=2021. Perspectives About Modulating Host Immune System in Targeting SARS-CoV-2 in India.|pdf=|usr=026}}
+{{tp|p=33815368|t=2021. Efficacy and Effect of Inhaled Adenosine Treatment in Hospitalized COVID-19 Patients.|pdf=|usr=026}}
+{{tp|p=33777055|t=2021. Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results.|pdf=|usr=026}}
+{{tp|p=33777030|t=2021. Induction of Potent and Durable Neutralizing Antibodies Against SARS-CoV-2 Using a Receptor Binding Domain-Based Immunogen.|pdf=|usr=026}}
+{{tp|p=33777024|t=2021. Lack of Effectiveness of Repurposed Drugs for COVID-19 Treatment.|pdf=|usr=026}}
+{{tp|p=33821251|t=2021. Tackling the pillars of ageing to fight COVID-19.|pdf=|usr=026}}
+{{tp|p=33812495|t=2021. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors.|pdf=|usr=026}}
+{{tp|p=33676592|t=2021. IL-6 blockade for COVID-19: a global scientific call to arms.|pdf=|usr=026}}
+{{tp|p=33676590|t=2021. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial.|pdf=|usr=026}}
+{{tp|p=33676589|t=2021. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial.|pdf=|usr=026}}
+{{tp|p=33806274|t=2021. Therapeutic Potential of EGCG, a Green Tea Polyphenol, for Treatment of Coronavirus Diseases.|pdf=|usr=026}}
+{{tp|p=33805385|t=2021. In Vitro Evaluation of the Activity of Terpenes and Cannabidiol against Human Coronavirus E229.|pdf=|usr=026}}
+{{tp|p=33803014|t=2021. Self-Reported Real-World Safety and Reactogenicity of COVID-19 Vaccines: A Vaccine Recipient Survey.|pdf=|usr=026}}
+{{tp|p=33802763|t=2021. Effects and Safety of Convalescent Plasma Administration in a Group of Polish Pediatric Patients with COVID-19: A Case Series.|pdf=|usr=026}}
+{{tp|p=33814087|t=2021. Vitamin D and COVID-19.|pdf=|usr=026}}
+{{tp|p=33823371|t=2021. Endotheliitis, endothelin, and endothelin receptor blockers in COVID-19.|pdf=|usr=026}}
+{{tp|p=33799158|t=2021. Methylene blue: Subduing the post COVID-19 blues!|pdf=|usr=026}}
+{{tp|p=33801645|t=2021. The Role of Nutrition in the COVID-19 Pandemic.|pdf=|usr=026}}
+{{tp|p=33804603|t=2021. Ketogenic Diet as a Preventive and Supportive Care for COVID-19 Patients.|pdf=|usr=026}}
+{{tp|p=33803015|t=2021. COVID-19: Role of Nutrition and Supplementation.|pdf=|usr=026}}
+{{tp|p=33799985|t=2021. In Vitro Effects of Doxycycline on Replication of Feline Coronavirus.|pdf=|usr=026}}
+{{tp|p=33804294|t=2021. Differential Effects of Antiseptic Mouth Rinses on SARS-CoV-2 Infectivity In Vitro.|pdf=|usr=026}}
+{{tp|p=33799977|t=2021. Association between Functional Inhibitors of Acid Sphingomyelinase (FIASMAs) and Reduced Risk of Death in COVID-19 Patients: A Retrospective Cohort Study.|pdf=|usr=026}}
+{{tp|p=33807743|t=2021. Rapamycin: Drug Repurposing in SARS-CoV-2 Infection.|pdf=|usr=026}}
+{{tp|p=33806331|t=2021. Repurposing of Some Natural Product Isolates as SARS-COV-2 Main Protease Inhibitors via In Vitro Cell Free and Cell-Based Antiviral Assessments and Molecular Modeling Approaches.|pdf=|usr=026}}
+{{tp|p=33807248|t=2021. Potent Antiviral Activity against HSV-1 and SARS-CoV-2 by Antimicrobial Peptoids.|pdf=|usr=026}}
+{{tp|p=33808025|t=2021. Development and Characterization of Inhaled Ethanol as a Novel Pharmacological Strategy Currently Evaluated in a Phase II Clinical Trial for Early-Stage SARS-CoV-2 Infection.|pdf=|usr=026}}
+{{tp|p=33802215|t=2021. Interaction of Remdesivir with Clinically Relevant Hepatic Drug Uptake Transporters.|pdf=|usr=026}}
+{{tp|p=33811957|t=2021. Traditional Chinese Medicine (TCM) in the treatment of COVID-19 and other viral infections: Efficacies and mechanisms.|pdf=|usr=026}}
+{{tp|p=33799224|t=2021. Association between use of Qingfei Paidu Tang and mortality in hospitalized patients with COVID-19: A national retrospective registry study.|pdf=|usr=026}}
+{{tp|p=33810568|t=2021. Synthesis and Characterization of a Minophosphonate Containing Chitosan Polymer Derivatives: Investigations of Cytotoxic Activity and in Silico Study of SARS-CoV-19.|pdf=|usr=026}}
+{{tp|p=33810527|t=2021. Niclosamide-Clay Intercalate Coated with Nonionic Polymer for Enhanced Bioavailability toward COVID-19 Treatment.|pdf=|usr=026}}
+{{tp|p=33705727|t=2021. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial.|pdf=|usr=026}}
+{{tp|p=33705726|t=2021. Adjuvantation helps to optimise COVID-19 vaccine candidate.|pdf=|usr=026}}
+{{tp|p=33676591|t=2021. COVID-19 and inhaled corticosteroids-another piece in an expanding puzzle.|pdf=|usr=026}}
+{{tp|p=33684947|t=2021. Allergische Reaktionen auf COVID-19-Impfungen - Was HNO-Arzte wissen sollten - Teil 1: Immunologische Grundlagen von Allergien auf Impfstoffe, Immunmechanismen von allergischen und pseudoallergischen Reaktionen; Teil 2: Charakteristika der mRNA-Impfstoffe BNT162b2- und mRNA-1273 zur Prophylaxe von COVID-19 und assoziierte Immunphanomene; Teil 3: Praktische Aspekte der Prophylaxe, Diagnostik und Therapie von Allergien auf COVID-19-Impfstoffe.|pdf=|usr=026}}
+{{tp|p=33729089|t=2021. Convalescent hyperimmune plasma in patients with hematologic malignancies and severe COVID-19 infections.|pdf=|usr=026}}
+{{tp|p=33742475|t=2021. Plain (1) H nuclear magnetic resonance analysis streamlines the quality control of antiviral favipiravir and congeneric World Health Organization essential medicines.|pdf=|usr=026}}
+{{tp|p=33574017|t=2021. Magnesium therapeutic potential against Covid-19: Could it be an "All-in-one" therapy?|pdf=|usr=026}}
+{{tp|p=33678604|t=2020. Dysmagnesemia in Covid-19 cohort patients: prevalence and associated factors.|pdf=|usr=026}}
+{{tp|p=33613817|t=2021. Efficacy of Traditional Chinese Medicine on COVID-19: Two Case Reports.|pdf=|usr=026}}
+{{tp|p=33613815|t=2021. Medical Acupuncture as a Treatment for Novel COVID-19-Related Respiratory Distress: Personal Experience from a Frontline Anesthesiologist.|pdf=|usr=026}}
+{{tp|p=33613814|t=2021. Properties of the Novel Chinese Herbal Medicine Formula Qu Du Qiang Fei I Hao Fang Warrant Further Research to Determine Its Clinical Efficacy in COVID-19 Treatment.|pdf=|usr=026}}
+{{tp|p=33563156|t=2021. Coumarins and Quinolones as Effective Multiple Targeted Agents Versus Covid-19: An in Silico Study.|pdf=|usr=026}}
+{{tp|p=33666909|t=2021. Treating COVID-19 Acute Severe Hypoxemic Respiratory Failure: First Case Report Utilizing Dexamethasone, Remdesivir, and Convalescent Plasma in Operation Inherent Resolve.|pdf=|usr=026}}
+{{tp|p=33684922|t=2021. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibodies in Neonatal Cord Blood After Vaccination in Pregnancy.|pdf=|usr=026}}
+{{tp|p=33583812|t=2020. Review: Herbs, Immunity and nCOVID-19: Old performers in new Pandemic.|pdf=|usr=026}}
+{{tp|p=33769223|t=2021. SUMO: a novel target for anti-coronavirus therapy.|pdf=|usr=026}}
+{{tp|p=33579813|t=2021. Remestemcel-L Therapy for COVID-19-Associated Multisystem Inflammatory Syndrome in Children.|pdf=|usr=026}}
+{{tp|p=33772933|t=2021. QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis.|pdf=|usr=026}}
+{{tp|p=33722710|t=2021. Resveratrol-mediated attenuation of superantigen-driven acute respiratory distress syndrome is mediated by microbiota in the lungs and gut.|pdf=|usr=026}}
+{{tp|p=33714279|t=2021. A hypothesis: Bitter taste receptors as a therapeutic target for the clinical symptoms of SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33711090|t=2021. Covalent and non-covalent binding free energy calculations for peptidomimetic inhibitors of SARS-CoV-2 main protease.|pdf=|usr=026}}
+{{tp|p=33688867|t=2021. 1'-Ribose cyano substitution allows Remdesivir to effectively inhibit nucleotide addition and proofreading during SARS-CoV-2 viral RNA replication.|pdf=|usr=026}}
+{{tp|p=33713539|t=2021. Corticosteroids and pulmonary rehabilitation reducing long-term morbidity in a patient with post-COVID-19 pneumonitis: A case study.|pdf=|usr=026}}
+{{tp|p=33786876|t=2021. Flavonoids as potential phytotherapeutics to combat cytokine storm in SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33778996|t=2021. Greater celandine (Chelidonium majus L.) for COVID-19: A twenty-case series.|pdf=|usr=026}}
+{{tp|p=33759279|t=2021. Plant-derived chemicals as potential inhibitors of SARS-CoV-2 main protease (6LU7), a virtual screening study.|pdf=|usr=026}}
+{{tp|p=33822421|t=2021. Silibinin as potential tool against SARS-Cov-2: In silico spike receptor-binding domain and main protease molecular docking analysis, and in vitro endothelial protective effects.|pdf=|usr=026}}
+{{tp|p=33817867|t=2021. Phyto-pharmacological perspective of Silymarin: A potential prophylactic or therapeutic agent for COVID-19, based on its promising immunomodulatory, anti-coagulant and anti-viral property.|pdf=|usr=026}}
+{{tp|p=33797123|t=2021. In silico approach of secondary metabolites from Brazilian herbal medicines to search for potential drugs against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33711848|t=2021. COVID-19-Impfungen bei Biologika-Therapie von Asthma bronchiale.|pdf=|usr=026}}
+{{tp|p=33583332|t=2021. Hydroxychloroquine Sulfate Related Hypoglycemia In A Non-Diabetic COVID-19 Patient: A Case Report and Literature Review.|pdf=|usr=026}}
+{{tp|p=33795478|t=2021. Clofazimine: another potential magic bullet for the treatment of COVID-19?|pdf=|usr=026}}
+{{tp|p=33591652|t=2021. [The role of supplying population with vitamin D in conditions of COVID-19 pandemic: foreign publications review].|pdf=|usr=026}}
+{{tp|p=33767711|t=2021. Editorial: Immune Responses to Persistent or Recurrent Antigens: Implications for Immunological Memory and Immunotherapy.|pdf=|usr=026}}
+{{tp|p=33767706|t=2021. The Case for S2: The Potential Benefits of the S2 Subunit of the SARS-CoV-2 Spike Protein as an Immunogen in Fighting the COVID-19 Pandemic.|pdf=|usr=026}}
+{{tp|p=33763085|t=2021. Vitamin D in Corona Virus Disease 2019 (COVID-19) Related Multisystem Inflammatory Syndrome in Children (MIS-C).|pdf=|usr=026}}
+{{tp|p=33763077|t=2021. The BCG Vaccine for COVID-19: First Verdict and Future Directions.|pdf=|usr=026}}
+{{tp|p=33746945|t=2021. Upregulated IL-6 Indicates a Poor COVID-19 Prognosis: A Call for Tocilizumab and Convalescent Plasma Treatment.|pdf=|usr=026}}
+{{tp|p=33732258|t=2021. A Novel DNA Vaccine Against SARS-CoV-2 Encoding a Chimeric Protein of Its Receptor-Binding Domain (RBD) Fused to the Amino-Terminal Region of Hepatitis B Virus preS1 With a W4P Mutation.|pdf=|usr=026}}
+{{tp|p=33717181|t=2021. Microbiota Modulation of the Gut-Lung Axis in COVID-19.|pdf=|usr=026}}
+{{tp|p=33717077|t=2021. A Proteome-Wide Immunoinformatics Tool to Accelerate T-Cell Epitope Discovery and Vaccine Design in the Context of Emerging Infectious Diseases: An Ethnicity-Oriented Approach.|pdf=|usr=026}}
+{{tp|p=33679771|t=2021. High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China.|pdf=|usr=026}}
+{{tp|p=33679770|t=2021. Anti-SARS-CoV-2 Antibodies Within IVIg Preparations: Cross-Reactivities With Seasonal Coronaviruses, Natural Autoimmunity, and Therapeutic Implications.|pdf=|usr=026}}
+{{tp|p=33643316|t=2021. The Immunopathology of COVID-19 and the Cannabis Paradigm.|pdf=|usr=026}}
+{{tp|p=33643308|t=2021. Immunomodulatory Effects of Azithromycin Revisited: Potential Applications to COVID-19.|pdf=|usr=026}}
+{{tp|p=33613573|t=2021. The Relevance of a Physical Active Lifestyle and Physical Fitness on Immune Defense: Mitigating Disease Burden, With Focus on COVID-19 Consequences.|pdf=|usr=026}}
+{{tp|p=33643285|t=2020. VISTA: A Target to Manage the Innate Cytokine Storm.|pdf=|usr=026}}
+{{tp|p=33633726|t=2020. Activation of the Cholinergic Anti-Inflammatory Pathway as a Novel Therapeutic Strategy for COVID-19.|pdf=|usr=026}}
+{{tp|p=33613542|t=2020. Update on Antiviral Strategies Against COVID-19: Unmet Needs and Prospects.|pdf=|usr=026}}
+{{tp|p=33584672|t=2020. Indicator Regularized Non-Negative Matrix Factorization Method-Based Drug Repurposing for COVID-19.|pdf=|usr=026}}
+{{tp|p=33584668|t=2020. Induction of SARS-CoV-2 Protein S-Specific CD8+ T Cells in the Lungs of gp96-Ig-S Vaccinated Mice.|pdf=|usr=026}}
+{{tp|p=33569053|t=2020. Could Perturbation of Gut Microbiota Possibly Exacerbate the Severity of COVID-19 via Cytokine Storm?|pdf=|usr=026}}
+{{tp|p=33687643|t=2021. Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial.|pdf=|usr=026}}
+{{tp|p=33816521|t=2021. Combination of Angiotensin (1-7) Agonists and Convalescent Plasma as a New Strategy to Overcome Angiotensin Converting Enzyme 2 (ACE2) Inhibition for the Treatment of COVID-19.|pdf=|usr=026}}
+{{tp|p=33816515|t=2021. Case Report: Administration of Amniotic Fluid-Derived Nanoparticles in Three Severely Ill COVID-19 Patients.|pdf=|usr=026}}
+{{tp|p=33777973|t=2021. COVID-19 Therapy: Could a Copper Derivative of Chlorophyll a Be Used to Treat Lymphopenia Associated With Severe Symptoms of SARS-CoV-2 Infection?|pdf=|usr=026}}
+{{tp|p=33768100|t=2021. D-Limonene Is a Potential Monoterpene to Inhibit PI3K/Akt/IKK-alpha/NF-kappaB p65 Signaling Pathway in Coronavirus Disease 2019 Pulmonary Fibrosis.|pdf=|usr=026}}
+{{tp|p=33718411|t=2021. COVID-19 and Risk of Acute Ischemic Stroke and Acute Lung Injury in Patients With Type II Diabetes Mellitus: The Anti-inflammatory Role of Metformin.|pdf=|usr=026}}
+{{tp|p=33718395|t=2021. Glucocorticoids Should Be Used With Caution in Patients With SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33681257|t=2021. An Open Label Trial to Assess Safety of Losartan for Treating Worsening Respiratory Illness in COVID-19.|pdf=|usr=026}}
+{{tp|p=33644099|t=2021. Furin Expression in Patients With Psoriasis-A Patient Cohort Endangered to SARS-COV2?|pdf=|usr=026}}
+{{tp|p=33634148|t=2021. Adverse Outcomes Associated With Corticosteroid Use in Critical COVID-19: A Retrospective Multicenter Cohort Study.|pdf=|usr=026}}
+{{tp|p=33614688|t=2021. Decreased Mortality Rate Among COVID-19 Patients Prescribed Statins: Data From Electronic Health Records in the US.|pdf=|usr=026}}
+{{tp|p=33585529|t=2021. Effect of Convalescent Plasma in Critically Ill Patients With COVID-19: An Observational Study.|pdf=|usr=026}}
+{{tp|p=33585519|t=2020. Commentary: Antifibrotics in COVID-19 Lung Disease: Let Us Stay Focused.|pdf=|usr=026}}
+{{tp|p=33585508|t=2020. Mortality Benefit of Remdesivir in COVID-19: A Systematic Review and Meta-Analysis.|pdf=|usr=026}}
+{{tp|p=33553219|t=2020. Can GPR4 Be a Potential Therapeutic Target for COVID-19?|pdf=|usr=026}}
+{{tp|p=33537320|t=2020. Vitamin C and COVID-19.|pdf=|usr=026}}
+{{tp|p=33746908|t=2020. Molecular Docking Reveals Ivermectin and Remdesivir as Potential Repurposed Drugs Against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33763450|t=2021. Emerging Therapeutic Approaches to Combat COVID-19: Present Status and Future Perspectives.|pdf=|usr=026}}
+{{tp|p=33718434|t=2021. Drug Repurposing Strategy (DRS): Emerging Approach to Identify Potential Therapeutics for Treatment of Novel Coronavirus Infection.|pdf=|usr=026}}
+{{tp|p=33659275|t=2021. Molecular Mechanisms Behind Anti SARS-CoV-2 Action of Lactoferrin.|pdf=|usr=026}}
+{{tp|p=33628764|t=2020. New Insights Into Potential Benefits of Bioactive Compounds of Bee Products on COVID-19: A Review and Assessment of Recent Research.|pdf=|usr=026}}
+{{tp|p=33614709|t=2020. Therapeutic Strategies in the Management of COVID-19.|pdf=|usr=026}}
+{{tp|p=33569392|t=2020. Elucidating the Interactions Between Heparin/Heparan Sulfate and SARS-CoV-2-Related Proteins-An Important Strategy for Developing Novel Therapeutics for the COVID-19 Pandemic.|pdf=|usr=026}}
+{{tp|p=33542917|t=2020. In silico Screening of Natural Compounds as Potential Inhibitors of SARS-CoV-2 Main Protease and Spike RBD: Targets for COVID-19.|pdf=|usr=026}}
+{{tp|p=33816542|t=2021. The Looming Effects of Estrogen in Covid-19: A Rocky Rollout.|pdf=|usr=026}}
+{{tp|p=33748170|t=2021. Negative Association Between Mediterranean Diet Adherence and COVID-19 Cases and Related Deaths in Spain and 23 OECD Countries: An Ecological Study.|pdf=|usr=026}}
+{{tp|p=33634160|t=2021. Plant-Derived Food Grade Substances (PDFGS) Active Against Respiratory Viruses: A Systematic Review of Non-clinical Studies.|pdf=|usr=026}}
+{{tp|p=33553234|t=2020. The Burden of Malnutrition and Fatal COVID-19: A Global Burden of Disease Analysis.|pdf=|usr=026}}
+{{tp|p=33708752|t=2020. Case Report: Use of Anakinra in Multisystem Inflammatory Syndrome During COVID-19 Pandemic.|pdf=|usr=026}}
+{{tp|p=33815126|t=2021. Repurposing Anti-Malaria Phytomedicine Artemisinin as a COVID-19 Drug.|pdf=|usr=026}}
+{{tp|p=33790785|t=2021. Evaluation of the Current Therapeutic Approaches for COVID-19: A Systematic Review and a Meta-analysis.|pdf=|usr=026}}
+{{tp|p=33776767|t=2021. Modeling of SARS-CoV-2 Treatment Effects for Informed Drug Repurposing.|pdf=|usr=026}}
+{{tp|p=33767626|t=2021. Anti-IL5 Drugs in COVID-19 Patients: Role of Eosinophils in SARS-CoV-2-Induced Immunopathology.|pdf=|usr=026}}
+{{tp|p=33767623|t=2021. The Anti-inflammatory Effect of the Tricyclic Antidepressant Clomipramine and Its High Penetration in the Brain Might Be Useful to Prevent the Psychiatric Consequences of SARS-CoV-2 Infection.|pdf=|usr=026}}
+{{tp|p=33767619|t=2021. Plant Products as Inhibitors of Coronavirus 3CL Protease.|pdf=|usr=026}}
+{{tp|p=33762960|t=2021. Aripiprazole as a Candidate Treatment of COVID-19 Identified Through Genomic Analysis.|pdf=|usr=026}}
+{{tp|p=33762954|t=2021. An Update on Antiviral Therapy Against SARS-CoV-2: How Far Have We Come?|pdf=|usr=026}}
+{{tp|p=33716752|t=2021. Discovering Potential RNA Dependent RNA Polymerase Inhibitors as Prospective Drugs Against COVID-19: An in silico Approach.|pdf=|usr=026}}
+{{tp|p=33716745|t=2021. The Potential Therapeutic Effect of RNA Interference and Natural Products on COVID-19: A Review of the Coronaviruses Infection.|pdf=|usr=026}}
+{{tp|p=33716737|t=2021. In silico Analyses of Immune System Protein Interactome Network, Single-Cell RNA Sequencing of Human Tissues, and Artificial Neural Networks Reveal Potential Therapeutic Targets for Drug Repurposing Against COVID-19.|pdf=|usr=026}}
+{{tp|p=33692695|t=2021. Drug Repurposing and Polypharmacology to Fight SARS-CoV-2 Through Inhibition of the Main Protease.|pdf=|usr=026}}
+{{tp|p=33584318|t=2021. Mitochondria Are Potential Targets for the Development of New Drugs Against Neutrophilic Inflammation in Severe Pneumonia Including COVID-19.|pdf=|usr=026}}
+{{tp|p=33815095|t=2020. A Scoping Insight on Potential Prophylactics, Vaccines and Therapeutic Weaponry for the Ongoing Novel Coronavirus (COVID-19) Pandemic- A Comprehensive Review.|pdf=|usr=026}}
+{{tp|p=33776751|t=2020. A Retrospective Study on the Use of Chinese Patent Medicine in 24 Medical Institutions for COVID-19 in China.|pdf=|usr=026}}
+{{tp|p=33746739|t=2020. Molecular Mechanism of Action of Repurposed Drugs and Traditional Chinese Medicine Used for the Treatment of Patients Infected With COVID-19: A Systematic Scoping Review.|pdf=|usr=026}}
+{{tp|p=33737877|t=2020. Repurposing Treatment of Wernicke-Korsakoff Syndrome for Th-17 Cell Immune Storm Syndrome and Neurological Symptoms in COVID-19: Thiamine Efficacy and Safety, In-Vitro Evidence and Pharmacokinetic Profile.|pdf=|usr=026}}
+{{tp|p=33737875|t=2020. Indian Medicinal Plants and Formulations and Their Potential Against COVID-19-Preclinical and Clinical Research.|pdf=|usr=026}}
+{{tp|p=33732148|t=2020. Yindan Jiedu Granules, a Traditional Chinese Medicinal Formulation, as a Potential Treatment for Coronavirus Disease 2019.|pdf=|usr=026}}
+{{tp|p=33716728|t=2020. Prospective: Evolution of Chinese Medicine to Treat COVID-19 Patients in China.|pdf=|usr=026}}
+{{tp|p=33716720|t=2020. Chinese Herbal Medicine Used With or Without Conventional Western Therapy for COVID-19: An Evidence Review of Clinical Studies.|pdf=|usr=026}}
+{{tp|p=33708124|t=2020. Targeting Neurological Manifestations of Coronaviruses by Candidate Phytochemicals: A Mechanistic Approach.|pdf=|usr=026}}
+{{tp|p=33708112|t=2020. Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33708109|t=2020. Calming the Storm: Natural Immunosuppressants as Adjuvants to Target the Cytokine Storm in COVID-19.|pdf=|usr=026}}
+{{tp|p=33692684|t=2020. Rational Drug Repurposing: Focus on Lysosomotropism, Targets in Disease Process, Drug Profile, and Pulmonary Tissue Accumulation in SARS-CoV-2 Infection/COVID-19.|pdf=|usr=026}}
+{{tp|p=33679384|t=2020. Potential Natural Products Against Respiratory Viruses: A Perspective to Develop Anti-COVID-19 Medicines.|pdf=|usr=026}}
+{{tp|p=33658931|t=2020. Phytochemicals: Potential Therapeutic Interventions Against Coronavirus-Associated Lung Injury.|pdf=|usr=026}}
+{{tp|p=33658924|t=2020. Cytotoxicity Evaluation of Chloroquine and Hydroxychloroquine in Multiple Cell Lines and Tissues by Dynamic Imaging System and Physiologically Based Pharmacokinetic Model.|pdf=|usr=026}}
+{{tp|p=33643034|t=2020. Development of a Physiologically Based Pharmacokinetic Model for Hydroxychloroquine and Its Application in Dose Optimization in Specific COVID-19 Patients.|pdf=|usr=026}}
+{{tp|p=33643033|t=2020. Modalities and Mechanisms of Treatment for Coronavirus Disease 2019.|pdf=|usr=026}}
+{{tp|p=33628169|t=2020. COVIEdb: A Database for Potential Immune Epitopes of Coronaviruses.|pdf=|usr=026}}
+{{tp|p=33613282|t=2020. Several FDA-Approved Drugs Effectively Inhibit SARS-CoV-2 Infection in vitro.|pdf=|usr=026}}
+{{tp|p=33597888|t=2020. Potency, Safety, and Pharmacokinetic Profiles of Potential Inhibitors Targeting SARS-CoV-2 Main Protease.|pdf=|usr=026}}
+{{tp|p=33584306|t=2020. HIF Prolyl Hydroxylase Inhibitors for COVID-19 Treatment: Pros and Cons.|pdf=|usr=026}}
+{{tp|p=33584285|t=2020. Protective Effect of Arbidol Against Pulmonary Fibrosis and Sepsis in Mice.|pdf=|usr=026}}
+{{tp|p=33584268|t=2020. Perspectives of Antidiabetic Drugs in Diabetes With Coronavirus Infections.|pdf=|usr=026}}
+{{tp|p=33584267|t=2020. Nasal Delivery of Hesperidin/Chitosan Nanoparticles Suppresses Cytokine Storm Syndrome in a Mouse Model of Acute Lung Injury.|pdf=|usr=026}}
+{{tp|p=33574761|t=2020. Commentary: Paracetamol-Induced Glutathione Consumption: Is There a Link With Severe COVID-19 Illness?|pdf=|usr=026}}
+{{tp|p=33574756|t=2020. Potential of Immune-Related Therapy in COVID-19.|pdf=|usr=026}}
+{{tp|p=33542685|t=2020. Statins as Adjuvant Therapy for COVID-19 to Calm the Stormy Immunothrombosis and Beyond.|pdf=|usr=026}}
+{{tp|p=33636368|t=2021. Micronized / ultramicronized palmitoylethanolamide (PEA) as natural neuroprotector against COVID-19 inflammation.|pdf=|usr=026}}
+{{tp|p=33787891|t=2021. COVID-19 vaccination-associated myelitis.|pdf=|usr=026}}
+{{tp|p=33642133|t=2021. VitaminD supplementation for the prevention and treatment of COVID-19: a position statement from the Spanish Society of Geriatrics and Gerontology.|pdf=|usr=026}}
+{{tp|p=33817742|t=2020. Letter to the Editor: Boron enhances the antiviral activity of the curcumin against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33795718|t=2021. Molecular dynamics and in silico mutagenesis on the reversible inhibitor-bound SARS-CoV-2 main protease complexes reveal the role of lateral pocket in enhancing the ligand affinity.|pdf=|usr=026}}
+{{tp|p=33602867|t=2021. SARS-CoV-2 M(pro) inhibitors with antiviral activity in a transgenic mouse model.|pdf=|usr=026}}
+{{tp|p=33688062|t=2021. Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes.|pdf=|usr=026}}
+{{tp|p=33618635|t=2021. Mesenchymal Stem Cell Derived-Exosomes as Effective Factors in Reducing Cytokine Storm Symptoms of COVID-19.|pdf=|usr=026}}
+{{tp|p=33636424|t=2021. Imagining the COVID-19 pandemic through the minds of 9-11 years old: findings from an art exhibition in India.|pdf=|usr=026}}
+{{tp|p=33725726|t=2021. The Theoretical Value of Whole-Lung Irradiation for COVID-19 Pneumonia: A Reasonable and Safe Solution until Targeted Treatments are Developed.|pdf=|usr=026}}
+{{tp|p=33687358|t=2021. L'elogio dell'incertezza: una revisione sistematica living per valutare l'efficacia e la sicurezza dei trattamenti farmacologici per pazienti affetti da covid-19.|pdf=|usr=026}}
+{{tp|p=33687352|t=2021. Vaccino contro la covid-19: una questione aperta.|pdf=|usr=026}}
+{{tp|p=33631907|t=2020. Infeccion diseminada por vacuna con bacilo de Calmette-Guerin y coinfeccion por SARS-CoV-2 en paciente con deficiencia de la subunidad beta1 del receptor de IL-12.|pdf=|usr=026}}
+{{tp|p=33694220|t=2021. Effects of chloroquine or hydroxychloroquine treatment on non-SARS-CoV2 viral infections: A systematic review of clinical studies.|pdf=|usr=026}}
+{{tp|p=33566918|t=2020. Transfusion de plasma convaleciente de pacientes con COVID-19.|pdf=|usr=026}}
+{{tp|p=33566898|t=2020. Dioxido de cloro y derivados del cloro para prevenir o tratar la COVID-19: revision sistematica.|pdf=|usr=026}}
+{{tp|p=33739711|t=2020. Hydroxychloroquine dans le Covid et liberte de prescription.|pdf=|usr=026}}
+{{tp|p=33551422|t=2021. [Successful steroid pulse therapy for COVID-19 associated respiratory failure initially mimicking bortezomib-induced lung injury].|pdf=|usr=026}}
+{{tp|p=33620985|t=2020. inverted question markEl plasma convaleciente es un tratamiento alternativo para pacientes con Covid-19?|pdf=|usr=026}}
+{{tp|p=33632917|t=2021. COVAX Statement on WHO emergency use listing for AstraZeneca/Oxford COVID-19 vaccine.|pdf=|usr=026}}
+{{tp|p=33632915|t=2021. Is chloroquine or hydroxychloroquine useful in treating people with COVID-19, or in preventing infection in people who have been exposed to the virus?|pdf=|usr=026}}
+{{tp|p=33795510|t=2021. WHO adds Janssen vaccine to list of safe and effective emergency tools against COVID-19.|pdf=|usr=026}}
+{{tp|p=33820835|t=2021. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates.|pdf=|usr=026}}
+{{tp|p=33674471|t=2021. WHO's treatment megatrial is at a standstill.|pdf=|usr=026}}
+{{tp|p=33686419|t=2021. Exclusion of pregnant and lactating women from COVID-19 vaccine trials: a missed opportunity.|pdf=|usr=026}}
+{{tp|p=33569601|t=2021. Re-purposed antiviral drugs without a purpose in COVID-19: a valuable lesson for clinicians.|pdf=|usr=026}}
+{{tp|p=33770576|t=2021. SARS-CoV-2 vaccines for cancer patients: a call to action.|pdf=|usr=026}}
+{{tp|p=33743480|t=2021. SARS-CoV-2 vaccines for cancer patients treated with immunotherapies: Recommendations from the French society for ImmunoTherapy of Cancer (FITC).|pdf=|usr=026}}
+{{tp|p=33393082|t=2021. Sustaining efficient immune functions with regular physical exercise in the COVID-19 era and beyond.|pdf=|usr=026}}
+{{tp|p=33742158|t=2021. Comments on nutritional recommendations for CoVID-19 quarantine.|pdf=|usr=026}}
+{{tp|p=33660020|t=2021. Repositioning HIV protease inhibitors and nucleos(t)ide RNA polymerase inhibitors for the treatment of SARS-CoV-2 infection and COVID-19.|pdf=|usr=026}}
+{{tp|p=33532896|t=2021. The effect of tocilizumab on mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials.|pdf=|usr=026}}
+{{tp|p=33634346|t=2021. External validity of phase III trials on vaccines against SARS-CoV-2 to a middle-aged and elderly Western European population.|pdf=|usr=026}}
+{{tp|p=33649879|t=2021. COVID-19 vaccine acceptance among pregnant women and mothers of young children: results of a survey in 16 countries.|pdf=|usr=026}}
+{{tp|p=33627476|t=2021. Does timing matter on tocilizumab administration? Clinical, analytical and radiological outcomes in COVID-19.|pdf=|usr=026}}
+{{tp|p=33619027|t=2021. The European COVID-19 drugs calculation tool: an aid for the estimation of the drugs needed during the SARS-CoV 2 pandemic.|pdf=|usr=026}}
+{{tp|p=33576494|t=2021. High neutralizing potency of swine glyco-humanized polyclonal antibodies against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33552315|t=2021. The preventive effect of Xuebijing injection against cytokine storm for severe patients with COVID-19: A prospective randomized controlled trial.|pdf=|usr=026}}
+{{tp|p=33581979|t=2021. Anakinra for patients with COVID-19: a meta-analysis of non-randomized cohort studies.|pdf=|usr=026}}
+{{tp|p=33746777|t=2021. Practical Recommendations Relevant to the Use of Resistance Training for COVID-19 Survivors.|pdf=|usr=026}}
+{{tp|p=33574769|t=2021. Targeting Endolysosomal Two-Pore Channels to Treat Cardiovascular Disorders in the Novel COronaVIrus Disease 2019.|pdf=|usr=026}}
+{{tp|p=33584335|t=2020. The Impact of Polyphenols-Based Diet on the Inflammatory Profile in COVID-19 Elderly and Obese Patients.|pdf=|usr=026}}
+{{tp|p=33551833|t=2020. CSF3 Is a Potential Drug Target for the Treatment of COVID-19.|pdf=|usr=026}}
+{{tp|p=33719281|t=2021. Cinnamon and Hop Extracts as Potential Immunomodulators for Severe COVID-19 Cases.|pdf=|usr=026}}
+{{tp|p=33664752|t=2020. Carvacrol, a Plant Metabolite Targeting Viral Protease (M(pro)) and ACE2 in Host Cells Can Be a Possible Candidate for COVID-19.|pdf=|usr=026}}
+{{tp|p=33584747|t=2020. Development of Plant-Produced Recombinant ACE2-Fc Fusion Protein as a Potential Therapeutic Agent Against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33821255|t=2021. Use of SGLT-2 inhibitor in COVID-19: A cautionary tale.|pdf=|usr=026}}
+{{tp|p=33821254|t=2021. A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential.|pdf=|usr=026}}
+{{tp|p=33799535|t=2021. The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients.|pdf=|usr=026}}
+{{tp|p=33807988|t=2021. Targeting the DEAD-Box RNA Helicase eIF4A with Rocaglates-A Pan-Antiviral Strategy for Minimizing the Impact of Future RNA Virus Pandemics.|pdf=|usr=026}}
+{{tp|p=33806624|t=2021. SARS-CoV-2 Disease Adjuvant Therapies and Supplements Breakthrough for the Infection Prevention.|pdf=|usr=026}}
+{{tp|p=33810287|t=2021. Lactiplantibacillus plantarum as a Potential Adjuvant and Delivery System for the Development of SARS-CoV-2 Oral Vaccines.|pdf=|usr=026}}
+{{tp|p=33804162|t=2021. COVID-19: Insights into Potential Vaccines.|pdf=|usr=026}}
+{{tp|p=33792313|t=2021. Role of Hydrogen Bonds in Formation of Co-amorphous Valsartan/Nicotinamide Compositions of High Solubility and Durability with Anti-hypertension and Anti-COVID-19 Potential.|pdf=|usr=026}}
+{{tp|p=33823303|t=2021. A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice.|pdf=|usr=026}}
+{{tp|p=33800013|t=2021. Structure-Based Virtual Screening Identifies Multiple Stable Binding Sites at the RecA Domains of SARS-CoV-2 Helicase Enzyme.|pdf=|usr=026}}
+{{tp|p=33807773|t=2021. SARS-CoV-2 Main Protease Active Site Ligands in the Human Metabolome.|pdf=|usr=026}}
+{{tp|p=33808054|t=2021. The Inhibitory Effects of Plant Derivate Polyphenols on the Main Protease of SARS Coronavirus 2 and Their Structure-Activity Relationship.|pdf=|usr=026}}
+{{tp|p=33805419|t=2021. Accelerated Repurposing and Drug Development of Pulmonary Hypertension Therapies for COVID-19 Treatment Using an AI-Integrated Biosimulation Platform.|pdf=|usr=026}}
+{{tp|p=33810416|t=2021. Molecular Basis of the Therapeutical Potential of Clove (Syzygium aromaticum L.) and Clues to Its Anti-COVID-19 Utility.|pdf=|usr=026}}
+{{tp|p=33809963|t=2021. Medicinal Plants, Phytochemicals, and Herbs to Combat Viral Pathogens Including SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33801151|t=2021. Identification of Potential SARS-CoV-2 Main Protease and Spike Protein Inhibitors from the Genus Aloe: An In Silico Study for Drug Development.|pdf=|usr=026}}
+{{tp|p=33800977|t=2021. Natural Products from Medicinal Plants with Anti-Human Coronavirus Activities.|pdf=|usr=026}}
+{{tp|p=33802860|t=2021. Is PF-00835231 a Pan-SARS-CoV-2 Mpro Inhibitor? A Comparative Study.|pdf=|usr=026}}
+{{tp|p=33799871|t=2021. Receptor-Based Pharmacophore Modeling in the Search for Natural Products for COVID-19 M(pro).|pdf=|usr=026}}
+{{tp|p=33794595|t=2021. The initial experience of COVID-19 vaccination from a tertiary care centre of India.|pdf=|usr=026}}
+{{tp|p=33755376|t=2021. SARS-CoV-2 Infection after Vaccination in Health Care Workers in California.|pdf=|usr=026}}
+{{tp|p=33755373|t=2021. BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers.|pdf=|usr=026}}
+{{tp|p=33755375|t=2021. Antibody Responses after a Single Dose of SARS-CoV-2 mRNA Vaccine.|pdf=|usr=026}}
+{{tp|p=33755374|t=2021. Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center.|pdf=|usr=026}}
+{{tp|p=33725432|t=2021. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.|pdf=|usr=026}}
+{{tp|p=33691060|t=2021. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine.|pdf=|usr=026}}
+{{tp|p=33807206|t=2021. Pea Protein Nanoemulsion Effectively Stabilizes Vitamin D in Food Products: A Potential Supplementation during the COVID-19 Pandemic.|pdf=|usr=026}}
+{{tp|p=33795671|t=2021. Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors.|pdf=|usr=026}}
+{{tp|p=33795856|t=2021. Concerns about SARS-CoV-2 evolution should not hold back efforts to expand vaccination.|pdf=|usr=026}}
+{{tp|p=33597220|t=2021. Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets.|pdf=|usr=026}}
+{{tp|p=33766944|t=2021. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection.|pdf=|usr=026}}
+{{tp|p=33646996|t=2021. FDA authorizes Pfizer-BioNTech COVID-19 vaccine.|pdf=|usr=026}}
+{{tp|p=33739278|t=2021. L'ARN polymerase COVID-19 - Le talon d'Achille du SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33687881|t=2021. The situation of small molecules targeting key proteins to combat SARS-CoV-2: Synthesis, metabolic pathway, mechanism of action, and potential therapeutic applications.|pdf=|usr=026}}
+{{tp|p=33797374|t=2021. Effectiveness of Azithromycin as add-on Therapy in COVID-19 Management.|pdf=|usr=026}}
+{{tp|p=33663367|t=2021. Recent Advance in Natural Products with Antiviral Activities.|pdf=|usr=026}}
+{{tp|p=33573545|t=2021. S.A.R.S Covid-19 A Medicinal Chemistry Approach.|pdf=|usr=026}}
+{{tp|p=33550970|t=2021. Coronavirus (COVID -19): Chemical entities of biological interest.|pdf=|usr=026}}
+{{tp|p=33535950|t=2021. Natural substances and semisynthetic derivatives as potential alternative products against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33655830|t=2021. Treatment approaches for COVID-19: A critical review.|pdf=|usr=026}}
+{{tp|p=33632095|t=2021. Elucidating the drug repurposing spectra of COVID-19 with its analogues SARS and MERS.|pdf=|usr=026}}
+{{tp|p=33596800|t=2021. A review on Remdesivir: A broad-spectrum antiviral molecule for possible COVID-19 treatment.|pdf=|usr=026}}
+{{tp|p=33568033|t=2021. Glycyrrhizin as a Potential Treatment for the Novel Coronavirus (COVID-19).|pdf=|usr=026}}
+{{tp|p=33787066|t=2021. An Integrative in silico Drug Repurposing Approach for Identification of Potential Inhibitors of SARS-CoV-2 Main Protease.|pdf=|usr=026}}
+{{tp|p=33657301|t=2021. Audio Interview: A New SARS-CoV-2 Vaccine and a New Look at Treatment.|pdf=|usr=026}}
+{{tp|p=33596347|t=2021. Delayed Second Dose versus Standard Regimen for Covid-19 Vaccination.|pdf=|usr=026}}
+{{tp|p=33567188|t=2021. Hydroxychloroquine in Hospitalized Patients with Covid-19. Reply.|pdf=|usr=026}}
+{{tp|p=33567187|t=2021. Hydroxychloroquine in Hospitalized Patients with Covid-19.|pdf=|usr=026}}
+{{tp|p=33534968|t=2021. Monoclonal Antibody for Patients with Covid-19. Reply.|pdf=|usr=026}}
+{{tp|p=33534967|t=2021. Monoclonal Antibody for Patients with Covid-19.|pdf=|usr=026}}
+{{tp|p=33730461|t=2021. Audio Interview: Efficacy of Current Covid-19 Vaccines against Variant Viruses.|pdf=|usr=026}}
+{{tp|p=33567190|t=2021. Maintaining Safety with SARS-CoV-2 Vaccines. Reply.|pdf=|usr=026}}
+{{tp|p=33567189|t=2021. Maintaining Safety with SARS-CoV-2 Vaccines.|pdf=|usr=026}}
+{{tp|p=33626259|t=2021. Audio Interview: The Real-World Effectiveness of Covid-19 Vaccination.|pdf=|usr=026}}
+{{tp|p=33822494|t=2021. Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19.|pdf=|usr=026}}
+{{tp|p=33596351|t=2021. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. Reply.|pdf=|usr=026}}
+{{tp|p=33596350|t=2021. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.|pdf=|usr=026}}
+{{tp|p=33596349|t=2021. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.|pdf=|usr=026}}
+{{tp|p=33596348|t=2021. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.|pdf=|usr=026}}
+{{tp|p=33657288|t=2021. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. Reply.|pdf=|usr=026}}
+{{tp|p=33657287|t=2021. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia. Reply.|pdf=|usr=026}}
+{{tp|p=33657286|t=2021. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.|pdf=|usr=026}}
+{{tp|p=33536629|t=2021. Treatment of influenza and SARS-CoV-2 infections via mRNA-encoded Cas13a in rodents.|pdf=|usr=026}}
+{{tp|p=33623157|t=2021. Biological activity-based modeling identifies antiviral leads against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33796820|t=2021. A deep learning framework for high-throughput mechanism-driven phenotype compound screening and its application to COVID-19 drug repurposing.|pdf=|usr=026}}
+{{tp|p=33782619|t=2021. Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine.|pdf=|usr=026}}
+{{tp|p=33772244|t=2021. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies.|pdf=|usr=026}}
+{{tp|p=33795870|t=2021. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33664494|t=2021. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies.|pdf=|usr=026}}
+{{tp|p=33654292|t=2021. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma.|pdf=|usr=026}}
+{{tp|p=33558724|t=2021. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera.|pdf=|usr=026}}
+{{tp|p=33769143|t=2021. Chlorogenic acid, a natural product as potential inhibitor of COVID-19: virtual screening experiment based on network pharmacology and molecular docking.|pdf=|usr=026}}
+{{tp|p=33707753|t=2021. FDA authorizes first single-shot COVID-19 vaccine.|pdf=|usr=026}}
+{{tp|p=33633370|t=2021. Trends in COVID-19 therapeutic clinical trials.|pdf=|usr=026}}
+{{tp|p=33674802|t=2021. Structural basis for inhibition of the SARS-CoV-2 RNA polymerase by suramin.|pdf=|usr=026}}
+{{tp|p=33780970|t=2021. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma.|pdf=|usr=026}}
+{{tp|p=33767445|t=2021. Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice.|pdf=|usr=026}}
+{{tp|p=33727703|t=2021. Clofazimine broadly inhibits coronaviruses including SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33706364|t=2021. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.|pdf=|usr=026}}
+{{tp|p=33772237|t=2021. Coronapod: the Oxford-AstraZeneca COVID vaccine - what you need to know.|pdf=|usr=026}}
+{{tp|p=33767467|t=2021. Latest results put Oxford-AstraZeneca COVID vaccine back on track.|pdf=|usr=026}}
+{{tp|p=33742175|t=2021. Coronapod: Why COVID antibody treatments may not be the answer.|pdf=|usr=026}}
+{{tp|p=33654255|t=2021. J&J's single-dose COVID vaccine raises hopes for faster rollout.|pdf=|usr=026}}
+{{tp|p=33712752|t=2021. COVID antibody treatments show promise for preventing severe disease.|pdf=|usr=026}}
+{{tp|p=33654298|t=2021. Some antibodies can dampen antiviral defences in people with severe COVID.|pdf=|usr=026}}
+{{tp|p=33623151|t=2021. Why COVID vaccines are so difficult to compare.|pdf=|usr=026}}
+{{tp|p=33561864|t=2021. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801.|pdf=|usr=026}}
+{{tp|p=33526898|t=2021. J&J's one-shot COVID vaccine offers hope for faster protection.|pdf=|usr=026}}
+{{tp|p=33811258|t=2021. Coronapod: How to define rare COVID vaccine side effects.|pdf=|usr=026}}
+{{tp|p=33707257|t=2021. Vaccine efficacy probable against COVID-19 variants.|pdf=|usr=026}}
+{{tp|p=33639344|t=2021. A new class of alpha-ketoamide derivatives with potent anticancer and anti-SARS-CoV-2 activities.|pdf=|usr=026}}
+{{tp|p=33618158|t=2021. Protease targeted COVID-19 drug discovery: What we have learned from the past SARS-CoV inhibitors?|pdf=|usr=026}}
+{{tp|p=33609889|t=2021. Synthetic and medicinal perspective of quinolines as antiviral agents.|pdf=|usr=026}}
+{{tp|p=33588180|t=2021. Discovery and structural optimization of 3-O-beta-chacotriosyl oleanane-type triterpenoids as potent entry inhibitors of SARS-CoV-2 virus infections.|pdf=|usr=026}}
+{{tp|p=33573699|t=2021. Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial.|pdf=|usr=026}}
+{{tp|p=33537632|t=2020. Breastfeeding during the COVID-19 pandemic.|pdf=|usr=026}}
+{{tp|p=33675368|t=2021. COVID-19 vaccine as a cause for unilateral lymphadenopathy detected by 18F-FDG PET/CT in a patient affected by melanoma.|pdf=|usr=026}}
+{{tp|p=33661328|t=2021. Oxford-AstraZeneca COVID-19 vaccination induced lymphadenopathy on [18F]Choline PET/CT-not only an FDG finding.|pdf=|usr=026}}
+{{tp|p=33774684|t=2021. Hypermetabolic lymphadenopathy following administration of BNT162b2 mRNA Covid-19 vaccine: incidence assessed by [(18)F]FDG PET-CT and relevance to study interpretation.|pdf=|usr=026}}
+{{tp|p=33638003|t=2021. COVID-19 vaccination induced axillary nodal uptake on [18F]FDG PET/CT.|pdf=|usr=026}}
+{{tp|p=33585950|t=2021. A key role for vitamin D binding protein in COVID-19?|pdf=|usr=026}}
+{{tp|p=33576843|t=2021. Reply to: A key role for vitamin D binding protein in COVID-19?|pdf=|usr=026}}
+{{tp|p=33788001|t=2021. The association between vitamin D levels and the clinical severity and inflammation markers in pediatric COVID-19 patients: single-center experience from a pandemic hospital.|pdf=|usr=026}}
+{{tp|p=33617948|t=2021. In silico identification of available drugs targeting cell surface BiP to disrupt SARS-CoV-2 binding and replication: Drug repurposing approach.|pdf=|usr=026}}
+{{tp|p=33775827|t=2021. In-silico screening for identification of potential inhibitors against SARS-CoV-2 transmembrane serine protease 2 (TMPRSS2).|pdf=|usr=026}}
+{{tp|p=33667455|t=2021. Potential repurposing of the HDAC inhibitor valproic acid for patients with COVID-19.|pdf=|usr=026}}
+{{tp|p=33639193|t=2021. Brief review on repurposed drugs and vaccines for possible treatment of COVID-19.|pdf=|usr=026}}
+{{tp|p=33722593|t=2021. COVID-19 and IL-6: Why vitamin D (probably) helps but tocilizumab might not.|pdf=|usr=026}}
+{{tp|p=33607104|t=2021. No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial.|pdf=|usr=026}}
+{{tp|p=33549577|t=2021. Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis.|pdf=|usr=026}}
+{{tp|p=33545161|t=2021. Chloroquine: Autophagy inhibitor, antimalarial, bitter taste receptor agonist in fight against COVID-19, a reality check?|pdf=|usr=026}}
+{{tp|p=33580785|t=2021. The strange case of hydroxychloroquine and COVID-19.|pdf=|usr=026}}
+{{tp|p=33623975|t=2020. QTc-interval prolongation and increased risk of sudden cardiac death associated with hydroxychloroquine.|pdf=|usr=026}}
+{{tp|p=33624070|t=2020. Amiodarone in COVID-19: let's not forget its potential for pulmonary toxicity.|pdf=|usr=026}}
+{{tp|p=33585912|t=2021. The hydroxychloroquine debate: a therapeutic dilemma for general practitioners.|pdf=|usr=026}}
+{{tp|p=33542051|t=2021. Genetic polymorphisms, vitamin D binding protein and vitamin D deficiency in COVID-19.|pdf=|usr=026}}
+{{tp|p=33795322|t=2021. Inhaled corticosteroids downregulate SARS-CoV-2-related genes in COPD: results from a RCT.|pdf=|usr=026}}
+{{tp|p=33602862|t=2021. Reply: Is high-dose glucocorticoid beneficial in COVID-19?|pdf=|usr=026}}
+{{tp|p=33574071|t=2021. Corticosteroids in COVID-19: one size does not fit all.|pdf=|usr=026}}
+{{tp|p=33568526|t=2021. Corticosteroids for CAP, influenza and COVID-19: when, how and benefits or harm?|pdf=|usr=026}}
+{{tp|p=33577063|t=2021. Effect of glucocorticoid therapy on the prognosis of patients with severe and critical COVID-19: a single-center retrospective cohort study.|pdf=|usr=026}}
+{{tp|p=33577009|t=2021. Molecular exploration of combinational therapy of orlistat with metformin prevents the COVID-19 consequences in obese diabetic patients.|pdf=|usr=026}}
+{{tp|p=33660833|t=2021. The interplay between vitamin D and COVID-19: protective or bystander?|pdf=|usr=026}}
+{{tp|p=33629336|t=2021. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.|pdf=|usr=026}}
+{{tp|p=33716536|t=2021. High-Dose Vitamin C Infusion for the Treatment of Covid-19: Beware of Paraben Intoxication.|pdf=|usr=026}}
+{{tp|p=33769252|t=2021. Robust antibody responses in 70-80-year-olds 3 weeks after the first or second doses of Pfizer/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021.|pdf=|usr=026}}
+{{tp|p=33706861|t=2021. Acute onset supraclavicular lymphadenopathy coinciding with intramuscular mRNA vaccination against COVID-19 may be related to vaccine injection technique, Spain, January and February 2021.|pdf=|usr=026}}
+{{tp|p=33663646|t=2021. Incidence of COVID-19 in patients exposed to chloroquine and hydroxychloroquine: results from a population-based prospective cohort in Catalonia, Spain, 2020.|pdf=|usr=026}}
+{{tp|p=33748066|t=2021. The Impact of Vitamin D Level on COVID-19 Infection: Systematic Review and Meta-Analysis.|pdf=|usr=026}}
+{{tp|p=33553096|t=2020. Vitamin D Deficiency as an Important Biomarker for the Increased Risk of Coronavirus (COVID-19) in People From Black and Asian Ethnic Minority Groups.|pdf=|usr=026}}
+{{tp|p=33778086|t=2021. Ethnomedicinal herbs in African traditional medicine with potential activity for the prevention, treatment, and management of coronavirus disease 2019.|pdf=|usr=026}}
+{{tp|p=33754123|t=2021. Therapeutic role of corticosteroids in COVID-19: a systematic review of registered clinical trials.|pdf=|usr=026}}
+{{tp|p=33576273|t=2021. Targeting the SARS-CoV-2 3CL(pro) and NO/cGMP/PDE5 pathway in COVID-19: a commentary on PDE5 inhibitors.|pdf=|usr=026}}
+{{tp|p=33590764|t=2021. De novo design of new chemical entities for SARS-CoV-2 using artificial intelligence.|pdf=|usr=026}}
+{{tp|p=33709775|t=2021. COVID-19 pneumonia: do not leave the corticosteroids behind!|pdf=|usr=026}}
+{{tp|p=33569984|t=2021. Dual targeting of Toll-like receptor 4 and angiotensin-converting enzyme 2: a proposed approach to SARS-CoV-2 treatment.|pdf=|usr=026}}
+{{tp|p=33538178|t=2021. The right immune-modulation at the right time: thymosin alpha1 for prevention of severe COVID-19 in cancer patients.|pdf=|usr=026}}
+{{tp|p=33705746|t=2021. The associations between pharmacological gastric acid suppression and adverse outcomes in patients with COVID-19.|pdf=|usr=026}}
+{{tp|p=33609504|t=2021. Lack of Consistent Associations Between Pharmacologic Gastric Acid Suppression and Adverse Outcomes in Patients With Coronavirus Disease 2019: Meta-Analysis of Observational Studies.|pdf=|usr=026}}
+{{tp|p=33814381|t=2021. COVAX Statement on WHO emergency use listing for AstraZeneca/Oxford COVID-19 vaccine.|pdf=|usr=026}}
+{{tp|p=33814379|t=2021. Is chloroquine or hydroxychloroquine useful in treating people with COVID-19, or in preventing infection in people who have been exposed to the virus?|pdf=|usr=026}}
+{{tp|p=33795636|t=2021. Antimicrobial peptide DP7 with potential activity against SARS coronavirus infections.|pdf=|usr=026}}
+{{tp|p=33810926|t=2021. COVID-19 Vaccines Based on Adenovirus Vectors.|pdf=|usr=026}}
+{{tp|p=33814228|t=2021. The role of multiple SARS-CoV-2 viral antigens in a vaccine-induced integrated immune response.|pdf=|usr=026}}
+{{tp|p=33810907|t=2021. Are vaccines against COVID-19 tailored to the most vulnerable people?|pdf=|usr=026}}
+{{tp|p=33807818|t=2021. SARS-CoV-2 Neutralizing Antibodies: A Network Meta-Analysis across Vaccines.|pdf=|usr=026}}
+{{tp|p=33807579|t=2021. Allergic Reactions to Current Available COVID-19 Vaccinations: Pathophysiology, Causality, and Therapeutic Considerations.|pdf=|usr=026}}
+{{tp|p=33806646|t=2021. COVID-19 Vaccine Failure in a Patient with Multiple Sclerosis on Ocrelizumab.|pdf=|usr=026}}
+{{tp|p=33802467|t=2021. Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies.|pdf=|usr=026}}
+{{tp|p=33805473|t=2021. Immunogenicity and Neutralizing Activity Comparison of SARS-CoV-2 Spike Full-Length and Subunit Domain Proteins in Young Adult and Old-Aged Mice.|pdf=|usr=026}}
+{{tp|p=33804981|t=2021. Soluble Spike DNA Vaccine Provides Long-Term Protective Immunity against SARS-CoV-2 in Mice and Nonhuman Primates.|pdf=|usr=026}}
+{{tp|p=33810026|t=2021. Potent Neutralization Antibodies Induced by a Recombinant Trimeric Spike Protein Vaccine Candidate Containing PIKA Adjuvant for COVID-19.|pdf=|usr=026}}
+{{tp|p=33801380|t=2021. SARS-CoV-2 Infection Is Asymptomatic in Nearly Half of Adults with Robust Anti-Spike Protein Receptor-Binding Domain Antibody Response.|pdf=|usr=026}}
+{{tp|p=33808708|t=2021. Opportunities for Refinement of Non-Human Primate Vaccine Studies.|pdf=|usr=026}}
+{{tp|p=33809002|t=2021. COVID-19 Vaccine Roll-Out in South Africa and Zimbabwe: Urgent Need to Address Community Preparedness, Fears and Hesitancy.|pdf=|usr=026}}
+{{tp|p=33799505|t=2021. Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19.|pdf=|usr=026}}
+{{tp|p=33802086|t=2021. COVID-19 Vaccines in the Pipeline, Are Antibodies Adequate?|pdf=|usr=026}}
+{{tp|p=33801926|t=2021. Simultaneous CD8(+) T-Cell Immune Response against SARS-Cov-2 S, M, and N Induced by Endogenously Engineered Extracellular Vesicles in Both Spleen and Lungs.|pdf=|usr=026}}
+{{tp|p=33801831|t=2021. Correlates of Vaccine-Induced Protection against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33800528|t=2021. Early Administration of Convalescent Plasma Improves Survival in Patients with Hematological Malignancies and COVID-19.|pdf=|usr=026}}
+{{tp|p=33800932|t=2021. The Combination of Bromelain and Acetylcysteine (BromAc) Synergistically Inactivates SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33807957|t=2021. Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection.|pdf=|usr=026}}
+{{tp|p=33807839|t=2021. Target Product Profile Analysis of COVID-19 Vaccines in Phase III Clinical Trials and Beyond: An Early 2021 Perspective.|pdf=|usr=026}}
+{{tp|p=33807769|t=2021. Antiviral Activity of the Propylamylatin(TM) Formula against the Novel Coronavirus SARS-CoV-2 In Vitro Using Direct Injection and Gas Assays in Virus Suspensions.|pdf=|usr=026}}
+{{tp|p=33807592|t=2021. Pharmacogenetics Approach for the Improvement of COVID-19 Treatment.|pdf=|usr=026}}
+{{tp|p=33808275|t=2021. In Vitro Antiviral Activities of Salinomycin on Porcine Epidemic Diarrhea Virus.|pdf=|usr=026}}
+{{tp|p=33597779|t=2021. COVID vaccines and safety: what the research says.|pdf=|usr=026}}
+{{tp|p=33795861|t=2021. Why is it so hard to investigate the rare side effects of COVID vaccines?|pdf=|usr=026}}
+{{tp|p=33762708|t=2021. What scientists do and don't know about the Oxford-AstraZeneca COVID vaccine.|pdf=|usr=026}}
+{{tp|p=33567448|t=2021. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants.|pdf=|usr=026}}
+{{tp|p=33737735|t=2020. Daily briefing: The five questions that scientists hunting a coronavirus vaccine must answer.|pdf=|usr=026}}
+{{tp|p=33723024|t=2021. Reader Response: A Prospective Study of Neurologic Disorders in Hospitalized Patients With COVID-19 in New York City.|pdf=|usr=026}}
+{{tp|p=33722093|t=2021. Needlestick Injuries Among Healthcare Workers Administering COVID-19 Vaccinations in the United States.|pdf=|usr=026}}
+{{tp|p=33811162|t=2021. X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease.|pdf=|usr=026}}
+{{tp|p=33574203|t=2021. Single-domain antibodies make a difference.|pdf=|usr=026}}
+{{tp|p=33555845|t=2021. Comparison of Associations between Glucocorticoids Treatment and Mortality in COVID-19 Patients and SARS Patients: A Systematic Review and Meta-Analysis.|pdf=|usr=026}}
+{{tp|p=33715385|t=2021. Research Progress of Mesenchymal Stem Cell Therapy for Severe COVID-19.|pdf=|usr=026}}
+{{tp|p=33720635|t=2021. [BCG, muramylpeptides, trained immunity (part II): a low molecular weight alternative to multicomponent bacterial immunostimulants for prevention of respiratory infections during a pandemic].|pdf=|usr=026}}
+{{tp|p=33720613|t=2020. [The role of vitamin D in seasonal acute respiratory viral infections and COVID-19].|pdf=|usr=026}}
+{{tp|p=33720612|t=2020. [Umifenovir and coronavirus infections: a review of research results and clinical practice].|pdf=|usr=026}}
+{{tp|p=33720607|t=2020. [Administration of the immunomodulatory drug aminodihydrophthalazinedione sodium for prevention of progression pneumonia induced COVID-19].|pdf=|usr=026}}
+{{tp|p=33720594|t=2020. [BCG, muramylpeptides, trained immunity (part I): linkages in the light of the COVID-19 pandemic].|pdf=|usr=026}}
+{{tp|p=33720587|t=2020. [Experience of olokizumab use in COVID-19 patients].|pdf=|usr=026}}
+{{tp|p=33641131|t=2020. Our Best Shot: Texas Physicians Help Find Safe, Effective COVID-19 Vaccines.|pdf=|usr=026}}
+{{tp|p=33677827|t=2021. Sulodexide in the Treatment of Patients with Early Stages of COVID-19: A Randomized Controlled Trial.|pdf=|usr=026}}
+{{tp|p=33749020|t=2021. Deterrents in recruitment of COVID-19 convalescent plasma donors: Experience from a hospital-based blood centre in India.|pdf=|usr=026}}
+{{tp|p=33784412|t=2021. Convalescent plasma treatment of critically ill intensive care COVID-19 patients.|pdf=|usr=026}}
+{{tp|p=33734448|t=2021. A trend of dropping anti-SARS-CoV-2 plaque reduction neutralization test titers over time in Canadian convalescent plasma donors.|pdf=|usr=026}}
+{{tp|p=33723852|t=2021. COVID-19 convalescent plasma; time for "goal directed therapy"?|pdf=|usr=026}}
+{{tp|p=33760230|t=2021. Personalized collection of plasma from healthy donors: A randomized controlled trial of a novel technology-enabled nomogram.|pdf=|usr=026}}
+{{tp|p=33715160|t=2021. Brief report: Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma.|pdf=|usr=026}}
+{{tp|p=33728702|t=2021. Adoptive transfer of ex vivo expanded SARS-CoV-2-specific cytotoxic lymphocytes: A viable strategy for COVID-19 immunosuppressed patients?|pdf=|usr=026}}
+{{tp|p=33560728|t=2021. Safety of the First Dose of SARS-CoV-2 Vaccination in Solid Organ Transplant Recipients.|pdf=|usr=026}}
+{{tp|p=33724242|t=2021. Casirivimab-Imdevimab for Treatment of COVID-19 in Solid Organ Transplant Recipients: an Early Experience.|pdf=|usr=026}}
+{{tp|p=33741844|t=2021. Kidney Transplant Recipients Rarely Show an Early Antibody Response Following the First COVID-19 Vaccine Administration.|pdf=|usr=026}}
+{{tp|p=33724250|t=2021. SARS-CoV-2 Vaccination and Solid Organ Transplant Patients: Data Needed to Inform Safety and Efficacy.|pdf=|usr=026}}
+{{tp|p=33612766|t=2020. Could antiseptic gargling prevent COVID-19?|pdf=|usr=026}}
+{{tp|p=33734065|t=2021. [SARS-CoV-2 vaccines].|pdf=|usr=026}}
+{{tp|p=33734074|t=2021. [Vaccination immunology in SARS-CoV-2].|pdf=|usr=026}}
+{{tp|p=33734524|t=2021. Benefits and potential harms of COVID-19 vaccination during pregnancy: evidence summary for patient counseling.|pdf=|usr=026}}
+{{tp|p=33648028|t=2021. Physiologic and biochemical rationale for treating COVID-19 patients with hyperbaric oxygen.|pdf=|usr=026}}
+{{tp|p=33810902|t=2021. The safety of BCG revaccination: A systematic review.|pdf=|usr=026}}
+{{tp|p=33737124|t=2021. Epidemiological transcriptomic data supports BCG protection in viral diseases including COVID-19.|pdf=|usr=026}}
+{{tp|p=33549712|t=2021. The use of mesenchymal stem cells in the process of treatment and tissue regeneration after recovery in patients with Covid-19.|pdf=|usr=026}}
+{{tp|p=33596123|t=2021. Adjusting extracellular pH to prevent entry of SARS-CoV-2 into human cells.|pdf=|usr=026}}
+{{tp|p=33722288|t=2021. SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human cell lines reveals low levels of viral backbone gene transcription alongside very high levels of SARS-CoV-2 S glycoprotein gene transcription.|pdf=|usr=026}}
+{{tp|p=33569701|t=2021. The impact of immuno-aging on SARS-CoV-2 vaccine development.|pdf=|usr=026}}
+{{tp|p=33627051|t=2021. Making a COVID-19 vaccine that works for everyone: ensuring equity and inclusivity in clinical trials.|pdf=|usr=026}}
+{{tp|p=33688588|t=2021. COVID-19 vaccines: implementation, limitations and opportunities.|pdf=|usr=026}}
+{{tp|p=33669357|t=2021. The Effect of Chair-Based Exercise on Physical Function in Older Adults: A Systematic Review and Meta-Analysis.|pdf=|usr=026}}
+{{tp|p=33671943|t=2021. Global Impact of COVID-19 on Weight and Weight-Related Behaviors in the Adult Population: A Scoping Review.|pdf=|usr=026}}
+{{tp|p=33726557|t=2021. A review: Mechanism of action of antiviral drugs.|pdf=|usr=026}}
+{{tp|p=33746095|t=2021. Interim estimates in null models of COVID-19 vaccine effectiveness.|pdf=|usr=026}}
+{{tp|p=33746092|t=2021. A case of COVID-19 diagnosed with favipiravir-induced drug fever based on a positive drug-induced lymphocyte stimulation test.|pdf=|usr=026}}
+{{tp|p=33647517|t=2021. A shorter symptom onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis.|pdf=|usr=026}}
+{{tp|p=33794380|t=2021. Bacille Calmette-Guerin (BCG) vaccine and potential cross-protection against SARS-CoV-2 infection - Assumptions, knowns, unknowns and need for developing an accurate scientific evidence base.|pdf=|usr=026}}
+{{tp|p=33540128|t=2021. Remdesivir and systemic corticosteroids for the treatment of COVID-19: A Bayesian re-analysis.|pdf=|usr=026}}
+{{tp|p=33737128|t=2021. The effect of tocilizumab, anakinra and prednisolone on antibody response to SARS-CoV-2 in patients with COVID-19: A prospective cohort study with multivariate analysis of factors affecting the antibody response.|pdf=|usr=026}}
+{{tp|p=33713817|t=2021. Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study.|pdf=|usr=026}}
+{{tp|p=33652065|t=2021. COVID-19 vaccines: Global challenges and prospects forum recommendations.|pdf=|usr=026}}
+{{tp|p=33647515|t=2021. Combination therapy with tocilizumab and corticosteroids for aged patients with severe COVID-19 pneumonia: A single-center retrospective study.|pdf=|usr=026}}
+{{tp|p=33636357|t=2021. Less severe course of COVID-19 is associated with elevated levels of antibodies against seasonal human coronaviruses OC43 and HKU1 (HCoV OC43, HCoV HKU1).|pdf=|usr=026}}
+{{tp|p=33609773|t=2021. Tocilizumab treatment in critically ill patients with COVID-19: A retrospective observational study.|pdf=|usr=026}}
+{{tp|p=33607305|t=2021. Convalescent plasma treatment is associated with lower mortality and better outcomes in high-risk COVID-19 patients - propensity-score matched case-control study.|pdf=|usr=026}}
+{{tp|p=33607304|t=2021. The role of ibrutinib in COVID-19 hyperinflammation: A case report.|pdf=|usr=026}}
+{{tp|p=33601033|t=2021. Letter to the editor on "Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial" by Udwadia et al.|pdf=|usr=026}}
+{{tp|p=33601032|t=2021. Response to the comments received on article "Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial" by Udwadia et al.|pdf=|usr=026}}
+{{tp|p=33592340|t=2021. Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study.|pdf=|usr=026}}
+{{tp|p=33592338|t=2021. Prioritizing second-generation SARS-CoV-2 vaccines through low-dosage challenge studies.|pdf=|usr=026}}
+{{tp|p=33578014|t=2021. Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico.|pdf=|usr=026}}
+{{tp|p=33578007|t=2021. The effect of probiotics on respiratory tract infection with special emphasis on COVID-19: Systemic review 2010-20.|pdf=|usr=026}}
+{{tp|p=33746604|t=2021. A network pharmacology based approach for predicting active ingredients and potential mechanism of Lianhuaqingwen capsule in treating COVID-19.|pdf=|usr=026}}
+{{tp|p=33746581|t=2021. Systematic elucidation of the mechanism of Jingyin granule in the treatment of Novel Coronavirus (COVID-19) Pneumonia via Network Pharmacology.|pdf=|usr=026}}
+{{tp|p=33628091|t=2021. Role of IL-6 inhibitor in treatment of COVID-19-related cytokine release syndrome.|pdf=|usr=026}}
+{{tp|p=33532356|t=2021. A single dose of in situ gel formulation of antimalarial drug chloroquine phosphate as a sustained prophylactic candidate for COVID-19.|pdf=|usr=026}}
+{{tp|p=33552658|t=2021. Approved mRNA Vaccines for SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33556464|t=2021. Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia.|pdf=|usr=026}}
+{{tp|p=33711496|t=2021. A Cost-Effectiveness Evaluation of Hospitalizations, Fatalities, and Economic Outcomes Associated with Universal Versus Anaphylaxis Risk-Stratified COVID-19 Vaccination Strategies.|pdf=|usr=026}}
+{{tp|p=33766582|t=2021. Nonirritant concentrations for skin testing with SARS-CoV-2 mRNA vaccine.|pdf=|usr=026}}
+{{tp|p=33529722|t=2021. The COVID-19 Pandemic in 2021: Avoiding Overdiagnosis of Anaphylaxis Risk While Safely Vaccinating the World.|pdf=|usr=026}}
+{{tp|p=33817690|t=2021. Toxicity of herbal medications suggested as treatment for COVID-19: A narrative review.|pdf=|usr=026}}
+{{tp|p=33605826|t=2021. An Evaluation of Serum 25-Hydroxy Vitamin D Levels in Patients with COVID-19 in New York City.|pdf=|usr=026}}
+{{tp|p=33600292|t=2021. Low Vitamin D Status at Admission as a Risk Factor for Poor Survival in Hospitalized Patients With COVID-19: An Italian Retrospective Study.|pdf=|usr=026}}
+{{tp|p=33713605|t=2021. Unilateral Lymphadenopathy After COVID-19 Vaccination: A Practical Management Plan for Radiologists Across Specialties.|pdf=|usr=026}}
+{{tp|p=33546986|t=2021. Summary of adverse drug events for hydroxychloroquine, azithromycin, and chloroquine during the COVID-19 pandemic.|pdf=|usr=026}}
+{{tp|p=33561203|t=2021. Comment on: Effectiveness of remdesivir in patients with COVID-19 under mechanical ventilation in an Italian ICU.|pdf=|usr=026}}
+{{tp|p=33559270|t=2021. Soybean-associated endophytic fungi as potential source for anti-COVID-19 metabolites supported by docking analysis.|pdf=|usr=026}}
+{{tp|p=33776210|t=2021. Docking and in silico toxicity assessment of Arthrospira compounds as potential antiviral agents against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33600286|t=2021. Dexamethasone and transdehydroandrosterone significantly reduce pulmonary epithelial cell injuries associated with mechanical ventilation.|pdf=|usr=026}}
+{{tp|p=33577360|t=2021. Montelukast in hospitalized patients diagnosed with COVID-19.|pdf=|usr=026}}
+{{tp|p=33746457|t=2021. Modulation of neutrophil (dys)function by Ayurvedic herbs and its potential influence on SARS-CoV-2 infection.|pdf=|usr=026}}
+{{tp|p=33727768|t=2021. Ayurveda co-interventions have supported complete recovery in Severe COVID- 19 infection with a Chest Severity Score 18/25: A Case Report.|pdf=|usr=026}}
+{{tp|p=33548227|t=2021. How glycobiology can help us treat and beat the COVID-19 pandemic.|pdf=|usr=026}}
+{{tp|p=33639165|t=2021. Glucosylceramide synthase inhibitors prevent replication of SARS-CoV-2 and Influenza virus.|pdf=|usr=026}}
+{{tp|p=33571675|t=2021. Drug repurposing for COVID-19 via knowledge graph completion.|pdf=|usr=026}}
+{{tp|p=33645443|t=2021. A potential peptide inhibitor of SARS-CoV-2 S and human ACE2 complex.|pdf=|usr=026}}
+{{tp|p=33612076|t=2021. Identification of the binding interactions of some novel antiviral compounds against Nsp1 protein from SARS-CoV-2 (COVID-19) through high throughput screening.|pdf=|usr=026}}
+{{tp|p=33525993|t=2021. Impact of dimerization and N3 binding on molecular dynamics of SARS-CoV and SARS-CoV-2 main proteases.|pdf=|usr=026}}
+{{tp|p=33599180|t=2021. In silico prediction of SARS-CoV-2 main protease and polymerase inhibitors: 3D-Pharmacophore modelling.|pdf=|usr=026}}
+{{tp|p=33596787|t=2021. Metabolomic profiling of three Araucaria species, and their possible potential role against COVID-19.|pdf=|usr=026}}
+{{tp|p=33590806|t=2021. Repurposing drugs and identification of inhibitors of integral proteins (spike protein and main protease) of SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33583350|t=2021. Anti-HIV-drug and phyto-flavonoid combination against SARS-CoV-2: a molecular docking-simulation base assessment.|pdf=|usr=026}}
+{{tp|p=33583328|t=2021. In silico identification and validation of natural antiviral compounds as potential inhibitors of SARS-CoV-2 methyltransferase.|pdf=|usr=026}}
+{{tp|p=33565387|t=2021. Artificially expanded genetic information systems (AEGISs) as potent inhibitors of the RNA-dependent RNA polymerase of the SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33526003|t=2021. Flavonol morin targets host ACE2, IMP-alpha, PARP-1 and viral proteins of SARS-CoV-2, SARS-CoV and MERS-CoV critical for infection and survival: a computational analysis.|pdf=|usr=026}}
+{{tp|p=33619888|t=2021. Blue photobiomodulation LED therapy impacts SARS-CoV-2 by limiting its replication in Vero cells.|pdf=|usr=026}}
+{{tp|p=33762863|t=2021. Correlation of Automated Chemiluminescent Method with Enzyme-Linked Immunosorbent Assay (ELISA) Antibody Titers in Convalescent COVID-19 Plasma Samples: Development of Rapid, Cost-Effective Semi-Quantitative Diagnostic Methods.|pdf=|usr=026}}
+{{tp|p=33673216|t=2021. Sinus Bradycardia Associated with Remdesivir Treatment in COVID-19: A Case Report and Literature Review.|pdf=|usr=026}}
+{{tp|p=33619758|t=2021. Tetracycline as an inhibitor to the SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33768214|t=2021. Possible Therapeutic Use of Natural Compounds Against COVID-19.|pdf=|usr=026}}
+{{tp|p=33655751|t=2021. Biostructural Models for the Binding of Nucleoside Analogs to SARS-CoV-2 RNA-Dependent RNA Polymerase.|pdf=|usr=026}}
+{{tp|p=33619962|t=2021. Shedding Light on the Inhibitory Mechanisms of SARS-CoV-1/CoV-2 Spike Proteins by ACE2-Designed Peptides.|pdf=|usr=026}}
+{{tp|p=33538596|t=2021. Targeting SARS-CoV-2 M3CLpro by HCV NS3/4a Inhibitors: In Silico Modeling and In Vitro Screening.|pdf=|usr=026}}
+{{tp|p=33734704|t=2021. Macrolides May Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Entry into Cells: A Quantitative Structure Activity Relationship Study and Experimental Validation.|pdf=|usr=026}}
+{{tp|p=33756448|t=2021. Development and validation of a simple, selective, and sensitive LC-MS/MS assay for the quantification of remdesivir in human plasma.|pdf=|usr=026}}
+{{tp|p=33544910|t=2021. Efficacy of convalescent plasma therapy for COVID-19: A systematic review and meta-analysis.|pdf=|usr=026}}
+{{tp|p=33616257|t=2021. A matched cohort study of convalescent plasma therapy for COVID-19.|pdf=|usr=026}}
+{{tp|p=33587767|t=2021. Donor tolerability of convalescent plasma donation.|pdf=|usr=026}}
+{{tp|p=33578448|t=2021. The use of therapeutic plasma exchange as adjunctive therapy in the treatment of coronavirus disease 2019: A critical appraisal of the current evidence.|pdf=|usr=026}}
+{{tp|p=33536704|t=2021. Smell/Taste alteration in COVID-19 may reflect zinc deficiency.|pdf=|usr=026}}
+{{tp|p=33560344|t=2021. Association of Metformin with Susceptibility to COVID-19 in People with Type 2 Diabetes.|pdf=|usr=026}}
+{{tp|p=33575003|t=2021. Is there scientific evidence of the mouthwashes effectiveness in reducing viral load in Covid-19? A systematic review.|pdf=|usr=026}}
+{{tp|p=33763778|t=2021. Interferon-beta Therapy in a Patient with Incontinentia Pigmenti and Autoantibodies against Type I IFNs Infected with SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33547548|t=2021. A Patient with X-Linked Agammaglobulinemia and COVID-19 Infection Treated with Remdesivir and Convalescent Plasma.|pdf=|usr=026}}
+{{tp|p=33611660|t=2021. Resolution of Persistent COVID-19 After Convalescent Plasma in a Patient with B Cell Aplasia.|pdf=|usr=026}}
+{{tp|p=33616813|t=2021. Plasma Exchange to Rescue Patients with Autoantibodies Against Type I Interferons and Life-Threatening COVID-19 Pneumonia.|pdf=|usr=026}}
+{{tp|p=33621214|t=2021. SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities.|pdf=|usr=026}}
+{{tp|p=33571169|t=2021. Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality.|pdf=|usr=026}}
+{{tp|p=33726984|t=2021. Association between antecedent statin use and severe disease outcomes in COVID-19: A retrospective study with propensity score matching.|pdf=|usr=026}}
+{{tp|p=33669218|t=2021. The Rheumatology Drugs for COVID-19 Management: Which and When?|pdf=|usr=026}}
+{{tp|p=33672805|t=2021. Effects of Methylprednisolone on Ventilator-Free Days in Mechanically Ventilated Patients with Acute Respiratory Distress Syndrome and COVID-19: A Retrospective Study.|pdf=|usr=026}}
+{{tp|p=33578922|t=2021. The Use of Antiviral Agents against SARS-CoV-2: Ineffective or Time and Age Dependent Result? A Retrospective, Observational Study among COVID-19 Older Adults.|pdf=|usr=026}}
+{{tp|p=33645763|t=2021. Repurposing functional inhibitors of acid sphingomyelinase (fiasmas): an opportunity against SARS-CoV-2 infection?|pdf=|usr=026}}
+{{tp|p=33638257|t=2021. Safety of tocilizumab in COVID-19 pregnant women and their newborn: A retrospective study.|pdf=|usr=026}}
+{{tp|p=33543766|t=2021. PEG That Reaction: A Case Series of Allergy to Polyethylene Glycol.|pdf=|usr=026}}
+{{tp|p=33552429|t=2021. Remdesivir in a pregnant patient with COVID-19 pneumonia.|pdf=|usr=026}}
+{{tp|p=33810356|t=2021. In Vitro Assessment of the Antiviral Activity of Ketotifen, Indomethacin and Naproxen, Alone and in Combination, against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33804989|t=2021. Amantadine Inhibits SARS-CoV-2 In Vitro.|pdf=|usr=026}}
+{{tp|p=33804957|t=2021. NSP16 2'-O-MTase in Coronavirus Pathogenesis: Possible Prevention and Treatments Strategies.|pdf=|usr=026}}
+{{tp|p=33807095|t=2021. Blockers of the SARS-CoV-2 3a Channel Identified by Targeted Drug Repurposing.|pdf=|usr=026}}
+{{tp|p=33706965|t=2021. Melatonin and healthy aging.|pdf=|usr=026}}
+{{tp|p=33683065|t=2021. [Interferon gamma in the treatment of patients with moderate COVID-19].|pdf=|usr=026}}
+{{tp|p=33533219|t=2020. [The use of viral RNA polymerase inhibitors in combination with a fusion inhibitor in the treatment of patients with COVID-19: hypothesis].|pdf=|usr=026}}
+{{tp|p=33772791|t=2021. Lessons learned in the collection of convalescent plasma during the COVID-19 pandemic.|pdf=|usr=026}}
+{{tp|p=33745163|t=2021. High-titre anti-SARS-CoV-2 convalescent plasma donation after donors' vaccination.|pdf=|usr=026}}
+{{tp|p=33734455|t=2021. Impact of pathogen reduction methods on immunological properties of the COVID-19 convalescent plasma.|pdf=|usr=026}}
+{{tp|p=33730761|t=2021. Understanding the role of therapeutic plasma exchange in COVID-19: preliminary guidance and practices.|pdf=|usr=026}}
+{{tp|p=33794556|t=2021. COVID-19 convalescent plasma therapy: hit fast, hit hard!|pdf=|usr=026}}
+{{tp|p=33798303|t=2021. [Observation of therapeutic effect on coronavirus disease 2019 with insomnia in treatment with baduanjin and auricular point sticking therapy].|pdf=|usr=026}}
+{{tp|p=33645139|t=2021. [Treatment strategy and thought on classical herbal formulae for coronavirus disease 2019].|pdf=|usr=026}}
+{{tp|p=33548966|t=2021. [Progress in the development of coronavirus disease 2019 vaccine].|pdf=|usr=026}}
+{{tp|p=33729129|t=2021. [Evaluation of the effects of immunotherapy and mesenchymal stem cells transplantation in the treatment of critically ill coronavirus disease 2019 patients].|pdf=|usr=026}}
+{{tp|p=33541491|t=2020. [Clinical efficacy and safety of different antiviral regimens in patients with coronavirus disease 2019].|pdf=|usr=026}}
+{{tp|p=33730835|t=2021. [Research study on nucleic acid testing of hemostatic stickers used and the surface of the recipients' hands after the inoculation of inactivated SARS-CoV-2 vaccine].|pdf=|usr=026}}
+{{tp|p=33631468|t=2021. Good nutrition critical to prevent Covid 19 mortality.|pdf=|usr=026}}
+{{tp|p=33817388|t=2021. Prediction of potential inhibitors of SARS-CoV-2 using 3D-QSAR, molecular docking modeling and ADMET properties.|pdf=|usr=026}}
+{{tp|p=33748511|t=2021. Use of vitamin/zinc supplements, medicinal plants, and immune boosting drinks during COVID-19 pandemic: A pilot study from Benha city, Egypt.|pdf=|usr=026}}
+{{tp|p=33748510|t=2021. Evaluation of flavonoids as 2019-nCoV cell entry inhibitor through molecular docking and pharmacological analysis.|pdf=|usr=026}}
+{{tp|p=33732940|t=2021. Discovery of Clioquinol and analogues as novel inhibitors of Severe Acute Respiratory Syndrome Coronavirus 2 infection, ACE2 and ACE2 - Spike protein interaction in vitro.|pdf=|usr=026}}
+{{tp|p=33693066|t=2021. Structural analogues of existing anti-viral drugs inhibit SARS-CoV-2 RNA dependent RNA polymerase: A computational hierarchical investigation.|pdf=|usr=026}}
+{{tp|p=33688584|t=2021. The study of antiviral drugs targeting SARS-CoV-2 nucleocapsid and spike proteins through large-scale compound repurposing.|pdf=|usr=026}}
+{{tp|p=33532640|t=2021. Potential compounds from several Indonesian plants to prevent SARS-CoV-2 infection: A mini-review of SARS-CoV-2 therapeutic targets.|pdf=|usr=026}}
+{{tp|p=33655086|t=2021. Antiviral and immunomodulatory activity of curcumin: A case for prophylactic therapy for COVID-19.|pdf=|usr=026}}
+{{tp|p=33655082|t=2021. Exploring existing drugs: proposing potential compounds in the treatment of COVID-19.|pdf=|usr=026}}
+{{tp|p=33615017|t=2021. Prospects of nutritional interventions in the care of COVID-19 patients.|pdf=|usr=026}}
+{{tp|p=33585706|t=2021. Can Echinacea be a potential candidate to target immunity, inflammation, and infection - The trinity of coronavirus disease 2019.|pdf=|usr=026}}
+{{tp|p=33553708|t=2021. Recent updates in the clinical trials of therapeutic monoclonal antibodies targeting cytokine storm for the management of COVID-19.|pdf=|usr=026}}
+{{tp|p=33623886|t=2021. SARS-CoV-2 Vaccines in Patients With Multiple Myeloma.|pdf=|usr=026}}
+{{tp|p=33817558|t=2021. CHALLENGES IN THE PRODUCTION OF COVID19 CONVALESCENT PLASMA - ANALYSIS OF DONOR RECRUITMENT.|pdf=|usr=026}}
+{{tp|p=33778377|t=2021. Suggested guidelines for convalescent plasma therapy for the treatment of COVID-19.|pdf=|usr=026}}
+{{tp|p=33577086|t=2021. AASLD Expert Panel Consensus Statement: Vaccines to Prevent COVID-19 Infection in Patients with Liver Disease.|pdf=|usr=026}}
+{{tp|p=33790052|t=2021. Optimising vitamin D levels in patients with COVID-19.|pdf=|usr=026}}
+{{tp|p=33677814|t=2021. COVID-19 vaccines: rapid development, implications, challenges and future prospects.|pdf=|usr=026}}
+{{tp|p=33527306|t=2021. mTOR inhibition: a double-edged sword in patients with COVID-19?|pdf=|usr=026}}
+{{tp|p=33640208|t=2021. Administration of high titer convalescent anti-SARS-CoV-2 plasma: From donor selection to monitoring recipient outcomes.|pdf=|usr=026}}
+{{tp|p=33632561|t=2021. Pharmacological approach for the reduction of inflammatory and prothrombotic hyperactive state in COVID-19 positive patients by acting on complement cascade.|pdf=|usr=026}}
+{{tp|p=33577681|t=2021. Integration of genetically regulated gene expression and pharmacological library provides therapeutic drug candidates.|pdf=|usr=026}}
+{{tp|p=33567446|t=2021. Potential Interplay between Nrf2, TRPA1, and TRPV1 in Nutrients for the Control of COVID-19.|pdf=|usr=026}}
+{{tp|p=33526960|t=2021. Presence of antibodies against SARS-CoV-2 spike protein in bovine whey IgG enriched fraction.|pdf=|usr=026}}
+{{tp|p=33715009|t=2021. Interleukin-6: From arthritis to CAR-T cell therapy and COVID-19.|pdf=|usr=026}}
+{{tp|p=33571745|t=2021. Immune response scenario and vaccine development for SARS-CoV-2 infection.|pdf=|usr=026}}
+{{tp|p=33765614|t=2021. The potential for Lactoferrin to reduce SARS-CoV-2 induced cytokine storm.|pdf=|usr=026}}
+{{tp|p=33735712|t=2021. Safety and efficacy of Favipiravir in moderate to severe SARS-CoV-2 pneumonia.|pdf=|usr=026}}
+{{tp|p=33714884|t=2021. The role of probiotics in coronavirus disease-19 infection in Wuhan: A retrospective study of 311 severe patients.|pdf=|usr=026}}
+{{tp|p=33631512|t=2021. Serum cytokine levels of COVID-19 patients after 7 days of treatment with Favipiravir or Kaletra.|pdf=|usr=026}}
+{{tp|p=33582019|t=2021. Efficacy and safety of convalescent plasma therapy in severe COVID-19 patients with acute respiratory distress syndrome.|pdf=|usr=026}}
+{{tp|p=33571819|t=2021. Leflunomide an immunomodulator with antineoplastic and antiviral potentials but drug-induced liver injury: A comprehensive review.|pdf=|usr=026}}
+{{tp|p=33540249|t=2021. Interferon-based therapies in COVID-19.|pdf=|usr=026}}
+{{tp|p=33714420|t=2021. Balanced evaluation of preliminary data on a candidate COVID-19 hydroxychloroquine treatment.|pdf=|usr=026}}
+{{tp|p=33596459|t=2021. Effect of hydroxychloroquine and azithromycin on the viral clearance of SARS-CoV-2: response to Herve Seligmann.|pdf=|usr=026}}
+{{tp|p=33722657|t=2021. Timing and dosage may be the key in the realisation of hydroxychloroquine + azithromycin treatment benefit in Covid-19 elderly patients.|pdf=|usr=026}}
+{{tp|p=33731132|t=2021. How COVID-19 lockdown and reopening affected daily steps: evidence based on 164,630 person-days of prospectively collected data from Shanghai, China.|pdf=|usr=026}}
+{{tp|p=33607132|t=2021. Underscoring the immense potential of chitosan in fighting a wide spectrum of viruses: A plausible molecule against SARS-CoV-2?|pdf=|usr=026}}
+{{tp|p=33794238|t=2021. A review on antiviral and immunomodulatory polysaccharides from Indian medicinal plants, which may be beneficial to COVID-19 infected patients.|pdf=|usr=026}}
+{{tp|p=33766591|t=2021. A review on the interaction of nucleoside analogues with SARS-CoV-2 RNA dependent RNA polymerase.|pdf=|usr=026}}
+{{tp|p=33385461|t=2021. Development of new vaccine target against SARS-CoV2 using envelope (E) protein: An evolutionary, molecular modeling and docking based study.|pdf=|usr=026}}
+{{tp|p=33716131|t=2021. Exploitation of polyphenols and proteins using nanoencapsulation for anti-viral and brain boosting properties - Evoking a synergistic strategy to combat COVID-19 pandemic.|pdf=|usr=026}}
+{{tp|p=33421473|t=2021. Denovo designing, retro-combinatorial synthesis, and molecular dynamics analysis identify novel antiviral VTRM1.1 against RNA-dependent RNA polymerase of SARS CoV2 virus.|pdf=|usr=026}}
+{{tp|p=33548314|t=2021. Epigallocatechin-3-gallate, an active ingredient of Traditional Chinese Medicines, inhibits the 3CLpro activity of SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33548321|t=2021. Targeting C-terminal Helical bundle of NCOVID19 Envelope (E) protein.|pdf=|usr=026}}
+{{tp|p=33767597|t=2021. Evaluation and characterization of HSPA5 (GRP78) expression profiles in normal individuals and cancer patients with COVID-19.|pdf=|usr=026}}
+{{tp|p=33390829|t=2021. Current advances in the development of SARS-CoV-2 vaccines.|pdf=|usr=026}}
+{{tp|p=33447763|t=2020. Cardiovascular medications and regulation of COVID-19 receptors expression.|pdf=|usr=026}}
+{{tp|p=33751323|t=2021. Sodium-glucose co-transporter 2 inhibitors in COVID-19: meeting at the crossroads between heart, diabetes and infectious diseases.|pdf=|usr=026}}
+{{tp|p=33555131|t=2021. The association between micronutrient and hemogram values and prognostic factors in COVID-19 patients: A single-center experience from Turkey.|pdf=|usr=026}}
+{{tp|p=33550688|t=2021. Therapeutic efficacy, mechanical ventilation, length of hospital stay, and mortality rate in severe COVID-19 patients treated with tocilizumab.|pdf=|usr=026}}
+{{tp|p=33650165|t=2021. Androgens and women: COVID-19 outcomes in women with acne vulgaris, polycystic ovarian syndrome, and hirsutism.|pdf=|usr=026}}
+{{tp|p=33419015|t=2021. Is It Time for Sports and Health in the Era of Covid-19 Pandemic?|pdf=|usr=026}}
+{{tp|p=33668304|t=2021. Cardiac Rehabilitation Based on the Walking Test and Telerehabilitation Improved Cardiorespiratory Fitness in People Diagnosed with Coronary Heart Disease during the COVID-19 Pandemic.|pdf=|usr=026}}
+{{tp|p=33668262|t=2021. A Pandemic within the Pandemic? Physical Activity Levels Substantially Decreased in Countries Affected by COVID-19.|pdf=|usr=026}}
+{{tp|p=33576451|t=2021. Pineal hormone melatonin as an adjuvant treatment for COVID19 (Review).|pdf=|usr=026}}
+{{tp|p=33576441|t=2021. Determining available strategies for prevention and therapy: Exploring COVID19 from the perspective of ACE2 (Review).|pdf=|usr=026}}
+{{tp|p=33537824|t=2021. Potential immunomodulatory effects of vitamin D in the prevention of severe coronavirus disease 2019: An ally for Latin America (Review).|pdf=|usr=026}}
+{{tp|p=33573283|t=2021. Pseudo-Dipeptide Bearing alpha,alpha-Difluoromethyl Ketone Moiety as Electrophilic Warhead with Activity against Coronaviruses.|pdf=|usr=026}}
+{{tp|p=33530554|t=2021. Mediterranean Diet for the Prevention of Gestational Diabetes in the Covid-19 Era: Implications of Il-6 In Diabesity.|pdf=|usr=026}}
+{{tp|p=33572480|t=2021. Human Milk Antibodies Against S1 and S2 Subunits from SARS-CoV-2, HCoV-OC43, and HCoV-229E in Mothers with A Confirmed COVID-19 PCR, Viral SYMPTOMS, and Unexposed Mothers.|pdf=|usr=026}}
+{{tp|p=33572274|t=2021. Understanding Viral Infection Mechanisms and Patient Symptoms for the Development of COVID-19 Therapeutics.|pdf=|usr=026}}
+{{tp|p=33557278|t=2021. Comparison of Antiviral Activity of Gemcitabine with 2'-Fluoro-2'-Deoxycytidine and Combination Therapy with Remdesivir against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33557253|t=2021. Predicting Potential SARS-COV-2 Drugs-In Depth Drug Database Screening Using Deep Neural Network Framework SSnet, Classical Virtual Screening and Docking.|pdf=|usr=026}}
+{{tp|p=33671104|t=2021. Nutraceuticals in the Prevention of Viral Infections, including COVID-19, among the Pediatric Population: A Review of the Literature.|pdf=|usr=026}}
+{{tp|p=33669738|t=2021. Computational Selectivity Assessment of Protease Inhibitors against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33671463|t=2021. Opportunities, Challenges and Pitfalls of Using Cannabidiol as an Adjuvant Drug in COVID-19.|pdf=|usr=026}}
+{{tp|p=33669456|t=2021. Adjunctive Nutraceutical Therapies for COVID-19.|pdf=|usr=026}}
+{{tp|p=33669167|t=2021. Phosphodiesterase Inhibitors in Acute Lung Injury: What Are the Perspectives?|pdf=|usr=026}}
+{{tp|p=33671877|t=2021. Neutralizing Human Antibodies against Severe Acute Respiratory Syndrome Coronavirus 2 Isolated from a Human Synthetic Fab Phage Display Library.|pdf=|usr=026}}
+{{tp|p=33668523|t=2021. Bioactive Alkaloids from Genus Aspergillus: Mechanistic Interpretation of Their Antimicrobial and Potential SARS-CoV-2 Inhibitory Activity Using Molecular Modelling.|pdf=|usr=026}}
+{{tp|p=33673372|t=2021. Platelet Lysate Nebulization Protocol for the Treatment of COVID-19 and Its Sequels: Proof of Concept and Scientific Rationale.|pdf=|usr=026}}
+{{tp|p=33670304|t=2021. Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19.|pdf=|usr=026}}
+{{tp|p=33688191|t=2021. New Acaciin-Loaded Self-Assembled Nanofibers as M(Pro) Inhibitors Against BCV as a Surrogate Model for SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33746660|t=2021. In-Silico Drug Designing of Spike Receptor with Its ACE2 Receptor and Nsp10/Nsp16 MTase Complex Against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33781885|t=2021. BRD4 targeting nanotherapy prevents lipopolysaccharide induced acute respiratory distress syndrome.|pdf=|usr=026}}
+{{tp|p=33540028|t=2021. Self-injectable extended release formulation of Remdesivir (SelfExRem): A potential formulation alternative for COVID-19 treatment.|pdf=|usr=026}}
+{{tp|p=33484917|t=2021. Visualizing the spatial localization of ciclesonide and its metabolites in rat lungs after inhalation of 1-mum aerosol of ciclesonide by desorption electrospray ionization-time of flight mass spectrometry imaging.|pdf=|usr=026}}
+{{tp|p=33785968|t=2021. Distance based and bond additive topological indices of certain repurposed antiviral drug compounds tested for treating COVID-19.|pdf=|usr=026}}
+{{tp|p=33612855|t=2020. Topological indices and QSPR/QSAR analysis of some antiviral drugs being investigated for the treatment of COVID-19 patients.|pdf=|usr=026}}
+{{tp|p=33677049|t=2021. Low-Dose Radiation Therapy for Severe COVID-19 Pneumonia: A Randomized Double-Blind Study.|pdf=|usr=026}}
+{{tp|p=33677050|t=2021. COVID-19 Vaccine-Induced Radiation Recall Phenomenon.|pdf=|usr=026}}
+{{tp|p=33722770|t=2021. Low Doses of Radiation Increase the Immunosuppressive Profile of Lung Macrophages During Viral Infection and Pneumonia.|pdf=|usr=026}}
+{{tp|p=33688993|t=2021. Potential role for interferon gamma in the treatment of recurrent ventilator-acquired pneumonia in patients with COVID-19: a hypothesis.|pdf=|usr=026}}
+{{tp|p=33694056|t=2021. Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID19 pneumonia and moderate hyperinflammation. A retrospective cohort study: reply.|pdf=|usr=026}}
+{{tp|p=33547620|t=2021. Timing of corticosteroids impacts mortality in hospitalized COVID-19 patients.|pdf=|usr=026}}
+{{tp|p=33598871|t=2021. Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID19 pneumonia and moderate hyperinflammation. A retrospective cohort study: comment.|pdf=|usr=026}}
+{{tp|p=33687691|t=2021. Deep vein thrombosis (DVT) occurring shortly after the second dose of mRNA SARS-CoV-2 vaccine.|pdf=|usr=026}}
+{{tp|p=33635496|t=2021. Adverse drug reactions in SARS-CoV-2 hospitalised patients: a case-series with a focus on drug-drug interactions-reply.|pdf=|usr=026}}
+{{tp|p=33583886|t=2021. Drug Fever Due to Favipiravir Administration for the Treatment of a COVID-19 Patient.|pdf=|usr=026}}
+{{tp|p=33580823|t=2021. Allergische Reaktionen auf COVID-19-Impfstoffe - Evidenz und praxisorientiertes Vorgehen.|pdf=|usr=026}}
+{{tp|p=33560450|t=2021. Impfstoffentwicklung zur Pravention von COVID-19 - Teil 2.|pdf=|usr=026}}
+{{tp|p=33788135|t=2021. Vigilance regarding immune thrombocytopenic purpura after COVID-19 vaccine.|pdf=|usr=026}}
+{{tp|p=33710481|t=2021. COVID-19 pandemic: vaccine and new monoclonal antibodies, point of view.|pdf=|usr=026}}
+{{tp|p=33598881|t=2021. The role of taurine derivatives in the putative therapy of COVID-19-induced inflammation.|pdf=|usr=026}}
+{{tp|p=33639626|t=2021. Mechanisms of COVID-19 Entry into the Cell: Potential Therapeutic Approaches Based on Virus Entry Inhibition in COVID-19 Patients with Underlying Diseases.|pdf=|usr=026}}
+{{tp|p=33639625|t=2021. Relationship between Bacillus Calmette Guerin Vaccination Policy and Coronavirus Disease-2019 (COVID-19) Incidence.|pdf=|usr=026}}
+{{tp|p=33787513|t=2021. Does prior immunization with measles, mumps, and rubella vaccines contribute to the antibody response to COVID-19 antigens?|pdf=|usr=026}}
+{{tp|p=33603991|t=2020. The efficacy of remdesivir in coronavirus disease 2019 (COVID-19): a systematic review.|pdf=|usr=026}}
+{{tp|p=33680028|t=2020. Approaches for the Treatment of SARS-CoV-2 Infection: A Pharmacologic View and Literature Review.|pdf=|usr=026}}
+{{tp|p=33708724|t=2020. Selected Micronutrients: An Option to Boost Immunity against COVID-19 and Prevent Adverse Pregnancy Outcomes in Pregnant Women: A Narrative Review.|pdf=|usr=026}}
+{{tp|p=33708723|t=2020. Convalescent Plasma in the Treatment of Severe COVID-19: A Systematic Review and Meta-Analysis.|pdf=|usr=026}}
+{{tp|p=33681723|t=2021. Targeting androgen regulation of TMPRSS2 and ACE2 as a therapeutic strategy to combat COVID-19.|pdf=|usr=026}}
+{{tp|p=33665567|t=2021. A computational framework of host-based drug repositioning for broad-spectrum antivirals against RNA viruses.|pdf=|usr=026}}
+{{tp|p=33585804|t=2021. Transcriptomic profiling of SARS-CoV-2 infected human cell lines identifies HSP90 as target for COVID-19 therapy.|pdf=|usr=026}}
+{{tp|p=33817567|t=2021. Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment.|pdf=|usr=026}}
+{{tp|p=33748696|t=2021. Learning from HIV-1 to predict the immunogenicity of T cell epitopes in SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33723528|t=2021. Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation.|pdf=|usr=026}}
+{{tp|p=33734623|t=2021. Peripheral Facial Nerve Palsy Following BNT162b2 (COVID-19) Vaccination.|pdf=|usr=026}}
+{{tp|p=33639998|t=2021. Breastfeeding and COVID-19 vaccination: position statement of the Italian scientific societies.|pdf=|usr=026}}
+{{tp|p=33588905|t=2021. Could nutritional supplements act as therapeutic adjuvants in COVID-19?|pdf=|usr=026}}
+{{tp|p=33764850|t=2021. Probiotics reduce self-reported symptoms of upper respiratory tract infection in overweight and obese adults: should we be considering probiotics during viral pandemics?|pdf=|usr=026}}
+{{tp|p=33651911|t=2021. Vaccination against COVID-19: Rationale, modalities and precautions for patients with haemophilia and other inherited bleeding disorders.|pdf=|usr=026}}
+{{tp|p=33647634|t=2021. Older adults' activity destinations before and during COVID-19 restrictions: From a variety of activities to mostly physical exercise close to home.|pdf=|usr=026}}
+{{tp|p=33623809|t=2021. Characteristics of the First 102 Severe COVID-19 Cases Treated With Convalescent Plasma or Tocilizumab or Both in Al-Nahdha Hospital, Oman.|pdf=|usr=026}}
+{{tp|p=33651967|t=2021. beta-glucans: wide-spectrum immune-balancing food-supplement-based enteric (beta-WIFE) vaccine adjuvant approach to COVID-19.|pdf=|usr=026}}
+{{tp|p=33577374|t=2021. Immunotherapies and immunomodulatory approaches in clinical trials - a mini review.|pdf=|usr=026}}
+{{tp|p=33606594|t=2021. Phylodynamic analysis in the understanding of the current COVID-19 pandemic and its utility in vaccine and antiviral design and assessment.|pdf=|usr=026}}
+{{tp|p=33536584|t=2021. Estrogen receptors are linked to angiotensin-converting enzyme 2 (ACE2), ADAM metallopeptidase domain 17 (ADAM-17), and transmembrane protease serine 2 (TMPRSS2) expression in the human atrium: insights into COVID-19.|pdf=|usr=026}}
+{{tp|p=33596958|t=2021. Unanticipated efficacy of SARS-CoV-2 vaccination in older adults.|pdf=|usr=026}}
+{{tp|p=33728100|t=2021. COVID-19 Antiviral and Treatment Candidates: Current Status.|pdf=|usr=026}}
+{{tp|p=33728098|t=2021. Ongoing Clinical Trials of Vaccines to Fight against COVID-19 Pandemic.|pdf=|usr=026}}
+{{tp|p=33728097|t=2021. Current Status of COVID-19 Vaccine Development: Focusing on Antigen Design and Clinical Trials on Later Stages.|pdf=|usr=026}}
+{{tp|p=33631118|t=2021. A modified vaccinia Ankara vector-based vaccine protects macaques from SARS-CoV-2 infection, immune pathology, and dysfunction in the lungs.|pdf=|usr=026}}
+{{tp|p=33557591|t=2021. Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma.|pdf=|usr=026}}
+{{tp|p=33753964|t=2021. Wild Sambucus nigra L. from north-east edge of the species range: A valuable germplasm with inhibitory capacity against SARS-CoV2 S-protein RBD and hACE2 binding in vitro.|pdf=|usr=026}}
+{{tp|p=33714413|t=2021. HCQ prophylaxis in COVID-19 did not show any QTc prolongation in Healthcare workers.|pdf=|usr=026}}
+{{tp|p=33814589|t=2021. Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study.|pdf=|usr=026}}
+{{tp|p=33814753|t=2021. Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic Review.|pdf=|usr=026}}
+{{tp|p=33551585|t=2021. Association of Vitamin D Status with COVID-19 Infection and Mortality in the Asia Pacific region: A Cross-Sectional Study.|pdf=|usr=026}}
+{{tp|p=33613002|t=2021. Trace Elements as Immunoregulators in SARS-CoV-2 and Other Viral Infections.|pdf=|usr=026}}
+{{tp|p=33623187|t=2020. Prospects of Vaccine against COVID-19.|pdf=|usr=026}}
+{{tp|p=33790504|t=2021. Tocilizumab: An Effective Therapy for Severely and Critically Ill COVID-19 Patients.|pdf=|usr=026}}
+{{tp|p=33790498|t=2021. Tocilizumab in COVID-19: Is the Temptation Worthwhile?|pdf=|usr=026}}
+{{tp|p=33707911|t=2021. Painful Blisters of Left Hand Following Extravasation of Remdesivir Infusion in COVID-19.|pdf=|usr=026}}
+{{tp|p=33746378|t=2021. Efficacy and Safety of Convalescent Plasma for COVID-19: A Systematic Review and Meta-analysis.|pdf=|usr=026}}
+{{tp|p=33781656|t=2021. The efficacy and safety of hydroxychloroquine (HCQ) in treatment of COVID19 -a systematic review and meta-analysis.|pdf=|usr=026}}
+{{tp|p=33533733|t=2021. Use of convalescent plasma for COVID-19 in India: A review & practical guidelines.|pdf=|usr=026}}
+{{tp|p=33595460|t=2021. Vitamin D supplementation in diabetic retinopathy in the era of COVID-19.|pdf=|usr=026}}
+{{tp|p=33614469|t=2021. Otorhinolaryngological Manifestations and Its Management in COVID 19 Patients.|pdf=|usr=026}}
+{{tp|p=33666200|t=2020. Efficacy and safety of steroid therapy in COVID-19: A rapid systematic review and Meta-analysis.|pdf=|usr=026}}
+{{tp|p=33666199|t=2020. Antiviral effect of amiodarone and its possible role in COVID-19: An appraisal.|pdf=|usr=026}}
+{{tp|p=33641858|t=2021. A review: Epidemiology, pathogenesis and prospect in developing vaccines for novel Coronavirus (COVID-19).|pdf=|usr=026}}
+{{tp|p=33641831|t=2021. BCG vaccination induced protection from COVID-19.|pdf=|usr=026}}
+{{tp|p=33706819|t=2021. Extensive environmental contamination and prolonged severe acute respiratory coronavirus-2 (SARS CoV-2) viability in immunosuppressed recent heart transplant recipients with clinical and virologic benefit with remdesivir.|pdf=|usr=026}}
+{{tp|p=33642866|t=2021. Inhibition of ACE2 Expression by Ascorbic Acid Alone and its Combinations with Other Natural Compounds.|pdf=|usr=026}}
+{{tp|p=33620019|t=2021. Corticosteroids and tocilizumab reduce in-hospital mortality in severe COVID-19 pneumonia: a retrospective study in a Spanish hospital.|pdf=|usr=026}}
+{{tp|p=33748805|t=2021. Mosaic vaccination schedule: An unexpected card to play against SARS-CoV-2?|pdf=|usr=026}}
+{{tp|p=33681861|t=2021. COVID-19 vaccines: Frequently asked questions and updated answers.|pdf=|usr=026}}
+{{tp|p=33585830|t=2021. BCG vaccination and COVID-19: Was flattening the curve just an illusion?|pdf=|usr=026}}
+{{tp|p=33731163|t=2021. Efficacy of the combination of modern medicine and traditional Chinese medicine in pulmonary fibrosis arising as a sequelae in convalescent COVID-19 patients: a randomized multicenter trial.|pdf=|usr=026}}
+{{tp|p=33726861|t=2021. Human coronaviruses and therapeutic drug discovery.|pdf=|usr=026}}
+{{tp|p=33532909|t=2021. Computational and Experimental Studies Reveal That Thymoquinone Blocks the Entry of Coronaviruses Into In Vitro Cells.|pdf=|usr=026}}
+{{tp|p=33738764|t=2021. Evaluating Clinical Efficacy of Antiviral Therapy for COVID-19: A Surrogate Endpoint Approach.|pdf=|usr=026}}
+{{tp|p=33790587|t=2021. BCG Vaccine-Induced Trained Immunity and COVID-19: Protective or Bystander?|pdf=|usr=026}}
+{{tp|p=33774178|t=2021. Molecular characterization of interactions between the D614G variant of SARS-CoV-2 S-protein and neutralizing antibodies: A computational approach.|pdf=|usr=026}}
+{{tp|p=33704465|t=2021. Barriers to Administering Vaccines in Inflammatory Bowel Disease Centers.|pdf=|usr=026}}
+{{tp|p=33740066|t=2021. Association of alpha-1-antitrypsin deficiency with vitamin D status: who is most at risk of getting severe COVID-19?|pdf=|usr=026}}
+{{tp|p=33608746|t=2021. Pharmacological mechanism of immunomodulatory agents for the treatment of severe cases of COVID-19 infection.|pdf=|usr=026}}
+{{tp|p=33751358|t=2021. A Dual Target-Directed Single Domain-Based Fusion Protein Against Interleukin-6 Receptor Decelerate Experimental Arthritis Progression Via Modulating JNK Expression.|pdf=|usr=026}}
+{{tp|p=33715284|t=2021. COVID-19-vaccinated plasma treatment for COVID-19 patients?|pdf=|usr=026}}
+{{tp|p=33649734|t=2021. Repurposing FDA-approved drugs to fight COVID-19 using in silico methods: Targeting SARS-CoV-2 RdRp enzyme and host cell receptors (ACE2, CD147) through virtual screening and molecular dynamic simulations.|pdf=|usr=026}}
+{{tp|p=33623816|t=2021. Evaluation of drug repositioning by molecular docking of pharmaceutical resources available in the Brazilian healthcare system against SARS-CoV-2.|pdf=|usr=026}}
+{{tp|p=33594342|t=2021. Identification of potential antivirals against SARS-CoV-2 using virtual screening method.|pdf=|usr=026}}
+{{tp|p=33553571|t=2021. The screening and evaluation of potential clinically significant HIV drug combinations against the SARS-CoV-2 virus.|pdf=|usr=026}}
+{{tp|p=33531865|t=2021. Aurintricarboxylic acid and its metal ion complexes in comparative virtual screening versus Lopinavir and Hydroxychloroquine in fighting COVID-19 pandemic: Synthesis and characterization.|pdf=|usr=026}}
+{{tp|p=33589845|t=2021. Are vanadium complexes druggable against the main protease M(pro) of SARS-CoV-2? - A computational approach.|pdf=|usr=026}}
+{{tp|p=33992805|t=2021. A SARS-CoV-2 targeted siRNA-nanoparticle therapy for COVID-19.|pdf=|usr=027}}
+{{tp|p=33333292|t=2021. Synergistic and Antagonistic Drug Combinations against SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=33984520|t=2021. Plant-derived exosomal microRNAs inhibit lung inflammation induced by exosomes SARS-CoV-2 Nsp12.|pdf=|usr=027}}
+{{tp|p=34007862|t=2021. Engineering mesenchymal stromal cells with neutralizing and anti-inflammatory capability against SARS-CoV-2 infection.|pdf=|usr=027}}
+{{tp|p=34072087|t=2021. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.|pdf=|usr=027}}
+{{tp|p=34070140|t=2021. Prioritisation of Compounds for 3CL(pro) Inhibitor Development on SARS-CoV-2 Variants.|pdf=|usr=027}}
+{{tp|p=33916461|t=2021. In Silico Mining of Terpenes from Red-Sea Invertebrates for SARS-CoV-2 Main Protease (M(pro)) Inhibitors.|pdf=|usr=027}}
+{{tp|p=33947107|t=2021. The Potency of Seaweed Sulfated Polysaccharides for the Correction of Hemostasis Disorders in COVID-19.|pdf=|usr=027}}
+{{tp|p=33946802|t=2021. Antiviral Properties of the NSAID Drug Naproxen Targeting the Nucleoprotein of SARS-CoV-2 Coronavirus.|pdf=|usr=027}}
+{{tp|p=33921378|t=2021. Molecular Dynamic Simulation Search for Possible Amphiphilic Drug Discovery for Covid-19.|pdf=|usr=027}}
+{{tp|p=33921289|t=2021. Efficacy of Phytochemicals Derived from Avicennia officinalis for the Management of COVID-19: A Combined In Silico and Biochemical Study.|pdf=|usr=027}}
+{{tp|p=33942600|t=2021. Lipid-lowering therapy in high cardiovascular risk patients during COVID-19 pandemic: keep focused on the target.|pdf=|usr=027}}
+{{tp|p=33947804|t=2021. Dietary Supplements and Nutraceuticals under Investigation for COVID-19 Prevention and Treatment.|pdf=|usr=027}}
+{{tp|p=34040779|t=2021. Effects of cytokine blocking agents on hospital mortality in patients admitted to ICU with acute respiratory distress syndrome by SARS-CoV-2 infection: retrospective cohort study.|pdf=|usr=027}}
+{{tp|p=33306283|t=2021. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.|pdf=|usr=027}}
+{{tp|p=33356051|t=2021. A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19.|pdf=|usr=027}}
+{{tp|p=33332779|t=2021. Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.|pdf=|usr=027}}
+{{tp|p=33332778|t=2021. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.|pdf=|usr=027}}
+{{tp|p=33289973|t=2021. A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19.|pdf=|usr=027}}
+{{tp|p=32706531|t=2021. The RECOVERY Platform.|pdf=|usr=027}}
+{{tp|p=33264557|t=2021. A Large, Simple Trial Leading to Complex Questions.|pdf=|usr=027}}
+{{tp|p=33264556|t=2021. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.|pdf=|usr=027}}
+{{tp|p=33963705|t=2021. [Salvianolic acid B and its magnesium salt inhibit SARS-CoV-2 infection of Vero-E6 cells by blocking spike protein-mediated membrane fusion].|pdf=|usr=027}}
+{{tp|p=33846686|t=2021. Lung-selective 25-hydroxycholesterol nanotherapeutics as a suppressor of COVID-19-associated cytokine storm.|pdf=|usr=027}}
+{{tp|p=34069866|t=2021. Unveiling the Potential Role of Nanozymes in Combating the COVID-19 Outbreak.|pdf=|usr=027}}
+{{tp|p=33982600|t=2021. Aerosolized nanoliposomal carrier of remdesivir: an effective alternative for COVID-19 treatment in vitro.|pdf=|usr=027}}
+{{tp|p=34045486|t=2021. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection.|pdf=|usr=027}}
+{{tp|p=34031399|t=2021. Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives.|pdf=|usr=027}}
+{{tp|p=33919991|t=2021. L-Carnitine Tartrate Downregulates the ACE2 Receptor and Limits SARS-CoV-2 Infection.|pdf=|usr=027}}
+{{tp|p=33924387|t=2021. Impact of COVID-19 Pandemic on Serum Vitamin D Level among Infants and Toddlers: An Interrupted Time Series Analysis and before-and-after Comparison.|pdf=|usr=027}}
+{{tp|p=33921297|t=2021. Does Evidence Exist to Blunt Inflammatory Response by Nutraceutical Supplementation during COVID-19 Pandemic? An Overview of Systematic Reviews of Vitamin D, Vitamin C, Melatonin, and Zinc.|pdf=|usr=027}}
+{{tp|p=33916257|t=2021. Vitamin C in the Treatment of COVID-19.|pdf=|usr=027}}
+{{tp|p=33916087|t=2021. Consequences of the COVID-19 Syndemic for Nutritional Health: A Systematic Review.|pdf=|usr=027}}
+{{tp|p=33895559|t=2021. Clinical efficacy of eucaloric ketogenic nutrition in the COVID-19 cytokine storm: A retrospective analysis of mortality and intensive care unit admission.|pdf=|usr=027}}
+{{tp|p=33321395|t=2021. An exploratory study of selenium status in healthy individuals and in patients with COVID-19 in a south Indian population: The case for adequate selenium status.|pdf=|usr=027}}
+{{tp|p=34014806|t=2021. The Relationship between COVID-19 Severity and Bacillus Calmette-Guerin (BCG)/ Mycobacterium tuberculosis exposure history in healthcare workers: a multi-center study.|pdf=|usr=027}}
+{{tp|p=33969249|t=2021. Alpha 1 Antitrypsin is an Inhibitor of the SARS-CoV-2-Priming Protease TMPRSS2.|pdf=|usr=027}}
+{{tp|p=34064210|t=2021. Dolosigranulum pigrum Modulates Immunity against SARS-CoV-2 in Respiratory Epithelial Cells.|pdf=|usr=027}}
+{{tp|p=34069460|t=2021. Strong Inhibitory Activity and Action Modes of Synthetic Maslinic Acid Derivative on Highly Pathogenic Coronaviruses: COVID-19 Drug Candidate.|pdf=|usr=027}}
+{{tp|p=34021797|t=2021. Favipiravir use in children with COVID-19 and acute kidney injury: is it safe?|pdf=|usr=027}}
+{{tp|p=33947420|t=2021. Severe COVID-19 in pediatric age: an update on the role of the anti-rheumatic agents.|pdf=|usr=027}}
+{{tp|p=33981493|t=2021. A molecular dynamics simulation study of the ACE2 receptor with screened natural inhibitors to identify novel drug candidate against COVID-19.|pdf=|usr=027}}
+{{tp|p=33954061|t=2021. Natural resources to control COVID-19: could lactoferrin amend SARS-CoV-2 infectivity?|pdf=|usr=027}}
+{{tp|p=33954055|t=2021. Identification of a novel inhibitor of SARS-CoV-2 3CL-PRO through virtual screening and molecular dynamics simulation.|pdf=|usr=027}}
+{{tp|p=34000327|t=2021. Review of antiviral peptides for use against zoonotic and selected non-zoonotic viruses.|pdf=|usr=027}}
+{{tp|p=34086487|t=2021. Pharmacogenomic considerations for repurposing of dexamethasone as a potential drug against SARS-CoV-2 infection.|pdf=|usr=027}}
+{{tp|p=34073502|t=2021. Immunotherapeutic Efficacy of IgY Antibodies Targeting the Full-Length Spike Protein in an Animal Model of Middle East Respiratory Syndrome Coronavirus Infection.|pdf=|usr=027}}
+{{tp|p=34069716|t=2021. Hydrotalcite-Niclosamide Nanohybrid as Oral Formulation towards SARS-CoV-2 Viral Infections.|pdf=|usr=027}}
+{{tp|p=34064831|t=2021. Tenofovir, Another Inexpensive, Well-Known and Widely Available Old Drug Repurposed for SARS-COV-2 Infection.|pdf=|usr=027}}
+{{tp|p=33801579|t=2021. Comprehensive and Rapid Quality Evaluation Method for the Ayurvedic Medicine Divya-Swasari-Vati Using Two Analytical Techniques: UPLC/QToF MS and HPLC-DAD.|pdf=|usr=027}}
+{{tp|p=33917573|t=2021. Ultramicronized Palmitoylethanolamide (um-PEA): A New Possible Adjuvant Treatment in COVID-19 patients.|pdf=|usr=027}}
+{{tp|p=33917313|t=2021. Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods.|pdf=|usr=027}}
+{{tp|p=33921724|t=2021. Phytochemicals from Plant Foods as Potential Source of Antiviral Agents: An Overview.|pdf=|usr=027}}
+{{tp|p=33924395|t=2021. Identification of Anti-SARS-CoV-2 Compounds from Food Using QSAR-Based Virtual Screening, Molecular Docking, and Molecular Dynamics Simulation Analysis.|pdf=|usr=027}}
+{{tp|p=34070725|t=2021. A Review of Repurposed Cancer Drugs in Clinical Trials for Potential Treatment of COVID-19.|pdf=|usr=027}}
+{{tp|p=34073500|t=2021. A Dry Powder Platform for Nose-to-Brain Delivery of Dexamethasone: Formulation Development and Nasal Deposition Studies.|pdf=|usr=027}}
+{{tp|p=34073456|t=2021. Biomedical Text Link Prediction for Drug Discovery: A Case Study with COVID-19.|pdf=|usr=027}}
+{{tp|p=34071116|t=2021. Lipophilicity, Pharmacokinetic Properties, and Molecular Docking Study on SARS-CoV-2 Target for Betulin Triazole Derivatives with Attached 1,4-Quinone.|pdf=|usr=027}}
+{{tp|p=33916409|t=2021. Tackling Immune Pathogenesis of COVID-19 through Molecular Pharmaceutics.|pdf=|usr=027}}
+{{tp|p=33918313|t=2021. A COVID-19 Drug Repurposing Strategy through Quantitative Homological Similarities Using a Topological Data Analysis-Based Framework.|pdf=|usr=027}}
+{{tp|p=33919660|t=2021. Drug Repurposing for COVID-19 Treatment by Integrating Network Pharmacology and Transcriptomics.|pdf=|usr=027}}
+{{tp|p=33315210|t=2021. Hospital Length of Stay for Patients with Severe COVID-19: Implications for Remdesivir's Value.|pdf=|usr=027}}
+{{tp|p=34075294|t=2021. Tocilizumab cost effective in reducing COVID-19-related deaths.|pdf=|usr=027}}
+{{tp|p=33948076|t=2021. Remdesivir cost effective for severe COVID-19 in China.|pdf=|usr=027}}
+{{tp|p=34052981|t=2021. The application of in silico experimental model in the assessment of ciprofloxacin and levofloxacin interaction with main SARS-CoV-2 targets: S-, E- and TMPRSS2 proteins, RNA-dependent RNA polymerase and papain-like protease (PLpro)-preliminary molecular docking analysis.|pdf=|usr=027}}
+{{tp|p=34085181|t=2021. Use of glucocorticoids and azithromycin in the therapy of COVID-19.|pdf=|usr=027}}
+{{tp|p=33970450|t=2021. Rifampicin and Letermovir as potential repurposed drug candidate for COVID-19 treatment: insights from an in-silico study.|pdf=|usr=027}}
+{{tp|p=33880743|t=2021. Role of pirfenidone in TGF-beta pathways and other inflammatory pathways in acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection: a theoretical perspective.|pdf=|usr=027}}
+{{tp|p=33359911|t=2021. Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19.|pdf=|usr=027}}
+{{tp|p=34089865|t=2021. Remdesivir in moderate to severe COVID-19: A matter of time?|pdf=|usr=027}}
+{{tp|p=33369210|t=2021. Targeting host cell proteases as a potential treatment strategy to limit the spread of SARS-CoV-2 in the respiratory tract.|pdf=|usr=027}}
+{{tp|p=33910199|t=2021. Utilizing Artificial Intelligence to Manage COVID-19 Scientific Evidence Torrent with Risklick AI: A Critical Tool for Pharmacology and Therapy Development.|pdf=|usr=027}}
+{{tp|p=33892181|t=2021. Antimicrobial photodynamic therapy with hypocrellin B against SARS-CoV-2 infection?|pdf=|usr=027}}
+{{tp|p=33838311|t=2021. Robust antimicrobial photodynamic therapy with curcumin-poly (lactic-co-glycolic acid) nanoparticles against COVID-19: A preliminary in vitro study in Vero cell line as a model.|pdf=|usr=027}}
+{{tp|p=33836277|t=2021. Photodynamic therapy with curcumin for combating SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=33836276|t=2021. Focused role of nanoparticles against COVID-19: Diagnosis and treatment.|pdf=|usr=027}}
+{{tp|p=33369281|t=2021. Might proton pump or sodium-hydrogen exchanger inhibitors be of value to ameliorate SARs-CoV-2 pathophysiology?|pdf=|usr=027}}
+{{tp|p=34093097|t=2021. Plant-derived lignans as potential antiviral agents: a systematic review.|pdf=|usr=027}}
+{{tp|p=34054380|t=2021. Flavonoids are promising safe therapy against COVID-19.|pdf=|usr=027}}
+{{tp|p=33867898|t=2021. Brazilian essential oils as source for the discovery of new anti-COVID-19 drug: a review guided by in silico study.|pdf=|usr=027}}
+{{tp|p=33376043|t=2021. Lycorine, a non-nucleoside RNA dependent RNA polymerase inhibitor, as potential treatment for emerging coronavirus infections.|pdf=|usr=027}}
+{{tp|p=34033999|t=2021. Sulforaphane inhibits the expression of interleukin-6 and interleukin-8 induced in bronchial epithelial IB3-1 cells by exposure to the SARS-CoV-2 Spike protein.|pdf=|usr=027}}
+{{tp|p=34029937|t=2021. Corilagin prevents SARS-CoV-2 infection by targeting RBD-ACE2 binding.|pdf=|usr=027}}
+{{tp|p=33961621|t=2021. Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes.|pdf=|usr=027}}
+{{tp|p=34061844|t=2021. Vitamin D and COVID-19 susceptibility and severity in the COVID-19 Host Genetics Initiative: A Mendelian randomization study.|pdf=|usr=027}}
+{{tp|p=34029332|t=2021. COVID-19 and helminth infection: Beyond the Th1/Th2 paradigm.|pdf=|usr=027}}
+{{tp|p=34061842|t=2021. Ivermectin as a potential treatment for COVID-19?|pdf=|usr=027}}
+{{tp|p=34106964|t=2021. Lack of efficacy of hydroxychloroquine and azithromycin in patients hospitalized for COVID-19 pneumonia: A retrospective study.|pdf=|usr=027}}
+{{tp|p=34106944|t=2021. Identification and evaluation of the inhibitory effect of Prunella vulgaris extract on SARS-coronavirus 2 virus entry.|pdf=|usr=027}}
+{{tp|p=34081722|t=2021. Inhaled corticosteroids do not adversely impact outcomes in COVID-19 positive patients with COPD: An analysis of Cleveland Clinic's COVID-19 registry.|pdf=|usr=027}}
+{{tp|p=34048457|t=2021. Avian antibodies (IgY) targeting spike glycoprotein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) inhibit receptor binding and viral replication.|pdf=|usr=027}}
+{{tp|p=34043733|t=2021. Molecular dynamics analysis of N-acetyl-D-glucosamine against specific SARS-CoV-2's pathogenicity factors.|pdf=|usr=027}}
+{{tp|p=34033648|t=2021. Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia.|pdf=|usr=027}}
+{{tp|p=34015003|t=2021. DPP-4 inhibitors may improve the mortality of coronavirus disease 2019: A meta-analysis.|pdf=|usr=027}}
+{{tp|p=34010326|t=2021. Unraveling the unbinding pathways of SARS-CoV-2 Papain-like proteinase known inhibitors by Supervised Molecular Dynamics simulation.|pdf=|usr=027}}
+{{tp|p=34010282|t=2021. Available medications used as potential therapeutics for COVID-19: What are the known safety profiles in pregnancy.|pdf=|usr=027}}
+{{tp|p=34003827|t=2021. Computational designing of a peptide that potentially blocks the entry of SARS-CoV, SARS-CoV-2 and MERS-CoV.|pdf=|usr=027}}
+{{tp|p=33989354|t=2021. Targeted antiviral treatment using non-ionizing radiation therapy for SARS-CoV-2 and viral pandemics preparedness: Technique, methods and practical notes for clinical application.|pdf=|usr=027}}
+{{tp|p=33984041|t=2021. Natural plant products as potential inhibitors of RNA dependent RNA polymerase of Severe Acute Respiratory Syndrome Coronavirus-2.|pdf=|usr=027}}
+{{tp|p=33974624|t=2021. Therapy with lopinavir/ritonavir and hydroxychloroquine is associated with acute kidney injury in COVID-19 patients.|pdf=|usr=027}}
+{{tp|p=33914780|t=2021. Risk factors for COVID-19 mortality: The effect of convalescent plasma administration.|pdf=|usr=027}}
+{{tp|p=33886614|t=2021. High-throughput screening of the ReFRAME, Pandemic Box, and COVID Box drug repurposing libraries against SARS-CoV-2 nsp15 endoribonuclease to identify small-molecule inhibitors of viral activity.|pdf=|usr=027}}
+{{tp|p=33882090|t=2021. The proportion and effect of corticosteroid therapy in patients with COVID-19 infection: A systematic review and meta-analysis.|pdf=|usr=027}}
+{{tp|p=33831046|t=2021. What about tocilizumab? A retrospective study from a NYC Hospital during the COVID-19 outbreak.|pdf=|usr=027}}
+{{tp|p=34003853|t=2021. Interactions of SARS-CoV-2 envelope protein with amilorides correlate with antiviral activity.|pdf=|usr=027}}
+{{tp|p=33836016|t=2021. Mutations derived from horseshoe bat ACE2 orthologs enhance ACE2-Fc neutralization of SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=34048156|t=2021. An asymptomatic course of SARS-CoV-2 infection in a patient with 3 different neoplasms and treated with bortezomib: a coincidence or new therapeutic possibility?|pdf=|usr=027}}
+{{tp|p=34020813|t=2021. Influenza and pneumococcal vaccinations are not associated to COVID-19 outcomes among patients admitted to a university hospital.|pdf=|usr=027}}
+{{tp|p=33341305|t=2021. BCG vaccine: Worrying proposal for COVID-19.|pdf=|usr=027}}
+{{tp|p=34071430|t=2021. Lymphopenia in COVID-19: gammadelta T Cells-Based Therapeutic Opportunities.|pdf=|usr=027}}
+{{tp|p=34073559|t=2021. The Relevance of Monoclonal Antibodies in the Treatment of COVID-19.|pdf=|usr=027}}
+{{tp|p=34065294|t=2021. The Association between Influenza Vaccination and COVID-19 and Its Outcomes: A Systematic Review and Meta-Analysis of Observational Studies.|pdf=|usr=027}}
+{{tp|p=34086221|t=2021. Rekonvaleszenten-Plasma mildert COVID-19-Verlauf bei Alteren.|pdf=|usr=027}}
+{{tp|p=34086220|t=2021. Ivermectin gegen Hakenwurm - und Coronavirus?|pdf=|usr=027}}
+{{tp|p=33904080|t=2021. Budesonid verhindert bei COVID-19 Ubergang zu schwerem Verlauf.|pdf=|usr=027}}
+{{tp|p=33840851|t=2021. Use of Convalescent Plasma in the Management of COVID-19.|pdf=|usr=027}}
+{{tp|p=34023987|t=2021. Targeting the intestinal TMPRSS2 protease to prevent SARS-CoV-2 entry into enterocytes-prospects and challenges.|pdf=|usr=027}}
+{{tp|p=33358936|t=2021. Nanobodies, the potent agents to detect and treat the Coronavirus infections: A systematic review.|pdf=|usr=027}}
+{{tp|p=33961167|t=2021. Identification of phytocompounds from Houttuynia cordata Thunb. as potential inhibitors for SARS-CoV-2 replication proteins through GC-MS/LC-MS characterization, molecular docking and molecular dynamics simulation.|pdf=|usr=027}}
+{{tp|p=34008129|t=2021. Meticulous assessment of natural compounds from NPASS database for identifying analogue of GRL0617, the only known inhibitor for SARS-CoV2 papain-like protease (PLpro) using rigorous computational workflow.|pdf=|usr=027}}
+{{tp|p=33856591|t=2021. Identification of potential plant-based inhibitor against viral proteases of SARS-CoV-2 through molecular docking, MM-PBSA binding energy calculations and molecular dynamics simulation.|pdf=|usr=027}}
+{{tp|p=33844135|t=2021. Structure-based identification of SARS-CoV-2 main protease inhibitors from anti-viral specific chemical libraries: an exhaustive computational screening approach.|pdf=|usr=027}}
+{{tp|p=33825097|t=2021. Identifying structural-functional analogue of GRL0617, the only well-established inhibitor for papain-like protease (PLpro) of SARS-CoV2 from the pool of fungal metabolites using docking and molecular dynamics simulation.|pdf=|usr=027}}
+{{tp|p=33837893|t=2021. Investigation of angucycline compounds as potential drug candidates against SARS Cov-2 main protease using docking and molecular dynamic approaches.|pdf=|usr=027}}
+{{tp|p=34068970|t=2021. Targeting Multiple Signal Transduction Pathways of SARS-CoV-2: Approaches to COVID-19 Therapeutic Candidates.|pdf=|usr=027}}
+{{tp|p=34064568|t=2021. Role of Resveratrol in Prevention and Control of Cardiovascular Disorders and Cardiovascular Complications Related to COVID-19 Disease: Mode of Action and Approaches Explored to Increase Its Bioavailability.|pdf=|usr=027}}
+{{tp|p=34068579|t=2021. In Silico Studies of Some Isoflavonoids as Potential Candidates against COVID-19 Targeting Human ACE2 (hACE2) and Viral Main Protease (M(pro)).|pdf=|usr=027}}
+{{tp|p=34062737|t=2021. Olive-Derived Triterpenes Suppress SARS COV-2 Main Protease: A Promising Scaffold for Future Therapeutics.|pdf=|usr=027}}
+{{tp|p=33918595|t=2021. Native Structure-Based Peptides as Potential Protein-Protein Interaction Inhibitors of SARS-CoV-2 Spike Protein and Human ACE2 Receptor.|pdf=|usr=027}}
+{{tp|p=33917694|t=2021. Algae-Derived Bioactive Molecules for the Potential Treatment of SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=33976229|t=2021. A SARS-CoV-2 antibody curbs viral nucleocapsid protein-induced complement hyperactivation.|pdf=|usr=027}}
+{{tp|p=33976198|t=2021. A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes.|pdf=|usr=027}}
+{{tp|p=34083527|t=2021. Drug repurposing screens identify chemical entities for the development of COVID-19 interventions.|pdf=|usr=027}}
+{{tp|p=33837182|t=2021. GCG inhibits SARS-CoV-2 replication by disrupting the liquid phase condensation of its nucleocapsid protein.|pdf=|usr=027}}
+{{tp|p=33863887|t=2021. Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model.|pdf=|usr=027}}
+{{tp|p=33859192|t=2021. Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials.|pdf=|usr=027}}
+{{tp|p=33273742|t=2021. Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets.|pdf=|usr=027}}
+{{tp|p=33977847|t=2021. Computational and experimental insights on the interaction of artemisinin, dihydroartemisinin and chloroquine with SARS-CoV-2 spike protein receptor-binding domain (RBD).|pdf=|usr=027}}
+{{tp|p=33875867|t=2021. Neutralizing monoclonal antibodies for treatment of COVID-19.|pdf=|usr=027}}
+{{tp|p=33850327|t=2021. Is IL-6 a key cytokine target for therapy in COVID-19?|pdf=|usr=027}}
+{{tp|p=33961065|t=2021. Current understanding on molecular drug targets and emerging treatment strategy for novel coronavirus-19.|pdf=|usr=027}}
+{{tp|p=33948424|t=2021. Inhibitory effect of anti-HIV compounds extracted from Indian medicinal plants to retard the replication and transcription process of SARS-CoV-2: an insight from molecular docking and MD-simulation studies.|pdf=|usr=027}}
+{{tp|p=33842188|t=2021. Binding ability of arginine, citrulline, N-acetyl citrulline and thiocitrulline with SARS COV-2 main protease using molecular docking studies.|pdf=|usr=027}}
+{{tp|p=34026229|t=2021. Convalescent plasma therapy as a conventional trick for treating COVID-19: a systematic review and meta-analysis study.|pdf=|usr=027}}
+{{tp|p=33976895|t=2021. A mini-review on sofosbuvir and daclatasvir treatment in coronavirus disease 2019.|pdf=|usr=027}}
+{{tp|p=33851074|t=2021. ICU admission rates in Istanbul following the addition of favipiravir to the national COVID-19 treatment protocol.|pdf=|usr=027}}
+{{tp|p=33829849|t=2021. Hypothesis regarding the connections between severe COVID-19 in children and nutrition: a narrative review.|pdf=|usr=027}}
+{{tp|p=34034769|t=2021. Nutritional screening based on objective indices at admission predicts in-hospital mortality in patients with COVID-19.|pdf=|usr=027}}
+{{tp|p=34020679|t=2021. The impact of vitamin D supplementation on body fat mass in elite male collegiate athletes.|pdf=|usr=027}}
+{{tp|p=33838992|t=2021. Statin and outcomes of coronavirus disease 2019 (COVID-19): A systematic review, meta-analysis, and meta-regression.|pdf=|usr=027}}
+{{tp|p=33308994|t=2021. Determinants of vitamin D activation in patients with acute coronary syndromes and its correlation with inflammatory markers.|pdf=|usr=027}}
+{{tp|p=33341894|t=2021. Potential benefits of dietary seaweeds as protection against COVID-19.|pdf=|usr=027}}
+{{tp|p=34064534|t=2021. Emergent Drug and Nutrition Interactions in COVID-19: A Comprehensive Narrative Review.|pdf=|usr=027}}
+{{tp|p=34072977|t=2021. Relation of Serum Copper Status to Survival in COVID-19.|pdf=|usr=027}}
+{{tp|p=34064175|t=2021. Calcifediol Treatment and Hospital Mortality Due to COVID-19: A Cohort Study.|pdf=|usr=027}}
+{{tp|p=34064053|t=2021. The Impact of Nutrition on the COVID-19 Pandemic and the Impact of the COVID-19 Pandemic on Nutrition.|pdf=|usr=027}}
+{{tp|p=34069656|t=2021. Mediterranean Diet and SARS-COV-2 Infection: Is There Any Association? A Proof-of-Concept Study.|pdf=|usr=027}}
+{{tp|p=34069412|t=2021. COVID-19 Disease Severity and Death in Relation to Vitamin D Status among SARS-CoV-2-Positive UAE Residents.|pdf=|usr=027}}
+{{tp|p=34068374|t=2021. Selenium as a Bioactive Micronutrient in the Human Diet and Its Cancer Chemopreventive Activity.|pdf=|usr=027}}
+{{tp|p=34068142|t=2021. Human Milk from Previously COVID-19-Infected Mothers: The Effect of Pasteurization on Specific Antibodies and Neutralization Capacity.|pdf=|usr=027}}
+{{tp|p=34068656|t=2021. Micronutrients Deficiency, Supplementation and Novel Coronavirus Infections-A Systematic Review and Meta-Analysis.|pdf=|usr=027}}
+{{tp|p=33800961|t=2021. In the Age of Viral Pandemic, Can Ingredients Inspired by Human Milk and Infant Nutrition Be Repurposed to Support the Immune System?|pdf=|usr=027}}
+{{tp|p=33807280|t=2021. Feasibility of Vitamin C in the Treatment of Post Viral Fatigue with Focus on Long COVID, Based on a Systematic Review of IV Vitamin C on Fatigue.|pdf=|usr=027}}
+{{tp|p=33801745|t=2021. Vitamin C: From Bench to Bedside.|pdf=|usr=027}}
+{{tp|p=33947070|t=2021. Oral and Topical Vitamin D, Sunshine, and UVB Phototherapy Safely Control Psoriasis in Patients with Normal Pretreatment Serum 25-Hydroxyvitamin D Concentrations: A Literature Review and Discussion of Health Implications.|pdf=|usr=027}}
+{{tp|p=33925932|t=2021. Vitamin D Status in Adolescents during COVID-19 Pandemic: A Cross-Sectional Comparative Study.|pdf=|usr=027}}
+{{tp|p=33925783|t=2021. Nutritional Interventions for COVID-19: A Role for Carnosine?|pdf=|usr=027}}
+{{tp|p=33880395|t=2021. Ivermectin against COVID-19: The unprecedented consequences in Latin America.|pdf=|usr=027}}
+{{tp|p=34102081|t=2021. Exploring the therapeutic potential of forkhead box O for outfoxing COVID-19.|pdf=|usr=027}}
+{{tp|p=33732750|t=2021. Cost-effectiveness of Remdesivir and Dexamethasone for COVID-19 Treatment in South Africa.|pdf=|usr=027}}
+{{tp|p=34036116|t=2021. Debating the Role of Vitamin D in COVID-19 - An interview with Dr. David Meltzer.|pdf=|usr=027}}
+{{tp|p=33880393|t=2021. A Case of Severe Acute Respiratory Syndrome Coronavirus 2 Treatment With Remdesivir in a Hepatitis C-Coinfected Patient Resulting in Temporary Viral Control and Posttreatment Flare.|pdf=|usr=027}}
+{{tp|p=33879509|t=2021. A nutraceutical strategy for downregulating TGFbeta signalling: prospects for prevention of fibrotic disorders, including post-COVID-19 pulmonary fibrosis.|pdf=|usr=027}}
+{{tp|p=33875563|t=2021. Anti-inflammatory activity of ivermectin in late-stage COVID-19 may reflect activation of systemic glycine receptors.|pdf=|usr=027}}
+{{tp|p=33869781|t=2021. COVID-19 severity in relation to sociodemographics and vitamin D use.|pdf=|usr=027}}
+{{tp|p=33364433|t=2021. Additional baricitinib loading dose improves clinical outcome in COVID-19.|pdf=|usr=027}}
+{{tp|p=33995792|t=2021. Probiotics potentials in mitigating coronavirus disease (COVID-19) pandemic.|pdf=|usr=027}}
+{{tp|p=33869886|t=2021. Impact of montelukast as add on treatment to the novel coronavirus pneumonia (COVID-19): protocol for an investigator-initiated open labeled randomized controlled pragmatic trial.|pdf=|usr=027}}
+{{tp|p=33842834|t=2021. Computational molecular docking and virtual screening revealed promising SARS-CoV-2 drugs.|pdf=|usr=027}}
+{{tp|p=33859954|t=2021. Positive Therapeutic Role of Selected Foods and Plant on Ailments with a Trend Towards COVID-19: A Review.|pdf=|usr=027}}
+{{tp|p=33894123|t=2021. Insight in the Current Progress in the Largest Clinical Trials for Covid-19 Drug Management (As of January 2021).|pdf=|usr=027}}
+{{tp|p=34006644|t=2021. Old vaccines for new infections: Exploiting innate immunity to control COVID-19 and prevent future pandemics.|pdf=|usr=027}}
+{{tp|p=33906951|t=2021. Network medicine framework for identifying drug-repurposing opportunities for COVID-19.|pdf=|usr=027}}
+{{tp|p=33893175|t=2021. Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice.|pdf=|usr=027}}
+{{tp|p=33303654|t=2021. A data-driven approach to identify risk profiles and protective drugs in COVID-19.|pdf=|usr=027}}
+{{tp|p=34031627|t=2021. Teletherapie - eine innovative Therapiemoglichkeit (auch) fur altere Menschen.|pdf=|usr=027}}
+{{tp|p=33915202|t=2021. Lipid homeostasis and mevalonate pathway in COVID-19: Basic concepts and potential therapeutic targets.|pdf=|usr=027}}
+{{tp|p=33967350|t=2021. Future antiviral polymers by plasma processing.|pdf=|usr=027}}
+{{tp|p=33864621|t=2021. High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors.|pdf=|usr=027}}
+{{tp|p=33852951|t=2021. An efficient system to generate truncated human angiotensin converting enzyme 2 (hACE2) capable of binding RBD and spike protein of SARS-CoV2.|pdf=|usr=027}}
+{{tp|p=33840006|t=2021. Milk Peptides as Novel Multi-Targeted Therapeutic Candidates for SARS-CoV2.|pdf=|usr=027}}
+{{tp|p=33290940|t=2021. Anti-viral properties of antipsychotic medications in the time of COVID-19.|pdf=|usr=027}}
+{{tp|p=33357253|t=2021. Evaluation of dietary supplement, functional food and herbal medicine use by dietitians during the COVID-19 pandemic.|pdf=|usr=027}}
+{{tp|p=33259924|t=2021. Scope of adjuvant therapy using roflumilast, a PDE-4 inhibitor against COVID-19.|pdf=|usr=027}}
+{{tp|p=34023513|t=2021. Tofacitinib reduces mortality in coronavirus disease 2019 Tofacitinib in COVID-19.|pdf=|usr=027}}
+{{tp|p=33933611|t=2021. Endothelin antagonism and sodium glucose Co-transporter 2 inhibition. A potential combination therapeutic strategy for COVID-19.|pdf=|usr=027}}
+{{tp|p=33284977|t=2021. Successful treatment of COVID-19 with colchicine in a kidney transplant recipient.|pdf=|usr=027}}
+{{tp|p=33972885|t=2021. Effectiveness and feasibility of convalescent blood transfusion to reduce COVID-19 fatality ratio.|pdf=|usr=027}}
+{{tp|p=33996135|t=2021. Cardiac TdP risk stratification modelling of anti-infective compounds including chloroquine and hydroxychloroquine.|pdf=|usr=027}}
+{{tp|p=34089436|t=2021. Tocilizumab effects in COVID-19 pneumonia: role of CT texture analysis in quantitative assessment of response to therapy.|pdf=|usr=027}}
+{{tp|p=33932453|t=2021. Nrf2 activation putatively mediates clinical benefits of low-dose radiotherapy in COVID-19 pneumonia and acute respiratory distress syndrome (ARDS): Novel mechanistic considerations.|pdf=|usr=027}}
+{{tp|p=33360293|t=2021. Hydroxychloroquine can potentially interfere with immune function in COVID-19 patients: Mechanisms and insights.|pdf=|usr=027}}
+{{tp|p=33988482|t=2021. Treatment of COVID-19 by stage: any space left for mesenchymal stem cell therapy?|pdf=|usr=027}}
+{{tp|p=33992585|t=2021. Complementary and alternative medicines use in COVID-19: A global perspective on practice, policy and research.|pdf=|usr=027}}
+{{tp|p=33932822|t=2021. Virucidal and antiviral effects of Thymus vulgaris essential oil on feline coronavirus.|pdf=|usr=027}}
+{{tp|p=34102594|t=2021. Extracorporeal cytokine hemadsorption in severe COVID-19 respiratory failure.|pdf=|usr=027}}
+{{tp|p=34087610|t=2021. Beneficial effects of inhaled surfactant in patients with COVID-19-associated acute respiratory distress syndrome.|pdf=|usr=027}}
+{{tp|p=33832495|t=2021. Letter to the editor: Vitamin D levels in acute illness and clinical severity in COVID-19 patients.|pdf=|usr=027}}
+{{tp|p=33907666|t=2021. Triazole, imidazole, and thiazole-based compounds as potential agents against coronavirus.|pdf=|usr=027}}
+{{tp|p=33829722|t=2021. Tocilizumab reduces the risk of ICU admission and mortality in patients with SARS-CoV-2 infection.|pdf=|usr=027}}
+{{tp|p=33982984|t=2021. Experience with the use of siltuximab in patients with SARS-CoV-2 infection.|pdf=|usr=027}}
+{{tp|p=34095859|t=2021. Protocol for constructing large size human antibody heavy chain variable domain (VH) library and selection of SARS-CoV-2 neutralizing antibody domains.|pdf=|usr=027}}
+{{tp|p=34078447|t=2021. The immune modulatory effects of umbilical cord-derived mesenchymal stromal cells in severe COVID-19 pneumonia.|pdf=|usr=027}}
+{{tp|p=33851324|t=2021. Targeting the PANoptosome with miRNA Loaded Mesenchymal Stem Cell Derived Extracellular Vesicles; a New Path to Fight Against the Covid-19?|pdf=|usr=027}}
+{{tp|p=34035820|t=2021. Mesenchymal Stem Cells and COVID-19: Cure, Prevention, and Vaccination.|pdf=|usr=027}}
+{{tp|p=34102020|t=2021. Umbilical cord mesenchymal stromal cells as critical COVID-19 adjuvant therapy: A randomized controlled trial.|pdf=|usr=027}}
+{{tp|p=34008922|t=2021. Advances in mesenchymal stem cell therapy for immune and inflammatory diseases: Use of cell-free products and human pluripotent stem cell-derived mesenchymal stem cells.|pdf=|usr=027}}
+{{tp|p=33867777|t=2021. The binding mechanism of ivermectin and levosalbutamol with spike protein of SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=33930306|t=2021. A monoclonal antibody against staphylococcal enterotoxin B superantigen inhibits SARS-CoV-2 entry in vitro.|pdf=|usr=027}}
+{{tp|p=33898692|t=2021. Ivermectin & COVID-19: Let's keep a One Health perspective.|pdf=|usr=027}}
+{{tp|p=33889481|t=2021. Indoor air quality improvement in COVID-19 pandemic: Review.|pdf=|usr=027}}
+{{tp|p=34010429|t=2021. Supplementation of the population during the COVID-19 pandemic with vitamins and micronutrients - how much evidence is needed?|pdf=|usr=027}}
+{{tp|p=33962652|t=2021. Repurposing existing medications for coronavirus disease 2019: protocol for a rapid and living systematic review.|pdf=|usr=027}}
+{{tp|p=33813870|t=2021. Translation, Adaptation, and Validation of Chronic Kidney Disease Self-Management and Knowledge Instruments for People at Pre-Dialysis Stage in the Arab World.|pdf=|usr=027}}
+{{tp|p=34009133|t=2021. Notes From the Field: The Combined Effects of Tocilizumab and Remdesivir in a Patient With Severe COVID-19 and Cytokine Release Syndrome.|pdf=|usr=027}}
+{{tp|p=33825689|t=2021. Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis.|pdf=|usr=027}}
+{{tp|p=34032815|t=2021. Mobile App-Reported Use of Traditional Medicine for Maintenance of Health in India During the COVID-19 Pandemic: Cross-sectional Questionnaire Study.|pdf=|usr=027}}
+{{tp|p=33997535|t=2021. Osmotic Tubulopathy in a Patient With COVID-19 Treated With Remdesivir.|pdf=|usr=027}}
+{{tp|p=33900614|t=2021. Tocilizumab bor overvagas i tidigt skede av svar covid-19.|pdf=|usr=027}}
+{{tp|p=34000257|t=2021. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.|pdf=|usr=027}}
+{{tp|p=34000255|t=2021. Convalescent plasma in patients hospitalised with COVID-19.|pdf=|usr=027}}
+{{tp|p=33933206|t=2021. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.|pdf=|usr=027}}
+{{tp|p=33933194|t=2021. Tocilizumab in COVID-19: some clarity amid controversy.|pdf=|usr=027}}
+{{tp|p=33545097|t=2021. Azithromycin, RECOVERY, and the power of large, simple trials.|pdf=|usr=027}}
+{{tp|p=34106642|t=2021. High-dose vitamin C intravenous infusion in the treatment of patients with COVID-19: A protocol for systematic review and meta-analysis.|pdf=|usr=027}}
+{{tp|p=34087822|t=2021. Retinal toxicity caused by hydroxychloroquine in patients with systemic lupus erythematosus: A case report.|pdf=|usr=027}}
+{{tp|p=33832097|t=2021. The relationship between nutritional status and the prognosis of COVID-19: A retrospective analysis of 63 patients.|pdf=|usr=027}}
+{{tp|p=33879697|t=2021. The effect of traditional Chinese medicine treatment for post-viral olfactory dysfunction: A protocol for systematic review and meta-analysis.|pdf=|usr=027}}
+{{tp|p=33879694|t=2021. The therapeutic effect and safety of the drugs for COVID-19: A systematic review and meta-analysis.|pdf=|usr=027}}
+{{tp|p=33996501|t=2021. Design of advanced siRNA therapeutics for the treatment of COVID-19.|pdf=|usr=027}}
+{{tp|p=32482538|t=2021. Propuesta de uso de anakinra en el distres respiratorio agudo secundario a COVID-19.|pdf=|usr=027}}
+{{tp|p=33967357|t=2021. Effects of Anacardic Acid Monoene on the Respiratory System of Mice Submitted to Acute Respiratory Distress Syndrome.|pdf=|usr=027}}
+{{tp|p=33317261|t=2021. COVID-19 and Acute Respiratory Distress Syndrome. Impact of corticosteroid treatment and predictors of poor outcome.|pdf=|usr=027}}
+{{tp|p=33902254|t=2021. Plitidepsina, un inhibidor del factor de elongacion celular eEF1a y molnupiravir un analogo del ribonucleosido citidina, dos nuevos compuestos quimicos con intensa actividad frente al SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=34007141|t=2021. Prevalence du COVID-19 chez les patients atteints de rhumatismes inflammatoires chroniques traites par biotherapies ou inhibiteurs des JAK : une etude basee sur la population au cours des deux premiers mois de l'epidemie de COVID-19 en Italie.|pdf=|usr=027}}
+{{tp|p=33875975|t=2021. Failure of chronic hydroxychloroquine in preventing severe complications of COVID-19 in patients with rheumatic diseases.|pdf=|usr=027}}
+{{tp|p=34089357|t=2021. COVID-19 in patients with gout on colchicine.|pdf=|usr=027}}
+{{tp|p=34028704|t=2021. The Rise and Fall of Hydroxychloroquine with the COVID-19 Pandemic: Narrative Review of Selected Data.|pdf=|usr=027}}
+{{tp|p=33895812|t=2021. Comment on: Gudu T, Stober C, Cope AP et al. Baricitinib set to join the Covid-19 therapeutic arsenal? Rheumatology (Oxford). 2021;60:1585-1587.|pdf=|usr=027}}
+{{tp|p=33856453|t=2021. Risk of COVID-19 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional DMARDs in Italy.|pdf=|usr=027}}
+{{tp|p=34092840|t=2021. Chemical constituents from coconut waste and their in silico evaluation as potential antiviral agents against SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=34046177|t=2021. Vitamin D regulation of the immune system and its implications for COVID-19: A mini review.|pdf=|usr=027}}
+{{tp|p=33824652|t=2021. Role of almitrine bismesylate in managing refractory hypoxemia in COVID19 acute respiratory distress syndrome.|pdf=|usr=027}}
+{{tp|p=33897263|t=2021. Research and effectiveness of anti-viral drugs against COVID-19; global public intervention to prevent coronavirus and to improve human health.|pdf=|usr=027}}
+{{tp|p=33935562|t=2021. Therapeutic development by repurposing drugs targeting SARS-CoV-2 spike protein interactions by simulation studies.|pdf=|usr=027}}
+{{tp|p=33835053|t=2021. Nutrition and the microbiota post-COVID-19.|pdf=|usr=027}}
+{{tp|p=33850422|t=2021. Calming the inflammatory storm in severe COVID-19 infections: Role of biologics- A narrative review.|pdf=|usr=027}}
+{{tp|p=34039613|t=2021. Inhalable Nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses.|pdf=|usr=027}}
+{{tp|p=33958322|t=2021. Structural insights into the cross-neutralization of SARS-CoV and SARS-CoV-2 by the human monoclonal antibody 47D11.|pdf=|usr=027}}
+{{tp|p=33318880|t=2021. Protoporphyrin IX and verteporfin potently inhibit SARS-CoV-2 infection in vitro and in a mouse model expressing human ACE2.|pdf=|usr=027}}
+{{tp|p=34010139|t=2021. A diamidobenzimidazole STING agonist protects against SARS-CoV-2 infection.|pdf=|usr=027}}
+{{tp|p=33958613|t=2021. Rapid development of neutralizing and diagnostic SARS-COV-2 mouse monoclonal antibodies.|pdf=|usr=027}}
+{{tp|p=33953295|t=2021. Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model.|pdf=|usr=027}}
+{{tp|p=33953223|t=2021. Network pharmacology approach to decipher signaling pathways associated with target proteins of NSAIDs against COVID-19.|pdf=|usr=027}}
+{{tp|p=34040117|t=2021. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials.|pdf=|usr=027}}
+{{tp|p=34040048|t=2021. A method for the rational selection of drug repurposing candidates from multimodal knowledge harmonization.|pdf=|usr=027}}
+{{tp|p=34040046|t=2021. Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=34031435|t=2021. Integrative web-based analysis of omics data for study of drugs against SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=34021229|t=2021. Corticosteroids for hospitalized patients with mild to critically-ill COVID-19: a multicenter, retrospective, propensity score-matched study.|pdf=|usr=027}}
+{{tp|p=34017029|t=2021. Impact of daily high dose oral vitamin D therapy on the inflammatory markers in patients with COVID 19 disease.|pdf=|usr=027}}
+{{tp|p=34012108|t=2021. A super-potent tetramerized ACE2 protein displays enhanced neutralization of SARS-CoV-2 virus infection.|pdf=|usr=027}}
+{{tp|p=34006961|t=2021. Implementing a method for engineering multivalency to substantially enhance binding of clinical trial anti-SARS-CoV-2 antibodies to wildtype spike and variants of concern proteins.|pdf=|usr=027}}
+{{tp|p=33986405|t=2021. Repurposing potential of posaconazole and grazoprevir as inhibitors of SARS-CoV-2 helicase.|pdf=|usr=027}}
+{{tp|p=33986382|t=2021. Exploring antibody repurposing for COVID-19: beyond presumed roles of therapeutic antibodies.|pdf=|usr=027}}
+{{tp|p=33986351|t=2021. In silico analysis suggests the RNAi-enhancing antibiotic enoxacin as a potential inhibitor of SARS-CoV-2 infection.|pdf=|usr=027}}
+{{tp|p=33976287|t=2021. Randomized controlled trial of convalescent plasma therapy against standard therapy in patients with severe COVID-19 disease.|pdf=|usr=027}}
+{{tp|p=33972631|t=2021. Development and characterization of two equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19.|pdf=|usr=027}}
+{{tp|p=34099831|t=2021. A metabolic modeling approach reveals promising therapeutic targets and antiviral drugs to combat COVID-19.|pdf=|usr=027}}
+{{tp|p=34099745|t=2021. Hydroxychloroquine plus standard of care compared with standard of care alone in COVID-19: a meta-analysis of randomized controlled trials.|pdf=|usr=027}}
+{{tp|p=34088975|t=2021. Regulation of the acetylcholine/alpha7nAChR anti-inflammatory pathway in COVID-19 patients.|pdf=|usr=027}}
+{{tp|p=34075090|t=2021. Targeting of the CD80/86 proinflammatory axis as a therapeutic strategy to prevent severe COVID-19.|pdf=|usr=027}}
+{{tp|p=33574416|t=2021. Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=33824382|t=2021. Distinct SARS-CoV-2 antibody reactivity patterns in coronavirus convalescent plasma revealed by a coronavirus antigen microarray.|pdf=|usr=027}}
+{{tp|p=33931664|t=2021. A SARS-CoV-2 (COVID-19) biological network to find targets for drug repurposing.|pdf=|usr=027}}
+{{tp|p=33927258|t=2021. The dimer-monomer equilibrium of SARS-CoV-2 main protease is affected by small molecule inhibitors.|pdf=|usr=027}}
+{{tp|p=33907251|t=2021. An open-label randomized controlled trial evaluating the efficacy of chloroquine/hydroxychloroquine in severe COVID-19 patients.|pdf=|usr=027}}
+{{tp|p=33907209|t=2021. A computational approach to aid clinicians in selecting anti-viral drugs for COVID-19 trials.|pdf=|usr=027}}
+{{tp|p=33893337|t=2021. Short term survival of critically ill COVID-19 Egyptian patients on assisted ventilation treated by either Dexamethasone or Tocilizumab.|pdf=|usr=027}}
+{{tp|p=33888840|t=2021. CpG-adjuvanted stable prefusion SARS-CoV-2 spike protein protected hamsters from SARS-CoV-2 challenge.|pdf=|usr=027}}
+{{tp|p=33888738|t=2021. Nanoparticle composite TPNT1 is effective against SARS-CoV-2 and influenza viruses.|pdf=|usr=027}}
+{{tp|p=33883570|t=2021. Evidence of a dysregulated vitamin D endocrine system in SARS-CoV-2 infected patient's lung cells.|pdf=|usr=027}}
+{{tp|p=33863950|t=2021. Reconcile the debate over protective effects of BCG vaccine against COVID-19.|pdf=|usr=027}}
+{{tp|p=33850241|t=2021. Development of a chiral HPLC method for the separation and quantification of hydroxychloroquine enantiomers.|pdf=|usr=027}}
+{{tp|p=33850184|t=2021. Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial.|pdf=|usr=027}}
+{{tp|p=34091342|t=2021. Transformation of antiviral ribavirin during ozone/PMS intensified disinfection amid COVID-19 pandemic.|pdf=|usr=027}}
+{{tp|p=34030377|t=2021. Can pharmaceutical drugs used to treat Covid-19 infection leads to human health risk? A hypothetical study to identify potential risk.|pdf=|usr=027}}
+{{tp|p=33360321|t=2021. A systematic review of the infectious complications of colchicine and the use of colchicine to treat infections.|pdf=|usr=027}}
+{{tp|p=33973446|t=2021. [Optimization of expression conditions and determination the proteolytic activity of codon-optimized SARS-CoV-2 main protease in Escherichia coli].|pdf=|usr=027}}
+{{tp|p=34052830|t=2021. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease.|pdf=|usr=027}}
+{{tp|p=34023849|t=2021. SARS-CoV-2 nanobodies 2.0.|pdf=|usr=027}}
+{{tp|p=34006835|t=2021. Ceftazidime is a potential drug to inhibit SARS-CoV-2 infection in vitro by blocking spike protein-ACE2 interaction.|pdf=|usr=027}}
+{{tp|p=34001849|t=2021. Safety and efficacy of meplazumab in healthy volunteers and COVID-19 patients: a randomized phase 1 and an exploratory phase 2 trial.|pdf=|usr=027}}
+{{tp|p=33994545|t=2021. Protein kinase CK2: a potential therapeutic target for diverse human diseases.|pdf=|usr=027}}
+{{tp|p=33972500|t=2021. Lenalidomide downregulates ACE2 protein abundance to alleviate infection by SARS-CoV-2 spike protein conditioned pseudoviruses.|pdf=|usr=027}}
+{{tp|p=34075025|t=2021. Identification of proteasome and caspase inhibitors targeting SARS-CoV-2 M(pro).|pdf=|usr=027}}
+{{tp|p=33837193|t=2021. FcgammaRIIb blockage: a promising immunotherapy target for severe COVID-19.|pdf=|usr=027}}
+{{tp|p=33895786|t=2021. An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19.|pdf=|usr=027}}
+{{tp|p=33895782|t=2021. Berbamine inhibits SARS-CoV-2 infection by compromising TRPMLs-mediated endolysosomal trafficking of ACE2.|pdf=|usr=027}}
+{{tp|p=33895772|t=2021. Proteome-wide epitope mapping identifies a resource of antibodies for SARS-CoV-2 detection and neutralization.|pdf=|usr=027}}
+{{tp|p=34078171|t=2021. Application of a High-Content Screening Assay Utilizing Primary Human Lung Fibroblasts to Identify Antifibrotic Drugs for Rapid Repurposing in COVID-19 Patients.|pdf=|usr=027}}
+{{tp|p=33874769|t=2021. A High-Throughput Radioactivity-Based Assay for Screening SARS-CoV-2 nsp10-nsp16 Complex.|pdf=|usr=027}}
+{{tp|p=33898925|t=2021. Repositioned Drugs for COVID-19-the Impact on Multiple Organs.|pdf=|usr=027}}
+{{tp|p=33875977|t=2021. Old Treatment for a New Disease: Can Rectal Ozone Insufflation Be Used for COVID-19 Management? A Case Report.|pdf=|usr=027}}
+{{tp|p=33870092|t=2021. A 3-Case Series of Autoimmune Haemolytic Anaemia and COVID-19: Is Plasma Exchange an Alternative?|pdf=|usr=027}}
+{{tp|p=33989977|t=2021. Tuning the Computational Evaluation of Spectroscopic, ELF, LOL, NCI analysis and Molecular Docking of Novel Anti COVID-19 Molecule 4-Dimethylamino Pyridinium 3, 5-Dichlorosalicylate.|pdf=|usr=027}}
+{{tp|p=34098482|t=2021. Computational details of molecular structure, spectroscopic properties, topological studies and SARS-Cov-2 enzyme molecular docking simulation of substituted triazolo pyrimidine thione heterocycles.|pdf=|usr=027}}
+{{tp|p=33333412|t=2021. Experimental design approach for development of spectrofluorimetric method for determination of favipiravir; a potential therapeutic agent against COVID-19 virus: Application to spiked human plasma.|pdf=|usr=027}}
+{{tp|p=34093778|t=2021. Potential role of Nigella sativa supplementation with physical activity in prophylaxis and treatment of COVID-19: a contemporary review.|pdf=|usr=027}}
+{{tp|p=33971318|t=2021. Locally harvested Covid-19 convalescent plasma could probably help combat the geographically determined SARS-CoV-2 viral variants.|pdf=|usr=027}}
+{{tp|p=33358868|t=2021. Strategies to DAMPen COVID-19-mediated lung and systemic inflammation and vascular injury.|pdf=|usr=027}}
+{{tp|p=33378571|t=2021. A retrospective matched cohort single-center study evaluating outcomes of COVID-19 and the impact of immunomodulation on COVID-19-related cytokine release syndrome in solid organ transplant recipients.|pdf=|usr=027}}
+{{tp|p=33316396|t=2021. Reply to Lebeaux D, Revest M. No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin.|pdf=|usr=027}}
+{{tp|p=34054222|t=2021. Potential protective mechanisms of green tea polyphenol EGCG against COVID-19.|pdf=|usr=027}}
+{{tp|p=33867130|t=2021. Therapeutic Potential of Targeting Plasminogen Activator Inhibitor-1 in COVID-19.|pdf=|usr=027}}
+{{tp|p=33910614|t=2021. Natural tannin extracts supplementation for COVID-19 patients (TanCOVID): a structured summary of a study protocol for a randomized controlled trial.|pdf=|usr=027}}
+{{tp|p=33874981|t=2021. A randomised, double-blind, placebo-controlled, pilot trial of intravenous plasma purified alpha-1 antitrypsin for SARS-CoV-2-induced Acute Respiratory Distress Syndrome: a structured summary of a study protocol for a randomised, controlled trial.|pdf=|usr=027}}
+{{tp|p=33845867|t=2021. Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial.|pdf=|usr=027}}
+{{tp|p=34015868|t=2021. Efficacy and Safety of Azithromycin for the Treatment of COVID-19: A Systematic Review and Meta-analysis.|pdf=|usr=027}}
+{{tp|p=34078038|t=2021. The Effect of the Timing of Dexamethasone Administration in Patients with COVID-19 Pneumonia.|pdf=|usr=027}}
+{{tp|p=34038993|t=2021. Dexamethasone and COVID-19 in a Developing Country: Appropriate Use?|pdf=|usr=027}}
+{{tp|p=33853308|t=2021. Agir COVID-19 enfeksiyonunda tosilizumab'in etkinligi: Guncel calismalarin derlemes.|pdf=|usr=027}}
+{{tp|p=33969238|t=2021. Randomized controlled trials of remdesivir in hospitalized coronavirus disease 2019 patients: A meta-analysis.|pdf=|usr=027}}
+{{tp|p=34092050|t=2021. History repeats itself: Horse originated Hyperimmune sera production against SARS CoV-2.|pdf=|usr=027}}
+{{tp|p=33878858|t=2021. Pulse Steroid Treatment for Hospitalized Adults with COVID-19.|pdf=|usr=027}}
+{{tp|p=33918368|t=2021. Deep Transfer Learning Approach for Automatic Recognition of Drug Toxicity and Inhibition of SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=33918301|t=2021. Glycyrrhizin Effectively Inhibits SARS-CoV-2 Replication by Inhibiting the Viral Main Protease.|pdf=|usr=027}}
+{{tp|p=33318996|t=2021. Longitudinal melanonychia and skin hyperpigmentation associated with hydroxychloroquine therapy.|pdf=|usr=027}}
+{{tp|p=34009353|t=2021. Reassessing the Association of Vitamin D Level With SARS-CoV-2 Seropositivity.|pdf=|usr=027}}
+{{tp|p=34009346|t=2021. Assessment of the Association of Vitamin D Level With SARS-CoV-2 Seropositivity Among Working-Age Adults.|pdf=|usr=027}}
+{{tp|p=33885775|t=2021. Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19: The TOGETHER Randomized Clinical Trial.|pdf=|usr=027}}
+{{tp|p=33880453|t=2021. Commentary: Therapeutic plasma exchange in COVID-19 pediatric patients: Is there a role?|pdf=|usr=027}}
+{{tp|p=34100005|t=2021. Combining immunomodulators and antivirals for COVID-19 - Authors' reply.|pdf=|usr=027}}
+{{tp|p=34100004|t=2021. Combining immunomodulators and antivirals for COVID-19.|pdf=|usr=027}}
+{{tp|p=34100001|t=2021. Convalescent plasma transfusion for pregnant patients with COVID-19.|pdf=|usr=027}}
+{{tp|p=33870260|t=2021. Getting hands on a drug for Covid-19: Inhaled and Intranasal Niclosamide.|pdf=|usr=027}}
+{{tp|p=33842908|t=2021. A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide: A broad spectrum antiviral candidate for treatment of COVID-19.|pdf=|usr=027}}
+{{tp|p=34015326|t=2021. Immunotherapy in COVID-19: why, who, and when?|pdf=|usr=027}}
+{{tp|p=33930329|t=2021. Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context.|pdf=|usr=027}}
+{{tp|p=33872590|t=2021. Interleukin-6: obstacles to targeting a complex cytokine in critical illness.|pdf=|usr=027}}
+{{tp|p=34090608|t=2021. Repurposing drugs for treatment of COVID-19.|pdf=|usr=027}}
+{{tp|p=34000236|t=2021. Cytokine adsorption in patients with severe COVID-19 pneumonia requiring extracorporeal membrane oxygenation (CYCOV): a single centre, open-label, randomised, controlled trial.|pdf=|usr=027}}
+{{tp|p=34000235|t=2021. Cytokine adsorption during ECMO for COVID-19-related ARDS.|pdf=|usr=027}}
+{{tp|p=33991509|t=2021. Inhaled budesonide for early treatment of COVID-19 - Authors' reply.|pdf=|usr=027}}
+{{tp|p=33991508|t=2021. Inhaled budesonide for early treatment of COVID-19.|pdf=|usr=027}}
+{{tp|p=33991507|t=2021. Inhaled budesonide for early treatment of COVID-19.|pdf=|usr=027}}
+{{tp|p=33991506|t=2021. Inhaled budesonide for early treatment of COVID-19.|pdf=|usr=027}}
+{{tp|p=33844998|t=2021. Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19.|pdf=|usr=027}}
+{{tp|p=33844996|t=2021. Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial.|pdf=|usr=027}}
+{{tp|p=33341157|t=2021. Remdesivir for COVID-19 in Europe: will it provide value for money?|pdf=|usr=027}}
+{{tp|p=34051878|t=2021. Exploiting an early immunological window of opportunity in COVID-19.|pdf=|usr=027}}
+{{tp|p=34051877|t=2021. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial.|pdf=|usr=027}}
+{{tp|p=33997800|t=2021. Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study.|pdf=|usr=027}}
+{{tp|p=33997799|t=2021. Non-steroidal anti-inflammatory drug use in COVID-19.|pdf=|usr=027}}
+{{tp|p=33349815|t=2021. Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform.|pdf=|usr=027}}
+{{tp|p=34031531|t=2021. Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19.|pdf=|usr=027}}
+{{tp|p=33990684|t=2021. JAK-inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis.|pdf=|usr=027}}
+{{tp|p=34002026|t=2021. Systematic review and meta-analysis of tocilizumab in persons with coronavirus disease-2019 (COVID-19).|pdf=|usr=027}}
+{{tp|p=34063766|t=2021. Strategies for the Production of Soluble Interferon-Alpha Consensus and Potential Application in Arboviruses and SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=33919577|t=2021. The Three Pillars of COVID-19 Convalescent Plasma Therapy.|pdf=|usr=027}}
+{{tp|p=33358906|t=2021. Targeting inflammatory cytokine storm to fight against COVID-19 associated severe complications.|pdf=|usr=027}}
+{{tp|p=33925791|t=2021. Micronutrients in Sepsis and COVID-19: A Narrative Review on What We Have Learned and What We Want to Know in Future Trials.|pdf=|usr=027}}
+{{tp|p=33950993|t=2021. Off-label tocilizumab and adjuvant iron chelator effectiveness in a group of severe COVID-19 pneumonia patients: A single center experience.|pdf=|usr=027}}
+{{tp|p=33950951|t=2021. A case report of COVID-19 in refractory myasthenia: Outcome with remdesivir and dexamethasone.|pdf=|usr=027}}
+{{tp|p=34032734|t=2021. Efficacy and safety of Lianhuaqingwen for mild or moderate coronavirus disease 2019: A meta-analysis of randomized controlled trials.|pdf=|usr=027}}
+{{tp|p=34032722|t=2021. No evidence of tocilizumab treatment efficacy for severe to critical SARS-CoV2 infected patients: Results from a retrospective controlled multicenter study.|pdf=|usr=027}}
+{{tp|p=34011029|t=2021. Corticosteroid therapy for COVID-19: A systematic review and meta-analysis of randomized controlled trials.|pdf=|usr=027}}
+{{tp|p=34011026|t=2021. Efficacy and safety of Xuanfei Baidu granules for treating COVID-19: A protocol for systematic review and meta-analysis.|pdf=|usr=027}}
+{{tp|p=34011025|t=2021. Efficacy of traditional herbal medicine for psychological sequelae in COVID-19 survivors: A protocol for systematic review and meta-analysis.|pdf=|usr=027}}
+{{tp|p=34106658|t=2021. Sarilumab (IL-6R antagonist) in critically ill patients with cytokine release syndrome by SARS-CoV2.|pdf=|usr=027}}
+{{tp|p=34056571|t=2021. Anti-viral treatment for SARS-CoV-2 infection: A race against time amidst the ongoing pandemic.|pdf=|usr=027}}
+{{tp|p=33301775|t=2021. Reply to Vitamin D deficiency in COVID-19: mixing up cause and consequence.|pdf=|usr=027}}
+{{tp|p=33920813|t=2021. Serum Zinc, Copper, and Other Biometals Are Associated with COVID-19 Severity Markers.|pdf=|usr=027}}
+{{tp|p=33888152|t=2021. Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment.|pdf=|usr=027}}
+{{tp|p=33933603|t=2021. Promising role of defensins peptides as therapeutics to combat against viral infection.|pdf=|usr=027}}
+{{tp|p=33932547|t=2021. Astemizole as a drug to inhibit the effect of SARS-COV-2 in vitro.|pdf=|usr=027}}
+{{tp|p=34033891|t=2021. Phytochemicals present in Indian ginseng possess potential to inhibit SARS-CoV-2 virulence: A molecular docking and MD simulation study.|pdf=|usr=027}}
+{{tp|p=33984466|t=2021. Molecular scaffolds from mother nature as possible lead compounds in drug design and discovery against coronaviruses: A landscape analysis of published literature and molecular docking studies.|pdf=|usr=027}}
+{{tp|p=34022374|t=2021. Lipopeptide-based pan-CoV fusion inhibitors potently inhibit HIV-1 infection.|pdf=|usr=027}}
+{{tp|p=33824542|t=2021. Eco-friendly UPLC-MS/MS analysis of possible add-on therapy for COVID-19 in human plasma: Insights of greenness assessment.|pdf=|usr=027}}
+{{tp|p=33916747|t=2021. A Study of 3CLpros as Promising Targets against SARS-CoV and SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=33925715|t=2021. Next-Generation Probiotics and Their Metabolites in COVID-19.|pdf=|usr=027}}
+{{tp|p=33921971|t=2021. Baicalein and Baicalin Inhibit SARS-CoV-2 RNA-Dependent-RNA Polymerase.|pdf=|usr=027}}
+{{tp|p=33920489|t=2021. A Phase II Study on the Use of Convalescent Plasma for the Treatment of Severe COVID-19- A Propensity Score-Matched Control Analysis.|pdf=|usr=027}}
+{{tp|p=33331748|t=2021. Extracorporeal immune modulation in COVID-19 induced immune dysfunction and secondary infections: the role of oXiris(R) membrane.|pdf=|usr=027}}
+{{tp|p=33823571|t=2021. Concomitant use of surfactant and extra-corporeal membrane oxygenation for COVID-19 in an 8-year-old boy.|pdf=|usr=027}}
+{{tp|p=33856141|t=2021. A TGF - beta2 enriched formula as an oral nutritional supplement for hospitalized COVID-19 patients.|pdf=|usr=027}}
+{{tp|p=34060731|t=2021. Preventive effects of Pycnogenol(R) on cardiovascular risk factors (including endothelial function) and microcirculation in subjects recovering from coronavirus disease 2019 (COVID-19).|pdf=|usr=027}}
+{{tp|p=33995692|t=2021. Eau tonique et quinine - un cocktail de bicentenaire servi en pleine effervescence.|pdf=|usr=027}}
+{{tp|p=34019535|t=2021. METHYLENE BLUE FOR TREATMENT OF HOSPITALIZED COVID-19 PATIENTS: A RANDOMIZED, CONTROLLED, OPEN-LABEL CLINICAL TRIAL, PHASE 2.|pdf=|usr=027}}
+{{tp|p=33870077|t=2021. Treatment of a Critically Ill COVID-19 Patient with the Seraph 100 Microbind Affinity Filter.|pdf=|usr=027}}
+{{tp|p=33995989|t=2021. Treatment with eltrombopag of severe immune thrombocytopenia and hemolytic anemia associated with COVID-19 pneumonia: a case report.|pdf=|usr=027}}
+{{tp|p=33854571|t=2021. Influence of colchicine prescription in COVID-19-related hospital admissions: a survival analysis.|pdf=|usr=027}}
+{{tp|p=33953559|t=2021. Chloroquine and Hydroxychloroquine for the Prevention and Treatment of COVID-19: A Fiction, Hope or Hype? An Updated Review.|pdf=|usr=027}}
+{{tp|p=33995653|t=2021. The therapeutic potential of inorganic polyphosphate: A versatile physiological polymer to control coronavirus disease (COVID-19).|pdf=|usr=027}}
+{{tp|p=33886017|t=2021. Insights into SARS-CoV-2: Medicinal Chemistry Approaches to Combat Its Structural and Functional Biology.|pdf=|usr=027}}
+{{tp|p=34058295|t=2021. Computational and experimental studies on the inhibitory mechanism of hydroxychloroquine on hERG.|pdf=|usr=027}}
+{{tp|p=34045121|t=2021. Convalescent plasma to treat COVID-19: Following the Argentinian lead.|pdf=|usr=027}}
+{{tp|p=33994107|t=2021. Preparedness and activities of the anti-SARS-CoV-2 convalescent plasma bank in the Veneto region (Italy): An organizational model for future emergencies.|pdf=|usr=027}}
+{{tp|p=33994106|t=2021. Efficacy of convalescent plasma therapy in severe COVID-19 patients.|pdf=|usr=027}}
+{{tp|p=33962885|t=2021. Effects on mortality of early vs late administration of convalescent plasma in the treatment of Covid-19.|pdf=|usr=027}}
+{{tp|p=33931359|t=2021. COVID19 immune plasma donation after vaccination: pros and cons.|pdf=|usr=027}}
+{{tp|p=33896671|t=2021. Plasma exchange followed by convalescent plasma transfusion in COVID-19 patients.|pdf=|usr=027}}
+{{tp|p=34102319|t=2021. Covid-19 convalescent plasma therapy: Analyzing the factors that led to its failure in India.|pdf=|usr=027}}
+{{tp|p=33965621|t=2021. Convalescent Plasma Therapy in the management of COVID-19 patients-The newer dimensions.|pdf=|usr=027}}
+{{tp|p=33931305|t=2021. Early and persistent viral clearance in COVID-19 patients treated with convalescent plasma.|pdf=|usr=027}}
+{{tp|p=33901641|t=2021. COVID-19 convalescent plasma as long-term therapy in immunodeficient patients?|pdf=|usr=027}}
+{{tp|p=33895379|t=2021. Psychological assessment and lived experiences of recovered COVID-19 patients who presented for convalescent plasma donation.|pdf=|usr=027}}
+{{tp|p=33839301|t=2021. What convalescent plasma in treating severe acute respiratory infections of viral aetiology can hint for COVID-19? Evidence from a meta-analysis.|pdf=|usr=027}}
+{{tp|p=33839300|t=2021. Bioethical perspective of convalescent plasma therapy for COVID-19: A systematic review.|pdf=|usr=027}}
+{{tp|p=33887552|t=2021. Exploring the utility of extracellular vesicles in ameliorating viral infection-associated inflammation, cytokine storm and tissue damage.|pdf=|usr=027}}
+{{tp|p=34034765|t=2021. Benefits of treatment with favipiravir in hospitalized patients for COVID-19: a retrospective observational case-control study.|pdf=|usr=027}}
+{{tp|p=34020680|t=2021. Intravenous immunoglobulin-based adjuvant therapy for severe COVID-19: a single-center retrospective cohort study.|pdf=|usr=027}}
+{{tp|p=34019233|t=2021. Anti-SARS-CoV-2 IgY Isolated from Egg Yolks of Hens Immunized with Inactivated SARS-CoV-2 for Immunoprophylaxis of COVID-19.|pdf=|usr=027}}
+{{tp|p=33370597|t=2021. Repurposing of renin inhibitors as SARS-COV-2 main protease inhibitors: A computational study.|pdf=|usr=027}}
+{{tp|p=34052578|t=2021. Azelastine inhibits viropexis of SARS-CoV-2 spike pseudovirus by binding to SARS-CoV-2 entry receptor ACE2.|pdf=|usr=027}}
+{{tp|p=34090962|t=2021. The folate antagonist methotrexate diminishes replication of the coronavirus SARS-CoV-2 and enhances the antiviral efficacy of remdesivir in cell culture models.|pdf=|usr=027}}
+{{tp|p=33359190|t=2021. Tmprss2 specific miRNAs as promising regulators for SARS-CoV-2 entry checkpoint.|pdf=|usr=027}}
+{{tp|p=33333102|t=2021. A retrospective comparison of drugs against COVID-19.|pdf=|usr=027}}
+{{tp|p=33845063|t=2021. Quantifying the effect of trypsin and elastase on in vitro SARS-CoV infections.|pdf=|usr=027}}
+{{tp|p=34099981|t=2021. Assessment of nitric oxide (NO) potential to mitigate COVID-19 severity.|pdf=|usr=027}}
+{{tp|p=33842675|t=2021. Potential combination therapy using twenty phytochemicals from twenty plants to prevent SARS- CoV-2 infection: An in silico Approach.|pdf=|usr=027}}
+{{tp|p=33842673|t=2021. Phytochemicals as potential drug candidates for targeting SARS CoV 2 proteins, an in silico study.|pdf=|usr=027}}
+{{tp|p=33948452|t=2021. Direct acting anti-hepatitis C combinations as potential COVID-19 protease inhibitors.|pdf=|usr=027}}
+{{tp|p=33869672|t=2021. Molecular docking and ADMET studies of Allium cepa, Azadirachta indica and Xylopia aethiopica isolates as potential anti-viral drugs for Covid-19.|pdf=|usr=027}}
+{{tp|p=34073401|t=2021. Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon.|pdf=|usr=027}}
+{{tp|p=34070524|t=2021. Noble Metal Organometallic Complexes Display Antiviral Activity against SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=34071034|t=2021. GABAA-Receptor Agonists Limit Pneumonitis and Death in Murine Coronavirus-Infected Mice.|pdf=|usr=027}}
+{{tp|p=34067381|t=2021. Remdesivir for Early COVID-19 Treatment of High-Risk Individuals Prior to or at Early Disease Onset-Lessons Learned.|pdf=|usr=027}}
+{{tp|p=34063247|t=2021. Scutellaria barbata D. Don Inhibits the Main Proteases (M(pro) and TMPRSS2) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.|pdf=|usr=027}}
+{{tp|p=34069827|t=2021. Aptamer BC 007's Affinity to Specific and Less-Specific Anti-SARS-CoV-2 Neutralizing Antibodies.|pdf=|usr=027}}
+{{tp|p=34069206|t=2021. Compelling Evidence for the Activity of Antiviral Peptides against SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=34068686|t=2021. The Repurposed Drugs Suramin and Quinacrine Cooperatively Inhibit SARS-CoV-2 3CL(pro) In Vitro.|pdf=|usr=027}}
+{{tp|p=33918958|t=2021. Screening of FDA-Approved Drugs Using a MERS-CoV Clinical Isolate from South Korea Identifies Potential Therapeutic Options for COVID-19.|pdf=|usr=027}}
+{{tp|p=33918914|t=2021. Broad-Spectrum Antiviral Activity of 3D8, a Nucleic Acid-Hydrolyzing Single-Chain Variable Fragment (scFv), Targeting SARS-CoV-2 and Multiple Coronaviruses In Vitro.|pdf=|usr=027}}
+{{tp|p=33918670|t=2021. Quinine Inhibits Infection of Human Cell Lines with SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=33918615|t=2021. The Photosensitizer Octakis(cholinyl)zinc Phthalocyanine with Ability to Bind to a Model Spike Protein Leads to a Loss of SARS-CoV-2 Infectivity In Vitro When Exposed to Far-Red LED.|pdf=|usr=027}}
+{{tp|p=33916927|t=2021. Neutralizing Antibody Therapeutics for COVID-19.|pdf=|usr=027}}
+{{tp|p=33946304|t=2021. Inhibitors of Protein Glycosylation Are Active against the Coronavirus Severe Acute Respiratory Syndrome Coronavirus SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=33340994|t=2021. Reducing transmission of SARS-CoV-2 with intranasal prophylaxis.|pdf=|usr=027}}
+{{tp|p=33997737|t=2021. Complement inhibition in severe COVID-19 - Blocking C5a seems to be key.|pdf=|usr=027}}
+{{tp|p=33937736|t=2021. Complement inhibition in severe COVID-19 - Blocking C5a seems to be key: Author's reply.|pdf=|usr=027}}
+{{tp|p=33903855|t=2021. Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial.|pdf=|usr=027}}
+{{tp|p=33870149|t=2021. RBD-specific polyclonal F(ab )2 fragments of equine antibodies in patients with moderate to severe COVID-19 disease: A randomized, multicenter, double-blind, placebo-controlled, adaptive phase 2/3 clinical trial.|pdf=|usr=027}}
+{{tp|p=33886937|t=2021. Convalescent plasma therapy in COVID-19 critically ill patients during advanced phases of clinical trials and their preliminary results.|pdf=|usr=027}}
+{{tp|p=34085928|t=2021. Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality.|pdf=|usr=027}}
+{{tp|p=34057039|t=2021. Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants.|pdf=|usr=027}}
+{{tp|p=33847245|t=2021. Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus.|pdf=|usr=027}}
+{{tp|p=33999367|t=2021. Vitamin D in the Covid-19 era: a review with recommendations from a G.I.O.S.E.G. expert panel.|pdf=|usr=027}}
+{{tp|p=33858814|t=2021. Malnutrition and nutrition support in COVID-19: The results of a nutrition support protocol.|pdf=|usr=027}}
+{{tp|p=34031634|t=2021. Nanozymes to fight the COVID-19 and future pandemics.|pdf=|usr=027}}
+{{tp|p=33841038|t=2021. An in silico approach to target RNA-dependent RNA polymerase of COVID-19 with naturally occurring phytochemicals.|pdf=|usr=027}}
+{{tp|p=33934306|t=2021. In silico screening of potent bioactive compounds from honeybee products against COVID-19 target enzymes.|pdf=|usr=027}}
+{{tp|p=33344687|t=2021. Recent case studies on the use of ozone to combat coronavirus: Problems and perspectives.|pdf=|usr=027}}
+{{tp|p=33957025|t=2021. Effectiveness of hydrogen peroxide as auxiliary treatment for hospitalized COVID-19 patients in Brazil: preliminary results of a randomized double-blind clinical trial.|pdf=|usr=027}}
+{{tp|p=34021807|t=2021. Mouthrinses against SARS-CoV-2: anti-inflammatory effectivity and a clinical pilot study.|pdf=|usr=027}}
+{{tp|p=33870079|t=2021. Cytosorb treatment in severe COVID-19 cardiac and pulmonary disease.|pdf=|usr=027}}
+{{tp|p=33982133|t=2021. Plasma concentrations of remdesivir metabolite in a critical COVID-19 patient needing continuous venovenous haemodialysis.|pdf=|usr=027}}
+{{tp|p=33966929|t=2021. Convalescent plasma in the management of COVID-19 pneumonia.|pdf=|usr=027}}
+{{tp|p=34023738|t=2021. A cyclic peptide inhibitor of the SARS-CoV-2 main protease.|pdf=|usr=027}}
+{{tp|p=33894564|t=2021. Phenoxazine nucleoside derivatives with a multiple activity against RNA and DNA viruses.|pdf=|usr=027}}
+{{tp|p=34054314|t=2021. Prophylactic effects of probiotics on respiratory viruses including COVID-19: a review.|pdf=|usr=027}}
+{{tp|p=34068930|t=2021. A Review of the Role of Micronutrients and Bioactive Compounds on Immune System Supporting to Fight against the COVID-19 Disease.|pdf=|usr=027}}
+{{tp|p=33347987|t=2021. The role of NO in COVID-19 and potential therapeutic strategies.|pdf=|usr=027}}
+{{tp|p=34017865|t=2021. In silico Exploration of Interactions Between Potential COVID-19 Antiviral Treatments and the Pore of the hERG Potassium Channel-A Drug Antitarget.|pdf=|usr=027}}
+{{tp|p=33969013|t=2021. Iloprost in COVID-19: The Rationale of Therapeutic Benefit.|pdf=|usr=027}}
+{{tp|p=33928083|t=2021. Acceleration of Translational Mesenchymal Stromal Cell Therapy Through Consistent Quality GMP Manufacturing.|pdf=|usr=027}}
+{{tp|p=33981629|t=2021. Fluticasone Propionate Suppresses Poly(I:C)-Induced ACE2 in Primary Human Nasal Epithelial Cells.|pdf=|usr=027}}
+{{tp|p=33968808|t=2021. Could Nutraceutical Approaches Possibly Attenuate the Cytokine Storm in COVID-19 Patients?|pdf=|usr=027}}
+{{tp|p=34041221|t=2021. Pharmacophore Modelling-Based Drug Repurposing Approaches for SARS-CoV-2 Therapeutics.|pdf=|usr=027}}
+{{tp|p=34017819|t=2021. Molecular Docking and Dynamics Simulation Revealed the Potential Inhibitory Activity of ACEIs Against SARS-CoV-2 Targeting the hACE2 Receptor.|pdf=|usr=027}}
+{{tp|p=33865880|t=2021. Antiviral strategies should focus on stimulating the biosynthesis of heparan sulfates, not their inhibition.|pdf=|usr=027}}
+{{tp|p=33316266|t=2021. Repurposing of histone deacetylase inhibitors: A promising strategy to combat pulmonary fibrosis promoted by TGF-beta signalling in COVID-19 survivors.|pdf=|usr=027}}
+{{tp|p=33310043|t=2021. Screened antipsychotic drugs inhibit SARS-CoV-2 binding with ACE2 in vitro.|pdf=|usr=027}}
+{{tp|p=33865879|t=2021. Therapeutic potential of mesenchymal stem cells in multiple organs affected by COVID-19.|pdf=|usr=027}}
+{{tp|p=34050796|t=2021. Tocilizumab in Hospitalized Patients with COVID-19: A Meta Analysis of Randomized Controlled Trials.|pdf=|usr=027}}
+{{tp|p=33942765|t=2021. Plasma therapy in COVID-19: All that glitters is not gold.|pdf=|usr=027}}
+{{tp|p=34024246|t=2021. Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies.|pdf=|usr=027}}
+{{tp|p=33958972|t=2021. Ivermectin and COVID-19.|pdf=|usr=027}}
+{{tp|p=33922914|t=2021. Dieckol and Its Derivatives as Potential Inhibitors of SARS-CoV-2 Spike Protein (UK Strain: VUI 202012/01): A Computational Study.|pdf=|usr=027}}
+{{tp|p=33921174|t=2021. Inhibition of SARS-CoV-2 Virus Entry by the Crude Polysaccharides of Seaweeds and Abalone Viscera In Vitro.|pdf=|usr=027}}
+{{tp|p=34094885|t=2021. Phenolic compounds as promising drug candidates against COVID-19 - An integrated molecular docking and dynamics simulation study.|pdf=|usr=027}}
+{{tp|p=33308613|t=2021. Immune-boosting role of vitamins D, C, E, zinc, selenium and omega-3 fatty acids: Could they help against COVID-19?|pdf=|usr=027}}
+{{tp|p=33958066|t=2021. In Reply-Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis.|pdf=|usr=027}}
+{{tp|p=33958065|t=2021. Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis.|pdf=|usr=027}}
+{{tp|p=33958057|t=2021. The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis.|pdf=|usr=027}}
+{{tp|p=33958056|t=2021. A Framework for Outpatient Infusion of Antispike Monoclonal Antibodies to High-Risk Patients with Mild-to-Moderate Coronavirus Disease-19: The Mayo Clinic Model.|pdf=|usr=027}}
+{{tp|p=34060334|t=2021. Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes.|pdf=|usr=027}}
+{{tp|p=33906927|t=2021. ColdZyme Maintains Integrity in SARS-CoV-2-Infected Airway Epithelia.|pdf=|usr=027}}
+{{tp|p=33879585|t=2021. Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma.|pdf=|usr=027}}
+{{tp|p=33307107|t=2021. Decreased serum levels of the inflammaging marker miR-146a are associated with clinical non-response to tocilizumab in COVID-19 patients.|pdf=|usr=027}}
+{{tp|p=34083071|t=2021. Efecto de la adicion de bemiparina y cefepime al tratamiento habitual en el paciente oncologico con infeccion por SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=34059357|t=2021. Prolongacion del intervalo QT en pacientes geriatricos bajo tratamiento por la infeccion por SARS-CoV-2: estudio OCTA-COVID.|pdf=|usr=027}}
+{{tp|p=33308853|t=2021. Incidencia de la COVID-19 en pacientes en tratamiento cronico con hidroxicloroquina.|pdf=|usr=027}}
+{{tp|p=33308854|t=2021. Cuestiones por resolver en el tratamiento con glucocorticoides de la infeccion COVID-19.|pdf=|usr=027}}
+{{tp|p=34056111|t=2021. Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation.|pdf=|usr=027}}
+{{tp|p=33846702|t=2021. The controversial therapeutic journey of chloroquine and hydroxychloroquine in the battle against SARS-CoV-2: A comprehensive review.|pdf=|usr=027}}
+{{tp|p=33878626|t=2021. Application of intravenous immunoglobulin (IVIG) to modulate inflammation in critical COVID-19 - A theoretical perspective.|pdf=|usr=027}}
+{{tp|p=33848919|t=2021. Role of NLRP3 inflammasome in COVID-19 and periodontitis: Possible protective effect of melatonin.|pdf=|usr=027}}
+{{tp|p=34102600|t=2021. A tale of two diseases: Sarcoidosis, COVID-19 and new therapeutic options with dual RAS inhibition and tetanus-diphtheria vaccine.|pdf=|usr=027}}
+{{tp|p=34098463|t=2021. Decorin as a possible strategy for the amelioration of COVID-19.|pdf=|usr=027}}
+{{tp|p=33360447|t=2021. Closing the portal to SARS-CoV-2 cellular entry: May open newer avenues....|pdf=|usr=027}}
+{{tp|p=33341328|t=2021. Does tetanus vaccination contribute to reduced severity of the COVID-19 infection?|pdf=|usr=027}}
+{{tp|p=33341032|t=2021. Methylene blue in covid-19.|pdf=|usr=027}}
+{{tp|p=33333472|t=2021. Statins and PCSK9 inhibitors: What is their role in coronavirus disease 2019?|pdf=|usr=027}}
+{{tp|p=33308938|t=2021. Inhaled milrinone for sick COVID-19 cohort: A pathophysiology driven hypothesis!|pdf=|usr=027}}
+{{tp|p=33308935|t=2021. Combating hypoxemia in COVID-19 patients with a natural oxygen carrier, HEMO2Life(R) (M101).|pdf=|usr=027}}
+{{tp|p=33867175|t=2021. Terapia combinada de tocilizumab y corticoides en la enfermedad grave por SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=33985821|t=2021. Dexametasona en COVID-19: inverted question markun medicamento para todos?|pdf=|usr=027}}
+{{tp|p=33277927|t=2021. Drug repurposing approach to combating coronavirus: Potential drugs and drug targets.|pdf=|usr=027}}
+{{tp|p=33828895|t=2021. BCG Protection Against COVID-19: Is it Reality or Illusion?|pdf=|usr=027}}
+{{tp|p=33967626|t=2021. Recombinant Human Thymosin Beta-4 Protects against Mouse Coronavirus Infection.|pdf=|usr=027}}
+{{tp|p=33974610|t=2021. Monoclonal Antibodies vs COVID-19: Eduardo Ojito-Magaz MS General Director, Molecular Immunology Center.|pdf=|usr=027}}
+{{tp|p=33974608|t=2021. An Experience with Cuban Biotech's Nasalferon to Prevent SARS-COV-2 Infections in International Travelers and their Contacts.|pdf=|usr=027}}
+{{tp|p=33906157|t=2021. Una nueva alternativa: terapia con plasma de convalecientes, posible antidoto en tiempos de COVID-19.|pdf=|usr=027}}
+{{tp|p=33906156|t=2021. Terapia con plasma de convalecientes en pacientes COVID-19.|pdf=|usr=027}}
+{{tp|p=34098567|t=2021. Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants.|pdf=|usr=027}}
+{{tp|p=33978988|t=2021. Malnutrition is associated with hyperinflammation and immunosuppression in COVID-19 patients: A prospective observational study.|pdf=|usr=027}}
+{{tp|p=34109257|t=2021. In Silico Evaluation of Cyclophilin Inhibitors as Potential Treatment for SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=34110959|t=2021. Possible therapeutic effects of Nigella sativa and its thymoquinone on COVID-19.|pdf=|usr=027}}
+{{tp|p=33835512|t=2021. Use of Remdesivir in Myasthenia gravis and COVID-19.|pdf=|usr=027}}
+{{tp|p=33860587|t=2021. The effect of propolis plus Hyoscyamus niger L. methanolic extract on clinical symptoms in patients with acute respiratory syndrome suspected to COVID-19: A clinical trial.|pdf=|usr=027}}
+{{tp|p=33979464|t=2021. Efficacy and safety of Xiyanping injection in the treatment of COVID-19: A multicenter, prospective, open-label and randomized controlled trial.|pdf=|usr=027}}
+{{tp|p=33928690|t=2021. New perspectives on natural flavonoids on COVID-19-induced lung injuries.|pdf=|usr=027}}
+{{tp|p=34111204|t=2021. Simulated sunlight decreases the viability of SARS-CoV-2 in mucus.|pdf=|usr=027}}
+{{tp|p=34111191|t=2021. Combination of (interferon beta-1b, lopinavir/ritonavir and ribavirin) versus favipiravir in hospitalized patients with non-critical COVID-19: A cohort study.|pdf=|usr=027}}
+{{tp|p=34103373|t=2021. Sofosbuvir with daclatasvir and the outcomes of patients with COVID-19: a systematic review and meta-analysis with GRADE assessment.|pdf=|usr=027}}
+{{tp|p=33973262|t=2021. ACE2-based decoy receptors for SARS coronavirus 2.|pdf=|usr=027}}
+{{tp|p=33893649|t=2021. Tackling Covid-19 using disordered-to-order transition of residues in the spike protein upon angiotensin-converting enzyme 2 binding.|pdf=|usr=027}}
+{{tp|p=34074129|t=2021. Wharton's Jelly Mesenchymal Stem Cell-Derived Extracellular Vesicles Reduce SARS-CoV2-Induced Inflammatory Cytokines Under High Glucose and Uremic Toxin Conditions.|pdf=|usr=027}}
+{{tp|p=34089033|t=2021. Antibody-laden nasal spray could provide COVID protection - and treatment.|pdf=|usr=027}}
+{{tp|p=33827113|t=2021. Drugs that inhibit TMEM16 proteins block SARS-CoV-2 spike-induced syncytia.|pdf=|usr=027}}
+{{tp|p=34082438|t=2021. Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants.|pdf=|usr=027}}
+{{tp|p=33932964|t=2021. The possibilities of using the effects of ozone therapy in neurology.|pdf=|usr=027}}
+{{tp|p=33368619|t=2021. Association Between Low Zinc Levels and Severity of Acute Respiratory Distress Syndrome by New Coronavirus SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=33858237|t=2021. Coronavirus management and control: Nutrition and alternative medicines.|pdf=|usr=027}}
+{{tp|p=33847299|t=2021. Neonates With SARS-CoV-2 Infection and Pulmonary Disease Safely Treated With Remdesivir.|pdf=|usr=027}}
+{{tp|p=33902077|t=2021. Novel Treatment of Infant With COVID-19 With the Sialidase Fusion Protein, DAS181.|pdf=|usr=027}}
+{{tp|p=33967228|t=2021. Safety and Antibody Kinetics of COVID-19 Convalescent Plasma for the Treatment of Moderate to Severe Cases of SARS-CoV-2 Infection in Pediatric Patients.|pdf=|usr=027}}
+{{tp|p=33316149|t=2021. The influence of the genetic background of the host on vitamin D deficiency in children with COVID-19.|pdf=|usr=027}}
+{{tp|p=33289321|t=2021. Tracing the path of inhaled nitric oxide: Biological consequences of protein nitrosylation.|pdf=|usr=027}}
+{{tp|p=33883243|t=2021. Compassionate Use of Remdesivir in Children With Severe COVID-19.|pdf=|usr=027}}
+{{tp|p=33964992|t=2021. Inhibition effects of eight anti-coronavirus drugs on glycosides metabolism and glycosidases in human gut microflora.|pdf=|usr=027}}
+{{tp|p=34009028|t=2021. Photodynamic Therapy and Photobiomodulation on Oral Lesion in Patient with Coronavirus Disease 2019: A Case Report.|pdf=|usr=027}}
+{{tp|p=33876086|t=2021. A crystallography-based investigation of weak interactions for drug design against COVID-19.|pdf=|usr=027}}
+{{tp|p=34008647|t=2021. Antiviral drug design based on the opening mechanism of spike glycoprotein in SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=34110678|t=2021. Therapeutic targets of natural products for the management of cardiovascular symptoms of coronavirus disease 2019.|pdf=|usr=027}}
+{{tp|p=33929758|t=2021. Andrographis paniculata (Burm. F) Wall ex Nees: Antiviral properties.|pdf=|usr=027}}
+{{tp|p=33882609|t=2021. Die Behandlung eines Patienten mit ausgepragtem Zytokinsturm bei schwerer COVID-19-Pneumonie unter Einsatz von Hamoadsorption in Kombination mit der Gabe von Tocilizumab.|pdf=|usr=027}}
+{{tp|p=33307968|t=2021. The Coronavirus Pandemic: A Pitfall or a Fast Track for Validating Cell Therapy Products?|pdf=|usr=027}}
+{{tp|p=34044609|t=2021. Human Umbilical Cord Mesenchymal Stromal Cell Treatment of Severe COVID-19 Patients: A 3-Month Follow-Up Study Following Hospital Discharge.|pdf=|usr=027}}
+{{tp|p=33888522|t=2021. Genetic polymorphisms, vitamin D binding protein and vitamin D deficiency in COVID-19.|pdf=|usr=027}}
+{{tp|p=34083403|t=2021. Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19-a randomised double-blinded placebo-controlled trial.|pdf=|usr=027}}
+{{tp|p=33361100|t=2021. Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial.|pdf=|usr=027}}
+{{tp|p=33303541|t=2021. Vitamin D status and seroconversion for COVID-19 in UK healthcare workers.|pdf=|usr=027}}
+{{tp|p=34002840|t=2021. Intravenous ozonized saline therapy as prophylaxis for healthcare workers (HCWs) in a dedicated COVID-19 hospital in India - A retrospective study.|pdf=|usr=027}}
+{{tp|p=33829465|t=2021. Therapeutic potential of N-acetyl cysteine (NAC) in preventing cytokine storm in COVID-19: review of current evidence.|pdf=|usr=027}}
+{{tp|p=33829464|t=2021. SARS-CoV-2 infection and H1N1 vaccination: does a relationship between the two factors really exist? A retrospective analysis of a territorial cohort in Ferrara, Italy.|pdf=|usr=027}}
+{{tp|p=33829431|t=2021. Comment on safety and efficacy of oral lopinavir/ritonavir in pediatric patients with coronavirus disease: a nationwide comparative analysis.|pdf=|usr=027}}
+{{tp|p=33829430|t=2021. Ozone therapy may be an option for COVID-19 patients.|pdf=|usr=027}}
+{{tp|p=33877683|t=2021. Dantrolene repurposed to treat sepsis or septic shock and COVID-19 patients.|pdf=|usr=027}}
+{{tp|p=33877681|t=2021. Prediction of potential therapeutic drugs against SARS-CoV-2 by using Connectivity Map based on transcriptome data.|pdf=|usr=027}}
+{{tp|p=34009333|t=2021. Modelling sudden cardiac death risks factors in patients with coronavirus disease of 2019: the hydroxychloroquine and azithromycin case.|pdf=|usr=027}}
+{{tp|p=33996744|t=2021. Pomegranate Peel Extract as an Inhibitor of SARS-CoV-2 Spike Binding to Human ACE2 Receptor (in vitro): A Promising Source of Novel Antiviral Drugs.|pdf=|usr=027}}
+{{tp|p=33889562|t=2021. Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main Protease.|pdf=|usr=027}}
+{{tp|p=33868174|t=2021. New Roles for Vitamin D Superagonists: From COVID to Cancer.|pdf=|usr=027}}
+{{tp|p=34093569|t=2021. Can Resveratrol-Inhaled Formulations Be Considered Potential Adjunct Treatments for COVID-19?|pdf=|usr=027}}
+{{tp|p=34093548|t=2021. Nasopharyngeal Type-I Interferon for Immediately Available Prophylaxis Against Emerging Respiratory Viral Infections.|pdf=|usr=027}}
+{{tp|p=34054866|t=2021. Intestinal Microbiota-A Promising Target for Antiviral Therapy?|pdf=|usr=027}}
+{{tp|p=34054808|t=2021. Human Surfactant Protein D Binds Spike Protein and Acts as an Entry Inhibitor of SARS-CoV-2 Pseudotyped Viral Particles.|pdf=|usr=027}}
+{{tp|p=34046038|t=2021. Case Report: Successful Response to Intravenous Immunoglobulin and Steroid Pulses in a Renal Transplant Recipient With Severe Covid-19 Disease and Associated Acute Allograft Failure.|pdf=|usr=027}}
+{{tp|p=34040614|t=2021. Vitamin C May Increase the Recovery Rate of Outpatient Cases of SARS-CoV-2 Infection by 70%: Reanalysis of the COVID A to Z Randomized Clinical Trial.|pdf=|usr=027}}
+{{tp|p=34025650|t=2021. Anti-TNF-alpha agents Modulate SARS-CoV-2 Receptors and Increase the Risk of Infection Through Notch-1 Signaling.|pdf=|usr=027}}
+{{tp|p=34012456|t=2021. Regulation of Tissue Immune Responses by Local Glucocorticoids at Epithelial Barriers and Their Impact on Interorgan Crosstalk.|pdf=|usr=027}}
+{{tp|p=34012436|t=2021. Case Report: Convalescent Plasma Achieves SARS-CoV-2 Viral Clearance in a Patient With Persistently High Viral Replication Over 8 Weeks Due to Severe Combined Immunodeficiency (SCID) and Graft Failure.|pdf=|usr=027}}
+{{tp|p=33995424|t=2021. Commentary: Mesenchymal Stem Cells: A New Piece in the Puzzle of COVID-19 Treatment.|pdf=|usr=027}}
+{{tp|p=33995420|t=2021. High Levels of Common Cold Coronavirus Antibodies in Convalescent Plasma Are Associated With Improved Survival in COVID-19 Patients.|pdf=|usr=027}}
+{{tp|p=33995419|t=2021. Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation.|pdf=|usr=027}}
+{{tp|p=33995361|t=2021. Mini-Factor H Modulates Complement-Dependent IL-6 and IL-10 Release in an Immune Cell Culture (PBMC) Model: Potential Benefits Against Cytokine Storm.|pdf=|usr=027}}
+{{tp|p=33968017|t=2021. Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery.|pdf=|usr=027}}
+{{tp|p=33897692|t=2021. Case Report: Interferon-gamma Restores Monocytic Human Leukocyte Antigen Receptor (mHLA-DR) in Severe COVID-19 With Acquired Immunosuppression Syndrome.|pdf=|usr=027}}
+{{tp|p=33868305|t=2021. Commentary: The Long History of Vitamin C: From Prevention of the Common Cold to Potential Aid in the Treatment of COVID-19.|pdf=|usr=027}}
+{{tp|p=33859652|t=2021. Repurposing Ivermectin for COVID-19: Molecular Aspects and Therapeutic Possibilities.|pdf=|usr=027}}
+{{tp|p=33841439|t=2021. Revisiting Pleiotropic Effects of Type I Interferons: Rationale for Its Prophylactic and Therapeutic Use Against SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=33833758|t=2021. Bovine Coronavirus Immune Milk Against COVID-19.|pdf=|usr=027}}
+{{tp|p=33909259|t=2021. Neutralizing monoclonal antibodies present new prospects to treat SARS-CoV-2 infections.|pdf=|usr=027}}
+{{tp|p=33909260|t=2021. Effects of Shuanghuanglian oral liquids on patients with COVID-19: a randomized, open-label, parallel-controlled, multicenter clinical trial.|pdf=|usr=027}}
+{{tp|p=34026798|t=2021. Phytochemical Moieties From Indian Traditional Medicine for Targeting Dual Hotspots on SARS-CoV-2 Spike Protein: An Integrative in-silico Approach.|pdf=|usr=027}}
+{{tp|p=34026778|t=2021. Vagus Nerve Stimulation: A Potential Adjunct Therapy for COVID-19.|pdf=|usr=027}}
+{{tp|p=33968969|t=2021. Efficacy Evaluation of Thymosin Alpha 1 in Non-severe Patients With COVID-19: A Retrospective Cohort Study Based on Propensity Score Matching.|pdf=|usr=027}}
+{{tp|p=33968948|t=2021. The Use of the Anticoagulant Heparin and Corticosteroid Dexamethasone as Prominent Treatments for COVID-19.|pdf=|usr=027}}
+{{tp|p=33937285|t=2021. Management of SARS-CoV-2 Infection: Key Focus in Macrolides Efficacy for COVID-19.|pdf=|usr=027}}
+{{tp|p=33898477|t=2021. Mortality Benefit of Convalescent Plasma in COVID-19: A Systematic Review and Meta-Analysis.|pdf=|usr=027}}
+{{tp|p=33889590|t=2021. Assessment of the Safety and Therapeutic Benefits of Convalescent Plasma in COVID-19 Treatment: A Systematic Review and Meta-Analysis.|pdf=|usr=027}}
+{{tp|p=34054782|t=2021. Therapeutic Potential of Exploiting Autophagy Cascade Against Coronavirus Infection.|pdf=|usr=027}}
+{{tp|p=33995308|t=2021. Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor in vitro.|pdf=|usr=027}}
+{{tp|p=33967984|t=2021. Computational Simulations Identified Marine-Derived Natural Bioactive Compounds as Replication Inhibitors of SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=34079818|t=2021. An Integrated Computational and Experimental Approach to Identifying Inhibitors for SARS-CoV-2 3CL Protease.|pdf=|usr=027}}
+{{tp|p=34055887|t=2021. Current Strategies of Antiviral Drug Discovery for COVID-19.|pdf=|usr=027}}
+{{tp|p=34046428|t=2021. Synthesis and Cytotoxic Activity of Novel Indole Derivatives and Their in silico Screening on Spike Glycoprotein of SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=34041263|t=2021. Prospective Role of Peptide-Based Antiviral Therapy Against the Main Protease of SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=34026833|t=2021. A Strategy Based on Loop Analysis to Develop Peptide Epitopes: Application to SARS-CoV-2 Spike Protein.|pdf=|usr=027}}
+{{tp|p=33937333|t=2021. Administration Timing and Efficacy of Tocilizumab in Patients With COVID-19 and Elevated IL-6.|pdf=|usr=027}}
+{{tp|p=33912587|t=2021. Inhibition of SARS-CoV-2 3CL M(pro) by Natural and Synthetic Inhibitors: Potential Implication for Vaccine Production Against COVID-19.|pdf=|usr=027}}
+{{tp|p=33898520|t=2021. Structure-Based Virtual Screening to Identify Novel Potential Compound as an Alternative to Remdesivir to Overcome the RdRp Protein Mutations in SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=33869283|t=2021. A Multifunctional Peptide From Bacillus Fermented Soybean for Effective Inhibition of SARS-CoV-2 S1 Receptor Binding Domain and Modulation of Toll Like Receptor 4: A Molecular Docking Study.|pdf=|usr=027}}
+{{tp|p=34054418|t=2021. Vitamin D, Depressive Symptoms, and Covid-19 Pandemic.|pdf=|usr=027}}
+{{tp|p=33927594|t=2021. Selective Vagus Nerve Stimulation as a Therapeutic Approach for the Treatment of ARDS: A Rationale for Neuro-Immunomodulation in COVID-19 Disease.|pdf=|usr=027}}
+{{tp|p=34095193|t=2021. Encapsulated Food Products as a Strategy to Strengthen Immunity Against COVID-19.|pdf=|usr=027}}
+{{tp|p=33855042|t=2021. Low Serum 25-hydroxyvitamin D (Vitamin D) Level Is Associated With Susceptibility to COVID-19, Severity, and Mortality: A Systematic Review and Meta-Analysis.|pdf=|usr=027}}
+{{tp|p=34093195|t=2021. A Large Impact of Obesity on the Disposition of Ivermectin, Moxidectin and Eprinomectin in a Canine Model: Relevance for COVID-19 Patients.|pdf=|usr=027}}
+{{tp|p=34079462|t=2021. Marine Sponge is a Promising Natural Source of Anti-SARS-CoV-2 Scaffold.|pdf=|usr=027}}
+{{tp|p=34054557|t=2021. Synergy Between Vitamin D and Sex Hormones in Respiratory Functionality of Patients Affected by COVID-19.|pdf=|usr=027}}
+{{tp|p=34054532|t=2021. Multi-Omics Approach in the Identification of Potential Therapeutic Biomolecule for COVID-19.|pdf=|usr=027}}
+{{tp|p=34054522|t=2021. Broad Anti-Viral Capacities of Lian-Hua-Qing-Wen Capsule and Jin-Hua-Qing-Gan Granule and Rational use Against COVID-19 Based on Literature Mining.|pdf=|usr=027}}
+{{tp|p=34054510|t=2021. beta-Caryophyllene, A Natural Dietary CB2 Receptor Selective Cannabinoid can be a Candidate to Target the Trinity of Infection, Immunity, and Inflammation in COVID-19.|pdf=|usr=027}}
+{{tp|p=34025433|t=2021. Curcumin as a Potential Treatment for COVID-19.|pdf=|usr=027}}
+{{tp|p=34025406|t=2021. The Anti-Viral and Anti-Inflammatory Properties of Edible Bird's Nest in Influenza and Coronavirus Infections: From Pre-Clinical to Potential Clinical Application.|pdf=|usr=027}}
+{{tp|p=34025393|t=2021. The Rise and Fall of Chloroquine/Hydroxychloroquine as Compassionate Therapy of COVID-19.|pdf=|usr=027}}
+{{tp|p=34017257|t=2021. Strategy, Progress, and Challenges of Drug Repurposing for Efficient Antiviral Discovery.|pdf=|usr=027}}
+{{tp|p=34017249|t=2021. The Cholinergic Drug Pyridostigmine Alleviates Inflammation During LPS-Induced Acute Respiratory Distress Syndrome.|pdf=|usr=027}}
+{{tp|p=34012398|t=2021. Comparative Effectiveness of Pharmacological Interventions for Covid-19: A Systematic Review and Network Meta-Analysis.|pdf=|usr=027}}
+{{tp|p=34012395|t=2021. A Survey Among Italian Physicians During COVID-19 Outbreak. Could Bacillus Calmette-Guerin Vaccine Be Effective Against SARS-CoV2?|pdf=|usr=027}}
+{{tp|p=34012391|t=2021. Natural Products Modulating Angiotensin Converting Enzyme 2 (ACE2) as Potential COVID-19 Therapies.|pdf=|usr=027}}
+{{tp|p=34012390|t=2021. Withania somnifera (L.) Dunal: Opportunity for Clinical Repurposing in COVID-19 Management.|pdf=|usr=027}}
+{{tp|p=33995094|t=2021. Pelargonium Extract EPs 7630 in the Treatment of Human Corona Virus-Associated Acute Respiratory Tract Infections - A Secondary Subgroup-Analysis of an Open-Label, Uncontrolled Clinical Trial.|pdf=|usr=027}}
+{{tp|p=33995078|t=2021. Edible and Herbal Plants for the Prevention and Management of COVID-19.|pdf=|usr=027}}
+{{tp|p=33995062|t=2021. Profiling Ribonucleotide and Deoxyribonucleotide Pools Perturbed by Remdesivir in Human Bronchial Epithelial Cells.|pdf=|usr=027}}
+{{tp|p=33995053|t=2021. Intermittent Hypoxic Preconditioning: A Potential New Powerful Strategy for COVID-19 Rehabilitation.|pdf=|usr=027}}
+{{tp|p=33986661|t=2021. Potential Mechanism Prediction of Herbal Medicine for Pulmonary Fibrosis Associated with SARS-CoV-2 Infection Based on Network Analysis and Molecular Docking.|pdf=|usr=027}}
+{{tp|p=33981235|t=2021. Phytochemicals as Potential Therapeutics for SARS-CoV-2-Induced Cardiovascular Complications: Thrombosis and Platelet Perspective.|pdf=|usr=027}}
+{{tp|p=33981229|t=2021. Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome.|pdf=|usr=027}}
+{{tp|p=33981214|t=2021. Therapeutic Potentials of Antiviral Plants Used in Traditional African Medicine With COVID-19 in Focus: A Nigerian Perspective.|pdf=|usr=027}}
+{{tp|p=33967777|t=2021. Pleiotropic Effects of Tetracyclines in the Management of COVID-19: Emerging Perspectives.|pdf=|usr=027}}
+{{tp|p=33967773|t=2021. High Dose Intravenous Vitamin C for Preventing The Disease Aggravation of Moderate COVID-19 Pneumonia. A Retrospective Propensity Matched Before-After Study.|pdf=|usr=027}}
+{{tp|p=33967755|t=2021. No Efficacy of the Combination of Lopinavir/Ritonavir Plus Hydroxychloroquine Versus Standard of Care in Patients Hospitalized With COVID-19: A Non-Randomized Comparison.|pdf=|usr=027}}
+{{tp|p=33959018|t=2021. Fluvoxamine: A Review of Its Mechanism of Action and Its Role in COVID-19.|pdf=|usr=027}}
+{{tp|p=33953674|t=2021. Giloy Ghanvati (Tinospora cordifolia (Willd.) Hook. f. and Thomson) Reversed SARS-CoV-2 Viral Spike-Protein Induced Disease Phenotype in the Xenotransplant Model of Humanized Zebrafish.|pdf=|usr=027}}
+{{tp|p=33953673|t=2021. Hydroxychloroquine Increased Anxiety-Like Behaviors and Disrupted the Expression of Some Related Genes in the Mouse Brain.|pdf=|usr=027}}
+{{tp|p=33935717|t=2021. Na(+)/K(+)-ATPase as a Target of Cardiac Glycosides for the Treatment of SARS-CoV-2 Infection.|pdf=|usr=027}}
+{{tp|p=33912048|t=2021. Commentary: Use of Cannabinoids to Treat Acute Respiratory Distress Syndrome and Cytokine Storm Associated With Coronavirus Disease-2019.|pdf=|usr=027}}
+{{tp|p=33912041|t=2021. Phytoconstituents, In Vitro Anti-Infective Activity of Buddleja indica Lam., and In Silico Evaluation of its SARS-CoV-2 Inhibitory Potential.|pdf=|usr=027}}
+{{tp|p=33912030|t=2021. Repurposing Chloroquine Against Multiple Diseases With Special Attention to SARS-CoV-2 and Associated Toxicity.|pdf=|usr=027}}
+{{tp|p=33897423|t=2021. 1,2,3,4,6-Pentagalloyl Glucose, a RBD-ACE2 Binding Inhibitor to Prevent SARS-CoV-2 Infection.|pdf=|usr=027}}
+{{tp|p=33841165|t=2021. Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.|pdf=|usr=027}}
+{{tp|p=33841143|t=2021. Medicinal Plants in COVID-19: Potential and Limitations.|pdf=|usr=027}}
+{{tp|p=33833683|t=2021. COVID-19: Famotidine, Histamine, Mast Cells, and Mechanisms.|pdf=|usr=027}}
+{{tp|p=33828481|t=2021. Fever and Antipyretic Supported by Traditional Chinese Medicine: A Multi-Pathway Regulation.|pdf=|usr=027}}
+{{tp|p=34093219|t=2021. Can Vitamin D Deficiency Increase the Susceptibility to COVID-19?|pdf=|usr=027}}
+{{tp|p=34054572|t=2021. The Cholinergic and ACE-2-Dependent Anti-Inflammatory Systems in the Lung: New Scenarios Emerging From COVID-19.|pdf=|usr=027}}
+{{tp|p=34077600|t=2021. Efficacy and safety of azithromycin in Covid-19 patients: A systematic review and meta-analysis of randomized clinical trials.|pdf=|usr=027}}
+{{tp|p=33882179|t=2021. Tocilizumab in COVID-19 pneumonia: Practical proposals based on a narrative review of randomised trials.|pdf=|usr=027}}
+{{tp|p=33999135|t=2021. Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: a systematic review and meta-analysis.|pdf=|usr=027}}
+{{tp|p=33872387|t=2021. Interactions between SARS coronavirus 2 papain-like protease and immune system: A potential drug target for the treatment of COVID-19.|pdf=|usr=027}}
+{{tp|p=34035117|t=2021. Complement control for COVID-19.|pdf=|usr=027}}
+{{tp|p=33915006|t=2021. Feasibility and safety of remdesivir in SARS-CoV2 infected renal transplant recipients: A retrospective cohort from a developing nation.|pdf=|usr=027}}
+{{tp|p=34046618|t=2021. Recent advances in the discovery of potent RNA-dependent RNA-polymerase (RdRp) inhibitors targeting viruses.|pdf=|usr=027}}
+{{tp|p=34046603|t=2021. Identification of LASSBio-1945 as an inhibitor of SARS-CoV-2 main protease (M(PRO)) through in silico screening supported by molecular docking and a fragment-based pharmacophore model.|pdf=|usr=027}}
+{{tp|p=33944732|t=2021. Ivermectin for COVID-19: Promising but not yet conclusive.|pdf=|usr=027}}
+{{tp|p=33944756|t=2021. A qualitative analysis of seven ivermectin formulations in South Africa.|pdf=|usr=027}}
+{{tp|p=34011224|t=2021. Robust classification-based molecular modelling of diverse chemical entities as potential SARS-CoV-2 3CL(pro) inhibitors: theoretical justification in light of experimental evidences.|pdf=|usr=027}}
+{{tp|p=34010142|t=2021. Pharmacological activation of STING blocks SARS-CoV-2 infection.|pdf=|usr=027}}
+{{tp|p=34081820|t=2021. Initial experience of bamlanivimab monotherapy use in solid organ transplant recipients.|pdf=|usr=027}}
+{{tp|p=33345848|t=2021. Off-label use of chloroquine, hydroxychloroquine, azithromycin and lopinavir/ritonavir in COVID-19 risks prolonging the QT interval by targeting the hERG channel.|pdf=|usr=027}}
+{{tp|p=34015316|t=2021. Evaluation of Th1 and Th2 mediated cellular and humoral immunity in patients with COVID-19 following the use of melatonin as an adjunctive treatment.|pdf=|usr=027}}
+{{tp|p=34004207|t=2021. Role of leukotriene pathway and montelukast in pulmonary and extrapulmonary manifestations of Covid-19: The enigmatic entity.|pdf=|usr=027}}
+{{tp|p=34015317|t=2021. Azithromycin: Immunomodulatory and antiviral properties for SARS-CoV-2 infection.|pdf=|usr=027}}
+{{tp|p=34104202|t=2021. Alkaloids as Potential Phytochemicals against SARS-CoV-2: Approaches to the Associated Pivotal Mechanisms.|pdf=|usr=027}}
+{{tp|p=34040501|t=2021. Selenium to selenoproteins - role in COVID-19.|pdf=|usr=027}}
+{{tp|p=33302737|t=2021. Protease-activated receptor 1 as a potential therapeutic target for COVID-19.|pdf=|usr=027}}
+{{tp|p=33899542|t=2021. Manipulation of genes could inhibit SARS-CoV-2 infection that causes COVID-19 pandemics.|pdf=|usr=027}}
+{{tp|p=33310152|t=2021. Metformin in acute respiratory distress syndrome: An opinion.|pdf=|usr=027}}
+{{tp|p=34035463|t=2021. Platycodin D, a natural component of Platycodon grandiflorum, prevents both lysosome- and TMPRSS2-driven SARS-CoV-2 infection by hindering membrane fusion.|pdf=|usr=027}}
+{{tp|p=33968179|t=2021. Efficiency of antiviral treatment in COVID-19.|pdf=|usr=027}}
+{{tp|p=33835886|t=2021. A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19.|pdf=|usr=027}}
+{{tp|p=33703986|t=2021. Considerations of the effects of commonly investigated drugs for COVID-19 in the cholesterol synthesis pathway.|pdf=|usr=027}}
+{{tp|p=33857397|t=2021. TLR4 as a therapeutic target for respiratory and neurological complications of SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=34015985|t=2021. Corticosteroids in SARS-COV2 infection: certainties and uncertainties in clinical practice.|pdf=|usr=027}}
+{{tp|p=33844613|t=2021. Antimicrobial peptides and other peptide-like therapeutics as promising candidates to combat SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=33823733|t=2021. Efficacy and safety of Tocilizumab in severe and critical COVID-19: A Systematic Review and Meta-Analysis.|pdf=|usr=027}}
+{{tp|p=33962524|t=2021. Antiviral treatment selection for SARS-CoV-2 pneumonia.|pdf=|usr=027}}
+{{tp|p=34015243|t=2021. Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations.|pdf=|usr=027}}
+{{tp|p=34046165|t=2021. Is butyrate a natural alternative to dexamethasone in the management of CoVID-19?|pdf=|usr=027}}
+{{tp|p=33968364|t=2021. Identifying potential drug targets and candidate drugs for COVID-19: biological networks and structural modeling approaches.|pdf=|usr=027}}
+{{tp|p=33763201|t=2021. Optimal use of tocilizumab for severe and critical COVID-19: a systematic review and meta-analysis.|pdf=|usr=027}}
+{{tp|p=33879541|t=2021. Rationales and uncertainties for aspirin use in COVID-19: a narrative review.|pdf=|usr=027}}
+{{tp|p=33894315|t=2021. Discovery of naturally occurring inhibitors against SARS-CoV-2 3CL(pro) from Ginkgo biloba leaves via large-scale screening.|pdf=|usr=027}}
+{{tp|p=33995121|t=2021. Proteomics and Machine Learning Approaches Reveal a Set of Prognostic Markers for COVID-19 Severity With Drug Repurposing Potential.|pdf=|usr=027}}
+{{tp|p=34054909|t=2021. Plant-Produced Receptor-Binding Domain of SARS-CoV-2 Elicits Potent Neutralizing Responses in Mice and Non-human Primates.|pdf=|usr=027}}
+{{tp|p=33315181|t=2021. Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: randomized control trial in Singapore.|pdf=|usr=027}}
+{{tp|p=34061787|t=2021. Vitamin D plasma levels in patients with COVID-19: a case series.|pdf=|usr=027}}
+{{tp|p=33325523|t=2021. Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry.|pdf=|usr=027}}
+{{tp|p=33860869|t=2021. Induction of Exaggerated Cytokine Production in Human Peripheral Blood Mononuclear Cells by a Recombinant SARS-CoV-2 Spike Glycoprotein S1 and Its Inhibition by Dexamethasone.|pdf=|usr=027}}
+{{tp|p=34075339|t=2021. Computational prediction of nimbanal as potential antagonist of respiratory syndrome coronavirus.|pdf=|usr=027}}
+{{tp|p=34075338|t=2021. Structural insights and inhibition mechanism of TMPRSS2 by experimentally known inhibitors Camostat mesylate, Nafamostat and Bromhexine hydrochloride to control SARS-coronavirus-2: A molecular modeling approach.|pdf=|usr=027}}
+{{tp|p=34028468|t=2021. The journey of antimalarial drugs against SARS-CoV-2: Review article.|pdf=|usr=027}}
+{{tp|p=33846694|t=2021. Computational prediction of potential siRNA and human miRNA sequences to silence orf1ab associated genes for future therapeutics against SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=33363251|t=2021. Computational and network pharmacology analysis of bioflavonoids as possible natural antiviral compounds in COVID-19.|pdf=|usr=027}}
+{{tp|p=33352565|t=2021. Spices to Control COVID-19 Symptoms: Yes, but Not Only....|pdf=|usr=027}}
+{{tp|p=33833556|t=2021. Preliminary Exploration of Setting the Disease Severity Score in the Nutritional Risk Screening of Patients with Severe Novel Coronavirus Pneumonia by Applying NRS2002.|pdf=|usr=027}}
+{{tp|p=33864917|t=2021. Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: An open-label randomized trial.|pdf=|usr=027}}
+{{tp|p=33848675|t=2021. A call to caution when hydroxychloroquine is given to elderly patients with COVID-19.|pdf=|usr=027}}
+{{tp|p=34052406|t=2021. Determinants of the protective effect of glucocorticoids on mortality in hospitalized patients with COVID-19: Insights from the Cardio-COVID-Italy multicenter study.|pdf=|usr=027}}
+{{tp|p=34048887|t=2021. Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: An interventional study.|pdf=|usr=027}}
+{{tp|p=33930480|t=2021. Lung Cancer and Heart Disease Risks Associated With Low-Dose Pulmonary Radiotherapy to COVID-19 Patients With Different Background Risks.|pdf=|usr=027}}
+{{tp|p=33957219|t=2021. Low dose radiation therapy for severe COVID-19 pneumonia: a randomized double-blind study.|pdf=|usr=027}}
+{{tp|p=33340603|t=2021. Immunomodulatory Low-Dose Whole-Lung Radiation for Patients with Coronavirus Disease 2019-Related Pneumonia.|pdf=|usr=027}}
+{{tp|p=33309910|t=2021. Clinician Attitudes to Using Low-Dose Radiation Therapy to Treat COVID-19 Lung Disease.|pdf=|usr=027}}
+{{tp|p=33840973|t=2021. Sudarshan Kriya Yoga: A Breath of Hope during COVID-19 Pandemic.|pdf=|usr=027}}
+{{tp|p=33960271|t=2021. Tuberculosis vaccine BCG: the magical effect of the old vaccine in the fight against the COVID-19 pandemic.|pdf=|usr=027}}
+{{tp|p=33876268|t=2021. Corticosteroids in COVID-19 and non-COVID-19 ARDS: a systematic review and meta-analysis.|pdf=|usr=027}}
+{{tp|p=34057560|t=2021. Time for tocilizumab in COVID-19?|pdf=|usr=027}}
+{{tp|p=34019122|t=2021. Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials.|pdf=|usr=027}}
+{{tp|p=33846824|t=2021. Camostat mesylate therapy in critically ill patients with COVID-19 pneumonia.|pdf=|usr=027}}
+{{tp|p=34035806|t=2021. Severity and Mortality Associated with Steroid Use among Patients with COVID-19: A Systematic Review and Meta-Analysis.|pdf=|usr=027}}
+{{tp|p=34037928|t=2021. High-dose steroids for the treatment of severe COVID-19: comment.|pdf=|usr=027}}
+{{tp|p=33876321|t=2021. High-dose steroids for the treatment of severe COVID-19: a new therapeutic tool?|pdf=|usr=027}}
+{{tp|p=33856664|t=2021. High-dose steroids for the treatment of severe COVID-19.|pdf=|usr=027}}
+{{tp|p=33837906|t=2021. A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm.|pdf=|usr=027}}
+{{tp|p=33355896|t=2021. Adverse drug reactions in SARS-CoV-2 hospitalised patients: a case-series with a focus on drug-drug interactions.|pdf=|usr=027}}
+{{tp|p=33328409|t=2021. Severe Coronavirus Disease 2019 That Recovered from Respiratory Failure by Treatment That Included High-dose Intravenous Immunoglobulin.|pdf=|usr=027}}
+{{tp|p=33847768|t=2021. Antikorpertherapie bei Patienten mit COVID-19.|pdf=|usr=027}}
+{{tp|p=33902268|t=2021. Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19.|pdf=|usr=027}}
+{{tp|p=34083855|t=2021. Hypothetical Protective Effects of Crocin Carotenoid against Coronavirus-Induced Organ Damage: The Possible Role of the NF-kappaB Signaling Pathway.|pdf=|usr=027}}
+{{tp|p=34083848|t=2021. A Narrative Review of a Pulmonary Aerosolized Formulation or a Nasal Drop Using Sera Containing Neutralizing Antibodies Collected from COVID-19-Recovered Patients as a Probable Therapy for COVID-19.|pdf=|usr=027}}
+{{tp|p=33937725|t=2021. Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice.|pdf=|usr=027}}
+{{tp|p=33913665|t=2021. Ultraviolet radiation, vitamin D, and COVID-19.|pdf=|usr=027}}
+{{tp|p=33860009|t=2021. Molecular optimization, docking, and dynamic simulation profiling of selective aromatic phytochemical ligands in blocking the SARS-CoV-2 S protein attachment to ACE2 receptor: an in silico approach of targeted drug designing.|pdf=|usr=027}}
+{{tp|p=34015930|t=2021. Epigallocatechin Gallate Inhibits the Uridylate-Specific Endoribonuclease Nsp15 and Efficiently Neutralizes the SARS-CoV-2 Strain.|pdf=|usr=027}}
+{{tp|p=33358557|t=2021. Commercial immunoglobulin products contain cross-reactive but not neutralizing antibodies against SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=33852936|t=2021. C5aR inhibition of nonimmune cells suppresses inflammation and maintains epithelial integrity in SARS-CoV-2-infected primary human airway epithelia.|pdf=|usr=027}}
+{{tp|p=34018723|t=2021. NMR Based SARS-CoV-2 Antibody Screening.|pdf=|usr=027}}
+{{tp|p=33832492|t=2021. The use of medicinal plants to prevent COVID-19 in Nepal.|pdf=|usr=027}}
+{{tp|p=33902620|t=2021. Contested or complementary healing paradigms? Women's narratives of COVID-19 remedies in Mwanza, Tanzania.|pdf=|usr=027}}
+{{tp|p=34102269|t=2021. Active components in Ephedra sinica stapf disrupt the interaction between ACE2 and SARS-CoV-2 RBD: Potent COVID-19 therapeutic agents.|pdf=|usr=027}}
+{{tp|p=34029640|t=2021. Positive effects of Lianhuaqingwen granules in COVID-19 patients: A retrospective study of 248 cases.|pdf=|usr=027}}
+{{tp|p=33831468|t=2021. In silico analysis of the potential mechanism of a preventive Chinese medicine formula on coronavirus disease 2019.|pdf=|usr=027}}
+{{tp|p=34057365|t=2021. Add-on Ayurveda Treatment for Early Stage COVID-19: A Single Center Retrospective Cohort Study From Gujarat, India.|pdf=|usr=027}}
+{{tp|p=33871567|t=2021. SARS-CoV-2 spike therapeutic antibodies in the age of variants.|pdf=|usr=027}}
+{{tp|p=34041139|t=2021. Hydroxychloroquine: A review of its safety and efficacy in COVID-19.|pdf=|usr=027}}
+{{tp|p=33838985|t=2021. Combined intravenous immunoglobulin and baricitinib treatment for severe COVID-19 with rhabdomyolysis: A case report.|pdf=|usr=027}}
+{{tp|p=34074579|t=2021. Assessing efficacy of antiviral therapy for COVID-19 patients: A case study on remdesivir with bayesian synthesis design and multistate analysis.|pdf=|usr=027}}
+{{tp|p=33897833|t=2021. Promising role of curcumin against viral diseases emphasizing COVID-19 management: A review on the mechanistic insights with reference to host-pathogen interaction and immunomodulation.|pdf=|usr=027}}
+{{tp|p=34055047|t=2021. Virgin coconut oil is effective in lowering C-reactive protein levels among suspect and probable cases of COVID-19.|pdf=|usr=027}}
+{{tp|p=33987794|t=2021. The Association Between Convalescent Plasma Treatment and Survival of Patients with COVID-19.|pdf=|usr=027}}
+{{tp|p=33904037|t=2021. Reply to the Letter to Editor by Lacout and colleagues: Chloroquine and Hydroxychloroquine for the Treatment of COVID-19: a Systematic Review and Meta-analysis.|pdf=|usr=027}}
+{{tp|p=34052520|t=2021. Epigallocatechin-3-gallate (EGCG): a potential molecule for the development of therapeutics against emerging SARS-CoV-1, MERS-CoV and SARS-CoV-2 coronaviruses.|pdf=|usr=027}}
+{{tp|p=33359936|t=2021. Treatment of a case of COVID-19 by intravenous immunoglobulin.|pdf=|usr=027}}
+{{tp|p=33307274|t=2021. Remdesivir for the treatment of coronavirus COVID-19: A meta-analysis of randomised controlled trials.|pdf=|usr=027}}
+{{tp|p=34055580|t=2021. Comparative retrospective open-label study of ayurvedic medicines and their combination with allopathic drugs on asymptomatic and mildly-symptomatic COVID-19 patients.|pdf=|usr=027}}
+{{tp|p=33865974|t=2021. Oral antiseptics against coronavirus: in-vitro and clinical evidence.|pdf=|usr=027}}
+{{tp|p=33298617|t=2021. Repurposed Tocilizumab in Patients with Severe COVID-19.|pdf=|usr=027}}
+{{tp|p=33837054|t=2021. IL-6 modulation for COVID-19: the right patients at the right time?|pdf=|usr=027}}
+{{tp|p=34029628|t=2021. Secukinumab in severe COVID-19 pneumonia: Does it have a clinical impact?|pdf=|usr=027}}
+{{tp|p=34052239|t=2021. Remdesivir treatment and transient bradycardia in patients with coronavirus diseases 2019 (COVID-19).|pdf=|usr=027}}
+{{tp|p=33992687|t=2021. Clinical efficacy of nitric oxide nasal spray (NONS) for the treatment of mild COVID-19 infection.|pdf=|usr=027}}
+{{tp|p=34020215|t=2021. Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials.|pdf=|usr=027}}
+{{tp|p=33341481|t=2021. Impact of repurposed drugs on the symptomatic COVID-19 patients.|pdf=|usr=027}}
+{{tp|p=34045883|t=2021. Fat-Soluble Vitamins and the Current Global Pandemic of COVID-19: Evidence-Based Efficacy from Literature Review.|pdf=|usr=027}}
+{{tp|p=33833542|t=2021. Anti-Inflammatory and Antiviral Osmotic Polymeric Film to Treat Covid-19 Early-Stage Infection.|pdf=|usr=027}}
+{{tp|p=33983065|t=2021. Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial.|pdf=|usr=027}}
+{{tp|p=33906526|t=2021. Oxygen saturation improved with nitrate-based nutritional formula in patients with COVID-19.|pdf=|usr=027}}
+{{tp|p=33349611|t=2021. Treatment of pulmonary fibrosis in one convalescent patient with corona virus disease 2019 by oral traditional Chinese medicine decoction: A case report.|pdf=|usr=027}}
+{{tp|p=33847265|t=2021. COVID-19 and TEN treated with IVIG and Total plasma exchange. Simultaneous systemic treatment for both diseases.|pdf=|usr=027}}
+{{tp|p=34105382|t=2021. Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania.|pdf=|usr=027}}
+{{tp|p=34054244|t=2021. Reviewing the Ethical Concerns of the Convalescent Plasma Therapy in COVID-19.|pdf=|usr=027}}
+{{tp|p=34010403|t=2021. Tocilizumab in the treatment of COVID-19 - a meta-analysis.|pdf=|usr=027}}
+{{tp|p=33989420|t=2021. Corticosteroids for treating mild COVID-19: Opening the floodgates of therapeutic misadventure.|pdf=|usr=027}}
+{{tp|p=33988903|t=2021. Graphene Oxide Nanosheets Interact and Interfere with SARS-CoV-2 Surface Proteins and Cell Receptors to Inhibit Infectivity.|pdf=|usr=027}}
+{{tp|p=33874878|t=2021. Probiotics/ prebiotics in viral respiratory infections: implication for emerging pathogens.|pdf=|usr=027}}
+{{tp|p=34009761|t=2021. Inefficacite de l'ivermectine sur les symptomes de Covid-19 leger.|pdf=|usr=027}}
+{{tp|p=33881236|t=2021. Covid-19 - vitamine D - traitement de l'osteoporose.|pdf=|usr=027}}
+{{tp|p=34083449|t=2021. Fe-S cofactors in the SARS-CoV-2 RNA-dependent RNA polymerase are potential antiviral targets.|pdf=|usr=027}}
+{{tp|p=34103349|t=2021. Senolytics reduce coronavirus-related mortality in old mice.|pdf=|usr=027}}
+{{tp|p=33843825|t=2021. Intrapleural Steroid Instillation for Critically Ill Patients With Covid-19 Severe Adult Respiratory Distress Syndrome.|pdf=|usr=027}}
+{{tp|p=34020394|t=2021. Insights on the mechanisms of action of ozone in the medical therapy against COVID-19.|pdf=|usr=027}}
+{{tp|p=34020392|t=2021. Intragastric and atomized administration of canagliflozin inhibit inflammatory cytokine storm in lipopolysaccharide-treated sepsis in mice: A potential COVID-19 treatment.|pdf=|usr=027}}
+{{tp|p=34015598|t=2021. Clinical outcomes of patients with mild COVID-19 following treatment with hydroxychloroquine in an outpatient setting.|pdf=|usr=027}}
+{{tp|p=33984718|t=2021. A pilot study for treatment of COVID-19 patients in moderate stage using intravenous administration of ozonized saline as an adjuvant treatment-registered clinical trial.|pdf=|usr=027}}
+{{tp|p=33882442|t=2021. Immunopharmacological perspective on zinc in SARS-CoV-2 infection.|pdf=|usr=027}}
+{{tp|p=33310665|t=2021. Ozone therapy for patients with COVID-19 pneumonia: Preliminary report of a prospective case-control study.|pdf=|usr=027}}
+{{tp|p=33348292|t=2021. Interferon-inducer antivirals: Potential candidates to combat COVID-19.|pdf=|usr=027}}
+{{tp|p=33338863|t=2021. Convalescent plasma may be a possible treatment for COVID-19: A systematic review.|pdf=|usr=027}}
+{{tp|p=33930705|t=2021. The role of vitamin D in reducing SARS-CoV-2 infection: An update.|pdf=|usr=027}}
+{{tp|p=33838224|t=2021. Therapeutic plasma exchange in patients with life-threatening COVID-19: a randomised controlled clinical trial.|pdf=|usr=027}}
+{{tp|p=33370568|t=2021. Plasma exchange in the treatment of complex COVID-19-related critical illness: controversies and perspectives.|pdf=|usr=027}}
+{{tp|p=33338559|t=2021. Early clinical outcomes with tocilizumab for severe COVID-19: a two-centre retrospective study.|pdf=|usr=027}}
+{{tp|p=33321211|t=2021. Reply to 'Low-dose hydroxychloroquine therapy and lower mortality in hospitalized patients with COVID-19: association does not mean causality'.|pdf=|usr=027}}
+{{tp|p=33609720|t=2021. Reply to "The perceived efficacy of hydroxychloroquine in observational studies: the results of the confounding effects of 'goals of care'".|pdf=|usr=027}}
+{{tp|p=33609717|t=2021. Perceived efficacy of hydroxychloroquine in observational studies: Results of the confounding effect of "goals of care".|pdf=|usr=027}}
+{{tp|p=34048833|t=2021. Classification, structure and mechanism of antiviral polysaccharides derived from edible and medicinal fungus.|pdf=|usr=027}}
+{{tp|p=33930442|t=2021. Chitin and chitosan as tools to combat COVID-19: A triple approach.|pdf=|usr=027}}
+{{tp|p=33915212|t=2021. Heparin: A simplistic repurposing to prevent SARS-CoV-2 transmission in light of its in-vitro nanomolar efficacy.|pdf=|usr=027}}
+{{tp|p=33901557|t=2021. Identification of Vitamin K3 and its analogues as covalent inhibitors of SARS-CoV-2 3CL(pro).|pdf=|usr=027}}
+{{tp|p=34051259|t=2021. Ethyl cellulose coated sustained release aspirin spherules for treating COVID-19: DOE led rapid optimization using arbitrary interface; applicable for emergency situations.|pdf=|usr=027}}
+{{tp|p=33309661|t=2021. Ritonavir may inhibit exoribonuclease activity of nsp14 from the SARS-CoV-2 virus and potentiate the activity of chain terminating drugs.|pdf=|usr=027}}
+{{tp|p=33907519|t=2021. In silico structure-based discovery of a SARS-CoV-2 main protease inhibitor.|pdf=|usr=027}}
+{{tp|p=33907517|t=2021. Hydroxychloroquine/Chloroquine as Therapeutics for COVID-19: Truth under the Mystery.|pdf=|usr=027}}
+{{tp|p=34000267|t=2021. Administration of Bamlanivimab to Skilled Nursing Facility Residents During a COVID-19 Outbreak, January-February 2021, Arizona.|pdf=|usr=027}}
+{{tp|p=33895839|t=2021. COVID-19 Trial Graph: A Linked Graph for COVID-19 Clinical Trials.|pdf=|usr=027}}
+{{tp|p=33880524|t=2021. In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2, the aetiological agent of COVID-19.|pdf=|usr=027}}
+{{tp|p=33712855|t=2021. Usage experience of remdesivir for SARS-CoV-2 infection in a patient with chronic cirrhosis of Child-Pugh class C.|pdf=|usr=027}}
+{{tp|p=33338232|t=2021. Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial.|pdf=|usr=027}}
+{{tp|p=33976504|t=2021. Potential for supportive Ayurvedic care in hypoxemic COVID-19 patients.|pdf=|usr=027}}
+{{tp|p=34054248|t=2021. "Standalone Ayurvedic Intervention with Home Quarantine in COVID-19 - Outcomes of Clinical Practice".|pdf=|usr=027}}
+{{tp|p=34054247|t=2021. Immune status determined as per guidelines of Ayurveda found associated with clinical outcomes of COVID-19 disease - Results of a cross-sectional pilot study.|pdf=|usr=027}}
+{{tp|p=34054246|t=2021. Evaluation of potency of the selected bioactive molecules from Indian medicinal plants with M(Pro) of SARS-CoV-2 through in silico analysis.|pdf=|usr=027}}
+{{tp|p=34024691|t=2021. A case series sharing novel experience of treating viral pandemic cases of morbid, mid aged, mild, moderate & severe grade with only Ayurvedic Medicines.|pdf=|usr=027}}
+{{tp|p=33654345|t=2021. In silico evaluation of the compounds of the ayurvedic drug, AYUSH-64, for the action against the SARS-CoV-2 main protease.|pdf=|usr=027}}
+{{tp|p=33897204|t=2021. A Randomized open label parallel group pilot study to evaluate efficacy of Ayurveda interventions in the management of Asymptomatic and Mild COVID-19 patients-Experiences of a Lucknow based Level 2 hospital of Uttar Pradesh, India.|pdf=|usr=027}}
+{{tp|p=34082895|t=2021. Significance of AYUSH: India's first line of defence against COVID-19.|pdf=|usr=027}}
+{{tp|p=33989635|t=2021. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template.|pdf=|usr=027}}
+{{tp|p=33895135|t=2021. Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells.|pdf=|usr=027}}
+{{tp|p=33891947|t=2021. Repression of transcription by the glucocorticoid receptor: A parsimonious model for the genomics era.|pdf=|usr=027}}
+{{tp|p=34052441|t=2021. Machine learning enabled identification of potential SARS-CoV-2 3CLpro inhibitors based on fixed molecular fingerprints and Graph-CNN neural representations.|pdf=|usr=027}}
+{{tp|p=33856612|t=2021. A COVID moonshot: assessment of ligand binding to the SARS-CoV-2 main protease by saturation transfer difference NMR spectroscopy.|pdf=|usr=027}}
+{{tp|p=33950784|t=2021. Mechanistic insights into the inhibitory activity of FDA approved ivermectin against SARS-CoV-2: old drug with new implications.|pdf=|usr=027}}
+{{tp|p=33949286|t=2021. Quantum biochemistry, molecular docking, and dynamics simulation revealed synthetic peptides induced conformational changes affecting the topology of the catalytic site of SARS-CoV-2 main protease.|pdf=|usr=027}}
+{{tp|p=33949279|t=2021. Antivirals virtual screening to SARS-CoV-2 non-structural proteins.|pdf=|usr=027}}
+{{tp|p=33939590|t=2021. In silico identification and validation of triarylchromones as potential inhibitor against main protease of severe acute respiratory syndrome coronavirus 2.|pdf=|usr=027}}
+{{tp|p=34033727|t=2021. How to face COVID-19: proposed treatments based on remdesivir and hydroxychloroquine in the presence of zinc sulfate. Docking/DFT/POM structural analysis.|pdf=|usr=027}}
+{{tp|p=34032180|t=2021. Virtual screening of quinoline derived library for SARS-COV-2 targeting viral entry and replication.|pdf=|usr=027}}
+{{tp|p=34018907|t=2021. Proposition of a new allosteric binding site for potential SARS-CoV-2 3CL protease inhibitors by utilizing molecular dynamics simulations and ensemble docking.|pdf=|usr=027}}
+{{tp|p=34014150|t=2021. Marine algal antagonists targeting 3CL protease and spike glycoprotein of SARS-CoV-2: a computational approach for anti-COVID-19 drug discovery.|pdf=|usr=027}}
+{{tp|p=33998954|t=2021. A large-scale computational screen identifies strong potential inhibitors for disrupting SARS-CoV-2 S-protein and human ACE2 interaction.|pdf=|usr=027}}
+{{tp|p=33988079|t=2021. Repurposing of the herbal formulations: molecular docking and molecular dynamics simulation studies to validate the efficacy of phytocompounds against SARS-CoV-2 proteins.|pdf=|usr=027}}
+{{tp|p=33988066|t=2021. Target SARS-CoV-2: theoretical exploration on clinical suitability of certain drugs.|pdf=|usr=027}}
+{{tp|p=33998950|t=2021. Computational basis of SARS-CoV 2 main protease inhibition: an insight from molecular dynamics simulation based findings.|pdf=|usr=027}}
+{{tp|p=33970798|t=2021. A higher flexibility at the SARS-CoV-2 main protease active site compared to SARS-CoV and its potentialities for new inhibitor virtual screening targeting multi-conformers.|pdf=|usr=027}}
+{{tp|p=34062110|t=2021. Chemical system biology approach to identify multi-targeting FDA inhibitors for treating COVID-19 and associated health complications.|pdf=|usr=027}}
+{{tp|p=34060418|t=2021. Molecular modeling of potent novel sulfonamide derivatives as non-peptide small molecule anti-COVID 19 agents.|pdf=|usr=027}}
+{{tp|p=33826483|t=2021. Identification of doxorubicin as a potential therapeutic against SARS-CoV-2 (COVID-19) protease: a molecular docking and dynamics simulation studies.|pdf=|usr=027}}
+{{tp|p=33896392|t=2021. Combined use of the hepatitis C drugs and amentoflavone could interfere with binding of the spike glycoprotein of SARS-CoV-2 to ACE2: the results of a molecular simulation study.|pdf=|usr=027}}
+{{tp|p=33879035|t=2021. The in silico mechanism of hVKOR interaction with acetaminophen and its metabolite, as well as N-acetyl cysteine: caution on application in COVID-19 patients.|pdf=|usr=027}}
+{{tp|p=33847241|t=2021. Inhibition of SARS-CoV-2 main protease: a repurposing study that targets the dimer interface of the protein.|pdf=|usr=027}}
+{{tp|p=33843474|t=2021. Elucidation of the inhibitory activity of ivermectin with host nuclear importin alpha and several SARS-CoV-2 targets.|pdf=|usr=027}}
+{{tp|p=34068104|t=2021. Effect of Hydroxychloroquine on QTc in Patients Diagnosed with COVID-19: A Systematic Review and Meta-Analysis.|pdf=|usr=027}}
+{{tp|p=34028178|t=2021. Targeting the glycans: A paradigm for host-targeted and COVID-19 drug design.|pdf=|usr=027}}
+{{tp|p=33336936|t=2021. Mortality and pre-hospitalization use of low-dose aspirin in COVID-19 patients with coronary artery disease.|pdf=|usr=027}}
+{{tp|p=33829781|t=2021. Benchmark of Popular Free Energy Approaches Revealing the Inhibitors Binding to SARS-CoV-2 Mpro.|pdf=|usr=027}}
+{{tp|p=34047191|t=2021. Benchmarking the Ability of Common Docking Programs to Correctly Reproduce and Score Binding Modes in SARS-CoV-2 Protease Mpro.|pdf=|usr=027}}
+{{tp|p=34052564|t=2021. Development and validation of a sensitive, fast and simple LC-MS / MS method for the quantitation of favipiravir in human serum.|pdf=|usr=027}}
+{{tp|p=33310480|t=2021. Cell membrane chromatography for the analysis of the interaction between chloroquine and hydroxychloroquine with ACE2 receptors.|pdf=|usr=027}}
+{{tp|p=34101091|t=2021. Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-beta.|pdf=|usr=027}}
+{{tp|p=34009544|t=2021. Neutralizing Autoantibodies to Type I Interferons in COVID-19 Convalescent Donor Plasma.|pdf=|usr=027}}
+{{tp|p=33844653|t=2021. Structure-based phylogeny identifies avoralstat as a TMPRSS2 inhibitor that prevents SARS-CoV-2 infection in mice.|pdf=|usr=027}}
+{{tp|p=33974559|t=2021. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19.|pdf=|usr=027}}
+{{tp|p=33306484|t=2021. BCG vaccination in health care providers and the protection against COVID-19.|pdf=|usr=027}}
+{{tp|p=33320842|t=2021. Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates.|pdf=|usr=027}}
+{{tp|p=33994121|t=2021. Statins in COVID-19 infection: A rehash of old themes or truly a new hope?|pdf=|usr=027}}
+{{tp|p=34071293|t=2021. Vitamin D Levels in COVID-19 Outpatients from Western Mexico: Clinical Correlation and Effect of Its Supplementation.|pdf=|usr=027}}
+{{tp|p=34070628|t=2021. Role of Iron Chelation and Protease Inhibition of Natural Products on COVID-19 Infection.|pdf=|usr=027}}
+{{tp|p=34069355|t=2021. Targeting the Complement Cascade in the Pathophysiology of COVID-19 Disease.|pdf=|usr=027}}
+{{tp|p=34068847|t=2021. Convalescent Plasma Efficacy in Life-Threatening COVID-19 Patients Admitted to the ICU: A Retrospective Cohort Study.|pdf=|usr=027}}
+{{tp|p=33918563|t=2021. Tocilizumab Improves the Prognosis of COVID-19 in Patients with High IL-6.|pdf=|usr=027}}
+{{tp|p=33917093|t=2021. Use of Anti-Cytokine Therapy in Kidney Transplant Recipients with COVID-19.|pdf=|usr=027}}
+{{tp|p=33916281|t=2021. Statin Use Is Associated with a Decreased Risk of Mortality among Patients with COVID-19.|pdf=|usr=027}}
+{{tp|p=33915784|t=2021. Adjunctive Use of Statins for COVID-19.|pdf=|usr=027}}
+{{tp|p=33992179|t=2021. Drug repurposing of selective serotonin reuptake inhibitors: Could these drugs help fight COVID-19 and save lives?|pdf=|usr=027}}
+{{tp|p=34007812|t=2021. Favipiravir-induced Liver Injury in Patients with Coronavirus Disease 2019.|pdf=|usr=027}}
+{{tp|p=34007810|t=2021. Rapid Recovery in COVID-19 Patients with Chronic Hepatitis B Virus Infection Treated with Tenofovir Disoproxil Fumarate.|pdf=|usr=027}}
+{{tp|p=34027204|t=2021. Interleukin-13 as a target to alleviate severe coronavirus disease 2019 and restore lung homeostasis.|pdf=|usr=027}}
+{{tp|p=33889318|t=2021. Experimental therapies under investigation for COVID-19.|pdf=|usr=027}}
+{{tp|p=33887951|t=2021. Testing the efficacy of tocilizumab in patients with COVID-19 pneumonia.|pdf=|usr=027}}
+{{tp|p=33622611|t=2021. Cheap and simple, could it get even cooler? Mild hypothermia and COVID-19.|pdf=|usr=027}}
+{{tp|p=33583631|t=2021. Successful use of mild therapeutic hypothermia as compassionate treatment for severe refractory hypoxemia in COVID-19.|pdf=|usr=027}}
+{{tp|p=33884425|t=2021. The impact of vedolizumab on COVID-19 outcomes among adult IBD patients in the SECURE-IBD registry.|pdf=|usr=027}}
+{{tp|p=33331120|t=2021. Is metformin a miracle or a menace in COVID-19 patients with type 2 diabetes?|pdf=|usr=027}}
+{{tp|p=33816359|t=2021. Vitamin D and COVID-19: is there a role?|pdf=|usr=027}}
+{{tp|p=33816358|t=2021. Dipeptidyl peptidase 4 (DPP4) inhibitor and outcome from coronavirus disease 2019 (COVID-19) in diabetic patients: a systematic review, meta-analysis, and meta-regression.|pdf=|usr=027}}
+{{tp|p=33649708|t=2021. The pulmonary route as a way to drug repositioning in COVID-19 therapy.|pdf=|usr=027}}
+{{tp|p=33617141|t=2021. Hydroxychloroquine-induced acute generalized exanthematous pustulosis: an adverse reaction to keep in mind during COVID-19 pandemic.|pdf=|usr=027}}
+{{tp|p=33688540|t=2021. Review of investigational drugs for coronavirus disease 2019.|pdf=|usr=027}}
+{{tp|p=34075313|t=2021. Innovative electrochemical sensor for the precise determination of the new antiviral COVID-19 treatment Favipiravir in the presence of coadministered drugs.|pdf=|usr=027}}
+{{tp|p=33353811|t=2021. Utility of Hypertonic Saline and Diazepam in COVID-19-Related Hydroxychloroquine Toxicity.|pdf=|usr=027}}
+{{tp|p=33840080|t=2021. Vitamin D and Vitamin D binding protein: the inseparable duo in COVID-19.|pdf=|usr=027}}
+{{tp|p=34053008|t=2021. Risks of potential drug-drug interactions in COVID-19 patients treated with corticosteroids: a single-center experience.|pdf=|usr=027}}
+{{tp|p=33980119|t=2021. Flavonoids as inhibitors of human neutrophil elastase.|pdf=|usr=027}}
+{{tp|p=34044222|t=2021. A literature review on beneficial role of vitamins and trace elements: Evidence from published clinical studies.|pdf=|usr=027}}
+{{tp|p=34026584|t=2021. Calendulaglycoside A Showing Potential Activity Against SARS-CoV-2 Main Protease: Molecular Docking, Molecular Dynamics, and SAR Studies.|pdf=|usr=027}}
+{{tp|p=34099976|t=2021. In-silico evaluation of bioactive compounds from tea as potential SARS-CoV-2 nonstructural protein 16 inhibitors.|pdf=|usr=027}}
+{{tp|p=33868970|t=2021. Virtual screening by targeting proteolytic sites of furin and TMPRSS2 to propose potential compounds obstructing the entry of SARS-CoV-2 virus into human host cells.|pdf=|usr=027}}
+{{tp|p=33778462|t=2021. Case study of a critically ill person with COVID-19 on ECMO successfully treated with leronlimab.|pdf=|usr=027}}
+{{tp|p=33971907|t=2021. Therapeutic mechanisms of mesenchymal stem cells in acute respiratory distress syndrome reveal potentials for Covid-19 treatment.|pdf=|usr=027}}
+{{tp|p=33781275|t=2021. The effect of omega-3 fatty acid supplementation on clinical and biochemical parameters of critically ill patients with COVID-19: a randomized clinical trial.|pdf=|usr=027}}
+{{tp|p=33902635|t=2021. Vitamin D status of Arab Gulf residents screened for SARS-CoV-2 and its association with COVID-19 infection: a multi-centre case-control study.|pdf=|usr=027}}
+{{tp|p=33888147|t=2021. MSC-derived exosomes carrying a cocktail of exogenous interfering RNAs an unprecedented therapy in era of COVID-19 outbreak.|pdf=|usr=027}}
+{{tp|p=34026595|t=2021. Virucidal effect of povidone iodine on COVID-19 in the nasopharynx: an open-label randomized clinical trial.|pdf=|usr=027}}
+{{tp|p=34099209|t=2021. Is the tuberculosis vaccine BCG an alternative weapon for developing countries to defeat COVID-19?|pdf=|usr=027}}
+{{tp|p=33985598|t=2021. Surveillance of adverse drug events associated with tocilizumab in hospitalized veterans with coronavirus disease 2019 (COVID-19) to inform patient safety and pandemic preparedness.|pdf=|usr=027}}
+{{tp|p=33974479|t=2021. Remdesivir for coronavirus disease 2019 (COVID-19): a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials.|pdf=|usr=027}}
+{{tp|p=34024240|t=2021. A short course of corticosteroids reduces the risk of mechanical ventilation and death in patients with moderate to severe COVID 19 pneumonia: results of a retrospective monocentric cohort.|pdf=|usr=027}}
+{{tp|p=34001244|t=2021. Tocilizumab treatment for COVID-19 patients: a systematic review and meta-analysis.|pdf=|usr=027}}
+{{tp|p=33874998|t=2021. Effectiveness of potential antiviral treatments in COVID-19 transmission control: a modelling study.|pdf=|usr=027}}
+{{tp|p=34067822|t=2021. Remdesivir Treatment for COVID 19 in Pregnant Patients with Moderate to Severe Symptoms: Serial Case Report.|pdf=|usr=027}}
+{{tp|p=33928532|t=2021. A Response to: Letter to the Editor Regarding Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort.|pdf=|usr=027}}
+{{tp|p=33914266|t=2021. Letter to the Editor Regarding Combination of Tocilizumab and Steroids to Improve Mortality in Patients with Severe COVID-19 Infection: A Spanish, Multicenter, Cohort Study.|pdf=|usr=027}}
+{{tp|p=33826106|t=2021. Pharmacokinetic and Pharmacodynamic Evaluation of Ravulizumab in Adults with Severe Coronavirus Disease 2019.|pdf=|usr=027}}
+{{tp|p=34040397|t=2021. Network Analysis of Herbs Recommended for the Treatment of COVID-19.|pdf=|usr=027}}
+{{tp|p=33880043|t=2021. The Role for Tocilizumab in COVID-19 Patients: Reflections on Monza Cohort Data.|pdf=|usr=027}}
+{{tp|p=34089909|t=2021. Designing an effective therapeutic siRNA to silence RdRp gene of SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=34052418|t=2021. Pathomechanisms, therapeutic targets and potent inhibitors of some beta-coronaviruses from bench-to-bedside.|pdf=|usr=027}}
+{{tp|p=33907516|t=2021. Glucocorticoids are double-edged sword in the treatment of COVID-19 and cancers.|pdf=|usr=027}}
+{{tp|p=33907515|t=2021. Developing effective siRNAs to reduce the expression of key viral genes of COVID-19.|pdf=|usr=027}}
+{{tp|p=33907512|t=2021. Development and application of therapeutic antibodies against COVID-19.|pdf=|usr=027}}
+{{tp|p=33332726|t=2021. Dexamethasone vs COVID-19: An experimental study in line with the preliminary findings of a large trial.|pdf=|usr=027}}
+{{tp|p=33300221|t=2021. Repurposing of some anti-infective drugs for COVID-19 treatment: A surveillance study supported by an in silico investigation.|pdf=|usr=027}}
+{{tp|p=34064793|t=2021. Does Trypsin Oral Spray (Viruprotect((R))/ColdZyme((R))) Protect against COVID-19 and Common Colds or Induce Mutation? Caveats in Medical Device Regulations in the European Union.|pdf=|usr=027}}
+{{tp|p=33801759|t=2021. Vitamin D Levels Are Reduced at the Time of Hospital Admission in Sicilian SARS-CoV-2-Positive Patients.|pdf=|usr=027}}
+{{tp|p=33924038|t=2021. Impact of COVID-19 Lockdown on Sun Exposure of UK Office Workers.|pdf=|usr=027}}
+{{tp|p=33919644|t=2021. COVID-19 Severity and Neonatal BCG Vaccination among Young Population in Taiwan.|pdf=|usr=027}}
+{{tp|p=33359949|t=2021. No clinical benefit in mortality associated with hydroxychloroquine treatment in patients with COVID-19.|pdf=|usr=027}}
+{{tp|p=33940189|t=2021. Does vitamin D serum level affect prognosis of COVID-19 patients?|pdf=|usr=027}}
+{{tp|p=33901652|t=2021. COVID-19 chemoprevention.|pdf=|usr=027}}
+{{tp|p=33892191|t=2021. Serum Calcium and Vitamin D levels: Correlation with severity of COVID-19 in hospitalized patients in Royal Hospital, Oman.|pdf=|usr=027}}
+{{tp|p=34087484|t=2021. Hydroxychloroquine as a primary prophylactic agent against SARS-CoV-2 infection: A cohort study.|pdf=|usr=027}}
+{{tp|p=33878462|t=2021. Effect of Ammonium Chloride in addition to standard of care in outpatients and hospitalized COVID-19 patients: A randomized clinical trial.|pdf=|usr=027}}
+{{tp|p=33333254|t=2021. Thalidomide combined with short-term low-dose glucocorticoid therapy for the treatment of severe COVID-19: A case-series study.|pdf=|usr=027}}
+{{tp|p=33333252|t=2021. Tocilizumab in the treatment of critical COVID-19 pneumonia: A retrospective cohort study of mechanically ventilated patients.|pdf=|usr=027}}
+{{tp|p=33333250|t=2021. A high-throughput drug screening strategy against coronaviruses.|pdf=|usr=027}}
+{{tp|p=33316389|t=2021. An umbrella review of systematic reviews with meta-analyses evaluating positive and negative outcomes of Hydroxychloroquine and chloroquine therapy.|pdf=|usr=027}}
+{{tp|p=33310109|t=2021. Response to "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients".|pdf=|usr=027}}
+{{tp|p=33310107|t=2021. Response to correspondence concerning: "Early hydroxychloroquine but not chloroquine use reduces ICU admission in COVID-19 patients".|pdf=|usr=027}}
+{{tp|p=33310106|t=2021. More gastro-intestinal adverse events in non-ICU hospitalised COVID-19 patients treated with chloroquine versus hydroxychloroquine.|pdf=|usr=027}}
+{{tp|p=34066560|t=2021. Probiotics, Photobiomodulation, and Disease Management: Controversies and Challenges.|pdf=|usr=027}}
+{{tp|p=34073529|t=2021. Could Histamine H1 Receptor Antagonists Be Used for Treating COVID-19?|pdf=|usr=027}}
+{{tp|p=34067243|t=2021. Possible Beneficial Actions of Caffeine in SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=34063964|t=2021. Existing Drugs Considered as Promising in COVID-19 Therapy.|pdf=|usr=027}}
+{{tp|p=34065735|t=2021. Immunological Aspects of SARS-CoV-2 Infection and the Putative Beneficial Role of Vitamin-D.|pdf=|usr=027}}
+{{tp|p=33917321|t=2021. Corticosteroids for COVID-19 Therapy: Potential Implications on Tuberculosis.|pdf=|usr=027}}
+{{tp|p=33920709|t=2021. COVID-19: Direct and Indirect Mechanisms of Statins.|pdf=|usr=027}}
+{{tp|p=33920748|t=2021. Pharmacological Modulators of Autophagy as a Potential Strategy for the Treatment of COVID-19.|pdf=|usr=027}}
+{{tp|p=33921228|t=2021. SARS-CoV-2 Papain-Like Protease Potential Inhibitors-In Silico Quantitative Assessment.|pdf=|usr=027}}
+{{tp|p=33867899|t=2021. In Silico Identification of Multi-target Anti-SARS-CoV-2 Peptides from Quinoa Seed Proteins.|pdf=|usr=027}}
+{{tp|p=33850482|t=2021. Identification of Potential Peptide Inhibitors of ACE-2 Target of SARS-CoV-2 from Buckwheat & Quinoa.|pdf=|usr=027}}
+{{tp|p=33880115|t=2021. Potential Antioxidative, Anti-inflammatory and Immunomodulatory Effects of Ghrelin, an Endogenous Peptide from the Stomach in SARS-CoV2 Infection.|pdf=|usr=027}}
+{{tp|p=33373651|t=2021. Sofosbuvir/daclatasvir in the treatment of COVID-19 infection: A meta-analysis.|pdf=|usr=027}}
+{{tp|p=33902990|t=2021. Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients.|pdf=|usr=027}}
+{{tp|p=33814353|t=2021. Two cases of novel coronavirus infection (COVID-19) with transient viral elevation using semi-quantitative real-time reverse transcription PCR and symptom relapse after completion of 10 days of favipiravir treatment.|pdf=|usr=027}}
+{{tp|p=33956648|t=2021. Nutritional status is closely related to the severity of COVID-19: a multi-center retrospective study.|pdf=|usr=027}}
+{{tp|p=33367731|t=2021. Fostamatinib Inhibits Neutrophils Extracellular Traps Induced by COVID-19 Patient Plasma: A Potential Therapeutic.|pdf=|usr=027}}
+{{tp|p=33885811|t=2021. Excessive Matrix Metalloproteinase-1 and Hyperactivation of Endothelial Cells Occurred in COVID-19 Patients and Were Associated With the Severity of COVID-19.|pdf=|usr=027}}
+{{tp|p=33961695|t=2021. beta-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells.|pdf=|usr=027}}
+{{tp|p=33866129|t=2021. Aminoglycosides as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study on FDA-approved antiviral and anti-infection agents.|pdf=|usr=027}}
+{{tp|p=33857725|t=2021. Recent knowledge in favor of remdesivir (GS-5734) as a therapeutic option for the COVID-19 infections.|pdf=|usr=027}}
+{{tp|p=33848890|t=2021. Essential oils as an effective alternative for the treatment of COVID-19: Molecular interaction analysis of protease (M(pro)) with pharmacokinetics and toxicological properties.|pdf=|usr=027}}
+{{tp|p=33984091|t=2021. A Novel Report on the Compassionate Use of Baricitinib in Treating a Pediatric Patient With Severe Symptoms of COVID-19 Infection.|pdf=|usr=027}}
+{{tp|p=33877845|t=2021. Betulonic Acid Derivatives Interfering with Human Coronavirus 229E Replication via the nsp15 Endoribonuclease.|pdf=|usr=027}}
+{{tp|p=34081439|t=2021. Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy.|pdf=|usr=027}}
+{{tp|p=33929200|t=2021. Supercoiling Structure-Based Design of a Trimeric Coiled-Coil Peptide with High Potency against HIV-1 and Human beta-Coronavirus Infection.|pdf=|usr=027}}
+{{tp|p=33872498|t=2021. Design, Synthesis, and Biological Evaluation of Peptidomimetic Aldehydes as Broad-Spectrum Inhibitors against Enterovirus and SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=34026588|t=2021. Molecular Docking Analysis of Anti-Severe Acute Respiratory Syndrome-Coronavirus 2 Ligands against Spike Glycoprotein and the 3-Chymotrypsin-Like Protease.|pdf=|usr=027}}
+{{tp|p=34090821|t=2021. Good response of low-dose steroid in a patient with COVID-19 pneumonia and autoimmune disease.|pdf=|usr=027}}
+{{tp|p=33373642|t=2021. Adverse effects of hydroxychloroquine and azithromycin on contractility and arrhythmogenicity revealed by human engineered cardiac tissues.|pdf=|usr=027}}
+{{tp|p=33333424|t=2021. Effect of nelfinavir stereoisomers on coronavirus main protease: Molecular docking, molecular dynamics simulation and MM/GBSA study.|pdf=|usr=027}}
+{{tp|p=33798836|t=2021. Rutin and flavone analogs as prospective SARS-CoV-2 main protease inhibitors: In silico drug discovery study.|pdf=|usr=027}}
+{{tp|p=33933885|t=2021. Modelling studies reveal the importance of the C-terminal inter motif loop of NSP1 as a promising target site for drug discovery and screening of potential phytochemicals to combat SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=33892297|t=2021. In silico approach for identifying natural lead molecules against SARS-COV-2.|pdf=|usr=027}}
+{{tp|p=33994607|t=2021. Inhibition of SARS-CoV-2 reproduction using Boswellia carterii: A theoretical study.|pdf=|usr=027}}
+{{tp|p=33746318|t=2021. Structural investigations, quantum mechanical studies on proton and metal affinity and biological activity predictions of selpercatinib.|pdf=|usr=027}}
+{{tp|p=33846661|t=2021. Construction, petro-collecting/dispersing capacities, antimicrobial activity, and molecular docking study of new cationic surfactant-sulfonamide conjugates.|pdf=|usr=027}}
+{{tp|p=34031621|t=2021. Molecular basis of the new COVID-19 target neuropilin-1 in complex with SARS-CoV-2 S1 C-end rule peptide and small-molecule antagonists.|pdf=|usr=027}}
+{{tp|p=33903781|t=2021. Charge-transfer chemistry of azithromycin, the antibiotic used worldwide to treat the coronavirus disease (COVID-19). Part III: A green protocol for facile synthesis of complexes with TCNQ, DDQ, and TFQ acceptors.|pdf=|usr=027}}
+{{tp|p=33879934|t=2021. Structurally modified compounds of hydroxychloroquine, remdesivir and tetrahydrocannabinol against main protease of SARS-CoV-2, a possible hope for COVID-19: Docking and molecular dynamics simulation studies.|pdf=|usr=027}}
+{{tp|p=33963942|t=2021. Analysis of natural compounds against the activity of SARS-CoV-2 NSP15 protein towards an effective treatment against COVID-19: a theoretical and computational biology approach.|pdf=|usr=027}}
+{{tp|p=34057647|t=2021. Plausible blockers of Spike RBD in SARS-CoV2-molecular design and underlying interaction dynamics from high-level structural descriptors.|pdf=|usr=027}}
+{{tp|p=33864532|t=2021. Multi-conformation representation of Mpro identifies promising candidates for drug repurposing against COVID-19.|pdf=|usr=027}}
+{{tp|p=33903779|t=2021. Synthesis, X-ray crystal structure, IR and Raman spectroscopic analysis, quantum chemical computational and molecular docking studies on hydrazone-pyridine compound: As an insight into the inhibitor capacity of main protease of SARS-CoV2.|pdf=|usr=027}}
+{{tp|p=33903778|t=2021. In search of RdRp and Mpro inhibitors against SARS CoV-2: Molecular docking, molecular dynamic simulations and ADMET analysis.|pdf=|usr=027}}
+{{tp|p=33903777|t=2021. New alpha-Hydrazinophosphonic acid: Synthesis, characterization, DFT study and in silico prediction of its potential inhibition of SARS-CoV-2 main protease.|pdf=|usr=027}}
+{{tp|p=33967344|t=2021. Screening of cryptogamic secondary metabolites as putative inhibitors of SARS-CoV-2 main protease and ribosomal binding domain of spike glycoprotein by molecular docking and molecular dynamics approaches.|pdf=|usr=027}}
+{{tp|p=33967343|t=2021. In silico detection of inhibitor potential of Passiflora compounds against SARS-Cov-2(Covid-19) main protease by using molecular docking and dynamic analyses.|pdf=|usr=027}}
+{{tp|p=34007088|t=2021. Design and synthesis of pyrazolone-based compounds as potent blockers of SARS-CoV-2 viral entry into the host cells.|pdf=|usr=027}}
+{{tp|p=34054142|t=2021. DFT, molecular docking and molecular dynamics simulation studies on some newly introduced natural products for their potential use against SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=34031619|t=2021. Chemical reactivities and molecular docking studies of parthenolide with the main protease of HEP-G2 and SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=33846658|t=2021. Synthesis, antimicrobial activity, density functional modelling and molecular docking with COVID-19 main protease studies of benzoxazole derivative: 2-(p-chloro-benzyl)-5-[3-(4-ethly-1-piperazynl) propionamido]-benzoxazole.|pdf=|usr=027}}
+{{tp|p=33840836|t=2021. The identification of novel inhibitors of human angiotensin-converting enzyme 2 and main protease of Sars-Cov-2: A combination of in silico methods for treatment of COVID-19.|pdf=|usr=027}}
+{{tp|p=33840835|t=2021. Rational design of flavonoid based potential inhibitors targeting SARS-CoV 3CL protease for the treatment of COVID-19.|pdf=|usr=027}}
+{{tp|p=33867575|t=2021. Molecular insights of hyaluronic acid-hydroxychloroquine conjugate as a promising drug in targeting SARS-CoV-2 viral proteins.|pdf=|usr=027}}
+{{tp|p=33928494|t=2021. Screening for inhibitory effects of crude drugs on furin-like enzymatic activities.|pdf=|usr=027}}
+{{tp|p=33352046|t=2021. Natural Products with Potential to Treat RNA Virus Pathogens Including SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=33844528|t=2021. Anti-SARS-CoV-2 Activity of Andrographis paniculata Extract and Its Major Component Andrographolide in Human Lung Epithelial Cells and Cytotoxicity Evaluation in Major Organ Cell Representatives.|pdf=|usr=027}}
+{{tp|p=33884222|t=2021. Chemo-Preventive Effect of Vegetables and Fruits Consumption on the COVID-19 Pandemic.|pdf=|usr=027}}
+{{tp|p=33949642|t=2021. Letter to the Editor: Challenges Providing Nutrition Care during the COVID-19 Pandemic: Canadian Dietitian Perspectives.|pdf=|usr=027}}
+{{tp|p=33367467|t=2021. A Correlation Analysis between the Nutritional Status and Prognosis of COVID-19 Patients.|pdf=|usr=027}}
+{{tp|p=33306130|t=2021. Severe Acute Respiratory Syndrome Coronavirus-2 Pneumonia in a Newborn Treated With Remdesivir and Coronavirus Disease 2019 Convalescent Plasma.|pdf=|usr=027}}
+{{tp|p=33842018|t=2021. Reducing SARS-CoV-2 pathological protein activity with small molecules.|pdf=|usr=027}}
+{{tp|p=34084043|t=2021. Hydroxychloroquine and Chloroquine in Prophylaxis and Treatment of COVID-19: What Is Known?|pdf=|usr=027}}
+{{tp|p=33831737|t=2021. A novel LC-MS/MS method for determination of the potential antiviral candidate favipiravir for the emergency treatment of SARS-CoV-2 virus in human plasma: Application to a bioequivalence study in Egyptian human volunteers.|pdf=|usr=027}}
+{{tp|p=34048671|t=2021. Lopinavir/Ritonavir for COVID-19: a Systematic Review and Meta-Analysis.|pdf=|usr=027}}
+{{tp|p=34048669|t=2021. Safety and Efficacy of Remdesivir for the Treatment of COVID-19: A Systematic Review and Meta-Analysis.|pdf=|usr=027}}
+{{tp|p=34048668|t=2021. Role of OATP4C1 in Renal Handling of Remdesivir and its Nucleoside Analog GS-441524: The First Approved Drug for Patients with COVID-19.|pdf=|usr=027}}
+{{tp|p=33939951|t=2021. Clinical Outcomes of COVID-19 Patients Treated with Convalescent Plasma or Remdesivir Alone and in Combination at a Community Hospital in California's Central Valley.|pdf=|usr=027}}
+{{tp|p=33912505|t=2020. Evaluation of the Prescribed Drugs to Elderly in a Tertiary Healthcare Center for Possible Drug Interactions with Investigational Drugs for COVID-19 Treatment.|pdf=|usr=027}}
+{{tp|p=34091026|t=2021. The relationship between 25(OH) vitamin D levels and COVID-19 onset and disease course in Spanish patients.|pdf=|usr=027}}
+{{tp|p=33864925|t=2021. Learning from previous methodological pitfalls to propose well-designed trials on vitamin D in COVID-19.|pdf=|usr=027}}
+{{tp|p=34059065|t=2021. Exosomes contribution in COVID-19 patients' treatment.|pdf=|usr=027}}
+{{tp|p=33853637|t=2021. Dodging COVID-19 infection: low expression and localization of ACE2 and TMPRSS2 in multiple donor-derived lines of human umbilical cord-derived mesenchymal stem cells.|pdf=|usr=027}}
+{{tp|p=33968608|t=2021. The face mask-touching behavior during the COVID-19 pandemic: Observational study of public transportation users in the greater Paris region: The French-mask-touch study.|pdf=|usr=027}}
+{{tp|p=34033406|t=2021. Tocilizumab|pdf=|usr=027}}
+{{tp|p=34033367|t=2021. Coronavirus (COVID-19) Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT)|pdf=|usr=027}}
+{{tp|p=34033365|t=2021. Monoclonal Antibody Therapy For High-Risk Coronavirus (COVID 19) Patients With Mild To Moderate Disease Presentations|pdf=|usr=027}}
+{{tp|p=34097371|t=2021. Coronavirus Disease 2019 (COVID-19) Emergency Use Authorizations (EUAs)|pdf=|usr=027}}
+{{tp|p=34009769|t=2020. Science Brief: COVID-19 Vaccines and Vaccination|pdf=|usr=027}}
+{{tp|p=34014630|t=2012. Covid-19 Drugs|pdf=|usr=027}}
+{{tp|p=34014629|t=2012. Covid-19 Vaccines|pdf=|usr=027}}
+{{tp|p=34014628|t=2012. Covid-19 Monoclonal Antibodies: Monoclonal Antibodies to SARS-CoV-2|pdf=|usr=027}}
+{{tp|p=31643344|t=2012. Baricitinib|pdf=|usr=027}}
+{{tp|p=33835300|t=2021. Next-Generation COVID-19 Vaccines Should Take Efficiency of Distribution into Consideration.|pdf=|usr=027}}
+{{tp|p=33985872|t=2021. Lymphadenopathy Following COVID-19 Vaccination: Imaging Findings Review.|pdf=|usr=027}}
+{{tp|p=33930273|t=2021. Glycyrrhizic Acid Nanoparticles as Antiviral and Anti-inflammatory Agents for COVID-19 Treatment.|pdf=|usr=027}}
+{{tp|p=33378177|t=2021. Cracking the Chloroquine Conundrum: The Application of Defective UiO-66 Metal-Organic Framework Materials to Prevent the Onset of Heart Defects-In Vivo and In Vitro.|pdf=|usr=027}}
+{{tp|p=34075346|t=2021. Simeprevir Potently Suppresses SARS-CoV-2 Replication and Synergizes with Remdesivir.|pdf=|usr=027}}
+{{tp|p=34075345|t=2021. Molecular Aspects Concerning the Use of the SARS-CoV-2 Receptor Binding Domain as a Target for Preventive Vaccines.|pdf=|usr=027}}
+{{tp|p=34075344|t=2021. Modifications in an Emergency: The Role of N1-Methylpseudouridine in COVID-19 Vaccines.|pdf=|usr=027}}
+{{tp|p=34056095|t=2021. Synthetic Siglec-9 Agonists Inhibit Neutrophil Activation Associated with COVID-19.|pdf=|usr=027}}
+{{tp|p=34056089|t=2021. Native-like SARS-CoV-2 Spike Glycoprotein Expressed by ChAdOx1 nCoV-19/AZD1222 Vaccine.|pdf=|usr=027}}
+{{tp|p=34056083|t=2021. A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development.|pdf=|usr=027}}
+{{tp|p=33979123|t=2021. Small-Molecule Inhibitors of the Coronavirus Spike: ACE2 Protein-Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=33849267|t=2021. Human Cathelicidin Inhibits SARS-CoV-2 Infection: Killing Two Birds with One Stone.|pdf=|usr=027}}
+{{tp|p=33876632|t=2021. Antibody Affinity Governs the Inhibition of SARS-CoV-2 Spike/ACE2 Binding in Patient Serum.|pdf=|usr=027}}
+{{tp|p=33854700|t=2021. Intriguing Antiviral Modified Nucleosides: A Retrospective View into the Future Treatment of COVID-19.|pdf=|usr=027}}
+{{tp|p=33850605|t=2021. Structural Insights into Plasticity and Discovery of Remdesivir Metabolite GS-441524 Binding in SARS-CoV-2 Macrodomain.|pdf=|usr=027}}
+{{tp|p=33373194|t=2021. Uncovering Flexible Active Site Conformations of SARS-CoV-2 3CL Proteases through Protease Pharmacophore Clusters and COVID-19 Drug Repurposing.|pdf=|usr=027}}
+{{tp|p=34056406|t=2021. Artificial Intelligence-Guided De Novo Molecular Design Targeting COVID-19.|pdf=|usr=027}}
+{{tp|p=34056192|t=2021. Progress Toward a Large-Scale Synthesis of Molnupiravir (MK-4482, EIDD-2801) from Cytidine.|pdf=|usr=027}}
+{{tp|p=33855277|t=2021. Synergistic Inhibition of SARS-CoV-2 Replication Using Disulfiram/Ebselen and Remdesivir.|pdf=|usr=027}}
+{{tp|p=33855276|t=2021. Tissue-Specific Proteomics Analysis of Anti-COVID-19 Nucleoside and Nucleotide Prodrug-Activating Enzymes Provides Insights into the Optimization of Prodrug Design and Pharmacotherapy Strategy.|pdf=|usr=027}}
+{{tp|p=33855275|t=2021. Repurposing Quinoline and Artemisinin Antimalarials as Therapeutics for SARS-CoV-2: Rationale and Implications.|pdf=|usr=027}}
+{{tp|p=34018145|t=2021. Acute disseminated encephalomyelitis-like presentation after an inactivated coronavirus vaccine.|pdf=|usr=027}}
+{{tp|p=34002386|t=2021. Neurological side effects of COVID-19 vaccines are rare.|pdf=|usr=027}}
+{{tp|p=34002379|t=2021. SARS-CoV-2 vaccines are not free of neurological side effects.|pdf=|usr=027}}
+{{tp|p=34002130|t=2021. SARS-CoV-2 cell entry and targeted antiviral development.|pdf=|usr=027}}
+{{tp|p=33850275|t=2021. The challenges and opportunities of traditional Chinese medicines against COVID-19: a way out from a network perspective.|pdf=|usr=027}}
+{{tp|p=33931765|t=2021. Pharmacokinetics-based identification of pseudoaldosterogenic compounds originating from Glycyrrhiza uralensis roots (Gancao) after dosing LianhuaQingwen capsule.|pdf=|usr=027}}
+{{tp|p=33907306|t=2021. A multi-targeting drug design strategy for identifying potent anti-SARS-CoV-2 inhibitors.|pdf=|usr=027}}
+{{tp|p=33350096|t=2021. SARS-CoV-2 effects on the renin-angiotensin-aldosterone system, therapeutic implications.|pdf=|usr=027}}
+{{tp|p=34012162|t=2021. Familiar dermatologic drugs as therapies for COVID-19.|pdf=|usr=027}}
+{{tp|p=33880039|t=2021. Chemoinformatic Analysis of Psychotropic and Antihistaminic Drugs in the Light of Experimental Anti-SARS-CoV-2 Activities.|pdf=|usr=027}}
+{{tp|p=33359141|t=2021. COVID-19 vaccines: The status and perspectives in delivery points of view.|pdf=|usr=027}}
+{{tp|p=33340620|t=2021. Non-viral COVID-19 vaccine delivery systems.|pdf=|usr=027}}
+{{tp|p=33316346|t=2021. Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection.|pdf=|usr=027}}
+{{tp|p=33309815|t=2021. Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy.|pdf=|usr=027}}
+{{tp|p=34060150|t=2021. Formulation of a Composite Nasal Spray Enabling Enhanced Surface Coverage and Prophylaxis of SARS-COV-2.|pdf=|usr=027}}
+{{tp|p=34022675|t=2021. Role of the early short-course corticosteroids treatment in ARDS caused by COVID-19: A single-center, retrospective analysis.|pdf=|usr=027}}
+{{tp|p=33966265|t=2021. Antifibrotics for COVID-19 related lung fibrosis: Agents with benefits?|pdf=|usr=027}}
+{{tp|p=33966262|t=2021. The relationship between the severity and mortality of SARS-CoV-2 infection and 25-hydroxyvitamin D concentration - a metaanalysis.|pdf=|usr=027}}
+{{tp|p=33966260|t=2021. A clinical profile and factors associated with severity of the disease among Polish patients hospitalized due to COVID-19 - an observational study.|pdf=|usr=027}}
+{{tp|p=33881163|t=2021. Pulmonary thromboembolism post-COVID convalescent plasma therapy: adding fuel to a smoldering fire!|pdf=|usr=027}}
+{{tp|p=33871042|t=2021. Timing of Anti-viral therapy in COVID-19: Key to success.|pdf=|usr=027}}
+{{tp|p=33850691|t=2021. Nitric Oxide to Fight Viral Infections.|pdf=|usr=027}}
+{{tp|p=34075554|t=2021. Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era.|pdf=|usr=027}}
+{{tp|p=34028041|t=2021. Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: Don't give up on the second dose!|pdf=|usr=027}}
+{{tp|p=33948956|t=2021. BNT162b2 mRNA COVID-19 vaccine induces antibodies of broader cross-reactivity than natural infection, but recognition of mutant viruses is up to 10-fold reduced.|pdf=|usr=027}}
+{{tp|p=33837568|t=2021. Silencing of SARS-CoV-2 with modified siRNA-peptide dendrimer formulation.|pdf=|usr=027}}
+{{tp|p=33993490|t=2021. Caspases and therapeutic potential of caspase inhibitors in moderate-severe SARS CoV2 infection and long COVID.|pdf=|usr=027}}
+{{tp|p=34020451|t=2021. Influence of vitamin D status on hospital length of stay and prognosis in hospitalized patients with moderate to severe COVID-19: a multicenter prospective cohort study.|pdf=|usr=027}}
+{{tp|p=34057236|t=2021. SARS-CoV-2 vaccination induces breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria on complement inhibitor.|pdf=|usr=027}}
+{{tp|p=33837984|t=2021. Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine.|pdf=|usr=027}}
+{{tp|p=34057243|t=2021. Covid-19 vaccination in patients with multiple myeloma: Focus on immune response.|pdf=|usr=027}}
+{{tp|p=33939851|t=2021. Hemolytic crisis due to Covid-19 vaccination in a woman with cold agglutinin disease.|pdf=|usr=027}}
+{{tp|p=33738273|t=2020. Anti-Infective, Anti-Inflammatory, and Immunomodulatory Properties of Breast Milk Factors for the Protection of Infants in the Pandemic From COVID-19.|pdf=|usr=027}}
+{{tp|p=34095323|t=2021. Potent phytochemicals against COVID-19 infection from phyto-materials used as antivirals in complementary medicines: a review.|pdf=|usr=027}}
+{{tp|p=34099962|t=2021. Druggability of cavity pockets within SARS-CoV-2 spike glycoprotein and pharmacophore-based drug discovery.|pdf=|usr=027}}
+{{tp|p=34055031|t=2021. Tocilizumab in the treatment of coronavirus disease 2019 pneumonia: real-world data from a case series.|pdf=|usr=027}}
+{{tp|p=33891952|t=2021. Reply.|pdf=|usr=027}}
+{{tp|p=33340538|t=2021. Potential Biases in Studies of Acid-Suppressing Drugs and COVID-19 Infection.|pdf=|usr=027}}
+{{tp|p=34045093|t=2021. Due to their anti-inflammatory, antioxidant and neurotrophic properties, second-generation antipsychotics are suitable in patients with schizophrenia and COVID-19.|pdf=|usr=027}}
+{{tp|p=33346100|t=2021. Recognition of plausible therapeutic agents to combat COVID-19: An omics data based combined approach.|pdf=|usr=027}}
+{{tp|p=33887367|t=2021. Inferring molecular mechanisms of dexamethasone therapy in severe COVID-19 from existing transcriptomic data.|pdf=|usr=027}}
+{{tp|p=34073716|t=2021. Genome-Scale Metabolic Model of Infection with SARS-CoV-2 Mutants Confirms Guanylate Kinase as Robust Potential Antiviral Target.|pdf=|usr=027}}
+{{tp|p=33321203|t=2021. A computational approach to design potential siRNA molecules as a prospective tool for silencing nucleocapsid phosphoprotein and surface glycoprotein gene of SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=33937567|t=2021. Investigator initiated clinical trial of remdesivir for the treatment of COVID-19 in Japan.|pdf=|usr=027}}
+{{tp|p=33987628|t=2021. Inclusion of Cephalexin in COVID-19 Treatment Combinations May Prevent Lung Involvement in Mild Infections: A Case Report with Pharmacological Genomics Perspective.|pdf=|usr=027}}
+{{tp|p=34104701|t=2021. Potential Role of Vitamins and Zinc on Acute Respiratory Infections Including Covid-19.|pdf=|usr=027}}
+{{tp|p=34026493|t=2021. Remdesivir-induced symptomatic bradycardia in the treatment of COVID-19 disease.|pdf=|usr=027}}
+{{tp|p=34007917|t=2021. Saffron: A potential drug-supplement for severe acute respiratory syndrome coronavirus (COVID) management.|pdf=|usr=027}}
+{{tp|p=33824915|t=2021. Design and identification of novel annomontine analogues against SARS-CoV-2: An in-silico approach.|pdf=|usr=027}}
+{{tp|p=33903854|t=2021. Convalescent plasma therapy - a silver lining for COVID-19 management?|pdf=|usr=027}}
+{{tp|p=33905094|t=2021. Role of Statins in Coronavirus-Related Disease (COVID-19): A Retrospective Cohort Study in Northern Italy.|pdf=|usr=027}}
+{{tp|p=33974497|t=2021. Perspectives on the use and risk of adverse events associated with cytokine-storm targeting antibodies and challenges associated with development of novel monoclonal antibodies for the treatment of COVID-19 clinical cases.|pdf=|usr=027}}
+{{tp|p=33913801|t=2021. Impact of influenza vaccination on the risk of SARS-CoV-2 infection in a middle-aged group of people.|pdf=|usr=027}}
+{{tp|p=33836142|t=2021. Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant.|pdf=|usr=027}}
+{{tp|p=33834387|t=2021. MyD88 and beyond: a perspective on MyD88-targeted therapeutic approach for modulation of host immunity.|pdf=|usr=027}}
+{{tp|p=34018464|t=2021. Anti-IgE monoclonal antibodies as potential treatment in COVID-19.|pdf=|usr=027}}
+{{tp|p=34015982|t=2021. Tranilast: a potential anti-Inflammatory and NLRP3 inflammasome inhibitor drug for COVID-19.|pdf=|usr=027}}
+{{tp|p=34057871|t=2021. Promising drug repurposing approach targeted for cytokine storm implicated in SARS-CoV-2 complications.|pdf=|usr=027}}
+{{tp|p=33906375|t=2021. Cytokine storm modulation in COVID-19: a proposed role for vitamin D and DPP-4 inhibitor combination therapy (VIDPP-4i).|pdf=|usr=027}}
+{{tp|p=33842191|t=2021. Computational screening of FDA approved drugs of fungal origin that may interfere with SARS-CoV-2 spike protein activation, viral RNA replication, and post-translational modification: a multiple target approach.|pdf=|usr=027}}
+{{tp|p=33842190|t=2021. In search of drugs to alleviate suppression of the host's innate immune responses against SARS-CoV-2 using a molecular modeling approach.|pdf=|usr=027}}
+{{tp|p=34045820|t=2021. Second-degree Heart Block Caused by Itolizumab-induced Infusion Reaction in COVID-19.|pdf=|usr=027}}
+{{tp|p=34045817|t=2021. Off-label Use of Itolizumab in Patients with COVID-19 ARDS: Our Clinical Experience in a Dedicated COVID Center.|pdf=|usr=027}}
+{{tp|p=34045812|t=2021. Evidence for Chloroquine/Hydroxychloroquine in the Treatment of COVID-19.|pdf=|usr=027}}
+{{tp|p=33846691|t=2021. Povidone Iodine (PVP-I) Oro-Nasal Spray: An Effective Shield for COVID-19 Protection for Health Care Worker (HCW), for all.|pdf=|usr=027}}
+{{tp|p=33973204|t=2021. Challenges of Cellular Therapy During the COVID-19 Pandemic.|pdf=|usr=027}}
+{{tp|p=33973199|t=2021. The COVID-19 Vaccine Landscape.|pdf=|usr=027}}
+{{tp|p=33973198|t=2021. Photobiomodulation and Antiviral Photodynamic Therapy in COVID-19 Management.|pdf=|usr=027}}
+{{tp|p=33973197|t=2021. Dietary Supplements for COVID-19.|pdf=|usr=027}}
+{{tp|p=33973196|t=2021. Nutrition and Immunity in COVID-19.|pdf=|usr=027}}
+{{tp|p=33973194|t=2021. Immune-Based Therapy for COVID-19.|pdf=|usr=027}}
+{{tp|p=33861442|t=2021. Possible Mechanisms and Special Clinical Considerations of Curcumin Supplementation in Patients with COVID-19.|pdf=|usr=027}}
+{{tp|p=33993131|t=2021. Safety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV.|pdf=|usr=027}}
+{{tp|p=34009000|t=2021. Frequency and Characteristics of Nodal and Deltoid FDG and 11C-Choline Uptake on PET Imaging Performed After COVID-19 Vaccination.|pdf=|usr=027}}
+{{tp|p=33980347|t=2021. Is nutraceutical supplementation appropriate for COVID-19 management?|pdf=|usr=027}}
+{{tp|p=33357261|t=2021. The war on infectious diseases: COVID-19 vaccines and the public: Challenges and solutions.|pdf=|usr=027}}
+{{tp|p=33373323|t=2021. Time to Enhance Immunity via Functional Foods and Supplements: Hope for SARS-CoV-2 Outbreak.|pdf=|usr=027}}
+{{tp|p=33891569|t=2021. Neem (Azadirachta Indica A. Juss) Capsules for Prophylaxis of COVID-19 Infection: A Pilot, Double-Blind, Randomized Controlled Trial.|pdf=|usr=027}}
+{{tp|p=34060795|t=2021. Case Report: Thrombotic Thrombocytopenia after COVID-19 Janssen Vaccination.|pdf=|usr=027}}
+{{tp|p=33853498|t=2021. Potential Role of Gut Microbiota in Traditional Chinese Medicine against COVID-19.|pdf=|usr=027}}
+{{tp|p=34047304|t=2021. Adverse Events After SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease.|pdf=|usr=027}}
+{{tp|p=33982938|t=2021. Comparative Effectiveness of Famotidine in Hospitalized COVID-19 Patients.|pdf=|usr=027}}
+{{tp|p=34038639|t=2021. Quinoline and Quinazoline Derivatives Inhibit Viral RNA Synthesis by SARS-CoV-2 RdRp.|pdf=|usr=027}}
+{{tp|p=33988136|t=2021. Implications of Interleukin-6 (IL-6)-blockade for severe COVID-19 infection in patients with Multiple Myeloma.|pdf=|usr=027}}
+{{tp|p=33898162|t=2021. Practical handling of allergic reactions to COVID-19 vaccines: A position paper from German and Austrian Allergy Societies AeDA, DGAKI, GPA and OGAI.|pdf=|usr=027}}
+{{tp|p=33962863|t=2021. Allergy to COVID-19 vaccines: A current update.|pdf=|usr=027}}
+{{tp|p=33842829|t=2021. COVID-19 vaccination of patients with allergies and type-2 inflammation with concurrent antibody therapy (biologicals) - A Position Paper of the German Society of Allergology and Clinical Immunology (DGAKI) and the German Society for Applied Allergology (AeDA).|pdf=|usr=027}}
+{{tp|p=33316045|t=2021. Chloroquine- and Hydroxychloroquine-Induced Cardiomyopathy: A Case Report and Brief Literature Review.|pdf=|usr=027}}
+{{tp|p=33994051|t=2021. COVID-19 vaccine adverse reactions bring patients to emergency departments.|pdf=|usr=027}}
+{{tp|p=33980419|t=2021. Thrombotic Thrombocytopenic Purpura after Ad26.COV2-S Vaccination.|pdf=|usr=027}}
+{{tp|p=34062319|t=2021. Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines.|pdf=|usr=027}}
+{{tp|p=34059386|t=2021. Extending the clinical spectrum of thrombotic thrombocytopenic syndrome attributable to adenovirus-based vaccines for Covid-19.|pdf=|usr=027}}
+{{tp|p=33348222|t=2021. Safety and efficacy of hydroxychloroquine in 152 outpatients with confirmed COVID-19: A pilot observational study.|pdf=|usr=027}}
+{{tp|p=33896653|t=2021. Thymosin a1 use is not associated with reduced COVID-19 mortality.|pdf=|usr=027}}
+{{tp|p=33847737|t=2021. Safety of Tenofovir Disoproxil Fumarate (TDF) for Pregnant Women facing the COVID-19 Pandemic.|pdf=|usr=027}}
+{{tp|p=33950198|t=2021. Peripheral infiltration of remdesivir in 3 patients with COVID-19: Case series and discussion.|pdf=|usr=027}}
+{{tp|p=33955454|t=2021. Pharmacy leadership, expertise imperative for successful COVID-19 vaccine rollout.|pdf=|usr=027}}
+{{tp|p=34023417|t=2021. Relapse of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine.|pdf=|usr=027}}
+{{tp|p=33839200|t=2021. Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine.|pdf=|usr=027}}
+{{tp|p=34019949|t=2021. Clinically Significant COVID-19 Following SARS-CoV-2 Vaccination in Kidney Transplant Recipients.|pdf=|usr=027}}
+{{tp|p=33992727|t=2021. An Additional Case of Minimal Change Disease Following the Pfizer-BioNTech COVID-19 Vaccine.|pdf=|usr=027}}
+{{tp|p=34059207|t=2021. Virucidal mouth rinses for patients during the coronavirus disease 2019 outbreak.|pdf=|usr=027}}
+{{tp|p=33894177|t=2021. Targeting Runt-Related Transcription Factor 1 Prevents Pulmonary Fibrosis and Reduces Expression of Severe Acute Respiratory Syndrome Coronavirus 2 Host Mediators.|pdf=|usr=027}}
+{{tp|p=33949212|t=2021. The effect of estrogen in coronavirus disease 2019.|pdf=|usr=027}}
+{{tp|p=33566663|t=2021. Enhancing the WHO's Proposed Framework for Distributing COVID-19 Vaccines Among Countries.|pdf=|usr=027}}
+{{tp|p=32955926|t=2021. Role of IL-6 in Severe Inflammation.|pdf=|usr=027}}
+{{tp|p=34085760|t=2021. Postvaccination SARS-CoV-2 infections among skilled nursing facility residents and staff members - Chicago, Illinois, December 2020-March 2021.|pdf=|usr=027}}
+{{tp|p=34080285|t=2021. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus: Not alarming, but should be taken gravely.|pdf=|usr=027}}
+{{tp|p=34058052|t=2021. Impaired anti-SARS-CoV-2 humoral and cellular immune response induced by Pfizer-BioNTech BNT162b2 mRNA vaccine in solid organ transplanted patients.|pdf=|usr=027}}
+{{tp|p=34043872|t=2021. Severe consequences of COVID-19 infection among vaccinated kidney transplant recipients.|pdf=|usr=027}}
+{{tp|p=34036720|t=2021. Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients.|pdf=|usr=027}}
+{{tp|p=33866672|t=2021. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus.|pdf=|usr=027}}
+{{tp|p=33864722|t=2021. Immunogenicity of SARS-CoV-2 BNT162b2 vaccine in solid organ transplant recipients.|pdf=|usr=027}}
+{{tp|p=33829628|t=2021. The future of SARS-CoV-2 vaccines in transplant recipients: To be determined.|pdf=|usr=027}}
+{{tp|p=33890410|t=2021. COVID-19 infection in solid organ transplant recipients after SARS-CoV-2 vaccination.|pdf=|usr=027}}
+{{tp|p=33950300|t=2021. Human cell receptors: potential drug targets to combat COVID-19.|pdf=|usr=027}}
+{{tp|p=33995537|t=2021. EVOLUCION DEL INTERVALO QTC EN PACIENTES CON INFECCION SARS-COV-2 TRATADOS CON FARMACOS ANTIVIRALES( lozenge).|pdf=|usr=027}}
+{{tp|p=33946037|t=2021. SARS-CoV-2 vaccination efficacy on hospitalisation and variants.|pdf=|usr=027}}
+{{tp|p=33895471|t=2021. COVID-19 vaccines surveillance in France: a global response to a major national challenge.|pdf=|usr=027}}
+{{tp|p=34033927|t=2021. Oxford-AstraZeneca COVID-19 vaccine-induced cerebral venous thrombosis and thrombocytopaenia: A missed opportunity for a rapid return of experience.|pdf=|usr=027}}
+{{tp|p=33901708|t=2021. SARS-CoV-2 vaccination efficacy on hospitalisation and variants.|pdf=|usr=027}}
+{{tp|p=33867032|t=2021. First electrochemical evaluation of favipiravir used as an antiviral option in the treatment of COVID-19: A study of its enhanced voltammetric determination in cationic surfactant media using a boron-doped diamond electrode.|pdf=|usr=027}}
+{{tp|p=33350010|t=2021. A Ligand Selection Strategy Identifies Chemical Probes Targeting the Proteases of SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=33860605|t=2021. Polysulfates Block SARS-CoV-2 Uptake through Electrostatic Interactions.|pdf=|usr=027}}
+{{tp|p=33915014|t=2021. Supramolecular Cylinders Target Bulge Structures in the 5' UTR of the RNA Genome of SARS-CoV-2 and Inhibit Viral Replication.|pdf=|usr=027}}
+{{tp|p=34022388|t=2021. Seroconversion after coronavirus disease 2019 vaccination in patients with immune deficiency.|pdf=|usr=027}}
+{{tp|p=33838338|t=2021. Disproportionality analysis of anaphylactic reactions after vaccination with messenger RNA coronavirus disease 2019 vaccines in the United States.|pdf=|usr=027}}
+{{tp|p=33962029|t=2021. Risk of allergic reaction in patients with atopic disease and recent coronavirus disease 2019 vaccination.|pdf=|usr=027}}
+{{tp|p=34020659|t=2021. Repurposing of antibiotics for clinical management of COVID-19: a narrative review.|pdf=|usr=027}}
+{{tp|p=34030782|t=2021. Idiopathic Thrombocytopenic Purpura and the Moderna Covid-19 Vaccine.|pdf=|usr=027}}
+{{tp|p=33349491|t=2021. Do Systemic Corticosteroids Reduce Mortality in Critically Ill Adult Patients With COVID-19?|pdf=|usr=027}}
+{{tp|p=33940219|t=2021. COVID-19 vaccine-induced immune thrombotic thrombocytopenia: An emerging cause of splanchnic vein thrombosis.|pdf=|usr=027}}
+{{tp|p=34057642|t=2021. Impact of dexamethasone on the incidence of ventilator-associated pneumonia and blood stream infections in COVID-19 patients requiring invasive mechanical ventilation: a multicenter retrospective study.|pdf=|usr=027}}
+{{tp|p=33956361|t=2021. The impact of hydroxychloroquine-azithromycin combination on Tpeak-to-end and Tpeak-to-end/QT ratio during a short treatment course.|pdf=|usr=027}}
+{{tp|p=34035003|t=2021. Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease.|pdf=|usr=027}}
+{{tp|p=33903110|t=2021. Overcoming Culture Restriction for SARS-CoV-2 in Human Cells Facilitates the Screening of Compounds Inhibiting Viral Replication.|pdf=|usr=027}}
+{{tp|p=34097489|t=2021. Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 In Vitro.|pdf=|usr=027}}
+{{tp|p=34042319|t=2021. Use of Tofacitinib in the Context of COVID-19 Vaccination: Comment on the American College of Rheumatology Clinical Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases.|pdf=|usr=027}}
+{{tp|p=34042308|t=2021. Reply.|pdf=|usr=027}}
+{{tp|p=33857328|t=2021. Can ketone bodies inactivate coronavirus spike protein? The potential of biocidal agents against SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=33938041|t=2021. Vitamin E at a high dose as an anti-ferroptosis drug and not just a supplement for COVID-19 treatment.|pdf=|usr=027}}
+{{tp|p=33338375|t=2021. Could Simultaneous Nasal and Oral Irrigation Be a Nontherapeutic Tool against SARS-CoV-2?|pdf=|usr=027}}
+{{tp|p=33860219|t=2021. Toward the Next-Generation COVID-19 Vaccines That Circumvent Antigenic Drift while Defusing Viral Infection.|pdf=|usr=027}}
+{{tp|p=33860218|t=2021. SARS-CoV-2 Glycosylation Suggests That Vaccines Should Have Adopted the S1 Subunit as Antigen.|pdf=|usr=027}}
+{{tp|p=33308005|t=2021. Bail-out extracorporeal membrane oxygenation for hydroxychloroquine intoxication: a warning for COVID-19 health-care givers.|pdf=|usr=027}}
+{{tp|p=34008482|t=2021. Ethical reflections on Covid-19 vaccines.|pdf=|usr=027}}
+{{tp|p=33428805|t=2021. Ruxolitinib in adult patients with secondary hemophagocytic lymphohistiocytosis.|pdf=|usr=027}}
+{{tp|p=33350698|t=2021. Remdesivir in The Treatment of COVID-19.|pdf=|usr=027}}
+{{tp|p=33350691|t=2021. Remdesivir Approved to Treat COVID-19 Amid Controversy.|pdf=|usr=027}}
+{{tp|p=33932943|t=2021. COVID-19 Vaccine Considerations during Pregnancy and Lactation.|pdf=|usr=027}}
+{{tp|p=34014798|t=2021. Interleukin-6 Inhibition Reduces Neuronal Injury In A Murine Model of Ventilator-Induced Lung Injury.|pdf=|usr=027}}
+{{tp|p=33961754|t=2021. Therapeutic Application of Alpha-1 Antitrypsin in COVID-19.|pdf=|usr=027}}
+{{tp|p=33852488|t=2021. Arrhythmias in Patients With Coronavirus Disease 2019 Treated With Hydroxychloroquine and/or Azithromycin.|pdf=|usr=027}}
+{{tp|p=34010161|t=2021. Tocilizumab-Associated Cecal Perforation in COVID-19 Pneumonia.|pdf=|usr=027}}
+{{tp|p=33346946|t=2021. Arterial abnormalities identified in kidneys transplanted into children during the COVID-19 pandemic.|pdf=|usr=027}}
+{{tp|p=33998136|t=2021. Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus: No cause for alarm.|pdf=|usr=027}}
+{{tp|p=34019051|t=2021. Green and sensitive spectrofluorimetric determination of Remdesivir, an FDA approved SARS-CoV-2 candidate antiviral; application in pharmaceutical dosage forms and spiked human plasma.|pdf=|usr=027}}
+{{tp|p=33369927|t=2021. Is Aspirin Effective in Preventing Intensive Care Unit Admission in Patients With Coronavirus Disease 2019 Pneumonia?|pdf=|usr=027}}
+{{tp|p=34018416|t=2021. A Possible Case of Hypertensive Crisis With Intracranial Haemorrhage After an mRNA Anti-COVID-19 Vaccine.|pdf=|usr=027}}
+{{tp|p=34004274|t=2021. Primary care provider-reported prevalence of vaccine and polyethylene glycol allergy in Canada.|pdf=|usr=027}}
+{{tp|p=33939483|t=2021. In South Africa, a 2-dose Oxford/AZ vaccine did not prevent mild to moderate COVID-19 (cases mainly B.1.351 variant).|pdf=|usr=027}}
+{{tp|p=34058104|t=2021. In COVID-19, tocilizumab reduces all-cause mortality at 28 d.|pdf=|usr=027}}
+{{tp|p=34058103|t=2021. In patients hospitalized with COVID-19, adding azithromycin to usual care did not reduce 28-d mortality.|pdf=|usr=027}}
+{{tp|p=34049853|t=2021. SARS-COV-2 vaccination after stem cell transplantation for scleroderma.|pdf=|usr=027}}
+{{tp|p=34031032|t=2021. High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases.|pdf=|usr=027}}
+{{tp|p=34031031|t=2021. Correspondence on 'Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort'.|pdf=|usr=027}}
+{{tp|p=33958323|t=2021. SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response.|pdf=|usr=027}}
+{{tp|p=33985941|t=2021. Response to: 'Correspondence on 'Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry'' by Rosenbaum et al.|pdf=|usr=027}}
+{{tp|p=33903096|t=2021. Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'.|pdf=|usr=027}}
+{{tp|p=33903095|t=2021. Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by Kaklamanos et al.|pdf=|usr=027}}
+{{tp|p=33883160|t=2021. Correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine'.|pdf=|usr=027}}
+{{tp|p=34001511|t=2021. Nodosome Inhibition as a Novel Broad-Spectrum Antiviral Strategy against Arboviruses, Enteroviruses, and SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=33972256|t=2021. Tolerability, Safety, Pharmacokinetics, and Immunogenicity of a Novel SARS-CoV-2 Neutralizing Antibody, Etesevimab, in Chinese Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study.|pdf=|usr=027}}
+{{tp|p=34033288|t=2021. Reasons to avoid vitamin D deficiency during COVID-19 pandemic.|pdf=|usr=027}}
+{{tp|p=34011777|t=2021. [MANAGEMENT, DIAGNOSIS, AND TREATMENT OF SEVERE ALLERGIC REACTIONS INCLUDING ANAPHYLAXIS TO COVID-19 VACCINE].|pdf=|usr=027}}
+{{tp|p=33881925|t=2021. Letter by Carmona et al Regarding Article, "Beneficial Effect of Statins in COVID-19-Related Outcomes-Brief Report: a National Population-Based Cohort Study".|pdf=|usr=027}}
+{{tp|p=33377184|t=2021. Polymyxin B hemoperfusion in coronavirus disease 2019 patients with endotoxic shock: Case series from EUPHAS2 registry.|pdf=|usr=027}}
+{{tp|p=33340765|t=2021. In vitro display evolution of IL-6R-binding unnatural peptides ribosomally initiated and cyclized with m-(chloromethyl)benzoic acid.|pdf=|usr=027}}
+{{tp|p=34077310|t=2021. Identifying the molecular targets and mechanisms of xuebijing injection for the treatment of COVID-19 via network parmacology and molecular docking.|pdf=|usr=027}}
+{{tp|p=33858291|t=2021. Can algae contribute to the war with Covid-19?|pdf=|usr=027}}
+{{tp|p=33962976|t=2021. Covid-19: Sputnik vaccine rockets, thanks to Lancet boost.|pdf=|usr=027}}
+{{tp|p=33958384|t=2021. Covid-19: Sputnik vaccine rockets, thanks to Lancet boost.|pdf=|usr=027}}
+{{tp|p=33952506|t=2021. Thromboembolism and the Oxford-AstraZeneca vaccine.|pdf=|usr=027}}
+{{tp|p=33952443|t=2021. Covid-19: Two doses of Pfizer vaccine are "highly effective" against infection, hospital admission, and death, study finds.|pdf=|usr=027}}
+{{tp|p=33952439|t=2021. Covid-19: Vaccines will be tested against variants of concern after pound29m funding boost from UK government.|pdf=|usr=027}}
+{{tp|p=34049897|t=2021. Suspend intellectual property rights for covid-19 vaccines.|pdf=|usr=027}}
+{{tp|p=34045236|t=2021. Covid-19: Pfizer-BioNTech vaccine is "likely" responsible for deaths of some elderly patients, Norwegian review finds.|pdf=|usr=027}}
+{{tp|p=34039569|t=2021. Covid-19: Variants are spreading in countries with low vaccination rates.|pdf=|usr=027}}
+{{tp|p=34035010|t=2021. Covid-19: Are high rates of B.1.617.2 linked to vaccine hesitancy?|pdf=|usr=027}}
+{{tp|p=34006591|t=2021. Covid-19 vaccines: In the rush for regulatory approval, do we need more data?|pdf=|usr=027}}
+{{tp|p=34006531|t=2021. Covid-19: Most UK adults had antibodies after one dose of AstraZeneca or Pfizer vaccine, data suggest.|pdf=|usr=027}}
+{{tp|p=34001499|t=2021. Antivirals against SARS-CoV-2 by autumn?|pdf=|usr=027}}
+{{tp|p=33980548|t=2021. Covid-19: Fever, chills, and aches more common when AstraZeneca and Pfizer vaccines are mixed, early data show.|pdf=|usr=027}}
+{{tp|p=34074627|t=2021. On the road to Recovery-the world's biggest covid-19 treatment trial.|pdf=|usr=027}}
+{{tp|p=33978844|t=2021. Convalescent plasma therapy and mortality in COVID-19 patients admitted to the ICU: a prospective observational study.|pdf=|usr=027}}
+{{tp|p=34029488|t=2021. Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case Series.|pdf=|usr=027}}
+{{tp|p=34029487|t=2021. Safety and Immunogenicity of Anti-SARS-CoV-2 Messenger RNA Vaccines in Recipients of Solid Organ Transplants.|pdf=|usr=027}}
+{{tp|p=34029484|t=2021. Symptoms After COVID-19 Vaccination in Patients With Persistent Symptoms After Acute Infection: A Case Series.|pdf=|usr=027}}
+{{tp|p=33844575|t=2021. A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated.|pdf=|usr=027}}
+{{tp|p=34094533|t=2021. Convalescent plasma as a treatment modality for Coronavirus Disease 2019 in Indonesia: A case reports.|pdf=|usr=027}}
+{{tp|p=33932508|t=2021. Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors.|pdf=|usr=027}}
+{{tp|p=33932501|t=2021. Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients.|pdf=|usr=027}}
+{{tp|p=33894725|t=2021. Efficacy and safety of Reduning injection in the treatment of COVID-19: a randomized, multicenter clinical study.|pdf=|usr=027}}
+{{tp|p=33849115|t=2021. Comparison of the antiviral effect of Arbidol and Chloroquine in treating COVID-19.|pdf=|usr=027}}
+{{tp|p=33894736|t=2021. A narrative review of COVID-19: magnesium isoglycyrrhizinate as a potential adjuvant treatment.|pdf=|usr=027}}
+{{tp|p=33832291|t=2021. Investigation into molecular mechanisms and high-frequency core TCM for pulmonary fibrosis secondary to COVID-19 based on network pharmacology and data mining.|pdf=|usr=027}}
+{{tp|p=33958324|t=2021. SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases.|pdf=|usr=027}}
+{{tp|p=33987222|t=2021. Day-90 survival in critically-ill patients with COVID-19 and hydroxychloroquine: a propensity analysis.|pdf=|usr=027}}
+{{tp|p=34066998|t=2021. Cnicin as an Anti-SARS-CoV-2: An Integrated In Silico and In Vitro Approach for the Rapid Identification of Potential COVID-19 Therapeutics.|pdf=|usr=027}}
+{{tp|p=33918619|t=2021. Potential Roles for Probiotics in the Treatment of COVID-19 Patients and Prevention of Complications Associated with Increased Antibiotic Use.|pdf=|usr=027}}
+{{tp|p=33920366|t=2021. Sinapic Acid Suppresses SARS CoV-2 Replication by Targeting Its Envelope Protein.|pdf=|usr=027}}
+{{tp|p=34069726|t=2021. Effects of Antioxidant Vitamins, Curry Consumption, and Heavy Metal Levels on Metabolic Syndrome with Comorbidities: A Korean Community-Based Cross-Sectional Study.|pdf=|usr=027}}
+{{tp|p=34069549|t=2021. The Efficacy of Antioxidant Oral Supplements on the Progression of COVID-19 in Non-Critically Ill Patients: A Randomized Controlled Trial.|pdf=|usr=027}}
+{{tp|p=33922049|t=2021. Can Prophylactic High Flow of Humidified and Warmed Filtered Air Improve Survival from Bacterial Pneumonia and SARS-CoV-2 in Elderly Individuals? The Role of Surfactant Protein A.|pdf=|usr=027}}
+{{tp|p=33894278|t=2021. A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase.|pdf=|usr=027}}
+{{tp|p=33872675|t=2021. Discovery of chebulagic acid and punicalagin as novel allosteric inhibitors of SARS-CoV-2 3CL(pro).|pdf=|usr=027}}
+{{tp|p=34010661|t=2021. Virucidal and antiviral activity of astodrimer sodium against SARS-CoV-2 in vitro.|pdf=|usr=027}}
+{{tp|p=33309540|t=2021. Antiviral activity against Middle East Respiratory Syndrome coronavirus by Montelukast, an anti-asthma drug.|pdf=|usr=027}}
+{{tp|p=33826068|t=2021. RNAi Technology and Investigation on Possible Vaccines to Combat SARS-CoV-2 Infection.|pdf=|usr=027}}
+{{tp|p=33959781|t=2021. Process development and scale-up optimization of the SARS-CoV-2 receptor binding domain-based vaccine candidate, RBD219-N1C1.|pdf=|usr=027}}
+{{tp|p=33950278|t=2021. Potential role of IFN-alpha in COVID-19 patients and its underlying treatment options.|pdf=|usr=027}}
+{{tp|p=33876282|t=2021. Potential "biopeptidal" therapeutics for severe respiratory syndrome coronaviruses: a review of antiviral peptides, viral mechanisms, and prospective needs.|pdf=|usr=027}}
+{{tp|p=33883784|t=2021. Antiviral peptides from aquatic organisms: Functionality and potential inhibitory effect on SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=33358224|t=2021. Posibilidad de sesgo en estudio retrospectivo de ivermectina para COVID-19.|pdf=|usr=027}}
+{{tp|p=33994631|t=2021. Smoker, Former Smoker and COVID-19: Nicotine Does Not Protect Against SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=33836322|t=2021. Nutritional determinants and COVID-19 outcomes of older patients with COVID-19: A systematic review.|pdf=|usr=027}}
+{{tp|p=32972773|t=2021. Status of Remdesivir: Not Yet Beyond Question!|pdf=|usr=027}}
+{{tp|p=32948379|t=2021. Response to: Status of Remdesivir: Not Yet Beyond Question!|pdf=|usr=027}}
+{{tp|p=34025857|t=2021. Virtual screening for small molecular non-covalent binders of the SARS-CoV-2 main protease.|pdf=|usr=027}}
+{{tp|p=34025855|t=2021. Could amantadine interfere with COVID-19 vaccines based on the LNP-mRNA platform?|pdf=|usr=027}}
+{{tp|p=34025827|t=2021. Improved COVID-19 ICU admission and mortality outcomes following treatment with statins: a systematic review and meta-analysis.|pdf=|usr=027}}
+{{tp|p=33747262|t=2021. Game of "crowning" season 8: RAS and reproductive hormones in COVID-19 - can we end this viral series?|pdf=|usr=027}}
+{{tp|p=33950349|t=2021. Investigation of potential inhibitor properties of ethanolic propolis extracts against ACE-II receptors for COVID-19 treatment by molecular docking study.|pdf=|usr=027}}
+{{tp|p=34047940|t=2021. COVID-19 and pulmonary fibrosis: therapeutics in clinical trials, repurposing, and potential development.|pdf=|usr=027}}
+{{tp|p=33893998|t=2021. Phytochemistry and pharmacological activity of the genus artemisia.|pdf=|usr=027}}
+{{tp|p=34059544|t=2021. Secondary immune thrombocytopenia supposedly attributable to COVID-19 vaccination.|pdf=|usr=027}}
+{{tp|p=33990984|t=2021. Real-life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVID-19 pneumonia.|pdf=|usr=027}}
+{{tp|p=33982806|t=2021. Interferon-alpha-2b aerosol inhalation is associated with improved clinical outcomes in patients with coronavirus disease-2019.|pdf=|usr=027}}
+{{tp|p=33855727|t=2021. Economic evaluation of remdesivir for the treatment of severe COVID-19 patients in China under different scenarios.|pdf=|usr=027}}
+{{tp|p=33847002|t=2021. SARS-CoV-2 mutations: A strain on efficacy of neutralizing monoclonal antibodies?|pdf=|usr=027}}
+{{tp|p=33982284|t=2021. Antibody responses to single-dose SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory disease.|pdf=|usr=027}}
+{{tp|p=33904168|t=2021. Chilblain lesions after COVID-19 mRNA vaccine.|pdf=|usr=027}}
+{{tp|p=33904157|t=2021. Pityriasis rosea-like eruption after Pfizer-BioNTech COVID-19 vaccination.|pdf=|usr=027}}
+{{tp|p=33893637|t=2021. Pernio after COVID-19 vaccination.|pdf=|usr=027}}
+{{tp|p=34097311|t=2021. Management of a patient with a rare congenital limb malformation syndrome after SARS-CoV-2 vaccine-induced thrombosis and thrombocytopenia (VITT).|pdf=|usr=027}}
+{{tp|p=34085278|t=2021. Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia.|pdf=|usr=027}}
+{{tp|p=34075578|t=2021. Exacerbation of immune thrombocytopenia following COVID-19 vaccination.|pdf=|usr=027}}
+{{tp|p=34036570|t=2021. AZD1222 vaccine-related coagulopathy and thrombocytopenia without thrombosis in a young female.|pdf=|usr=027}}
+{{tp|p=33934330|t=2021. Immune thrombocytopenic purpura after SARS-CoV-2 vaccine.|pdf=|usr=027}}
+{{tp|p=34044900|t=2021. Plant stanol esters might optimise the immune response and improve the SARS-CoV-2/COVID-19 vaccine efficacy in overweight and obese subjects.|pdf=|usr=027}}
+{{tp|p=33977890|t=2021. Vitamin D status of children with Paediatric Inflammatory Multisystem Syndrome Temporally associated with Severe acute respiratory syndrome coronavirus 2 (PIMS-TS).|pdf=|usr=027}}
+{{tp|p=34096487|t=2021. Beyond probiotic legend: ESSAP gut microbiota health score to delineate SARS-COV-2 infection severity.|pdf=|usr=027}}
+{{tp|p=34061355|t=2021. Therapeutic potential of megadose vitamin C to reverse organ dysfunction in sepsis and COVID-19.|pdf=|usr=027}}
+{{tp|p=33825201|t=2021. Drug synergy of combinatory treatment with remdesivir and the repurposed drugs fluoxetine and itraconazole effectively impairs SARS-CoV-2 infection in vitro.|pdf=|usr=027}}
+{{tp|p=34058750|t=2021. Quercetin for COVID-19 and DENGUE co-infection: a potential therapeutic strategy of targeting critical host signal pathways triggered by SARS-CoV-2 and DENV.|pdf=|usr=027}}
+{{tp|p=34036326|t=2021. A multi-modal data harmonisation approach for discovery of COVID-19 drug targets.|pdf=|usr=027}}
+{{tp|p=33993214|t=2021. Structure-based drug repurposing against COVID-19 and emerging infectious diseases: methods, resources and discoveries.|pdf=|usr=027}}
+{{tp|p=34081143|t=2021. A transferable deep learning approach to fast screen potential antiviral drugs against SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=34089044|t=2021. Infectious disease mRNA vaccines and a review on epitope prediction for vaccine design.|pdf=|usr=027}}
+{{tp|p=33831281|t=2021. Annual influenza vaccination effect on the susceptibility to COVID-19 infection.|pdf=|usr=027}}
+{{tp|p=33949124|t=2021. Atomistic De-novo Inhibitor Generation-Guided Drug Repurposing for SARS-CoV-2 Spike Protein with Free-Energy Validation by Well-Tempered Metadynamics.|pdf=|usr=027}}
+{{tp|p=33894099|t=2021. Computational design and modeling of nanobodies toward SARS-CoV-2 receptor binding domain.|pdf=|usr=027}}
+{{tp|p=34008627|t=2021. Discovery of SARS-CoV-2 main protease inhibitors using a synthesis-directed de novo design model.|pdf=|usr=027}}
+{{tp|p=34002456|t=2021. Metal Complexes as Antiviral Agents for SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=33348462|t=2021. Action of Dipeptidyl Peptidase-4 Inhibitors on SARS-CoV-2 Main Protease.|pdf=|usr=027}}
+{{tp|p=34092298|t=2021. Chemical profiling of Huashi Baidu prescription, an effective anti-COVID-19 TCM formula, by UPLC-Q-TOF/MS.|pdf=|usr=027}}
+{{tp|p=33825239|t=2021. Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine.|pdf=|usr=027}}
+{{tp|p=33969530|t=2021. COVID-19 vaccines do not trigger psoriasis flares in patients with psoriasis treated with apremilast.|pdf=|usr=027}}
+{{tp|p=34081806|t=2021. COVID-19 vaccine-induced Stevens-Johnson syndrome.|pdf=|usr=027}}
+{{tp|p=34080223|t=2021. Radiation recall dermatitis triggered by inactivated COVID-19 vaccine.|pdf=|usr=027}}
+{{tp|p=33835617|t=2021. Ribonucleic acid COVID-19 vaccine-associated cutaneous adverse drug events: a case series of two patients.|pdf=|usr=027}}
+{{tp|p=33896010|t=2021. Ivermectin in dermatology: why it 'mite' be useless against COVID-19.|pdf=|usr=027}}
+{{tp|p=34061349|t=2021. Human CD4(+) T cells specific for dominant epitopes of SARS-CoV-2 Spike and Nucleocapsid proteins with therapeutic potential.|pdf=|usr=027}}
+{{tp|p=33836994|t=2021. What do we know about China's covid-19 vaccines?|pdf=|usr=027}}
+{{tp|p=33827801|t=2021. Incarcerated people should be prioritised for covid-19 vaccination.|pdf=|usr=027}}
+{{tp|p=33931384|t=2021. Covid-19: Most people admitted to hospital after vaccination were infected before immunity could develop, research shows.|pdf=|usr=027}}
+{{tp|p=33883164|t=2021. Covid-19: Unusual blood clots are "very rare side effect" of Janssen vaccine, says EMA.|pdf=|usr=027}}
+{{tp|p=33863757|t=2021. Covid-19: Risk of cerebral blood clots from disease is 10 times that from vaccination, study finds.|pdf=|usr=027}}
+{{tp|p=33858846|t=2021. Covid-19: Single dose of Pfizer or AstraZeneca vaccine produces strong antibody response in over 80s.|pdf=|usr=027}}
+{{tp|p=33853865|t=2021. Thrombosis after covid-19 vaccination.|pdf=|usr=027}}
+{{tp|p=33849903|t=2021. Covid-19: Moderna and Novavax vaccines to be tested in mixing vaccines trial.|pdf=|usr=027}}
+{{tp|p=33849900|t=2021. Covid-19: EU investigates four reports of blood clots after Janssen vaccine.|pdf=|usr=027}}
+{{tp|p=33849893|t=2021. Covid-19: Chinese vaccines may need changes to improve efficacy, admits official.|pdf=|usr=027}}
+{{tp|p=33846162|t=2021. Covid-19: Rare immune response may cause clots after AstraZeneca vaccine, say researchers.|pdf=|usr=027}}
+{{tp|p=33846122|t=2021. Reporting of AstraZeneca studies may have caused vaccine reservations.|pdf=|usr=027}}
+{{tp|p=33846115|t=2021. Covid-19: Budesonide shortens recovery time in patients not admitted to hospital, study finds.|pdf=|usr=027}}
+{{tp|p=33888547|t=2021. Misleading clinical evidence and systematic reviews on ivermectin for COVID-19.|pdf=|usr=027}}
+{{tp|p=33871897|t=2021. Pharmacovigilance-based drug repurposing: The search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections.|pdf=|usr=027}}
+{{tp|p=33993472|t=2021. Ivermectin in the management of a scabies outbreak in a long-term care facility.|pdf=|usr=027}}
+{{tp|p=34045261|t=2021. Regional lymphadenopathy following COVID-19 vaccination: considerations for primary care management.|pdf=|usr=027}}
+{{tp|p=33355153|t=2021. Vitamin D and COVID-19 in older age: evidence versus expectations.|pdf=|usr=027}}
+{{tp|p=33314018|t=2021. Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies.|pdf=|usr=027}}
+{{tp|p=33336562|t=2021. Determinants of physical activity among adults in the United Kingdom during the COVID-19 pandemic: The DUK-COVID study.|pdf=|usr=027}}
+{{tp|p=33372846|t=2021. Considerations for COVID-19 Vaccination in Lactation.|pdf=|usr=027}}
+{{tp|p=33372839|t=2021. President's Corner: Introduction to ABM's Statement on Considerations for COVID-19 Vaccination in Lactation.|pdf=|usr=027}}
+{{tp|p=33990347|t=2021. Blood Cancers Diminish Response to COVID-19 Vaccine.|pdf=|usr=027}}
+{{tp|p=33318035|t=2021. How Cancer Vaccine Tech Shaped COVID Response.|pdf=|usr=027}}
+{{tp|p=33331360|t=2021. A novel STING agonist for cancer immunotherapy and a SARS-CoV-2 vaccine adjuvant.|pdf=|usr=027}}
+{{tp|p=34009959|t=2021. Safety of mRNA-Based Vaccines for SARS CoV-2.|pdf=|usr=027}}
+{{tp|p=33325938|t=2021. Biocatalytic routes to anti-viral agents and their synthetic intermediates.|pdf=|usr=027}}
+{{tp|p=33350032|t=2021. Ferritin as a Platform for Creating Antiviral Mosaic Nanocages: Prospects for Treating COVID-19.|pdf=|usr=027}}
+{{tp|p=34061468|t=2021. Poly-l-lysine Glycoconjugates Inhibit DC-SIGN-mediated Attachment of Pandemic Viruses.|pdf=|usr=027}}
+{{tp|p=33970560|t=2021. An Androsterone-H2 @C60 hybrid: Synthesis, Properties and Molecular Docking Simulations with SARS-Cov-2.|pdf=|usr=027}}
+{{tp|p=33875170|t=2021. Comprehensive profiling and characterization of the absorbed components and metabolites in mice serum and tissues following oral administration of Qing-Fei-Pai-Du decoction by UHPLC-Q-Exactive-Orbitrap HRMS.|pdf=|usr=027}}
+{{tp|p=33838087|t=2021. Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series.|pdf=|usr=027}}
+{{tp|p=33914926|t=2021. A flare of pre-existing erythema multiforme following BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine.|pdf=|usr=027}}
+{{tp|p=33535790|t=2021. Beneficial Effect of Statins in COVID-19-Related Outcomes-Brief Report: A National Population-Based Cohort Study.|pdf=|usr=027}}
+{{tp|p=34007828|t=2021. Skin testing with Pfizer SARS-CoV-2 vaccine and PEG 2000.|pdf=|usr=027}}
+{{tp|p=33793439|t=2021. Topical Ocular Povidone-Iodine as an Adjunctive Preventative Practice in the Era of COVID-19.|pdf=|usr=027}}
+{{tp|p=33360711|t=2021. Finding Horcrux of psychiatric symptoms in COVID-19: Deficiencies of amino acids and vitamin D.|pdf=|usr=027}}
+{{tp|p=34059849|t=2021. Immunising older Australians: Pre-COVID-19 vaccine perspectives from general practice training.|pdf=|usr=027}}
+{{tp|p=33911335|t=2021. ChAdOx1-S vaccine for prevention of COVID-19.|pdf=|usr=027}}
+{{tp|p=33911334|t=2021. BNT162b2 vaccine for prevention of COVID-19.|pdf=|usr=027}}
+{{tp|p=33326855|t=2021. Combined Anakinra and Ruxolitinib treatment to rescue extremely ill COVID-19 patients: A pilot study.|pdf=|usr=027}}
+{{tp|p=34026905|t=2021. Can trace element supplementations (Cu, Se, and Zn) enhance human immunity against COVID-19 and its new variants?|pdf=|usr=027}}
+{{tp|p=33773923|t=2021. Maternal vaccines-safety in pregnancy.|pdf=|usr=027}}
+{{tp|p=33965331|t=2021. Uptake of vaccination in pregnancy.|pdf=|usr=027}}
+{{tp|p=34056140|t=2021. Accommodating receptor flexibility and free energy calculation to reduce false positive binders in the discovery of natural products blockers of SARS-COV-2 spike RBD-ACE2 interface.|pdf=|usr=027}}
+{{tp|p=33364445|t=2021. Analysis of non-structural proteins, NSPs of SARS-CoV-2 as targets for computational drug designing.|pdf=|usr=027}}
+{{tp|p=33309272|t=2021. Identification of antiviral antihistamines for COVID-19 repurposing.|pdf=|usr=027}}
+{{tp|p=33872570|t=2021. Discovery of a AHR pelargonidin agonist that counter-regulates Ace2 expression and attenuates ACE2-SARS-CoV-2 interaction.|pdf=|usr=027}}
+{{tp|p=34082041|t=2021. Essential sufficiency of zinc, omega-3 polyunsaturated fatty acids, vitamin D and magnesium for prevention and treatment of COVID-19, diabetes, cardiovascular diseases, lung diseases and cancer.|pdf=|usr=027}}
+{{tp|p=33951913|t=2021. Self-Assembling Nanoparticle Vaccines Displaying the Receptor Binding Domain of SARS-CoV-2 Elicit Robust Protective Immune Responses in Rhesus Monkeys.|pdf=|usr=027}}
+{{tp|p=33356169|t=2021. Rationally Designed ACE2-Derived Peptides Inhibit SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=33888980|t=2021. Prediction of Anti-COVID 19 Therapeutic Power of Medicinal Moroccan Plants Using Molecular Docking.|pdf=|usr=027}}
+{{tp|p=34062724|t=2021. Molecular Docking and Dynamics Simulation Study of Hyrtios erectus Isolated Scalarane Sesterterpenes as Potential SARS-CoV-2 Dual Target Inhibitors.|pdf=|usr=027}}
+{{tp|p=33910079|t=2021. PEGylated nanoparticle albumin-bound steroidal ginsenoside derivatives ameliorate SARS-CoV-2-mediated hyper-inflammatory responses.|pdf=|usr=027}}
+{{tp|p=33360781|t=2021. 4-Aminoquinoline compounds from the Spanish flu to COVID-19.|pdf=|usr=027}}
+{{tp|p=33894625|t=2021. Resveratrol-zinc nanoparticles or pterostilbene-zinc: Potential COVID-19 mono and adjuvant therapy.|pdf=|usr=027}}
+{{tp|p=33866132|t=2021. Babaodan controls excessive immune responses and may represent a cytokine-targeted agent suitable for COVID-19 treatment.|pdf=|usr=027}}
+{{tp|p=33848774|t=2021. Will curcumin nanosystems be the next promising antiviral alternatives in COVID-19 treatment trials?|pdf=|usr=027}}
+{{tp|p=33360048|t=2021. Could natural products modulate early inflammatory responses, preventing acute respiratory distress syndrome in COVID-19-confirmed patients?|pdf=|usr=027}}
+{{tp|p=34052565|t=2021. Main protease inhibitors and drug surface hotspots for the treatment of COVID-19: A drug repurposing and molecular docking approach.|pdf=|usr=027}}
+{{tp|p=34051617|t=2021. Theobroma cacao L. compounds: Theoretical study and molecular modeling as inhibitors of main SARS-CoV-2 protease.|pdf=|usr=027}}
+{{tp|p=34095308|t=2021. Virtual Screening of Phytochemicals by Targeting HR1 Domain of SARS-CoV-2 S Protein: Molecular Docking, Molecular Dynamics Simulations, and DFT Studies.|pdf=|usr=027}}
+{{tp|p=34066608|t=2021. Methodical Design of Viral Vaccines Based on Avant-Garde Nanocarriers: A Multi-Domain Narrative Review.|pdf=|usr=027}}
+{{tp|p=34063015|t=2021. Association of Calcitriol Supplementation with Reduced COVID-19 Mortality in Patients with Chronic Kidney Disease: A Population-Based Study.|pdf=|usr=027}}
+{{tp|p=34067609|t=2021. Predicting COVID-19-Comorbidity Pathway Crosstalk-Based Targets and Drugs: Towards Personalized COVID-19 Management.|pdf=|usr=027}}
+{{tp|p=33918402|t=2021. Rutin Is a Low Micromolar Inhibitor of SARS-CoV-2 Main Protease 3CLpro: Implications for Drug Design of Quercetin Analogs.|pdf=|usr=027}}
+{{tp|p=33919584|t=2021. Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro.|pdf=|usr=027}}
+{{tp|p=33372165|t=2021. COVID-19 Vaccine: Critical Questions with Complicated Answers.|pdf=|usr=027}}
+{{tp|p=34071582|t=2021. Binding of SARS-CoV Covalent Non-Covalent Inhibitors to the SARS-CoV-2 Papain-Like Protease and Ovarian Tumor Domain Deubiquitinases.|pdf=|usr=027}}
+{{tp|p=34071060|t=2021. Attacking COVID-19 Progression Using Multi-Drug Therapy for Synergetic Target Engagement.|pdf=|usr=027}}
+{{tp|p=34069869|t=2021. Povidone-Iodine Attenuates Viral Replication in Ocular Cells: Implications for Ocular Transmission of RNA Viruses.|pdf=|usr=027}}
+{{tp|p=33946644|t=2021. Computational Identification of Potential Anti-Inflammatory Natural Compounds Targeting the p38 Mitogen-Activated Protein Kinase (MAPK): Implications for COVID-19-Induced Cytokine Storm.|pdf=|usr=027}}
+{{tp|p=33921886|t=2021. SARS-CoV-2 M(pro): A Potential Target for Peptidomimetics and Small-Molecule Inhibitors.|pdf=|usr=027}}
+{{tp|p=33919870|t=2021. Molecular Simulation-Based Investigation of Highly Potent Natural Products to Abrogate Formation of the nsp10-nsp16 Complex of SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=33862474|t=2021. Novel inhibitors of the main protease enzyme of SARS-CoV-2 identified via molecular dynamics simulation-guided in vitro assay.|pdf=|usr=027}}
+{{tp|p=33975232|t=2021. Synthesis, molecular docking, and in silico ADMET studies of 4-benzyl-1-(2,4,6-trimethyl-benzyl)-piperidine: Potential Inhibitor of SARS-CoV2.|pdf=|usr=027}}
+{{tp|p=33915460|t=2021. Ebsulfur and Ebselen as highly potent scaffolds for the development of potential SARS-CoV-2 antivirals.|pdf=|usr=027}}
+{{tp|p=33831697|t=2021. Identification of SARS-CoV-2 viral entry inhibitors using machine learning and cell-based pseudotyped particle assay.|pdf=|usr=027}}
+{{tp|p=33957246|t=2021. Identification of non-covalent 3C-like protease inhibitors against severe acute respiratory syndrome coronavirus-2 via virtual screening of a Korean compound library.|pdf=|usr=027}}
+{{tp|p=33984473|t=2021. Promising anti-SARS-CoV-2 drugs by effective dual targeting against the viral and host proteases.|pdf=|usr=027}}
+{{tp|p=33940136|t=2021. Exploring the potential of novel phenolic compounds as potential therapeutic candidates against SARS-CoV-2, using quantum chemistry, molecular docking and dynamic studies.|pdf=|usr=027}}
+{{tp|p=33887440|t=2021. Development of ciclesonide analogues that block SARS-CoV-2 RNA replication.|pdf=|usr=027}}
+{{tp|p=34089978|t=2021. A computational evaluation of targeted oxidation strategy (TOS) for potential inhibition of SARS-CoV-2 by disulfiram and analogues.|pdf=|usr=027}}
+{{tp|p=33962341|t=2021. Proposal of novel natural inhibitors of severe acute respiratory syndrome coronavirus 2 main protease: Molecular docking and ab initio fragment molecular orbital calculations.|pdf=|usr=027}}
+{{tp|p=33935291|t=2021. Gaseous Nitric Oxide and Dinitrosyl Iron Complexes with Thiol-Containing Ligands as Potential Medicines that Can Relieve COVID-19.|pdf=|usr=027}}
+{{tp|p=33342929|t=2021. Efficacy of early hydroxychloroquine treatment in preventing COVID-19 pneumonia aggravation, the experience from Shanghai, China.|pdf=|usr=027}}
+{{tp|p=33994673|t=2021. SARS-CoV-PL(pro)-Inhibitoren als mogliche Breitspektrum-Virostatika.|pdf=|usr=027}}
+{{tp|p=33666158|t=2021. Methylprednisolone as rescue therapy after tocilizumab failure in patients with severe COVID-19 pneumonia.|pdf=|usr=027}}
+{{tp|p=34050731|t=2021. Neutralization heterogeneity of United Kingdom and South-African SARS-CoV-2 variants in BNT162b2-vaccinated or convalescent COVID-19 healthcare workers.|pdf=|usr=027}}
+{{tp|p=34036334|t=2021. It is time to determine Tocilizumab place in COVID-19.|pdf=|usr=027}}
+{{tp|p=34015087|t=2021. Circulating SARS-CoV-2 Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients.|pdf=|usr=027}}
+{{tp|p=33999992|t=2021. Cost-effectiveness of tocilizumab in severe COVID-19: to see or not to see.|pdf=|usr=027}}
+{{tp|p=33999127|t=2021. The effectiveness of the TWO-DOSE BNT162b2 vaccine: analysis of real-world data.|pdf=|usr=027}}
+{{tp|p=33993265|t=2021. Reduced BNT162b2 mRNA vaccine response in SARS-CoV-2-naive nursing home residents.|pdf=|usr=027}}
+{{tp|p=33993228|t=2021. BNT162b2 mRNA vaccination did not prevent an outbreak of SARS COV-2 variant 501Y.V2 in an elderly nursing home but reduced transmission and disease severity.|pdf=|usr=027}}
+{{tp|p=33989390|t=2021. Immediate reactions following the first dose of the SARS-CoV2 mRNA vaccines do not preclude second dose administration.|pdf=|usr=027}}
+{{tp|p=34091665|t=2021. Adverse Outcomes Associated with SARS-CoV-2 variant B.1.351 Infection in Vaccinated Residents of a Long Term Care Home, Ontario, Canada.|pdf=|usr=027}}
+{{tp|p=34091664|t=2021. Early Monoclonal Antibody Administration Can Reduce Both Hospitalizations and Mortality in High-Risk Outpatients with COVID-19.|pdf=|usr=027}}
+{{tp|p=34086881|t=2021. Incidence and Characteristics of Delayed Injection Site Reaction to the mRNA-1273 SARS-CoV2 Vaccine (Moderna) in a Cohort of Hospital Employees.|pdf=|usr=027}}
+{{tp|p=33735520|t=2021. Pentoxifylline or theophylline use in hospitalized COVID-19 patients requiring oxygen support.|pdf=|usr=027}}
+{{tp|p=34057814|t=2021. Potential benefit of vitamin d supplementation in people with respiratory illnesses, during the Covid-19 pandemic.|pdf=|usr=027}}
+{{tp|p=33982445|t=2021. A phase I study of high dose camostat mesylate in healthy adults provides a rationale to repurpose the TMPRSS2 inhibitor for the treatment of COVID-19.|pdf=|usr=027}}
+{{tp|p=34041932|t=2021. COVID-19 vaccine trials: The potential for "hybrid" analyses.|pdf=|usr=027}}
+{{tp|p=34029238|t=2021. Keratoplasty Rejection After the BNT162b2 messenger RNA Vaccine.|pdf=|usr=027}}
+{{tp|p=34091550|t=2021. Vaccine allergy: evidence to consider for COVID-19 vaccines.|pdf=|usr=027}}
+{{tp|p=34090785|t=2021. Antiphospholipid antibodies and risk of post-COVID-19 vaccination thrombophilia: The straw that breaks the camel's back?|pdf=|usr=027}}
+{{tp|p=33940227|t=2021. Hepatobiliary Adverse Drug Reactions Associated With Remdesivir: The WHO International Pharmacovigilance Study.|pdf=|usr=027}}
+{{tp|p=32761148|t=2021. Hydroxychloroquine Failure: The End Does Not Justify the Means.|pdf=|usr=027}}
+{{tp|p=34079995|t=2021. The potential declining efficacy of the ChAdOx1 nCoV-19 vaccine(AZD1222) on inoculators with NSAIDs intake.|pdf=|usr=027}}
+{{tp|p=34045299|t=2021. mRNA COVID-19 Vaccine for People with Kidney Failure.|pdf=|usr=027}}
+{{tp|p=34031182|t=2021. Antibody Response to mRNA-1273 SARS-CoV-2 Vaccine in Hemodialysis Patients with and without Prior COVID-19.|pdf=|usr=027}}
+{{tp|p=33824157|t=2021. Humoral Response to the Pfizer BNT162b2 Vaccine in Patients Undergoing Maintenance Hemodialysis.|pdf=|usr=027}}
+{{tp|p=33883486|t=2021. False-Positive Axillary Lymph Nodes on FDG PET/CT Resulting From COVID-19 Immunization.|pdf=|usr=027}}
+{{tp|p=34024569|t=2021. Can an anti-inflammatory diet be effective in preventing or treating viral respiratory diseases? A systematic narrative review.|pdf=|usr=027}}
+{{tp|p=33340409|t=2021. Remdesivir and Acute Renal Failure: A Potential Safety Signal From Disproportionality Analysis of the WHO Safety Database.|pdf=|usr=027}}
+{{tp|p=34029377|t=2021. Vitamin D supplementation for the treatment of COVID-19: a living systematic review.|pdf=|usr=027}}
+{{tp|p=34013969|t=2021. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.|pdf=|usr=027}}
+{{tp|p=34077341|t=2021. Identification of Generalized Peptide Regions for Designing Vaccine Effective for All Significant Mutated Strains of SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=34077664|t=2021. Vaccines for COVID-19: An Overview.|pdf=|usr=027}}
+{{tp|p=33951604|t=2021. Exploring the effectiveness of the TSR-based protein 3-D structural comparison method for protein clustering, and structural motif identification and discovery of protein kinases, hydrolases, and SARS-CoV-2's protein via the application of amino acid grouping.|pdf=|usr=027}}
+{{tp|p=34049307|t=2021. Using Nonheparin Anticoagulant to Treat a Near-Fatal Case With Multiple Venous Thrombotic Lesions During ChAdOx1 nCoV-19 Vaccination-Related Vaccine-Induced Immune Thrombotic Thrombocytopenia.|pdf=|usr=027}}
+{{tp|p=34034298|t=2021. Increased Glucocorticoid Receptor Alpha Expression and Signaling in Critically Ill Coronavirus Disease 2019 Patients.|pdf=|usr=027}}
+{{tp|p=34049310|t=2021. Glucocorticoid-Glucocorticoid Receptor Response to Severe Acute Respiratory Syndrome Coronavirus 2.|pdf=|usr=027}}
+{{tp|p=33870924|t=2021. Convalescent Plasma and Coronavirus Disease 2019: Time for Reassessment.|pdf=|usr=027}}
+{{tp|p=33870923|t=2021. Severe Acute Respiratory Syndrome Coronavirus 2 Convalescent Plasma Versus Standard Plasma in Coronavirus Disease 2019 Infected Hospitalized Patients in New York: A Double-Blind Randomized Trial.|pdf=|usr=027}}
+{{tp|p=34024199|t=2021. Lopinavir/Ritonavir: A Review of Analytical Methodologies for the Drug Substances, Pharmaceutical Formulations and Biological Matrices.|pdf=|usr=027}}
+{{tp|p=33949929|t=2021. Machine Learning in Discovery of New Antivirals and Optimization of Viral Infections Therapy.|pdf=|usr=027}}
+{{tp|p=34042026|t=2021. Interfering with Host Proteases in SARS-CoV-2 Entry as a Promising Therapeutic Strategy.|pdf=|usr=027}}
+{{tp|p=34042025|t=2021. COVID-19: The significance of platelets, mitochondria, vitamin D, serotonin and the gut microbiota.|pdf=|usr=027}}
+{{tp|p=33992054|t=2021. Structural Basis for the Understanding of Entry Inhibitors Against SARS Viruses.|pdf=|usr=027}}
+{{tp|p=33881969|t=2021. SARS-CoV-2 Entry inhibitors targeting virus-ACE2 or virus-TMPRSS2 interactions.|pdf=|usr=027}}
+{{tp|p=33982651|t=2021. To vaccinate or not to vaccinate; that is the question! (New insights on COVID-19 Vaccination).|pdf=|usr=027}}
+{{tp|p=34077352|t=2021. Evaluation of Dual Inhibitory Effect of Anagliptin, Ramipril, and Lisinopril on Angiotensin-Converting Enzyme and DPP-4 Activities.|pdf=|usr=027}}
+{{tp|p=33829974|t=2021. C-Phycocyanin-derived Phycocyanobilin as a Potential Nutraceutical Approach for Major Neurodegenerative Disorders and COVID-19-induced Damage to the Nervous System.|pdf=|usr=027}}
+{{tp|p=34074880|t=2021. Coronavirus disease 2019 vaccination in transplant recipients.|pdf=|usr=027}}
+{{tp|p=33990506|t=2021. Coronavirus disease 2019, vitamin D and kidney function.|pdf=|usr=027}}
+{{tp|p=34097590|t=2021. Identification of novel drug candidates for the inhibition of catalytic cleavage activity of coronavirus 3CL-like protease enzyme.|pdf=|usr=027}}
+{{tp|p=33882805|t=2021. Potential Candidates against COVID-19 Targeting RNA-Dependent RNA Polymerase: A Comprehensive Review.|pdf=|usr=027}}
+{{tp|p=33845735|t=2021. Olive oil consumption can prevent non-communicable diseases and COVID-19 : Review.|pdf=|usr=027}}
+{{tp|p=34009111|t=2021. Viral Diseases and Natural Products: Prospects in COVID-19 Treatment (Part II).|pdf=|usr=027}}
+{{tp|p=33308117|t=2021. Chloroquine Analogs: An Overview of Natural and Synthetic Quinolines as Broad Spectrum Antiviral Agents.|pdf=|usr=027}}
+{{tp|p=33302855|t=2021. Anti-malarial Drugs are Not Created Equal for SARS-CoV-2 Treatment: A Computational Analysis Evidence.|pdf=|usr=027}}
+{{tp|p=34028347|t=2021. Azithromycin Use in COVID-19 Patients: Implications on the Antimicrobial Resistance.|pdf=|usr=027}}
+{{tp|p=33970846|t=2021. The Effect of Recombinant Human Interferon Alpha Nasal Drops to Prevent COVID-19 Pneumonia for Medical Staff in an Epidemic Area.|pdf=|usr=027}}
+{{tp|p=33851937|t=2021. Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines and Cutaneous Adverse Reactions: A Review.|pdf=|usr=027}}
+{{tp|p=33314794|t=2021. Computational drug repurposing study of the RNA binding domain of SARS-CoV-2 nucleocapsid protein with antiviral agents.|pdf=|usr=027}}
+{{tp|p=34002690|t=2021. Revisiting vitamin D status and supplementation for in-patients with intellectual and developmental disability in the North of England, UK.|pdf=|usr=027}}
+{{tp|p=33988688|t=2021. Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2.|pdf=|usr=027}}
+{{tp|p=33861303|t=2021. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia.|pdf=|usr=027}}
+{{tp|p=33945618|t=2021. COVID-19 vaccines induce severe hemolysis in paroxysmal nocturnal hemoglobinuria.|pdf=|usr=027}}
+{{tp|p=33945605|t=2021. A flow cytometric assay to detect platelet-activating antibodies in VITT after ChAdOx1 nCov-19 vaccination.|pdf=|usr=027}}
+{{tp|p=33861315|t=2021. Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose.|pdf=|usr=027}}
+{{tp|p=33857940|t=2021. Endotoxin Adsorbent Therapy in Severe COVID-19 Pneumonia.|pdf=|usr=027}}
+{{tp|p=34059190|t=2021. Position paper on the use of COVID-19 convalescent plasma: an update.|pdf=|usr=027}}
+{{tp|p=33832440|t=2021. Common low complexity regions for SARS-CoV-2 and human proteomes as potential multidirectional risk factor in vaccine development.|pdf=|usr=027}}
+{{tp|p=33962573|t=2021. Impact of high dose of baricitinib in severe COVID-19 pneumonia: a prospective cohort study in Bangladesh.|pdf=|usr=027}}
+{{tp|p=33947344|t=2021. Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients.|pdf=|usr=027}}
+{{tp|p=34058989|t=2021. Effects of early corticosteroid use in patients with severe coronavirus disease 2019.|pdf=|usr=027}}
+{{tp|p=34044777|t=2021. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis.|pdf=|usr=027}}
+{{tp|p=34011281|t=2021. Association between fatality rate of COVID-19 and selenium deficiency in China.|pdf=|usr=027}}
+{{tp|p=34006228|t=2021. Lack of association between vitamin D insufficiency and clinical outcomes of patients with COVID-19 infection.|pdf=|usr=027}}
+{{tp|p=33863281|t=2021. Methylene blue photochemical treatment as a reliable SARS-CoV-2 plasma virus inactivation method for blood safety and convalescent plasma therapy for COVID-19.|pdf=|usr=027}}
+{{tp|p=33838657|t=2021. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial.|pdf=|usr=027}}
+{{tp|p=33952445|t=2021. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study.|pdf=|usr=027}}
+{{tp|p=34035040|t=2021. Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study.|pdf=|usr=027}}
+{{tp|p=33985964|t=2021. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study.|pdf=|usr=027}}
+{{tp|p=33980718|t=2021. Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study.|pdf=|usr=027}}
+{{tp|p=33975825|t=2021. Use of repurposed and adjuvant drugs in hospital patients with covid-19: multinational network cohort study.|pdf=|usr=027}}
+{{tp|p=33903131|t=2021. Prophylaxis against covid-19: living systematic review and network meta-analysis.|pdf=|usr=027}}
+{{tp|p=33762295|t=2021. Lateral ST-elevation myocardial infarction after donation of COVID-19 convalescent plasma in a naive donor.|pdf=|usr=027}}
+{{tp|p=33888484|t=2021. Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1.|pdf=|usr=027}}
+{{tp|p=34049903|t=2021. Association between vitamin D supplementation or serum vitamin D level and susceptibility to SARS-CoV-2 infection or COVID-19 including clinical course, morbidity and mortality outcomes? A systematic review.|pdf=|usr=027}}
+{{tp|p=33574155|t=2021. Safety and feasibility of using acellular sterile filtered amniotic fluid as a treatment for patients with COVID-19: protocol for a randomised, double-blinded, placebo-controlled clinical trial.|pdf=|usr=027}}
+{{tp|p=33853806|t=2021. Multicentre randomised double-blinded placebo-controlled trial of favipiravir in adults with mild COVID-19.|pdf=|usr=027}}
+{{tp|p=33358041|t=2021. Does opioid substitution treatment have a protective effect on the clinical manifestations of COVID-19? Comment on Br J Anaesth 2020; 125: e382-3.|pdf=|usr=027}}
+{{tp|p=33769875|t=2021. COVID-19 vaccination: intramuscular injection technique.|pdf=|usr=027}}
+{{tp|p=33910885|t=2021. Characteristics of endothelial corneal transplant rejection following immunisation with SARS-CoV-2 messenger RNA vaccine.|pdf=|usr=027}}
+{{tp|p=33947605|t=2021. COVID-19 vaccination and low cervical lymphadenopathy in the two week neck lump clinic - a follow up audit.|pdf=|usr=027}}
+{{tp|p=34075664|t=2021. Exacerbation of subacute cutaneous lupus erythematosus following vaccination with BNT162b2 mRNA vaccine.|pdf=|usr=027}}
+{{tp|p=34033207|t=2021. Tumor necrosis factor inhibitors are associated with a decreased risk of COVID-19-associated hospitalization in patients with psoriasis-A population-based cohort study.|pdf=|usr=027}}
+{{tp|p=34031953|t=2021. Local reactions to the second dose of the BNT162 COVID-19 vaccine.|pdf=|usr=027}}
+{{tp|p=33955644|t=2021. Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine.|pdf=|usr=027}}
+{{tp|p=34038246|t=2021. Reckoning gamma-Glutamyl-S-allylcysteine as a potential main protease (m(pro)) inhibitor of novel SARS-CoV-2 virus identified using docking and molecular dynamics simulation.|pdf=|usr=027}}
+{{tp|p=33960002|t=2021. TWIRLS, a knowledge-mining technology, suggests a possible mechanism for the pathological changes in the human host after coronavirus infection via ACE2.|pdf=|usr=027}}
+{{tp|p=33847382|t=2021. Potential antiviral activity of isorhamnetin against SARS-CoV-2 spike pseudotyped virus in vitro.|pdf=|usr=027}}
+{{tp|p=34089595|t=2021. Do Anti-androgens Have Potential as Therapeutics for COVID-19?|pdf=|usr=027}}
+{{tp|p=33928745|t=2021. COVID-19: vaccination problems.|pdf=|usr=027}}
+{{tp|p=34001753|t=2021. Theoretical Framework for Retrospective Studies of the Effectiveness of SARS-CoV-2 Vaccines.|pdf=|usr=027}}
+{{tp|p=33987882|t=2021. COVID-19 vaccine-associated immune thrombosis and thrombocytopenia (VITT): Diagnostic and therapeutic recommendations for a new syndrome.|pdf=|usr=027}}
+{{tp|p=34092488|t=2021. Thrombosis with Thrombocytopenia Syndrome associated with viral vector COVID-19 vaccines.|pdf=|usr=027}}
+{{tp|p=34090750|t=2021. SARS-CoV-2 vaccine-induced cerebral venous thrombosis.|pdf=|usr=027}}
+{{tp|p=34058925|t=2021. How can we accelerate COVID-19 vaccine discovery?|pdf=|usr=027}}
+{{tp|p=34088250|t=2021. NSAIDs/nitazoxanide/azithromycin repurposed for COVID-19: potential mitigation of the cytokine storm interleukin-6 amplifier via immunomodulatory effects.|pdf=|usr=027}}
+{{tp|p=34078215|t=2021. COVID-19 pandemic: SARS-CoV-2 specific vaccines and challenges, protection via BCG trained immunity, and clinical trials.|pdf=|usr=027}}
+{{tp|p=34092166|t=2021. Reported adverse effects following COVID-19 vaccination at a tertiary care hospital, focus on cerebral venous sinus thrombosis (CVST).|pdf=|usr=027}}
+{{tp|p=34004056|t=2021. Disruption of disulfides within RBD of SARS-CoV-2 spike protein prevents fusion and represents a target for viral entry inhibition by registered drugs.|pdf=|usr=027}}
+{{tp|p=34058321|t=2021. Nrf2 activator PB125(R) as a carnosic acid-based therapeutic agent against respiratory viral diseases, including COVID-19.|pdf=|usr=027}}
+{{tp|p=34027650|t=2021. Phytotherapy for treatment of cytokine storm in COVID-19.|pdf=|usr=027}}
+{{tp|p=33973280|t=2021. COVID-19 in DMARD-treated patients with inflammatory rheumatic diseases: Insights from an analysis of the World Health Organization pharmacovigilance database.|pdf=|usr=027}}
+{{tp|p=33369768|t=2021. Remdesivir potently inhibits carboxylesterase-2 through covalent modifications: signifying strong drug-drug interactions.|pdf=|usr=027}}
+{{tp|p=33829614|t=2021. Delirium triggered by COVID-19 vaccine in an elderly patient.|pdf=|usr=027}}
+{{tp|p=34085396|t=2021. Acute kidney injury secondary to chlorine dioxide use for COVID-19 prevention.|pdf=|usr=027}}
+{{tp|p=34033528|t=2021. COVID-19 vaccine platforms: Delivering on a promise?|pdf=|usr=027}}
+{{tp|p=33966665|t=2021. Severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in asymptomatic vaccinated healthcare workers.|pdf=|usr=027}}
+{{tp|p=33928831|t=2021. Drug delivery of amoxicillin molecule as a suggested treatment for covid-19 implementing functionalized mesoporous SBA-15 with aminopropyl groups.|pdf=|usr=027}}
+{{tp|p=33818031|t=2021. Drugs intervention study in COVID-19 management.|pdf=|usr=027}}
+{{tp|p=33378773|t=2021. Development of a Physiologically-Based Pharmacokinetic (PBPK) Model of Nebulized Hydroxychloroquine for Pulmonary Delivery to COVID-19 Patients.|pdf=|usr=027}}
+{{tp|p=33890267|t=2021. A Concept for the Reduction of Mucosal SARS-CoV-2 Load using Hypochloric Acid Solutions.|pdf=|usr=027}}
+{{tp|p=33931565|t=2021. COVID-19 vaccination in pregnancy.|pdf=|usr=027}}
+{{tp|p=34061008|t=2021. Revisiting the antiviral efficacy of terpenoids: Plausible adjunct therapeutics for novel SARS-CoV-2?|pdf=|usr=027}}
+{{tp|p=34057409|t=2021. Physicians' opinions on the necessity of COVID-19 vaccination in patients with epilepsy.|pdf=|usr=027}}
+{{tp|p=32725108|t=2021. End-stage heart failure secondary to low-dose hydroxychloroquine treatment.|pdf=|usr=027}}
+{{tp|p=33878713|t=2021. Pigs Don't Fly and You Cannot Expect Absolutely Safe COVID-19 Vaccines (But You Should Expect a Fair Compensation).|pdf=|usr=027}}
+{{tp|p=33963635|t=2021. Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients - a prospective cohort study.|pdf=|usr=027}}
+{{tp|p=34031153|t=2021. Petechial skin rash associated with CoronaVac vaccination: first cutaneous side effect report before phase 3 results.|pdf=|usr=027}}
+{{tp|p=33990390|t=2021. Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19.|pdf=|usr=027}}
+{{tp|p=34083222|t=2021. Benefit versus toxicity risk of digoxin in patients with COVID-19.|pdf=|usr=027}}
+{{tp|p=33832918|t=2021. Electronic monitoring of potential adverse drug events related to lopinavir/ritonavir and hydroxychloroquine during the first wave of COVID-19.|pdf=|usr=027}}
+{{tp|p=33930196|t=2021. JAK inhibitors: Ten years after.|pdf=|usr=027}}
+{{tp|p=33832827|t=2021. Safety of treatment with chloroquine and hydroxychloroquine: A ten-year systematic review and meta-analysis.|pdf=|usr=027}}
+{{tp|p=33966314|t=2021. SARS-CoV-2 vaccine-related neurological complications need large collaborative studies, not single case reports or small descriptive series.|pdf=|usr=027}}
+{{tp|p=33843287|t=2021. Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: A case report.|pdf=|usr=027}}
+{{tp|p=33886388|t=2021. Immunomodulatory extracellular vesicles: an alternative to cell therapy for COVID-19.|pdf=|usr=027}}
+{{tp|p=33957833|t=2021. Machine learning techniques applied to the drug design and discovery of new antivirals: a brief look over the past decade.|pdf=|usr=027}}
+{{tp|p=33307875|t=2021. Are academia-pharma partnerships essential for novel drug discovery in the time of the COVID-19 pandemic?|pdf=|usr=027}}
+{{tp|p=33345645|t=2021. Can drug repurposing strategies be the solution to the COVID-19 crisis?|pdf=|usr=027}}
+{{tp|p=33874829|t=2021. The role of IL-6 and IL-6 blockade in COVID-19.|pdf=|usr=027}}
+{{tp|p=33331197|t=2021. The COVID-19 pandemic: a target for surfactant therapy?|pdf=|usr=027}}
+{{tp|p=33858268|t=2021. Effects of select dietary supplements on the prevention and treatment of viral respiratory tract infections: a systematic review of randomized controlled trials.|pdf=|usr=027}}
+{{tp|p=33945381|t=2021. Does methylprednisolone reduce the mortality risk in hospitalized COVID-19 patients? A meta-analysis of randomized control trials.|pdf=|usr=027}}
+{{tp|p=33853488|t=2021. Progress in research on the S protein as the target of COVID-19 vaccines.|pdf=|usr=027}}
+{{tp|p=33350389|t=2021. Supplementation en vitamine D et Covid-19 : consensus d'experts et recommandations.|pdf=|usr=027}}
+{{tp|p=33860513|t=2021. Consensus Recommendations for Intramuscular COVID-19 Vaccination in Patients with Hemophilia.|pdf=|usr=027}}
+{{tp|p=34034356|t=2021. Analysis of Homeopathic Genus Epidemicus for COVID-19 Patients in Spain.|pdf=|usr=027}}
+{{tp|p=33348417|t=2021. COVID-19 Pneumonia: A Potential Role of Homeopathy.|pdf=|usr=027}}
+{{tp|p=33930904|t=2021. Homeopathic Remedies in COVID-19: Prognostic Factor Research.|pdf=|usr=027}}
+{{tp|p=33853178|t=2021. Clinical Repurposing of Medicines is Intrinsic to Homeopathy: Research Initiatives on COVID-19 in India.|pdf=|usr=027}}
+{{tp|p=33853177|t=2021. Antimonium Tartaricum as a Possible Homeopathic Prophylactic Remedy in the COVID-19 Epidemic.|pdf=|usr=027}}
+{{tp|p=34005841|t=2021. Association between vitamin D level and prognostic factors among patients infected with SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=33998533|t=2021. A review of monoclonal antibodies in COVID-19: Role in immunotherapy, vaccine development and viral detection.|pdf=|usr=027}}
+{{tp|p=33858231|t=2021. Current Update on Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development with a Special Emphasis on Gene Therapy Viral Vector Design and Construction for Vaccination.|pdf=|usr=027}}
+{{tp|p=34033732|t=2021. Reactive arthritis after COVID-19 vaccination.|pdf=|usr=027}}
+{{tp|p=34032555|t=2021. Guillain-Barre syndrome should be monitored upon mass vaccination against SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=33857399|t=2021. Countries with high deaths due to flu and tuberculosis demonstrate lower COVID-19 mortality: roles of vaccinations.|pdf=|usr=027}}
+{{tp|p=34015240|t=2021. Acute relapse and poor immunization following COVID-19 vaccination in a rituximab-treated multiple sclerosis patient.|pdf=|usr=027}}
+{{tp|p=33377817|t=2021. The association of previous influenza vaccination and coronavirus disease-2019.|pdf=|usr=027}}
+{{tp|p=34081583|t=2021. LUNAR :Drug Screening for Novel Coronavirus Based on Representation Learning Graph Convolutional Network.|pdf=|usr=027}}
+{{tp|p=33914685|t=2021. Detection of Binding Sites on SARS-CoV-2 Spike Protein Receptor-Binding Domain by Molecular Dynamics Simulations in Mixed Solvents.|pdf=|usr=027}}
+{{tp|p=33941025|t=2021. Interplay of Anti-Viral Vaccines with Biologic Agents and Immunomodulators in Individuals with Autoimmune and Autoinflammatory Diseases.|pdf=|usr=027}}
+{{tp|p=33830864|t=2021. Better, Faster, Stronger: mRNA Vaccines Show Promise for Influenza Vaccination in Older Adults.|pdf=|usr=027}}
+{{tp|p=33955564|t=2021. A century of BCG: Impact on tuberculosis control and beyond.|pdf=|usr=027}}
+{{tp|p=34057870|t=2021. Repurposing metformin for covid-19 complications in patients with type 2 diabetes and insulin resistance.|pdf=|usr=027}}
+{{tp|p=34032546|t=2021. Neuroprotective role of camphor against ciprofloxacin induced depression in rats: modulation of Nrf-2 and TLR4.|pdf=|usr=027}}
+{{tp|p=33356684|t=2021. Different aspects of convalescent plasma therapy for COVID-19 treatment; a critical review.|pdf=|usr=027}}
+{{tp|p=34047261|t=2021. A short review on key role of plants and their extracts in boosting up immune response to combat COVID-19.|pdf=|usr=027}}
+{{tp|p=33313690|t=2021. COVID-19 vaccine and Guillain-Barre syndrome: let's not leap to associations.|pdf=|usr=027}}
+{{tp|p=33857630|t=2021. Cerebral venous sinus thrombosis and thrombocytopenia after COVID-19 vaccination - A report of two UK cases.|pdf=|usr=027}}
+{{tp|p=33842899|t=2021. Boosting nitric oxide in stress and respiratory infection: Potential relevance for asthma and COVID-19.|pdf=|usr=027}}
+{{tp|p=33355812|t=2021. COVID-19 and Methylene Blue.|pdf=|usr=027}}
+{{tp|p=33866350|t=2021. Is acupuncture effective in the treatment of COVID-19 related symptoms? Based on bioinformatics/network topology strategy.|pdf=|usr=027}}
+{{tp|p=33839760|t=2021. Bioinformatics and machine learning approach identifies potential drug targets and pathways in COVID-19.|pdf=|usr=027}}
+{{tp|p=33839740|t=2021. SMMPPI: a machine learning-based approach for prediction of modulators of protein-protein interactions and its application for identification of novel inhibitors for RBD:hACE2 interactions in SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=34009266|t=2021. DeepImmuno: deep learning-empowered prediction and generation of immunogenic peptides for T-cell immunity.|pdf=|usr=027}}
+{{tp|p=34009288|t=2021. Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19.|pdf=|usr=027}}
+{{tp|p=33416848|t=2021. SARS-CoV-2 3D database: understanding the coronavirus proteome and evaluating possible drug targets.|pdf=|usr=027}}
+{{tp|p=33875896|t=2021. COVID-19 vaccin et anaphylaxie.|pdf=|usr=027}}
+{{tp|p=33902920|t=2021. La vaccination anti-COVID-19 et patients atteints de cancer : etat de l'art et synthese des recommandations.|pdf=|usr=027}}
+{{tp|p=33902918|t=2021. Vaccination contre la COVID-19 des patients atteints de cancer solide : revue et preconisations d'un inter-groupe oncologique francais (CGO, TNCD, UNICANCER).|pdf=|usr=027}}
+{{tp|p=34025112|t=2021. Serial computed tomography findings of Coronavirus disease 2019 (COVID-19) pneumonia treated with favipiravir and steroid therapy: report of 11 cases.|pdf=|usr=027}}
+{{tp|p=33947599|t=2021. Timing of COVID-19 vaccination in the major burns patient.|pdf=|usr=027}}
+{{tp|p=33903009|t=2021. Radiotherapie de faible dose pour la pneumopathie covid-19 : rationnel biologique et revue de la litterature.|pdf=|usr=027}}
+{{tp|p=34090218|t=2021. COVID-19 patients' sera induce epithelial mesenchymal transition in cancer cells.|pdf=|usr=027}}
+{{tp|p=33910715|t=2021. Sulfobutylether-beta-cyclodextrin-enabled antiviral remdesivir: Characterization of electrospun- and lyophilized formulations.|pdf=|usr=027}}
+{{tp|p=34015720|t=2021. Marine sulfated polysaccharides as potential antiviral drug candidates to treat Corona Virus disease (COVID-19).|pdf=|usr=027}}
+{{tp|p=33927910|t=2021. Vitamin D Deficiency Rickets and COVID-19 Pandemic.|pdf=|usr=027}}
+{{tp|p=33836156|t=2021. TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation.|pdf=|usr=027}}
+{{tp|p=34087172|t=2021. Tackling COVID-19 with neutralizing monoclonal antibodies.|pdf=|usr=027}}
+{{tp|p=34051873|t=2021. A traditional medicine, respiratory detox shot (RDS), inhibits the infection of SARS-CoV, SARS-CoV-2, and the influenza A virus in vitro.|pdf=|usr=027}}
+{{tp|p=33979649|t=2021. Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=34031383|t=2021. Targeting novel LSD1-dependent ACE2 demethylation domains inhibits SARS-CoV-2 replication.|pdf=|usr=027}}
+{{tp|p=33894127|t=2021. A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection.|pdf=|usr=027}}
+{{tp|p=33359760|t=2021. Effects of vitamin D on macrophages and myeloid-derived suppressor cells (MDSCs) hyperinflammatory response in the lungs of COVID-19 patients.|pdf=|usr=027}}
+{{tp|p=33958745|t=2021. Identification and characterization of a monoclonal antibody blocking the SARS-CoV-2 spike protein-ACE2 interaction.|pdf=|usr=027}}
+{{tp|p=34059790|t=2021. Fludarabine inhibits type I interferon-induced expression of the SARS-CoV-2 receptor angiotensin-converting enzyme 2.|pdf=|usr=027}}
+{{tp|p=33984267|t=2021. Hepatitis C virus drugs that inhibit SARS-CoV-2 papain-like protease synergize with remdesivir to suppress viral replication in cell culture.|pdf=|usr=027}}
+{{tp|p=33852916|t=2021. Hypoxic and pharmacological activation of HIF inhibits SARS-CoV-2 infection of lung epithelial cells.|pdf=|usr=027}}
+{{tp|p=34074163|t=2021. Combined Use of Tocilizumab and Mesenchymal Stromal Cells in the Treatment of Severe Covid-19: Case Report.|pdf=|usr=027}}
+{{tp|p=33845643|t=2021. Recent Findings on Cell-Based Therapies for COVID19-Related Pulmonary Fibrosis.|pdf=|usr=027}}
+{{tp|p=34067054|t=2021. The Discovery of Naringenin as Endolysosomal Two-Pore Channel Inhibitor and Its Emerging Role in SARS-CoV-2 Infection.|pdf=|usr=027}}
+{{tp|p=34068958|t=2021. Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae?|pdf=|usr=027}}
+{{tp|p=33917481|t=2021. Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19.|pdf=|usr=027}}
+{{tp|p=33946869|t=2021. Remdesivir and Ledipasvir among the FDA-Approved Antiviral Drugs Have Potential to Inhibit SARS-CoV-2 Replication.|pdf=|usr=027}}
+{{tp|p=33887223|t=2021. Potent toxic effects of Taroxaz-104 on the replication of SARS-CoV-2 particles.|pdf=|usr=027}}
+{{tp|p=33991505|t=2021. A novel nano therapeutic using convalescent plasma derived exosomal (CP(Exo)) for COVID-19: A combined hyperactive immune modulation and diagnostics.|pdf=|usr=027}}
+{{tp|p=33974898|t=2021. Elucidating of oxidative distress in COVID-19 and methods of its prevention.|pdf=|usr=027}}
+{{tp|p=34007086|t=2021. Antiviral nucleoside analogs.|pdf=|usr=027}}
+{{tp|p=34007082|t=2021. Modeling the binding of protoporphyrin IX, verteporfin, and chlorin e6 to SARS-CoV-2 proteins.|pdf=|usr=027}}
+{{tp|p=33850334|t=2021. In silico investigation of potential small molecule inhibitors of the SARS-CoV-2 nsp10-nsp16 methyltransferase complex.|pdf=|usr=027}}
+{{tp|p=33362291|t=2021. Unraveling the origin of interactions of hydroxychloroquine with the receptor-binding domain of SARS-CoV-2 in aqueous medium.|pdf=|usr=027}}
+{{tp|p=34024911|t=2021. Non-competitive interactions between hydroxychloroquine and azithromycin: Systematic density functional, molecular dynamics, and docking calculations.|pdf=|usr=027}}
+{{tp|p=33994552|t=2021. Low rotational barriers for the most dynamically active methyl groups in the proposed antiviral drugs for treatment of SARS-CoV-2, apilimod and tetrandrine.|pdf=|usr=027}}
+{{tp|p=33994655|t=2021. An insight into the inhibitory mechanism of phytochemicals and FDA-approved drugs on the ACE2-Spike complex of SARS-CoV-2 using computational methods.|pdf=|usr=027}}
+{{tp|p=34025012|t=2021. Discovery of (E)-N-(4-cyanobenzylidene)- 6-fluoro- 3-hydroxypyrazine-2 -carboxamide (cyanorona-20): the first potent and specific anti-COVID-19 drug.|pdf=|usr=027}}
+{{tp|p=34010501|t=2021. Computational Approaches to Discover Novel Natural Compounds for SARS-CoV-2 Therapeutics.|pdf=|usr=027}}
+{{tp|p=33965141|t=2021. Questioning Tocilizumab Use in Hospitalized Patients With Coronavirus Disease 2019.|pdf=|usr=027}}
+{{tp|p=33965138|t=2021. Standard Dose Ivermectin for COVID-19.|pdf=|usr=027}}
+{{tp|p=33965137|t=2021. Remarks About Retrospective Analysis of Ivermectin Effectiveness on Coronavirus Disease 2019 (ICON Study).|pdf=|usr=027}}
+{{tp|p=33965134|t=2021. Corticosteroid Plus Tocilizumab in COVID-19: When Two Is Better Than One.|pdf=|usr=027}}
+{{tp|p=33965120|t=2021. One Size Does Not Fit All: Moving Towards a Personalized Approach for Steroids in COVID-19.|pdf=|usr=027}}
+{{tp|p=33316235|t=2021. Corticosteroid Therapy Is Associated With Improved Outcome in Critically Ill Patients With COVID-19 With Hyperinflammatory Phenotype.|pdf=|usr=027}}
+{{tp|p=34021998|t=2021. Etoposide for Cytokine Storm Because of Coronavirus Disease 2019.|pdf=|usr=027}}
+{{tp|p=34031814|t=2021. Chinese Medicine Rescues Acute Respiratory Dyspnea Syndrome Caused by COVID-19: A Case Report.|pdf=|usr=027}}
+{{tp|p=34018412|t=2021. Thrombotic Events in COVID-19: Inquires About the Deleterious Procoagulant Effect of Corticosteroid Therapy.|pdf=|usr=027}}
+{{tp|p=33999204|t=2021. COVID-19 Vaccination in Patients With Inflammatory Bowel Disease and History of Reaction to Injectable Therapies.|pdf=|usr=027}}
+{{tp|p=33878754|t=2021. Spices and COVID-19.|pdf=|usr=027}}
+{{tp|p=34047498|t=2021. Olfactory dysfunction after coronavirus disease 2019 (COVID-19) vaccination.|pdf=|usr=027}}
+{{tp|p=34080261|t=2021. Promising effects of atorvastatin on mortality and need for mechanical ventilation in patients with severe COVID-19; a retrospective cohort study.|pdf=|usr=027}}
+{{tp|p=33971067|t=2021. Effectiveness of ozone therapy in addition to conventional treatment on mortality in patients with COVID-19.|pdf=|usr=027}}
+{{tp|p=34089534|t=2021. COVID-19 vaccines and nanomedicine.|pdf=|usr=027}}
+{{tp|p=33998677|t=2021. Recurrent varicella following SARS-CoV-2 vaccination with BNT162b2.|pdf=|usr=027}}
+{{tp|p=33900629|t=2021. Acral chilblain-like lesions following inactivated SARS-CoV-2 vaccination.|pdf=|usr=027}}
+{{tp|p=33855706|t=2021. Cutaneous reaction to BNT162b2 mRNA COVID-19 vaccine.|pdf=|usr=027}}
+{{tp|p=33928638|t=2021. Leukocytoclastic vasculitis flare following the COVID-19 vaccine.|pdf=|usr=027}}
+{{tp|p=34037266|t=2021. The use of cow dung and urine to cure COVID-19 in India: A public health concern.|pdf=|usr=027}}
+{{tp|p=33973379|t=2021. Recommendations for COVID-19 vaccination in people with rheumatic disease: Developed by the Singapore Chapter of Rheumatologists.|pdf=|usr=027}}
+{{tp|p=34075419|t=2021. Concordance between the results of randomized and non-randomized interventional clinical trials assessing the efficacy of drugs for COVID-19: a cross-sectional study.|pdf=|usr=027}}
+{{tp|p=34075418|t=2021. Pharmacokinetic modelling to estimate intracellular favipiravir ribofuranosyl-5'-triphosphate exposure to support posology for SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=34037760|t=2021. Efficacy and safety of sofosbuvir/velpatasvir versus the standard of care in adults hospitalized with COVID-19: a single-centre, randomized controlled trial.|pdf=|usr=027}}
+{{tp|p=33973313|t=2021. Drug-induced organ injury in coronavirus disease 2019 pharmacotherapy: Mechanisms and challenges in differential diagnosis and potential protective strategies.|pdf=|usr=027}}
+{{tp|p=34001719|t=2021. Could Dapagliflozin Attenuate COVID-19 Progression in High-Risk Patients With or Without Diabetes? Behind DARE-19 Concept.|pdf=|usr=027}}
+{{tp|p=33993519|t=2021. Recombinant CD137-Fc, its synthesis, and applications for improving the immune system functions, such as tumor immunotherapy and to reduce the inflammation due to the novel coronavirus.|pdf=|usr=027}}
+{{tp|p=34097036|t=2021. Calcifediol treatment and COVID-19-related outcomes.|pdf=|usr=027}}
+{{tp|p=33959987|t=2021. Medication safety in a pandemic: A multicentre point prevalence study of QTc monitoring of hydroxychloroquine for COVID-19.|pdf=|usr=027}}
+{{tp|p=33870531|t=2021. Baricitinib: From Rheumatoid Arthritis to COVID-19.|pdf=|usr=027}}
+{{tp|p=34008285|t=2021. Could isotretinoin be a protective agent against COVID-19?: A dermatologist perspective.|pdf=|usr=027}}
+{{tp|p=33978291|t=2021. Yellow-white fluorescence on the nails: A novel finding of Favipiravir used for the treatment of COVID-19.|pdf=|usr=027}}
+{{tp|p=34074197|t=2021. Is carbonic anhydrase inhibition useful as a complementary therapy of Covid-19 infection?|pdf=|usr=027}}
+{{tp|p=33817822|t=2021. Immunomodulatory and anti-inflammatory potential of crocin in COVID-19 treatment.|pdf=|usr=027}}
+{{tp|p=33913803|t=2021. Effective in vitro inactivation of SARS-CoV-2 by commercially available mouthwashes.|pdf=|usr=027}}
+{{tp|p=33891534|t=2021. Investigative study into whether an insect repellent has virucidal activity against SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=33830908|t=2021. The green tea catechin epigallocatechin gallate inhibits SARS-CoV-2 infection.|pdf=|usr=027}}
+{{tp|p=34054274|t=2021. Will Remdesivir Reshape Cardiovascular Practice in COVID 19 Era?|pdf=|usr=027}}
+{{tp|p=33998306|t=2021. Successful use of CytoSorb in a Covid-19 patient with secondary septic shock due to a sacral decubitus infection.|pdf=|usr=027}}
+{{tp|p=33862126|t=2021. Insulin fast-dissolving film for intranasal delivery via olfactory region, a promising approach for the treatment of anosmia in COVID-19 patients: Design, in-vitro characterization and clinical evaluation.|pdf=|usr=027}}
+{{tp|p=33332179|t=2021. Reply to: regarding: 'the risk of induced cancer and ischemic heart disease following low dose lung irradiation for COVID-19: estimation based on a virtual case'.|pdf=|usr=027}}
+{{tp|p=33320755|t=2021. Low-dose radiotherapy (LD-RT) for COVID-19-induced pneumopathy: a worth considering approach.|pdf=|usr=027}}
+{{tp|p=33320738|t=2021. Regarding: "the risk of induced cancer and ischemic heart disease following low dose lung irradiation for COVID-19: estimation based on a virtual case".|pdf=|usr=027}}
+{{tp|p=33301368|t=2021. Could Dietary Factors Reduce COVID-19 Mortality Rates? Moderating the Inflammatory State.|pdf=|usr=027}}
+{{tp|p=33211596|t=2021. Intravenous sulforhodamine B reduces alveolar surface tension, improves oxygenation, and reduces ventilation injury in a respiratory distress model.|pdf=|usr=027}}
+{{tp|p=33934592|t=2021. SARS-CoV-2 infection versus the body immune defenses: the role of immune responses and mechanism of action of dexamethasone.|pdf=|usr=027}}
+{{tp|p=33904269|t=2021. Monoclonal antibody therapy in COVID-19.|pdf=|usr=027}}
+{{tp|p=33896155|t=2021. Antibodies for COVID-19 - which, when and how long?|pdf=|usr=027}}
+{{tp|p=33982533|t=2021. Glycyrrhizin for topical use and prophylaxis of COVID-19: an interesting pharmacological perspective.|pdf=|usr=027}}
+{{tp|p=33947317|t=2021. The non-specific antiviral activity of polysulfates to fight SARS-CoV-2, its mutants and viruses with cationic spikes.|pdf=|usr=027}}
+{{tp|p=33970805|t=2021. Medicinal plant compounds as promising inhibitors of coronavirus (COVID-19) main protease: an in silico study.|pdf=|usr=027}}
+{{tp|p=33685364|t=2021. An in-silico approach to identify the potential hot spots in SARS-CoV-2 spike RBD to block the interaction with ACE2 receptor.|pdf=|usr=027}}
+{{tp|p=33826484|t=2021. Computational exploration of natural peptides targeting ACE2.|pdf=|usr=027}}
+{{tp|p=33928870|t=2021. In a search for potential drug candidates for combating COVID-19: computational study revealed salvianolic acid B as a potential therapeutic targeting 3CLpro and spike proteins.|pdf=|usr=027}}
+{{tp|p=33908318|t=2021. Cameroonian medicinal plants as potential candidates of SARS-CoV-2 inhibitors.|pdf=|usr=027}}
+{{tp|p=33372280|t=2021. Immunomodulatory effects of nanocurcumin on Th17 cell responses in mild and severe COVID-19 patients.|pdf=|usr=027}}
+{{tp|p=33368439|t=2021. Real-world prevalence and consequences of potential drug-drug interactions in the first-wave COVID-19 treatments.|pdf=|usr=027}}
+{{tp|p=33350472|t=2021. Amantadine for COVID-19.|pdf=|usr=027}}
+{{tp|p=33843779|t=2021. Antibodies: Friends, Foes, or Both? Lessons From COVID-19 for the Rheumatologist.|pdf=|usr=027}}
+{{tp|p=33962499|t=2021. Herbal supplement (Combi-5) in the management of COVID 19 individual with mild to moderate symptoms: a case report.|pdf=|usr=027}}
+{{tp|p=33915020|t=2021. Evaluation of the frequency and intensity of favipiravir-associated yellow-green fluorescence in lunulae, hair, and face.|pdf=|usr=027}}
+{{tp|p=33977807|t=2021. Lactoferrin for Mental Health: Neuro-Redox Regulation and Neuroprotective Effects across the Blood-Brain Barrier with Special Reference to Neuro-COVID-19.|pdf=|usr=027}}
+{{tp|p=33760271|t=2021. Study on the mechanism of active components of Liupao tea on 3CL(pro) based on HPLC-DAD fingerprint and molecular docking technique.|pdf=|usr=027}}
+{{tp|p=34084491|t=2021. Corticosteroid therapy for 2019-nCoV-infected patients: A case series of eight mechanically ventilated patients.|pdf=|usr=027}}
+{{tp|p=33936671|t=2021. Response to pegylated interferon in a COVID-19-positive elderly woman with primary myelofibrosis treated with ruxolitinib.|pdf=|usr=027}}
+{{tp|p=33972060|t=2021. Is the BCG vaccine a useful tool against COVID-19?|pdf=|usr=027}}
+{{tp|p=33997476|t=2021. The predictors of high titer of anti-SARS-CoV-2 antibody of convalescent plasma donors.|pdf=|usr=027}}
+{{tp|p=33969237|t=2021. The use of Janus Kinase inhibitors in hospitalized patients with COVID-19: Systematic review and meta-analysis.|pdf=|usr=027}}
+{{tp|p=33845194|t=2021. The microbiota-mediated dietary and nutritional interventions for COVID-19.|pdf=|usr=027}}
+{{tp|p=33838340|t=2021. Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products.|pdf=|usr=027}}
+{{tp|p=33956936|t=2021. Combination therapy with tocilizumab and dexamethasone cost-effectively reduces Coronavirus disease 2019 mortality.|pdf=|usr=027}}
+{{tp|p=32588884|t=2021. Influence of Corticosteroid Dose on Viral Shedding Duration in Patients With COVID-19.|pdf=|usr=027}}
+{{tp|p=33905481|t=2021. Vaccinated and convalescent donor-derived SARS-CoV-2-specific T cells as adoptive immunotherapy for high-risk COVID-19 patients.|pdf=|usr=027}}
+{{tp|p=33861337|t=2021. Impact of convalescent plasma therapy on SARS CoV-2 antibody profile in COVID-19 patients.|pdf=|usr=027}}
+{{tp|p=33846730|t=2021. Real-World Experience of Bamlanivimab for COVID-19: A Case-Control Study.|pdf=|usr=027}}
+{{tp|p=33953913|t=2021. Treatment for severe COVID-19 with a biomimetic sorbent haemoperfusion device in patients on haemodialysis.|pdf=|usr=027}}
+{{tp|p=33479100|t=2021. Vitamin D.|pdf=|usr=027}}
+{{tp|p=33355217|t=2021. Effectiveness of early treatment of lopinavir-ritonavir in patients with severe COVID-19: a case series.|pdf=|usr=027}}
+{{tp|p=34048876|t=2021. An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-beta-1a and hydroxychloroquine in hospitalized patients with COVID-19.|pdf=|usr=027}}
+{{tp|p=34044151|t=2021. Use of an antiviral mouthwash as a barrier measure in the SARS-CoV-2 transmission in adults with asymptomatic to mild COVID-19: a multicentre, randomized, double-blind controlled trial.|pdf=|usr=027}}
+{{tp|p=34020032|t=2021. Intravenous immunoglobulin treatment for patients with severe COVID-19: a retrospective multicentre study.|pdf=|usr=027}}
+{{tp|p=33878505|t=2021. Patient-blood management for COVID19 convalescent plasma therapy: relevance of affinity and donor-recipient differences in concentration of neutralizing antibodies.|pdf=|usr=027}}
+{{tp|p=33915284|t=2021. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update.|pdf=|usr=027}}
+{{tp|p=33316402|t=2021. Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: a population-based cohort study.|pdf=|usr=027}}
+{{tp|p=34084692|t=2021. Effectiveness of convalescent plasma therapy in a patient with severe COVID-19-associated acute kidney injury.|pdf=|usr=027}}
+{{tp|p=33933296|t=2021. Polydatin and COVID-19.|pdf=|usr=027}}
+{{tp|p=33933295|t=2021. Nutritional risk at hospital admission is associated with prolonged length of hospital stay in old patients with COVID-19.|pdf=|usr=027}}
+{{tp|p=33933299|t=2021. Influence of foods and nutrients on COVID-19 recovery: A multivariate analysis of data from 170 countries using a generalized linear model.|pdf=|usr=027}}
+{{tp|p=33933297|t=2021. Early caloric deficit is associated with a higher risk of death in invasive ventilated COVID-19 patients.|pdf=|usr=027}}
+{{tp|p=33933298|t=2021. Region-specific COVID-19 risk scores and nutritional status of a high-risk population based on individual vulnerability assessment in the national survey data.|pdf=|usr=027}}
+{{tp|p=33353766|t=2021. Different barriers to nutritional therapy among critically-ill patients with COVID-19.|pdf=|usr=027}}
+{{tp|p=33349484|t=2021. The differential roles of zinc in immune responses and their potential implications in antiviral immunity against SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=34049750|t=2021. Nutritional status in post SARS-Cov2 rehabilitation patients.|pdf=|usr=027}}
+{{tp|p=33934925|t=2021. Mediterranean diet and the risk of COVID-19 in the 'Seguimiento Universidad de Navarra' cohort.|pdf=|usr=027}}
+{{tp|p=34024561|t=2021. Safety and tolerance of enteral nutrition in COVID-19 critically ill patients, a retrospective study.|pdf=|usr=027}}
+{{tp|p=34024545|t=2021. Strengthening the immunity of the Swiss population with micronutrients: A narrative review and call for action.|pdf=|usr=027}}
+{{tp|p=34024544|t=2021. Energy expenditure and feeding practices and tolerance during the acute and late phase of critically ill COVID-19 patients.|pdf=|usr=027}}
+{{tp|p=34024543|t=2021. The validity of the global leadership initiative on malnutrition criteria for diagnosing malnutrition in critically ill patients with COVID-19: A prospective cohort study.|pdf=|usr=027}}
+{{tp|p=34024542|t=2021. Poor nutritional status, risk of sarcopenia and nutrition related complaints are prevalent in COVID-19 patients during and after hospital admission.|pdf=|usr=027}}
+{{tp|p=34024527|t=2021. Serum vitamin D, calcium, and zinc levels in patients with COVID-19.|pdf=|usr=027}}
+{{tp|p=34024521|t=2021. Outcomes of nutritionally at-risk Coronavirus Disease 2019 (COVID 19) patients admitted in a tertiary government hospital: A follow-up study of the MalnutriCoV study.|pdf=|usr=027}}
+{{tp|p=34024518|t=2021. Influence of nutritional status on clinical outcomes among hospitalized patients with COVID-19.|pdf=|usr=027}}
+{{tp|p=34024514|t=2021. Glucose-6-phosphate dehydrogenase inhibitor for treatment of severe COVID-19: Polydatin.|pdf=|usr=027}}
+{{tp|p=34024511|t=2021. Prevalence and outcomes of malnutrition among hospitalized COVID-19 patients: A systematic review and meta-analysis.|pdf=|usr=027}}
+{{tp|p=33864625|t=2021. Comment on "Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin-6".|pdf=|usr=027}}
+{{tp|p=33864624|t=2021. Authors' Reply to Cattaneo et al.: "Comment on: Comparative Population Pharmacokinetics of Darunavir in SARS-CoV-2 Patients vs. HIV Patients: The Role of Interleukin6".|pdf=|usr=027}}
+{{tp|p=33956042|t=2021. Patient safety recommendations and management in patients with COVID-19 pneumonia suspicion: a retrospective study.|pdf=|usr=027}}
+{{tp|p=34052007|t=2021. Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-blind, Randomized, Controlled Clinical Trial.|pdf=|usr=027}}
+{{tp|p=34049725|t=2021. SARS-CoV-2 Monoclonal Antibodies in Children: Ethical Considerations.|pdf=|usr=027}}
+{{tp|p=34026115|t=2021. Dynamics of antibodies to SARS-CoV-2 in convalescent plasma donors.|pdf=|usr=027}}
+{{tp|p=34013493|t=2021. Saving time in the radiotherapy procedures for COVID-19 pneumonia treatment. A single-institution experience.|pdf=|usr=027}}
+{{tp|p=34008772|t=2021. Efficacy and safety of umbilical cord mesenchymal stem cells for the treatment of patients with COVID-19.|pdf=|usr=027}}
+{{tp|p=33824151|t=2021. Le remdesivir chez les patients atteints de la COVID-19.|pdf=|usr=027}}
+{{tp|p=33866523|t=2021. Clinically Significant Drug Interactions Between Psychotropic Agents and Repurposed COVID-19 Therapies.|pdf=|usr=027}}
+{{tp|p=33838582|t=2021. Antiviral zinc oxide nanoparticles mediated by hesperidin and in silico comparison study between antiviral phenolics as anti-SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=34079039|t=2021. JAK inhibitors dampen activation of interferon-stimulated transcription of ACE2 isoforms in human airway epithelial cells.|pdf=|usr=027}}
+{{tp|p=33893388|t=2021. Structure and function analysis of a potent human neutralizing antibody CA521(FALA) against SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=33995820|t=2021. Therapeutic application of light and electromagnetic fields to reduce hyper-inflammation triggered by COVID-19.|pdf=|usr=027}}
+{{tp|p=33839522|t=2021. Traditional Chinese exercise potential role as prevention and adjuvant therapy in patients with COVID-19.|pdf=|usr=027}}
+{{tp|p=33989861|t=2021. Adjunctive homeopathic treatment of hospitalized COVID-19 patients (COVIHOM): A retrospective case series.|pdf=|usr=027}}
+{{tp|p=34091029|t=2021. Therapeutic effects and safety of oral Chinese patent medicine for COVID-19: A rapid systematic review and meta-analysis of randomized controlled trials.|pdf=|usr=027}}
+{{tp|p=33984653|t=2021. Designing potential siRNA molecule for the nucleocapsid(N) gene silencing of different SARS-CoV-2 strains of Bangladesh: Computational approach.|pdf=|usr=027}}
+{{tp|p=33845430|t=2021. The role of human C5a as a non-genomic target in corticosteroid therapy for management of severe COVID19.|pdf=|usr=027}}
+{{tp|p=33360831|t=2021. A computational drug repurposing approach in identifying the cephalosporin antibiotic and anti-hepatitis C drug derivatives for COVID-19 treatment.|pdf=|usr=027}}
+{{tp|p=33352458|t=2021. Identification of FDA approved drugs and nucleoside analogues as potential SARS-CoV-2 A1pp domain inhibitor: An in silico study.|pdf=|usr=027}}
+{{tp|p=33915361|t=2021. Promising phytochemicals of traditional Himalayan medicinal plants against putative replication and transmission targets of SARS-CoV-2 by computational investigation.|pdf=|usr=027}}
+{{tp|p=33895457|t=2021. Identification of potential antiviral compounds against SARS-CoV-2 structural and non structural protein targets: A pharmacoinformatics study of the CAS COVID-19 dataset.|pdf=|usr=027}}
+{{tp|p=33894500|t=2021. Screening of potent phytochemical inhibitors against SARS-CoV-2 protease and its two Asian mutants.|pdf=|usr=027}}
+{{tp|p=33862305|t=2021. Virtual screening of peptides with high affinity for SARS-CoV-2 main protease.|pdf=|usr=027}}
+{{tp|p=33845270|t=2021. Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning.|pdf=|usr=027}}
+{{tp|p=34090015|t=2021. Screening of natural compounds from Cyperus rotundus Linn against SARS-CoV-2 main protease (M(pro)): An integrated computational approach.|pdf=|usr=027}}
+{{tp|p=34020130|t=2021. The interaction of the bioflavonoids with five SARS-CoV-2 proteins targets: An in silico study.|pdf=|usr=027}}
+{{tp|p=34020129|t=2021. QSAR modeling and pharmacoinformatics of SARS coronavirus 3C-like protease inhibitors.|pdf=|usr=027}}
+{{tp|p=34015671|t=2021. Facilitating SARS CoV-2 RNA-Dependent RNA polymerase (RdRp) drug discovery by the aid of HCV NS5B palm subdomain binders: In silico approaches and benchmarking.|pdf=|usr=027}}
+{{tp|p=33915479|t=2021. Dual targeting of cytokine storm and viral replication in COVID-19 by plant-derived steroidal pregnanes: An in silico perspective.|pdf=|usr=027}}
+{{tp|p=33990955|t=2021. Vitamin D and COVID-19: Role of ACE2, age, gender, and ethnicity.|pdf=|usr=027}}
+{{tp|p=33951210|t=2021. Maternal selenium status plays a crucial role on clinical outcomes of pregnant women with COVID-19 infection.|pdf=|usr=027}}
+{{tp|p=33942327|t=2021. Feasibility of convalescent plasma therapy in severe COVID-19 patients with persistent SARS-CoV-2 viremia.|pdf=|usr=027}}
+{{tp|p=33913549|t=2021. Decreased in-hospital mortality associated with aspirin administration in hospitalized patients due to severe COVID-19.|pdf=|usr=027}}
+{{tp|p=33851732|t=2021. Targeting the viral-entry facilitators of SARS-CoV-2 as a therapeutic strategy in COVID-19.|pdf=|usr=027}}
+{{tp|p=33788302|t=2021. Hypothesis of zinc ascorbate as best zinc ionophore for raising antiviral resistance against Covid-19.|pdf=|usr=027}}
+{{tp|p=34076901|t=2021. Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled study.|pdf=|usr=027}}
+{{tp|p=33856708|t=2021. Interferon beta-1b for patients with moderate to severe COVID-19 in the inflammatory phase of the disease.|pdf=|usr=027}}
+{{tp|p=33792956|t=2021. Different incidences of acute kidney injury (AKI) and outcomes in COVID-19 patients with and without non-azithromycin antibiotics: A retrospective study.|pdf=|usr=027}}
+{{tp|p=33788273|t=2021. Remdesivir for the treatment of COVID-19 in pregnancy.|pdf=|usr=027}}
+{{tp|p=33755218|t=2021. Use of chlorhexidine to eradicate oropharyngeal SARS-CoV-2 in COVID-19 patients.|pdf=|usr=027}}
+{{tp|p=33710631|t=2021. Assessment of the role of zinc in the prevention of COVID-19 infections and mortality: A retrospective study in the Asian and European population.|pdf=|usr=027}}
+{{tp|p=33675235|t=2021. The role of teicoplanin in the treatment of SARS-CoV-2 infection: A retrospective study in critically ill COVID-19 patients (Tei-COVID study).|pdf=|usr=027}}
+{{tp|p=33982105|t=2021. The Role of Nutrition in COVID-19 Susceptibility and Severity of Disease: A Systematic Review.|pdf=|usr=027}}
+{{tp|p=33982128|t=2021. Low Circulating Vitamin D in Intensive Care Unit-Admitted COVID-19 Patients as a Predictor of Negative Outcomes.|pdf=|usr=027}}
+{{tp|p=33938523|t=2021. Receptor-binding Domain Severe Acute Respiratory Syndrome Coronavirus 2-specific Antibodies in Human Milk From Mothers With Coronavirus Disease 2019 Polymerase Chain Reaction or With Symptoms Suggestive of Coronavirus Disease 2019.|pdf=|usr=027}}
+{{tp|p=33980583|t=2021. Characterization of the SARS-CoV-2 Neutralization Potential of COVID-19-Convalescent Donors.|pdf=|usr=027}}
+{{tp|p=33860730|t=2021. From nicotine to the cholinergic anti-inflammatory reflex - Can nicotine alleviate the dysregulated inflammation in COVID-19?|pdf=|usr=027}}
+{{tp|p=34085075|t=2021. Nanoparticle-mediated surfactant therapy in patients with severe COVID-19: a perspective.|pdf=|usr=027}}
+{{tp|p=33539089|t=2021. Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.|pdf=|usr=027}}
+{{tp|p=33775096|t=2021. Antimalarial Quinacrine and Chloroquine Lose Their Activity by Decreasing Cationic Amphiphilic Structure with a Slight Decrease in pH.|pdf=|usr=027}}
+{{tp|p=33891389|t=2021. Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors.|pdf=|usr=027}}
+{{tp|p=33835812|t=2021. Prodrugs of a 1'-CN-4-Aza-7,9-dideazaadenosine C-Nucleoside Leading to the Discovery of Remdesivir (GS-5734) as a Potent Inhibitor of Respiratory Syncytial Virus with Efficacy in the African Green Monkey Model of RSV.|pdf=|usr=027}}
+{{tp|p=33689397|t=2021. Plant Metabolites as Antiviral Preparations Against Coronaviruses.|pdf=|usr=027}}
+{{tp|p=32926302|t=2021. Hydroxychloroquine Overdose: What Are the Exact Roles of Diazepam and Potassium Infusion?|pdf=|usr=027}}
+{{tp|p=34061377|t=2021. Inhibitory effect on SARS-CoV-2 infection of neferine by blocking Ca(2+) -dependent membrane fusion.|pdf=|usr=027}}
+{{tp|p=33314173|t=2021. Administration of intravenous immunoglobulin in the treatment of COVID-19: A review of available evidence.|pdf=|usr=027}}
+{{tp|p=33336811|t=2021. Respiratory syndrome coronavirus-2 response: Microbiota as lactobacilli could make the difference.|pdf=|usr=027}}
+{{tp|p=33372690|t=2021. Rebuttal to overinterpretation of the antiviral results for human coronavirus 229E relative to severe acute respiratory syndrome coronavirus-2 by Rowpar Pharmaceuticals.|pdf=|usr=027}}
+{{tp|p=33368412|t=2021. Co-infection of malaria and early clearance of SARS-CoV-2 in healthcare workers.|pdf=|usr=027}}
+{{tp|p=33325032|t=2021. The safety of remdesivir for COVID-19 patients.|pdf=|usr=027}}
+{{tp|p=33314219|t=2021. mTOR inhibition in COVID-19: A commentary and review of efficacy in RNA viruses.|pdf=|usr=027}}
+{{tp|p=33314166|t=2021. The association between the level of serum 25(OH) vitamin D, obesity, and underlying diseases with the risk of developing COVID-19 infection: A case-control study of hospitalized patients in Tehran, Iran.|pdf=|usr=027}}
+{{tp|p=33980349|t=2021. A Combined Molecular Docking and Density Functional Theory Nuclear Magnetic Resonance Study of Trans-Dehydrocrotonin Interacting with COVID-19 Main Protease and Severe Acute Respiratory Syndrome Coronavirus 2 3C-Like Protease.|pdf=|usr=027}}
+{{tp|p=33560122|t=2021. Axial Chiral Binaphthoquinone and Perylenequinones from the Stromata of Hypocrella bambusae Are SARS-CoV-2 Entry Inhibitors.|pdf=|usr=027}}
+{{tp|p=33934125|t=2021. Is Hydroxychloroquine with Azithromycin a Good Combination in COVID-19 Compared to Hydroxychloroquine Alone from Cardiac Perspective? A Systematic Review and Meta-Analysis.|pdf=|usr=027}}
+{{tp|p=33906514|t=2021. The Rise and Fall of Hydroxychloroquine and Chloroquine in COVID-19.|pdf=|usr=027}}
+{{tp|p=33882724|t=2021. Treatment of Severe Hypertriglyceridemia With Insulin Infusions in Severe COVID-19: A Case Series.|pdf=|usr=027}}
+{{tp|p=33853438|t=2021. Probable Interaction Between Warfarin and the Combination of Remdesivir With Dexamethasone for Coronavirus Disease 2019 (COVID-19) Treatment: A 2 Case Report.|pdf=|usr=027}}
+{{tp|p=33302762|t=2021. A Response to the Recommendations for Using Dexamethasone for the Treatment of COVID-19: The Dark Side of Dexamethasone.|pdf=|usr=027}}
+{{tp|p=33903133|t=2021. Bradycardia associated with remdesivir therapy for COVID-19 in a 59-year-old man.|pdf=|usr=027}}
+{{tp|p=34055238|t=2021. Prediction of repurposed drugs for Coronaviruses using artificial intelligence and machine learning.|pdf=|usr=027}}
+{{tp|p=34002118|t=2021. Computational optimization of angiotensin-converting enzyme 2 for SARS-CoV-2 Spike molecular recognition.|pdf=|usr=027}}
+{{tp|p=33936562|t=2021. Resources and computational strategies to advance small molecule SARS-CoV-2 discovery: Lessons from the pandemic and preparing for future health crises.|pdf=|usr=027}}
+{{tp|p=33841751|t=2021. Identification of multipotent drugs for COVID-19 therapeutics with the evaluation of their SARS-CoV2 inhibitory activity.|pdf=|usr=027}}
+{{tp|p=33312453|t=2021. Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses.|pdf=|usr=027}}
+{{tp|p=34074458|t=2021. The link between vitamin D and COVID-19.|pdf=|usr=027}}
+{{tp|p=34074457|t=2021. Response to the letter to the editor: "The link between Vitamin D and COVID-19".|pdf=|usr=027}}
+{{tp|p=34074339|t=2021. Hemofiltration with the Seraph((R)) 100 Microbind((R)) Affinity filter decreases SARS-CoV-2 nucleocapsid protein in critically ill COVID-19 patients.|pdf=|usr=027}}
+{{tp|p=34036275|t=2021. Cytokine Blockade in Coronavirus Disease 2019: Keeping an Open Mind.|pdf=|usr=027}}
+{{tp|p=33834168|t=2021. In Vitro-Administered Dexamethasone Suppresses T Cell Function With Reversal by Interleukin-7 in Coronavirus Disease 2019.|pdf=|usr=027}}
+{{tp|p=33986957|t=2021. The Use of Dornase Alfa in the Management of COVID-19-Associated Adult Respiratory Distress Syndrome.|pdf=|usr=027}}
+{{tp|p=33981518|t=2021. Clinical Impact of the Early Use of Monoclonal Antibody LY-CoV555 (Bamlanivimab) on Mortality and Hospitalization Among Elderly Nursing Home Patients: A Multicenter Retrospective Study.|pdf=|usr=027}}
+{{tp|p=33936897|t=2021. Clearing the Fog: Is Hydroxychloroquine Effective in Reducing Coronavirus Disease-2019 Progression? A Randomized Controlled Trial.|pdf=|usr=027}}
+{{tp|p=33564538|t=2021. Safety and Efficacy of Low-Dose Corticosteroids in Patients With Non-severe Coronavirus Disease 2019: A Retrospective Cohort Study.|pdf=|usr=027}}
+{{tp|p=34035996|t=2021. Azithromycin in the Successful Management of COVID-19: A Family Physician's Perspective.|pdf=|usr=027}}
+{{tp|p=33890544|t=2021. Effectiveness and safety of favipiravir compared to supportive care in moderately to critically ill COVID-19 patients: a retrospective study with propensity score matching sensitivity analysis.|pdf=|usr=027}}
+{{tp|p=33877545|t=2021. A Network Pharmacology Study to Uncover the Multiple Molecular Mechanism of the Chinese Patent Medicine Toujiequwen Granules in the Treatment of Corona Virus Disease 2019 (COVID-19).|pdf=|usr=027}}
+{{tp|p=33948913|t=2021. Keeping a Balance During the Pandemic: a Narrative Review on the Important Role of Micronutrients in Preventing Infection and Reducing Complications of COVID-19.|pdf=|usr=027}}
+{{tp|p=33835432|t=2021. A Mechanistic Link Between Selenium and Coronavirus Disease 2019 (COVID-19).|pdf=|usr=027}}
+{{tp|p=33323712|t=2021. Editorial: COVID-19 in older persons: the role of nutrition.|pdf=|usr=027}}
+{{tp|p=34052732|t=2021. Remdesivir for the treatment of Covid-19: the value of biochemical studies.|pdf=|usr=027}}
+{{tp|p=34029993|t=2021. Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection.|pdf=|usr=027}}
+{{tp|p=33907665|t=2021. Indomethacin: Can It Counteract Bradykinin Effects in COVID-19 Patients?|pdf=|usr=027}}
+{{tp|p=33926774|t=2021. Perspectives on anti-IL-1 inhibitors as potential therapeutic interventions for severe COVID-19.|pdf=|usr=027}}
+{{tp|p=33333393|t=2021. Experience of using tocilizumab for treatment in Indonesian patients with severe COVID-19.|pdf=|usr=027}}
+{{tp|p=33992887|t=2021. COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon.|pdf=|usr=027}}
+{{tp|p=34053857|t=2021. Mesenchymal stromal cell therapy for coronavirus disease 2019: which? when? and how much?|pdf=|usr=027}}
+{{tp|p=33898670|t=2021. Design and manufacturability data on additively manufactured solutions for COVID-19.|pdf=|usr=027}}
+{{tp|p=33869690|t=2021. Data on the docking of phytoconstituents of betel plant and matcha green tea on SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=33855133|t=2021. Dataset of AMBER force field parameters of drugs, natural products and steroids for simulations using GROMACS.|pdf=|usr=027}}
+{{tp|p=33404148|t=2021. Fluorescence of nails and hair on Wood's lamp examination in Covid pandemic; undefined effect of Favipiravir in humans.|pdf=|usr=027}}
+{{tp|p=33354849|t=2021. Tetracyclines in COVID-19 patients quarantined at home: Literature evidence supporting real-world data from a multicenter observational study targeting inflammatory and infectious dermatoses.|pdf=|usr=027}}
+{{tp|p=33838614|t=2021. Dipeptidyl peptidase-4 (DPP-4) inhibitor and mortality in coronavirus disease 2019 (COVID-19) - A systematic review, meta-analysis, and meta-regression.|pdf=|usr=027}}
+{{tp|p=33319454|t=2021. Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study.|pdf=|usr=027}}
+{{tp|p=33310173|t=2021. Association of metformin with mortality or ARDS in patients with COVID-19 and type 2 diabetes: A retrospective cohort study.|pdf=|usr=027}}
+{{tp|p=33947009|t=2021. Dolutegravir Plus Lamivudine Two-Drug Regimen: Safety, Efficacy and Diagnostic Considerations for Its Use in Real-Life Clinical Practice-A Refined Approach in the COVID-19 Era.|pdf=|usr=027}}
+{{tp|p=34025036|t=2021. Theoretical investigation of favipiravir antiviral drug based on fullerene and boron nitride nanocages.|pdf=|usr=027}}
+{{tp|p=33919780|t=2021. Potential Effects of Melatonin and Micronutrients on Mitochondrial Dysfunction during a Cytokine Storm Typical of Oxidative/Inflammatory Diseases.|pdf=|usr=027}}
+{{tp|p=33867892|t=2021. Possible Potential Effects of Honey and Its Main Components Against Covid-19 Infection.|pdf=|usr=027}}
+{{tp|p=33976534|t=2021. Thymoquinone: A Promising Natural Compound with Potential Benefits for COVID-19 Prevention and Cure.|pdf=|usr=027}}
+{{tp|p=34048893|t=2021. High-throughput screening assays for SARS-CoV-2 drug development: Current status and future directions.|pdf=|usr=027}}
+{{tp|p=33309533|t=2021. Potential SARS-CoV-2 main protease inhibitors.|pdf=|usr=027}}
+{{tp|p=33892145|t=2021. Web resources facilitate drug discovery in treatment of COVID-19.|pdf=|usr=027}}
+{{tp|p=33128226|t=2021. Tutankhamun's Antimalarial Drug for Covid-19.|pdf=|usr=027}}
+{{tp|p=33864232|t=2021. Safety and Efficacy of Ivermectin and Doxycycline Monotherapy and in Combination in the Treatment of COVID-19: A Scoping Review.|pdf=|usr=027}}
+{{tp|p=34047956|t=2021. Comment on: "Prior Treatment with Statins is Associated with Improved Outcomes of Patients with COVID-19: Data from the SEMI-COVID-19 Registry".|pdf=|usr=027}}
+{{tp|p=33828607|t=2021. The effect of azoximer bromide (Polyoxidonium(R)) in patients hospitalized with coronavirus disease (COVID-19): an open-label, multicentre, interventional clinical study.|pdf=|usr=027}}
+{{tp|p=34097570|t=2021. A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351.|pdf=|usr=027}}
+{{tp|p=34074219|t=2021. 501Y.V2 and 501Y.V3 variants of SARS-CoV-2 lose binding to bamlanivimab in vitro.|pdf=|usr=027}}
+{{tp|p=33993282|t=2021. The Challenging but Imperative Path to Monoclonal Antibody Use Against COVID-19 for a Small Overseas Military Hospital.|pdf=|usr=027}}
+{{tp|p=33993281|t=2021. Bamlanivimab Use in a Military Treatment Facility.|pdf=|usr=027}}
+{{tp|p=33904240|t=2021. Targeting SARS-CoV-2 Spike Protein/ACE2 Protein-Protein Interactions: a Computational Study.|pdf=|usr=027}}
+{{tp|p=34018687|t=2021. In silico Studies on the Interaction between Mpro and PLpro From SARS-CoV-2 and Ebselen, its Metabolites and Derivatives.|pdf=|usr=027}}
+{{tp|p=33963053|t=2021. Targeting the Conserved Stem Loop 2 Motif in the SARS-CoV-2 Genome.|pdf=|usr=027}}
+{{tp|p=33910954|t=2021. Inhibitors of Coronavirus 3CL Proteases Protect Cells from Protease-Mediated Cytotoxicity.|pdf=|usr=027}}
+{{tp|p=33963054|t=2021. ILRUN Downregulates ACE2 Expression and Blocks Infection of Human Cells by SARS-CoV-2.|pdf=|usr=027}}
+{{tp|p=33961002|t=2021. Precision Medicine for COVID-19: Phenotype Anarchy or Promise Realized?|pdf=|usr=027}}
+{{tp|p=33306087|t=2021. An EUA for Bamlanivimab-A Monoclonal Antibody for COVID-19.|pdf=|usr=027}}
+{{tp|p=34081086|t=2021. Could Statins Do More Than Lower Cholesterol in Patients With COVID-19?|pdf=|usr=027}}
+{{tp|p=34081075|t=2021. Bamlanivimab for Prevention of COVID-19.|pdf=|usr=027}}
+{{tp|p=34081073|t=2021. Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities: A Randomized Clinical Trial.|pdf=|usr=027}}
+{{tp|p=34028504|t=2021. Effectiveness of Tocilizumab in Patients Hospitalized With COVID-19: A Follow-up of the CORIMUNO-TOCI-1 Randomized Clinical Trial.|pdf=|usr=027}}
+{{tp|p=33914069|t=2021. Regarding Use of Povidone Iodine to Reduce Nasopharyngeal Viral Load in Patients With COVID-19.|pdf=|usr=027}}
+{{tp|p=33914066|t=2021. Regarding Use of Povidone Iodine to Reduce Nasopharyngeal Viral Load in Patients With COVID-19-Reply.|pdf=|usr=027}}
+{{tp|p=34087041|t=2021. Synthesis, comparative in vitro antibacterial, antioxidant and UV fluorescence studies of bis indole Schiff bases and molecular docking with ct-DNA and SARS-CoV-2 M(pro).|pdf=|usr=027}}
+{{tp|p=33958069|t=2021. In Reply - Safety of Convalescent Plasma Transfusion.|pdf=|usr=027}}
+{{tp|p=33958067|t=2021. Safety of Convalescent Plasma Transfusion.|pdf=|usr=027}}
+{{tp|p=33976099|t=2021. Fluvoxamine for COVID-19?|pdf=|usr=027}}
+{{tp|p=33830966|t=2021. An EUA for bamlanivimab and etesevimab for COVID-19.|pdf=|usr=027}}
+{{tp|p=33212200|t=2021. An updated and comprehensive review of the antiviral potential of essential oils and their chemical constituents with special focus on their mechanism of action against various influenza and coronaviruses.|pdf=|usr=027}}
+{{tp|p=33845740|t=2021. A therapeutic journey of potential drugs against COVID-19.|pdf=|usr=027}}
+{{tp|p=33355053|t=2021. Repurposed Antiviral Drugs for the Treatment of COVID-19: Syntheses, Mechanism of Infection and Clinical Trials.|pdf=|usr=027}}
+{{tp|p=33280595|t=2021. Synthetic and Semi-synthetic Drugs as a Promising Therapeutic Option for the Treatment of COVID-19.|pdf=|usr=027}}
+{{tp|p=33844232|t=2021. Antikorper-Duo verhindert schwere COVID-19-Verlaufe.|pdf=|usr=027}}
+{{tp|p=33328281|t=2021. Relevance of the Bruton Tyrosine Kinase as a Target for COVID-19 Therapy.|pdf=|usr=027}}
+{{tp|p=33945284|t=2021. siRNA Therapeutics for the Therapy of COVID-19 and Other Coronaviruses.|pdf=|usr=027}}
+{{tp|p=33356050|t=2021. Tocilizumab in Covid-19. Reply.|pdf=|usr=027}}
+{{tp|p=33356049|t=2021. Tocilizumab in Covid-19.|pdf=|usr=027}}
+{{tp|p=33378611|t=2021. Neutralizing Antibody LY-CoV555 for Outpatient Covid-19. Reply.|pdf=|usr=027}}
+{{tp|p=33378610|t=2021. Neutralizing Antibody LY-CoV555 for Outpatient Covid-19.|pdf=|usr=027}}
+{{tp|p=33826817|t=2021. Preparing for the Future - Nanobodies for Covid-19?|pdf=|usr=027}}
+{{tp|p=33900318|t=2021. Inhibition mechanism and hot-spot prediction of nine potential drugs for SARS-CoV-2 M(pro) by large-scale molecular dynamic simulations combined with accurate binding free energy calculations.|pdf=|usr=027}}
+{{tp|p=33986543|t=2021. Tocilizumab for the treatment of severe COVID-19.|pdf=|usr=027}}
+{{tp|p=33837377|t=2021. Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19.|pdf=|usr=027}}
+{{tp|p=33949277|t=2021. Molecular docking of compounds from Clinacanthus nutans extract detected by GC-MS analysis with the SARS-CoV-2 main protease and ACE2 protein.|pdf=|usr=027}}
+{{tp|p=33949276|t=2021. Potential of (Citrus nobilis Lour x Citrus deliciosa Tenora) metabolites on COVID-19 virus main protease supported by in silico analysis.|pdf=|usr=027}}
+{{tp|p=33949266|t=2021. Can nutraceuticals assist treatment and improve covid-19 symptoms?|pdf=|usr=027}}
+{{tp|p=34027770|t=2021. Natural metabolites from the soft coral Nephthea sp. as potential SARS-CoV-2 main protease inhibitors.|pdf=|usr=027}}
+{{tp|p=33864035|t=2021. RECOVERY 1 year on: a rare success in the COVID-19 clinical trial landscape.|pdf=|usr=027}}
+{{tp|p=33981021|t=2021. Structural basis for broad coronavirus neutralization.|pdf=|usr=027}}
+{{tp|p=33963326|t=2021. International COVID-19 trial to restart with focus on immune responses.|pdf=|usr=027}}